data_2m3j_residue save_MolProbity _Software.Sf_category software _Software.Sf_framecode MolProbity _Software.Entry_ID ? _Software.ID 1 _Software.Name MolProbity _Software.Version 4.0 _Software.Details . save_ save_CYRANGE _Software.Sf_category software _Software.Sf_framecode CYRANGE _Software.Entry_ID ? _Software.ID 2 _Software.Name CYRANGE _Software.Version 2.0 _Software.Details . save_ save_Structure_validation_residue _Structure_validation_residue.Sf_category structure_validation _Structure_validation_residue.Sf_framecode Structure_validation_residue _Structure_validation_residue.Entry_ID ? _Structure_validation_residue.List_ID 1 _Structure_validation_residue.PDB_accession_code 2m3j _Structure_validation_residue.Date_analyzed 2016-10-07 loop_ _Residue_analysis_software.Software_ID _Residue_analysis_software.Software_label _Residue_analysis_software.Method_ID _Residue_analysis_software.Method_label _Residue_analysis_software.Entry_ID _Residue_analysis_software.Structure_validation_oneline_list_ID 1 MolProbity . . ? 1 2 CYRANGE . . ? 1 stop_ loop_ _Residue_analysis.ID _Residue_analysis.PDB_model_num _Residue_analysis.Hydrogen_positions _Residue_analysis.MolProbity_flips _Residue_analysis.Cyrange_core_flag _Residue_analysis.Two_letter_chain_ID _Residue_analysis.PDB_strand_ID _Residue_analysis.PDB_residue_no _Residue_analysis.PDB_ins_code _Residue_analysis.PDB_residue_name _Residue_analysis.Assembly_ID _Residue_analysis.Entity_assembly_ID _Residue_analysis.Entity_ID _Residue_analysis.Comp_ID _Residue_analysis.Comp_index_ID _Residue_analysis.Clash_value _Residue_analysis.Clash_source_PDB_atom_name _Residue_analysis.Clash_destination_PDB_atom_name _Residue_analysis.Clash_destination_PDB_strand_ID _Residue_analysis.Clash_destination_PDB_residue_no _Residue_analysis.Clash_destination_PDB_ins_code _Residue_analysis.Clash_destination_PDB_residue_name _Residue_analysis.Cbeta_deviation_value _Residue_analysis.Rotamer_score _Residue_analysis.Rotamer_name _Residue_analysis.Ramachandran_phi _Residue_analysis.Ramachandran_psi _Residue_analysis.Ramachandran_score _Residue_analysis.Ramachandran_evaluation _Residue_analysis.Ramachandran_type _Residue_analysis.Bond_outlier_count _Residue_analysis.Worst_bond _Residue_analysis.Worst_bond_value _Residue_analysis.Worst_bond_sigma _Residue_analysis.Angle_outlier_count _Residue_analysis.Worst_angle _Residue_analysis.Worst_angle_value _Residue_analysis.Worst_angle_sigma _Residue_analysis.RNA_phosphate_perpendicular_outlier _Residue_analysis.RNA_suitness_score _Residue_analysis.RNA_suite_conformer _Residue_analysis.RNA_suite_triage _Residue_analysis.Max_b_factor _Residue_analysis.Tau_angle _Residue_analysis.Omega_dihedral _Residue_analysis.Disulfide_chi1 _Residue_analysis.Disulfide_chi2 _Residue_analysis.Disulfide_chi3 _Residue_analysis.Disulfide_ss_angle _Residue_analysis.Disulfide_ss _Residue_analysis.Disulfide_ss_angle_prime _Residue_analysis.Disulfide_chi2prime _Residue_analysis.Disulfide_chi1prime _Residue_analysis.Outlier_count_separate_geometry _Residue_analysis.Outlier_count _Residue_analysis.Entry_ID _Residue_analysis.Structure_validation_residue_list_ID . 001 nuclear orig core ' A' A ' 2' ' ' PRO . . . . . 0.534 ' HD3' ' ND2' ' A' ' 13' ' ' ASN . 81.1 Cg_endo . . . . . 0 CA--C 1.545 1.034 0 N-CA-C 112.942 0.324 . . . . 0.0 112.942 . . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -145.77 -159.22 8.06 Favored Glycine 0 C--N 1.337 0.632 0 N-CA-C 111.547 -0.621 . . . . 0.0 111.547 179.189 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 19.7 tt0 -71.3 125.84 28.05 Favored 'General case' 0 N--CA 1.472 0.668 0 CA-C-N 116.901 0.35 . . . . 0.0 111.072 179.631 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 88.22 16.65 58.8 Favored Glycine 0 C--N 1.339 0.724 0 CA-C-N 115.659 -0.7 . . . . 0.0 113.097 -179.541 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 43.1 mt-10 -127.95 166.91 17.43 Favored 'General case' 0 C--O 1.237 0.433 0 C-N-CA 122.333 0.253 . . . . 0.0 110.719 -179.775 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 7' ' ' GLN . . . . . 0.433 ' HA ' ' O ' ' A' ' 28' ' ' GLY . 0.2 OUTLIER -81.05 152.04 28.08 Favored 'General case' 0 C--N 1.346 0.436 0 CA-C-N 116.502 -0.317 . . . . 0.0 110.974 179.89 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 6.3 p -147.12 156.24 42.83 Favored 'General case' 0 C--O 1.235 0.307 0 CA-C-N 115.963 -0.562 . . . . 0.0 111.583 -178.965 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 4.8 t70 -117.36 149.13 41.01 Favored 'General case' 0 C--O 1.234 0.263 0 CA-C-N 115.452 -0.794 . . . . 0.0 109.589 178.918 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 15.7 m -102.38 24.49 1.48 Allowed 'Isoleucine or valine' 0 CA--C 1.542 0.655 0 CA-C-N 116.225 -0.443 . . . . 0.0 111.905 -179.493 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 43.9 mt-10 -120.63 -50.89 2.18 Favored 'General case' 0 N--CA 1.466 0.333 0 N-CA-C 112.063 0.394 . . . . 0.0 112.063 -179.044 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 12' ' ' PHE . . . . . . . . . . . . . 13.7 m-85 -133.35 -27.23 1.59 Allowed 'General case' 0 N--CA 1.47 0.541 0 N-CA-C 112.181 0.437 . . . . 0.0 112.181 -178.706 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 13' ' ' ASN . . . . . 0.534 ' ND2' ' HD3' ' A' ' 2' ' ' PRO . 6.3 t30 -116.03 73.91 5.11 Favored Pre-proline 0 CA--C 1.549 0.934 0 O-C-N 123.435 0.459 . . . . 0.0 112.174 -177.467 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 14' ' ' PRO . . . . . 0.4 ' O ' ' HD2' ' A' ' 2' ' ' PRO . 60.8 Cg_endo -76.1 179.09 6.67 Favored 'Trans proline' 0 C--N 1.372 1.777 0 C-N-CA 122.43 2.087 . . . . 0.0 112.125 178.746 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 1.9 t -79.67 119.9 23.24 Favored 'General case' 0 N--CA 1.47 0.566 0 CA-C-O 120.499 0.19 . . . . 0.0 110.938 179.75 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER -57.86 -54.07 59.23 Favored Pre-proline 0 N--CA 1.477 0.915 0 CA-C-O 118.973 -0.537 . . . . 0.0 111.757 179.651 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 51.9 Cg_endo -70.39 168.19 23.08 Favored 'Trans proline' 0 C--N 1.378 2.118 0 C-N-CA 122.025 1.817 . . . . 0.0 111.8 178.25 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 49.8 Cg_endo -71.01 60.88 2.39 Favored 'Trans proline' 0 C--N 1.372 1.796 0 C-N-CA 121.945 1.763 . . . . 0.0 112.427 178.807 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 22.6 mt -122.42 171.58 8.97 Favored 'General case' 0 C--O 1.235 0.325 0 CA-C-N 115.411 -0.813 . . . . 0.0 111.421 -179.269 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 20' ' ' THR . . . . . 0.469 ' O ' ' HA ' ' A' ' 30' ' ' CYS . 28.5 m -107.72 153.69 22.58 Favored 'General case' 0 CA--C 1.533 0.306 0 CA-C-N 115.676 -0.693 . . . . 0.0 111.227 -178.676 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 4.8 t -103.06 104.97 15.19 Favored 'General case' 0 C--O 1.237 0.426 0 CA-C-N 115.593 -0.731 . . . . 0.0 109.553 178.626 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 22' ' ' ILE . . . . . . . . . . . . . 3.4 mt -127.12 129.34 23.97 Favored Pre-proline 0 CA--C 1.543 0.686 0 CA-C-N 115.874 -0.603 . . . . 0.0 110.47 -178.805 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 37.6 Cg_endo -67.46 -48.69 0.23 Allowed 'Cis proline' 0 C--N 1.374 1.913 0 C-N-CA 124.713 -0.953 . . . . 0.0 113.848 -0.294 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 80.5 40.74 12.35 Favored Glycine 0 C--N 1.347 1.145 0 C-N-CA 121.264 -0.493 . . . . 0.0 112.761 -179.891 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 8.2 m-20 -141.6 79.31 17.21 Favored Pre-proline 0 CA--C 1.544 0.744 0 C-N-CA 122.443 0.297 . . . . 0.0 110.837 -179.709 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 1.5 Cg_endo -82.49 -32.72 3.29 Favored 'Cis proline' 0 C--N 1.371 1.746 0 C-N-CA 125.074 -0.803 . . . . 0.0 113.028 -0.125 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 27' ' ' TYR . . . . . . . . . . . . . 71.7 m-85 -98.11 171.43 8.25 Favored 'General case' 0 C--O 1.24 0.563 0 CA-C-N 115.913 -0.585 . . . . 0.0 111.568 -178.973 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 28' ' ' GLY . . . . . 0.433 ' O ' ' HA ' ' A' ' 7' ' ' GLN . . . -173.03 -159.84 20.44 Favored Glycine 0 C--N 1.338 0.653 0 CA-C-N 115.784 -0.644 . . . . 0.0 112.365 179.301 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 29' ' ' ILE . . . . . 0.517 ' HB ' ' CE2' ' A' ' 31' ' ' TYR . 2.9 mm -124.21 151.18 29.13 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 N-CA-C 109.735 -0.468 . . . . 0.0 109.735 179.737 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 30' ' ' CYS . . . . . 0.469 ' HA ' ' O ' ' A' ' 20' ' ' THR . 23.4 m -79.94 103.24 9.69 Favored 'General case' 0 CA--C 1.536 0.412 0 CA-C-O 121.225 0.536 . . . . 0.0 111.432 -179.812 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 31' ' ' TYR . . . . . 0.517 ' CE2' ' HB ' ' A' ' 29' ' ' ILE . 38.2 m-85 -129.07 167.77 17.04 Favored 'General case' 0 C--O 1.233 0.211 0 CA-C-N 115.014 -0.993 . . . . 0.0 110.923 -179.623 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 2.7 tp -100.95 131.43 48.62 Favored 'Isoleucine or valine' 0 CA--C 1.542 0.645 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.315 179.411 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 33' ' ' ILE . . . . . 0.452 ' O ' HD12 ' A' ' 33' ' ' ILE . 1.9 pp . . . . . 0 C--O 1.249 1.051 0 CA-C-O 118.395 -0.812 . . . . 0.0 111.413 179.954 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 2' ' ' PRO . . . . . 0.485 ' HD3' ' ND2' ' A' ' 13' ' ' ASN . 88.6 Cg_endo . . . . . 0 CA--C 1.543 0.926 0 N-CA-C 112.963 0.332 . . . . 0.0 112.963 . . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -149.46 -159.58 8.7 Favored Glycine 0 C--N 1.338 0.67 0 N-CA-C 111.623 -0.591 . . . . 0.0 111.623 179.229 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 17.2 tt0 -70.05 121.29 17.17 Favored 'General case' 0 N--CA 1.474 0.73 0 CA-C-O 120.763 0.315 . . . . 0.0 111.241 179.811 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 93.37 15.15 51.99 Favored Glycine 0 C--N 1.34 0.782 0 CA-C-N 115.614 -0.721 . . . . 0.0 113.164 -179.776 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 43.1 mt-10 -128.75 166.63 18.62 Favored 'General case' 0 C--O 1.24 0.56 0 C-N-CA 122.514 0.326 . . . . 0.0 110.816 179.959 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 7' ' ' GLN . . . . . 0.42 ' HA ' ' O ' ' A' ' 28' ' ' GLY . 0.2 OUTLIER -81.43 152.55 27.35 Favored 'General case' 0 C--N 1.346 0.435 0 O-C-N 123.195 0.309 . . . . 0.0 111.137 -179.88 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 7.9 p -145.84 154.53 42.1 Favored 'General case' 0 N--CA 1.466 0.354 0 CA-C-N 115.957 -0.565 . . . . 0.0 111.502 -179.12 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 6.2 t70 -118.12 153.82 33.15 Favored 'General case' 0 C--O 1.236 0.345 0 CA-C-N 115.393 -0.821 . . . . 0.0 109.898 179.139 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 13.5 m -105.33 17.92 5.44 Favored 'Isoleucine or valine' 0 CA--C 1.542 0.661 0 CA-C-N 116.286 -0.416 . . . . 0.0 112.033 -179.422 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 46.3 mt-10 -110.74 -52.9 2.75 Favored 'General case' 0 N--CA 1.466 0.36 0 N-CA-C 111.898 0.332 . . . . 0.0 111.898 -179.149 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 12' ' ' PHE . . . . . . . . . . . . . 13.4 t80 -138.76 -15.66 1.17 Allowed 'General case' 0 N--CA 1.469 0.493 0 N-CA-C 112.406 0.521 . . . . 0.0 112.406 -178.945 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 13' ' ' ASN . . . . . 0.485 ' ND2' ' HD3' ' A' ' 2' ' ' PRO . 7.4 t30 -120.62 73.35 22.73 Favored Pre-proline 0 CA--C 1.549 0.929 0 O-C-N 122.935 0.147 . . . . 0.0 111.343 -179.204 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 14' ' ' PRO . . . . . 0.41 ' O ' ' HD2' ' A' ' 2' ' ' PRO . 60.5 Cg_endo -76.43 176.56 9.92 Favored 'Trans proline' 0 C--N 1.371 1.75 0 C-N-CA 122.428 2.085 . . . . 0.0 112.48 179.342 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 1.4 m -79.67 118.9 21.91 Favored 'General case' 0 N--CA 1.469 0.488 0 O-C-N 123.199 0.312 . . . . 0.0 111.422 179.923 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER -58.03 -53.87 61.43 Favored Pre-proline 0 N--CA 1.477 0.906 0 CA-C-N 115.865 -0.607 . . . . 0.0 111.776 179.81 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 53.3 Cg_endo -70.28 168.65 21.61 Favored 'Trans proline' 0 C--N 1.379 2.132 0 C-N-CA 121.983 1.789 . . . . 0.0 111.736 178.351 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 56.0 Cg_endo -72.4 47.34 1.09 Allowed 'Trans proline' 0 C--N 1.37 1.673 0 C-N-CA 121.872 1.714 . . . . 0.0 112.855 178.987 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 19' ' ' LEU . . . . . 0.444 ' HB2' ' SG ' ' A' ' 30' ' ' CYS . 13.0 mt -107.58 171.08 7.59 Favored 'General case' 0 CA--C 1.533 0.32 0 CA-C-N 115.921 -0.582 . . . . 0.0 110.955 -179.537 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 28.6 m -104.43 148.84 25.98 Favored 'General case' 0 CA--C 1.531 0.25 0 CA-C-N 115.829 -0.623 . . . . 0.0 111.108 -178.76 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 5.9 t -98.49 103.03 14.95 Favored 'General case' 0 C--O 1.238 0.499 0 N-CA-C 109.421 -0.585 . . . . 0.0 109.421 178.384 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 22' ' ' ILE . . . . . . . . . . . . . 2.5 mt -126.62 129.02 24.19 Favored Pre-proline 0 CA--C 1.543 0.703 0 CA-C-N 115.817 -0.629 . . . . 0.0 110.742 -178.547 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 37.4 Cg_endo -67.67 -48.55 0.24 Allowed 'Cis proline' 0 C--N 1.374 1.908 0 C-N-CA 124.719 -0.95 . . . . 0.0 113.782 -0.262 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 79.38 38.7 20.79 Favored Glycine 0 C--N 1.348 1.227 0 C-N-CA 121.37 -0.443 . . . . 0.0 112.894 -179.991 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 8.4 m-20 -140.71 79.99 18.72 Favored Pre-proline 0 CA--C 1.544 0.735 0 C-N-CA 122.447 0.299 . . . . 0.0 110.869 -179.728 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 1.8 Cg_endo -82.23 -32.63 3.41 Favored 'Cis proline' 0 C--N 1.372 1.811 0 C-N-CA 125.15 -0.771 . . . . 0.0 112.945 -0.127 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 27' ' ' TYR . . . . . . . . . . . . . 68.0 m-85 -99.37 171.64 7.84 Favored 'General case' 0 C--O 1.238 0.482 0 CA-C-N 115.786 -0.643 . . . . 0.0 111.652 -179.096 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 28' ' ' GLY . . . . . 0.42 ' O ' ' HA ' ' A' ' 7' ' ' GLN . . . -174.64 -159.79 21.56 Favored Glycine 0 C--N 1.337 0.62 0 CA-C-N 115.801 -0.636 . . . . 0.0 112.268 179.185 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 29' ' ' ILE . . . . . 0.544 ' HB ' ' CE2' ' A' ' 31' ' ' TYR . 1.8 mm -124.12 152.1 29.57 Favored 'Isoleucine or valine' 0 C--O 1.233 0.236 0 N-CA-C 109.755 -0.461 . . . . 0.0 109.755 179.627 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 30' ' ' CYS . . . . . 0.444 ' SG ' ' HB2' ' A' ' 19' ' ' LEU . 0.5 OUTLIER -80.12 104.49 10.71 Favored 'General case' 0 C--O 1.238 0.454 0 CA-C-N 115.974 -0.557 . . . . 0.0 110.99 -179.856 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 31' ' ' TYR . . . . . 0.544 ' CE2' ' HB ' ' A' ' 29' ' ' ILE . 36.1 m-85 -130.22 166.62 19.92 Favored 'General case' 0 C--O 1.233 0.189 0 CA-C-N 115.431 -0.804 . . . . 0.0 111.141 -179.501 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 2.8 tp -100.93 131.42 48.61 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.547 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.438 179.431 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 33' ' ' ILE . . . . . 0.451 ' O ' HD13 ' A' ' 33' ' ' ILE . 1.9 pp . . . . . 0 C--O 1.249 1.042 0 CA-C-O 118.28 -0.866 . . . . 0.0 111.518 179.903 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 2' ' ' PRO . . . . . 0.527 ' HD3' ' ND2' ' A' ' 13' ' ' ASN . 84.1 Cg_endo . . . . . 0 CA--C 1.543 0.933 0 N-CA-C 112.845 0.287 . . . . 0.0 112.845 . . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -147.12 -161.71 9.54 Favored Glycine 0 C--N 1.338 0.665 0 N-CA-C 111.696 -0.562 . . . . 0.0 111.696 179.194 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 19.4 tt0 -67.8 124.03 22.17 Favored 'General case' 0 N--CA 1.474 0.747 0 C-N-CA 122.488 0.315 . . . . 0.0 111.212 179.68 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 91.07 15.08 56.76 Favored Glycine 0 C--N 1.338 0.681 0 CA-C-N 115.66 -0.7 . . . . 0.0 113.125 -179.718 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 43.1 mt-10 -129.06 165.22 21.62 Favored 'General case' 0 C--O 1.237 0.414 0 C-N-CA 122.29 0.236 . . . . 0.0 110.802 -179.942 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 7' ' ' GLN . . . . . . . . . . . . . 0.2 OUTLIER -81.55 152.98 27.0 Favored 'General case' 0 C--N 1.346 0.454 0 CA-C-N 116.43 -0.35 . . . . 0.0 110.936 179.915 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 3.2 p -142.23 152.07 42.72 Favored 'General case' 0 C--O 1.234 0.249 0 CA-C-N 115.821 -0.627 . . . . 0.0 111.208 -179.255 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -110.04 141.32 43.02 Favored 'General case' 0 C--O 1.232 0.163 0 CA-C-N 115.541 -0.754 . . . . 0.0 109.492 179.38 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 8.8 m -96.59 21.5 1.15 Allowed 'Isoleucine or valine' 0 CA--C 1.543 0.675 0 CA-C-N 116.326 -0.397 . . . . 0.0 111.566 -179.984 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 45.5 mt-10 -113.81 -54.83 2.57 Favored 'General case' 0 C--O 1.236 0.351 0 N-CA-C 112.048 0.388 . . . . 0.0 112.048 -179.042 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 12' ' ' PHE . . . . . . . . . . . . . 10.5 t80 -137.62 -18.56 1.24 Allowed 'General case' 0 N--CA 1.471 0.625 0 N-CA-C 112.516 0.561 . . . . 0.0 112.516 -178.891 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 13' ' ' ASN . . . . . 0.527 ' ND2' ' HD3' ' A' ' 2' ' ' PRO . 9.2 t30 -119.2 73.83 14.06 Favored Pre-proline 0 CA--C 1.55 0.954 0 O-C-N 122.918 0.136 . . . . 0.0 111.118 -179.332 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 14' ' ' PRO . . . . . 0.407 ' O ' ' HD2' ' A' ' 2' ' ' PRO . 60.5 Cg_endo -75.69 -178.84 4.6 Favored 'Trans proline' 0 C--N 1.371 1.745 0 C-N-CA 122.443 2.095 . . . . 0.0 112.506 179.481 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 15' ' ' CYS . . . . . 0.519 ' SG ' ' HB2' ' A' ' 19' ' ' LEU . 4.3 t -79.47 120.48 23.93 Favored 'General case' 0 N--CA 1.471 0.623 0 O-C-N 123.079 0.237 . . . . 0.0 111.095 179.981 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER -60.27 -54.49 54.63 Favored Pre-proline 0 N--CA 1.476 0.847 0 CA-C-O 119.062 -0.494 . . . . 0.0 111.577 179.45 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 56.7 Cg_endo -71.22 168.81 22.28 Favored 'Trans proline' 0 C--N 1.381 2.241 0 C-N-CA 122.096 1.864 . . . . 0.0 111.614 178.123 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 48.4 Cg_endo -70.48 61.29 2.12 Favored 'Trans proline' 0 C--N 1.37 1.677 0 C-N-CA 121.918 1.745 . . . . 0.0 112.78 179.048 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 19' ' ' LEU . . . . . 0.519 ' HB2' ' SG ' ' A' ' 15' ' ' CYS . 90.7 mt -122.2 166.62 14.31 Favored 'General case' 0 C--O 1.235 0.331 0 CA-C-N 115.713 -0.676 . . . . 0.0 111.189 -179.869 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 20' ' ' THR . . . . . 0.454 ' OG1' HG12 ' A' ' 33' ' ' ILE . 89.5 m -106.32 149.65 26.73 Favored 'General case' 0 CA--C 1.533 0.302 0 CA-C-N 115.305 -0.861 . . . . 0.0 110.947 -179.3 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 21' ' ' CYS . . . . . 0.497 ' HA ' ' O ' ' A' ' 29' ' ' ILE . 1.9 t -95.25 106.94 19.02 Favored 'General case' 0 C--O 1.24 0.555 0 CA-C-N 115.726 -0.67 . . . . 0.0 110.244 178.917 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 22' ' ' ILE . . . . . . . . . . . . . 5.9 mt -125.47 128.5 24.67 Favored Pre-proline 0 CA--C 1.544 0.717 0 CA-C-N 115.928 -0.578 . . . . 0.0 110.531 -179.185 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 37.4 Cg_endo -67.19 -48.0 0.25 Allowed 'Cis proline' 0 C--N 1.375 1.963 0 C-N-CA 124.685 -0.964 . . . . 0.0 113.757 -0.35 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 83.07 35.75 17.29 Favored Glycine 0 C--N 1.345 1.07 0 C-N-CA 121.433 -0.413 . . . . 0.0 112.918 179.781 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 7.6 m-20 -143.91 83.6 10.27 Favored Pre-proline 0 CA--C 1.546 0.819 0 C-N-CA 122.478 0.311 . . . . 0.0 111.04 -179.661 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 69.7 Cg_endo -82.15 -31.73 4.01 Favored 'Cis proline' 0 C--N 1.372 1.813 0 C-N-CA 124.814 -0.911 . . . . 0.0 113.479 -0.218 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 27' ' ' TYR . . . . . . . . . . . . . 59.8 m-85 -96.92 163.32 13.01 Favored 'General case' 0 N--CA 1.47 0.548 0 CA-C-N 115.956 -0.565 . . . . 0.0 111.208 -179.16 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 28' ' ' GLY . . . . . 0.432 ' O ' HD11 ' A' ' 29' ' ' ILE . . . -157.89 -162.01 11.39 Favored Glycine 0 C--N 1.339 0.746 0 C-N-CA 120.92 -0.657 . . . . 0.0 113.098 179.815 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 29' ' ' ILE . . . . . 0.497 ' O ' ' HA ' ' A' ' 21' ' ' CYS . 5.0 mm -130.53 154.81 41.14 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.222 0 N-CA-C 109.709 -0.478 . . . . 0.0 109.709 179.948 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 30' ' ' CYS . . . . . . . . . . . . . 26.2 m -83.72 92.81 7.8 Favored 'General case' 0 C--O 1.238 0.489 0 CA-C-O 121.483 0.659 . . . . 0.0 111.403 -179.968 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 31' ' ' TYR . . . . . 0.431 ' CE2' ' HB ' ' A' ' 29' ' ' ILE . 37.1 m-85 -124.26 167.26 14.56 Favored 'General case' 0 N--CA 1.464 0.241 0 CA-C-N 114.962 -1.017 . . . . 0.0 110.902 179.945 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 2.8 tp -99.98 131.66 46.99 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.605 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.449 179.378 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 33' ' ' ILE . . . . . 0.454 HG12 ' OG1' ' A' ' 20' ' ' THR . 1.3 pt . . . . . 0 C--O 1.249 1.048 0 CA-C-O 118.142 -0.932 . . . . 0.0 111.416 179.832 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 2' ' ' PRO . . . . . 0.542 ' HD3' ' ND2' ' A' ' 13' ' ' ASN . 85.2 Cg_endo . . . . . 0 CA--C 1.543 0.954 0 N-CA-C 112.832 0.282 . . . . 0.0 112.832 . . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -146.59 -160.92 9.01 Favored Glycine 0 C--N 1.337 0.603 0 N-CA-C 111.661 -0.576 . . . . 0.0 111.661 179.141 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 19.6 tt0 -68.21 124.5 23.65 Favored 'General case' 0 N--CA 1.475 0.824 0 CA-C-N 116.816 0.308 . . . . 0.0 111.145 179.673 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 90.73 15.07 57.27 Favored Glycine 0 C--N 1.338 0.667 0 CA-C-N 115.663 -0.699 . . . . 0.0 113.143 -179.692 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 43.1 mt-10 -129.02 165.11 21.8 Favored 'General case' 0 C--O 1.239 0.53 0 C-N-CA 122.339 0.256 . . . . 0.0 110.807 -179.891 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 7' ' ' GLN . . . . . . . . . . . . . 0.2 OUTLIER -81.65 152.9 26.91 Favored 'General case' 0 C--N 1.346 0.433 0 O-C-N 123.179 0.3 . . . . 0.0 110.895 179.874 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 3.2 p -141.68 151.79 43.33 Favored 'General case' 0 C--O 1.234 0.242 0 CA-C-N 115.8 -0.636 . . . . 0.0 111.099 -179.272 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -110.34 143.56 40.38 Favored 'General case' 0 C--O 1.234 0.26 0 CA-C-N 115.481 -0.782 . . . . 0.0 109.532 179.423 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 10' ' ' VAL . . . . . 0.417 HG21 ' O ' ' A' ' 26' ' ' PRO . 6.1 m -98.28 21.06 1.52 Allowed 'Isoleucine or valine' 0 CA--C 1.541 0.606 0 O-C-N 123.238 0.336 . . . . 0.0 111.514 -179.899 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 8.5 mm-40 -115.53 -52.48 2.64 Favored 'General case' 0 C--O 1.235 0.304 0 N-CA-C 112.252 0.464 . . . . 0.0 112.252 -179.125 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 12' ' ' PHE . . . . . . . . . . . . . 13.0 t80 -141.04 -9.21 1.01 Allowed 'General case' 0 N--CA 1.473 0.709 0 N-CA-C 112.722 0.638 . . . . 0.0 112.722 -178.666 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 13' ' ' ASN . . . . . 0.542 ' ND2' ' HD3' ' A' ' 2' ' ' PRO . 7.6 t30 -129.64 64.94 73.55 Favored Pre-proline 0 CA--C 1.551 0.986 0 CA-C-N 117.496 0.135 . . . . 0.0 111.25 -179.075 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 15.8 Cg_exo -69.04 -178.66 2.16 Favored 'Trans proline' 0 C--N 1.372 1.808 0 C-N-CA 122.957 2.438 . . . . 0.0 112.266 179.009 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 15' ' ' CYS . . . . . 0.516 ' SG ' ' HB2' ' A' ' 19' ' ' LEU . 4.0 t -79.65 121.79 25.73 Favored 'General case' 0 N--CA 1.472 0.64 0 O-C-N 123.135 0.272 . . . . 0.0 111.331 -179.781 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER -61.35 -54.32 54.04 Favored Pre-proline 0 CA--C 1.547 0.845 0 CA-C-O 119.024 -0.512 . . . . 0.0 111.43 179.22 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 56.7 Cg_endo -71.19 169.21 21.22 Favored 'Trans proline' 0 C--N 1.38 2.225 0 C-N-CA 121.96 1.773 . . . . 0.0 111.719 178.193 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 49.0 Cg_endo -70.56 59.12 2.0 Favored 'Trans proline' 0 C--N 1.372 1.795 0 C-N-CA 121.918 1.746 . . . . 0.0 112.896 179.071 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 19' ' ' LEU . . . . . 0.516 ' HB2' ' SG ' ' A' ' 15' ' ' CYS . 92.2 mt -119.99 165.2 14.98 Favored 'General case' 0 C--O 1.235 0.31 0 CA-C-N 115.751 -0.659 . . . . 0.0 111.176 -179.95 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 87.5 m -104.08 150.58 24.17 Favored 'General case' 0 CA--C 1.532 0.285 0 CA-C-N 115.327 -0.851 . . . . 0.0 110.978 -179.464 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 21' ' ' CYS . . . . . 0.494 ' HA ' ' O ' ' A' ' 29' ' ' ILE . 1.9 t -96.57 104.55 16.54 Favored 'General case' 0 C--O 1.238 0.464 0 CA-C-N 115.669 -0.696 . . . . 0.0 109.98 178.94 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 22' ' ' ILE . . . . . . . . . . . . . 6.1 mt -122.83 128.01 25.53 Favored Pre-proline 0 CA--C 1.543 0.705 0 CA-C-N 115.865 -0.607 . . . . 0.0 110.546 -179.178 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 36.8 Cg_endo -66.96 -47.57 0.26 Allowed 'Cis proline' 0 C--N 1.376 1.977 0 C-N-CA 124.632 -0.987 . . . . 0.0 113.801 -0.302 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 83.73 32.85 23.29 Favored Glycine 0 C--N 1.345 1.081 0 C-N-CA 121.305 -0.474 . . . . 0.0 113.021 179.719 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 7.7 m-20 -144.18 86.57 8.27 Favored Pre-proline 0 CA--C 1.545 0.772 0 C-N-CA 122.56 0.344 . . . . 0.0 110.532 -179.654 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 26' ' ' PRO . . . . . 0.417 ' O ' HG21 ' A' ' 10' ' ' VAL . 1.1 Cg_endo -81.47 -31.34 4.49 Favored 'Cis proline' 0 C--N 1.371 1.733 0 C-N-CA 125.164 -0.765 . . . . 0.0 112.888 0.018 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 27' ' ' TYR . . . . . . . . . . . . . 41.3 m-85 -101.76 166.56 10.61 Favored 'General case' 0 C--O 1.237 0.398 0 CA-C-N 115.712 -0.676 . . . . 0.0 111.104 -179.137 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 28' ' ' GLY . . . . . 0.419 ' O ' HD13 ' A' ' 29' ' ' ILE . . . -160.63 -160.82 10.93 Favored Glycine 0 C--N 1.341 0.807 0 C-N-CA 120.911 -0.661 . . . . 0.0 113.21 179.999 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 29' ' ' ILE . . . . . 0.494 ' O ' ' HA ' ' A' ' 21' ' ' CYS . 4.8 mm -129.76 155.29 41.3 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.255 0 CA-C-N 115.273 -0.464 . . . . 0.0 109.887 -179.995 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 30' ' ' CYS . . . . . . . . . . . . . 30.1 m -84.04 93.78 8.17 Favored 'General case' 0 C--O 1.237 0.433 0 CA-C-O 121.39 0.614 . . . . 0.0 111.302 179.926 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 31' ' ' TYR . . . . . 0.43 ' CE2' ' HB ' ' A' ' 29' ' ' ILE . 35.4 m-85 -124.37 168.4 13.07 Favored 'General case' 0 N--CA 1.464 0.255 0 CA-C-N 115.012 -0.994 . . . . 0.0 111.14 -179.863 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 2.6 tp -100.68 133.48 43.7 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.598 0 CA-C-N 116.082 -0.508 . . . . 0.0 110.343 179.391 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 33' ' ' ILE . . . . . 0.428 HD11 ' OXT' ' A' ' 33' ' ' ILE . 1.6 pp . . . . . 0 C--O 1.249 1.031 0 CA-C-O 118.081 -0.961 . . . . 0.0 111.519 179.888 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 2' ' ' PRO . . . . . 0.478 ' HD3' HD22 ' A' ' 13' ' ' ASN . 94.5 Cg_endo . . . . . 0 CA--C 1.545 1.032 0 N-CA-C 112.937 0.322 . . . . 0.0 112.937 . . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -143.95 -153.53 5.9 Favored Glycine 0 C--N 1.339 0.724 0 N-CA-C 111.669 -0.573 . . . . 0.0 111.669 179.381 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 17.7 tt0 -73.92 130.26 39.52 Favored 'General case' 0 N--CA 1.472 0.668 0 C-N-CA 122.546 0.338 . . . . 0.0 111.265 179.578 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 85.81 15.35 65.64 Favored Glycine 0 C--N 1.339 0.709 0 CA-C-N 115.921 -0.582 . . . . 0.0 113.452 -179.756 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 43.1 mt-10 -126.02 161.13 28.26 Favored 'General case' 0 C--O 1.237 0.406 0 C-N-CA 122.243 0.217 . . . . 0.0 110.849 -179.829 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 7' ' ' GLN . . . . . 0.66 ' HA ' ' O ' ' A' ' 28' ' ' GLY . 18.9 tt0 -87.01 134.81 33.45 Favored 'General case' 0 C--N 1.346 0.422 0 CA-C-O 121.176 0.512 . . . . 0.0 111.311 179.89 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 8' ' ' CYS . . . . . 0.401 ' SG ' ' SG ' ' A' ' 30' ' ' CYS . 2.5 p -129.3 161.41 30.29 Favored 'General case' 0 C--O 1.239 0.522 0 CA-C-N 114.538 -1.21 . . . . 0.0 110.989 -179.528 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 9' ' ' ASP . . . . . 0.582 ' OD1' ' HB3' ' A' ' 13' ' ' ASN . 0.7 OUTLIER -120.69 142.68 49.26 Favored 'General case' 0 N--CA 1.463 0.222 0 CA-C-N 115.725 -0.67 . . . . 0.0 110.042 178.528 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 23.2 m -90.78 13.85 1.59 Allowed 'Isoleucine or valine' 0 CA--C 1.543 0.697 0 CA-C-N 115.994 -0.548 . . . . 0.0 111.593 -179.398 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 45.9 mt-10 -97.05 -51.96 4.03 Favored 'General case' 0 C--O 1.235 0.304 0 CA-C-N 116.029 -0.532 . . . . 0.0 111.938 -178.804 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 12' ' ' PHE . . . . . . . . . . . . . 7.2 t80 -144.97 -21.56 0.5 Allowed 'General case' 0 N--CA 1.473 0.691 0 N-CA-C 112.657 0.614 . . . . 0.0 112.657 -178.771 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 13' ' ' ASN . . . . . 0.582 ' HB3' ' OD1' ' A' ' 9' ' ' ASP . 13.2 t30 -120.03 75.13 21.32 Favored Pre-proline 0 CA--C 1.548 0.88 0 CA-C-N 117.521 0.146 . . . . 0.0 111.324 -178.889 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 61.4 Cg_endo -76.84 -175.89 2.87 Favored 'Trans proline' 0 C--N 1.372 1.774 0 C-N-CA 122.57 2.18 . . . . 0.0 112.16 178.731 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 0.8 OUTLIER -79.99 121.61 25.7 Favored 'General case' 0 N--CA 1.472 0.633 0 O-C-N 123.02 0.2 . . . . 0.0 111.189 179.879 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER -58.16 -53.56 64.69 Favored Pre-proline 0 N--CA 1.478 0.965 0 CA-C-N 116.137 -0.483 . . . . 0.0 111.593 179.106 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 41.5 Cg_endo -67.72 169.65 15.59 Favored 'Trans proline' 0 C--N 1.379 2.172 0 C-N-CA 122.148 1.899 . . . . 0.0 111.852 178.165 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 55.2 Cg_endo -71.84 47.8 1.01 Allowed 'Trans proline' 0 C--N 1.371 1.753 0 C-N-CA 122.007 1.805 . . . . 0.0 112.755 178.658 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 19.5 mt -108.8 165.4 11.59 Favored 'General case' 0 C--O 1.236 0.375 0 CA-C-N 115.7 -0.682 . . . . 0.0 111.285 -179.451 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 20' ' ' THR . . . . . 0.512 ' O ' ' HA ' ' A' ' 30' ' ' CYS . 30.7 m -103.24 152.53 21.39 Favored 'General case' 0 CA--C 1.531 0.227 0 CA-C-N 115.569 -0.742 . . . . 0.0 111.038 -178.833 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 2.2 t -102.64 99.75 9.76 Favored 'General case' 0 C--O 1.237 0.435 0 CA-C-N 115.753 -0.658 . . . . 0.0 109.594 178.902 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 22' ' ' ILE . . . . . . . . . . . . . 2.9 mt -120.88 128.78 25.6 Favored Pre-proline 0 CA--C 1.542 0.652 0 CA-C-N 115.637 -0.71 . . . . 0.0 110.372 -178.973 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 37.0 Cg_endo -66.81 -47.5 0.26 Allowed 'Cis proline' 0 C--N 1.375 1.936 0 C-N-CA 124.77 -0.929 . . . . 0.0 113.867 -0.232 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 79.11 34.03 34.48 Favored Glycine 0 C--N 1.347 1.173 0 C-N-CA 121.277 -0.487 . . . . 0.0 112.894 179.969 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 8.3 m-20 -139.73 83.26 16.85 Favored Pre-proline 0 CA--C 1.543 0.686 0 C-N-CA 122.561 0.344 . . . . 0.0 110.538 -179.712 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 3.1 Cg_exo -80.61 -32.05 4.18 Favored 'Cis proline' 0 C--N 1.371 1.746 0 C-N-CA 125.095 -0.794 . . . . 0.0 112.948 -0.099 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 27' ' ' TYR . . . . . 0.552 ' CD2' ' HB3' ' A' ' 9' ' ' ASP . 62.6 m-85 -106.85 172.67 6.69 Favored 'General case' 0 C--O 1.239 0.552 0 CA-C-N 115.753 -0.658 . . . . 0.0 111.751 -178.95 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 28' ' ' GLY . . . . . 0.66 ' O ' ' HA ' ' A' ' 7' ' ' GLN . . . -176.53 -164.08 29.95 Favored Glycine 0 C--N 1.338 0.693 0 CA-C-N 115.732 -0.667 . . . . 0.0 112.655 178.452 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 29' ' ' ILE . . . . . 0.535 ' HB ' ' CE2' ' A' ' 31' ' ' TYR . 2.6 mm -114.72 151.3 16.49 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 N-CA-C 110.082 -0.34 . . . . 0.0 110.082 -179.718 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 30' ' ' CYS . . . . . 0.512 ' HA ' ' O ' ' A' ' 20' ' ' THR . 40.7 m -79.87 105.74 11.38 Favored 'General case' 0 C--O 1.237 0.395 0 CA-C-N 115.843 -0.617 . . . . 0.0 111.482 -179.801 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 31' ' ' TYR . . . . . 0.535 ' CE2' ' HB ' ' A' ' 29' ' ' ILE . 36.6 m-85 -130.42 167.1 19.14 Favored 'General case' 0 C--O 1.233 0.205 0 CA-C-N 114.938 -1.028 . . . . 0.0 111.011 -179.406 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 2.9 tp -99.64 130.28 48.94 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.607 0 CA-C-N 116.27 -0.423 . . . . 0.0 110.348 179.436 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 33' ' ' ILE . . . . . 0.454 ' O ' HD11 ' A' ' 33' ' ' ILE . 1.9 pp . . . . . 0 C--O 1.248 0.993 0 CA-C-O 118.335 -0.84 . . . . 0.0 111.528 179.879 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 2' ' ' PRO . . . . . 0.478 ' HD3' HD22 ' A' ' 13' ' ' ASN . 92.2 Cg_endo . . . . . 0 CA--C 1.543 0.975 0 N-CA-C 112.953 0.328 . . . . 0.0 112.953 . . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -143.83 -153.45 5.88 Favored Glycine 0 C--N 1.339 0.701 0 N-CA-C 111.821 -0.512 . . . . 0.0 111.821 179.383 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 17.7 tt0 -74.04 130.17 39.3 Favored 'General case' 0 N--CA 1.473 0.702 0 C-N-CA 122.702 0.401 . . . . 0.0 111.134 179.586 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 85.76 15.54 65.38 Favored Glycine 0 C--N 1.339 0.705 0 O-C-N 123.712 0.632 . . . . 0.0 113.386 -179.85 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 43.0 mt-10 -126.11 161.25 28.06 Favored 'General case' 0 C--O 1.238 0.474 0 C-N-CA 122.276 0.23 . . . . 0.0 110.85 -179.915 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 7' ' ' GLN . . . . . 0.661 ' HA ' ' O ' ' A' ' 28' ' ' GLY . 18.6 tt0 -87.1 134.81 33.47 Favored 'General case' 0 C--N 1.344 0.363 0 CA-C-O 121.258 0.552 . . . . 0.0 111.241 179.915 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 8' ' ' CYS . . . . . 0.401 ' SG ' ' SG ' ' A' ' 30' ' ' CYS . 2.5 p -129.3 161.42 30.27 Favored 'General case' 0 C--O 1.238 0.488 0 CA-C-N 114.511 -1.222 . . . . 0.0 111.017 -179.589 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 9' ' ' ASP . . . . . 0.582 ' OD1' ' HB3' ' A' ' 13' ' ' ASN . 0.7 OUTLIER -120.7 142.86 49.11 Favored 'General case' 0 N--CA 1.464 0.269 0 CA-C-N 115.693 -0.685 . . . . 0.0 109.992 178.557 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 22.5 m -90.89 13.76 1.63 Allowed 'Isoleucine or valine' 0 CA--C 1.543 0.677 0 CA-C-N 115.924 -0.58 . . . . 0.0 111.501 -179.337 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 46.0 mt-10 -96.94 -51.91 4.07 Favored 'General case' 0 C--O 1.235 0.327 0 CA-C-N 116.158 -0.474 . . . . 0.0 111.986 -178.802 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 12' ' ' PHE . . . . . . . . . . . . . 6.8 t80 -145.16 -21.49 0.49 Allowed 'General case' 0 N--CA 1.472 0.639 0 N-CA-C 112.671 0.619 . . . . 0.0 112.671 -178.845 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 13' ' ' ASN . . . . . 0.582 ' HB3' ' OD1' ' A' ' 9' ' ' ASP . 13.3 t30 -119.91 75.19 20.52 Favored Pre-proline 0 CA--C 1.548 0.887 0 CA-C-N 117.557 0.162 . . . . 0.0 111.336 -179.017 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 62.7 Cg_endo -76.85 -175.87 2.86 Favored 'Trans proline' 0 C--N 1.37 1.679 0 C-N-CA 122.663 2.242 . . . . 0.0 112.204 178.672 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 0.8 OUTLIER -79.99 121.56 25.64 Favored 'General case' 0 N--CA 1.471 0.603 0 CA-C-O 120.462 0.172 . . . . 0.0 111.168 179.9 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER -58.17 -53.52 65.15 Favored Pre-proline 0 N--CA 1.479 0.978 0 CA-C-O 119.049 -0.501 . . . . 0.0 111.568 179.117 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 41.7 Cg_endo -67.75 169.69 15.56 Favored 'Trans proline' 0 C--N 1.38 2.22 0 C-N-CA 122.104 1.869 . . . . 0.0 111.865 178.202 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 55.3 Cg_endo -71.77 47.69 0.98 Allowed 'Trans proline' 0 C--N 1.373 1.818 0 C-N-CA 121.981 1.787 . . . . 0.0 112.735 178.731 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 19.4 mt -108.78 165.38 11.6 Favored 'General case' 0 C--O 1.235 0.332 0 CA-C-N 115.681 -0.691 . . . . 0.0 111.272 -179.359 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 20' ' ' THR . . . . . 0.511 ' O ' ' HA ' ' A' ' 30' ' ' CYS . 30.5 m -103.19 152.37 21.54 Favored 'General case' 0 CA--C 1.531 0.227 0 CA-C-N 115.623 -0.717 . . . . 0.0 111.084 -178.902 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 2.2 t -102.45 99.75 9.82 Favored 'General case' 0 C--O 1.237 0.445 0 CA-C-N 115.719 -0.673 . . . . 0.0 109.6 178.837 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 22' ' ' ILE . . . . . . . . . . . . . 2.9 mt -120.91 128.73 25.63 Favored Pre-proline 0 CA--C 1.541 0.615 0 CA-C-N 115.677 -0.692 . . . . 0.0 110.4 -179.026 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 37.1 Cg_endo -66.92 -47.36 0.26 Allowed 'Cis proline' 0 C--N 1.374 1.919 0 C-N-CA 124.636 -0.985 . . . . 0.0 113.859 -0.112 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 79.03 33.99 34.89 Favored Glycine 0 C--N 1.348 1.196 0 C-N-CA 121.228 -0.51 . . . . 0.0 112.916 179.961 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 8.3 m-20 -139.68 83.24 16.99 Favored Pre-proline 0 CA--C 1.544 0.721 0 C-N-CA 122.576 0.35 . . . . 0.0 110.647 -179.793 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 3.2 Cg_exo -80.7 -31.92 4.26 Favored 'Cis proline' 0 C--N 1.371 1.729 0 C-N-CA 125.102 -0.791 . . . . 0.0 112.957 -0.005 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 27' ' ' TYR . . . . . 0.553 ' CD2' ' HB3' ' A' ' 9' ' ' ASP . 62.6 m-85 -106.96 172.66 6.7 Favored 'General case' 0 C--O 1.238 0.49 0 CA-C-N 115.737 -0.665 . . . . 0.0 111.705 -178.957 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 28' ' ' GLY . . . . . 0.661 ' O ' ' HA ' ' A' ' 7' ' ' GLN . . . -176.45 -164.17 30.06 Favored Glycine 0 C--N 1.34 0.771 0 CA-C-N 115.74 -0.664 . . . . 0.0 112.559 178.474 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 29' ' ' ILE . . . . . 0.535 ' HB ' ' CE2' ' A' ' 31' ' ' TYR . 2.6 mm -114.68 151.35 16.44 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 O-C-N 123.75 0.324 . . . . 0.0 110.155 -179.733 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 30' ' ' CYS . . . . . 0.511 ' HA ' ' O ' ' A' ' 20' ' ' THR . 41.4 m -79.82 105.72 11.31 Favored 'General case' 0 C--O 1.237 0.425 0 CA-C-N 115.981 -0.554 . . . . 0.0 111.399 -179.729 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 31' ' ' TYR . . . . . 0.535 ' CE2' ' HB ' ' A' ' 29' ' ' ILE . 37.1 m-85 -130.48 167.18 19.04 Favored 'General case' 0 C--O 1.233 0.205 0 CA-C-N 114.989 -1.005 . . . . 0.0 111.018 -179.566 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 2.9 tp -99.63 130.2 49.04 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.584 0 CA-C-N 116.121 -0.491 . . . . 0.0 110.343 179.562 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 33' ' ' ILE . . . . . 0.455 ' O ' HD12 ' A' ' 33' ' ' ILE . 1.9 pp . . . . . 0 C--O 1.249 1.051 0 CA-C-O 118.331 -0.843 . . . . 0.0 111.521 179.858 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 2' ' ' PRO . . . . . 0.43 ' HD3' ' ND2' ' A' ' 13' ' ' ASN . 97.6 Cg_endo . . . . . 0 CA--C 1.544 1.013 0 N-CA-C 112.965 0.333 . . . . 0.0 112.965 . . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -145.12 -154.99 6.29 Favored Glycine 0 C--N 1.339 0.727 0 N-CA-C 111.78 -0.528 . . . . 0.0 111.78 179.393 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 17.9 tt0 -73.3 128.85 36.66 Favored 'General case' 0 N--CA 1.472 0.674 0 C-N-CA 122.565 0.346 . . . . 0.0 111.186 179.581 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 86.31 16.06 63.2 Favored Glycine 0 C--N 1.34 0.789 0 CA-C-N 115.784 -0.643 . . . . 0.0 113.184 -179.862 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 43.0 mt-10 -127.42 161.69 28.1 Favored 'General case' 0 N--CA 1.466 0.367 0 C-N-CA 122.312 0.245 . . . . 0.0 110.804 -179.859 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 7' ' ' GLN . . . . . 0.683 ' HA ' ' O ' ' A' ' 28' ' ' GLY . 19.3 tt0 -85.36 134.53 34.09 Favored 'General case' 0 C--N 1.346 0.415 0 CA-C-O 121.166 0.507 . . . . 0.0 111.256 179.978 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 8' ' ' CYS . . . . . 0.404 ' SG ' ' SG ' ' A' ' 30' ' ' CYS . 3.1 p -127.72 160.24 32.28 Favored 'General case' 0 C--O 1.237 0.447 0 CA-C-N 114.593 -1.185 . . . . 0.0 111.036 -179.553 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 9' ' ' ASP . . . . . 0.439 ' OD2' ' HB2' ' A' ' 11' ' ' GLU . 15.8 t70 -115.42 147.64 40.33 Favored 'General case' 0 C--O 1.234 0.26 0 CA-C-N 115.475 -0.784 . . . . 0.0 109.53 178.762 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 15.5 m -97.45 22.23 1.16 Allowed 'Isoleucine or valine' 0 CA--C 1.543 0.689 0 CA-C-N 116.312 -0.404 . . . . 0.0 111.963 -179.451 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 11' ' ' GLU . . . . . 0.439 ' HB2' ' OD2' ' A' ' 9' ' ' ASP . 44.1 mt-10 -119.68 -52.68 2.23 Favored 'General case' 0 N--CA 1.466 0.371 0 N-CA-C 112.372 0.508 . . . . 0.0 112.372 -179.068 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 12' ' ' PHE . . . . . . . . . . . . . 13.6 t80 -137.83 -8.98 1.6 Allowed 'General case' 0 N--CA 1.47 0.559 0 N-CA-C 112.649 0.611 . . . . 0.0 112.649 -178.659 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 13' ' ' ASN . . . . . 0.43 ' ND2' ' HD3' ' A' ' 2' ' ' PRO . 6.0 t30 -129.65 63.81 69.45 Favored Pre-proline 0 CA--C 1.548 0.904 0 N-CA-C 111.579 0.214 . . . . 0.0 111.579 -179.195 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 13.6 Cg_exo -70.23 176.78 6.67 Favored 'Trans proline' 0 C--N 1.372 1.767 0 C-N-CA 122.801 2.334 . . . . 0.0 112.06 178.914 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 1.0 OUTLIER -79.84 121.04 24.91 Favored 'General case' 0 N--CA 1.469 0.499 0 CA-C-O 120.453 0.168 . . . . 0.0 111.155 179.983 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER -57.75 -53.01 70.18 Favored Pre-proline 0 N--CA 1.477 0.924 0 CA-C-O 118.985 -0.531 . . . . 0.0 111.535 179.316 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 44.8 Cg_endo -68.67 169.53 17.25 Favored 'Trans proline' 0 C--N 1.379 2.133 0 C-N-CA 122.102 1.868 . . . . 0.0 111.747 178.008 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 55.7 Cg_endo -72.27 48.81 1.27 Allowed 'Trans proline' 0 C--N 1.372 1.785 0 C-N-CA 122.011 1.808 . . . . 0.0 112.701 178.759 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 20.5 mt -109.61 167.6 10.02 Favored 'General case' 0 C--O 1.236 0.356 0 CA-C-N 115.692 -0.685 . . . . 0.0 111.316 -179.309 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 20' ' ' THR . . . . . 0.51 ' O ' ' HA ' ' A' ' 30' ' ' CYS . 32.6 m -105.03 153.37 21.55 Favored 'General case' 0 CA--C 1.532 0.279 0 CA-C-N 115.622 -0.717 . . . . 0.0 111.059 -178.794 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 1.9 t -102.71 103.27 13.5 Favored 'General case' 0 C--O 1.238 0.487 0 CA-C-N 115.672 -0.694 . . . . 0.0 109.672 178.861 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 22' ' ' ILE . . . . . . . . . . . . . 2.8 mt -125.33 129.1 24.57 Favored Pre-proline 0 CA--C 1.542 0.646 0 CA-C-N 115.774 -0.648 . . . . 0.0 110.24 -179.094 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 38.1 Cg_endo -67.43 -48.47 0.24 Allowed 'Cis proline' 0 C--N 1.374 1.897 0 C-N-CA 124.74 -0.942 . . . . 0.0 113.895 -0.113 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 81.26 36.86 19.79 Favored Glycine 0 C--N 1.347 1.141 0 C-N-CA 121.192 -0.528 . . . . 0.0 112.959 -179.927 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 4.6 t70 -139.78 82.23 18.22 Favored Pre-proline 0 CA--C 1.548 0.884 0 C-N-CA 122.454 0.301 . . . . 0.0 110.376 -179.818 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 2.6 Cg_endo -81.06 -31.72 4.33 Favored 'Cis proline' 0 C--N 1.371 1.761 0 C-N-CA 125.113 -0.786 . . . . 0.0 112.951 0.104 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 27' ' ' TYR . . . . . . . . . . . . . 60.3 m-85 -106.55 174.12 6.02 Favored 'General case' 0 C--O 1.238 0.475 0 CA-C-N 115.748 -0.66 . . . . 0.0 111.558 -179.037 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 28' ' ' GLY . . . . . 0.683 ' O ' ' HA ' ' A' ' 7' ' ' GLN . . . -175.22 -162.08 25.91 Favored Glycine 0 CA--C 1.502 -0.737 0 CA-C-N 115.627 -0.715 . . . . 0.0 112.561 178.397 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 29' ' ' ILE . . . . . 0.528 ' HB ' ' CE2' ' A' ' 31' ' ' TYR . 2.7 mm -115.35 150.36 17.32 Favored 'Isoleucine or valine' 0 C--O 1.234 0.257 0 N-CA-C 110.059 -0.349 . . . . 0.0 110.059 -179.86 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 30' ' ' CYS . . . . . 0.51 ' HA ' ' O ' ' A' ' 20' ' ' THR . 32.2 m -79.9 105.18 10.99 Favored 'General case' 0 C--O 1.236 0.372 0 CA-C-O 121.372 0.606 . . . . 0.0 111.408 -179.745 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 31' ' ' TYR . . . . . 0.528 ' CE2' ' HB ' ' A' ' 29' ' ' ILE . 37.1 m-85 -129.57 167.93 17.18 Favored 'General case' 0 C--O 1.234 0.28 0 CA-C-N 114.922 -1.036 . . . . 0.0 111.085 -179.466 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 2.7 tp -100.25 130.71 49.04 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.617 0 CA-C-N 116.275 -0.421 . . . . 0.0 110.317 179.402 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 33' ' ' ILE . . . . . 0.451 ' OXT' HD13 ' A' ' 33' ' ' ILE . 1.9 pp . . . . . 0 C--O 1.249 1.031 0 CA-C-O 118.206 -0.902 . . . . 0.0 111.454 179.911 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 2' ' ' PRO . . . . . 0.433 ' HD3' ' ND2' ' A' ' 13' ' ' ASN . 98.3 Cg_endo . . . . . 0 CA--C 1.545 1.045 0 N-CA-C 112.939 0.323 . . . . 0.0 112.939 . . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -145.7 -155.47 6.5 Favored Glycine 0 C--N 1.338 0.676 0 N-CA-C 111.901 -0.48 . . . . 0.0 111.901 179.386 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 18.0 tt0 -73.35 129.52 38.19 Favored 'General case' 0 N--CA 1.474 0.738 0 C-N-CA 122.536 0.334 . . . . 0.0 111.198 179.658 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 85.6 16.28 64.25 Favored Glycine 0 C--N 1.339 0.748 0 CA-C-N 115.741 -0.663 . . . . 0.0 113.196 -179.849 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 43.1 mt-10 -127.61 161.49 28.73 Favored 'General case' 0 C--O 1.237 0.447 0 C-N-CA 122.188 0.195 . . . . 0.0 110.824 -179.862 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 7' ' ' GLN . . . . . 0.688 ' HA ' ' O ' ' A' ' 28' ' ' GLY . 18.7 tt0 -84.94 134.24 34.26 Favored 'General case' 0 C--N 1.345 0.381 0 CA-C-O 121.228 0.537 . . . . 0.0 111.293 179.804 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 8' ' ' CYS . . . . . 0.411 ' SG ' ' SG ' ' A' ' 30' ' ' CYS . 3.7 p -127.99 160.62 31.34 Favored 'General case' 0 C--O 1.237 0.447 0 CA-C-N 114.584 -1.189 . . . . 0.0 111.116 -179.383 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 9' ' ' ASP . . . . . 0.435 ' OD2' ' HB2' ' A' ' 11' ' ' GLU . 15.7 t70 -114.7 151.72 33.17 Favored 'General case' 0 C--O 1.236 0.352 0 CA-C-N 115.496 -0.774 . . . . 0.0 109.497 178.623 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 15.6 m -102.37 16.8 4.69 Favored 'Isoleucine or valine' 0 CA--C 1.544 0.717 0 N-CA-C 111.912 0.338 . . . . 0.0 111.912 -179.339 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 11' ' ' GLU . . . . . 0.435 ' HB2' ' OD2' ' A' ' 9' ' ' ASP . 9.5 mm-40 -110.34 -52.49 2.78 Favored 'General case' 0 N--CA 1.466 0.326 0 N-CA-C 112.082 0.401 . . . . 0.0 112.082 -178.979 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 12' ' ' PHE . . . . . . . . . . . . . 10.9 t80 -137.74 -17.51 1.26 Allowed 'General case' 0 N--CA 1.469 0.52 0 N-CA-C 112.589 0.588 . . . . 0.0 112.589 -178.812 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 13' ' ' ASN . . . . . 0.433 ' ND2' ' HD3' ' A' ' 2' ' ' PRO . 7.9 t30 -120.21 73.43 20.23 Favored Pre-proline 0 CA--C 1.547 0.851 0 N-CA-C 111.373 0.138 . . . . 0.0 111.373 -179.184 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 60.4 Cg_endo -76.79 177.6 8.65 Favored 'Trans proline' 0 C--N 1.371 1.729 0 C-N-CA 122.352 2.035 . . . . 0.0 112.314 179.027 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 1.3 t -79.79 120.2 23.72 Favored 'General case' 0 N--CA 1.471 0.605 0 CA-C-O 120.508 0.194 . . . . 0.0 110.911 179.895 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER -56.94 -53.44 65.11 Favored Pre-proline 0 N--CA 1.477 0.89 0 CA-C-O 119.09 -0.481 . . . . 0.0 111.634 179.425 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 44.8 Cg_endo -68.62 169.25 17.79 Favored 'Trans proline' 0 C--N 1.379 2.163 0 C-N-CA 122.152 1.901 . . . . 0.0 111.789 178.057 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 55.6 Cg_endo -72.3 50.46 1.57 Allowed 'Trans proline' 0 C--N 1.371 1.755 0 C-N-CA 122.085 1.857 . . . . 0.0 112.538 178.728 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 20.9 mt -111.41 167.92 9.93 Favored 'General case' 0 C--O 1.235 0.317 0 CA-C-N 115.626 -0.716 . . . . 0.0 111.383 -179.386 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 20' ' ' THR . . . . . 0.506 ' O ' ' HA ' ' A' ' 30' ' ' CYS . 33.5 m -105.6 153.47 21.74 Favored 'General case' 0 CA--C 1.533 0.291 0 CA-C-N 115.622 -0.717 . . . . 0.0 110.995 -178.774 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 2.0 t -102.77 103.36 13.57 Favored 'General case' 0 C--O 1.236 0.389 0 CA-C-N 115.709 -0.678 . . . . 0.0 109.676 178.932 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 22' ' ' ILE . . . . . . . . . . . . . 2.8 mt -125.43 129.13 24.53 Favored Pre-proline 0 CA--C 1.542 0.635 0 CA-C-N 115.754 -0.657 . . . . 0.0 110.259 -178.99 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 38.1 Cg_endo -67.69 -48.15 0.26 Allowed 'Cis proline' 0 C--N 1.375 1.933 0 C-N-CA 124.688 -0.963 . . . . 0.0 113.906 0.056 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 81.58 36.45 19.84 Favored Glycine 0 C--N 1.348 1.202 0 C-N-CA 121.153 -0.546 . . . . 0.0 112.899 -179.968 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 8.4 m-20 -139.91 82.73 17.16 Favored Pre-proline 0 CA--C 1.544 0.726 0 C-N-CA 122.587 0.355 . . . . 0.0 110.636 -179.743 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 2.9 Cg_endo -80.37 -32.06 4.23 Favored 'Cis proline' 0 C--N 1.372 1.773 0 C-N-CA 125.134 -0.778 . . . . 0.0 112.933 -0.118 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 27' ' ' TYR . . . . . . . . . . . . . 59.6 m-85 -107.24 175.06 5.62 Favored 'General case' 0 C--O 1.239 0.535 0 CA-C-N 115.785 -0.643 . . . . 0.0 111.643 -179.014 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 28' ' ' GLY . . . . . 0.688 ' O ' ' HA ' ' A' ' 7' ' ' GLN . . . -175.7 -161.18 24.59 Favored Glycine 0 CA--C 1.504 -0.609 0 CA-C-N 115.734 -0.666 . . . . 0.0 112.574 178.468 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 29' ' ' ILE . . . . . 0.534 ' HB ' ' CE2' ' A' ' 31' ' ' TYR . 2.7 mm -115.83 150.04 17.9 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 O-C-N 123.801 0.354 . . . . 0.0 110.067 -179.738 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 30' ' ' CYS . . . . . 0.506 ' HA ' ' O ' ' A' ' 20' ' ' THR . 23.7 m -79.88 104.99 10.83 Favored 'General case' 0 CA--C 1.535 0.402 0 CA-C-O 121.319 0.581 . . . . 0.0 111.303 -179.767 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 31' ' ' TYR . . . . . 0.534 ' CE2' ' HB ' ' A' ' 29' ' ' ILE . 36.7 m-85 -129.25 168.08 16.72 Favored 'General case' 0 C--O 1.233 0.197 0 CA-C-N 114.889 -1.051 . . . . 0.0 111.019 -179.465 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 2.7 tp -100.29 130.9 48.79 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.627 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.277 179.449 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 33' ' ' ILE . . . . . 0.501 ' CG1' ' HG1' ' A' ' 20' ' ' THR . 1.9 pp . . . . . 0 C--O 1.249 1.061 0 CA-C-O 118.328 -0.844 . . . . 0.0 111.479 179.865 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 2' ' ' PRO . . . . . 0.58 ' HD2' ' O ' ' A' ' 14' ' ' PRO . 73.4 Cg_endo . . . . . 0 N--CA 1.488 1.191 0 N-CA-C 113.9 0.692 . . . . 0.0 113.9 . . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -142.76 -159.52 7.98 Favored Glycine 0 C--N 1.342 0.888 0 O-C-N 123.544 0.528 . . . . 0.0 112.487 179.832 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 17.4 tt0 -68.42 122.51 18.57 Favored 'General case' 0 N--CA 1.474 0.73 0 C-N-CA 122.816 0.447 . . . . 0.0 111.515 -179.925 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 92.41 14.54 55.52 Favored Glycine 0 C--N 1.341 0.82 0 CA-C-N 115.578 -0.737 . . . . 0.0 113.243 -179.882 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 43.1 mt-10 -127.42 165.64 19.41 Favored 'General case' 0 C--O 1.239 0.546 0 C-N-CA 122.438 0.295 . . . . 0.0 110.946 179.962 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 7' ' ' GLN . . . . . 0.52 ' HA ' ' O ' ' A' ' 28' ' ' GLY . 0.9 OUTLIER -83.46 145.55 28.89 Favored 'General case' 0 N--CA 1.469 0.478 0 CA-C-N 116.357 -0.383 . . . . 0.0 111.372 179.886 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 8.1 p -139.18 155.38 47.87 Favored 'General case' 0 C--O 1.237 0.44 0 CA-C-N 115.544 -0.753 . . . . 0.0 111.317 -179.786 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 6.9 t70 -118.87 153.13 35.03 Favored 'General case' 0 C--O 1.236 0.364 0 CA-C-N 115.42 -0.809 . . . . 0.0 109.652 179.045 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 14.9 m -101.86 20.89 2.47 Favored 'Isoleucine or valine' 0 CA--C 1.544 0.746 0 CA-C-N 116.296 -0.411 . . . . 0.0 111.99 -179.404 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 44.6 mt-10 -117.8 -53.03 2.42 Favored 'General case' 0 N--CA 1.465 0.32 0 N-CA-C 112.319 0.489 . . . . 0.0 112.319 -179.252 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 12' ' ' PHE . . . . . . . . . . . . . 15.7 t80 -138.96 -7.28 1.4 Allowed 'General case' 0 N--CA 1.47 0.574 0 N-CA-C 112.58 0.585 . . . . 0.0 112.58 -178.771 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 13' ' ' ASN . . . . . . . . . . . . . 8.6 t30 -129.44 63.47 67.83 Favored Pre-proline 0 CA--C 1.551 1.006 0 N-CA-C 111.369 0.137 . . . . 0.0 111.369 -179.093 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 14' ' ' PRO . . . . . 0.58 ' O ' ' HD2' ' A' ' 2' ' ' PRO . 15.8 Cg_exo -69.08 177.7 4.86 Favored 'Trans proline' 0 C--N 1.372 1.812 0 C-N-CA 122.733 2.288 . . . . 0.0 112.253 179.282 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 1.5 m -79.45 119.6 22.68 Favored 'General case' 0 N--CA 1.471 0.577 0 C-N-CA 122.382 0.273 . . . . 0.0 111.352 -179.848 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 16' ' ' CYS . . . . . 0.551 ' HB2' ' O ' ' A' ' 2' ' ' PRO . 0.0 OUTLIER -57.36 -53.2 67.98 Favored Pre-proline 0 N--CA 1.481 1.112 0 CA-C-N 115.971 -0.559 . . . . 0.0 111.518 179.548 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 57.7 Cg_endo -72.72 169.34 22.21 Favored 'Trans proline' 0 C--N 1.38 2.205 0 C-N-CA 122.042 1.828 . . . . 0.0 111.8 178.168 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 55.8 Cg_endo -72.21 44.54 0.7 Allowed 'Trans proline' 0 C--N 1.371 1.759 0 C-N-CA 122.034 1.823 . . . . 0.0 112.956 178.86 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 19' ' ' LEU . . . . . 0.426 ' HB2' ' SG ' ' A' ' 30' ' ' CYS . 12.9 mt -104.43 172.78 6.61 Favored 'General case' 0 CA--C 1.534 0.336 0 CA-C-N 115.875 -0.602 . . . . 0.0 110.917 -179.634 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 25.5 m -103.38 150.2 24.04 Favored 'General case' 0 CA--C 1.534 0.335 0 CA-C-N 115.934 -0.575 . . . . 0.0 111.034 -178.793 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 5.5 t -100.32 103.13 14.53 Favored 'General case' 0 C--O 1.237 0.427 0 CA-C-N 115.874 -0.603 . . . . 0.0 109.381 178.491 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 22' ' ' ILE . . . . . . . . . . . . . 2.5 mt -127.36 129.27 23.91 Favored Pre-proline 0 CA--C 1.543 0.697 0 CA-C-N 115.825 -0.625 . . . . 0.0 110.72 -178.462 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 38.0 Cg_endo -67.94 -48.55 0.25 Allowed 'Cis proline' 0 C--N 1.374 1.902 0 C-N-CA 124.77 -0.929 . . . . 0.0 113.71 -0.441 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 79.67 37.13 24.11 Favored Glycine 0 C--N 1.346 1.137 0 C-N-CA 121.39 -0.434 . . . . 0.0 112.835 179.954 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 8.4 m-20 -140.31 81.25 18.24 Favored Pre-proline 0 CA--C 1.544 0.721 0 C-N-CA 122.477 0.311 . . . . 0.0 110.837 -179.694 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 2.2 Cg_endo -81.62 -32.17 3.85 Favored 'Cis proline' 0 C--N 1.372 1.787 0 C-N-CA 125.027 -0.822 . . . . 0.0 112.928 -0.166 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 27' ' ' TYR . . . . . . . . . . . . . 66.7 m-85 -102.35 173.29 6.43 Favored 'General case' 0 C--O 1.238 0.496 0 CA-C-N 115.77 -0.65 . . . . 0.0 111.561 -179.125 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 28' ' ' GLY . . . . . 0.52 ' O ' ' HA ' ' A' ' 7' ' ' GLN . . . -175.59 -159.31 21.32 Favored Glycine 0 C--N 1.338 0.658 0 CA-C-N 115.75 -0.659 . . . . 0.0 112.451 178.974 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 29' ' ' ILE . . . . . 0.544 ' HB ' ' CE2' ' A' ' 31' ' ' TYR . 1.3 mm -123.17 152.13 27.85 Favored 'Isoleucine or valine' 0 C--O 1.235 0.332 0 N-CA-C 109.882 -0.414 . . . . 0.0 109.882 179.713 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 30' ' ' CYS . . . . . 0.426 ' SG ' ' HB2' ' A' ' 19' ' ' LEU . 0.5 OUTLIER -80.07 106.92 12.44 Favored 'General case' 0 C--O 1.238 0.472 0 CA-C-N 116.029 -0.532 . . . . 0.0 110.923 -179.975 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 31' ' ' TYR . . . . . 0.544 ' CE2' ' HB ' ' A' ' 29' ' ' ILE . 36.2 m-85 -132.11 167.04 20.43 Favored 'General case' 0 N--CA 1.466 0.334 0 CA-C-N 115.534 -0.757 . . . . 0.0 111.088 -179.251 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 2.8 tp -101.88 131.8 49.09 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.614 0 CA-C-N 116.081 -0.509 . . . . 0.0 110.347 179.458 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 33' ' ' ILE . . . . . 0.447 ' O ' HD11 ' A' ' 33' ' ' ILE . 1.9 pp . . . . . 0 C--O 1.247 0.961 0 CA-C-O 118.357 -0.83 . . . . 0.0 111.399 179.976 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 2' ' ' PRO . . . . . 0.484 ' HD3' HD22 ' A' ' 13' ' ' ASN . 95.6 Cg_endo . . . . . 0 CA--C 1.545 1.043 0 N-CA-C 112.937 0.322 . . . . 0.0 112.937 . . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -145.39 -154.0 6.03 Favored Glycine 0 C--N 1.339 0.711 0 N-CA-C 111.813 -0.515 . . . . 0.0 111.813 179.493 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 18.5 tt0 -73.27 129.68 38.55 Favored 'General case' 0 N--CA 1.472 0.667 0 C-N-CA 122.68 0.392 . . . . 0.0 111.319 179.596 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 85.92 15.45 65.2 Favored Glycine 0 C--N 1.34 0.754 0 CA-C-N 115.793 -0.639 . . . . 0.0 113.554 -179.984 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 12.7 tt0 -126.87 161.9 27.18 Favored 'General case' 0 C--O 1.238 0.462 0 CA-C-N 116.604 0.202 . . . . 0.0 110.656 -179.842 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 7' ' ' GLN . . . . . 0.647 ' HA ' ' O ' ' A' ' 28' ' ' GLY . 18.6 tt0 -86.81 136.35 33.01 Favored 'General case' 0 C--N 1.344 0.331 0 CA-C-O 121.218 0.533 . . . . 0.0 111.407 179.962 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 8' ' ' CYS . . . . . 0.405 ' SG ' ' SG ' ' A' ' 30' ' ' CYS . 2.6 p -130.65 161.34 31.83 Favored 'General case' 0 C--O 1.239 0.517 0 CA-C-N 114.465 -1.243 . . . . 0.0 111.023 -179.58 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 9' ' ' ASP . . . . . 0.581 ' OD1' ' HB3' ' A' ' 13' ' ' ASN . 0.7 OUTLIER -120.52 143.54 48.52 Favored 'General case' 0 N--CA 1.465 0.276 0 CA-C-N 115.687 -0.688 . . . . 0.0 110.09 178.494 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 22.3 m -92.02 14.63 1.69 Allowed 'Isoleucine or valine' 0 CA--C 1.542 0.655 0 CA-C-N 116.083 -0.508 . . . . 0.0 111.509 -179.245 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 9.9 mm-40 -98.68 -51.56 3.88 Favored 'General case' 0 C--O 1.234 0.283 0 CA-C-N 116.159 -0.473 . . . . 0.0 112.085 -178.789 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 12' ' ' PHE . . . . . . . . . . . . . 6.9 t80 -144.09 -22.84 0.56 Allowed 'General case' 0 N--CA 1.472 0.67 0 N-CA-C 112.698 0.629 . . . . 0.0 112.698 -178.877 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 13' ' ' ASN . . . . . 0.581 ' HB3' ' OD1' ' A' ' 9' ' ' ASP . 13.9 t30 -119.32 75.74 16.64 Favored Pre-proline 0 CA--C 1.548 0.901 0 CA-C-N 117.539 0.154 . . . . 0.0 111.355 -178.969 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 61.7 Cg_endo -76.77 -176.09 2.97 Favored 'Trans proline' 0 C--N 1.372 1.763 0 C-N-CA 122.542 2.162 . . . . 0.0 112.22 178.676 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 0.9 OUTLIER -79.94 121.76 25.85 Favored 'General case' 0 N--CA 1.471 0.609 0 CA-C-O 120.454 0.168 . . . . 0.0 111.252 179.95 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER -58.38 -53.76 62.79 Favored Pre-proline 0 N--CA 1.478 0.949 0 CA-C-N 116.124 -0.489 . . . . 0.0 111.552 179.115 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 44.0 Cg_endo -67.8 169.79 15.41 Favored 'Trans proline' 0 C--N 1.379 2.171 0 C-N-CA 122.187 1.925 . . . . 0.0 111.851 178.21 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 55.5 Cg_endo -72.08 47.46 1.03 Allowed 'Trans proline' 0 C--N 1.371 1.724 0 C-N-CA 122.027 1.818 . . . . 0.0 112.792 178.839 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 42.9 mt -108.68 166.3 10.9 Favored 'General case' 0 C--O 1.234 0.266 0 CA-C-N 115.926 -0.579 . . . . 0.0 111.201 -179.588 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 20' ' ' THR . . . . . 0.502 ' O ' ' HA ' ' A' ' 30' ' ' CYS . 33.5 m -103.58 152.74 21.38 Favored 'General case' 0 CA--C 1.532 0.287 0 CA-C-N 115.503 -0.771 . . . . 0.0 110.962 -178.848 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 2.3 t -102.44 99.93 10.02 Favored 'General case' 0 C--O 1.239 0.535 0 CA-C-N 115.725 -0.67 . . . . 0.0 109.601 178.841 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 22' ' ' ILE . . . . . . . . . . . . . 3.0 mt -121.04 128.7 25.62 Favored Pre-proline 0 CA--C 1.541 0.622 0 CA-C-N 115.783 -0.644 . . . . 0.0 110.424 -178.976 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 37.1 Cg_endo -66.89 -47.47 0.26 Allowed 'Cis proline' 0 C--N 1.375 1.958 0 C-N-CA 124.69 -0.962 . . . . 0.0 113.874 -0.187 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 78.92 34.4 34.1 Favored Glycine 0 C--N 1.346 1.131 0 C-N-CA 121.379 -0.438 . . . . 0.0 112.942 179.977 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 4.6 t70 -139.91 83.05 16.69 Favored Pre-proline 0 CA--C 1.546 0.823 0 C-N-CA 122.607 0.363 . . . . 0.0 110.345 -179.68 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 3.2 Cg_exo -80.86 -32.02 4.15 Favored 'Cis proline' 0 C--N 1.371 1.743 0 C-N-CA 125.095 -0.794 . . . . 0.0 112.895 0.036 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 27' ' ' TYR . . . . . 0.55 ' CD2' ' HB3' ' A' ' 9' ' ' ASP . 63.6 m-85 -106.91 172.68 6.69 Favored 'General case' 0 CA--C 1.537 0.448 0 CA-C-N 115.838 -0.619 . . . . 0.0 111.592 -178.892 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 28' ' ' GLY . . . . . 0.647 ' O ' ' HA ' ' A' ' 7' ' ' GLN . . . -176.53 -163.88 29.64 Favored Glycine 0 C--N 1.339 0.716 0 CA-C-N 115.629 -0.714 . . . . 0.0 112.636 178.558 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 29' ' ' ILE . . . . . 0.534 ' HB ' ' CE2' ' A' ' 31' ' ' TYR . 2.5 mm -114.68 151.15 16.47 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 O-C-N 123.748 0.322 . . . . 0.0 110.259 -179.898 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 30' ' ' CYS . . . . . 0.502 ' HA ' ' O ' ' A' ' 20' ' ' THR . 33.9 m -79.88 105.42 11.15 Favored 'General case' 0 CA--C 1.535 0.392 0 CA-C-O 121.328 0.585 . . . . 0.0 111.365 -179.717 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 31' ' ' TYR . . . . . 0.534 ' CE2' ' HB ' ' A' ' 29' ' ' ILE . 37.1 m-85 -130.28 166.88 19.43 Favored 'General case' 0 C--O 1.233 0.193 0 CA-C-N 114.917 -1.038 . . . . 0.0 111.02 -179.472 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 2.9 tp -99.59 130.24 48.93 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.604 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.372 179.496 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 33' ' ' ILE . . . . . 0.464 HG12 ' OG1' ' A' ' 20' ' ' THR . 1.4 pt . . . . . 0 C--O 1.249 1.045 0 CA-C-O 118.136 -0.935 . . . . 0.0 111.463 179.883 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 2' ' ' PRO . . . . . 0.544 ' HD3' ' ND2' ' A' ' 13' ' ' ASN . 95.1 Cg_endo . . . . . 0 CA--C 1.543 0.933 0 N-CA-C 112.827 0.28 . . . . 0.0 112.827 . . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -147.3 -161.39 9.38 Favored Glycine 0 C--N 1.337 0.632 0 N-CA-C 111.593 -0.603 . . . . 0.0 111.593 179.216 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 19.0 tt0 -68.33 124.06 22.46 Favored 'General case' 0 N--CA 1.473 0.679 0 C-N-CA 122.548 0.339 . . . . 0.0 111.183 179.851 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 91.28 14.69 56.99 Favored Glycine 0 C--N 1.338 0.682 0 CA-C-N 115.646 -0.706 . . . . 0.0 113.228 -179.699 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 6' ' ' GLU . . . . . 0.446 ' HG2' ' NE2' ' A' ' 7' ' ' GLN . 13.9 tt0 -129.0 166.18 19.7 Favored 'General case' 0 C--O 1.238 0.479 0 C-N-CA 122.287 0.235 . . . . 0.0 110.599 -179.933 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 7' ' ' GLN . . . . . 0.446 ' NE2' ' HG2' ' A' ' 6' ' ' GLU . 0.2 OUTLIER -82.07 153.3 26.18 Favored 'General case' 0 C--N 1.346 0.433 0 O-C-N 123.288 0.367 . . . . 0.0 110.929 -179.876 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 3.3 p -142.64 151.8 41.81 Favored 'General case' 0 C--O 1.235 0.306 0 CA-C-N 115.817 -0.629 . . . . 0.0 111.297 -179.4 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -110.23 139.8 45.02 Favored 'General case' 0 C--O 1.234 0.253 0 CA-C-N 115.765 -0.652 . . . . 0.0 109.559 179.348 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 10' ' ' VAL . . . . . 0.479 HG21 ' O ' ' A' ' 26' ' ' PRO . 7.7 m -94.89 26.65 0.48 Allowed 'Isoleucine or valine' 0 CA--C 1.543 0.702 0 O-C-N 123.31 0.381 . . . . 0.0 111.635 -179.842 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 42.6 mt-10 -124.2 -52.26 1.75 Allowed 'General case' 0 N--CA 1.465 0.291 0 N-CA-C 112.251 0.464 . . . . 0.0 112.251 -179.135 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 12' ' ' PHE . . . . . . . . . . . . . 11.5 t80 -138.51 -10.38 1.41 Allowed 'General case' 0 N--CA 1.471 0.617 0 N-CA-C 112.833 0.679 . . . . 0.0 112.833 -178.627 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 13' ' ' ASN . . . . . 0.544 ' ND2' ' HD3' ' A' ' 2' ' ' PRO . 6.9 t30 -129.88 64.86 73.62 Favored Pre-proline 0 CA--C 1.549 0.928 0 CA-C-N 117.458 0.117 . . . . 0.0 111.206 -179.151 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 16.4 Cg_exo -68.86 179.81 2.98 Favored 'Trans proline' 0 C--N 1.373 1.843 0 C-N-CA 122.948 2.432 . . . . 0.0 112.22 179.141 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 15' ' ' CYS . . . . . 0.505 ' SG ' ' HB2' ' A' ' 19' ' ' LEU . 3.8 t -79.71 122.0 26.03 Favored 'General case' 0 N--CA 1.471 0.603 0 O-C-N 123.102 0.251 . . . . 0.0 111.247 -179.786 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER -60.85 -54.16 57.16 Favored Pre-proline 0 N--CA 1.476 0.855 0 CA-C-O 119.023 -0.513 . . . . 0.0 111.443 179.298 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 56.3 Cg_endo -70.95 169.27 20.84 Favored 'Trans proline' 0 C--N 1.379 2.176 0 C-N-CA 122.115 1.877 . . . . 0.0 111.702 178.173 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 49.7 Cg_endo -70.76 58.09 2.0 Allowed 'Trans proline' 0 C--N 1.371 1.748 0 C-N-CA 121.975 1.784 . . . . 0.0 112.909 179.01 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 19' ' ' LEU . . . . . 0.505 ' HB2' ' SG ' ' A' ' 15' ' ' CYS . 93.8 mt -118.19 167.8 11.17 Favored 'General case' 0 C--O 1.235 0.331 0 CA-C-N 115.704 -0.68 . . . . 0.0 111.24 -179.876 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 89.3 m -106.99 150.84 26.07 Favored 'General case' 0 CA--C 1.533 0.303 0 CA-C-N 115.315 -0.857 . . . . 0.0 110.94 -179.277 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 21' ' ' CYS . . . . . 0.497 ' HA ' ' O ' ' A' ' 29' ' ' ILE . 1.9 t -97.3 106.71 19.09 Favored 'General case' 0 C--O 1.238 0.476 0 CA-C-N 115.732 -0.667 . . . . 0.0 110.029 178.949 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 22' ' ' ILE . . . . . . . . . . . . . 5.7 mt -125.32 128.69 24.68 Favored Pre-proline 0 CA--C 1.543 0.697 0 CA-C-N 115.807 -0.633 . . . . 0.0 110.564 -179.16 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 37.3 Cg_endo -67.24 -47.78 0.26 Allowed 'Cis proline' 0 C--N 1.376 2.009 0 C-N-CA 124.681 -0.966 . . . . 0.0 113.81 -0.223 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 81.66 38.11 15.04 Favored Glycine 0 C--N 1.347 1.144 0 C-N-CA 121.332 -0.461 . . . . 0.0 112.88 179.822 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 8.0 m-20 -142.58 80.64 14.19 Favored Pre-proline 0 CA--C 1.546 0.817 0 C-N-CA 122.445 0.298 . . . . 0.0 111.052 -179.565 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 26' ' ' PRO . . . . . 0.479 ' O ' HG21 ' A' ' 10' ' ' VAL . 67.9 Cg_endo -84.08 -29.38 5.12 Favored 'Cis proline' 0 C--N 1.372 1.788 0 C-N-CA 124.698 -0.959 . . . . 0.0 113.439 -0.236 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 27' ' ' TYR . . . . . . . . . . . . . 57.0 m-85 -95.31 161.49 14.07 Favored 'General case' 0 N--CA 1.469 0.492 0 O-C-N 123.513 0.508 . . . . 0.0 111.304 -179.097 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 28' ' ' GLY . . . . . 0.424 ' O ' HD11 ' A' ' 29' ' ' ILE . . . -159.03 -161.91 11.53 Favored Glycine 0 C--N 1.341 0.842 0 C-N-CA 120.917 -0.659 . . . . 0.0 113.089 179.832 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 29' ' ' ILE . . . . . 0.497 ' O ' ' HA ' ' A' ' 21' ' ' CYS . 5.1 mm -129.95 155.17 41.31 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.238 0 N-CA-C 109.674 -0.491 . . . . 0.0 109.674 -179.932 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 30' ' ' CYS . . . . . . . . . . . . . 28.8 m -83.68 92.8 7.77 Favored 'General case' 0 CA--C 1.538 0.482 0 CA-C-O 121.368 0.604 . . . . 0.0 111.362 -179.955 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 31' ' ' TYR . . . . . 0.437 ' CE2' ' HB ' ' A' ' 29' ' ' ILE . 37.8 m-85 -124.33 166.81 15.28 Favored 'General case' 0 N--CA 1.464 0.26 0 CA-C-N 114.972 -1.013 . . . . 0.0 110.992 179.822 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 2.8 tp -99.76 131.49 47.05 Favored 'Isoleucine or valine' 0 CA--C 1.542 0.644 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.448 179.401 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 33' ' ' ILE . . . . . 0.455 HD12 ' OXT' ' A' ' 33' ' ' ILE . 1.8 pp . . . . . 0 C--O 1.249 1.056 0 CA-C-O 118.168 -0.92 . . . . 0.0 111.429 179.843 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 2' ' ' PRO . . . . . 0.595 ' HD2' ' O ' ' A' ' 14' ' ' PRO . 73.0 Cg_endo . . . . . 0 N--CA 1.488 1.192 0 N-CA-C 113.935 0.706 . . . . 0.0 113.935 . . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -143.5 -159.68 8.08 Favored Glycine 0 C--N 1.341 0.837 0 CA-C-N 116.146 -0.479 . . . . 0.0 112.477 179.83 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 16.7 tt0 -66.43 124.23 22.18 Favored 'General case' 0 N--CA 1.474 0.734 0 C-N-CA 122.841 0.456 . . . . 0.0 111.603 -179.711 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 95.03 -11.01 69.89 Favored Glycine 0 C--N 1.34 0.772 0 CA-C-N 115.641 -0.708 . . . . 0.0 113.282 -179.971 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 42.8 mt-10 -101.16 166.66 10.67 Favored 'General case' 0 C--O 1.24 0.601 0 C-N-CA 122.432 0.293 . . . . 0.0 110.967 -179.8 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 7' ' ' GLN . . . . . . . . . . . . . 0.2 OUTLIER -84.85 154.83 22.05 Favored 'General case' 0 C--N 1.346 0.446 0 CA-C-N 116.167 -0.47 . . . . 0.0 111.039 179.899 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 7.9 p -147.54 155.02 41.45 Favored 'General case' 0 N--CA 1.466 0.371 0 CA-C-N 115.886 -0.597 . . . . 0.0 111.511 -179.131 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 8.0 t70 -120.17 150.52 40.5 Favored 'General case' 0 C--O 1.234 0.275 0 CA-C-N 115.325 -0.852 . . . . 0.0 109.633 178.885 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 15.6 m -98.7 18.8 2.28 Favored 'Isoleucine or valine' 0 CA--C 1.543 0.677 0 CA-C-N 116.287 -0.415 . . . . 0.0 112.072 -179.41 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 46.2 mt-10 -110.13 -55.46 2.45 Favored 'General case' 0 N--CA 1.466 0.358 0 N-CA-C 112.11 0.411 . . . . 0.0 112.11 -179.106 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 12' ' ' PHE . . . . . . . . . . . . . 12.2 t80 -137.99 -15.2 1.34 Allowed 'General case' 0 N--CA 1.47 0.556 0 N-CA-C 112.429 0.529 . . . . 0.0 112.429 -178.939 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 13' ' ' ASN . . . . . 0.437 HD22 ' HD3' ' A' ' 2' ' ' PRO . 11.5 t30 -120.21 73.01 19.61 Favored Pre-proline 0 CA--C 1.55 0.955 0 O-C-N 122.969 0.168 . . . . 0.0 111.161 -179.377 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 14' ' ' PRO . . . . . 0.595 ' O ' ' HD2' ' A' ' 2' ' ' PRO . 60.4 Cg_endo -76.13 178.74 7.09 Favored 'Trans proline' 0 C--N 1.371 1.744 0 C-N-CA 122.314 2.009 . . . . 0.0 112.501 179.587 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 1.4 m -79.38 118.65 21.47 Favored 'General case' 0 N--CA 1.47 0.547 0 O-C-N 123.118 0.261 . . . . 0.0 111.195 179.972 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 16' ' ' CYS . . . . . 0.55 ' HB2' ' O ' ' A' ' 2' ' ' PRO . 0.0 OUTLIER -56.58 -53.27 66.22 Favored Pre-proline 0 N--CA 1.48 1.073 0 CA-C-O 118.961 -0.542 . . . . 0.0 111.679 179.581 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 57.7 Cg_endo -72.65 169.23 22.42 Favored 'Trans proline' 0 C--N 1.378 2.13 0 C-N-CA 122.028 1.819 . . . . 0.0 111.738 178.194 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 55.7 Cg_endo -72.51 45.33 0.83 Allowed 'Trans proline' 0 C--N 1.373 1.839 0 C-N-CA 122.012 1.808 . . . . 0.0 112.865 178.826 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 19' ' ' LEU . . . . . 0.422 ' HB2' ' SG ' ' A' ' 30' ' ' CYS . 11.8 mt -104.92 172.9 6.54 Favored 'General case' 0 C--O 1.237 0.401 0 CA-C-N 115.931 -0.577 . . . . 0.0 111.046 -179.628 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 24.5 m -103.98 149.3 25.27 Favored 'General case' 0 CA--C 1.531 0.228 0 CA-C-N 115.966 -0.561 . . . . 0.0 111.046 -178.945 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 5.9 t -99.35 102.74 14.43 Favored 'General case' 0 C--O 1.237 0.444 0 CA-C-N 115.856 -0.611 . . . . 0.0 109.39 178.467 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 22' ' ' ILE . . . . . . . . . . . . . 2.5 mt -126.78 129.65 24.0 Favored Pre-proline 0 CA--C 1.543 0.679 0 CA-C-N 115.787 -0.642 . . . . 0.0 110.68 -178.571 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 37.5 Cg_endo -67.65 -48.13 0.26 Allowed 'Cis proline' 0 C--N 1.374 1.885 0 C-N-CA 124.699 -0.959 . . . . 0.0 113.814 -0.434 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 78.57 37.61 26.6 Favored Glycine 0 C--N 1.348 1.242 0 C-N-CA 121.308 -0.472 . . . . 0.0 113.013 -179.962 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 4.5 t70 -140.55 80.7 18.28 Favored Pre-proline 0 CA--C 1.548 0.884 0 C-N-CA 122.372 0.269 . . . . 0.0 110.533 -179.614 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 1.9 Cg_endo -82.07 -31.81 3.98 Favored 'Cis proline' 0 C--N 1.372 1.787 0 C-N-CA 125.058 -0.809 . . . . 0.0 112.956 -0.2 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 27' ' ' TYR . . . . . . . . . . . . . 70.0 m-85 -102.0 172.55 6.85 Favored 'General case' 0 C--O 1.237 0.434 0 CA-C-N 115.822 -0.626 . . . . 0.0 111.578 -179.033 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -175.95 -160.57 23.67 Favored Glycine 0 C--N 1.337 0.634 0 CA-C-N 115.657 -0.701 . . . . 0.0 112.207 179.071 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 29' ' ' ILE . . . . . 0.541 ' HB ' ' CE2' ' A' ' 31' ' ' TYR . 1.8 mm -122.6 153.04 27.23 Favored 'Isoleucine or valine' 0 C--O 1.236 0.36 0 N-CA-C 109.87 -0.418 . . . . 0.0 109.87 179.691 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 30' ' ' CYS . . . . . 0.422 ' SG ' ' HB2' ' A' ' 19' ' ' LEU . 0.5 OUTLIER -79.92 106.72 12.15 Favored 'General case' 0 CA--C 1.539 0.521 0 CA-C-N 116.018 -0.537 . . . . 0.0 110.916 -179.919 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 31' ' ' TYR . . . . . 0.541 ' CE2' ' HB ' ' A' ' 29' ' ' ILE . 39.1 m-85 -131.34 166.68 20.71 Favored 'General case' 0 N--CA 1.463 0.216 0 CA-C-N 115.479 -0.782 . . . . 0.0 111.201 -179.314 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 2.7 tp -101.76 132.04 48.48 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.582 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.437 179.434 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 33' ' ' ILE . . . . . 0.452 ' O ' HD11 ' A' ' 33' ' ' ILE . 1.9 pp . . . . . 0 C--O 1.249 1.078 0 CA-C-O 118.346 -0.835 . . . . 0.0 111.504 179.945 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 2' ' ' PRO . . . . . 0.434 ' HD3' ' ND2' ' A' ' 13' ' ' ASN . 95.3 Cg_endo . . . . . 0 CA--C 1.545 1.04 0 N-CA-C 112.969 0.334 . . . . 0.0 112.969 . . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -145.39 -155.44 6.47 Favored Glycine 0 C--N 1.339 0.727 0 N-CA-C 111.687 -0.565 . . . . 0.0 111.687 179.45 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 18.0 tt0 -73.24 129.16 37.43 Favored 'General case' 0 N--CA 1.47 0.55 0 C-N-CA 122.575 0.35 . . . . 0.0 111.221 179.74 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 85.68 16.25 64.14 Favored Glycine 0 C--N 1.339 0.738 0 CA-C-N 115.832 -0.622 . . . . 0.0 113.294 -179.844 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 12.9 tt0 -127.86 162.52 26.5 Favored 'General case' 0 C--O 1.236 0.39 0 C-N-CA 122.176 0.19 . . . . 0.0 110.488 -179.865 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 7' ' ' GLN . . . . . 0.686 ' HA ' ' O ' ' A' ' 28' ' ' GLY . 18.6 tt0 -85.35 134.76 34.08 Favored 'General case' 0 C--N 1.345 0.386 0 CA-C-O 121.298 0.571 . . . . 0.0 111.239 -179.994 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 8' ' ' CYS . . . . . 0.412 ' SG ' ' SG ' ' A' ' 30' ' ' CYS . 3.6 p -127.77 160.2 32.46 Favored 'General case' 0 C--O 1.239 0.508 0 CA-C-N 114.545 -1.207 . . . . 0.0 111.098 -179.396 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 9' ' ' ASP . . . . . 0.434 ' OD2' ' HB2' ' A' ' 11' ' ' GLU . 16.8 t70 -114.86 150.52 35.43 Favored 'General case' 0 CA--C 1.532 0.272 0 CA-C-N 115.542 -0.754 . . . . 0.0 109.477 178.766 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 15.5 m -100.91 20.12 2.47 Favored 'Isoleucine or valine' 0 CA--C 1.543 0.689 0 CA-C-N 116.22 -0.446 . . . . 0.0 112.008 -179.465 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 11' ' ' GLU . . . . . 0.434 ' HB2' ' OD2' ' A' ' 9' ' ' ASP . 44.7 mt-10 -117.51 -52.46 2.47 Favored 'General case' 0 N--CA 1.465 0.313 0 N-CA-C 112.224 0.453 . . . . 0.0 112.224 -178.969 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 12' ' ' PHE . . . . . . . . . . . . . 14.6 t80 -138.42 -8.43 1.49 Allowed 'General case' 0 N--CA 1.472 0.652 0 N-CA-C 112.596 0.591 . . . . 0.0 112.596 -178.689 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 13' ' ' ASN . . . . . 0.434 ' ND2' ' HD3' ' A' ' 2' ' ' PRO . 6.3 t30 -129.6 63.79 69.26 Favored Pre-proline 0 CA--C 1.55 0.959 0 N-CA-C 111.552 0.205 . . . . 0.0 111.552 -179.091 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 14.0 Cg_exo -70.09 177.12 6.13 Favored 'Trans proline' 0 C--N 1.371 1.744 0 C-N-CA 122.86 2.373 . . . . 0.0 112.002 178.885 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 1.1 t -79.9 121.02 24.92 Favored 'General case' 0 N--CA 1.471 0.58 0 CA-C-O 120.503 0.192 . . . . 0.0 111.052 -179.983 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER -57.57 -53.09 69.18 Favored Pre-proline 0 N--CA 1.478 0.943 0 CA-C-O 119.069 -0.491 . . . . 0.0 111.541 179.282 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 44.4 Cg_endo -68.81 169.44 17.66 Favored 'Trans proline' 0 C--N 1.38 2.199 0 C-N-CA 122.159 1.906 . . . . 0.0 111.782 178.059 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 55.5 Cg_endo -72.22 49.33 1.34 Allowed 'Trans proline' 0 C--N 1.373 1.833 0 C-N-CA 122.044 1.829 . . . . 0.0 112.589 178.799 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 20.9 mt -110.1 168.24 9.58 Favored 'General case' 0 C--O 1.236 0.372 0 CA-C-N 115.741 -0.663 . . . . 0.0 111.34 -179.337 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 20' ' ' THR . . . . . 0.519 ' O ' ' HA ' ' A' ' 30' ' ' CYS . 29.3 m -105.31 153.82 21.11 Favored 'General case' 0 CA--C 1.533 0.31 0 CA-C-N 115.624 -0.716 . . . . 0.0 111.056 -178.804 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 2.0 t -103.42 103.89 13.93 Favored 'General case' 0 C--O 1.238 0.493 0 CA-C-N 115.678 -0.692 . . . . 0.0 109.666 178.869 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 22' ' ' ILE . . . . . . . . . . . . . 2.9 mt -125.9 129.11 24.39 Favored Pre-proline 0 CA--C 1.541 0.634 0 CA-C-N 115.768 -0.651 . . . . 0.0 110.223 -179.157 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 38.4 Cg_endo -67.77 -48.26 0.25 Allowed 'Cis proline' 0 C--N 1.375 1.941 0 C-N-CA 124.679 -0.967 . . . . 0.0 113.941 -0.155 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 81.92 36.83 17.63 Favored Glycine 0 C--N 1.348 1.229 0 C-N-CA 121.108 -0.568 . . . . 0.0 112.852 -179.977 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 8.3 m-20 -139.99 82.58 17.18 Favored Pre-proline 0 CA--C 1.543 0.701 0 C-N-CA 122.53 0.332 . . . . 0.0 110.701 -179.91 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 3.0 Cg_endo -80.54 -32.07 4.18 Favored 'Cis proline' 0 C--N 1.372 1.795 0 C-N-CA 125.191 -0.754 . . . . 0.0 112.923 0.077 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 27' ' ' TYR . . . . . . . . . . . . . 59.3 m-85 -106.96 175.07 5.62 Favored 'General case' 0 C--O 1.238 0.466 0 CA-C-N 115.68 -0.691 . . . . 0.0 111.532 -179.001 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 28' ' ' GLY . . . . . 0.686 ' O ' ' HA ' ' A' ' 7' ' ' GLN . . . -175.52 -161.26 24.65 Favored Glycine 0 C--N 1.339 0.701 0 CA-C-N 115.626 -0.715 . . . . 0.0 112.618 178.49 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 29' ' ' ILE . . . . . 0.523 ' HB ' ' CE2' ' A' ' 31' ' ' TYR . 2.8 mm -115.6 149.76 17.74 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 N-CA-C 110.084 -0.339 . . . . 0.0 110.084 -179.814 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 30' ' ' CYS . . . . . 0.519 ' HA ' ' O ' ' A' ' 20' ' ' THR . 26.8 m -79.85 105.1 10.89 Favored 'General case' 0 C--O 1.238 0.464 0 CA-C-N 115.955 -0.566 . . . . 0.0 111.35 -179.802 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 31' ' ' TYR . . . . . 0.523 ' CE2' ' HB ' ' A' ' 29' ' ' ILE . 36.9 m-85 -128.74 168.46 15.81 Favored 'General case' 0 C--O 1.233 0.205 0 CA-C-N 115.087 -0.961 . . . . 0.0 111.099 -179.552 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 1.8 tt -101.06 130.33 50.64 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.585 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.363 179.651 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 33' ' ' ILE . . . . . 0.421 ' O ' HD13 ' A' ' 33' ' ' ILE . 1.6 pp . . . . . 0 C--O 1.248 0.986 0 CA-C-O 118.386 -0.816 . . . . 0.0 111.525 179.881 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 2' ' ' PRO . . . . . 0.575 ' HD2' ' O ' ' A' ' 14' ' ' PRO . 73.7 Cg_endo . . . . . 0 N--CA 1.488 1.152 0 N-CA-C 113.949 0.711 . . . . 0.0 113.949 . . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -143.5 -159.09 7.83 Favored Glycine 0 C--N 1.34 0.778 0 O-C-N 123.511 0.507 . . . . 0.0 112.543 179.877 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 16.6 tt0 -68.39 122.93 19.43 Favored 'General case' 0 N--CA 1.472 0.642 0 C-N-CA 122.849 0.46 . . . . 0.0 111.524 -179.893 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 92.12 14.47 56.05 Favored Glycine 0 C--N 1.339 0.736 0 CA-C-N 115.681 -0.691 . . . . 0.0 113.242 -179.864 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 43.0 mt-10 -127.9 165.83 19.46 Favored 'General case' 0 C--O 1.239 0.535 0 C-N-CA 122.447 0.299 . . . . 0.0 110.813 179.942 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 7' ' ' GLN . . . . . 0.531 ' HA ' ' O ' ' A' ' 28' ' ' GLY . 15.6 mt-30 -85.11 145.15 27.79 Favored 'General case' 0 C--N 1.346 0.415 0 CA-C-N 116.371 -0.377 . . . . 0.0 111.515 179.966 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 7.4 p -138.26 155.59 48.48 Favored 'General case' 0 C--O 1.236 0.385 0 CA-C-N 115.274 -0.876 . . . . 0.0 111.292 -179.51 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 6.1 t70 -118.25 152.46 35.68 Favored 'General case' 0 C--O 1.235 0.335 0 CA-C-N 115.35 -0.841 . . . . 0.0 109.668 179.003 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 14.4 m -101.1 21.63 1.97 Allowed 'Isoleucine or valine' 0 CA--C 1.541 0.624 0 CA-C-N 116.18 -0.464 . . . . 0.0 112.058 -179.466 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 44.5 mt-10 -118.51 -53.0 2.34 Favored 'General case' 0 N--CA 1.465 0.319 0 N-CA-C 112.196 0.443 . . . . 0.0 112.196 -179.18 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 12' ' ' PHE . . . . . . . . . . . . . 15.1 t80 -139.01 -7.49 1.39 Allowed 'General case' 0 N--CA 1.47 0.564 0 N-CA-C 112.534 0.568 . . . . 0.0 112.534 -178.784 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 13' ' ' ASN . . . . . . . . . . . . . 8.6 t30 -129.34 63.22 66.74 Favored Pre-proline 0 CA--C 1.55 0.943 0 N-CA-C 111.415 0.154 . . . . 0.0 111.415 -179.144 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 14' ' ' PRO . . . . . 0.575 ' O ' ' HD2' ' A' ' 2' ' ' PRO . 15.6 Cg_exo -68.93 178.03 4.44 Favored 'Trans proline' 0 C--N 1.373 1.865 0 C-N-CA 122.828 2.352 . . . . 0.0 112.372 179.235 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 1.5 m -79.54 119.45 22.54 Favored 'General case' 0 N--CA 1.471 0.605 0 O-C-N 123.144 0.278 . . . . 0.0 111.315 -179.86 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 16' ' ' CYS . . . . . 0.554 ' HB2' ' O ' ' A' ' 2' ' ' PRO . 0.0 OUTLIER -57.13 -53.18 67.97 Favored Pre-proline 0 N--CA 1.483 1.182 0 CA-C-N 115.923 -0.581 . . . . 0.0 111.554 179.489 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 57.9 Cg_endo -72.71 169.28 22.35 Favored 'Trans proline' 0 C--N 1.38 2.191 0 C-N-CA 121.994 1.796 . . . . 0.0 111.815 178.178 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 55.9 Cg_endo -72.27 44.69 0.72 Allowed 'Trans proline' 0 C--N 1.371 1.76 0 C-N-CA 122.012 1.808 . . . . 0.0 113.062 178.778 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 19' ' ' LEU . . . . . 0.427 ' HB2' ' SG ' ' A' ' 30' ' ' CYS . 12.2 mt -104.39 172.74 6.63 Favored 'General case' 0 C--O 1.236 0.361 0 CA-C-N 115.911 -0.586 . . . . 0.0 110.996 -179.761 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 25.4 m -103.32 150.19 24.01 Favored 'General case' 0 CA--C 1.534 0.335 0 CA-C-N 115.987 -0.551 . . . . 0.0 110.982 -178.903 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 5.1 t -100.38 103.03 14.4 Favored 'General case' 0 C--O 1.238 0.453 0 CA-C-N 115.724 -0.671 . . . . 0.0 109.407 178.412 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 22' ' ' ILE . . . . . . . . . . . . . 2.5 mt -127.16 129.04 24.02 Favored Pre-proline 0 CA--C 1.541 0.629 0 CA-C-N 115.803 -0.635 . . . . 0.0 110.826 -178.457 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 37.6 Cg_endo -67.99 -48.52 0.25 Allowed 'Cis proline' 0 C--N 1.375 1.938 0 C-N-CA 124.674 -0.969 . . . . 0.0 113.726 -0.261 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 79.12 37.79 24.14 Favored Glycine 0 C--N 1.347 1.19 0 C-N-CA 121.456 -0.402 . . . . 0.0 112.883 -179.991 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 4.6 t70 -140.12 80.57 19.92 Favored Pre-proline 0 CA--C 1.549 0.912 0 C-N-CA 122.338 0.255 . . . . 0.0 110.461 -179.686 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 1.9 Cg_endo -82.24 -31.71 4.0 Favored 'Cis proline' 0 C--N 1.372 1.774 0 C-N-CA 125.112 -0.787 . . . . 0.0 112.973 -0.134 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 27' ' ' TYR . . . . . . . . . . . . . 66.8 m-85 -101.7 171.98 7.22 Favored 'General case' 0 C--O 1.237 0.424 0 CA-C-N 115.796 -0.638 . . . . 0.0 111.591 -179.146 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 28' ' ' GLY . . . . . 0.531 ' O ' ' HA ' ' A' ' 7' ' ' GLN . . . -174.93 -160.26 22.6 Favored Glycine 0 C--N 1.337 0.621 0 CA-C-N 115.667 -0.697 . . . . 0.0 112.409 178.905 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 29' ' ' ILE . . . . . 0.545 ' HB ' ' CE2' ' A' ' 31' ' ' TYR . 1.4 mm -122.37 152.14 26.48 Favored 'Isoleucine or valine' 0 C--O 1.233 0.191 0 N-CA-C 109.807 -0.442 . . . . 0.0 109.807 179.609 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 30' ' ' CYS . . . . . 0.427 ' SG ' ' HB2' ' A' ' 19' ' ' LEU . 0.5 OUTLIER -80.02 106.92 12.4 Favored 'General case' 0 CA--C 1.537 0.467 0 CA-C-N 115.961 -0.563 . . . . 0.0 110.919 -179.986 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 31' ' ' TYR . . . . . 0.545 ' CE2' ' HB ' ' A' ' 29' ' ' ILE . 36.3 m-85 -132.15 167.17 20.24 Favored 'General case' 0 N--CA 1.463 0.222 0 CA-C-N 115.449 -0.796 . . . . 0.0 111.155 -179.332 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 2.7 tp -101.82 131.67 49.28 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.611 0 CA-C-N 116.081 -0.509 . . . . 0.0 110.412 179.493 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 33' ' ' ILE . . . . . 0.446 HD12 ' OXT' ' A' ' 33' ' ' ILE . 1.9 pp . . . . . 0 C--O 1.249 1.04 0 CA-C-O 118.133 -0.937 . . . . 0.0 111.568 179.873 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 2' ' ' PRO . . . . . 0.507 ' HD3' ' ND2' ' A' ' 13' ' ' ASN . 81.2 Cg_endo . . . . . 0 CA--C 1.543 0.964 0 N-CA-C 112.886 0.302 . . . . 0.0 112.886 . . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -145.28 -156.63 6.92 Favored Glycine 0 C--N 1.34 0.767 0 N-CA-C 111.562 -0.615 . . . . 0.0 111.562 179.151 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 18.1 tt0 -73.43 129.49 38.11 Favored 'General case' 0 N--CA 1.471 0.624 0 C-N-CA 122.445 0.298 . . . . 0.0 111.208 179.595 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 88.13 14.14 62.89 Favored Glycine 0 C--N 1.34 0.778 0 CA-C-N 115.765 -0.652 . . . . 0.0 113.274 -179.845 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 43.2 mt-10 -129.81 162.19 29.04 Favored 'General case' 0 C--O 1.237 0.404 0 C-N-CA 122.277 0.231 . . . . 0.0 110.733 -179.897 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 7' ' ' GLN . . . . . 0.464 ' HA ' ' O ' ' A' ' 28' ' ' GLY . 9.4 tt0 -83.82 136.77 34.01 Favored 'General case' 0 C--N 1.345 0.374 0 CA-C-O 121.305 0.574 . . . . 0.0 111.296 179.815 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 4.0 p -125.57 160.25 30.06 Favored 'General case' 0 C--O 1.243 0.712 0 CA-C-N 114.471 -1.241 . . . . 0.0 110.89 -179.554 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 9' ' ' ASP . . . . . 0.441 ' OD1' ' HD2' ' A' ' 27' ' ' TYR . 2.5 m-20 -114.58 150.11 35.51 Favored 'General case' 0 C--O 1.235 0.313 0 CA-C-N 115.58 -0.736 . . . . 0.0 109.684 179.432 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 11.2 m -103.24 16.78 5.1 Favored 'Isoleucine or valine' 0 CA--C 1.542 0.64 0 CA-C-N 116.398 -0.364 . . . . 0.0 111.766 -179.686 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 9.6 mm-40 -110.73 -52.53 2.78 Favored 'General case' 0 C--O 1.235 0.312 0 N-CA-C 112.118 0.414 . . . . 0.0 112.118 -178.937 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 12' ' ' PHE . . . . . . . . . . . . . 17.2 t80 -142.01 -7.84 0.93 Allowed 'General case' 0 N--CA 1.472 0.663 0 N-CA-C 112.569 0.581 . . . . 0.0 112.569 -178.788 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 13' ' ' ASN . . . . . 0.507 ' ND2' ' HD3' ' A' ' 2' ' ' PRO . 6.7 t30 -129.58 64.37 71.38 Favored Pre-proline 0 CA--C 1.55 0.952 0 N-CA-C 111.559 0.207 . . . . 0.0 111.559 -179.075 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 15.0 Cg_exo -69.64 179.95 3.28 Favored 'Trans proline' 0 C--N 1.372 1.792 0 C-N-CA 122.888 2.392 . . . . 0.0 111.993 178.947 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 1.3 t -79.76 121.25 25.12 Favored 'General case' 0 N--CA 1.47 0.573 0 CA-C-O 120.519 0.2 . . . . 0.0 111.142 -179.951 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER -57.88 -53.61 63.96 Favored Pre-proline 0 N--CA 1.478 0.952 0 CA-C-O 118.992 -0.528 . . . . 0.0 111.573 179.325 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 45.1 Cg_endo -69.06 169.61 17.63 Favored 'Trans proline' 0 C--N 1.378 2.099 0 C-N-CA 122.12 1.88 . . . . 0.0 111.725 178.181 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -71.8 49.67 1.27 Allowed 'Trans proline' 0 C--N 1.372 1.794 0 C-N-CA 121.957 1.771 . . . . 0.0 112.688 178.794 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 22.0 mt -110.08 168.32 9.52 Favored 'General case' 0 C--O 1.236 0.389 0 CA-C-N 115.703 -0.681 . . . . 0.0 111.284 -179.363 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 20' ' ' THR . . . . . 0.496 ' O ' ' HA ' ' A' ' 30' ' ' CYS . 27.9 m -105.19 154.48 20.14 Favored 'General case' 0 CA--C 1.533 0.304 0 CA-C-N 115.641 -0.709 . . . . 0.0 111.191 -178.71 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 1.8 t -103.78 102.37 12.19 Favored 'General case' 0 C--O 1.238 0.453 0 CA-C-N 115.594 -0.73 . . . . 0.0 109.626 178.817 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 22' ' ' ILE . . . . . . . . . . . . . 2.8 mt -125.31 129.86 24.33 Favored Pre-proline 0 CA--C 1.542 0.665 0 CA-C-N 115.655 -0.702 . . . . 0.0 110.308 -179.071 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 35.3 Cg_endo -65.93 -48.9 0.21 Allowed 'Cis proline' 0 C--N 1.375 1.922 0 C-N-CA 124.723 -0.949 . . . . 0.0 113.817 -0.21 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 77.97 33.62 40.67 Favored Glycine 0 C--N 1.347 1.179 0 C-N-CA 121.256 -0.497 . . . . 0.0 112.901 179.872 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 4.6 t70 -139.49 82.84 17.92 Favored Pre-proline 0 CA--C 1.546 0.794 0 C-N-CA 122.556 0.343 . . . . 0.0 110.166 -179.641 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 2.5 Cg_endo -81.52 -32.54 3.61 Favored 'Cis proline' 0 C--N 1.37 1.7 0 C-N-CA 125.146 -0.772 . . . . 0.0 113.048 -0.028 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 27' ' ' TYR . . . . . 0.441 ' HD2' ' OD1' ' A' ' 9' ' ' ASP . 46.4 m-85 -103.46 167.59 9.71 Favored 'General case' 0 C--O 1.239 0.5 0 O-C-N 123.669 0.606 . . . . 0.0 111.476 -178.889 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 28' ' ' GLY . . . . . 0.464 ' O ' ' HA ' ' A' ' 7' ' ' GLN . . . -170.0 -163.14 23.54 Favored Glycine 0 C--N 1.342 0.899 0 C-N-CA 120.853 -0.689 . . . . 0.0 113.327 178.543 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 29' ' ' ILE . . . . . 0.501 ' HB ' ' CE2' ' A' ' 31' ' ' TYR . 2.7 mm -118.21 154.86 20.28 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.284 0 O-C-N 124.108 0.534 . . . . 0.0 110.149 -179.931 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 30' ' ' CYS . . . . . 0.496 ' HA ' ' O ' ' A' ' 20' ' ' THR . 24.5 m -83.29 103.48 12.71 Favored 'General case' 0 C--O 1.237 0.431 0 CA-C-N 115.941 -0.572 . . . . 0.0 111.22 -179.961 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 31' ' ' TYR . . . . . 0.501 ' CE2' ' HB ' ' A' ' 29' ' ' ILE . 38.6 m-85 -129.55 167.37 18.01 Favored 'General case' 0 CA--C 1.531 0.212 0 CA-C-N 115.01 -0.996 . . . . 0.0 111.074 -179.586 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 2.8 tp -100.43 131.11 48.6 Favored 'Isoleucine or valine' 0 CA--C 1.542 0.639 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.271 179.534 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 33' ' ' ILE . . . . . 0.456 ' O ' HD11 ' A' ' 33' ' ' ILE . 1.9 pp . . . . . 0 C--O 1.248 0.988 0 CA-C-O 118.387 -0.816 . . . . 0.0 111.48 179.866 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 2' ' ' PRO . . . . . 0.527 ' HD3' ' ND2' ' A' ' 13' ' ' ASN . 84.7 Cg_endo . . . . . 0 CA--C 1.543 0.957 0 N-CA-C 112.926 0.318 . . . . 0.0 112.926 . . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -148.23 -158.42 7.96 Favored Glycine 0 C--N 1.338 0.671 0 N-CA-C 111.63 -0.588 . . . . 0.0 111.63 179.276 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 17.9 tt0 -70.32 123.83 22.68 Favored 'General case' 0 N--CA 1.473 0.702 0 C-N-CA 122.489 0.316 . . . . 0.0 111.516 179.891 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 98.42 -11.19 63.34 Favored Glycine 0 C--N 1.34 0.799 0 CA-C-N 115.748 -0.66 . . . . 0.0 113.58 179.809 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 43.0 mt-10 -105.34 166.02 10.71 Favored 'General case' 0 C--O 1.238 0.465 0 CA-C-N 116.705 0.253 . . . . 0.0 111.01 -179.735 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 7' ' ' GLN . . . . . 0.428 ' HA ' ' HA ' ' A' ' 29' ' ' ILE . 6.5 tt0 -86.73 140.39 29.81 Favored 'General case' 0 C--N 1.347 0.466 0 CA-C-O 121.113 0.482 . . . . 0.0 111.132 179.744 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 8' ' ' CYS . . . . . 0.421 ' SG ' ' SG ' ' A' ' 15' ' ' CYS . 5.8 p -127.02 158.49 36.8 Favored 'General case' 0 C--O 1.239 0.53 0 CA-C-N 114.696 -1.138 . . . . 0.0 111.128 -179.599 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -114.92 149.73 36.78 Favored 'General case' 0 C--O 1.234 0.27 0 CA-C-N 115.377 -0.829 . . . . 0.0 109.711 179.348 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 10' ' ' VAL . . . . . 0.515 HG21 ' O ' ' A' ' 26' ' ' PRO . 10.4 m -103.83 17.87 4.78 Favored 'Isoleucine or valine' 0 CA--C 1.542 0.661 0 O-C-N 123.31 0.381 . . . . 0.0 111.621 179.926 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 9.7 mm-40 -109.45 -53.08 2.7 Favored 'General case' 0 C--O 1.234 0.287 0 CA-C-N 116.347 -0.388 . . . . 0.0 111.997 -179.186 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 12' ' ' PHE . . . . . . . . . . . . . 12.2 t80 -139.74 -18.05 0.96 Allowed 'General case' 0 N--CA 1.471 0.62 0 N-CA-C 112.423 0.527 . . . . 0.0 112.423 -179.04 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 13' ' ' ASN . . . . . 0.527 ' ND2' ' HD3' ' A' ' 2' ' ' PRO . 8.3 t30 -118.7 74.67 12.46 Favored Pre-proline 0 CA--C 1.549 0.929 0 O-C-N 122.977 0.173 . . . . 0.0 111.222 -179.25 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 60.0 Cg_endo -75.48 178.11 7.78 Favored 'Trans proline' 0 C--N 1.372 1.768 0 C-N-CA 122.421 2.081 . . . . 0.0 112.649 179.201 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 15' ' ' CYS . . . . . 0.421 ' SG ' ' SG ' ' A' ' 8' ' ' CYS . 1.6 m -79.66 119.83 23.14 Favored 'General case' 0 N--CA 1.471 0.596 0 O-C-N 123.151 0.282 . . . . 0.0 111.623 179.983 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER -58.91 -54.27 58.11 Favored Pre-proline 0 N--CA 1.477 0.908 0 CA-C-N 115.91 -0.586 . . . . 0.0 111.598 179.667 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 48.0 Cg_endo -68.95 169.02 18.82 Favored 'Trans proline' 0 C--N 1.38 2.207 0 C-N-CA 121.965 1.777 . . . . 0.0 111.687 178.382 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 56.1 Cg_endo -72.43 45.89 0.9 Allowed 'Trans proline' 0 C--N 1.37 1.702 0 C-N-CA 121.929 1.752 . . . . 0.0 112.939 179.048 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 19' ' ' LEU . . . . . 0.49 ' HB2' ' SG ' ' A' ' 30' ' ' CYS . 44.4 mt -106.44 169.83 8.28 Favored 'General case' 0 C--O 1.236 0.358 0 CA-C-N 116.118 -0.492 . . . . 0.0 111.038 -179.632 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 32.6 m -104.12 149.89 24.83 Favored 'General case' 0 CA--C 1.533 0.31 0 CA-C-N 115.737 -0.665 . . . . 0.0 111.095 -178.904 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 2.7 t -98.44 102.54 14.32 Favored 'General case' 0 C--O 1.238 0.464 0 CA-C-N 115.88 -0.6 . . . . 0.0 109.555 178.545 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 22' ' ' ILE . . . . . . . . . . . . . 2.4 mt -126.64 130.68 23.8 Favored Pre-proline 0 CA--C 1.542 0.671 0 CA-C-N 115.704 -0.68 . . . . 0.0 110.457 -178.728 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 36.8 Cg_endo -66.88 -48.22 0.24 Allowed 'Cis proline' 0 C--N 1.374 1.917 0 C-N-CA 124.833 -0.903 . . . . 0.0 113.784 -0.088 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 75.31 41.23 31.5 Favored Glycine 0 C--N 1.348 1.246 0 C-N-CA 121.31 -0.471 . . . . 0.0 112.811 -179.948 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 8.1 m-20 -136.24 75.36 53.13 Favored Pre-proline 0 CA--C 1.545 0.761 0 C-N-CA 122.428 0.291 . . . . 0.0 110.863 -179.627 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 26' ' ' PRO . . . . . 0.515 ' O ' HG21 ' A' ' 10' ' ' VAL . 56.8 Cg_endo -88.49 -16.91 22.33 Favored 'Cis proline' 0 C--N 1.37 1.708 0 C-N-CA 124.79 -0.921 . . . . 0.0 113.773 -0.088 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 27' ' ' TYR . . . . . 0.468 ' CE2' ' HG2' ' A' ' 26' ' ' PRO . 21.0 m-85 -106.82 163.97 12.5 Favored 'General case' 0 C--O 1.238 0.497 0 CA-C-N 116.276 -0.42 . . . . 0.0 111.457 -179.026 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -173.64 -162.18 25.08 Favored Glycine 0 C--N 1.341 0.846 0 C-N-CA 120.889 -0.672 . . . . 0.0 113.291 178.493 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 29' ' ' ILE . . . . . 0.537 ' HB ' ' CE2' ' A' ' 31' ' ' TYR . 1.9 mm -118.51 154.68 20.68 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.232 0 O-C-N 124.031 0.489 . . . . 0.0 110.049 -179.912 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 30' ' ' CYS . . . . . 0.49 ' SG ' ' HB2' ' A' ' 19' ' ' LEU . 0.5 OUTLIER -81.97 105.49 13.12 Favored 'General case' 0 CA--C 1.537 0.464 0 CA-C-N 115.893 -0.594 . . . . 0.0 110.986 179.974 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 31' ' ' TYR . . . . . 0.537 ' CE2' ' HB ' ' A' ' 29' ' ' ILE . 38.4 m-85 -131.04 165.44 23.22 Favored 'General case' 0 N--CA 1.464 0.23 0 CA-C-N 115.406 -0.815 . . . . 0.0 111.205 -179.415 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 2.9 tp -100.08 131.3 47.8 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.592 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.461 179.571 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 33' ' ' ILE . . . . . 0.452 ' OXT' HD13 ' A' ' 33' ' ' ILE . 1.9 pp . . . . . 0 C--O 1.249 1.033 0 CA-C-O 118.191 -0.909 . . . . 0.0 111.468 179.956 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 2' ' ' PRO . . . . . 0.559 ' O ' ' HB2' ' A' ' 16' ' ' CYS . 87.5 Cg_endo . . . . . 0 N--CA 1.489 1.253 0 N-CA-C 113.854 0.675 . . . . 0.0 113.854 . . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -134.49 -154.56 7.23 Favored Glycine 0 C--N 1.342 0.895 0 CA-C-N 116.09 -0.504 . . . . 0.0 112.287 179.979 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 16.1 tt0 -73.72 137.67 44.17 Favored 'General case' 0 N--CA 1.472 0.637 0 C-N-CA 122.845 0.458 . . . . 0.0 111.407 -179.854 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 82.61 12.92 79.37 Favored Glycine 0 C--N 1.341 0.832 0 CA-C-N 115.689 -0.687 . . . . 0.0 113.277 -179.771 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 43.1 mt-10 -125.95 161.53 27.29 Favored 'General case' 0 C--O 1.237 0.421 0 C-N-CA 122.346 0.258 . . . . 0.0 110.935 -179.875 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 7' ' ' GLN . . . . . 0.693 ' HA ' ' O ' ' A' ' 28' ' ' GLY . 21.0 tt0 -88.54 133.96 34.0 Favored 'General case' 0 C--N 1.344 0.363 0 CA-C-O 121.216 0.532 . . . . 0.0 111.275 179.872 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 2.0 p -128.73 161.64 29.24 Favored 'General case' 0 C--O 1.239 0.54 0 CA-C-N 114.557 -1.201 . . . . 0.0 111.149 -179.738 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 12.2 t70 -117.1 147.02 42.76 Favored 'General case' 0 C--O 1.234 0.254 0 CA-C-N 115.677 -0.692 . . . . 0.0 109.562 178.769 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 15.8 m -93.73 24.98 0.52 Allowed 'Isoleucine or valine' 0 CA--C 1.544 0.74 0 CA-C-N 116.268 -0.423 . . . . 0.0 111.805 -179.43 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 43.7 mt-10 -121.51 -52.79 2.02 Favored 'General case' 0 CA--C 1.533 0.293 0 N-CA-C 112.268 0.47 . . . . 0.0 112.268 -178.98 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 12' ' ' PHE . . . . . . . . . . . . . 9.9 t80 -138.27 -10.59 1.46 Allowed 'General case' 0 N--CA 1.47 0.546 0 N-CA-C 112.812 0.671 . . . . 0.0 112.812 -178.622 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 13' ' ' ASN . . . . . . . . . . . . . 7.3 t30 -129.57 62.79 65.19 Favored Pre-proline 0 CA--C 1.55 0.953 0 N-CA-C 111.655 0.243 . . . . 0.0 111.655 -179.277 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 14' ' ' PRO . . . . . 0.553 ' O ' ' HD2' ' A' ' 2' ' ' PRO . 13.5 Cg_exo -70.1 -179.97 3.45 Favored 'Trans proline' 0 C--N 1.374 1.878 0 C-N-CA 122.649 2.233 . . . . 0.0 111.962 178.985 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 1.8 t -79.57 120.83 24.48 Favored 'General case' 0 N--CA 1.47 0.541 0 C-N-CA 121.989 0.116 . . . . 0.0 110.849 -179.947 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 16' ' ' CYS . . . . . 0.559 ' HB2' ' O ' ' A' ' 2' ' ' PRO . 0.0 OUTLIER -55.66 -52.56 71.05 Favored Pre-proline 0 N--CA 1.483 1.214 0 CA-C-O 118.952 -0.547 . . . . 0.0 111.643 179.572 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 56.5 Cg_endo -71.98 169.84 20.36 Favored 'Trans proline' 0 C--N 1.378 2.13 0 C-N-CA 122.155 1.903 . . . . 0.0 111.667 178.111 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 55.2 Cg_endo -71.91 48.55 1.13 Allowed 'Trans proline' 0 C--N 1.373 1.861 0 C-N-CA 121.976 1.784 . . . . 0.0 112.928 178.857 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 28.2 mt -108.32 171.06 7.63 Favored 'General case' 0 C--O 1.236 0.383 0 CA-C-N 115.679 -0.691 . . . . 0.0 111.271 -179.655 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 20' ' ' THR . . . . . 0.509 ' O ' ' HA ' ' A' ' 30' ' ' CYS . 20.0 m -105.07 153.56 21.32 Favored 'General case' 0 CA--C 1.533 0.294 0 CA-C-N 115.927 -0.579 . . . . 0.0 111.044 -178.879 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 2.7 t -105.58 99.5 9.1 Favored 'General case' 0 C--O 1.236 0.367 0 CA-C-N 115.646 -0.706 . . . . 0.0 109.366 178.776 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 22' ' ' ILE . . . . . . . . . . . . . 3.6 mt -120.71 129.92 25.09 Favored Pre-proline 0 CA--C 1.543 0.682 0 CA-C-N 115.595 -0.729 . . . . 0.0 110.345 -178.782 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 36.8 Cg_endo -66.78 -47.01 0.27 Allowed 'Cis proline' 0 C--N 1.375 1.93 0 C-N-CA 124.647 -0.981 . . . . 0.0 113.965 -0.069 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 79.51 33.43 34.84 Favored Glycine 0 C--N 1.346 1.09 0 C-N-CA 121.223 -0.513 . . . . 0.0 112.957 179.8 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 8.3 m-20 -139.26 83.97 17.06 Favored Pre-proline 0 CA--C 1.544 0.735 0 C-N-CA 122.523 0.329 . . . . 0.0 110.588 -179.762 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 2.9 Cg_endo -80.25 -31.67 4.54 Favored 'Cis proline' 0 C--N 1.37 1.697 0 C-N-CA 125.074 -0.803 . . . . 0.0 112.907 -0.044 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 27' ' ' TYR . . . . . . . . . . . . . 59.8 m-85 -108.22 173.16 6.44 Favored 'General case' 0 C--O 1.239 0.541 0 CA-C-N 115.824 -0.625 . . . . 0.0 111.701 -179.053 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 28' ' ' GLY . . . . . 0.693 ' O ' ' HA ' ' A' ' 7' ' ' GLN . . . -175.54 -164.32 29.82 Favored Glycine 0 C--N 1.338 0.685 0 CA-C-N 115.694 -0.685 . . . . 0.0 112.491 178.495 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 29' ' ' ILE . . . . . 0.537 ' HB ' ' CE2' ' A' ' 31' ' ' TYR . 2.3 mm -113.99 152.82 15.61 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 O-C-N 123.654 0.267 . . . . 0.0 110.282 -179.825 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 30' ' ' CYS . . . . . 0.509 ' HA ' ' O ' ' A' ' 20' ' ' THR . 33.9 m -79.73 106.02 11.44 Favored 'General case' 0 C--O 1.237 0.409 0 CA-C-N 115.918 -0.583 . . . . 0.0 111.432 -179.874 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 31' ' ' TYR . . . . . 0.537 ' CE2' ' HB ' ' A' ' 29' ' ' ILE . 38.6 m-85 -130.51 167.83 18.03 Favored 'General case' 0 C--O 1.233 0.187 0 CA-C-N 115.081 -0.963 . . . . 0.0 111.113 -179.463 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 2.8 tp -101.21 131.13 49.54 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.551 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.31 179.514 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 33' ' ' ILE . . . . . 0.456 HD12 ' OXT' ' A' ' 33' ' ' ILE . 1.8 pp . . . . . 0 C--O 1.249 1.074 0 CA-C-O 118.158 -0.925 . . . . 0.0 111.443 179.913 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 2' ' ' PRO . . . . . 0.576 ' HD2' ' O ' ' A' ' 14' ' ' PRO . 91.6 Cg_endo . . . . . 0 N--CA 1.488 1.205 0 N-CA-C 113.961 0.716 . . . . 0.0 113.961 . . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -135.86 -157.74 7.96 Favored Glycine 0 C--N 1.341 0.817 0 CA-C-N 115.977 -0.556 . . . . 0.0 112.053 179.778 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 18.0 tt0 -73.07 135.46 44.82 Favored 'General case' 0 N--CA 1.471 0.608 0 C-N-CA 122.721 0.408 . . . . 0.0 111.345 -179.957 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 88.31 9.44 69.86 Favored Glycine 0 C--N 1.34 0.797 0 CA-C-N 115.797 -0.638 . . . . 0.0 113.396 -179.707 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 42.6 mt-10 -128.6 166.62 18.52 Favored 'General case' 0 C--O 1.239 0.505 0 C-N-CA 122.298 0.239 . . . . 0.0 110.883 -179.963 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 7' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER -81.74 152.48 27.0 Favored 'General case' 0 C--N 1.347 0.483 0 CA-C-N 116.581 -0.281 . . . . 0.0 110.867 179.909 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 4.9 p -140.48 150.58 43.95 Favored 'General case' 0 C--O 1.235 0.327 0 CA-C-N 115.852 -0.613 . . . . 0.0 111.116 -179.283 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -111.01 141.87 43.91 Favored 'General case' 0 C--O 1.234 0.277 0 CA-C-N 115.4 -0.818 . . . . 0.0 109.59 179.671 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 10' ' ' VAL . . . . . 0.442 HG22 ' O ' ' A' ' 26' ' ' PRO . 6.8 m -96.09 22.58 0.92 Allowed 'Isoleucine or valine' 0 CA--C 1.541 0.611 0 CA-C-N 116.559 -0.291 . . . . 0.0 111.651 -179.926 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 45.3 mt-10 -115.29 -54.34 2.55 Favored 'General case' 0 C--O 1.235 0.305 0 N-CA-C 112.079 0.4 . . . . 0.0 112.079 -179.067 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 12' ' ' PHE . . . . . . . . . . . . . 11.9 t80 -141.53 -9.17 0.95 Allowed 'General case' 0 N--CA 1.473 0.676 0 N-CA-C 112.548 0.573 . . . . 0.0 112.548 -178.791 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 13' ' ' ASN . . . . . 0.437 HD22 ' HD3' ' A' ' 2' ' ' PRO . 9.9 t30 -129.94 63.53 68.91 Favored Pre-proline 0 CA--C 1.551 0.981 0 N-CA-C 111.369 0.137 . . . . 0.0 111.369 -179.19 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 14' ' ' PRO . . . . . 0.576 ' O ' ' HD2' ' A' ' 2' ' ' PRO . 13.3 Cg_exo -70.37 -174.54 1.05 Allowed 'Trans proline' 0 C--N 1.375 1.922 0 C-N-CA 122.784 2.322 . . . . 0.0 112.039 179.118 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 2.1 t -79.27 120.61 23.98 Favored 'General case' 0 N--CA 1.472 0.627 0 O-C-N 122.909 0.131 . . . . 0.0 110.991 -179.902 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 16' ' ' CYS . . . . . 0.549 ' HB2' ' O ' ' A' ' 2' ' ' PRO . 0.0 OUTLIER -57.03 -52.5 73.67 Favored Pre-proline 0 N--CA 1.483 1.198 0 CA-C-O 119.073 -0.489 . . . . 0.0 111.551 179.458 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 56.9 Cg_endo -72.29 169.95 20.36 Favored 'Trans proline' 0 C--N 1.38 2.205 0 C-N-CA 122.1 1.867 . . . . 0.0 111.712 178.013 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 53.1 Cg_endo -71.45 49.86 1.19 Allowed 'Trans proline' 0 C--N 1.373 1.861 0 C-N-CA 121.978 1.785 . . . . 0.0 112.852 178.871 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 32.9 mt -108.7 172.5 6.81 Favored 'General case' 0 CA--C 1.533 0.321 0 CA-C-N 115.722 -0.672 . . . . 0.0 111.235 -179.574 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 20' ' ' THR . . . . . 0.404 ' O ' ' HA ' ' A' ' 30' ' ' CYS . 25.0 m -106.63 153.96 21.61 Favored 'General case' 0 CA--C 1.533 0.308 0 CA-C-N 115.811 -0.631 . . . . 0.0 111.462 -178.497 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 3.5 t -103.57 104.18 14.2 Favored 'General case' 0 C--O 1.236 0.392 0 CA-C-N 115.512 -0.767 . . . . 0.0 109.474 178.568 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 22' ' ' ILE . . . . . . . . . . . . . 4.8 mt -125.56 129.66 24.33 Favored Pre-proline 0 CA--C 1.543 0.703 0 CA-C-N 115.757 -0.656 . . . . 0.0 110.665 -178.914 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 35.6 Cg_endo -66.45 -48.11 0.24 Allowed 'Cis proline' 0 C--N 1.376 1.998 0 C-N-CA 124.683 -0.965 . . . . 0.0 113.801 -0.207 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 80.46 34.4 28.86 Favored Glycine 0 C--N 1.347 1.141 0 C-N-CA 121.253 -0.498 . . . . 0.0 112.904 179.877 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 8.0 m-20 -142.81 84.27 10.87 Favored Pre-proline 0 CA--C 1.544 0.719 0 C-N-CA 122.525 0.33 . . . . 0.0 110.542 -179.604 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 26' ' ' PRO . . . . . 0.442 ' O ' HG22 ' A' ' 10' ' ' VAL . 1.1 Cg_endo -81.77 -31.73 4.12 Favored 'Cis proline' 0 C--N 1.373 1.821 0 C-N-CA 125.075 -0.802 . . . . 0.0 113.06 -0.098 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 27' ' ' TYR . . . . . . . . . . . . . 41.2 m-85 -101.26 167.56 10.12 Favored 'General case' 0 C--O 1.239 0.532 0 CA-C-N 115.797 -0.638 . . . . 0.0 111.158 -178.981 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -164.88 -161.21 13.37 Favored Glycine 0 C--N 1.34 0.799 0 C-N-CA 120.839 -0.696 . . . . 0.0 113.264 179.619 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 29' ' ' ILE . . . . . 0.488 ' HB ' ' CE2' ' A' ' 31' ' ' TYR . 3.9 mm -127.93 155.26 39.32 Favored 'Isoleucine or valine' 0 C--O 1.234 0.268 0 CA-C-N 115.175 -0.512 . . . . 0.0 109.877 179.944 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 30' ' ' CYS . . . . . 0.404 ' HA ' ' O ' ' A' ' 20' ' ' THR . 23.7 m -81.96 100.61 9.77 Favored 'General case' 0 CA--C 1.536 0.435 0 CA-C-O 121.278 0.561 . . . . 0.0 111.446 -179.911 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 31' ' ' TYR . . . . . 0.488 ' CE2' ' HB ' ' A' ' 29' ' ' ILE . 38.4 m-85 -130.04 166.16 20.72 Favored 'General case' 0 N--CA 1.464 0.246 0 CA-C-N 115.12 -0.946 . . . . 0.0 110.937 -179.872 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 2.9 tp -101.0 131.71 48.15 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.546 0 CA-C-N 116.077 -0.511 . . . . 0.0 110.367 179.558 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 33' ' ' ILE . . . . . 0.459 ' OXT' HD13 ' A' ' 33' ' ' ILE . 1.8 pp . . . . . 0 C--O 1.25 1.097 0 CA-C-O 118.241 -0.885 . . . . 0.0 111.486 179.876 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 2' ' ' PRO . . . . . 0.567 ' HD2' ' O ' ' A' ' 14' ' ' PRO . 92.3 Cg_endo . . . . . 0 N--CA 1.488 1.195 0 N-CA-C 113.907 0.695 . . . . 0.0 113.907 . . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -135.79 -156.54 7.59 Favored Glycine 0 C--N 1.342 0.894 0 CA-C-N 116.027 -0.533 . . . . 0.0 112.387 179.829 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 16.0 tt0 -74.31 138.78 43.76 Favored 'General case' 0 N--CA 1.471 0.593 0 C-N-CA 122.693 0.397 . . . . 0.0 111.377 -179.707 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 84.53 10.62 79.27 Favored Glycine 0 C--N 1.34 0.754 0 CA-C-N 115.809 -0.632 . . . . 0.0 113.333 179.99 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 43.1 mt-10 -129.16 160.98 31.17 Favored 'General case' 0 N--CA 1.467 0.4 0 C-N-CA 122.206 0.202 . . . . 0.0 110.846 -179.841 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 7' ' ' GLN . . . . . 0.479 ' HA ' ' O ' ' A' ' 28' ' ' GLY . 7.5 tt0 -84.85 133.65 34.31 Favored 'General case' 0 C--N 1.344 0.366 0 CA-C-O 121.331 0.586 . . . . 0.0 111.215 179.765 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 3.3 p -122.85 161.75 23.48 Favored 'General case' 0 C--O 1.241 0.615 0 CA-C-N 114.44 -1.254 . . . . 0.0 110.824 -179.638 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 9' ' ' ASP . . . . . 0.447 ' OD1' ' HD2' ' A' ' 27' ' ' TYR . 1.8 m-20 -114.91 152.01 33.04 Favored 'General case' 0 C--O 1.235 0.31 0 CA-C-N 115.511 -0.768 . . . . 0.0 109.77 179.41 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 10.1 m -103.79 13.03 7.44 Favored 'Isoleucine or valine' 0 CA--C 1.542 0.651 0 O-C-N 123.254 0.346 . . . . 0.0 111.801 -179.818 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 45.9 mt-10 -100.95 -55.67 2.51 Favored 'General case' 0 C--O 1.235 0.304 0 N-CA-C 111.812 0.301 . . . . 0.0 111.812 -179.073 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 12' ' ' PHE . . . . . . . . . . . . . 12.6 t80 -141.25 -14.23 0.89 Allowed 'General case' 0 N--CA 1.47 0.564 0 N-CA-C 112.218 0.451 . . . . 0.0 112.218 -179.251 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 13' ' ' ASN . . . . . 0.452 HD22 ' HD3' ' A' ' 2' ' ' PRO . 12.6 t30 -120.47 72.91 21.09 Favored Pre-proline 0 CA--C 1.55 0.955 0 O-C-N 122.903 0.127 . . . . 0.0 111.184 -179.406 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 14' ' ' PRO . . . . . 0.567 ' O ' ' HD2' ' A' ' 2' ' ' PRO . 60.8 Cg_endo -76.44 -176.4 3.08 Favored 'Trans proline' 0 C--N 1.371 1.735 0 C-N-CA 122.367 2.044 . . . . 0.0 112.207 179.245 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 2.0 t -79.34 119.64 22.67 Favored 'General case' 0 N--CA 1.473 0.71 0 O-C-N 123.017 0.198 . . . . 0.0 110.642 179.861 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 16' ' ' CYS . . . . . 0.555 ' HB2' ' O ' ' A' ' 2' ' ' PRO . 0.0 OUTLIER -54.94 -52.48 70.49 Favored Pre-proline 0 N--CA 1.483 1.178 0 CA-C-O 119.005 -0.521 . . . . 0.0 111.664 179.715 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 57.6 Cg_endo -72.39 169.79 20.83 Favored 'Trans proline' 0 C--N 1.378 2.126 0 C-N-CA 122.06 1.84 . . . . 0.0 111.789 178.021 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 55.1 Cg_endo -71.87 50.28 1.4 Allowed 'Trans proline' 0 C--N 1.374 1.895 0 C-N-CA 122.065 1.844 . . . . 0.0 112.742 178.808 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 32.4 mt -110.03 172.13 7.04 Favored 'General case' 0 CA--C 1.533 0.323 0 CA-C-N 115.666 -0.697 . . . . 0.0 111.311 -179.33 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 20' ' ' THR . . . . . 0.48 ' O ' ' HA ' ' A' ' 30' ' ' CYS . 21.2 m -106.04 154.38 20.71 Favored 'General case' 0 CA--C 1.533 0.293 0 CA-C-N 115.606 -0.724 . . . . 0.0 111.002 -178.948 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 2.0 t -105.35 99.7 9.3 Favored 'General case' 0 C--O 1.237 0.398 0 CA-C-N 115.644 -0.707 . . . . 0.0 109.363 178.597 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 22' ' ' ILE . . . . . . . . . . . . . 3.0 mt -122.53 130.53 24.62 Favored Pre-proline 0 CA--C 1.542 0.658 0 CA-C-N 115.559 -0.746 . . . . 0.0 110.382 -178.713 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 32.5 Cg_endo -65.07 -48.47 0.21 Allowed 'Cis proline' 0 C--N 1.375 1.944 0 C-N-CA 124.76 -0.933 . . . . 0.0 113.942 -0.226 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 77.19 31.36 52.51 Favored Glycine 0 C--N 1.348 1.215 0 C-N-CA 121.165 -0.54 . . . . 0.0 113.004 179.725 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 8.3 m-20 -138.86 83.71 18.56 Favored Pre-proline 0 CA--C 1.544 0.717 0 C-N-CA 122.49 0.316 . . . . 0.0 110.432 -179.771 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 3.0 Cg_exo -81.17 -32.34 3.83 Favored 'Cis proline' 0 C--N 1.372 1.772 0 C-N-CA 125.101 -0.791 . . . . 0.0 113.07 -0.08 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 27' ' ' TYR . . . . . 0.447 ' HD2' ' OD1' ' A' ' 9' ' ' ASP . 45.4 m-85 -104.4 166.76 10.19 Favored 'General case' 0 N--CA 1.469 0.485 0 CA-C-N 115.864 -0.607 . . . . 0.0 111.465 -178.884 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 28' ' ' GLY . . . . . 0.479 ' O ' ' HA ' ' A' ' 7' ' ' GLN . . . -169.95 -164.85 26.36 Favored Glycine 0 C--N 1.341 0.842 0 C-N-CA 120.93 -0.652 . . . . 0.0 113.356 178.492 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 29' ' ' ILE . . . . . 0.526 ' HB ' ' CE2' ' A' ' 31' ' ' TYR . 1.9 mm -117.38 153.07 19.22 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.225 0 O-C-N 124.045 0.497 . . . . 0.0 110.22 -179.938 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 30' ' ' CYS . . . . . 0.48 ' HA ' ' O ' ' A' ' 20' ' ' THR . 20.5 m -80.06 104.66 10.78 Favored 'General case' 0 CA--C 1.536 0.42 0 CA-C-N 115.923 -0.581 . . . . 0.0 111.21 -179.866 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 31' ' ' TYR . . . . . 0.526 ' CE2' ' HB ' ' A' ' 29' ' ' ILE . 39.7 m-85 -130.12 167.51 18.24 Favored 'General case' 0 C--O 1.233 0.223 0 CA-C-N 115.098 -0.956 . . . . 0.0 111.044 -179.54 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 2.6 tp -100.95 131.84 47.82 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.524 0 CA-C-N 116.056 -0.52 . . . . 0.0 110.426 179.486 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 33' ' ' ILE . . . . . 0.442 ' O ' HD12 ' A' ' 33' ' ' ILE . 1.7 pp . . . . . 0 C--O 1.248 0.998 0 CA-C-O 118.383 -0.818 . . . . 0.0 111.522 179.856 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 2' ' ' PRO . . . . . 0.587 ' HD2' ' O ' ' A' ' 14' ' ' PRO . 94.6 Cg_endo . . . . . 0 N--CA 1.489 1.243 0 N-CA-C 113.801 0.654 . . . . 0.0 113.801 . . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -136.4 -158.1 7.97 Favored Glycine 0 C--N 1.342 0.89 0 CA-C-N 115.852 -0.613 . . . . 0.0 112.232 179.749 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 18.3 tt0 -73.52 136.51 44.11 Favored 'General case' 0 N--CA 1.472 0.625 0 C-N-CA 122.717 0.407 . . . . 0.0 111.382 -179.978 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 87.85 9.23 71.61 Favored Glycine 0 C--N 1.339 0.703 0 O-C-N 123.775 0.672 . . . . 0.0 113.398 -179.796 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 3.2 tp10 -129.0 166.49 19.09 Favored 'General case' 0 C--O 1.239 0.53 0 C-N-CA 122.218 0.207 . . . . 0.0 110.576 -179.816 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 7' ' ' GLN . . . . . . . . . . . . . 0.2 OUTLIER -80.6 152.81 28.36 Favored 'General case' 0 C--N 1.347 0.483 0 CA-C-N 116.517 -0.31 . . . . 0.0 110.822 179.782 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 6.2 p -140.85 152.24 44.97 Favored 'General case' 0 C--O 1.234 0.245 0 CA-C-N 115.958 -0.565 . . . . 0.0 111.163 -179.12 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -112.41 146.12 38.92 Favored 'General case' 0 C--O 1.235 0.337 0 CA-C-N 115.397 -0.82 . . . . 0.0 109.626 179.498 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 10' ' ' VAL . . . . . 0.445 HG21 ' O ' ' A' ' 26' ' ' PRO . 6.5 m -101.26 17.91 3.63 Favored 'Isoleucine or valine' 0 CA--C 1.543 0.674 0 CA-C-N 116.46 -0.336 . . . . 0.0 111.604 179.988 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 47.0 mt-10 -107.55 -55.01 2.41 Favored 'General case' 0 N--CA 1.467 0.383 0 CA-C-N 116.346 -0.388 . . . . 0.0 111.873 -179.155 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 12' ' ' PHE . . . . . . . . . . . . . 10.8 t80 -140.35 -16.77 0.92 Allowed 'General case' 0 N--CA 1.471 0.596 0 N-CA-C 112.31 0.485 . . . . 0.0 112.31 -179.193 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 13' ' ' ASN . . . . . 0.476 HD22 ' HD3' ' A' ' 2' ' ' PRO . 13.3 t30 -120.56 72.98 21.76 Favored Pre-proline 0 CA--C 1.548 0.899 0 O-C-N 122.937 0.148 . . . . 0.0 111.139 -179.337 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 14' ' ' PRO . . . . . 0.587 ' O ' ' HD2' ' A' ' 2' ' ' PRO . 62.4 Cg_endo -76.71 -175.13 2.44 Favored 'Trans proline' 0 C--N 1.372 1.806 0 C-N-CA 122.484 2.123 . . . . 0.0 112.347 179.318 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 2.2 t -79.48 119.59 22.68 Favored 'General case' 0 N--CA 1.472 0.651 0 CA-C-O 120.452 0.168 . . . . 0.0 110.727 179.932 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 16' ' ' CYS . . . . . 0.556 ' HB2' ' O ' ' A' ' 2' ' ' PRO . 0.0 OUTLIER -56.25 -52.59 71.8 Favored Pre-proline 0 N--CA 1.481 1.101 0 CA-C-O 119.005 -0.521 . . . . 0.0 111.712 179.611 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 56.9 Cg_endo -72.36 169.67 21.1 Favored 'Trans proline' 0 C--N 1.38 2.205 0 C-N-CA 122.065 1.844 . . . . 0.0 111.721 177.969 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -71.69 51.87 1.6 Allowed 'Trans proline' 0 C--N 1.373 1.859 0 C-N-CA 121.963 1.776 . . . . 0.0 112.769 178.79 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 37.5 mt -110.6 173.12 6.48 Favored 'General case' 0 C--O 1.236 0.37 0 CA-C-N 115.58 -0.736 . . . . 0.0 111.333 -179.565 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 28.8 m -107.92 152.88 23.85 Favored 'General case' 0 CA--C 1.533 0.318 0 CA-C-N 115.874 -0.603 . . . . 0.0 111.346 -178.565 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 3.9 t -101.82 104.25 15.0 Favored 'General case' 0 C--O 1.238 0.471 0 CA-C-N 115.437 -0.801 . . . . 0.0 109.622 178.463 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 22' ' ' ILE . . . . . . . . . . . . . 4.5 mt -125.92 129.75 24.2 Favored Pre-proline 0 CA--C 1.544 0.717 0 CA-C-N 115.918 -0.583 . . . . 0.0 110.544 -178.775 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 23' ' ' PRO . . . . . 0.475 ' HB2' ' OD2' ' A' ' 25' ' ' ASP . 35.2 Cg_endo -66.01 -48.76 0.21 Allowed 'Cis proline' 0 C--N 1.376 1.979 0 C-N-CA 124.71 -0.954 . . . . 0.0 113.807 -0.354 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 80.55 35.61 25.38 Favored Glycine 0 C--N 1.347 1.156 0 C-N-CA 121.299 -0.477 . . . . 0.0 112.91 179.826 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 25' ' ' ASP . . . . . 0.475 ' OD2' ' HB2' ' A' ' 23' ' ' PRO . 2.5 p30 -143.72 84.1 10.11 Favored Pre-proline 0 CA--C 1.548 0.898 0 C-N-CA 122.551 0.34 . . . . 0.0 110.759 -179.789 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 26' ' ' PRO . . . . . 0.445 ' O ' HG21 ' A' ' 10' ' ' VAL . 1.2 Cg_endo -81.41 -32.1 3.95 Favored 'Cis proline' 0 C--N 1.371 1.712 0 C-N-CA 125.15 -0.771 . . . . 0.0 113.087 0.011 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 27' ' ' TYR . . . . . . . . . . . . . 40.1 m-85 -101.79 169.69 8.64 Favored 'General case' 0 C--O 1.239 0.533 0 CA-C-N 115.754 -0.657 . . . . 0.0 111.213 -178.888 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -167.49 -159.42 13.04 Favored Glycine 0 C--N 1.341 0.815 0 C-N-CA 120.888 -0.672 . . . . 0.0 113.243 179.517 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 29' ' ' ILE . . . . . 0.489 ' HB ' ' CE2' ' A' ' 31' ' ' TYR . 4.2 mm -128.17 154.4 38.78 Favored 'Isoleucine or valine' 0 C--O 1.233 0.193 0 CA-C-N 115.276 -0.462 . . . . 0.0 109.853 179.969 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 30' ' ' CYS . . . . . . . . . . . . . 18.2 m -81.55 101.48 9.99 Favored 'General case' 0 CA--C 1.536 0.42 0 CA-C-N 116.02 -0.536 . . . . 0.0 111.395 179.989 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 31' ' ' TYR . . . . . 0.489 ' CE2' ' HB ' ' A' ' 29' ' ' ILE . 38.4 m-85 -130.0 166.53 19.9 Favored 'General case' 0 N--CA 1.464 0.228 0 CA-C-N 115.145 -0.934 . . . . 0.0 110.995 -179.714 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 2.8 tp -101.5 131.96 48.29 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.624 0 CA-C-N 116.141 -0.482 . . . . 0.0 110.377 179.51 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 33' ' ' ILE . . . . . 0.459 ' O ' HD12 ' A' ' 33' ' ' ILE . 1.8 pp . . . . . 0 C--O 1.249 1.057 0 CA-C-O 118.382 -0.818 . . . . 0.0 111.521 179.945 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 5.8 p . . . . . 0 N--CA 1.485 1.311 0 CA-C-O 119.724 -0.179 . . . . 0.0 111.279 . . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' A' A ' 2' ' ' PRO . . . . . 0.534 ' HD3' ' ND2' ' A' ' 13' ' ' ASN . 81.1 Cg_endo -83.07 -172.88 1.5 Allowed 'Trans proline' 0 C--N 1.368 1.556 0 C-N-CA 122.59 2.194 . . . . 0.0 112.942 179.631 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -145.77 -159.22 8.06 Favored Glycine 0 C--N 1.337 0.632 0 N-CA-C 111.547 -0.621 . . . . 0.0 111.547 179.189 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 19.7 tt0 -71.3 125.84 28.05 Favored 'General case' 0 N--CA 1.472 0.668 0 CA-C-N 116.901 0.35 . . . . 0.0 111.072 179.631 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 88.22 16.65 58.8 Favored Glycine 0 C--N 1.339 0.724 0 CA-C-N 115.659 -0.7 . . . . 0.0 113.097 -179.541 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 43.1 mt-10 -127.95 166.91 17.43 Favored 'General case' 0 C--O 1.237 0.433 0 C-N-CA 122.333 0.253 . . . . 0.0 110.719 -179.775 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 7' ' ' GLN . . . . . 0.433 ' HA ' ' O ' ' A' ' 28' ' ' GLY . 0.2 OUTLIER -81.05 152.04 28.08 Favored 'General case' 0 C--N 1.346 0.436 0 CA-C-N 116.502 -0.317 . . . . 0.0 110.974 179.89 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 6.3 p -147.12 156.24 42.83 Favored 'General case' 0 C--O 1.235 0.307 0 CA-C-N 115.963 -0.562 . . . . 0.0 111.583 -178.965 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 4.8 t70 -117.36 149.13 41.01 Favored 'General case' 0 C--O 1.234 0.263 0 CA-C-N 115.452 -0.794 . . . . 0.0 109.589 178.918 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 15.7 m -102.38 24.49 1.48 Allowed 'Isoleucine or valine' 0 CA--C 1.542 0.655 0 CA-C-N 116.225 -0.443 . . . . 0.0 111.905 -179.493 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 43.9 mt-10 -120.63 -50.89 2.18 Favored 'General case' 0 N--CA 1.466 0.333 0 N-CA-C 112.063 0.394 . . . . 0.0 112.063 -179.044 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 12' ' ' PHE . . . . . . . . . . . . . 13.7 m-85 -133.35 -27.23 1.59 Allowed 'General case' 0 N--CA 1.47 0.541 0 N-CA-C 112.181 0.437 . . . . 0.0 112.181 -178.706 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 13' ' ' ASN . . . . . 0.534 ' ND2' ' HD3' ' A' ' 2' ' ' PRO . 6.3 t30 -116.03 73.91 5.11 Favored Pre-proline 0 CA--C 1.549 0.934 0 O-C-N 123.435 0.459 . . . . 0.0 112.174 -177.467 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 14' ' ' PRO . . . . . 0.4 ' O ' ' HD2' ' A' ' 2' ' ' PRO . 60.8 Cg_endo -76.1 179.09 6.67 Favored 'Trans proline' 0 C--N 1.372 1.777 0 C-N-CA 122.43 2.087 . . . . 0.0 112.125 178.746 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 1.9 t -79.67 119.9 23.24 Favored 'General case' 0 N--CA 1.47 0.566 0 CA-C-O 120.499 0.19 . . . . 0.0 110.938 179.75 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER -57.86 -54.07 59.23 Favored Pre-proline 0 N--CA 1.477 0.915 0 CA-C-O 118.973 -0.537 . . . . 0.0 111.757 179.651 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 51.9 Cg_endo -70.39 168.19 23.08 Favored 'Trans proline' 0 C--N 1.378 2.118 0 C-N-CA 122.025 1.817 . . . . 0.0 111.8 178.25 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 49.8 Cg_endo -71.01 60.88 2.39 Favored 'Trans proline' 0 C--N 1.372 1.796 0 C-N-CA 121.945 1.763 . . . . 0.0 112.427 178.807 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 22.6 mt -122.42 171.58 8.97 Favored 'General case' 0 C--O 1.235 0.325 0 CA-C-N 115.411 -0.813 . . . . 0.0 111.421 -179.269 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 20' ' ' THR . . . . . 0.469 ' O ' ' HA ' ' A' ' 30' ' ' CYS . 28.5 m -107.72 153.69 22.58 Favored 'General case' 0 CA--C 1.533 0.306 0 CA-C-N 115.676 -0.693 . . . . 0.0 111.227 -178.676 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 4.8 t -103.06 104.97 15.19 Favored 'General case' 0 C--O 1.237 0.426 0 CA-C-N 115.593 -0.731 . . . . 0.0 109.553 178.626 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 22' ' ' ILE . . . . . . . . . . . . . 3.4 mt -127.12 129.34 23.97 Favored Pre-proline 0 CA--C 1.543 0.686 0 CA-C-N 115.874 -0.603 . . . . 0.0 110.47 -178.805 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 37.6 Cg_endo -67.46 -48.69 0.23 Allowed 'Cis proline' 0 C--N 1.374 1.913 0 C-N-CA 124.713 -0.953 . . . . 0.0 113.848 -0.294 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 80.5 40.74 12.35 Favored Glycine 0 C--N 1.347 1.145 0 C-N-CA 121.264 -0.493 . . . . 0.0 112.761 -179.891 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 8.2 m-20 -141.6 79.31 17.21 Favored Pre-proline 0 CA--C 1.544 0.744 0 C-N-CA 122.443 0.297 . . . . 0.0 110.837 -179.709 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 1.5 Cg_endo -82.49 -32.72 3.29 Favored 'Cis proline' 0 C--N 1.371 1.746 0 C-N-CA 125.074 -0.803 . . . . 0.0 113.028 -0.125 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 27' ' ' TYR . . . . . . . . . . . . . 71.7 m-85 -98.11 171.43 8.25 Favored 'General case' 0 C--O 1.24 0.563 0 CA-C-N 115.913 -0.585 . . . . 0.0 111.568 -178.973 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 28' ' ' GLY . . . . . 0.433 ' O ' ' HA ' ' A' ' 7' ' ' GLN . . . -173.03 -159.84 20.44 Favored Glycine 0 C--N 1.338 0.653 0 CA-C-N 115.784 -0.644 . . . . 0.0 112.365 179.301 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 29' ' ' ILE . . . . . 0.517 ' HB ' ' CE2' ' A' ' 31' ' ' TYR . 2.9 mm -124.21 151.18 29.13 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 N-CA-C 109.735 -0.468 . . . . 0.0 109.735 179.737 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 30' ' ' CYS . . . . . 0.469 ' HA ' ' O ' ' A' ' 20' ' ' THR . 23.4 m -79.94 103.24 9.69 Favored 'General case' 0 CA--C 1.536 0.412 0 CA-C-O 121.225 0.536 . . . . 0.0 111.432 -179.812 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 31' ' ' TYR . . . . . 0.517 ' CE2' ' HB ' ' A' ' 29' ' ' ILE . 38.2 m-85 -129.07 167.77 17.04 Favored 'General case' 0 C--O 1.233 0.211 0 CA-C-N 115.014 -0.993 . . . . 0.0 110.923 -179.623 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 2.7 tp -100.95 131.43 48.62 Favored 'Isoleucine or valine' 0 CA--C 1.542 0.645 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.315 179.411 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 33' ' ' ILE . . . . . 0.452 ' O ' HD12 ' A' ' 33' ' ' ILE . 1.9 pp . . . . . 0 C--O 1.249 1.051 0 CA-C-O 118.395 -0.812 . . . . 0.0 111.413 179.954 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 6.7 p . . . . . 0 N--CA 1.485 1.283 0 CA-C-O 119.778 -0.153 . . . . 0.0 111.161 . . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' A' A ' 2' ' ' PRO . . . . . 0.485 ' HD3' ' ND2' ' A' ' 13' ' ' ASN . 88.6 Cg_endo -82.31 -172.69 1.5 Allowed 'Trans proline' 0 C--N 1.368 1.553 0 C-N-CA 122.57 2.18 . . . . 0.0 112.963 179.437 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -149.46 -159.58 8.7 Favored Glycine 0 C--N 1.338 0.67 0 N-CA-C 111.623 -0.591 . . . . 0.0 111.623 179.229 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 17.2 tt0 -70.05 121.29 17.17 Favored 'General case' 0 N--CA 1.474 0.73 0 CA-C-O 120.763 0.315 . . . . 0.0 111.241 179.811 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 93.37 15.15 51.99 Favored Glycine 0 C--N 1.34 0.782 0 CA-C-N 115.614 -0.721 . . . . 0.0 113.164 -179.776 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 43.1 mt-10 -128.75 166.63 18.62 Favored 'General case' 0 C--O 1.24 0.56 0 C-N-CA 122.514 0.326 . . . . 0.0 110.816 179.959 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 7' ' ' GLN . . . . . 0.42 ' HA ' ' O ' ' A' ' 28' ' ' GLY . 0.2 OUTLIER -81.43 152.55 27.35 Favored 'General case' 0 C--N 1.346 0.435 0 O-C-N 123.195 0.309 . . . . 0.0 111.137 -179.88 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 7.9 p -145.84 154.53 42.1 Favored 'General case' 0 N--CA 1.466 0.354 0 CA-C-N 115.957 -0.565 . . . . 0.0 111.502 -179.12 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 6.2 t70 -118.12 153.82 33.15 Favored 'General case' 0 C--O 1.236 0.345 0 CA-C-N 115.393 -0.821 . . . . 0.0 109.898 179.139 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 13.5 m -105.33 17.92 5.44 Favored 'Isoleucine or valine' 0 CA--C 1.542 0.661 0 CA-C-N 116.286 -0.416 . . . . 0.0 112.033 -179.422 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 46.3 mt-10 -110.74 -52.9 2.75 Favored 'General case' 0 N--CA 1.466 0.36 0 N-CA-C 111.898 0.332 . . . . 0.0 111.898 -179.149 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 12' ' ' PHE . . . . . . . . . . . . . 13.4 t80 -138.76 -15.66 1.17 Allowed 'General case' 0 N--CA 1.469 0.493 0 N-CA-C 112.406 0.521 . . . . 0.0 112.406 -178.945 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 13' ' ' ASN . . . . . 0.485 ' ND2' ' HD3' ' A' ' 2' ' ' PRO . 7.4 t30 -120.62 73.35 22.73 Favored Pre-proline 0 CA--C 1.549 0.929 0 O-C-N 122.935 0.147 . . . . 0.0 111.343 -179.204 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 14' ' ' PRO . . . . . 0.41 ' O ' ' HD2' ' A' ' 2' ' ' PRO . 60.5 Cg_endo -76.43 176.56 9.92 Favored 'Trans proline' 0 C--N 1.371 1.75 0 C-N-CA 122.428 2.085 . . . . 0.0 112.48 179.342 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 1.4 m -79.67 118.9 21.91 Favored 'General case' 0 N--CA 1.469 0.488 0 O-C-N 123.199 0.312 . . . . 0.0 111.422 179.923 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER -58.03 -53.87 61.43 Favored Pre-proline 0 N--CA 1.477 0.906 0 CA-C-N 115.865 -0.607 . . . . 0.0 111.776 179.81 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 53.3 Cg_endo -70.28 168.65 21.61 Favored 'Trans proline' 0 C--N 1.379 2.132 0 C-N-CA 121.983 1.789 . . . . 0.0 111.736 178.351 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 56.0 Cg_endo -72.4 47.34 1.09 Allowed 'Trans proline' 0 C--N 1.37 1.673 0 C-N-CA 121.872 1.714 . . . . 0.0 112.855 178.987 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 19' ' ' LEU . . . . . 0.444 ' HB2' ' SG ' ' A' ' 30' ' ' CYS . 13.0 mt -107.58 171.08 7.59 Favored 'General case' 0 CA--C 1.533 0.32 0 CA-C-N 115.921 -0.582 . . . . 0.0 110.955 -179.537 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 28.6 m -104.43 148.84 25.98 Favored 'General case' 0 CA--C 1.531 0.25 0 CA-C-N 115.829 -0.623 . . . . 0.0 111.108 -178.76 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 5.9 t -98.49 103.03 14.95 Favored 'General case' 0 C--O 1.238 0.499 0 N-CA-C 109.421 -0.585 . . . . 0.0 109.421 178.384 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 22' ' ' ILE . . . . . . . . . . . . . 2.5 mt -126.62 129.02 24.19 Favored Pre-proline 0 CA--C 1.543 0.703 0 CA-C-N 115.817 -0.629 . . . . 0.0 110.742 -178.547 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 37.4 Cg_endo -67.67 -48.55 0.24 Allowed 'Cis proline' 0 C--N 1.374 1.908 0 C-N-CA 124.719 -0.95 . . . . 0.0 113.782 -0.262 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 79.38 38.7 20.79 Favored Glycine 0 C--N 1.348 1.227 0 C-N-CA 121.37 -0.443 . . . . 0.0 112.894 -179.991 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 8.4 m-20 -140.71 79.99 18.72 Favored Pre-proline 0 CA--C 1.544 0.735 0 C-N-CA 122.447 0.299 . . . . 0.0 110.869 -179.728 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 1.8 Cg_endo -82.23 -32.63 3.41 Favored 'Cis proline' 0 C--N 1.372 1.811 0 C-N-CA 125.15 -0.771 . . . . 0.0 112.945 -0.127 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 27' ' ' TYR . . . . . . . . . . . . . 68.0 m-85 -99.37 171.64 7.84 Favored 'General case' 0 C--O 1.238 0.482 0 CA-C-N 115.786 -0.643 . . . . 0.0 111.652 -179.096 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 28' ' ' GLY . . . . . 0.42 ' O ' ' HA ' ' A' ' 7' ' ' GLN . . . -174.64 -159.79 21.56 Favored Glycine 0 C--N 1.337 0.62 0 CA-C-N 115.801 -0.636 . . . . 0.0 112.268 179.185 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 29' ' ' ILE . . . . . 0.544 ' HB ' ' CE2' ' A' ' 31' ' ' TYR . 1.8 mm -124.12 152.1 29.57 Favored 'Isoleucine or valine' 0 C--O 1.233 0.236 0 N-CA-C 109.755 -0.461 . . . . 0.0 109.755 179.627 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 30' ' ' CYS . . . . . 0.444 ' SG ' ' HB2' ' A' ' 19' ' ' LEU . 0.5 OUTLIER -80.12 104.49 10.71 Favored 'General case' 0 C--O 1.238 0.454 0 CA-C-N 115.974 -0.557 . . . . 0.0 110.99 -179.856 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 31' ' ' TYR . . . . . 0.544 ' CE2' ' HB ' ' A' ' 29' ' ' ILE . 36.1 m-85 -130.22 166.62 19.92 Favored 'General case' 0 C--O 1.233 0.189 0 CA-C-N 115.431 -0.804 . . . . 0.0 111.141 -179.501 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 2.8 tp -100.93 131.42 48.61 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.547 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.438 179.431 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 33' ' ' ILE . . . . . 0.451 ' O ' HD13 ' A' ' 33' ' ' ILE . 1.9 pp . . . . . 0 C--O 1.249 1.042 0 CA-C-O 118.28 -0.866 . . . . 0.0 111.518 179.903 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 5.9 p . . . . . 0 N--CA 1.487 1.375 0 CA-C-O 119.766 -0.159 . . . . 0.0 111.226 . . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' A' A ' 2' ' ' PRO . . . . . 0.527 ' HD3' ' ND2' ' A' ' 13' ' ' ASN . 84.1 Cg_endo -82.63 -172.51 1.43 Allowed 'Trans proline' 0 C--N 1.367 1.531 0 C-N-CA 122.593 2.195 . . . . 0.0 112.845 179.554 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -147.12 -161.71 9.54 Favored Glycine 0 C--N 1.338 0.665 0 N-CA-C 111.696 -0.562 . . . . 0.0 111.696 179.194 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 19.4 tt0 -67.8 124.03 22.17 Favored 'General case' 0 N--CA 1.474 0.747 0 C-N-CA 122.488 0.315 . . . . 0.0 111.212 179.68 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 91.07 15.08 56.76 Favored Glycine 0 C--N 1.338 0.681 0 CA-C-N 115.66 -0.7 . . . . 0.0 113.125 -179.718 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 43.1 mt-10 -129.06 165.22 21.62 Favored 'General case' 0 C--O 1.237 0.414 0 C-N-CA 122.29 0.236 . . . . 0.0 110.802 -179.942 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 7' ' ' GLN . . . . . . . . . . . . . 0.2 OUTLIER -81.55 152.98 27.0 Favored 'General case' 0 C--N 1.346 0.454 0 CA-C-N 116.43 -0.35 . . . . 0.0 110.936 179.915 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 3.2 p -142.23 152.07 42.72 Favored 'General case' 0 C--O 1.234 0.249 0 CA-C-N 115.821 -0.627 . . . . 0.0 111.208 -179.255 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -110.04 141.32 43.02 Favored 'General case' 0 C--O 1.232 0.163 0 CA-C-N 115.541 -0.754 . . . . 0.0 109.492 179.38 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 8.8 m -96.59 21.5 1.15 Allowed 'Isoleucine or valine' 0 CA--C 1.543 0.675 0 CA-C-N 116.326 -0.397 . . . . 0.0 111.566 -179.984 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 45.5 mt-10 -113.81 -54.83 2.57 Favored 'General case' 0 C--O 1.236 0.351 0 N-CA-C 112.048 0.388 . . . . 0.0 112.048 -179.042 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 12' ' ' PHE . . . . . . . . . . . . . 10.5 t80 -137.62 -18.56 1.24 Allowed 'General case' 0 N--CA 1.471 0.625 0 N-CA-C 112.516 0.561 . . . . 0.0 112.516 -178.891 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 13' ' ' ASN . . . . . 0.527 ' ND2' ' HD3' ' A' ' 2' ' ' PRO . 9.2 t30 -119.2 73.83 14.06 Favored Pre-proline 0 CA--C 1.55 0.954 0 O-C-N 122.918 0.136 . . . . 0.0 111.118 -179.332 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 14' ' ' PRO . . . . . 0.407 ' O ' ' HD2' ' A' ' 2' ' ' PRO . 60.5 Cg_endo -75.69 -178.84 4.6 Favored 'Trans proline' 0 C--N 1.371 1.745 0 C-N-CA 122.443 2.095 . . . . 0.0 112.506 179.481 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 15' ' ' CYS . . . . . 0.519 ' SG ' ' HB2' ' A' ' 19' ' ' LEU . 4.3 t -79.47 120.48 23.93 Favored 'General case' 0 N--CA 1.471 0.623 0 O-C-N 123.079 0.237 . . . . 0.0 111.095 179.981 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER -60.27 -54.49 54.63 Favored Pre-proline 0 N--CA 1.476 0.847 0 CA-C-O 119.062 -0.494 . . . . 0.0 111.577 179.45 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 56.7 Cg_endo -71.22 168.81 22.28 Favored 'Trans proline' 0 C--N 1.381 2.241 0 C-N-CA 122.096 1.864 . . . . 0.0 111.614 178.123 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 48.4 Cg_endo -70.48 61.29 2.12 Favored 'Trans proline' 0 C--N 1.37 1.677 0 C-N-CA 121.918 1.745 . . . . 0.0 112.78 179.048 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 19' ' ' LEU . . . . . 0.519 ' HB2' ' SG ' ' A' ' 15' ' ' CYS . 90.7 mt -122.2 166.62 14.31 Favored 'General case' 0 C--O 1.235 0.331 0 CA-C-N 115.713 -0.676 . . . . 0.0 111.189 -179.869 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 20' ' ' THR . . . . . 0.454 ' OG1' HG12 ' A' ' 33' ' ' ILE . 89.5 m -106.32 149.65 26.73 Favored 'General case' 0 CA--C 1.533 0.302 0 CA-C-N 115.305 -0.861 . . . . 0.0 110.947 -179.3 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 21' ' ' CYS . . . . . 0.497 ' HA ' ' O ' ' A' ' 29' ' ' ILE . 1.9 t -95.25 106.94 19.02 Favored 'General case' 0 C--O 1.24 0.555 0 CA-C-N 115.726 -0.67 . . . . 0.0 110.244 178.917 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 22' ' ' ILE . . . . . . . . . . . . . 5.9 mt -125.47 128.5 24.67 Favored Pre-proline 0 CA--C 1.544 0.717 0 CA-C-N 115.928 -0.578 . . . . 0.0 110.531 -179.185 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 37.4 Cg_endo -67.19 -48.0 0.25 Allowed 'Cis proline' 0 C--N 1.375 1.963 0 C-N-CA 124.685 -0.964 . . . . 0.0 113.757 -0.35 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 83.07 35.75 17.29 Favored Glycine 0 C--N 1.345 1.07 0 C-N-CA 121.433 -0.413 . . . . 0.0 112.918 179.781 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 7.6 m-20 -143.91 83.6 10.27 Favored Pre-proline 0 CA--C 1.546 0.819 0 C-N-CA 122.478 0.311 . . . . 0.0 111.04 -179.661 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 69.7 Cg_endo -82.15 -31.73 4.01 Favored 'Cis proline' 0 C--N 1.372 1.813 0 C-N-CA 124.814 -0.911 . . . . 0.0 113.479 -0.218 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 27' ' ' TYR . . . . . . . . . . . . . 59.8 m-85 -96.92 163.32 13.01 Favored 'General case' 0 N--CA 1.47 0.548 0 CA-C-N 115.956 -0.565 . . . . 0.0 111.208 -179.16 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 28' ' ' GLY . . . . . 0.432 ' O ' HD11 ' A' ' 29' ' ' ILE . . . -157.89 -162.01 11.39 Favored Glycine 0 C--N 1.339 0.746 0 C-N-CA 120.92 -0.657 . . . . 0.0 113.098 179.815 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 29' ' ' ILE . . . . . 0.497 ' O ' ' HA ' ' A' ' 21' ' ' CYS . 5.0 mm -130.53 154.81 41.14 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.222 0 N-CA-C 109.709 -0.478 . . . . 0.0 109.709 179.948 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 30' ' ' CYS . . . . . . . . . . . . . 26.2 m -83.72 92.81 7.8 Favored 'General case' 0 C--O 1.238 0.489 0 CA-C-O 121.483 0.659 . . . . 0.0 111.403 -179.968 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 31' ' ' TYR . . . . . 0.431 ' CE2' ' HB ' ' A' ' 29' ' ' ILE . 37.1 m-85 -124.26 167.26 14.56 Favored 'General case' 0 N--CA 1.464 0.241 0 CA-C-N 114.962 -1.017 . . . . 0.0 110.902 179.945 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 2.8 tp -99.98 131.66 46.99 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.605 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.449 179.378 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 33' ' ' ILE . . . . . 0.454 HG12 ' OG1' ' A' ' 20' ' ' THR . 1.3 pt . . . . . 0 C--O 1.249 1.048 0 CA-C-O 118.142 -0.932 . . . . 0.0 111.416 179.832 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 5.8 p . . . . . 0 N--CA 1.486 1.347 0 CA-C-O 119.823 -0.132 . . . . 0.0 111.199 . . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' A' A ' 2' ' ' PRO . . . . . 0.542 ' HD3' ' ND2' ' A' ' 13' ' ' ASN . 85.2 Cg_endo -82.82 -172.57 1.44 Allowed 'Trans proline' 0 C--N 1.366 1.497 0 C-N-CA 122.598 2.199 . . . . 0.0 112.832 179.514 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -146.59 -160.92 9.01 Favored Glycine 0 C--N 1.337 0.603 0 N-CA-C 111.661 -0.576 . . . . 0.0 111.661 179.141 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 19.6 tt0 -68.21 124.5 23.65 Favored 'General case' 0 N--CA 1.475 0.824 0 CA-C-N 116.816 0.308 . . . . 0.0 111.145 179.673 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 90.73 15.07 57.27 Favored Glycine 0 C--N 1.338 0.667 0 CA-C-N 115.663 -0.699 . . . . 0.0 113.143 -179.692 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 43.1 mt-10 -129.02 165.11 21.8 Favored 'General case' 0 C--O 1.239 0.53 0 C-N-CA 122.339 0.256 . . . . 0.0 110.807 -179.891 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 7' ' ' GLN . . . . . . . . . . . . . 0.2 OUTLIER -81.65 152.9 26.91 Favored 'General case' 0 C--N 1.346 0.433 0 O-C-N 123.179 0.3 . . . . 0.0 110.895 179.874 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 3.2 p -141.68 151.79 43.33 Favored 'General case' 0 C--O 1.234 0.242 0 CA-C-N 115.8 -0.636 . . . . 0.0 111.099 -179.272 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -110.34 143.56 40.38 Favored 'General case' 0 C--O 1.234 0.26 0 CA-C-N 115.481 -0.782 . . . . 0.0 109.532 179.423 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 10' ' ' VAL . . . . . 0.417 HG21 ' O ' ' A' ' 26' ' ' PRO . 6.1 m -98.28 21.06 1.52 Allowed 'Isoleucine or valine' 0 CA--C 1.541 0.606 0 O-C-N 123.238 0.336 . . . . 0.0 111.514 -179.899 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 8.5 mm-40 -115.53 -52.48 2.64 Favored 'General case' 0 C--O 1.235 0.304 0 N-CA-C 112.252 0.464 . . . . 0.0 112.252 -179.125 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 12' ' ' PHE . . . . . . . . . . . . . 13.0 t80 -141.04 -9.21 1.01 Allowed 'General case' 0 N--CA 1.473 0.709 0 N-CA-C 112.722 0.638 . . . . 0.0 112.722 -178.666 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 13' ' ' ASN . . . . . 0.542 ' ND2' ' HD3' ' A' ' 2' ' ' PRO . 7.6 t30 -129.64 64.94 73.55 Favored Pre-proline 0 CA--C 1.551 0.986 0 CA-C-N 117.496 0.135 . . . . 0.0 111.25 -179.075 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 15.8 Cg_exo -69.04 -178.66 2.16 Favored 'Trans proline' 0 C--N 1.372 1.808 0 C-N-CA 122.957 2.438 . . . . 0.0 112.266 179.009 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 15' ' ' CYS . . . . . 0.516 ' SG ' ' HB2' ' A' ' 19' ' ' LEU . 4.0 t -79.65 121.79 25.73 Favored 'General case' 0 N--CA 1.472 0.64 0 O-C-N 123.135 0.272 . . . . 0.0 111.331 -179.781 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER -61.35 -54.32 54.04 Favored Pre-proline 0 CA--C 1.547 0.845 0 CA-C-O 119.024 -0.512 . . . . 0.0 111.43 179.22 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 56.7 Cg_endo -71.19 169.21 21.22 Favored 'Trans proline' 0 C--N 1.38 2.225 0 C-N-CA 121.96 1.773 . . . . 0.0 111.719 178.193 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 49.0 Cg_endo -70.56 59.12 2.0 Favored 'Trans proline' 0 C--N 1.372 1.795 0 C-N-CA 121.918 1.746 . . . . 0.0 112.896 179.071 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 19' ' ' LEU . . . . . 0.516 ' HB2' ' SG ' ' A' ' 15' ' ' CYS . 92.2 mt -119.99 165.2 14.98 Favored 'General case' 0 C--O 1.235 0.31 0 CA-C-N 115.751 -0.659 . . . . 0.0 111.176 -179.95 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 87.5 m -104.08 150.58 24.17 Favored 'General case' 0 CA--C 1.532 0.285 0 CA-C-N 115.327 -0.851 . . . . 0.0 110.978 -179.464 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 21' ' ' CYS . . . . . 0.494 ' HA ' ' O ' ' A' ' 29' ' ' ILE . 1.9 t -96.57 104.55 16.54 Favored 'General case' 0 C--O 1.238 0.464 0 CA-C-N 115.669 -0.696 . . . . 0.0 109.98 178.94 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 22' ' ' ILE . . . . . . . . . . . . . 6.1 mt -122.83 128.01 25.53 Favored Pre-proline 0 CA--C 1.543 0.705 0 CA-C-N 115.865 -0.607 . . . . 0.0 110.546 -179.178 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 36.8 Cg_endo -66.96 -47.57 0.26 Allowed 'Cis proline' 0 C--N 1.376 1.977 0 C-N-CA 124.632 -0.987 . . . . 0.0 113.801 -0.302 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 83.73 32.85 23.29 Favored Glycine 0 C--N 1.345 1.081 0 C-N-CA 121.305 -0.474 . . . . 0.0 113.021 179.719 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 7.7 m-20 -144.18 86.57 8.27 Favored Pre-proline 0 CA--C 1.545 0.772 0 C-N-CA 122.56 0.344 . . . . 0.0 110.532 -179.654 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 26' ' ' PRO . . . . . 0.417 ' O ' HG21 ' A' ' 10' ' ' VAL . 1.1 Cg_endo -81.47 -31.34 4.49 Favored 'Cis proline' 0 C--N 1.371 1.733 0 C-N-CA 125.164 -0.765 . . . . 0.0 112.888 0.018 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 27' ' ' TYR . . . . . . . . . . . . . 41.3 m-85 -101.76 166.56 10.61 Favored 'General case' 0 C--O 1.237 0.398 0 CA-C-N 115.712 -0.676 . . . . 0.0 111.104 -179.137 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 28' ' ' GLY . . . . . 0.419 ' O ' HD13 ' A' ' 29' ' ' ILE . . . -160.63 -160.82 10.93 Favored Glycine 0 C--N 1.341 0.807 0 C-N-CA 120.911 -0.661 . . . . 0.0 113.21 179.999 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 29' ' ' ILE . . . . . 0.494 ' O ' ' HA ' ' A' ' 21' ' ' CYS . 4.8 mm -129.76 155.29 41.3 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.255 0 CA-C-N 115.273 -0.464 . . . . 0.0 109.887 -179.995 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 30' ' ' CYS . . . . . . . . . . . . . 30.1 m -84.04 93.78 8.17 Favored 'General case' 0 C--O 1.237 0.433 0 CA-C-O 121.39 0.614 . . . . 0.0 111.302 179.926 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 31' ' ' TYR . . . . . 0.43 ' CE2' ' HB ' ' A' ' 29' ' ' ILE . 35.4 m-85 -124.37 168.4 13.07 Favored 'General case' 0 N--CA 1.464 0.255 0 CA-C-N 115.012 -0.994 . . . . 0.0 111.14 -179.863 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 2.6 tp -100.68 133.48 43.7 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.598 0 CA-C-N 116.082 -0.508 . . . . 0.0 110.343 179.391 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 33' ' ' ILE . . . . . 0.428 HD11 ' OXT' ' A' ' 33' ' ' ILE . 1.6 pp . . . . . 0 C--O 1.249 1.031 0 CA-C-O 118.081 -0.961 . . . . 0.0 111.519 179.888 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 3.9 p . . . . . 0 N--CA 1.486 1.327 0 CA-C-O 119.818 -0.134 . . . . 0.0 111.329 . . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' A' A ' 2' ' ' PRO . . . . . 0.478 ' HD3' HD22 ' A' ' 13' ' ' ASN . 94.5 Cg_endo -83.96 -171.88 1.16 Allowed 'Trans proline' 0 C--N 1.368 1.588 0 C-N-CA 122.541 2.161 . . . . 0.0 112.937 179.71 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -143.95 -153.53 5.9 Favored Glycine 0 C--N 1.339 0.724 0 N-CA-C 111.669 -0.573 . . . . 0.0 111.669 179.381 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 17.7 tt0 -73.92 130.26 39.52 Favored 'General case' 0 N--CA 1.472 0.668 0 C-N-CA 122.546 0.338 . . . . 0.0 111.265 179.578 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 85.81 15.35 65.64 Favored Glycine 0 C--N 1.339 0.709 0 CA-C-N 115.921 -0.582 . . . . 0.0 113.452 -179.756 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 43.1 mt-10 -126.02 161.13 28.26 Favored 'General case' 0 C--O 1.237 0.406 0 C-N-CA 122.243 0.217 . . . . 0.0 110.849 -179.829 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 7' ' ' GLN . . . . . 0.66 ' HA ' ' O ' ' A' ' 28' ' ' GLY . 18.9 tt0 -87.01 134.81 33.45 Favored 'General case' 0 C--N 1.346 0.422 0 CA-C-O 121.176 0.512 . . . . 0.0 111.311 179.89 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 8' ' ' CYS . . . . . 0.401 ' SG ' ' SG ' ' A' ' 30' ' ' CYS . 2.5 p -129.3 161.41 30.29 Favored 'General case' 0 C--O 1.239 0.522 0 CA-C-N 114.538 -1.21 . . . . 0.0 110.989 -179.528 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 9' ' ' ASP . . . . . 0.582 ' OD1' ' HB3' ' A' ' 13' ' ' ASN . 0.7 OUTLIER -120.69 142.68 49.26 Favored 'General case' 0 N--CA 1.463 0.222 0 CA-C-N 115.725 -0.67 . . . . 0.0 110.042 178.528 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 23.2 m -90.78 13.85 1.59 Allowed 'Isoleucine or valine' 0 CA--C 1.543 0.697 0 CA-C-N 115.994 -0.548 . . . . 0.0 111.593 -179.398 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 45.9 mt-10 -97.05 -51.96 4.03 Favored 'General case' 0 C--O 1.235 0.304 0 CA-C-N 116.029 -0.532 . . . . 0.0 111.938 -178.804 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 12' ' ' PHE . . . . . . . . . . . . . 7.2 t80 -144.97 -21.56 0.5 Allowed 'General case' 0 N--CA 1.473 0.691 0 N-CA-C 112.657 0.614 . . . . 0.0 112.657 -178.771 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 13' ' ' ASN . . . . . 0.582 ' HB3' ' OD1' ' A' ' 9' ' ' ASP . 13.2 t30 -120.03 75.13 21.32 Favored Pre-proline 0 CA--C 1.548 0.88 0 CA-C-N 117.521 0.146 . . . . 0.0 111.324 -178.889 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 61.4 Cg_endo -76.84 -175.89 2.87 Favored 'Trans proline' 0 C--N 1.372 1.774 0 C-N-CA 122.57 2.18 . . . . 0.0 112.16 178.731 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 0.8 OUTLIER -79.99 121.61 25.7 Favored 'General case' 0 N--CA 1.472 0.633 0 O-C-N 123.02 0.2 . . . . 0.0 111.189 179.879 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER -58.16 -53.56 64.69 Favored Pre-proline 0 N--CA 1.478 0.965 0 CA-C-N 116.137 -0.483 . . . . 0.0 111.593 179.106 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 41.5 Cg_endo -67.72 169.65 15.59 Favored 'Trans proline' 0 C--N 1.379 2.172 0 C-N-CA 122.148 1.899 . . . . 0.0 111.852 178.165 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 55.2 Cg_endo -71.84 47.8 1.01 Allowed 'Trans proline' 0 C--N 1.371 1.753 0 C-N-CA 122.007 1.805 . . . . 0.0 112.755 178.658 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 19.5 mt -108.8 165.4 11.59 Favored 'General case' 0 C--O 1.236 0.375 0 CA-C-N 115.7 -0.682 . . . . 0.0 111.285 -179.451 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 20' ' ' THR . . . . . 0.512 ' O ' ' HA ' ' A' ' 30' ' ' CYS . 30.7 m -103.24 152.53 21.39 Favored 'General case' 0 CA--C 1.531 0.227 0 CA-C-N 115.569 -0.742 . . . . 0.0 111.038 -178.833 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 2.2 t -102.64 99.75 9.76 Favored 'General case' 0 C--O 1.237 0.435 0 CA-C-N 115.753 -0.658 . . . . 0.0 109.594 178.902 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 22' ' ' ILE . . . . . . . . . . . . . 2.9 mt -120.88 128.78 25.6 Favored Pre-proline 0 CA--C 1.542 0.652 0 CA-C-N 115.637 -0.71 . . . . 0.0 110.372 -178.973 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 37.0 Cg_endo -66.81 -47.5 0.26 Allowed 'Cis proline' 0 C--N 1.375 1.936 0 C-N-CA 124.77 -0.929 . . . . 0.0 113.867 -0.232 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 79.11 34.03 34.48 Favored Glycine 0 C--N 1.347 1.173 0 C-N-CA 121.277 -0.487 . . . . 0.0 112.894 179.969 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 8.3 m-20 -139.73 83.26 16.85 Favored Pre-proline 0 CA--C 1.543 0.686 0 C-N-CA 122.561 0.344 . . . . 0.0 110.538 -179.712 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 3.1 Cg_exo -80.61 -32.05 4.18 Favored 'Cis proline' 0 C--N 1.371 1.746 0 C-N-CA 125.095 -0.794 . . . . 0.0 112.948 -0.099 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 27' ' ' TYR . . . . . 0.552 ' CD2' ' HB3' ' A' ' 9' ' ' ASP . 62.6 m-85 -106.85 172.67 6.69 Favored 'General case' 0 C--O 1.239 0.552 0 CA-C-N 115.753 -0.658 . . . . 0.0 111.751 -178.95 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 28' ' ' GLY . . . . . 0.66 ' O ' ' HA ' ' A' ' 7' ' ' GLN . . . -176.53 -164.08 29.95 Favored Glycine 0 C--N 1.338 0.693 0 CA-C-N 115.732 -0.667 . . . . 0.0 112.655 178.452 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 29' ' ' ILE . . . . . 0.535 ' HB ' ' CE2' ' A' ' 31' ' ' TYR . 2.6 mm -114.72 151.3 16.49 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 N-CA-C 110.082 -0.34 . . . . 0.0 110.082 -179.718 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 30' ' ' CYS . . . . . 0.512 ' HA ' ' O ' ' A' ' 20' ' ' THR . 40.7 m -79.87 105.74 11.38 Favored 'General case' 0 C--O 1.237 0.395 0 CA-C-N 115.843 -0.617 . . . . 0.0 111.482 -179.801 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 31' ' ' TYR . . . . . 0.535 ' CE2' ' HB ' ' A' ' 29' ' ' ILE . 36.6 m-85 -130.42 167.1 19.14 Favored 'General case' 0 C--O 1.233 0.205 0 CA-C-N 114.938 -1.028 . . . . 0.0 111.011 -179.406 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 2.9 tp -99.64 130.28 48.94 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.607 0 CA-C-N 116.27 -0.423 . . . . 0.0 110.348 179.436 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 33' ' ' ILE . . . . . 0.454 ' O ' HD11 ' A' ' 33' ' ' ILE . 1.9 pp . . . . . 0 C--O 1.248 0.993 0 CA-C-O 118.335 -0.84 . . . . 0.0 111.528 179.879 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 3.9 p . . . . . 0 N--CA 1.486 1.329 0 CA-C-O 119.766 -0.159 . . . . 0.0 111.325 . . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' A' A ' 2' ' ' PRO . . . . . 0.478 ' HD3' HD22 ' A' ' 13' ' ' ASN . 92.2 Cg_endo -83.96 -171.93 1.17 Allowed 'Trans proline' 0 C--N 1.368 1.588 0 C-N-CA 122.527 2.151 . . . . 0.0 112.953 179.641 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -143.83 -153.45 5.88 Favored Glycine 0 C--N 1.339 0.701 0 N-CA-C 111.821 -0.512 . . . . 0.0 111.821 179.383 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 17.7 tt0 -74.04 130.17 39.3 Favored 'General case' 0 N--CA 1.473 0.702 0 C-N-CA 122.702 0.401 . . . . 0.0 111.134 179.586 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 85.76 15.54 65.38 Favored Glycine 0 C--N 1.339 0.705 0 O-C-N 123.712 0.632 . . . . 0.0 113.386 -179.85 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 43.0 mt-10 -126.11 161.25 28.06 Favored 'General case' 0 C--O 1.238 0.474 0 C-N-CA 122.276 0.23 . . . . 0.0 110.85 -179.915 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 7' ' ' GLN . . . . . 0.661 ' HA ' ' O ' ' A' ' 28' ' ' GLY . 18.6 tt0 -87.1 134.81 33.47 Favored 'General case' 0 C--N 1.344 0.363 0 CA-C-O 121.258 0.552 . . . . 0.0 111.241 179.915 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 8' ' ' CYS . . . . . 0.401 ' SG ' ' SG ' ' A' ' 30' ' ' CYS . 2.5 p -129.3 161.42 30.27 Favored 'General case' 0 C--O 1.238 0.488 0 CA-C-N 114.511 -1.222 . . . . 0.0 111.017 -179.589 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 9' ' ' ASP . . . . . 0.582 ' OD1' ' HB3' ' A' ' 13' ' ' ASN . 0.7 OUTLIER -120.7 142.86 49.11 Favored 'General case' 0 N--CA 1.464 0.269 0 CA-C-N 115.693 -0.685 . . . . 0.0 109.992 178.557 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 22.5 m -90.89 13.76 1.63 Allowed 'Isoleucine or valine' 0 CA--C 1.543 0.677 0 CA-C-N 115.924 -0.58 . . . . 0.0 111.501 -179.337 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 46.0 mt-10 -96.94 -51.91 4.07 Favored 'General case' 0 C--O 1.235 0.327 0 CA-C-N 116.158 -0.474 . . . . 0.0 111.986 -178.802 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 12' ' ' PHE . . . . . . . . . . . . . 6.8 t80 -145.16 -21.49 0.49 Allowed 'General case' 0 N--CA 1.472 0.639 0 N-CA-C 112.671 0.619 . . . . 0.0 112.671 -178.845 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 13' ' ' ASN . . . . . 0.582 ' HB3' ' OD1' ' A' ' 9' ' ' ASP . 13.3 t30 -119.91 75.19 20.52 Favored Pre-proline 0 CA--C 1.548 0.887 0 CA-C-N 117.557 0.162 . . . . 0.0 111.336 -179.017 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 62.7 Cg_endo -76.85 -175.87 2.86 Favored 'Trans proline' 0 C--N 1.37 1.679 0 C-N-CA 122.663 2.242 . . . . 0.0 112.204 178.672 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 0.8 OUTLIER -79.99 121.56 25.64 Favored 'General case' 0 N--CA 1.471 0.603 0 CA-C-O 120.462 0.172 . . . . 0.0 111.168 179.9 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER -58.17 -53.52 65.15 Favored Pre-proline 0 N--CA 1.479 0.978 0 CA-C-O 119.049 -0.501 . . . . 0.0 111.568 179.117 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 41.7 Cg_endo -67.75 169.69 15.56 Favored 'Trans proline' 0 C--N 1.38 2.22 0 C-N-CA 122.104 1.869 . . . . 0.0 111.865 178.202 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 55.3 Cg_endo -71.77 47.69 0.98 Allowed 'Trans proline' 0 C--N 1.373 1.818 0 C-N-CA 121.981 1.787 . . . . 0.0 112.735 178.731 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 19.4 mt -108.78 165.38 11.6 Favored 'General case' 0 C--O 1.235 0.332 0 CA-C-N 115.681 -0.691 . . . . 0.0 111.272 -179.359 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 20' ' ' THR . . . . . 0.511 ' O ' ' HA ' ' A' ' 30' ' ' CYS . 30.5 m -103.19 152.37 21.54 Favored 'General case' 0 CA--C 1.531 0.227 0 CA-C-N 115.623 -0.717 . . . . 0.0 111.084 -178.902 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 2.2 t -102.45 99.75 9.82 Favored 'General case' 0 C--O 1.237 0.445 0 CA-C-N 115.719 -0.673 . . . . 0.0 109.6 178.837 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 22' ' ' ILE . . . . . . . . . . . . . 2.9 mt -120.91 128.73 25.63 Favored Pre-proline 0 CA--C 1.541 0.615 0 CA-C-N 115.677 -0.692 . . . . 0.0 110.4 -179.026 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 37.1 Cg_endo -66.92 -47.36 0.26 Allowed 'Cis proline' 0 C--N 1.374 1.919 0 C-N-CA 124.636 -0.985 . . . . 0.0 113.859 -0.112 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 79.03 33.99 34.89 Favored Glycine 0 C--N 1.348 1.196 0 C-N-CA 121.228 -0.51 . . . . 0.0 112.916 179.961 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 8.3 m-20 -139.68 83.24 16.99 Favored Pre-proline 0 CA--C 1.544 0.721 0 C-N-CA 122.576 0.35 . . . . 0.0 110.647 -179.793 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 3.2 Cg_exo -80.7 -31.92 4.26 Favored 'Cis proline' 0 C--N 1.371 1.729 0 C-N-CA 125.102 -0.791 . . . . 0.0 112.957 -0.005 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 27' ' ' TYR . . . . . 0.553 ' CD2' ' HB3' ' A' ' 9' ' ' ASP . 62.6 m-85 -106.96 172.66 6.7 Favored 'General case' 0 C--O 1.238 0.49 0 CA-C-N 115.737 -0.665 . . . . 0.0 111.705 -178.957 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 28' ' ' GLY . . . . . 0.661 ' O ' ' HA ' ' A' ' 7' ' ' GLN . . . -176.45 -164.17 30.06 Favored Glycine 0 C--N 1.34 0.771 0 CA-C-N 115.74 -0.664 . . . . 0.0 112.559 178.474 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 29' ' ' ILE . . . . . 0.535 ' HB ' ' CE2' ' A' ' 31' ' ' TYR . 2.6 mm -114.68 151.35 16.44 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 O-C-N 123.75 0.324 . . . . 0.0 110.155 -179.733 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 30' ' ' CYS . . . . . 0.511 ' HA ' ' O ' ' A' ' 20' ' ' THR . 41.4 m -79.82 105.72 11.31 Favored 'General case' 0 C--O 1.237 0.425 0 CA-C-N 115.981 -0.554 . . . . 0.0 111.399 -179.729 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 31' ' ' TYR . . . . . 0.535 ' CE2' ' HB ' ' A' ' 29' ' ' ILE . 37.1 m-85 -130.48 167.18 19.04 Favored 'General case' 0 C--O 1.233 0.205 0 CA-C-N 114.989 -1.005 . . . . 0.0 111.018 -179.566 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 2.9 tp -99.63 130.2 49.04 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.584 0 CA-C-N 116.121 -0.491 . . . . 0.0 110.343 179.562 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 33' ' ' ILE . . . . . 0.455 ' O ' HD12 ' A' ' 33' ' ' ILE . 1.9 pp . . . . . 0 C--O 1.249 1.051 0 CA-C-O 118.331 -0.843 . . . . 0.0 111.521 179.858 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 4.3 p . . . . . 0 N--CA 1.486 1.373 0 CA-C-O 119.801 -0.142 . . . . 0.0 111.233 . . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' A' A ' 2' ' ' PRO . . . . . 0.43 ' HD3' ' ND2' ' A' ' 13' ' ' ASN . 97.6 Cg_endo -82.43 -172.27 1.38 Allowed 'Trans proline' 0 C--N 1.367 1.53 0 C-N-CA 122.577 2.185 . . . . 0.0 112.965 179.596 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -145.12 -154.99 6.29 Favored Glycine 0 C--N 1.339 0.727 0 N-CA-C 111.78 -0.528 . . . . 0.0 111.78 179.393 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 17.9 tt0 -73.3 128.85 36.66 Favored 'General case' 0 N--CA 1.472 0.674 0 C-N-CA 122.565 0.346 . . . . 0.0 111.186 179.581 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 86.31 16.06 63.2 Favored Glycine 0 C--N 1.34 0.789 0 CA-C-N 115.784 -0.643 . . . . 0.0 113.184 -179.862 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 43.0 mt-10 -127.42 161.69 28.1 Favored 'General case' 0 N--CA 1.466 0.367 0 C-N-CA 122.312 0.245 . . . . 0.0 110.804 -179.859 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 7' ' ' GLN . . . . . 0.683 ' HA ' ' O ' ' A' ' 28' ' ' GLY . 19.3 tt0 -85.36 134.53 34.09 Favored 'General case' 0 C--N 1.346 0.415 0 CA-C-O 121.166 0.507 . . . . 0.0 111.256 179.978 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 8' ' ' CYS . . . . . 0.404 ' SG ' ' SG ' ' A' ' 30' ' ' CYS . 3.1 p -127.72 160.24 32.28 Favored 'General case' 0 C--O 1.237 0.447 0 CA-C-N 114.593 -1.185 . . . . 0.0 111.036 -179.553 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 9' ' ' ASP . . . . . 0.439 ' OD2' ' HB2' ' A' ' 11' ' ' GLU . 15.8 t70 -115.42 147.64 40.33 Favored 'General case' 0 C--O 1.234 0.26 0 CA-C-N 115.475 -0.784 . . . . 0.0 109.53 178.762 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 15.5 m -97.45 22.23 1.16 Allowed 'Isoleucine or valine' 0 CA--C 1.543 0.689 0 CA-C-N 116.312 -0.404 . . . . 0.0 111.963 -179.451 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 11' ' ' GLU . . . . . 0.439 ' HB2' ' OD2' ' A' ' 9' ' ' ASP . 44.1 mt-10 -119.68 -52.68 2.23 Favored 'General case' 0 N--CA 1.466 0.371 0 N-CA-C 112.372 0.508 . . . . 0.0 112.372 -179.068 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 12' ' ' PHE . . . . . . . . . . . . . 13.6 t80 -137.83 -8.98 1.6 Allowed 'General case' 0 N--CA 1.47 0.559 0 N-CA-C 112.649 0.611 . . . . 0.0 112.649 -178.659 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 13' ' ' ASN . . . . . 0.43 ' ND2' ' HD3' ' A' ' 2' ' ' PRO . 6.0 t30 -129.65 63.81 69.45 Favored Pre-proline 0 CA--C 1.548 0.904 0 N-CA-C 111.579 0.214 . . . . 0.0 111.579 -179.195 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 13.6 Cg_exo -70.23 176.78 6.67 Favored 'Trans proline' 0 C--N 1.372 1.767 0 C-N-CA 122.801 2.334 . . . . 0.0 112.06 178.914 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 1.0 OUTLIER -79.84 121.04 24.91 Favored 'General case' 0 N--CA 1.469 0.499 0 CA-C-O 120.453 0.168 . . . . 0.0 111.155 179.983 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER -57.75 -53.01 70.18 Favored Pre-proline 0 N--CA 1.477 0.924 0 CA-C-O 118.985 -0.531 . . . . 0.0 111.535 179.316 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 44.8 Cg_endo -68.67 169.53 17.25 Favored 'Trans proline' 0 C--N 1.379 2.133 0 C-N-CA 122.102 1.868 . . . . 0.0 111.747 178.008 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 55.7 Cg_endo -72.27 48.81 1.27 Allowed 'Trans proline' 0 C--N 1.372 1.785 0 C-N-CA 122.011 1.808 . . . . 0.0 112.701 178.759 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 20.5 mt -109.61 167.6 10.02 Favored 'General case' 0 C--O 1.236 0.356 0 CA-C-N 115.692 -0.685 . . . . 0.0 111.316 -179.309 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 20' ' ' THR . . . . . 0.51 ' O ' ' HA ' ' A' ' 30' ' ' CYS . 32.6 m -105.03 153.37 21.55 Favored 'General case' 0 CA--C 1.532 0.279 0 CA-C-N 115.622 -0.717 . . . . 0.0 111.059 -178.794 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 1.9 t -102.71 103.27 13.5 Favored 'General case' 0 C--O 1.238 0.487 0 CA-C-N 115.672 -0.694 . . . . 0.0 109.672 178.861 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 22' ' ' ILE . . . . . . . . . . . . . 2.8 mt -125.33 129.1 24.57 Favored Pre-proline 0 CA--C 1.542 0.646 0 CA-C-N 115.774 -0.648 . . . . 0.0 110.24 -179.094 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 38.1 Cg_endo -67.43 -48.47 0.24 Allowed 'Cis proline' 0 C--N 1.374 1.897 0 C-N-CA 124.74 -0.942 . . . . 0.0 113.895 -0.113 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 81.26 36.86 19.79 Favored Glycine 0 C--N 1.347 1.141 0 C-N-CA 121.192 -0.528 . . . . 0.0 112.959 -179.927 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 4.6 t70 -139.78 82.23 18.22 Favored Pre-proline 0 CA--C 1.548 0.884 0 C-N-CA 122.454 0.301 . . . . 0.0 110.376 -179.818 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 2.6 Cg_endo -81.06 -31.72 4.33 Favored 'Cis proline' 0 C--N 1.371 1.761 0 C-N-CA 125.113 -0.786 . . . . 0.0 112.951 0.104 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 27' ' ' TYR . . . . . . . . . . . . . 60.3 m-85 -106.55 174.12 6.02 Favored 'General case' 0 C--O 1.238 0.475 0 CA-C-N 115.748 -0.66 . . . . 0.0 111.558 -179.037 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 28' ' ' GLY . . . . . 0.683 ' O ' ' HA ' ' A' ' 7' ' ' GLN . . . -175.22 -162.08 25.91 Favored Glycine 0 CA--C 1.502 -0.737 0 CA-C-N 115.627 -0.715 . . . . 0.0 112.561 178.397 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 29' ' ' ILE . . . . . 0.528 ' HB ' ' CE2' ' A' ' 31' ' ' TYR . 2.7 mm -115.35 150.36 17.32 Favored 'Isoleucine or valine' 0 C--O 1.234 0.257 0 N-CA-C 110.059 -0.349 . . . . 0.0 110.059 -179.86 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 30' ' ' CYS . . . . . 0.51 ' HA ' ' O ' ' A' ' 20' ' ' THR . 32.2 m -79.9 105.18 10.99 Favored 'General case' 0 C--O 1.236 0.372 0 CA-C-O 121.372 0.606 . . . . 0.0 111.408 -179.745 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 31' ' ' TYR . . . . . 0.528 ' CE2' ' HB ' ' A' ' 29' ' ' ILE . 37.1 m-85 -129.57 167.93 17.18 Favored 'General case' 0 C--O 1.234 0.28 0 CA-C-N 114.922 -1.036 . . . . 0.0 111.085 -179.466 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 2.7 tp -100.25 130.71 49.04 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.617 0 CA-C-N 116.275 -0.421 . . . . 0.0 110.317 179.402 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 33' ' ' ILE . . . . . 0.451 ' OXT' HD13 ' A' ' 33' ' ' ILE . 1.9 pp . . . . . 0 C--O 1.249 1.031 0 CA-C-O 118.206 -0.902 . . . . 0.0 111.454 179.911 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 4.4 p . . . . . 0 N--CA 1.486 1.36 0 CA-C-O 119.752 -0.166 . . . . 0.0 111.294 . . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' A' A ' 2' ' ' PRO . . . . . 0.433 ' HD3' ' ND2' ' A' ' 13' ' ' ASN . 98.3 Cg_endo -82.49 -172.16 1.35 Allowed 'Trans proline' 0 C--N 1.366 1.478 0 C-N-CA 122.594 2.196 . . . . 0.0 112.939 179.646 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -145.7 -155.47 6.5 Favored Glycine 0 C--N 1.338 0.676 0 N-CA-C 111.901 -0.48 . . . . 0.0 111.901 179.386 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 18.0 tt0 -73.35 129.52 38.19 Favored 'General case' 0 N--CA 1.474 0.738 0 C-N-CA 122.536 0.334 . . . . 0.0 111.198 179.658 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 85.6 16.28 64.25 Favored Glycine 0 C--N 1.339 0.748 0 CA-C-N 115.741 -0.663 . . . . 0.0 113.196 -179.849 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 43.1 mt-10 -127.61 161.49 28.73 Favored 'General case' 0 C--O 1.237 0.447 0 C-N-CA 122.188 0.195 . . . . 0.0 110.824 -179.862 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 7' ' ' GLN . . . . . 0.688 ' HA ' ' O ' ' A' ' 28' ' ' GLY . 18.7 tt0 -84.94 134.24 34.26 Favored 'General case' 0 C--N 1.345 0.381 0 CA-C-O 121.228 0.537 . . . . 0.0 111.293 179.804 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 8' ' ' CYS . . . . . 0.411 ' SG ' ' SG ' ' A' ' 30' ' ' CYS . 3.7 p -127.99 160.62 31.34 Favored 'General case' 0 C--O 1.237 0.447 0 CA-C-N 114.584 -1.189 . . . . 0.0 111.116 -179.383 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 9' ' ' ASP . . . . . 0.435 ' OD2' ' HB2' ' A' ' 11' ' ' GLU . 15.7 t70 -114.7 151.72 33.17 Favored 'General case' 0 C--O 1.236 0.352 0 CA-C-N 115.496 -0.774 . . . . 0.0 109.497 178.623 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 15.6 m -102.37 16.8 4.69 Favored 'Isoleucine or valine' 0 CA--C 1.544 0.717 0 N-CA-C 111.912 0.338 . . . . 0.0 111.912 -179.339 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 11' ' ' GLU . . . . . 0.435 ' HB2' ' OD2' ' A' ' 9' ' ' ASP . 9.5 mm-40 -110.34 -52.49 2.78 Favored 'General case' 0 N--CA 1.466 0.326 0 N-CA-C 112.082 0.401 . . . . 0.0 112.082 -178.979 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 12' ' ' PHE . . . . . . . . . . . . . 10.9 t80 -137.74 -17.51 1.26 Allowed 'General case' 0 N--CA 1.469 0.52 0 N-CA-C 112.589 0.588 . . . . 0.0 112.589 -178.812 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 13' ' ' ASN . . . . . 0.433 ' ND2' ' HD3' ' A' ' 2' ' ' PRO . 7.9 t30 -120.21 73.43 20.23 Favored Pre-proline 0 CA--C 1.547 0.851 0 N-CA-C 111.373 0.138 . . . . 0.0 111.373 -179.184 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 60.4 Cg_endo -76.79 177.6 8.65 Favored 'Trans proline' 0 C--N 1.371 1.729 0 C-N-CA 122.352 2.035 . . . . 0.0 112.314 179.027 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 1.3 t -79.79 120.2 23.72 Favored 'General case' 0 N--CA 1.471 0.605 0 CA-C-O 120.508 0.194 . . . . 0.0 110.911 179.895 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER -56.94 -53.44 65.11 Favored Pre-proline 0 N--CA 1.477 0.89 0 CA-C-O 119.09 -0.481 . . . . 0.0 111.634 179.425 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 44.8 Cg_endo -68.62 169.25 17.79 Favored 'Trans proline' 0 C--N 1.379 2.163 0 C-N-CA 122.152 1.901 . . . . 0.0 111.789 178.057 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 55.6 Cg_endo -72.3 50.46 1.57 Allowed 'Trans proline' 0 C--N 1.371 1.755 0 C-N-CA 122.085 1.857 . . . . 0.0 112.538 178.728 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 20.9 mt -111.41 167.92 9.93 Favored 'General case' 0 C--O 1.235 0.317 0 CA-C-N 115.626 -0.716 . . . . 0.0 111.383 -179.386 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 20' ' ' THR . . . . . 0.506 ' O ' ' HA ' ' A' ' 30' ' ' CYS . 33.5 m -105.6 153.47 21.74 Favored 'General case' 0 CA--C 1.533 0.291 0 CA-C-N 115.622 -0.717 . . . . 0.0 110.995 -178.774 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 2.0 t -102.77 103.36 13.57 Favored 'General case' 0 C--O 1.236 0.389 0 CA-C-N 115.709 -0.678 . . . . 0.0 109.676 178.932 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 22' ' ' ILE . . . . . . . . . . . . . 2.8 mt -125.43 129.13 24.53 Favored Pre-proline 0 CA--C 1.542 0.635 0 CA-C-N 115.754 -0.657 . . . . 0.0 110.259 -178.99 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 38.1 Cg_endo -67.69 -48.15 0.26 Allowed 'Cis proline' 0 C--N 1.375 1.933 0 C-N-CA 124.688 -0.963 . . . . 0.0 113.906 0.056 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 81.58 36.45 19.84 Favored Glycine 0 C--N 1.348 1.202 0 C-N-CA 121.153 -0.546 . . . . 0.0 112.899 -179.968 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 8.4 m-20 -139.91 82.73 17.16 Favored Pre-proline 0 CA--C 1.544 0.726 0 C-N-CA 122.587 0.355 . . . . 0.0 110.636 -179.743 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 2.9 Cg_endo -80.37 -32.06 4.23 Favored 'Cis proline' 0 C--N 1.372 1.773 0 C-N-CA 125.134 -0.778 . . . . 0.0 112.933 -0.118 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 27' ' ' TYR . . . . . . . . . . . . . 59.6 m-85 -107.24 175.06 5.62 Favored 'General case' 0 C--O 1.239 0.535 0 CA-C-N 115.785 -0.643 . . . . 0.0 111.643 -179.014 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 28' ' ' GLY . . . . . 0.688 ' O ' ' HA ' ' A' ' 7' ' ' GLN . . . -175.7 -161.18 24.59 Favored Glycine 0 CA--C 1.504 -0.609 0 CA-C-N 115.734 -0.666 . . . . 0.0 112.574 178.468 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 29' ' ' ILE . . . . . 0.534 ' HB ' ' CE2' ' A' ' 31' ' ' TYR . 2.7 mm -115.83 150.04 17.9 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 O-C-N 123.801 0.354 . . . . 0.0 110.067 -179.738 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 30' ' ' CYS . . . . . 0.506 ' HA ' ' O ' ' A' ' 20' ' ' THR . 23.7 m -79.88 104.99 10.83 Favored 'General case' 0 CA--C 1.535 0.402 0 CA-C-O 121.319 0.581 . . . . 0.0 111.303 -179.767 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 31' ' ' TYR . . . . . 0.534 ' CE2' ' HB ' ' A' ' 29' ' ' ILE . 36.7 m-85 -129.25 168.08 16.72 Favored 'General case' 0 C--O 1.233 0.197 0 CA-C-N 114.889 -1.051 . . . . 0.0 111.019 -179.465 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 2.7 tp -100.29 130.9 48.79 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.627 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.277 179.449 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 33' ' ' ILE . . . . . 0.501 ' CG1' ' HG1' ' A' ' 20' ' ' THR . 1.9 pp . . . . . 0 C--O 1.249 1.061 0 CA-C-O 118.328 -0.844 . . . . 0.0 111.479 179.865 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 N--CA 1.486 1.353 0 CA-C-O 119.629 -0.224 . . . . 0.0 111.081 . . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 2' ' ' PRO . . . . . 0.58 ' HD2' ' O ' ' A' ' 14' ' ' PRO . 73.4 Cg_endo -69.49 -170.78 0.39 Allowed 'Trans proline' 0 C--N 1.374 1.902 0 C-N-CA 123.184 2.589 . . . . 0.0 113.9 -178.918 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -142.76 -159.52 7.98 Favored Glycine 0 C--N 1.342 0.888 0 O-C-N 123.544 0.528 . . . . 0.0 112.487 179.832 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 17.4 tt0 -68.42 122.51 18.57 Favored 'General case' 0 N--CA 1.474 0.73 0 C-N-CA 122.816 0.447 . . . . 0.0 111.515 -179.925 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 92.41 14.54 55.52 Favored Glycine 0 C--N 1.341 0.82 0 CA-C-N 115.578 -0.737 . . . . 0.0 113.243 -179.882 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 43.1 mt-10 -127.42 165.64 19.41 Favored 'General case' 0 C--O 1.239 0.546 0 C-N-CA 122.438 0.295 . . . . 0.0 110.946 179.962 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 7' ' ' GLN . . . . . 0.52 ' HA ' ' O ' ' A' ' 28' ' ' GLY . 0.9 OUTLIER -83.46 145.55 28.89 Favored 'General case' 0 N--CA 1.469 0.478 0 CA-C-N 116.357 -0.383 . . . . 0.0 111.372 179.886 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 8.1 p -139.18 155.38 47.87 Favored 'General case' 0 C--O 1.237 0.44 0 CA-C-N 115.544 -0.753 . . . . 0.0 111.317 -179.786 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 6.9 t70 -118.87 153.13 35.03 Favored 'General case' 0 C--O 1.236 0.364 0 CA-C-N 115.42 -0.809 . . . . 0.0 109.652 179.045 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 14.9 m -101.86 20.89 2.47 Favored 'Isoleucine or valine' 0 CA--C 1.544 0.746 0 CA-C-N 116.296 -0.411 . . . . 0.0 111.99 -179.404 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 44.6 mt-10 -117.8 -53.03 2.42 Favored 'General case' 0 N--CA 1.465 0.32 0 N-CA-C 112.319 0.489 . . . . 0.0 112.319 -179.252 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 12' ' ' PHE . . . . . . . . . . . . . 15.7 t80 -138.96 -7.28 1.4 Allowed 'General case' 0 N--CA 1.47 0.574 0 N-CA-C 112.58 0.585 . . . . 0.0 112.58 -178.771 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 13' ' ' ASN . . . . . . . . . . . . . 8.6 t30 -129.44 63.47 67.83 Favored Pre-proline 0 CA--C 1.551 1.006 0 N-CA-C 111.369 0.137 . . . . 0.0 111.369 -179.093 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 14' ' ' PRO . . . . . 0.58 ' O ' ' HD2' ' A' ' 2' ' ' PRO . 15.8 Cg_exo -69.08 177.7 4.86 Favored 'Trans proline' 0 C--N 1.372 1.812 0 C-N-CA 122.733 2.288 . . . . 0.0 112.253 179.282 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 1.5 m -79.45 119.6 22.68 Favored 'General case' 0 N--CA 1.471 0.577 0 C-N-CA 122.382 0.273 . . . . 0.0 111.352 -179.848 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 16' ' ' CYS . . . . . 0.551 ' HB2' ' O ' ' A' ' 2' ' ' PRO . 0.0 OUTLIER -57.36 -53.2 67.98 Favored Pre-proline 0 N--CA 1.481 1.112 0 CA-C-N 115.971 -0.559 . . . . 0.0 111.518 179.548 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 57.7 Cg_endo -72.72 169.34 22.21 Favored 'Trans proline' 0 C--N 1.38 2.205 0 C-N-CA 122.042 1.828 . . . . 0.0 111.8 178.168 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 55.8 Cg_endo -72.21 44.54 0.7 Allowed 'Trans proline' 0 C--N 1.371 1.759 0 C-N-CA 122.034 1.823 . . . . 0.0 112.956 178.86 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 19' ' ' LEU . . . . . 0.426 ' HB2' ' SG ' ' A' ' 30' ' ' CYS . 12.9 mt -104.43 172.78 6.61 Favored 'General case' 0 CA--C 1.534 0.336 0 CA-C-N 115.875 -0.602 . . . . 0.0 110.917 -179.634 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 25.5 m -103.38 150.2 24.04 Favored 'General case' 0 CA--C 1.534 0.335 0 CA-C-N 115.934 -0.575 . . . . 0.0 111.034 -178.793 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 5.5 t -100.32 103.13 14.53 Favored 'General case' 0 C--O 1.237 0.427 0 CA-C-N 115.874 -0.603 . . . . 0.0 109.381 178.491 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 22' ' ' ILE . . . . . . . . . . . . . 2.5 mt -127.36 129.27 23.91 Favored Pre-proline 0 CA--C 1.543 0.697 0 CA-C-N 115.825 -0.625 . . . . 0.0 110.72 -178.462 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 38.0 Cg_endo -67.94 -48.55 0.25 Allowed 'Cis proline' 0 C--N 1.374 1.902 0 C-N-CA 124.77 -0.929 . . . . 0.0 113.71 -0.441 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 79.67 37.13 24.11 Favored Glycine 0 C--N 1.346 1.137 0 C-N-CA 121.39 -0.434 . . . . 0.0 112.835 179.954 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 8.4 m-20 -140.31 81.25 18.24 Favored Pre-proline 0 CA--C 1.544 0.721 0 C-N-CA 122.477 0.311 . . . . 0.0 110.837 -179.694 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 2.2 Cg_endo -81.62 -32.17 3.85 Favored 'Cis proline' 0 C--N 1.372 1.787 0 C-N-CA 125.027 -0.822 . . . . 0.0 112.928 -0.166 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 27' ' ' TYR . . . . . . . . . . . . . 66.7 m-85 -102.35 173.29 6.43 Favored 'General case' 0 C--O 1.238 0.496 0 CA-C-N 115.77 -0.65 . . . . 0.0 111.561 -179.125 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 28' ' ' GLY . . . . . 0.52 ' O ' ' HA ' ' A' ' 7' ' ' GLN . . . -175.59 -159.31 21.32 Favored Glycine 0 C--N 1.338 0.658 0 CA-C-N 115.75 -0.659 . . . . 0.0 112.451 178.974 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 29' ' ' ILE . . . . . 0.544 ' HB ' ' CE2' ' A' ' 31' ' ' TYR . 1.3 mm -123.17 152.13 27.85 Favored 'Isoleucine or valine' 0 C--O 1.235 0.332 0 N-CA-C 109.882 -0.414 . . . . 0.0 109.882 179.713 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 30' ' ' CYS . . . . . 0.426 ' SG ' ' HB2' ' A' ' 19' ' ' LEU . 0.5 OUTLIER -80.07 106.92 12.44 Favored 'General case' 0 C--O 1.238 0.472 0 CA-C-N 116.029 -0.532 . . . . 0.0 110.923 -179.975 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 31' ' ' TYR . . . . . 0.544 ' CE2' ' HB ' ' A' ' 29' ' ' ILE . 36.2 m-85 -132.11 167.04 20.43 Favored 'General case' 0 N--CA 1.466 0.334 0 CA-C-N 115.534 -0.757 . . . . 0.0 111.088 -179.251 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 2.8 tp -101.88 131.8 49.09 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.614 0 CA-C-N 116.081 -0.509 . . . . 0.0 110.347 179.458 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 33' ' ' ILE . . . . . 0.447 ' O ' HD11 ' A' ' 33' ' ' ILE . 1.9 pp . . . . . 0 C--O 1.247 0.961 0 CA-C-O 118.357 -0.83 . . . . 0.0 111.399 179.976 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 3.7 p . . . . . 0 N--CA 1.486 1.332 0 CA-C-O 119.71 -0.186 . . . . 0.0 111.323 . . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' A' A ' 2' ' ' PRO . . . . . 0.484 ' HD3' HD22 ' A' ' 13' ' ' ASN . 95.6 Cg_endo -83.52 -171.8 1.18 Allowed 'Trans proline' 0 C--N 1.368 1.567 0 C-N-CA 122.562 2.175 . . . . 0.0 112.937 179.634 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -145.39 -154.0 6.03 Favored Glycine 0 C--N 1.339 0.711 0 N-CA-C 111.813 -0.515 . . . . 0.0 111.813 179.493 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 18.5 tt0 -73.27 129.68 38.55 Favored 'General case' 0 N--CA 1.472 0.667 0 C-N-CA 122.68 0.392 . . . . 0.0 111.319 179.596 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 85.92 15.45 65.2 Favored Glycine 0 C--N 1.34 0.754 0 CA-C-N 115.793 -0.639 . . . . 0.0 113.554 -179.984 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 12.7 tt0 -126.87 161.9 27.18 Favored 'General case' 0 C--O 1.238 0.462 0 CA-C-N 116.604 0.202 . . . . 0.0 110.656 -179.842 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 7' ' ' GLN . . . . . 0.647 ' HA ' ' O ' ' A' ' 28' ' ' GLY . 18.6 tt0 -86.81 136.35 33.01 Favored 'General case' 0 C--N 1.344 0.331 0 CA-C-O 121.218 0.533 . . . . 0.0 111.407 179.962 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 8' ' ' CYS . . . . . 0.405 ' SG ' ' SG ' ' A' ' 30' ' ' CYS . 2.6 p -130.65 161.34 31.83 Favored 'General case' 0 C--O 1.239 0.517 0 CA-C-N 114.465 -1.243 . . . . 0.0 111.023 -179.58 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 9' ' ' ASP . . . . . 0.581 ' OD1' ' HB3' ' A' ' 13' ' ' ASN . 0.7 OUTLIER -120.52 143.54 48.52 Favored 'General case' 0 N--CA 1.465 0.276 0 CA-C-N 115.687 -0.688 . . . . 0.0 110.09 178.494 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 22.3 m -92.02 14.63 1.69 Allowed 'Isoleucine or valine' 0 CA--C 1.542 0.655 0 CA-C-N 116.083 -0.508 . . . . 0.0 111.509 -179.245 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 9.9 mm-40 -98.68 -51.56 3.88 Favored 'General case' 0 C--O 1.234 0.283 0 CA-C-N 116.159 -0.473 . . . . 0.0 112.085 -178.789 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 12' ' ' PHE . . . . . . . . . . . . . 6.9 t80 -144.09 -22.84 0.56 Allowed 'General case' 0 N--CA 1.472 0.67 0 N-CA-C 112.698 0.629 . . . . 0.0 112.698 -178.877 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 13' ' ' ASN . . . . . 0.581 ' HB3' ' OD1' ' A' ' 9' ' ' ASP . 13.9 t30 -119.32 75.74 16.64 Favored Pre-proline 0 CA--C 1.548 0.901 0 CA-C-N 117.539 0.154 . . . . 0.0 111.355 -178.969 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 61.7 Cg_endo -76.77 -176.09 2.97 Favored 'Trans proline' 0 C--N 1.372 1.763 0 C-N-CA 122.542 2.162 . . . . 0.0 112.22 178.676 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 0.9 OUTLIER -79.94 121.76 25.85 Favored 'General case' 0 N--CA 1.471 0.609 0 CA-C-O 120.454 0.168 . . . . 0.0 111.252 179.95 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER -58.38 -53.76 62.79 Favored Pre-proline 0 N--CA 1.478 0.949 0 CA-C-N 116.124 -0.489 . . . . 0.0 111.552 179.115 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 44.0 Cg_endo -67.8 169.79 15.41 Favored 'Trans proline' 0 C--N 1.379 2.171 0 C-N-CA 122.187 1.925 . . . . 0.0 111.851 178.21 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 55.5 Cg_endo -72.08 47.46 1.03 Allowed 'Trans proline' 0 C--N 1.371 1.724 0 C-N-CA 122.027 1.818 . . . . 0.0 112.792 178.839 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 42.9 mt -108.68 166.3 10.9 Favored 'General case' 0 C--O 1.234 0.266 0 CA-C-N 115.926 -0.579 . . . . 0.0 111.201 -179.588 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 20' ' ' THR . . . . . 0.502 ' O ' ' HA ' ' A' ' 30' ' ' CYS . 33.5 m -103.58 152.74 21.38 Favored 'General case' 0 CA--C 1.532 0.287 0 CA-C-N 115.503 -0.771 . . . . 0.0 110.962 -178.848 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 2.3 t -102.44 99.93 10.02 Favored 'General case' 0 C--O 1.239 0.535 0 CA-C-N 115.725 -0.67 . . . . 0.0 109.601 178.841 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 22' ' ' ILE . . . . . . . . . . . . . 3.0 mt -121.04 128.7 25.62 Favored Pre-proline 0 CA--C 1.541 0.622 0 CA-C-N 115.783 -0.644 . . . . 0.0 110.424 -178.976 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 37.1 Cg_endo -66.89 -47.47 0.26 Allowed 'Cis proline' 0 C--N 1.375 1.958 0 C-N-CA 124.69 -0.962 . . . . 0.0 113.874 -0.187 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 78.92 34.4 34.1 Favored Glycine 0 C--N 1.346 1.131 0 C-N-CA 121.379 -0.438 . . . . 0.0 112.942 179.977 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 4.6 t70 -139.91 83.05 16.69 Favored Pre-proline 0 CA--C 1.546 0.823 0 C-N-CA 122.607 0.363 . . . . 0.0 110.345 -179.68 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 3.2 Cg_exo -80.86 -32.02 4.15 Favored 'Cis proline' 0 C--N 1.371 1.743 0 C-N-CA 125.095 -0.794 . . . . 0.0 112.895 0.036 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 27' ' ' TYR . . . . . 0.55 ' CD2' ' HB3' ' A' ' 9' ' ' ASP . 63.6 m-85 -106.91 172.68 6.69 Favored 'General case' 0 CA--C 1.537 0.448 0 CA-C-N 115.838 -0.619 . . . . 0.0 111.592 -178.892 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 28' ' ' GLY . . . . . 0.647 ' O ' ' HA ' ' A' ' 7' ' ' GLN . . . -176.53 -163.88 29.64 Favored Glycine 0 C--N 1.339 0.716 0 CA-C-N 115.629 -0.714 . . . . 0.0 112.636 178.558 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 29' ' ' ILE . . . . . 0.534 ' HB ' ' CE2' ' A' ' 31' ' ' TYR . 2.5 mm -114.68 151.15 16.47 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 O-C-N 123.748 0.322 . . . . 0.0 110.259 -179.898 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 30' ' ' CYS . . . . . 0.502 ' HA ' ' O ' ' A' ' 20' ' ' THR . 33.9 m -79.88 105.42 11.15 Favored 'General case' 0 CA--C 1.535 0.392 0 CA-C-O 121.328 0.585 . . . . 0.0 111.365 -179.717 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 31' ' ' TYR . . . . . 0.534 ' CE2' ' HB ' ' A' ' 29' ' ' ILE . 37.1 m-85 -130.28 166.88 19.43 Favored 'General case' 0 C--O 1.233 0.193 0 CA-C-N 114.917 -1.038 . . . . 0.0 111.02 -179.472 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 2.9 tp -99.59 130.24 48.93 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.604 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.372 179.496 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 33' ' ' ILE . . . . . 0.464 HG12 ' OG1' ' A' ' 20' ' ' THR . 1.4 pt . . . . . 0 C--O 1.249 1.045 0 CA-C-O 118.136 -0.935 . . . . 0.0 111.463 179.883 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 5.7 p . . . . . 0 N--CA 1.486 1.345 0 CA-C-O 119.716 -0.183 . . . . 0.0 111.253 . . . . . . . . . 0 0 . 1 . 011 nuclear orig full ' A' A ' 2' ' ' PRO . . . . . 0.544 ' HD3' ' ND2' ' A' ' 13' ' ' ASN . 95.1 Cg_endo -82.24 -172.34 1.41 Allowed 'Trans proline' 0 C--N 1.367 1.529 0 C-N-CA 122.581 2.187 . . . . 0.0 112.827 179.498 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -147.3 -161.39 9.38 Favored Glycine 0 C--N 1.337 0.632 0 N-CA-C 111.593 -0.603 . . . . 0.0 111.593 179.216 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 19.0 tt0 -68.33 124.06 22.46 Favored 'General case' 0 N--CA 1.473 0.679 0 C-N-CA 122.548 0.339 . . . . 0.0 111.183 179.851 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 91.28 14.69 56.99 Favored Glycine 0 C--N 1.338 0.682 0 CA-C-N 115.646 -0.706 . . . . 0.0 113.228 -179.699 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 6' ' ' GLU . . . . . 0.446 ' HG2' ' NE2' ' A' ' 7' ' ' GLN . 13.9 tt0 -129.0 166.18 19.7 Favored 'General case' 0 C--O 1.238 0.479 0 C-N-CA 122.287 0.235 . . . . 0.0 110.599 -179.933 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 7' ' ' GLN . . . . . 0.446 ' NE2' ' HG2' ' A' ' 6' ' ' GLU . 0.2 OUTLIER -82.07 153.3 26.18 Favored 'General case' 0 C--N 1.346 0.433 0 O-C-N 123.288 0.367 . . . . 0.0 110.929 -179.876 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 3.3 p -142.64 151.8 41.81 Favored 'General case' 0 C--O 1.235 0.306 0 CA-C-N 115.817 -0.629 . . . . 0.0 111.297 -179.4 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -110.23 139.8 45.02 Favored 'General case' 0 C--O 1.234 0.253 0 CA-C-N 115.765 -0.652 . . . . 0.0 109.559 179.348 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 10' ' ' VAL . . . . . 0.479 HG21 ' O ' ' A' ' 26' ' ' PRO . 7.7 m -94.89 26.65 0.48 Allowed 'Isoleucine or valine' 0 CA--C 1.543 0.702 0 O-C-N 123.31 0.381 . . . . 0.0 111.635 -179.842 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 42.6 mt-10 -124.2 -52.26 1.75 Allowed 'General case' 0 N--CA 1.465 0.291 0 N-CA-C 112.251 0.464 . . . . 0.0 112.251 -179.135 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 12' ' ' PHE . . . . . . . . . . . . . 11.5 t80 -138.51 -10.38 1.41 Allowed 'General case' 0 N--CA 1.471 0.617 0 N-CA-C 112.833 0.679 . . . . 0.0 112.833 -178.627 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 13' ' ' ASN . . . . . 0.544 ' ND2' ' HD3' ' A' ' 2' ' ' PRO . 6.9 t30 -129.88 64.86 73.62 Favored Pre-proline 0 CA--C 1.549 0.928 0 CA-C-N 117.458 0.117 . . . . 0.0 111.206 -179.151 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 16.4 Cg_exo -68.86 179.81 2.98 Favored 'Trans proline' 0 C--N 1.373 1.843 0 C-N-CA 122.948 2.432 . . . . 0.0 112.22 179.141 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 15' ' ' CYS . . . . . 0.505 ' SG ' ' HB2' ' A' ' 19' ' ' LEU . 3.8 t -79.71 122.0 26.03 Favored 'General case' 0 N--CA 1.471 0.603 0 O-C-N 123.102 0.251 . . . . 0.0 111.247 -179.786 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER -60.85 -54.16 57.16 Favored Pre-proline 0 N--CA 1.476 0.855 0 CA-C-O 119.023 -0.513 . . . . 0.0 111.443 179.298 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 56.3 Cg_endo -70.95 169.27 20.84 Favored 'Trans proline' 0 C--N 1.379 2.176 0 C-N-CA 122.115 1.877 . . . . 0.0 111.702 178.173 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 49.7 Cg_endo -70.76 58.09 2.0 Allowed 'Trans proline' 0 C--N 1.371 1.748 0 C-N-CA 121.975 1.784 . . . . 0.0 112.909 179.01 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 19' ' ' LEU . . . . . 0.505 ' HB2' ' SG ' ' A' ' 15' ' ' CYS . 93.8 mt -118.19 167.8 11.17 Favored 'General case' 0 C--O 1.235 0.331 0 CA-C-N 115.704 -0.68 . . . . 0.0 111.24 -179.876 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 89.3 m -106.99 150.84 26.07 Favored 'General case' 0 CA--C 1.533 0.303 0 CA-C-N 115.315 -0.857 . . . . 0.0 110.94 -179.277 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 21' ' ' CYS . . . . . 0.497 ' HA ' ' O ' ' A' ' 29' ' ' ILE . 1.9 t -97.3 106.71 19.09 Favored 'General case' 0 C--O 1.238 0.476 0 CA-C-N 115.732 -0.667 . . . . 0.0 110.029 178.949 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 22' ' ' ILE . . . . . . . . . . . . . 5.7 mt -125.32 128.69 24.68 Favored Pre-proline 0 CA--C 1.543 0.697 0 CA-C-N 115.807 -0.633 . . . . 0.0 110.564 -179.16 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 37.3 Cg_endo -67.24 -47.78 0.26 Allowed 'Cis proline' 0 C--N 1.376 2.009 0 C-N-CA 124.681 -0.966 . . . . 0.0 113.81 -0.223 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 81.66 38.11 15.04 Favored Glycine 0 C--N 1.347 1.144 0 C-N-CA 121.332 -0.461 . . . . 0.0 112.88 179.822 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 8.0 m-20 -142.58 80.64 14.19 Favored Pre-proline 0 CA--C 1.546 0.817 0 C-N-CA 122.445 0.298 . . . . 0.0 111.052 -179.565 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 26' ' ' PRO . . . . . 0.479 ' O ' HG21 ' A' ' 10' ' ' VAL . 67.9 Cg_endo -84.08 -29.38 5.12 Favored 'Cis proline' 0 C--N 1.372 1.788 0 C-N-CA 124.698 -0.959 . . . . 0.0 113.439 -0.236 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 27' ' ' TYR . . . . . . . . . . . . . 57.0 m-85 -95.31 161.49 14.07 Favored 'General case' 0 N--CA 1.469 0.492 0 O-C-N 123.513 0.508 . . . . 0.0 111.304 -179.097 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 28' ' ' GLY . . . . . 0.424 ' O ' HD11 ' A' ' 29' ' ' ILE . . . -159.03 -161.91 11.53 Favored Glycine 0 C--N 1.341 0.842 0 C-N-CA 120.917 -0.659 . . . . 0.0 113.089 179.832 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 29' ' ' ILE . . . . . 0.497 ' O ' ' HA ' ' A' ' 21' ' ' CYS . 5.1 mm -129.95 155.17 41.31 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.238 0 N-CA-C 109.674 -0.491 . . . . 0.0 109.674 -179.932 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 30' ' ' CYS . . . . . . . . . . . . . 28.8 m -83.68 92.8 7.77 Favored 'General case' 0 CA--C 1.538 0.482 0 CA-C-O 121.368 0.604 . . . . 0.0 111.362 -179.955 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 31' ' ' TYR . . . . . 0.437 ' CE2' ' HB ' ' A' ' 29' ' ' ILE . 37.8 m-85 -124.33 166.81 15.28 Favored 'General case' 0 N--CA 1.464 0.26 0 CA-C-N 114.972 -1.013 . . . . 0.0 110.992 179.822 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 2.8 tp -99.76 131.49 47.05 Favored 'Isoleucine or valine' 0 CA--C 1.542 0.644 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.448 179.401 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 33' ' ' ILE . . . . . 0.455 HD12 ' OXT' ' A' ' 33' ' ' ILE . 1.8 pp . . . . . 0 C--O 1.249 1.056 0 CA-C-O 118.168 -0.92 . . . . 0.0 111.429 179.843 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 N--CA 1.487 1.385 0 CA-C-O 119.771 -0.157 . . . . 0.0 111.093 . . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 2' ' ' PRO . . . . . 0.595 ' HD2' ' O ' ' A' ' 14' ' ' PRO . 73.0 Cg_endo -69.33 -170.71 0.38 Allowed 'Trans proline' 0 C--N 1.376 1.989 0 C-N-CA 123.23 2.62 . . . . 0.0 113.935 -179.044 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -143.5 -159.68 8.08 Favored Glycine 0 C--N 1.341 0.837 0 CA-C-N 116.146 -0.479 . . . . 0.0 112.477 179.83 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 16.7 tt0 -66.43 124.23 22.18 Favored 'General case' 0 N--CA 1.474 0.734 0 C-N-CA 122.841 0.456 . . . . 0.0 111.603 -179.711 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 95.03 -11.01 69.89 Favored Glycine 0 C--N 1.34 0.772 0 CA-C-N 115.641 -0.708 . . . . 0.0 113.282 -179.971 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 42.8 mt-10 -101.16 166.66 10.67 Favored 'General case' 0 C--O 1.24 0.601 0 C-N-CA 122.432 0.293 . . . . 0.0 110.967 -179.8 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 7' ' ' GLN . . . . . . . . . . . . . 0.2 OUTLIER -84.85 154.83 22.05 Favored 'General case' 0 C--N 1.346 0.446 0 CA-C-N 116.167 -0.47 . . . . 0.0 111.039 179.899 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 7.9 p -147.54 155.02 41.45 Favored 'General case' 0 N--CA 1.466 0.371 0 CA-C-N 115.886 -0.597 . . . . 0.0 111.511 -179.131 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 8.0 t70 -120.17 150.52 40.5 Favored 'General case' 0 C--O 1.234 0.275 0 CA-C-N 115.325 -0.852 . . . . 0.0 109.633 178.885 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 15.6 m -98.7 18.8 2.28 Favored 'Isoleucine or valine' 0 CA--C 1.543 0.677 0 CA-C-N 116.287 -0.415 . . . . 0.0 112.072 -179.41 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 46.2 mt-10 -110.13 -55.46 2.45 Favored 'General case' 0 N--CA 1.466 0.358 0 N-CA-C 112.11 0.411 . . . . 0.0 112.11 -179.106 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 12' ' ' PHE . . . . . . . . . . . . . 12.2 t80 -137.99 -15.2 1.34 Allowed 'General case' 0 N--CA 1.47 0.556 0 N-CA-C 112.429 0.529 . . . . 0.0 112.429 -178.939 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 13' ' ' ASN . . . . . 0.437 HD22 ' HD3' ' A' ' 2' ' ' PRO . 11.5 t30 -120.21 73.01 19.61 Favored Pre-proline 0 CA--C 1.55 0.955 0 O-C-N 122.969 0.168 . . . . 0.0 111.161 -179.377 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 14' ' ' PRO . . . . . 0.595 ' O ' ' HD2' ' A' ' 2' ' ' PRO . 60.4 Cg_endo -76.13 178.74 7.09 Favored 'Trans proline' 0 C--N 1.371 1.744 0 C-N-CA 122.314 2.009 . . . . 0.0 112.501 179.587 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 1.4 m -79.38 118.65 21.47 Favored 'General case' 0 N--CA 1.47 0.547 0 O-C-N 123.118 0.261 . . . . 0.0 111.195 179.972 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 16' ' ' CYS . . . . . 0.55 ' HB2' ' O ' ' A' ' 2' ' ' PRO . 0.0 OUTLIER -56.58 -53.27 66.22 Favored Pre-proline 0 N--CA 1.48 1.073 0 CA-C-O 118.961 -0.542 . . . . 0.0 111.679 179.581 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 57.7 Cg_endo -72.65 169.23 22.42 Favored 'Trans proline' 0 C--N 1.378 2.13 0 C-N-CA 122.028 1.819 . . . . 0.0 111.738 178.194 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 55.7 Cg_endo -72.51 45.33 0.83 Allowed 'Trans proline' 0 C--N 1.373 1.839 0 C-N-CA 122.012 1.808 . . . . 0.0 112.865 178.826 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 19' ' ' LEU . . . . . 0.422 ' HB2' ' SG ' ' A' ' 30' ' ' CYS . 11.8 mt -104.92 172.9 6.54 Favored 'General case' 0 C--O 1.237 0.401 0 CA-C-N 115.931 -0.577 . . . . 0.0 111.046 -179.628 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 24.5 m -103.98 149.3 25.27 Favored 'General case' 0 CA--C 1.531 0.228 0 CA-C-N 115.966 -0.561 . . . . 0.0 111.046 -178.945 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 5.9 t -99.35 102.74 14.43 Favored 'General case' 0 C--O 1.237 0.444 0 CA-C-N 115.856 -0.611 . . . . 0.0 109.39 178.467 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 22' ' ' ILE . . . . . . . . . . . . . 2.5 mt -126.78 129.65 24.0 Favored Pre-proline 0 CA--C 1.543 0.679 0 CA-C-N 115.787 -0.642 . . . . 0.0 110.68 -178.571 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 37.5 Cg_endo -67.65 -48.13 0.26 Allowed 'Cis proline' 0 C--N 1.374 1.885 0 C-N-CA 124.699 -0.959 . . . . 0.0 113.814 -0.434 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 78.57 37.61 26.6 Favored Glycine 0 C--N 1.348 1.242 0 C-N-CA 121.308 -0.472 . . . . 0.0 113.013 -179.962 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 4.5 t70 -140.55 80.7 18.28 Favored Pre-proline 0 CA--C 1.548 0.884 0 C-N-CA 122.372 0.269 . . . . 0.0 110.533 -179.614 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 1.9 Cg_endo -82.07 -31.81 3.98 Favored 'Cis proline' 0 C--N 1.372 1.787 0 C-N-CA 125.058 -0.809 . . . . 0.0 112.956 -0.2 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 27' ' ' TYR . . . . . . . . . . . . . 70.0 m-85 -102.0 172.55 6.85 Favored 'General case' 0 C--O 1.237 0.434 0 CA-C-N 115.822 -0.626 . . . . 0.0 111.578 -179.033 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -175.95 -160.57 23.67 Favored Glycine 0 C--N 1.337 0.634 0 CA-C-N 115.657 -0.701 . . . . 0.0 112.207 179.071 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 29' ' ' ILE . . . . . 0.541 ' HB ' ' CE2' ' A' ' 31' ' ' TYR . 1.8 mm -122.6 153.04 27.23 Favored 'Isoleucine or valine' 0 C--O 1.236 0.36 0 N-CA-C 109.87 -0.418 . . . . 0.0 109.87 179.691 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 30' ' ' CYS . . . . . 0.422 ' SG ' ' HB2' ' A' ' 19' ' ' LEU . 0.5 OUTLIER -79.92 106.72 12.15 Favored 'General case' 0 CA--C 1.539 0.521 0 CA-C-N 116.018 -0.537 . . . . 0.0 110.916 -179.919 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 31' ' ' TYR . . . . . 0.541 ' CE2' ' HB ' ' A' ' 29' ' ' ILE . 39.1 m-85 -131.34 166.68 20.71 Favored 'General case' 0 N--CA 1.463 0.216 0 CA-C-N 115.479 -0.782 . . . . 0.0 111.201 -179.314 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 2.7 tp -101.76 132.04 48.48 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.582 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.437 179.434 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 33' ' ' ILE . . . . . 0.452 ' O ' HD11 ' A' ' 33' ' ' ILE . 1.9 pp . . . . . 0 C--O 1.249 1.078 0 CA-C-O 118.346 -0.835 . . . . 0.0 111.504 179.945 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 4.5 p . . . . . 0 N--CA 1.486 1.346 0 CA-C-O 119.746 -0.169 . . . . 0.0 111.272 . . . . . . . . . 0 0 . 1 . 013 nuclear orig full ' A' A ' 2' ' ' PRO . . . . . 0.434 ' HD3' ' ND2' ' A' ' 13' ' ' ASN . 95.3 Cg_endo -82.36 -172.35 1.41 Allowed 'Trans proline' 0 C--N 1.367 1.539 0 C-N-CA 122.598 2.199 . . . . 0.0 112.969 179.474 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -145.39 -155.44 6.47 Favored Glycine 0 C--N 1.339 0.727 0 N-CA-C 111.687 -0.565 . . . . 0.0 111.687 179.45 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 18.0 tt0 -73.24 129.16 37.43 Favored 'General case' 0 N--CA 1.47 0.55 0 C-N-CA 122.575 0.35 . . . . 0.0 111.221 179.74 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 85.68 16.25 64.14 Favored Glycine 0 C--N 1.339 0.738 0 CA-C-N 115.832 -0.622 . . . . 0.0 113.294 -179.844 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 12.9 tt0 -127.86 162.52 26.5 Favored 'General case' 0 C--O 1.236 0.39 0 C-N-CA 122.176 0.19 . . . . 0.0 110.488 -179.865 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 7' ' ' GLN . . . . . 0.686 ' HA ' ' O ' ' A' ' 28' ' ' GLY . 18.6 tt0 -85.35 134.76 34.08 Favored 'General case' 0 C--N 1.345 0.386 0 CA-C-O 121.298 0.571 . . . . 0.0 111.239 -179.994 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 8' ' ' CYS . . . . . 0.412 ' SG ' ' SG ' ' A' ' 30' ' ' CYS . 3.6 p -127.77 160.2 32.46 Favored 'General case' 0 C--O 1.239 0.508 0 CA-C-N 114.545 -1.207 . . . . 0.0 111.098 -179.396 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 9' ' ' ASP . . . . . 0.434 ' OD2' ' HB2' ' A' ' 11' ' ' GLU . 16.8 t70 -114.86 150.52 35.43 Favored 'General case' 0 CA--C 1.532 0.272 0 CA-C-N 115.542 -0.754 . . . . 0.0 109.477 178.766 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 15.5 m -100.91 20.12 2.47 Favored 'Isoleucine or valine' 0 CA--C 1.543 0.689 0 CA-C-N 116.22 -0.446 . . . . 0.0 112.008 -179.465 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 11' ' ' GLU . . . . . 0.434 ' HB2' ' OD2' ' A' ' 9' ' ' ASP . 44.7 mt-10 -117.51 -52.46 2.47 Favored 'General case' 0 N--CA 1.465 0.313 0 N-CA-C 112.224 0.453 . . . . 0.0 112.224 -178.969 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 12' ' ' PHE . . . . . . . . . . . . . 14.6 t80 -138.42 -8.43 1.49 Allowed 'General case' 0 N--CA 1.472 0.652 0 N-CA-C 112.596 0.591 . . . . 0.0 112.596 -178.689 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 13' ' ' ASN . . . . . 0.434 ' ND2' ' HD3' ' A' ' 2' ' ' PRO . 6.3 t30 -129.6 63.79 69.26 Favored Pre-proline 0 CA--C 1.55 0.959 0 N-CA-C 111.552 0.205 . . . . 0.0 111.552 -179.091 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 14.0 Cg_exo -70.09 177.12 6.13 Favored 'Trans proline' 0 C--N 1.371 1.744 0 C-N-CA 122.86 2.373 . . . . 0.0 112.002 178.885 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 1.1 t -79.9 121.02 24.92 Favored 'General case' 0 N--CA 1.471 0.58 0 CA-C-O 120.503 0.192 . . . . 0.0 111.052 -179.983 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER -57.57 -53.09 69.18 Favored Pre-proline 0 N--CA 1.478 0.943 0 CA-C-O 119.069 -0.491 . . . . 0.0 111.541 179.282 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 44.4 Cg_endo -68.81 169.44 17.66 Favored 'Trans proline' 0 C--N 1.38 2.199 0 C-N-CA 122.159 1.906 . . . . 0.0 111.782 178.059 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 55.5 Cg_endo -72.22 49.33 1.34 Allowed 'Trans proline' 0 C--N 1.373 1.833 0 C-N-CA 122.044 1.829 . . . . 0.0 112.589 178.799 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 20.9 mt -110.1 168.24 9.58 Favored 'General case' 0 C--O 1.236 0.372 0 CA-C-N 115.741 -0.663 . . . . 0.0 111.34 -179.337 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 20' ' ' THR . . . . . 0.519 ' O ' ' HA ' ' A' ' 30' ' ' CYS . 29.3 m -105.31 153.82 21.11 Favored 'General case' 0 CA--C 1.533 0.31 0 CA-C-N 115.624 -0.716 . . . . 0.0 111.056 -178.804 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 2.0 t -103.42 103.89 13.93 Favored 'General case' 0 C--O 1.238 0.493 0 CA-C-N 115.678 -0.692 . . . . 0.0 109.666 178.869 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 22' ' ' ILE . . . . . . . . . . . . . 2.9 mt -125.9 129.11 24.39 Favored Pre-proline 0 CA--C 1.541 0.634 0 CA-C-N 115.768 -0.651 . . . . 0.0 110.223 -179.157 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 38.4 Cg_endo -67.77 -48.26 0.25 Allowed 'Cis proline' 0 C--N 1.375 1.941 0 C-N-CA 124.679 -0.967 . . . . 0.0 113.941 -0.155 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 81.92 36.83 17.63 Favored Glycine 0 C--N 1.348 1.229 0 C-N-CA 121.108 -0.568 . . . . 0.0 112.852 -179.977 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 8.3 m-20 -139.99 82.58 17.18 Favored Pre-proline 0 CA--C 1.543 0.701 0 C-N-CA 122.53 0.332 . . . . 0.0 110.701 -179.91 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 3.0 Cg_endo -80.54 -32.07 4.18 Favored 'Cis proline' 0 C--N 1.372 1.795 0 C-N-CA 125.191 -0.754 . . . . 0.0 112.923 0.077 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 27' ' ' TYR . . . . . . . . . . . . . 59.3 m-85 -106.96 175.07 5.62 Favored 'General case' 0 C--O 1.238 0.466 0 CA-C-N 115.68 -0.691 . . . . 0.0 111.532 -179.001 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 28' ' ' GLY . . . . . 0.686 ' O ' ' HA ' ' A' ' 7' ' ' GLN . . . -175.52 -161.26 24.65 Favored Glycine 0 C--N 1.339 0.701 0 CA-C-N 115.626 -0.715 . . . . 0.0 112.618 178.49 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 29' ' ' ILE . . . . . 0.523 ' HB ' ' CE2' ' A' ' 31' ' ' TYR . 2.8 mm -115.6 149.76 17.74 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 N-CA-C 110.084 -0.339 . . . . 0.0 110.084 -179.814 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 30' ' ' CYS . . . . . 0.519 ' HA ' ' O ' ' A' ' 20' ' ' THR . 26.8 m -79.85 105.1 10.89 Favored 'General case' 0 C--O 1.238 0.464 0 CA-C-N 115.955 -0.566 . . . . 0.0 111.35 -179.802 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 31' ' ' TYR . . . . . 0.523 ' CE2' ' HB ' ' A' ' 29' ' ' ILE . 36.9 m-85 -128.74 168.46 15.81 Favored 'General case' 0 C--O 1.233 0.205 0 CA-C-N 115.087 -0.961 . . . . 0.0 111.099 -179.552 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 1.8 tt -101.06 130.33 50.64 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.585 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.363 179.651 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 33' ' ' ILE . . . . . 0.421 ' O ' HD13 ' A' ' 33' ' ' ILE . 1.6 pp . . . . . 0 C--O 1.248 0.986 0 CA-C-O 118.386 -0.816 . . . . 0.0 111.525 179.881 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 N--CA 1.488 1.455 0 CA-C-O 119.757 -0.163 . . . . 0.0 111.045 . . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 2' ' ' PRO . . . . . 0.575 ' HD2' ' O ' ' A' ' 14' ' ' PRO . 73.7 Cg_endo -69.22 -170.6 0.36 Allowed 'Trans proline' 0 C--N 1.376 1.991 0 C-N-CA 123.204 2.603 . . . . 0.0 113.949 -178.955 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -143.5 -159.09 7.83 Favored Glycine 0 C--N 1.34 0.778 0 O-C-N 123.511 0.507 . . . . 0.0 112.543 179.877 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 16.6 tt0 -68.39 122.93 19.43 Favored 'General case' 0 N--CA 1.472 0.642 0 C-N-CA 122.849 0.46 . . . . 0.0 111.524 -179.893 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 92.12 14.47 56.05 Favored Glycine 0 C--N 1.339 0.736 0 CA-C-N 115.681 -0.691 . . . . 0.0 113.242 -179.864 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 43.0 mt-10 -127.9 165.83 19.46 Favored 'General case' 0 C--O 1.239 0.535 0 C-N-CA 122.447 0.299 . . . . 0.0 110.813 179.942 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 7' ' ' GLN . . . . . 0.531 ' HA ' ' O ' ' A' ' 28' ' ' GLY . 15.6 mt-30 -85.11 145.15 27.79 Favored 'General case' 0 C--N 1.346 0.415 0 CA-C-N 116.371 -0.377 . . . . 0.0 111.515 179.966 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 7.4 p -138.26 155.59 48.48 Favored 'General case' 0 C--O 1.236 0.385 0 CA-C-N 115.274 -0.876 . . . . 0.0 111.292 -179.51 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 6.1 t70 -118.25 152.46 35.68 Favored 'General case' 0 C--O 1.235 0.335 0 CA-C-N 115.35 -0.841 . . . . 0.0 109.668 179.003 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 14.4 m -101.1 21.63 1.97 Allowed 'Isoleucine or valine' 0 CA--C 1.541 0.624 0 CA-C-N 116.18 -0.464 . . . . 0.0 112.058 -179.466 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 44.5 mt-10 -118.51 -53.0 2.34 Favored 'General case' 0 N--CA 1.465 0.319 0 N-CA-C 112.196 0.443 . . . . 0.0 112.196 -179.18 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 12' ' ' PHE . . . . . . . . . . . . . 15.1 t80 -139.01 -7.49 1.39 Allowed 'General case' 0 N--CA 1.47 0.564 0 N-CA-C 112.534 0.568 . . . . 0.0 112.534 -178.784 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 13' ' ' ASN . . . . . . . . . . . . . 8.6 t30 -129.34 63.22 66.74 Favored Pre-proline 0 CA--C 1.55 0.943 0 N-CA-C 111.415 0.154 . . . . 0.0 111.415 -179.144 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 14' ' ' PRO . . . . . 0.575 ' O ' ' HD2' ' A' ' 2' ' ' PRO . 15.6 Cg_exo -68.93 178.03 4.44 Favored 'Trans proline' 0 C--N 1.373 1.865 0 C-N-CA 122.828 2.352 . . . . 0.0 112.372 179.235 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 1.5 m -79.54 119.45 22.54 Favored 'General case' 0 N--CA 1.471 0.605 0 O-C-N 123.144 0.278 . . . . 0.0 111.315 -179.86 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 16' ' ' CYS . . . . . 0.554 ' HB2' ' O ' ' A' ' 2' ' ' PRO . 0.0 OUTLIER -57.13 -53.18 67.97 Favored Pre-proline 0 N--CA 1.483 1.182 0 CA-C-N 115.923 -0.581 . . . . 0.0 111.554 179.489 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 57.9 Cg_endo -72.71 169.28 22.35 Favored 'Trans proline' 0 C--N 1.38 2.191 0 C-N-CA 121.994 1.796 . . . . 0.0 111.815 178.178 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 55.9 Cg_endo -72.27 44.69 0.72 Allowed 'Trans proline' 0 C--N 1.371 1.76 0 C-N-CA 122.012 1.808 . . . . 0.0 113.062 178.778 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 19' ' ' LEU . . . . . 0.427 ' HB2' ' SG ' ' A' ' 30' ' ' CYS . 12.2 mt -104.39 172.74 6.63 Favored 'General case' 0 C--O 1.236 0.361 0 CA-C-N 115.911 -0.586 . . . . 0.0 110.996 -179.761 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 25.4 m -103.32 150.19 24.01 Favored 'General case' 0 CA--C 1.534 0.335 0 CA-C-N 115.987 -0.551 . . . . 0.0 110.982 -178.903 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 5.1 t -100.38 103.03 14.4 Favored 'General case' 0 C--O 1.238 0.453 0 CA-C-N 115.724 -0.671 . . . . 0.0 109.407 178.412 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 22' ' ' ILE . . . . . . . . . . . . . 2.5 mt -127.16 129.04 24.02 Favored Pre-proline 0 CA--C 1.541 0.629 0 CA-C-N 115.803 -0.635 . . . . 0.0 110.826 -178.457 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 37.6 Cg_endo -67.99 -48.52 0.25 Allowed 'Cis proline' 0 C--N 1.375 1.938 0 C-N-CA 124.674 -0.969 . . . . 0.0 113.726 -0.261 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 79.12 37.79 24.14 Favored Glycine 0 C--N 1.347 1.19 0 C-N-CA 121.456 -0.402 . . . . 0.0 112.883 -179.991 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 4.6 t70 -140.12 80.57 19.92 Favored Pre-proline 0 CA--C 1.549 0.912 0 C-N-CA 122.338 0.255 . . . . 0.0 110.461 -179.686 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 1.9 Cg_endo -82.24 -31.71 4.0 Favored 'Cis proline' 0 C--N 1.372 1.774 0 C-N-CA 125.112 -0.787 . . . . 0.0 112.973 -0.134 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 27' ' ' TYR . . . . . . . . . . . . . 66.8 m-85 -101.7 171.98 7.22 Favored 'General case' 0 C--O 1.237 0.424 0 CA-C-N 115.796 -0.638 . . . . 0.0 111.591 -179.146 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 28' ' ' GLY . . . . . 0.531 ' O ' ' HA ' ' A' ' 7' ' ' GLN . . . -174.93 -160.26 22.6 Favored Glycine 0 C--N 1.337 0.621 0 CA-C-N 115.667 -0.697 . . . . 0.0 112.409 178.905 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 29' ' ' ILE . . . . . 0.545 ' HB ' ' CE2' ' A' ' 31' ' ' TYR . 1.4 mm -122.37 152.14 26.48 Favored 'Isoleucine or valine' 0 C--O 1.233 0.191 0 N-CA-C 109.807 -0.442 . . . . 0.0 109.807 179.609 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 30' ' ' CYS . . . . . 0.427 ' SG ' ' HB2' ' A' ' 19' ' ' LEU . 0.5 OUTLIER -80.02 106.92 12.4 Favored 'General case' 0 CA--C 1.537 0.467 0 CA-C-N 115.961 -0.563 . . . . 0.0 110.919 -179.986 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 31' ' ' TYR . . . . . 0.545 ' CE2' ' HB ' ' A' ' 29' ' ' ILE . 36.3 m-85 -132.15 167.17 20.24 Favored 'General case' 0 N--CA 1.463 0.222 0 CA-C-N 115.449 -0.796 . . . . 0.0 111.155 -179.332 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 2.7 tp -101.82 131.67 49.28 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.611 0 CA-C-N 116.081 -0.509 . . . . 0.0 110.412 179.493 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 33' ' ' ILE . . . . . 0.446 HD12 ' OXT' ' A' ' 33' ' ' ILE . 1.9 pp . . . . . 0 C--O 1.249 1.04 0 CA-C-O 118.133 -0.937 . . . . 0.0 111.568 179.873 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 4.8 p . . . . . 0 N--CA 1.485 1.313 0 CA-C-O 119.719 -0.182 . . . . 0.0 111.263 . . . . . . . . . 0 0 . 1 . 015 nuclear orig full ' A' A ' 2' ' ' PRO . . . . . 0.507 ' HD3' ' ND2' ' A' ' 13' ' ' ASN . 81.2 Cg_endo -82.88 -172.65 1.45 Allowed 'Trans proline' 0 C--N 1.367 1.508 0 C-N-CA 122.619 2.213 . . . . 0.0 112.886 179.59 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -145.28 -156.63 6.92 Favored Glycine 0 C--N 1.34 0.767 0 N-CA-C 111.562 -0.615 . . . . 0.0 111.562 179.151 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 18.1 tt0 -73.43 129.49 38.11 Favored 'General case' 0 N--CA 1.471 0.624 0 C-N-CA 122.445 0.298 . . . . 0.0 111.208 179.595 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 88.13 14.14 62.89 Favored Glycine 0 C--N 1.34 0.778 0 CA-C-N 115.765 -0.652 . . . . 0.0 113.274 -179.845 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 43.2 mt-10 -129.81 162.19 29.04 Favored 'General case' 0 C--O 1.237 0.404 0 C-N-CA 122.277 0.231 . . . . 0.0 110.733 -179.897 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 7' ' ' GLN . . . . . 0.464 ' HA ' ' O ' ' A' ' 28' ' ' GLY . 9.4 tt0 -83.82 136.77 34.01 Favored 'General case' 0 C--N 1.345 0.374 0 CA-C-O 121.305 0.574 . . . . 0.0 111.296 179.815 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 4.0 p -125.57 160.25 30.06 Favored 'General case' 0 C--O 1.243 0.712 0 CA-C-N 114.471 -1.241 . . . . 0.0 110.89 -179.554 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 9' ' ' ASP . . . . . 0.441 ' OD1' ' HD2' ' A' ' 27' ' ' TYR . 2.5 m-20 -114.58 150.11 35.51 Favored 'General case' 0 C--O 1.235 0.313 0 CA-C-N 115.58 -0.736 . . . . 0.0 109.684 179.432 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 11.2 m -103.24 16.78 5.1 Favored 'Isoleucine or valine' 0 CA--C 1.542 0.64 0 CA-C-N 116.398 -0.364 . . . . 0.0 111.766 -179.686 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 9.6 mm-40 -110.73 -52.53 2.78 Favored 'General case' 0 C--O 1.235 0.312 0 N-CA-C 112.118 0.414 . . . . 0.0 112.118 -178.937 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 12' ' ' PHE . . . . . . . . . . . . . 17.2 t80 -142.01 -7.84 0.93 Allowed 'General case' 0 N--CA 1.472 0.663 0 N-CA-C 112.569 0.581 . . . . 0.0 112.569 -178.788 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 13' ' ' ASN . . . . . 0.507 ' ND2' ' HD3' ' A' ' 2' ' ' PRO . 6.7 t30 -129.58 64.37 71.38 Favored Pre-proline 0 CA--C 1.55 0.952 0 N-CA-C 111.559 0.207 . . . . 0.0 111.559 -179.075 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 15.0 Cg_exo -69.64 179.95 3.28 Favored 'Trans proline' 0 C--N 1.372 1.792 0 C-N-CA 122.888 2.392 . . . . 0.0 111.993 178.947 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 1.3 t -79.76 121.25 25.12 Favored 'General case' 0 N--CA 1.47 0.573 0 CA-C-O 120.519 0.2 . . . . 0.0 111.142 -179.951 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER -57.88 -53.61 63.96 Favored Pre-proline 0 N--CA 1.478 0.952 0 CA-C-O 118.992 -0.528 . . . . 0.0 111.573 179.325 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 45.1 Cg_endo -69.06 169.61 17.63 Favored 'Trans proline' 0 C--N 1.378 2.099 0 C-N-CA 122.12 1.88 . . . . 0.0 111.725 178.181 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -71.8 49.67 1.27 Allowed 'Trans proline' 0 C--N 1.372 1.794 0 C-N-CA 121.957 1.771 . . . . 0.0 112.688 178.794 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 22.0 mt -110.08 168.32 9.52 Favored 'General case' 0 C--O 1.236 0.389 0 CA-C-N 115.703 -0.681 . . . . 0.0 111.284 -179.363 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 20' ' ' THR . . . . . 0.496 ' O ' ' HA ' ' A' ' 30' ' ' CYS . 27.9 m -105.19 154.48 20.14 Favored 'General case' 0 CA--C 1.533 0.304 0 CA-C-N 115.641 -0.709 . . . . 0.0 111.191 -178.71 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 1.8 t -103.78 102.37 12.19 Favored 'General case' 0 C--O 1.238 0.453 0 CA-C-N 115.594 -0.73 . . . . 0.0 109.626 178.817 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 22' ' ' ILE . . . . . . . . . . . . . 2.8 mt -125.31 129.86 24.33 Favored Pre-proline 0 CA--C 1.542 0.665 0 CA-C-N 115.655 -0.702 . . . . 0.0 110.308 -179.071 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 35.3 Cg_endo -65.93 -48.9 0.21 Allowed 'Cis proline' 0 C--N 1.375 1.922 0 C-N-CA 124.723 -0.949 . . . . 0.0 113.817 -0.21 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 77.97 33.62 40.67 Favored Glycine 0 C--N 1.347 1.179 0 C-N-CA 121.256 -0.497 . . . . 0.0 112.901 179.872 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 4.6 t70 -139.49 82.84 17.92 Favored Pre-proline 0 CA--C 1.546 0.794 0 C-N-CA 122.556 0.343 . . . . 0.0 110.166 -179.641 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 2.5 Cg_endo -81.52 -32.54 3.61 Favored 'Cis proline' 0 C--N 1.37 1.7 0 C-N-CA 125.146 -0.772 . . . . 0.0 113.048 -0.028 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 27' ' ' TYR . . . . . 0.441 ' HD2' ' OD1' ' A' ' 9' ' ' ASP . 46.4 m-85 -103.46 167.59 9.71 Favored 'General case' 0 C--O 1.239 0.5 0 O-C-N 123.669 0.606 . . . . 0.0 111.476 -178.889 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 28' ' ' GLY . . . . . 0.464 ' O ' ' HA ' ' A' ' 7' ' ' GLN . . . -170.0 -163.14 23.54 Favored Glycine 0 C--N 1.342 0.899 0 C-N-CA 120.853 -0.689 . . . . 0.0 113.327 178.543 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 29' ' ' ILE . . . . . 0.501 ' HB ' ' CE2' ' A' ' 31' ' ' TYR . 2.7 mm -118.21 154.86 20.28 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.284 0 O-C-N 124.108 0.534 . . . . 0.0 110.149 -179.931 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 30' ' ' CYS . . . . . 0.496 ' HA ' ' O ' ' A' ' 20' ' ' THR . 24.5 m -83.29 103.48 12.71 Favored 'General case' 0 C--O 1.237 0.431 0 CA-C-N 115.941 -0.572 . . . . 0.0 111.22 -179.961 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 31' ' ' TYR . . . . . 0.501 ' CE2' ' HB ' ' A' ' 29' ' ' ILE . 38.6 m-85 -129.55 167.37 18.01 Favored 'General case' 0 CA--C 1.531 0.212 0 CA-C-N 115.01 -0.996 . . . . 0.0 111.074 -179.586 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 2.8 tp -100.43 131.11 48.6 Favored 'Isoleucine or valine' 0 CA--C 1.542 0.639 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.271 179.534 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 33' ' ' ILE . . . . . 0.456 ' O ' HD11 ' A' ' 33' ' ' ILE . 1.9 pp . . . . . 0 C--O 1.248 0.988 0 CA-C-O 118.387 -0.816 . . . . 0.0 111.48 179.866 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 6.0 p . . . . . 0 N--CA 1.485 1.295 0 CA-C-O 119.796 -0.145 . . . . 0.0 111.22 . . . . . . . . . 0 0 . 1 . 016 nuclear orig full ' A' A ' 2' ' ' PRO . . . . . 0.527 ' HD3' ' ND2' ' A' ' 13' ' ' ASN . 84.7 Cg_endo -83.12 -172.29 1.34 Allowed 'Trans proline' 0 C--N 1.367 1.528 0 C-N-CA 122.545 2.164 . . . . 0.0 112.926 179.629 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -148.23 -158.42 7.96 Favored Glycine 0 C--N 1.338 0.671 0 N-CA-C 111.63 -0.588 . . . . 0.0 111.63 179.276 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 17.9 tt0 -70.32 123.83 22.68 Favored 'General case' 0 N--CA 1.473 0.702 0 C-N-CA 122.489 0.316 . . . . 0.0 111.516 179.891 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 98.42 -11.19 63.34 Favored Glycine 0 C--N 1.34 0.799 0 CA-C-N 115.748 -0.66 . . . . 0.0 113.58 179.809 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 43.0 mt-10 -105.34 166.02 10.71 Favored 'General case' 0 C--O 1.238 0.465 0 CA-C-N 116.705 0.253 . . . . 0.0 111.01 -179.735 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 7' ' ' GLN . . . . . 0.428 ' HA ' ' HA ' ' A' ' 29' ' ' ILE . 6.5 tt0 -86.73 140.39 29.81 Favored 'General case' 0 C--N 1.347 0.466 0 CA-C-O 121.113 0.482 . . . . 0.0 111.132 179.744 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 8' ' ' CYS . . . . . 0.421 ' SG ' ' SG ' ' A' ' 15' ' ' CYS . 5.8 p -127.02 158.49 36.8 Favored 'General case' 0 C--O 1.239 0.53 0 CA-C-N 114.696 -1.138 . . . . 0.0 111.128 -179.599 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -114.92 149.73 36.78 Favored 'General case' 0 C--O 1.234 0.27 0 CA-C-N 115.377 -0.829 . . . . 0.0 109.711 179.348 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 10' ' ' VAL . . . . . 0.515 HG21 ' O ' ' A' ' 26' ' ' PRO . 10.4 m -103.83 17.87 4.78 Favored 'Isoleucine or valine' 0 CA--C 1.542 0.661 0 O-C-N 123.31 0.381 . . . . 0.0 111.621 179.926 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 9.7 mm-40 -109.45 -53.08 2.7 Favored 'General case' 0 C--O 1.234 0.287 0 CA-C-N 116.347 -0.388 . . . . 0.0 111.997 -179.186 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 12' ' ' PHE . . . . . . . . . . . . . 12.2 t80 -139.74 -18.05 0.96 Allowed 'General case' 0 N--CA 1.471 0.62 0 N-CA-C 112.423 0.527 . . . . 0.0 112.423 -179.04 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 13' ' ' ASN . . . . . 0.527 ' ND2' ' HD3' ' A' ' 2' ' ' PRO . 8.3 t30 -118.7 74.67 12.46 Favored Pre-proline 0 CA--C 1.549 0.929 0 O-C-N 122.977 0.173 . . . . 0.0 111.222 -179.25 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 60.0 Cg_endo -75.48 178.11 7.78 Favored 'Trans proline' 0 C--N 1.372 1.768 0 C-N-CA 122.421 2.081 . . . . 0.0 112.649 179.201 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 15' ' ' CYS . . . . . 0.421 ' SG ' ' SG ' ' A' ' 8' ' ' CYS . 1.6 m -79.66 119.83 23.14 Favored 'General case' 0 N--CA 1.471 0.596 0 O-C-N 123.151 0.282 . . . . 0.0 111.623 179.983 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER -58.91 -54.27 58.11 Favored Pre-proline 0 N--CA 1.477 0.908 0 CA-C-N 115.91 -0.586 . . . . 0.0 111.598 179.667 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 48.0 Cg_endo -68.95 169.02 18.82 Favored 'Trans proline' 0 C--N 1.38 2.207 0 C-N-CA 121.965 1.777 . . . . 0.0 111.687 178.382 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 56.1 Cg_endo -72.43 45.89 0.9 Allowed 'Trans proline' 0 C--N 1.37 1.702 0 C-N-CA 121.929 1.752 . . . . 0.0 112.939 179.048 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 19' ' ' LEU . . . . . 0.49 ' HB2' ' SG ' ' A' ' 30' ' ' CYS . 44.4 mt -106.44 169.83 8.28 Favored 'General case' 0 C--O 1.236 0.358 0 CA-C-N 116.118 -0.492 . . . . 0.0 111.038 -179.632 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 32.6 m -104.12 149.89 24.83 Favored 'General case' 0 CA--C 1.533 0.31 0 CA-C-N 115.737 -0.665 . . . . 0.0 111.095 -178.904 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 2.7 t -98.44 102.54 14.32 Favored 'General case' 0 C--O 1.238 0.464 0 CA-C-N 115.88 -0.6 . . . . 0.0 109.555 178.545 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 22' ' ' ILE . . . . . . . . . . . . . 2.4 mt -126.64 130.68 23.8 Favored Pre-proline 0 CA--C 1.542 0.671 0 CA-C-N 115.704 -0.68 . . . . 0.0 110.457 -178.728 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 36.8 Cg_endo -66.88 -48.22 0.24 Allowed 'Cis proline' 0 C--N 1.374 1.917 0 C-N-CA 124.833 -0.903 . . . . 0.0 113.784 -0.088 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 75.31 41.23 31.5 Favored Glycine 0 C--N 1.348 1.246 0 C-N-CA 121.31 -0.471 . . . . 0.0 112.811 -179.948 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 8.1 m-20 -136.24 75.36 53.13 Favored Pre-proline 0 CA--C 1.545 0.761 0 C-N-CA 122.428 0.291 . . . . 0.0 110.863 -179.627 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 26' ' ' PRO . . . . . 0.515 ' O ' HG21 ' A' ' 10' ' ' VAL . 56.8 Cg_endo -88.49 -16.91 22.33 Favored 'Cis proline' 0 C--N 1.37 1.708 0 C-N-CA 124.79 -0.921 . . . . 0.0 113.773 -0.088 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 27' ' ' TYR . . . . . 0.468 ' CE2' ' HG2' ' A' ' 26' ' ' PRO . 21.0 m-85 -106.82 163.97 12.5 Favored 'General case' 0 C--O 1.238 0.497 0 CA-C-N 116.276 -0.42 . . . . 0.0 111.457 -179.026 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -173.64 -162.18 25.08 Favored Glycine 0 C--N 1.341 0.846 0 C-N-CA 120.889 -0.672 . . . . 0.0 113.291 178.493 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 29' ' ' ILE . . . . . 0.537 ' HB ' ' CE2' ' A' ' 31' ' ' TYR . 1.9 mm -118.51 154.68 20.68 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.232 0 O-C-N 124.031 0.489 . . . . 0.0 110.049 -179.912 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 30' ' ' CYS . . . . . 0.49 ' SG ' ' HB2' ' A' ' 19' ' ' LEU . 0.5 OUTLIER -81.97 105.49 13.12 Favored 'General case' 0 CA--C 1.537 0.464 0 CA-C-N 115.893 -0.594 . . . . 0.0 110.986 179.974 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 31' ' ' TYR . . . . . 0.537 ' CE2' ' HB ' ' A' ' 29' ' ' ILE . 38.4 m-85 -131.04 165.44 23.22 Favored 'General case' 0 N--CA 1.464 0.23 0 CA-C-N 115.406 -0.815 . . . . 0.0 111.205 -179.415 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 2.9 tp -100.08 131.3 47.8 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.592 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.461 179.571 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 33' ' ' ILE . . . . . 0.452 ' OXT' HD13 ' A' ' 33' ' ' ILE . 1.9 pp . . . . . 0 C--O 1.249 1.033 0 CA-C-O 118.191 -0.909 . . . . 0.0 111.468 179.956 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 0.3 OUTLIER . . . . . 0 N--CA 1.487 1.417 0 CA-C-O 119.794 -0.146 . . . . 0.0 111.07 . . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 2' ' ' PRO . . . . . 0.559 ' O ' ' HB2' ' A' ' 16' ' ' CYS . 87.5 Cg_endo -71.35 -172.28 0.73 Allowed 'Trans proline' 0 C--N 1.375 1.923 0 C-N-CA 123.224 2.616 . . . . 0.0 113.854 -178.885 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -134.49 -154.56 7.23 Favored Glycine 0 C--N 1.342 0.895 0 CA-C-N 116.09 -0.504 . . . . 0.0 112.287 179.979 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 16.1 tt0 -73.72 137.67 44.17 Favored 'General case' 0 N--CA 1.472 0.637 0 C-N-CA 122.845 0.458 . . . . 0.0 111.407 -179.854 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 82.61 12.92 79.37 Favored Glycine 0 C--N 1.341 0.832 0 CA-C-N 115.689 -0.687 . . . . 0.0 113.277 -179.771 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 43.1 mt-10 -125.95 161.53 27.29 Favored 'General case' 0 C--O 1.237 0.421 0 C-N-CA 122.346 0.258 . . . . 0.0 110.935 -179.875 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 7' ' ' GLN . . . . . 0.693 ' HA ' ' O ' ' A' ' 28' ' ' GLY . 21.0 tt0 -88.54 133.96 34.0 Favored 'General case' 0 C--N 1.344 0.363 0 CA-C-O 121.216 0.532 . . . . 0.0 111.275 179.872 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 2.0 p -128.73 161.64 29.24 Favored 'General case' 0 C--O 1.239 0.54 0 CA-C-N 114.557 -1.201 . . . . 0.0 111.149 -179.738 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 12.2 t70 -117.1 147.02 42.76 Favored 'General case' 0 C--O 1.234 0.254 0 CA-C-N 115.677 -0.692 . . . . 0.0 109.562 178.769 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 15.8 m -93.73 24.98 0.52 Allowed 'Isoleucine or valine' 0 CA--C 1.544 0.74 0 CA-C-N 116.268 -0.423 . . . . 0.0 111.805 -179.43 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 43.7 mt-10 -121.51 -52.79 2.02 Favored 'General case' 0 CA--C 1.533 0.293 0 N-CA-C 112.268 0.47 . . . . 0.0 112.268 -178.98 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 12' ' ' PHE . . . . . . . . . . . . . 9.9 t80 -138.27 -10.59 1.46 Allowed 'General case' 0 N--CA 1.47 0.546 0 N-CA-C 112.812 0.671 . . . . 0.0 112.812 -178.622 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 13' ' ' ASN . . . . . . . . . . . . . 7.3 t30 -129.57 62.79 65.19 Favored Pre-proline 0 CA--C 1.55 0.953 0 N-CA-C 111.655 0.243 . . . . 0.0 111.655 -179.277 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 14' ' ' PRO . . . . . 0.553 ' O ' ' HD2' ' A' ' 2' ' ' PRO . 13.5 Cg_exo -70.1 -179.97 3.45 Favored 'Trans proline' 0 C--N 1.374 1.878 0 C-N-CA 122.649 2.233 . . . . 0.0 111.962 178.985 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 1.8 t -79.57 120.83 24.48 Favored 'General case' 0 N--CA 1.47 0.541 0 C-N-CA 121.989 0.116 . . . . 0.0 110.849 -179.947 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 16' ' ' CYS . . . . . 0.559 ' HB2' ' O ' ' A' ' 2' ' ' PRO . 0.0 OUTLIER -55.66 -52.56 71.05 Favored Pre-proline 0 N--CA 1.483 1.214 0 CA-C-O 118.952 -0.547 . . . . 0.0 111.643 179.572 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 56.5 Cg_endo -71.98 169.84 20.36 Favored 'Trans proline' 0 C--N 1.378 2.13 0 C-N-CA 122.155 1.903 . . . . 0.0 111.667 178.111 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 55.2 Cg_endo -71.91 48.55 1.13 Allowed 'Trans proline' 0 C--N 1.373 1.861 0 C-N-CA 121.976 1.784 . . . . 0.0 112.928 178.857 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 28.2 mt -108.32 171.06 7.63 Favored 'General case' 0 C--O 1.236 0.383 0 CA-C-N 115.679 -0.691 . . . . 0.0 111.271 -179.655 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 20' ' ' THR . . . . . 0.509 ' O ' ' HA ' ' A' ' 30' ' ' CYS . 20.0 m -105.07 153.56 21.32 Favored 'General case' 0 CA--C 1.533 0.294 0 CA-C-N 115.927 -0.579 . . . . 0.0 111.044 -178.879 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 2.7 t -105.58 99.5 9.1 Favored 'General case' 0 C--O 1.236 0.367 0 CA-C-N 115.646 -0.706 . . . . 0.0 109.366 178.776 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 22' ' ' ILE . . . . . . . . . . . . . 3.6 mt -120.71 129.92 25.09 Favored Pre-proline 0 CA--C 1.543 0.682 0 CA-C-N 115.595 -0.729 . . . . 0.0 110.345 -178.782 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 36.8 Cg_endo -66.78 -47.01 0.27 Allowed 'Cis proline' 0 C--N 1.375 1.93 0 C-N-CA 124.647 -0.981 . . . . 0.0 113.965 -0.069 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 79.51 33.43 34.84 Favored Glycine 0 C--N 1.346 1.09 0 C-N-CA 121.223 -0.513 . . . . 0.0 112.957 179.8 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 8.3 m-20 -139.26 83.97 17.06 Favored Pre-proline 0 CA--C 1.544 0.735 0 C-N-CA 122.523 0.329 . . . . 0.0 110.588 -179.762 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 2.9 Cg_endo -80.25 -31.67 4.54 Favored 'Cis proline' 0 C--N 1.37 1.697 0 C-N-CA 125.074 -0.803 . . . . 0.0 112.907 -0.044 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 27' ' ' TYR . . . . . . . . . . . . . 59.8 m-85 -108.22 173.16 6.44 Favored 'General case' 0 C--O 1.239 0.541 0 CA-C-N 115.824 -0.625 . . . . 0.0 111.701 -179.053 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 28' ' ' GLY . . . . . 0.693 ' O ' ' HA ' ' A' ' 7' ' ' GLN . . . -175.54 -164.32 29.82 Favored Glycine 0 C--N 1.338 0.685 0 CA-C-N 115.694 -0.685 . . . . 0.0 112.491 178.495 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 29' ' ' ILE . . . . . 0.537 ' HB ' ' CE2' ' A' ' 31' ' ' TYR . 2.3 mm -113.99 152.82 15.61 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 O-C-N 123.654 0.267 . . . . 0.0 110.282 -179.825 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 30' ' ' CYS . . . . . 0.509 ' HA ' ' O ' ' A' ' 20' ' ' THR . 33.9 m -79.73 106.02 11.44 Favored 'General case' 0 C--O 1.237 0.409 0 CA-C-N 115.918 -0.583 . . . . 0.0 111.432 -179.874 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 31' ' ' TYR . . . . . 0.537 ' CE2' ' HB ' ' A' ' 29' ' ' ILE . 38.6 m-85 -130.51 167.83 18.03 Favored 'General case' 0 C--O 1.233 0.187 0 CA-C-N 115.081 -0.963 . . . . 0.0 111.113 -179.463 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 2.8 tp -101.21 131.13 49.54 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.551 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.31 179.514 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 33' ' ' ILE . . . . . 0.456 HD12 ' OXT' ' A' ' 33' ' ' ILE . 1.8 pp . . . . . 0 C--O 1.249 1.074 0 CA-C-O 118.158 -0.925 . . . . 0.0 111.443 179.913 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 0.2 OUTLIER . . . . . 0 N--CA 1.487 1.418 0 CA-C-O 119.803 -0.141 . . . . 0.0 111.094 . . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 2' ' ' PRO . . . . . 0.576 ' HD2' ' O ' ' A' ' 14' ' ' PRO . 91.6 Cg_endo -71.51 -172.46 0.78 Allowed 'Trans proline' 0 C--N 1.375 1.946 0 C-N-CA 123.252 2.635 . . . . 0.0 113.961 -178.761 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -135.86 -157.74 7.96 Favored Glycine 0 C--N 1.341 0.817 0 CA-C-N 115.977 -0.556 . . . . 0.0 112.053 179.778 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 18.0 tt0 -73.07 135.46 44.82 Favored 'General case' 0 N--CA 1.471 0.608 0 C-N-CA 122.721 0.408 . . . . 0.0 111.345 -179.957 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 88.31 9.44 69.86 Favored Glycine 0 C--N 1.34 0.797 0 CA-C-N 115.797 -0.638 . . . . 0.0 113.396 -179.707 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 42.6 mt-10 -128.6 166.62 18.52 Favored 'General case' 0 C--O 1.239 0.505 0 C-N-CA 122.298 0.239 . . . . 0.0 110.883 -179.963 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 7' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER -81.74 152.48 27.0 Favored 'General case' 0 C--N 1.347 0.483 0 CA-C-N 116.581 -0.281 . . . . 0.0 110.867 179.909 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 4.9 p -140.48 150.58 43.95 Favored 'General case' 0 C--O 1.235 0.327 0 CA-C-N 115.852 -0.613 . . . . 0.0 111.116 -179.283 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -111.01 141.87 43.91 Favored 'General case' 0 C--O 1.234 0.277 0 CA-C-N 115.4 -0.818 . . . . 0.0 109.59 179.671 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 10' ' ' VAL . . . . . 0.442 HG22 ' O ' ' A' ' 26' ' ' PRO . 6.8 m -96.09 22.58 0.92 Allowed 'Isoleucine or valine' 0 CA--C 1.541 0.611 0 CA-C-N 116.559 -0.291 . . . . 0.0 111.651 -179.926 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 45.3 mt-10 -115.29 -54.34 2.55 Favored 'General case' 0 C--O 1.235 0.305 0 N-CA-C 112.079 0.4 . . . . 0.0 112.079 -179.067 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 12' ' ' PHE . . . . . . . . . . . . . 11.9 t80 -141.53 -9.17 0.95 Allowed 'General case' 0 N--CA 1.473 0.676 0 N-CA-C 112.548 0.573 . . . . 0.0 112.548 -178.791 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 13' ' ' ASN . . . . . 0.437 HD22 ' HD3' ' A' ' 2' ' ' PRO . 9.9 t30 -129.94 63.53 68.91 Favored Pre-proline 0 CA--C 1.551 0.981 0 N-CA-C 111.369 0.137 . . . . 0.0 111.369 -179.19 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 14' ' ' PRO . . . . . 0.576 ' O ' ' HD2' ' A' ' 2' ' ' PRO . 13.3 Cg_exo -70.37 -174.54 1.05 Allowed 'Trans proline' 0 C--N 1.375 1.922 0 C-N-CA 122.784 2.322 . . . . 0.0 112.039 179.118 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 2.1 t -79.27 120.61 23.98 Favored 'General case' 0 N--CA 1.472 0.627 0 O-C-N 122.909 0.131 . . . . 0.0 110.991 -179.902 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 16' ' ' CYS . . . . . 0.549 ' HB2' ' O ' ' A' ' 2' ' ' PRO . 0.0 OUTLIER -57.03 -52.5 73.67 Favored Pre-proline 0 N--CA 1.483 1.198 0 CA-C-O 119.073 -0.489 . . . . 0.0 111.551 179.458 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 56.9 Cg_endo -72.29 169.95 20.36 Favored 'Trans proline' 0 C--N 1.38 2.205 0 C-N-CA 122.1 1.867 . . . . 0.0 111.712 178.013 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 53.1 Cg_endo -71.45 49.86 1.19 Allowed 'Trans proline' 0 C--N 1.373 1.861 0 C-N-CA 121.978 1.785 . . . . 0.0 112.852 178.871 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 32.9 mt -108.7 172.5 6.81 Favored 'General case' 0 CA--C 1.533 0.321 0 CA-C-N 115.722 -0.672 . . . . 0.0 111.235 -179.574 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 20' ' ' THR . . . . . 0.404 ' O ' ' HA ' ' A' ' 30' ' ' CYS . 25.0 m -106.63 153.96 21.61 Favored 'General case' 0 CA--C 1.533 0.308 0 CA-C-N 115.811 -0.631 . . . . 0.0 111.462 -178.497 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 3.5 t -103.57 104.18 14.2 Favored 'General case' 0 C--O 1.236 0.392 0 CA-C-N 115.512 -0.767 . . . . 0.0 109.474 178.568 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 22' ' ' ILE . . . . . . . . . . . . . 4.8 mt -125.56 129.66 24.33 Favored Pre-proline 0 CA--C 1.543 0.703 0 CA-C-N 115.757 -0.656 . . . . 0.0 110.665 -178.914 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 35.6 Cg_endo -66.45 -48.11 0.24 Allowed 'Cis proline' 0 C--N 1.376 1.998 0 C-N-CA 124.683 -0.965 . . . . 0.0 113.801 -0.207 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 80.46 34.4 28.86 Favored Glycine 0 C--N 1.347 1.141 0 C-N-CA 121.253 -0.498 . . . . 0.0 112.904 179.877 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 8.0 m-20 -142.81 84.27 10.87 Favored Pre-proline 0 CA--C 1.544 0.719 0 C-N-CA 122.525 0.33 . . . . 0.0 110.542 -179.604 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 26' ' ' PRO . . . . . 0.442 ' O ' HG22 ' A' ' 10' ' ' VAL . 1.1 Cg_endo -81.77 -31.73 4.12 Favored 'Cis proline' 0 C--N 1.373 1.821 0 C-N-CA 125.075 -0.802 . . . . 0.0 113.06 -0.098 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 27' ' ' TYR . . . . . . . . . . . . . 41.2 m-85 -101.26 167.56 10.12 Favored 'General case' 0 C--O 1.239 0.532 0 CA-C-N 115.797 -0.638 . . . . 0.0 111.158 -178.981 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -164.88 -161.21 13.37 Favored Glycine 0 C--N 1.34 0.799 0 C-N-CA 120.839 -0.696 . . . . 0.0 113.264 179.619 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 29' ' ' ILE . . . . . 0.488 ' HB ' ' CE2' ' A' ' 31' ' ' TYR . 3.9 mm -127.93 155.26 39.32 Favored 'Isoleucine or valine' 0 C--O 1.234 0.268 0 CA-C-N 115.175 -0.512 . . . . 0.0 109.877 179.944 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 30' ' ' CYS . . . . . 0.404 ' HA ' ' O ' ' A' ' 20' ' ' THR . 23.7 m -81.96 100.61 9.77 Favored 'General case' 0 CA--C 1.536 0.435 0 CA-C-O 121.278 0.561 . . . . 0.0 111.446 -179.911 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 31' ' ' TYR . . . . . 0.488 ' CE2' ' HB ' ' A' ' 29' ' ' ILE . 38.4 m-85 -130.04 166.16 20.72 Favored 'General case' 0 N--CA 1.464 0.246 0 CA-C-N 115.12 -0.946 . . . . 0.0 110.937 -179.872 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 2.9 tp -101.0 131.71 48.15 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.546 0 CA-C-N 116.077 -0.511 . . . . 0.0 110.367 179.558 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 33' ' ' ILE . . . . . 0.459 ' OXT' HD13 ' A' ' 33' ' ' ILE . 1.8 pp . . . . . 0 C--O 1.25 1.097 0 CA-C-O 118.241 -0.885 . . . . 0.0 111.486 179.876 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 0.2 OUTLIER . . . . . 0 N--CA 1.486 1.34 0 CA-C-O 119.777 -0.154 . . . . 0.0 111.068 . . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 2' ' ' PRO . . . . . 0.567 ' HD2' ' O ' ' A' ' 14' ' ' PRO . 92.3 Cg_endo -71.43 -172.32 0.75 Allowed 'Trans proline' 0 C--N 1.375 1.929 0 C-N-CA 123.27 2.647 . . . . 0.0 113.907 -178.842 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -135.79 -156.54 7.59 Favored Glycine 0 C--N 1.342 0.894 0 CA-C-N 116.027 -0.533 . . . . 0.0 112.387 179.829 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 16.0 tt0 -74.31 138.78 43.76 Favored 'General case' 0 N--CA 1.471 0.593 0 C-N-CA 122.693 0.397 . . . . 0.0 111.377 -179.707 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 84.53 10.62 79.27 Favored Glycine 0 C--N 1.34 0.754 0 CA-C-N 115.809 -0.632 . . . . 0.0 113.333 179.99 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 43.1 mt-10 -129.16 160.98 31.17 Favored 'General case' 0 N--CA 1.467 0.4 0 C-N-CA 122.206 0.202 . . . . 0.0 110.846 -179.841 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 7' ' ' GLN . . . . . 0.479 ' HA ' ' O ' ' A' ' 28' ' ' GLY . 7.5 tt0 -84.85 133.65 34.31 Favored 'General case' 0 C--N 1.344 0.366 0 CA-C-O 121.331 0.586 . . . . 0.0 111.215 179.765 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 3.3 p -122.85 161.75 23.48 Favored 'General case' 0 C--O 1.241 0.615 0 CA-C-N 114.44 -1.254 . . . . 0.0 110.824 -179.638 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 9' ' ' ASP . . . . . 0.447 ' OD1' ' HD2' ' A' ' 27' ' ' TYR . 1.8 m-20 -114.91 152.01 33.04 Favored 'General case' 0 C--O 1.235 0.31 0 CA-C-N 115.511 -0.768 . . . . 0.0 109.77 179.41 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 10.1 m -103.79 13.03 7.44 Favored 'Isoleucine or valine' 0 CA--C 1.542 0.651 0 O-C-N 123.254 0.346 . . . . 0.0 111.801 -179.818 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 45.9 mt-10 -100.95 -55.67 2.51 Favored 'General case' 0 C--O 1.235 0.304 0 N-CA-C 111.812 0.301 . . . . 0.0 111.812 -179.073 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 12' ' ' PHE . . . . . . . . . . . . . 12.6 t80 -141.25 -14.23 0.89 Allowed 'General case' 0 N--CA 1.47 0.564 0 N-CA-C 112.218 0.451 . . . . 0.0 112.218 -179.251 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 13' ' ' ASN . . . . . 0.452 HD22 ' HD3' ' A' ' 2' ' ' PRO . 12.6 t30 -120.47 72.91 21.09 Favored Pre-proline 0 CA--C 1.55 0.955 0 O-C-N 122.903 0.127 . . . . 0.0 111.184 -179.406 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 14' ' ' PRO . . . . . 0.567 ' O ' ' HD2' ' A' ' 2' ' ' PRO . 60.8 Cg_endo -76.44 -176.4 3.08 Favored 'Trans proline' 0 C--N 1.371 1.735 0 C-N-CA 122.367 2.044 . . . . 0.0 112.207 179.245 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 2.0 t -79.34 119.64 22.67 Favored 'General case' 0 N--CA 1.473 0.71 0 O-C-N 123.017 0.198 . . . . 0.0 110.642 179.861 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 16' ' ' CYS . . . . . 0.555 ' HB2' ' O ' ' A' ' 2' ' ' PRO . 0.0 OUTLIER -54.94 -52.48 70.49 Favored Pre-proline 0 N--CA 1.483 1.178 0 CA-C-O 119.005 -0.521 . . . . 0.0 111.664 179.715 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 57.6 Cg_endo -72.39 169.79 20.83 Favored 'Trans proline' 0 C--N 1.378 2.126 0 C-N-CA 122.06 1.84 . . . . 0.0 111.789 178.021 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 55.1 Cg_endo -71.87 50.28 1.4 Allowed 'Trans proline' 0 C--N 1.374 1.895 0 C-N-CA 122.065 1.844 . . . . 0.0 112.742 178.808 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 32.4 mt -110.03 172.13 7.04 Favored 'General case' 0 CA--C 1.533 0.323 0 CA-C-N 115.666 -0.697 . . . . 0.0 111.311 -179.33 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 20' ' ' THR . . . . . 0.48 ' O ' ' HA ' ' A' ' 30' ' ' CYS . 21.2 m -106.04 154.38 20.71 Favored 'General case' 0 CA--C 1.533 0.293 0 CA-C-N 115.606 -0.724 . . . . 0.0 111.002 -178.948 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 2.0 t -105.35 99.7 9.3 Favored 'General case' 0 C--O 1.237 0.398 0 CA-C-N 115.644 -0.707 . . . . 0.0 109.363 178.597 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 22' ' ' ILE . . . . . . . . . . . . . 3.0 mt -122.53 130.53 24.62 Favored Pre-proline 0 CA--C 1.542 0.658 0 CA-C-N 115.559 -0.746 . . . . 0.0 110.382 -178.713 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 32.5 Cg_endo -65.07 -48.47 0.21 Allowed 'Cis proline' 0 C--N 1.375 1.944 0 C-N-CA 124.76 -0.933 . . . . 0.0 113.942 -0.226 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 77.19 31.36 52.51 Favored Glycine 0 C--N 1.348 1.215 0 C-N-CA 121.165 -0.54 . . . . 0.0 113.004 179.725 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 8.3 m-20 -138.86 83.71 18.56 Favored Pre-proline 0 CA--C 1.544 0.717 0 C-N-CA 122.49 0.316 . . . . 0.0 110.432 -179.771 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 3.0 Cg_exo -81.17 -32.34 3.83 Favored 'Cis proline' 0 C--N 1.372 1.772 0 C-N-CA 125.101 -0.791 . . . . 0.0 113.07 -0.08 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 27' ' ' TYR . . . . . 0.447 ' HD2' ' OD1' ' A' ' 9' ' ' ASP . 45.4 m-85 -104.4 166.76 10.19 Favored 'General case' 0 N--CA 1.469 0.485 0 CA-C-N 115.864 -0.607 . . . . 0.0 111.465 -178.884 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 28' ' ' GLY . . . . . 0.479 ' O ' ' HA ' ' A' ' 7' ' ' GLN . . . -169.95 -164.85 26.36 Favored Glycine 0 C--N 1.341 0.842 0 C-N-CA 120.93 -0.652 . . . . 0.0 113.356 178.492 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 29' ' ' ILE . . . . . 0.526 ' HB ' ' CE2' ' A' ' 31' ' ' TYR . 1.9 mm -117.38 153.07 19.22 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.225 0 O-C-N 124.045 0.497 . . . . 0.0 110.22 -179.938 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 30' ' ' CYS . . . . . 0.48 ' HA ' ' O ' ' A' ' 20' ' ' THR . 20.5 m -80.06 104.66 10.78 Favored 'General case' 0 CA--C 1.536 0.42 0 CA-C-N 115.923 -0.581 . . . . 0.0 111.21 -179.866 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 31' ' ' TYR . . . . . 0.526 ' CE2' ' HB ' ' A' ' 29' ' ' ILE . 39.7 m-85 -130.12 167.51 18.24 Favored 'General case' 0 C--O 1.233 0.223 0 CA-C-N 115.098 -0.956 . . . . 0.0 111.044 -179.54 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 2.6 tp -100.95 131.84 47.82 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.524 0 CA-C-N 116.056 -0.52 . . . . 0.0 110.426 179.486 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 33' ' ' ILE . . . . . 0.442 ' O ' HD12 ' A' ' 33' ' ' ILE . 1.7 pp . . . . . 0 C--O 1.248 0.998 0 CA-C-O 118.383 -0.818 . . . . 0.0 111.522 179.856 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 0.2 OUTLIER . . . . . 0 N--CA 1.487 1.402 0 CA-C-O 119.753 -0.165 . . . . 0.0 111.045 . . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 2' ' ' PRO . . . . . 0.587 ' HD2' ' O ' ' A' ' 14' ' ' PRO . 94.6 Cg_endo -71.52 -172.63 0.81 Allowed 'Trans proline' 0 C--N 1.375 1.931 0 C-N-CA 123.299 2.666 . . . . 0.0 113.801 -178.816 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -136.4 -158.1 7.97 Favored Glycine 0 C--N 1.342 0.89 0 CA-C-N 115.852 -0.613 . . . . 0.0 112.232 179.749 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 18.3 tt0 -73.52 136.51 44.11 Favored 'General case' 0 N--CA 1.472 0.625 0 C-N-CA 122.717 0.407 . . . . 0.0 111.382 -179.978 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 87.85 9.23 71.61 Favored Glycine 0 C--N 1.339 0.703 0 O-C-N 123.775 0.672 . . . . 0.0 113.398 -179.796 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 3.2 tp10 -129.0 166.49 19.09 Favored 'General case' 0 C--O 1.239 0.53 0 C-N-CA 122.218 0.207 . . . . 0.0 110.576 -179.816 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 7' ' ' GLN . . . . . . . . . . . . . 0.2 OUTLIER -80.6 152.81 28.36 Favored 'General case' 0 C--N 1.347 0.483 0 CA-C-N 116.517 -0.31 . . . . 0.0 110.822 179.782 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 6.2 p -140.85 152.24 44.97 Favored 'General case' 0 C--O 1.234 0.245 0 CA-C-N 115.958 -0.565 . . . . 0.0 111.163 -179.12 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -112.41 146.12 38.92 Favored 'General case' 0 C--O 1.235 0.337 0 CA-C-N 115.397 -0.82 . . . . 0.0 109.626 179.498 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 10' ' ' VAL . . . . . 0.445 HG21 ' O ' ' A' ' 26' ' ' PRO . 6.5 m -101.26 17.91 3.63 Favored 'Isoleucine or valine' 0 CA--C 1.543 0.674 0 CA-C-N 116.46 -0.336 . . . . 0.0 111.604 179.988 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 47.0 mt-10 -107.55 -55.01 2.41 Favored 'General case' 0 N--CA 1.467 0.383 0 CA-C-N 116.346 -0.388 . . . . 0.0 111.873 -179.155 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 12' ' ' PHE . . . . . . . . . . . . . 10.8 t80 -140.35 -16.77 0.92 Allowed 'General case' 0 N--CA 1.471 0.596 0 N-CA-C 112.31 0.485 . . . . 0.0 112.31 -179.193 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 13' ' ' ASN . . . . . 0.476 HD22 ' HD3' ' A' ' 2' ' ' PRO . 13.3 t30 -120.56 72.98 21.76 Favored Pre-proline 0 CA--C 1.548 0.899 0 O-C-N 122.937 0.148 . . . . 0.0 111.139 -179.337 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 14' ' ' PRO . . . . . 0.587 ' O ' ' HD2' ' A' ' 2' ' ' PRO . 62.4 Cg_endo -76.71 -175.13 2.44 Favored 'Trans proline' 0 C--N 1.372 1.806 0 C-N-CA 122.484 2.123 . . . . 0.0 112.347 179.318 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 2.2 t -79.48 119.59 22.68 Favored 'General case' 0 N--CA 1.472 0.651 0 CA-C-O 120.452 0.168 . . . . 0.0 110.727 179.932 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 16' ' ' CYS . . . . . 0.556 ' HB2' ' O ' ' A' ' 2' ' ' PRO . 0.0 OUTLIER -56.25 -52.59 71.8 Favored Pre-proline 0 N--CA 1.481 1.101 0 CA-C-O 119.005 -0.521 . . . . 0.0 111.712 179.611 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 56.9 Cg_endo -72.36 169.67 21.1 Favored 'Trans proline' 0 C--N 1.38 2.205 0 C-N-CA 122.065 1.844 . . . . 0.0 111.721 177.969 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -71.69 51.87 1.6 Allowed 'Trans proline' 0 C--N 1.373 1.859 0 C-N-CA 121.963 1.776 . . . . 0.0 112.769 178.79 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 37.5 mt -110.6 173.12 6.48 Favored 'General case' 0 C--O 1.236 0.37 0 CA-C-N 115.58 -0.736 . . . . 0.0 111.333 -179.565 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 28.8 m -107.92 152.88 23.85 Favored 'General case' 0 CA--C 1.533 0.318 0 CA-C-N 115.874 -0.603 . . . . 0.0 111.346 -178.565 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 3.9 t -101.82 104.25 15.0 Favored 'General case' 0 C--O 1.238 0.471 0 CA-C-N 115.437 -0.801 . . . . 0.0 109.622 178.463 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 22' ' ' ILE . . . . . . . . . . . . . 4.5 mt -125.92 129.75 24.2 Favored Pre-proline 0 CA--C 1.544 0.717 0 CA-C-N 115.918 -0.583 . . . . 0.0 110.544 -178.775 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 23' ' ' PRO . . . . . 0.475 ' HB2' ' OD2' ' A' ' 25' ' ' ASP . 35.2 Cg_endo -66.01 -48.76 0.21 Allowed 'Cis proline' 0 C--N 1.376 1.979 0 C-N-CA 124.71 -0.954 . . . . 0.0 113.807 -0.354 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 80.55 35.61 25.38 Favored Glycine 0 C--N 1.347 1.156 0 C-N-CA 121.299 -0.477 . . . . 0.0 112.91 179.826 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 25' ' ' ASP . . . . . 0.475 ' OD2' ' HB2' ' A' ' 23' ' ' PRO . 2.5 p30 -143.72 84.1 10.11 Favored Pre-proline 0 CA--C 1.548 0.898 0 C-N-CA 122.551 0.34 . . . . 0.0 110.759 -179.789 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 26' ' ' PRO . . . . . 0.445 ' O ' HG21 ' A' ' 10' ' ' VAL . 1.2 Cg_endo -81.41 -32.1 3.95 Favored 'Cis proline' 0 C--N 1.371 1.712 0 C-N-CA 125.15 -0.771 . . . . 0.0 113.087 0.011 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 27' ' ' TYR . . . . . . . . . . . . . 40.1 m-85 -101.79 169.69 8.64 Favored 'General case' 0 C--O 1.239 0.533 0 CA-C-N 115.754 -0.657 . . . . 0.0 111.213 -178.888 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -167.49 -159.42 13.04 Favored Glycine 0 C--N 1.341 0.815 0 C-N-CA 120.888 -0.672 . . . . 0.0 113.243 179.517 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 29' ' ' ILE . . . . . 0.489 ' HB ' ' CE2' ' A' ' 31' ' ' TYR . 4.2 mm -128.17 154.4 38.78 Favored 'Isoleucine or valine' 0 C--O 1.233 0.193 0 CA-C-N 115.276 -0.462 . . . . 0.0 109.853 179.969 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 30' ' ' CYS . . . . . . . . . . . . . 18.2 m -81.55 101.48 9.99 Favored 'General case' 0 CA--C 1.536 0.42 0 CA-C-N 116.02 -0.536 . . . . 0.0 111.395 179.989 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 31' ' ' TYR . . . . . 0.489 ' CE2' ' HB ' ' A' ' 29' ' ' ILE . 38.4 m-85 -130.0 166.53 19.9 Favored 'General case' 0 N--CA 1.464 0.228 0 CA-C-N 115.145 -0.934 . . . . 0.0 110.995 -179.714 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 2.8 tp -101.5 131.96 48.29 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.624 0 CA-C-N 116.141 -0.482 . . . . 0.0 110.377 179.51 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 33' ' ' ILE . . . . . 0.459 ' O ' HD12 ' A' ' 33' ' ' ILE . 1.8 pp . . . . . 0 C--O 1.249 1.057 0 CA-C-O 118.382 -0.818 . . . . 0.0 111.521 179.945 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 2' ' ' PRO . . . . . 0.415 ' HD2' ' O ' ' A' ' 14' ' ' PRO . 81.1 Cg_endo . . . . . 0 CA--C 1.545 1.034 0 N-CA-C 112.942 0.324 . . . . 0.0 112.942 . . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -145.77 -159.22 8.06 Favored Glycine 0 C--N 1.337 0.632 0 N-CA-C 111.547 -0.621 . . . . 0.0 111.547 179.189 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 19.7 tt0 -71.3 125.84 28.05 Favored 'General case' 0 N--CA 1.472 0.668 0 CA-C-N 116.901 0.35 . . . . 0.0 111.072 179.631 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 88.22 16.65 58.8 Favored Glycine 0 C--N 1.339 0.724 0 CA-C-N 115.659 -0.7 . . . . 0.0 113.097 -179.541 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 43.1 mt-10 -127.95 166.91 17.43 Favored 'General case' 0 C--O 1.237 0.433 0 C-N-CA 122.333 0.253 . . . . 0.0 110.719 -179.775 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 7' ' ' GLN . . . . . 0.459 ' HA ' ' O ' ' A' ' 28' ' ' GLY . 0.2 OUTLIER -81.05 152.04 28.08 Favored 'General case' 0 C--N 1.346 0.436 0 CA-C-N 116.502 -0.317 . . . . 0.0 110.974 179.89 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 6.3 p -147.12 156.24 42.83 Favored 'General case' 0 C--O 1.235 0.307 0 CA-C-N 115.963 -0.562 . . . . 0.0 111.583 -178.965 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 4.8 t70 -117.36 149.13 41.01 Favored 'General case' 0 C--O 1.234 0.263 0 CA-C-N 115.452 -0.794 . . . . 0.0 109.589 178.918 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 15.7 m -102.38 24.49 1.48 Allowed 'Isoleucine or valine' 0 CA--C 1.542 0.655 0 CA-C-N 116.225 -0.443 . . . . 0.0 111.905 -179.493 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 43.9 mt-10 -120.63 -50.89 2.18 Favored 'General case' 0 N--CA 1.466 0.333 0 N-CA-C 112.063 0.394 . . . . 0.0 112.063 -179.044 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 12' ' ' PHE . . . . . . . . . . . . . 13.7 m-85 -133.35 -27.23 1.59 Allowed 'General case' 0 N--CA 1.47 0.541 0 N-CA-C 112.181 0.437 . . . . 0.0 112.181 -178.706 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 13' ' ' ASN . . . . . . . . . . . . . 3.6 t-20 -116.03 73.91 5.11 Favored Pre-proline 0 CA--C 1.549 0.934 0 O-C-N 123.435 0.459 . . . . 0.0 112.174 -177.467 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 14' ' ' PRO . . . . . 0.415 ' O ' ' HD2' ' A' ' 2' ' ' PRO . 60.8 Cg_endo -76.1 179.09 6.67 Favored 'Trans proline' 0 C--N 1.372 1.777 0 C-N-CA 122.43 2.087 . . . . 0.0 112.125 178.746 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 1.9 t -79.67 119.9 23.24 Favored 'General case' 0 N--CA 1.47 0.566 0 CA-C-O 120.499 0.19 . . . . 0.0 110.938 179.75 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER -57.86 -54.07 59.23 Favored Pre-proline 0 N--CA 1.477 0.915 0 CA-C-O 118.973 -0.537 . . . . 0.0 111.757 179.651 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 17' ' ' PRO . . . . . 0.621 ' HG2' HD12 ' A' ' 19' ' ' LEU . 51.9 Cg_endo -70.39 168.19 23.08 Favored 'Trans proline' 0 C--N 1.378 2.118 0 C-N-CA 122.025 1.817 . . . . 0.0 111.8 178.25 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 49.8 Cg_endo -71.01 60.88 2.39 Favored 'Trans proline' 0 C--N 1.372 1.796 0 C-N-CA 121.945 1.763 . . . . 0.0 112.427 178.807 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 19' ' ' LEU . . . . . 0.621 HD12 ' HG2' ' A' ' 17' ' ' PRO . 22.6 mt -122.42 171.58 8.97 Favored 'General case' 0 C--O 1.235 0.325 0 CA-C-N 115.411 -0.813 . . . . 0.0 111.421 -179.269 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 20' ' ' THR . . . . . 0.492 ' O ' ' HA ' ' A' ' 30' ' ' CYS . 28.5 m -107.72 153.69 22.58 Favored 'General case' 0 CA--C 1.533 0.306 0 CA-C-N 115.676 -0.693 . . . . 0.0 111.227 -178.676 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 4.8 t -103.06 104.97 15.19 Favored 'General case' 0 C--O 1.237 0.426 0 CA-C-N 115.593 -0.731 . . . . 0.0 109.553 178.626 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 22' ' ' ILE . . . . . 0.712 HD12 ' HB2' ' A' ' 31' ' ' TYR . 3.4 mt -127.12 129.34 23.97 Favored Pre-proline 0 CA--C 1.543 0.686 0 CA-C-N 115.874 -0.603 . . . . 0.0 110.47 -178.805 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 37.6 Cg_endo -67.46 -48.69 0.23 Allowed 'Cis proline' 0 C--N 1.374 1.913 0 C-N-CA 124.713 -0.953 . . . . 0.0 113.848 -0.294 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 80.5 40.74 12.35 Favored Glycine 0 C--N 1.347 1.145 0 C-N-CA 121.264 -0.493 . . . . 0.0 112.761 -179.891 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 8.2 m-20 -141.6 79.31 17.21 Favored Pre-proline 0 CA--C 1.544 0.744 0 C-N-CA 122.443 0.297 . . . . 0.0 110.837 -179.709 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 1.5 Cg_endo -82.49 -32.72 3.29 Favored 'Cis proline' 0 C--N 1.371 1.746 0 C-N-CA 125.074 -0.803 . . . . 0.0 113.028 -0.125 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 27' ' ' TYR . . . . . . . . . . . . . 71.7 m-85 -98.11 171.43 8.25 Favored 'General case' 0 C--O 1.24 0.563 0 CA-C-N 115.913 -0.585 . . . . 0.0 111.568 -178.973 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 28' ' ' GLY . . . . . 0.459 ' O ' ' HA ' ' A' ' 7' ' ' GLN . . . -173.03 -159.84 20.44 Favored Glycine 0 C--N 1.338 0.653 0 CA-C-N 115.784 -0.644 . . . . 0.0 112.365 179.301 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 29' ' ' ILE . . . . . 0.518 ' HB ' ' CE2' ' A' ' 31' ' ' TYR . 2.9 mm -124.21 151.18 29.13 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 N-CA-C 109.735 -0.468 . . . . 0.0 109.735 179.737 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 30' ' ' CYS . . . . . 0.492 ' HA ' ' O ' ' A' ' 20' ' ' THR . 23.4 m -79.94 103.24 9.69 Favored 'General case' 0 CA--C 1.536 0.412 0 CA-C-O 121.225 0.536 . . . . 0.0 111.432 -179.812 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 31' ' ' TYR . . . . . 0.712 ' HB2' HD12 ' A' ' 22' ' ' ILE . 38.2 m-85 -129.07 167.77 17.04 Favored 'General case' 0 C--O 1.233 0.211 0 CA-C-N 115.014 -0.993 . . . . 0.0 110.923 -179.623 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 2.7 tp -100.95 131.43 48.62 Favored 'Isoleucine or valine' 0 CA--C 1.542 0.645 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.315 179.411 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 33' ' ' ILE . . . . . 0.498 HG23 HD11 ' A' ' 22' ' ' ILE . 1.9 pp . . . . . 0 C--O 1.249 1.051 0 CA-C-O 118.395 -0.812 . . . . 0.0 111.413 179.954 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 2' ' ' PRO . . . . . 0.425 ' HD2' ' O ' ' A' ' 14' ' ' PRO . 88.6 Cg_endo . . . . . 0 CA--C 1.543 0.926 0 N-CA-C 112.963 0.332 . . . . 0.0 112.963 . . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -149.46 -159.58 8.7 Favored Glycine 0 C--N 1.338 0.67 0 N-CA-C 111.623 -0.591 . . . . 0.0 111.623 179.229 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 17.2 tt0 -70.05 121.29 17.17 Favored 'General case' 0 N--CA 1.474 0.73 0 CA-C-O 120.763 0.315 . . . . 0.0 111.241 179.811 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 93.37 15.15 51.99 Favored Glycine 0 C--N 1.34 0.782 0 CA-C-N 115.614 -0.721 . . . . 0.0 113.164 -179.776 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 43.1 mt-10 -128.75 166.63 18.62 Favored 'General case' 0 C--O 1.24 0.56 0 C-N-CA 122.514 0.326 . . . . 0.0 110.816 179.959 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 7' ' ' GLN . . . . . 0.443 ' HA ' ' O ' ' A' ' 28' ' ' GLY . 0.2 OUTLIER -81.43 152.55 27.35 Favored 'General case' 0 C--N 1.346 0.435 0 O-C-N 123.195 0.309 . . . . 0.0 111.137 -179.88 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 7.9 p -145.84 154.53 42.1 Favored 'General case' 0 N--CA 1.466 0.354 0 CA-C-N 115.957 -0.565 . . . . 0.0 111.502 -179.12 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 6.2 t70 -118.12 153.82 33.15 Favored 'General case' 0 C--O 1.236 0.345 0 CA-C-N 115.393 -0.821 . . . . 0.0 109.898 179.139 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 13.5 m -105.33 17.92 5.44 Favored 'Isoleucine or valine' 0 CA--C 1.542 0.661 0 CA-C-N 116.286 -0.416 . . . . 0.0 112.033 -179.422 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 46.3 mt-10 -110.74 -52.9 2.75 Favored 'General case' 0 N--CA 1.466 0.36 0 N-CA-C 111.898 0.332 . . . . 0.0 111.898 -179.149 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 12' ' ' PHE . . . . . . . . . . . . . 13.4 t80 -138.76 -15.66 1.17 Allowed 'General case' 0 N--CA 1.469 0.493 0 N-CA-C 112.406 0.521 . . . . 0.0 112.406 -178.945 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 13' ' ' ASN . . . . . . . . . . . . . 5.8 t-20 -120.62 73.35 22.73 Favored Pre-proline 0 CA--C 1.549 0.929 0 O-C-N 122.935 0.147 . . . . 0.0 111.343 -179.204 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 14' ' ' PRO . . . . . 0.425 ' O ' ' HD2' ' A' ' 2' ' ' PRO . 60.5 Cg_endo -76.43 176.56 9.92 Favored 'Trans proline' 0 C--N 1.371 1.75 0 C-N-CA 122.428 2.085 . . . . 0.0 112.48 179.342 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 1.4 m -79.67 118.9 21.91 Favored 'General case' 0 N--CA 1.469 0.488 0 O-C-N 123.199 0.312 . . . . 0.0 111.422 179.923 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER -58.03 -53.87 61.43 Favored Pre-proline 0 N--CA 1.477 0.906 0 CA-C-N 115.865 -0.607 . . . . 0.0 111.776 179.81 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 17' ' ' PRO . . . . . 0.459 ' HG2' HD12 ' A' ' 19' ' ' LEU . 53.3 Cg_endo -70.28 168.65 21.61 Favored 'Trans proline' 0 C--N 1.379 2.132 0 C-N-CA 121.983 1.789 . . . . 0.0 111.736 178.351 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 56.0 Cg_endo -72.4 47.34 1.09 Allowed 'Trans proline' 0 C--N 1.37 1.673 0 C-N-CA 121.872 1.714 . . . . 0.0 112.855 178.987 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 19' ' ' LEU . . . . . 0.462 ' HB2' ' SG ' ' A' ' 30' ' ' CYS . 13.0 mt -107.58 171.08 7.59 Favored 'General case' 0 CA--C 1.533 0.32 0 CA-C-N 115.921 -0.582 . . . . 0.0 110.955 -179.537 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 28.6 m -104.43 148.84 25.98 Favored 'General case' 0 CA--C 1.531 0.25 0 CA-C-N 115.829 -0.623 . . . . 0.0 111.108 -178.76 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 5.9 t -98.49 103.03 14.95 Favored 'General case' 0 C--O 1.238 0.499 0 N-CA-C 109.421 -0.585 . . . . 0.0 109.421 178.384 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 22' ' ' ILE . . . . . 0.715 HD12 ' HB2' ' A' ' 31' ' ' TYR . 2.5 mt -126.62 129.02 24.19 Favored Pre-proline 0 CA--C 1.543 0.703 0 CA-C-N 115.817 -0.629 . . . . 0.0 110.742 -178.547 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 37.4 Cg_endo -67.67 -48.55 0.24 Allowed 'Cis proline' 0 C--N 1.374 1.908 0 C-N-CA 124.719 -0.95 . . . . 0.0 113.782 -0.262 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 79.38 38.7 20.79 Favored Glycine 0 C--N 1.348 1.227 0 C-N-CA 121.37 -0.443 . . . . 0.0 112.894 -179.991 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 8.4 m-20 -140.71 79.99 18.72 Favored Pre-proline 0 CA--C 1.544 0.735 0 C-N-CA 122.447 0.299 . . . . 0.0 110.869 -179.728 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 1.8 Cg_endo -82.23 -32.63 3.41 Favored 'Cis proline' 0 C--N 1.372 1.811 0 C-N-CA 125.15 -0.771 . . . . 0.0 112.945 -0.127 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 27' ' ' TYR . . . . . . . . . . . . . 68.0 m-85 -99.37 171.64 7.84 Favored 'General case' 0 C--O 1.238 0.482 0 CA-C-N 115.786 -0.643 . . . . 0.0 111.652 -179.096 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 28' ' ' GLY . . . . . 0.443 ' O ' ' HA ' ' A' ' 7' ' ' GLN . . . -174.64 -159.79 21.56 Favored Glycine 0 C--N 1.337 0.62 0 CA-C-N 115.801 -0.636 . . . . 0.0 112.268 179.185 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 29' ' ' ILE . . . . . 0.556 ' HB ' ' CE2' ' A' ' 31' ' ' TYR . 1.8 mm -124.12 152.1 29.57 Favored 'Isoleucine or valine' 0 C--O 1.233 0.236 0 N-CA-C 109.755 -0.461 . . . . 0.0 109.755 179.627 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 30' ' ' CYS . . . . . 0.462 ' SG ' ' HB2' ' A' ' 19' ' ' LEU . 0.5 OUTLIER -80.12 104.49 10.71 Favored 'General case' 0 C--O 1.238 0.454 0 CA-C-N 115.974 -0.557 . . . . 0.0 110.99 -179.856 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 31' ' ' TYR . . . . . 0.715 ' HB2' HD12 ' A' ' 22' ' ' ILE . 36.1 m-85 -130.22 166.62 19.92 Favored 'General case' 0 C--O 1.233 0.189 0 CA-C-N 115.431 -0.804 . . . . 0.0 111.141 -179.501 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 2.8 tp -100.93 131.42 48.61 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.547 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.438 179.431 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 33' ' ' ILE . . . . . 0.47 ' H ' HG13 ' A' ' 33' ' ' ILE . 1.9 pp . . . . . 0 C--O 1.249 1.042 0 CA-C-O 118.28 -0.866 . . . . 0.0 111.518 179.903 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 2' ' ' PRO . . . . . 0.424 ' HD2' ' O ' ' A' ' 14' ' ' PRO . 84.1 Cg_endo . . . . . 0 CA--C 1.543 0.933 0 N-CA-C 112.845 0.287 . . . . 0.0 112.845 . . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -147.12 -161.71 9.54 Favored Glycine 0 C--N 1.338 0.665 0 N-CA-C 111.696 -0.562 . . . . 0.0 111.696 179.194 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 19.4 tt0 -67.8 124.03 22.17 Favored 'General case' 0 N--CA 1.474 0.747 0 C-N-CA 122.488 0.315 . . . . 0.0 111.212 179.68 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 91.07 15.08 56.76 Favored Glycine 0 C--N 1.338 0.681 0 CA-C-N 115.66 -0.7 . . . . 0.0 113.125 -179.718 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 43.1 mt-10 -129.06 165.22 21.62 Favored 'General case' 0 C--O 1.237 0.414 0 C-N-CA 122.29 0.236 . . . . 0.0 110.802 -179.942 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 7' ' ' GLN . . . . . . . . . . . . . 0.2 OUTLIER -81.55 152.98 27.0 Favored 'General case' 0 C--N 1.346 0.454 0 CA-C-N 116.43 -0.35 . . . . 0.0 110.936 179.915 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 3.2 p -142.23 152.07 42.72 Favored 'General case' 0 C--O 1.234 0.249 0 CA-C-N 115.821 -0.627 . . . . 0.0 111.208 -179.255 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -110.04 141.32 43.02 Favored 'General case' 0 C--O 1.232 0.163 0 CA-C-N 115.541 -0.754 . . . . 0.0 109.492 179.38 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 8.8 m -96.59 21.5 1.15 Allowed 'Isoleucine or valine' 0 CA--C 1.543 0.675 0 CA-C-N 116.326 -0.397 . . . . 0.0 111.566 -179.984 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 45.5 mt-10 -113.81 -54.83 2.57 Favored 'General case' 0 C--O 1.236 0.351 0 N-CA-C 112.048 0.388 . . . . 0.0 112.048 -179.042 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 12' ' ' PHE . . . . . . . . . . . . . 10.5 t80 -137.62 -18.56 1.24 Allowed 'General case' 0 N--CA 1.471 0.625 0 N-CA-C 112.516 0.561 . . . . 0.0 112.516 -178.891 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 13' ' ' ASN . . . . . . . . . . . . . 6.7 t-20 -119.2 73.83 14.06 Favored Pre-proline 0 CA--C 1.55 0.954 0 O-C-N 122.918 0.136 . . . . 0.0 111.118 -179.332 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 14' ' ' PRO . . . . . 0.424 ' O ' ' HD2' ' A' ' 2' ' ' PRO . 60.5 Cg_endo -75.69 -178.84 4.6 Favored 'Trans proline' 0 C--N 1.371 1.745 0 C-N-CA 122.443 2.095 . . . . 0.0 112.506 179.481 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 15' ' ' CYS . . . . . 0.531 ' SG ' ' HB2' ' A' ' 19' ' ' LEU . 4.3 t -79.47 120.48 23.93 Favored 'General case' 0 N--CA 1.471 0.623 0 O-C-N 123.079 0.237 . . . . 0.0 111.095 179.981 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER -60.27 -54.49 54.63 Favored Pre-proline 0 N--CA 1.476 0.847 0 CA-C-O 119.062 -0.494 . . . . 0.0 111.577 179.45 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 56.7 Cg_endo -71.22 168.81 22.28 Favored 'Trans proline' 0 C--N 1.381 2.241 0 C-N-CA 122.096 1.864 . . . . 0.0 111.614 178.123 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 48.4 Cg_endo -70.48 61.29 2.12 Favored 'Trans proline' 0 C--N 1.37 1.677 0 C-N-CA 121.918 1.745 . . . . 0.0 112.78 179.048 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 19' ' ' LEU . . . . . 0.531 ' HB2' ' SG ' ' A' ' 15' ' ' CYS . 90.7 mt -122.2 166.62 14.31 Favored 'General case' 0 C--O 1.235 0.331 0 CA-C-N 115.713 -0.676 . . . . 0.0 111.189 -179.869 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 20' ' ' THR . . . . . 0.471 ' OG1' HG12 ' A' ' 33' ' ' ILE . 89.5 m -106.32 149.65 26.73 Favored 'General case' 0 CA--C 1.533 0.302 0 CA-C-N 115.305 -0.861 . . . . 0.0 110.947 -179.3 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 21' ' ' CYS . . . . . 0.503 ' HA ' ' O ' ' A' ' 29' ' ' ILE . 1.9 t -95.25 106.94 19.02 Favored 'General case' 0 C--O 1.24 0.555 0 CA-C-N 115.726 -0.67 . . . . 0.0 110.244 178.917 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 22' ' ' ILE . . . . . 0.72 HD12 ' HB2' ' A' ' 31' ' ' TYR . 5.9 mt -125.47 128.5 24.67 Favored Pre-proline 0 CA--C 1.544 0.717 0 CA-C-N 115.928 -0.578 . . . . 0.0 110.531 -179.185 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 37.4 Cg_endo -67.19 -48.0 0.25 Allowed 'Cis proline' 0 C--N 1.375 1.963 0 C-N-CA 124.685 -0.964 . . . . 0.0 113.757 -0.35 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 83.07 35.75 17.29 Favored Glycine 0 C--N 1.345 1.07 0 C-N-CA 121.433 -0.413 . . . . 0.0 112.918 179.781 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 7.6 m-20 -143.91 83.6 10.27 Favored Pre-proline 0 CA--C 1.546 0.819 0 C-N-CA 122.478 0.311 . . . . 0.0 111.04 -179.661 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 69.7 Cg_endo -82.15 -31.73 4.01 Favored 'Cis proline' 0 C--N 1.372 1.813 0 C-N-CA 124.814 -0.911 . . . . 0.0 113.479 -0.218 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 27' ' ' TYR . . . . . . . . . . . . . 59.8 m-85 -96.92 163.32 13.01 Favored 'General case' 0 N--CA 1.47 0.548 0 CA-C-N 115.956 -0.565 . . . . 0.0 111.208 -179.16 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 28' ' ' GLY . . . . . 0.443 ' O ' HD13 ' A' ' 29' ' ' ILE . . . -157.89 -162.01 11.39 Favored Glycine 0 C--N 1.339 0.746 0 C-N-CA 120.92 -0.657 . . . . 0.0 113.098 179.815 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 29' ' ' ILE . . . . . 0.503 ' O ' ' HA ' ' A' ' 21' ' ' CYS . 5.0 mm -130.53 154.81 41.14 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.222 0 N-CA-C 109.709 -0.478 . . . . 0.0 109.709 179.948 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 30' ' ' CYS . . . . . . . . . . . . . 26.2 m -83.72 92.81 7.8 Favored 'General case' 0 C--O 1.238 0.489 0 CA-C-O 121.483 0.659 . . . . 0.0 111.403 -179.968 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 31' ' ' TYR . . . . . 0.72 ' HB2' HD12 ' A' ' 22' ' ' ILE . 37.1 m-85 -124.26 167.26 14.56 Favored 'General case' 0 N--CA 1.464 0.241 0 CA-C-N 114.962 -1.017 . . . . 0.0 110.902 179.945 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 2.8 tp -99.98 131.66 46.99 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.605 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.449 179.378 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 33' ' ' ILE . . . . . 0.471 HG12 ' OG1' ' A' ' 20' ' ' THR . 1.3 pt . . . . . 0 C--O 1.249 1.048 0 CA-C-O 118.142 -0.932 . . . . 0.0 111.416 179.832 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 2' ' ' PRO . . . . . 0.402 ' HD3' ' OD1' ' A' ' 13' ' ' ASN . 85.2 Cg_endo . . . . . 0 CA--C 1.543 0.954 0 N-CA-C 112.832 0.282 . . . . 0.0 112.832 . . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -146.59 -160.92 9.01 Favored Glycine 0 C--N 1.337 0.603 0 N-CA-C 111.661 -0.576 . . . . 0.0 111.661 179.141 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 19.6 tt0 -68.21 124.5 23.65 Favored 'General case' 0 N--CA 1.475 0.824 0 CA-C-N 116.816 0.308 . . . . 0.0 111.145 179.673 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 90.73 15.07 57.27 Favored Glycine 0 C--N 1.338 0.667 0 CA-C-N 115.663 -0.699 . . . . 0.0 113.143 -179.692 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 43.1 mt-10 -129.02 165.11 21.8 Favored 'General case' 0 C--O 1.239 0.53 0 C-N-CA 122.339 0.256 . . . . 0.0 110.807 -179.891 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 7' ' ' GLN . . . . . . . . . . . . . 0.2 OUTLIER -81.65 152.9 26.91 Favored 'General case' 0 C--N 1.346 0.433 0 O-C-N 123.179 0.3 . . . . 0.0 110.895 179.874 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 3.2 p -141.68 151.79 43.33 Favored 'General case' 0 C--O 1.234 0.242 0 CA-C-N 115.8 -0.636 . . . . 0.0 111.099 -179.272 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -110.34 143.56 40.38 Favored 'General case' 0 C--O 1.234 0.26 0 CA-C-N 115.481 -0.782 . . . . 0.0 109.532 179.423 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 10' ' ' VAL . . . . . 0.428 HG22 ' O ' ' A' ' 26' ' ' PRO . 6.1 m -98.28 21.06 1.52 Allowed 'Isoleucine or valine' 0 CA--C 1.541 0.606 0 O-C-N 123.238 0.336 . . . . 0.0 111.514 -179.899 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 8.5 mm-40 -115.53 -52.48 2.64 Favored 'General case' 0 C--O 1.235 0.304 0 N-CA-C 112.252 0.464 . . . . 0.0 112.252 -179.125 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 12' ' ' PHE . . . . . . . . . . . . . 13.0 t80 -141.04 -9.21 1.01 Allowed 'General case' 0 N--CA 1.473 0.709 0 N-CA-C 112.722 0.638 . . . . 0.0 112.722 -178.666 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 13' ' ' ASN . . . . . 0.402 ' OD1' ' HD3' ' A' ' 2' ' ' PRO . 6.2 t-20 -129.64 64.94 73.55 Favored Pre-proline 0 CA--C 1.551 0.986 0 CA-C-N 117.496 0.135 . . . . 0.0 111.25 -179.075 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 14' ' ' PRO . . . . . 0.401 ' O ' ' HD2' ' A' ' 2' ' ' PRO . 15.8 Cg_exo -69.04 -178.66 2.16 Favored 'Trans proline' 0 C--N 1.372 1.808 0 C-N-CA 122.957 2.438 . . . . 0.0 112.266 179.009 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 15' ' ' CYS . . . . . 0.53 ' SG ' ' HB2' ' A' ' 19' ' ' LEU . 4.0 t -79.65 121.79 25.73 Favored 'General case' 0 N--CA 1.472 0.64 0 O-C-N 123.135 0.272 . . . . 0.0 111.331 -179.781 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER -61.35 -54.32 54.04 Favored Pre-proline 0 CA--C 1.547 0.845 0 CA-C-O 119.024 -0.512 . . . . 0.0 111.43 179.22 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 56.7 Cg_endo -71.19 169.21 21.22 Favored 'Trans proline' 0 C--N 1.38 2.225 0 C-N-CA 121.96 1.773 . . . . 0.0 111.719 178.193 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 49.0 Cg_endo -70.56 59.12 2.0 Favored 'Trans proline' 0 C--N 1.372 1.795 0 C-N-CA 121.918 1.746 . . . . 0.0 112.896 179.071 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 19' ' ' LEU . . . . . 0.53 ' HB2' ' SG ' ' A' ' 15' ' ' CYS . 92.2 mt -119.99 165.2 14.98 Favored 'General case' 0 C--O 1.235 0.31 0 CA-C-N 115.751 -0.659 . . . . 0.0 111.176 -179.95 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 87.5 m -104.08 150.58 24.17 Favored 'General case' 0 CA--C 1.532 0.285 0 CA-C-N 115.327 -0.851 . . . . 0.0 110.978 -179.464 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 21' ' ' CYS . . . . . 0.499 ' HA ' ' O ' ' A' ' 29' ' ' ILE . 1.9 t -96.57 104.55 16.54 Favored 'General case' 0 C--O 1.238 0.464 0 CA-C-N 115.669 -0.696 . . . . 0.0 109.98 178.94 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 22' ' ' ILE . . . . . 0.72 HD12 ' HB2' ' A' ' 31' ' ' TYR . 6.1 mt -122.83 128.01 25.53 Favored Pre-proline 0 CA--C 1.543 0.705 0 CA-C-N 115.865 -0.607 . . . . 0.0 110.546 -179.178 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 36.8 Cg_endo -66.96 -47.57 0.26 Allowed 'Cis proline' 0 C--N 1.376 1.977 0 C-N-CA 124.632 -0.987 . . . . 0.0 113.801 -0.302 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 83.73 32.85 23.29 Favored Glycine 0 C--N 1.345 1.081 0 C-N-CA 121.305 -0.474 . . . . 0.0 113.021 179.719 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 7.7 m-20 -144.18 86.57 8.27 Favored Pre-proline 0 CA--C 1.545 0.772 0 C-N-CA 122.56 0.344 . . . . 0.0 110.532 -179.654 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 26' ' ' PRO . . . . . 0.428 ' O ' HG22 ' A' ' 10' ' ' VAL . 1.1 Cg_endo -81.47 -31.34 4.49 Favored 'Cis proline' 0 C--N 1.371 1.733 0 C-N-CA 125.164 -0.765 . . . . 0.0 112.888 0.018 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 27' ' ' TYR . . . . . . . . . . . . . 41.3 m-85 -101.76 166.56 10.61 Favored 'General case' 0 C--O 1.237 0.398 0 CA-C-N 115.712 -0.676 . . . . 0.0 111.104 -179.137 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 28' ' ' GLY . . . . . 0.428 ' O ' HD13 ' A' ' 29' ' ' ILE . . . -160.63 -160.82 10.93 Favored Glycine 0 C--N 1.341 0.807 0 C-N-CA 120.911 -0.661 . . . . 0.0 113.21 179.999 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 29' ' ' ILE . . . . . 0.499 ' O ' ' HA ' ' A' ' 21' ' ' CYS . 4.8 mm -129.76 155.29 41.3 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.255 0 CA-C-N 115.273 -0.464 . . . . 0.0 109.887 -179.995 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 30' ' ' CYS . . . . . . . . . . . . . 30.1 m -84.04 93.78 8.17 Favored 'General case' 0 C--O 1.237 0.433 0 CA-C-O 121.39 0.614 . . . . 0.0 111.302 179.926 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 31' ' ' TYR . . . . . 0.72 ' HB2' HD12 ' A' ' 22' ' ' ILE . 35.4 m-85 -124.37 168.4 13.07 Favored 'General case' 0 N--CA 1.464 0.255 0 CA-C-N 115.012 -0.994 . . . . 0.0 111.14 -179.863 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 2.6 tp -100.68 133.48 43.7 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.598 0 CA-C-N 116.082 -0.508 . . . . 0.0 110.343 179.391 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 33' ' ' ILE . . . . . 0.436 ' OXT' HD12 ' A' ' 33' ' ' ILE . 1.6 pp . . . . . 0 C--O 1.249 1.031 0 CA-C-O 118.081 -0.961 . . . . 0.0 111.519 179.888 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 2' ' ' PRO . . . . . . . . . . . . . 94.5 Cg_endo . . . . . 0 CA--C 1.545 1.032 0 N-CA-C 112.937 0.322 . . . . 0.0 112.937 . . . . . . . . . 0 0 . 1 . 005 nuclear build core ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -143.95 -153.53 5.9 Favored Glycine 0 C--N 1.339 0.724 0 N-CA-C 111.669 -0.573 . . . . 0.0 111.669 179.381 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 17.7 tt0 -73.92 130.26 39.52 Favored 'General case' 0 N--CA 1.472 0.668 0 C-N-CA 122.546 0.338 . . . . 0.0 111.265 179.578 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 85.81 15.35 65.64 Favored Glycine 0 C--N 1.339 0.709 0 CA-C-N 115.921 -0.582 . . . . 0.0 113.452 -179.756 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 43.1 mt-10 -126.02 161.13 28.26 Favored 'General case' 0 C--O 1.237 0.406 0 C-N-CA 122.243 0.217 . . . . 0.0 110.849 -179.829 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 7' ' ' GLN . . . . . 0.69 ' HA ' ' O ' ' A' ' 28' ' ' GLY . 18.9 tt0 -87.01 134.81 33.45 Favored 'General case' 0 C--N 1.346 0.422 0 CA-C-O 121.176 0.512 . . . . 0.0 111.311 179.89 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 8' ' ' CYS . . . . . 0.401 ' SG ' ' SG ' ' A' ' 30' ' ' CYS . 2.5 p -129.3 161.41 30.29 Favored 'General case' 0 C--O 1.239 0.522 0 CA-C-N 114.538 -1.21 . . . . 0.0 110.989 -179.528 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 9' ' ' ASP . . . . . 0.591 ' OD1' ' HB3' ' A' ' 13' ' ' ASN . 0.7 OUTLIER -120.69 142.68 49.26 Favored 'General case' 0 N--CA 1.463 0.222 0 CA-C-N 115.725 -0.67 . . . . 0.0 110.042 178.528 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 23.2 m -90.78 13.85 1.59 Allowed 'Isoleucine or valine' 0 CA--C 1.543 0.697 0 CA-C-N 115.994 -0.548 . . . . 0.0 111.593 -179.398 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 45.9 mt-10 -97.05 -51.96 4.03 Favored 'General case' 0 C--O 1.235 0.304 0 CA-C-N 116.029 -0.532 . . . . 0.0 111.938 -178.804 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 12' ' ' PHE . . . . . . . . . . . . . 7.2 t80 -144.97 -21.56 0.5 Allowed 'General case' 0 N--CA 1.473 0.691 0 N-CA-C 112.657 0.614 . . . . 0.0 112.657 -178.771 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 13' ' ' ASN . . . . . 0.591 ' HB3' ' OD1' ' A' ' 9' ' ' ASP . 13.2 t-20 -120.03 75.13 21.32 Favored Pre-proline 0 CA--C 1.548 0.88 0 CA-C-N 117.521 0.146 . . . . 0.0 111.324 -178.889 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 61.4 Cg_endo -76.84 -175.89 2.87 Favored 'Trans proline' 0 C--N 1.372 1.774 0 C-N-CA 122.57 2.18 . . . . 0.0 112.16 178.731 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 0.8 OUTLIER -79.99 121.61 25.7 Favored 'General case' 0 N--CA 1.472 0.633 0 O-C-N 123.02 0.2 . . . . 0.0 111.189 179.879 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER -58.16 -53.56 64.69 Favored Pre-proline 0 N--CA 1.478 0.965 0 CA-C-N 116.137 -0.483 . . . . 0.0 111.593 179.106 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 17' ' ' PRO . . . . . 0.501 ' HG2' HD12 ' A' ' 19' ' ' LEU . 41.5 Cg_endo -67.72 169.65 15.59 Favored 'Trans proline' 0 C--N 1.379 2.172 0 C-N-CA 122.148 1.899 . . . . 0.0 111.852 178.165 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 55.2 Cg_endo -71.84 47.8 1.01 Allowed 'Trans proline' 0 C--N 1.371 1.753 0 C-N-CA 122.007 1.805 . . . . 0.0 112.755 178.658 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 19' ' ' LEU . . . . . 0.501 HD12 ' HG2' ' A' ' 17' ' ' PRO . 19.5 mt -108.8 165.4 11.59 Favored 'General case' 0 C--O 1.236 0.375 0 CA-C-N 115.7 -0.682 . . . . 0.0 111.285 -179.451 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 20' ' ' THR . . . . . 0.529 ' O ' ' HA ' ' A' ' 30' ' ' CYS . 30.7 m -103.24 152.53 21.39 Favored 'General case' 0 CA--C 1.531 0.227 0 CA-C-N 115.569 -0.742 . . . . 0.0 111.038 -178.833 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 2.2 t -102.64 99.75 9.76 Favored 'General case' 0 C--O 1.237 0.435 0 CA-C-N 115.753 -0.658 . . . . 0.0 109.594 178.902 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 22' ' ' ILE . . . . . 0.705 HD12 ' HB2' ' A' ' 31' ' ' TYR . 2.9 mt -120.88 128.78 25.6 Favored Pre-proline 0 CA--C 1.542 0.652 0 CA-C-N 115.637 -0.71 . . . . 0.0 110.372 -178.973 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 37.0 Cg_endo -66.81 -47.5 0.26 Allowed 'Cis proline' 0 C--N 1.375 1.936 0 C-N-CA 124.77 -0.929 . . . . 0.0 113.867 -0.232 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 79.11 34.03 34.48 Favored Glycine 0 C--N 1.347 1.173 0 C-N-CA 121.277 -0.487 . . . . 0.0 112.894 179.969 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 8.3 m-20 -139.73 83.26 16.85 Favored Pre-proline 0 CA--C 1.543 0.686 0 C-N-CA 122.561 0.344 . . . . 0.0 110.538 -179.712 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 3.1 Cg_exo -80.61 -32.05 4.18 Favored 'Cis proline' 0 C--N 1.371 1.746 0 C-N-CA 125.095 -0.794 . . . . 0.0 112.948 -0.099 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 27' ' ' TYR . . . . . 0.561 ' CD2' ' HB3' ' A' ' 9' ' ' ASP . 62.6 m-85 -106.85 172.67 6.69 Favored 'General case' 0 C--O 1.239 0.552 0 CA-C-N 115.753 -0.658 . . . . 0.0 111.751 -178.95 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 28' ' ' GLY . . . . . 0.69 ' O ' ' HA ' ' A' ' 7' ' ' GLN . . . -176.53 -164.08 29.95 Favored Glycine 0 C--N 1.338 0.693 0 CA-C-N 115.732 -0.667 . . . . 0.0 112.655 178.452 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 29' ' ' ILE . . . . . 0.544 ' HB ' ' CE2' ' A' ' 31' ' ' TYR . 2.6 mm -114.72 151.3 16.49 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 N-CA-C 110.082 -0.34 . . . . 0.0 110.082 -179.718 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 30' ' ' CYS . . . . . 0.529 ' HA ' ' O ' ' A' ' 20' ' ' THR . 40.7 m -79.87 105.74 11.38 Favored 'General case' 0 C--O 1.237 0.395 0 CA-C-N 115.843 -0.617 . . . . 0.0 111.482 -179.801 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 31' ' ' TYR . . . . . 0.705 ' HB2' HD12 ' A' ' 22' ' ' ILE . 36.6 m-85 -130.42 167.1 19.14 Favored 'General case' 0 C--O 1.233 0.205 0 CA-C-N 114.938 -1.028 . . . . 0.0 111.011 -179.406 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 2.9 tp -99.64 130.28 48.94 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.607 0 CA-C-N 116.27 -0.423 . . . . 0.0 110.348 179.436 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 33' ' ' ILE . . . . . 0.499 HG23 HD11 ' A' ' 22' ' ' ILE . 1.9 pp . . . . . 0 C--O 1.248 0.993 0 CA-C-O 118.335 -0.84 . . . . 0.0 111.528 179.879 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 2' ' ' PRO . . . . . . . . . . . . . 92.2 Cg_endo . . . . . 0 CA--C 1.543 0.975 0 N-CA-C 112.953 0.328 . . . . 0.0 112.953 . . . . . . . . . 0 0 . 1 . 006 nuclear build core ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -143.83 -153.45 5.88 Favored Glycine 0 C--N 1.339 0.701 0 N-CA-C 111.821 -0.512 . . . . 0.0 111.821 179.383 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 17.7 tt0 -74.04 130.17 39.3 Favored 'General case' 0 N--CA 1.473 0.702 0 C-N-CA 122.702 0.401 . . . . 0.0 111.134 179.586 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 85.76 15.54 65.38 Favored Glycine 0 C--N 1.339 0.705 0 O-C-N 123.712 0.632 . . . . 0.0 113.386 -179.85 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 43.0 mt-10 -126.11 161.25 28.06 Favored 'General case' 0 C--O 1.238 0.474 0 C-N-CA 122.276 0.23 . . . . 0.0 110.85 -179.915 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 7' ' ' GLN . . . . . 0.691 ' HA ' ' O ' ' A' ' 28' ' ' GLY . 18.6 tt0 -87.1 134.81 33.47 Favored 'General case' 0 C--N 1.344 0.363 0 CA-C-O 121.258 0.552 . . . . 0.0 111.241 179.915 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 8' ' ' CYS . . . . . 0.401 ' SG ' ' SG ' ' A' ' 30' ' ' CYS . 2.5 p -129.3 161.42 30.27 Favored 'General case' 0 C--O 1.238 0.488 0 CA-C-N 114.511 -1.222 . . . . 0.0 111.017 -179.589 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 9' ' ' ASP . . . . . 0.591 ' OD1' ' HB3' ' A' ' 13' ' ' ASN . 0.7 OUTLIER -120.7 142.86 49.11 Favored 'General case' 0 N--CA 1.464 0.269 0 CA-C-N 115.693 -0.685 . . . . 0.0 109.992 178.557 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 22.5 m -90.89 13.76 1.63 Allowed 'Isoleucine or valine' 0 CA--C 1.543 0.677 0 CA-C-N 115.924 -0.58 . . . . 0.0 111.501 -179.337 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 46.0 mt-10 -96.94 -51.91 4.07 Favored 'General case' 0 C--O 1.235 0.327 0 CA-C-N 116.158 -0.474 . . . . 0.0 111.986 -178.802 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 12' ' ' PHE . . . . . . . . . . . . . 6.8 t80 -145.16 -21.49 0.49 Allowed 'General case' 0 N--CA 1.472 0.639 0 N-CA-C 112.671 0.619 . . . . 0.0 112.671 -178.845 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 13' ' ' ASN . . . . . 0.591 ' HB3' ' OD1' ' A' ' 9' ' ' ASP . 13.3 t-20 -119.91 75.19 20.52 Favored Pre-proline 0 CA--C 1.548 0.887 0 CA-C-N 117.557 0.162 . . . . 0.0 111.336 -179.017 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 62.7 Cg_endo -76.85 -175.87 2.86 Favored 'Trans proline' 0 C--N 1.37 1.679 0 C-N-CA 122.663 2.242 . . . . 0.0 112.204 178.672 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 0.8 OUTLIER -79.99 121.56 25.64 Favored 'General case' 0 N--CA 1.471 0.603 0 CA-C-O 120.462 0.172 . . . . 0.0 111.168 179.9 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER -58.17 -53.52 65.15 Favored Pre-proline 0 N--CA 1.479 0.978 0 CA-C-O 119.049 -0.501 . . . . 0.0 111.568 179.117 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 17' ' ' PRO . . . . . 0.501 ' HG2' HD12 ' A' ' 19' ' ' LEU . 41.7 Cg_endo -67.75 169.69 15.56 Favored 'Trans proline' 0 C--N 1.38 2.22 0 C-N-CA 122.104 1.869 . . . . 0.0 111.865 178.202 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 55.3 Cg_endo -71.77 47.69 0.98 Allowed 'Trans proline' 0 C--N 1.373 1.818 0 C-N-CA 121.981 1.787 . . . . 0.0 112.735 178.731 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 19' ' ' LEU . . . . . 0.501 HD12 ' HG2' ' A' ' 17' ' ' PRO . 19.4 mt -108.78 165.38 11.6 Favored 'General case' 0 C--O 1.235 0.332 0 CA-C-N 115.681 -0.691 . . . . 0.0 111.272 -179.359 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 20' ' ' THR . . . . . 0.528 ' O ' ' HA ' ' A' ' 30' ' ' CYS . 30.5 m -103.19 152.37 21.54 Favored 'General case' 0 CA--C 1.531 0.227 0 CA-C-N 115.623 -0.717 . . . . 0.0 111.084 -178.902 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 2.2 t -102.45 99.75 9.82 Favored 'General case' 0 C--O 1.237 0.445 0 CA-C-N 115.719 -0.673 . . . . 0.0 109.6 178.837 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 22' ' ' ILE . . . . . 0.705 HD12 ' HB2' ' A' ' 31' ' ' TYR . 2.9 mt -120.91 128.73 25.63 Favored Pre-proline 0 CA--C 1.541 0.615 0 CA-C-N 115.677 -0.692 . . . . 0.0 110.4 -179.026 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 37.1 Cg_endo -66.92 -47.36 0.26 Allowed 'Cis proline' 0 C--N 1.374 1.919 0 C-N-CA 124.636 -0.985 . . . . 0.0 113.859 -0.112 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 79.03 33.99 34.89 Favored Glycine 0 C--N 1.348 1.196 0 C-N-CA 121.228 -0.51 . . . . 0.0 112.916 179.961 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 8.3 m-20 -139.68 83.24 16.99 Favored Pre-proline 0 CA--C 1.544 0.721 0 C-N-CA 122.576 0.35 . . . . 0.0 110.647 -179.793 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 3.2 Cg_exo -80.7 -31.92 4.26 Favored 'Cis proline' 0 C--N 1.371 1.729 0 C-N-CA 125.102 -0.791 . . . . 0.0 112.957 -0.005 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 27' ' ' TYR . . . . . 0.562 ' CD2' ' HB3' ' A' ' 9' ' ' ASP . 62.6 m-85 -106.96 172.66 6.7 Favored 'General case' 0 C--O 1.238 0.49 0 CA-C-N 115.737 -0.665 . . . . 0.0 111.705 -178.957 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 28' ' ' GLY . . . . . 0.691 ' O ' ' HA ' ' A' ' 7' ' ' GLN . . . -176.45 -164.17 30.06 Favored Glycine 0 C--N 1.34 0.771 0 CA-C-N 115.74 -0.664 . . . . 0.0 112.559 178.474 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 29' ' ' ILE . . . . . 0.543 ' HB ' ' CE2' ' A' ' 31' ' ' TYR . 2.6 mm -114.68 151.35 16.44 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 O-C-N 123.75 0.324 . . . . 0.0 110.155 -179.733 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 30' ' ' CYS . . . . . 0.528 ' HA ' ' O ' ' A' ' 20' ' ' THR . 41.4 m -79.82 105.72 11.31 Favored 'General case' 0 C--O 1.237 0.425 0 CA-C-N 115.981 -0.554 . . . . 0.0 111.399 -179.729 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 31' ' ' TYR . . . . . 0.705 ' HB2' HD12 ' A' ' 22' ' ' ILE . 37.1 m-85 -130.48 167.18 19.04 Favored 'General case' 0 C--O 1.233 0.205 0 CA-C-N 114.989 -1.005 . . . . 0.0 111.018 -179.566 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 2.9 tp -99.63 130.2 49.04 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.584 0 CA-C-N 116.121 -0.491 . . . . 0.0 110.343 179.562 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 33' ' ' ILE . . . . . 0.502 HG23 HD11 ' A' ' 22' ' ' ILE . 1.9 pp . . . . . 0 C--O 1.249 1.051 0 CA-C-O 118.331 -0.843 . . . . 0.0 111.521 179.858 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 2' ' ' PRO . . . . . . . . . . . . . 97.6 Cg_endo . . . . . 0 CA--C 1.544 1.013 0 N-CA-C 112.965 0.333 . . . . 0.0 112.965 . . . . . . . . . 0 0 . 1 . 007 nuclear build core ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -145.12 -154.99 6.29 Favored Glycine 0 C--N 1.339 0.727 0 N-CA-C 111.78 -0.528 . . . . 0.0 111.78 179.393 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 17.9 tt0 -73.3 128.85 36.66 Favored 'General case' 0 N--CA 1.472 0.674 0 C-N-CA 122.565 0.346 . . . . 0.0 111.186 179.581 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 86.31 16.06 63.2 Favored Glycine 0 C--N 1.34 0.789 0 CA-C-N 115.784 -0.643 . . . . 0.0 113.184 -179.862 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 43.0 mt-10 -127.42 161.69 28.1 Favored 'General case' 0 N--CA 1.466 0.367 0 C-N-CA 122.312 0.245 . . . . 0.0 110.804 -179.859 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 7' ' ' GLN . . . . . 0.715 ' HA ' ' O ' ' A' ' 28' ' ' GLY . 19.3 tt0 -85.36 134.53 34.09 Favored 'General case' 0 C--N 1.346 0.415 0 CA-C-O 121.166 0.507 . . . . 0.0 111.256 179.978 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 8' ' ' CYS . . . . . 0.404 ' SG ' ' SG ' ' A' ' 30' ' ' CYS . 3.1 p -127.72 160.24 32.28 Favored 'General case' 0 C--O 1.237 0.447 0 CA-C-N 114.593 -1.185 . . . . 0.0 111.036 -179.553 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 9' ' ' ASP . . . . . 0.437 ' OD2' ' HB2' ' A' ' 11' ' ' GLU . 15.8 t70 -115.42 147.64 40.33 Favored 'General case' 0 C--O 1.234 0.26 0 CA-C-N 115.475 -0.784 . . . . 0.0 109.53 178.762 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 15.5 m -97.45 22.23 1.16 Allowed 'Isoleucine or valine' 0 CA--C 1.543 0.689 0 CA-C-N 116.312 -0.404 . . . . 0.0 111.963 -179.451 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 11' ' ' GLU . . . . . 0.437 ' HB2' ' OD2' ' A' ' 9' ' ' ASP . 44.1 mt-10 -119.68 -52.68 2.23 Favored 'General case' 0 N--CA 1.466 0.371 0 N-CA-C 112.372 0.508 . . . . 0.0 112.372 -179.068 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 12' ' ' PHE . . . . . . . . . . . . . 13.6 t80 -137.83 -8.98 1.6 Allowed 'General case' 0 N--CA 1.47 0.559 0 N-CA-C 112.649 0.611 . . . . 0.0 112.649 -178.659 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 13' ' ' ASN . . . . . . . . . . . . . 6.4 t-20 -129.65 63.81 69.45 Favored Pre-proline 0 CA--C 1.548 0.904 0 N-CA-C 111.579 0.214 . . . . 0.0 111.579 -179.195 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 13.6 Cg_exo -70.23 176.78 6.67 Favored 'Trans proline' 0 C--N 1.372 1.767 0 C-N-CA 122.801 2.334 . . . . 0.0 112.06 178.914 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 1.0 OUTLIER -79.84 121.04 24.91 Favored 'General case' 0 N--CA 1.469 0.499 0 CA-C-O 120.453 0.168 . . . . 0.0 111.155 179.983 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER -57.75 -53.01 70.18 Favored Pre-proline 0 N--CA 1.477 0.924 0 CA-C-O 118.985 -0.531 . . . . 0.0 111.535 179.316 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 17' ' ' PRO . . . . . 0.506 ' HG2' HD12 ' A' ' 19' ' ' LEU . 44.8 Cg_endo -68.67 169.53 17.25 Favored 'Trans proline' 0 C--N 1.379 2.133 0 C-N-CA 122.102 1.868 . . . . 0.0 111.747 178.008 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 55.7 Cg_endo -72.27 48.81 1.27 Allowed 'Trans proline' 0 C--N 1.372 1.785 0 C-N-CA 122.011 1.808 . . . . 0.0 112.701 178.759 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 19' ' ' LEU . . . . . 0.506 HD12 ' HG2' ' A' ' 17' ' ' PRO . 20.5 mt -109.61 167.6 10.02 Favored 'General case' 0 C--O 1.236 0.356 0 CA-C-N 115.692 -0.685 . . . . 0.0 111.316 -179.309 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 20' ' ' THR . . . . . 0.529 ' O ' ' HA ' ' A' ' 30' ' ' CYS . 32.6 m -105.03 153.37 21.55 Favored 'General case' 0 CA--C 1.532 0.279 0 CA-C-N 115.622 -0.717 . . . . 0.0 111.059 -178.794 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 1.9 t -102.71 103.27 13.5 Favored 'General case' 0 C--O 1.238 0.487 0 CA-C-N 115.672 -0.694 . . . . 0.0 109.672 178.861 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 22' ' ' ILE . . . . . 0.709 HD12 ' HB2' ' A' ' 31' ' ' TYR . 2.8 mt -125.33 129.1 24.57 Favored Pre-proline 0 CA--C 1.542 0.646 0 CA-C-N 115.774 -0.648 . . . . 0.0 110.24 -179.094 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 38.1 Cg_endo -67.43 -48.47 0.24 Allowed 'Cis proline' 0 C--N 1.374 1.897 0 C-N-CA 124.74 -0.942 . . . . 0.0 113.895 -0.113 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 81.26 36.86 19.79 Favored Glycine 0 C--N 1.347 1.141 0 C-N-CA 121.192 -0.528 . . . . 0.0 112.959 -179.927 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 4.6 t70 -139.78 82.23 18.22 Favored Pre-proline 0 CA--C 1.548 0.884 0 C-N-CA 122.454 0.301 . . . . 0.0 110.376 -179.818 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 2.6 Cg_endo -81.06 -31.72 4.33 Favored 'Cis proline' 0 C--N 1.371 1.761 0 C-N-CA 125.113 -0.786 . . . . 0.0 112.951 0.104 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 27' ' ' TYR . . . . . . . . . . . . . 60.3 m-85 -106.55 174.12 6.02 Favored 'General case' 0 C--O 1.238 0.475 0 CA-C-N 115.748 -0.66 . . . . 0.0 111.558 -179.037 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 28' ' ' GLY . . . . . 0.715 ' O ' ' HA ' ' A' ' 7' ' ' GLN . . . -175.22 -162.08 25.91 Favored Glycine 0 CA--C 1.502 -0.737 0 CA-C-N 115.627 -0.715 . . . . 0.0 112.561 178.397 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 29' ' ' ILE . . . . . 0.537 ' HB ' ' CE2' ' A' ' 31' ' ' TYR . 2.7 mm -115.35 150.36 17.32 Favored 'Isoleucine or valine' 0 C--O 1.234 0.257 0 N-CA-C 110.059 -0.349 . . . . 0.0 110.059 -179.86 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 30' ' ' CYS . . . . . 0.529 ' HA ' ' O ' ' A' ' 20' ' ' THR . 32.2 m -79.9 105.18 10.99 Favored 'General case' 0 C--O 1.236 0.372 0 CA-C-O 121.372 0.606 . . . . 0.0 111.408 -179.745 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 31' ' ' TYR . . . . . 0.709 ' HB2' HD12 ' A' ' 22' ' ' ILE . 37.1 m-85 -129.57 167.93 17.18 Favored 'General case' 0 C--O 1.234 0.28 0 CA-C-N 114.922 -1.036 . . . . 0.0 111.085 -179.466 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 2.7 tp -100.25 130.71 49.04 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.617 0 CA-C-N 116.275 -0.421 . . . . 0.0 110.317 179.402 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 33' ' ' ILE . . . . . 0.5 HG23 HD11 ' A' ' 22' ' ' ILE . 1.9 pp . . . . . 0 C--O 1.249 1.031 0 CA-C-O 118.206 -0.902 . . . . 0.0 111.454 179.911 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 2' ' ' PRO . . . . . . . . . . . . . 98.3 Cg_endo . . . . . 0 CA--C 1.545 1.045 0 N-CA-C 112.939 0.323 . . . . 0.0 112.939 . . . . . . . . . 0 0 . 1 . 008 nuclear build core ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -145.7 -155.47 6.5 Favored Glycine 0 C--N 1.338 0.676 0 N-CA-C 111.901 -0.48 . . . . 0.0 111.901 179.386 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 18.0 tt0 -73.35 129.52 38.19 Favored 'General case' 0 N--CA 1.474 0.738 0 C-N-CA 122.536 0.334 . . . . 0.0 111.198 179.658 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 85.6 16.28 64.25 Favored Glycine 0 C--N 1.339 0.748 0 CA-C-N 115.741 -0.663 . . . . 0.0 113.196 -179.849 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 43.1 mt-10 -127.61 161.49 28.73 Favored 'General case' 0 C--O 1.237 0.447 0 C-N-CA 122.188 0.195 . . . . 0.0 110.824 -179.862 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 7' ' ' GLN . . . . . 0.723 ' HA ' ' O ' ' A' ' 28' ' ' GLY . 18.7 tt0 -84.94 134.24 34.26 Favored 'General case' 0 C--N 1.345 0.381 0 CA-C-O 121.228 0.537 . . . . 0.0 111.293 179.804 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 8' ' ' CYS . . . . . 0.411 ' SG ' ' SG ' ' A' ' 30' ' ' CYS . 3.7 p -127.99 160.62 31.34 Favored 'General case' 0 C--O 1.237 0.447 0 CA-C-N 114.584 -1.189 . . . . 0.0 111.116 -179.383 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 9' ' ' ASP . . . . . 0.431 ' OD2' ' HB2' ' A' ' 11' ' ' GLU . 15.7 t70 -114.7 151.72 33.17 Favored 'General case' 0 C--O 1.236 0.352 0 CA-C-N 115.496 -0.774 . . . . 0.0 109.497 178.623 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 15.6 m -102.37 16.8 4.69 Favored 'Isoleucine or valine' 0 CA--C 1.544 0.717 0 N-CA-C 111.912 0.338 . . . . 0.0 111.912 -179.339 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 11' ' ' GLU . . . . . 0.431 ' HB2' ' OD2' ' A' ' 9' ' ' ASP . 9.5 mm-40 -110.34 -52.49 2.78 Favored 'General case' 0 N--CA 1.466 0.326 0 N-CA-C 112.082 0.401 . . . . 0.0 112.082 -178.979 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 12' ' ' PHE . . . . . . . . . . . . . 10.9 t80 -137.74 -17.51 1.26 Allowed 'General case' 0 N--CA 1.469 0.52 0 N-CA-C 112.589 0.588 . . . . 0.0 112.589 -178.812 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 13' ' ' ASN . . . . . . . . . . . . . 6.8 t-20 -120.21 73.43 20.23 Favored Pre-proline 0 CA--C 1.547 0.851 0 N-CA-C 111.373 0.138 . . . . 0.0 111.373 -179.184 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 60.4 Cg_endo -76.79 177.6 8.65 Favored 'Trans proline' 0 C--N 1.371 1.729 0 C-N-CA 122.352 2.035 . . . . 0.0 112.314 179.027 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 1.3 t -79.79 120.2 23.72 Favored 'General case' 0 N--CA 1.471 0.605 0 CA-C-O 120.508 0.194 . . . . 0.0 110.911 179.895 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER -56.94 -53.44 65.11 Favored Pre-proline 0 N--CA 1.477 0.89 0 CA-C-O 119.09 -0.481 . . . . 0.0 111.634 179.425 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 17' ' ' PRO . . . . . 0.519 ' HG2' HD12 ' A' ' 19' ' ' LEU . 44.8 Cg_endo -68.62 169.25 17.79 Favored 'Trans proline' 0 C--N 1.379 2.163 0 C-N-CA 122.152 1.901 . . . . 0.0 111.789 178.057 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 55.6 Cg_endo -72.3 50.46 1.57 Allowed 'Trans proline' 0 C--N 1.371 1.755 0 C-N-CA 122.085 1.857 . . . . 0.0 112.538 178.728 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 19' ' ' LEU . . . . . 0.519 HD12 ' HG2' ' A' ' 17' ' ' PRO . 20.9 mt -111.41 167.92 9.93 Favored 'General case' 0 C--O 1.235 0.317 0 CA-C-N 115.626 -0.716 . . . . 0.0 111.383 -179.386 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 20' ' ' THR . . . . . 0.525 ' O ' ' HA ' ' A' ' 30' ' ' CYS . 33.5 m -105.6 153.47 21.74 Favored 'General case' 0 CA--C 1.533 0.291 0 CA-C-N 115.622 -0.717 . . . . 0.0 110.995 -178.774 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 2.0 t -102.77 103.36 13.57 Favored 'General case' 0 C--O 1.236 0.389 0 CA-C-N 115.709 -0.678 . . . . 0.0 109.676 178.932 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 22' ' ' ILE . . . . . 0.703 HD12 ' HB2' ' A' ' 31' ' ' TYR . 2.8 mt -125.43 129.13 24.53 Favored Pre-proline 0 CA--C 1.542 0.635 0 CA-C-N 115.754 -0.657 . . . . 0.0 110.259 -178.99 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 38.1 Cg_endo -67.69 -48.15 0.26 Allowed 'Cis proline' 0 C--N 1.375 1.933 0 C-N-CA 124.688 -0.963 . . . . 0.0 113.906 0.056 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 81.58 36.45 19.84 Favored Glycine 0 C--N 1.348 1.202 0 C-N-CA 121.153 -0.546 . . . . 0.0 112.899 -179.968 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 8.4 m-20 -139.91 82.73 17.16 Favored Pre-proline 0 CA--C 1.544 0.726 0 C-N-CA 122.587 0.355 . . . . 0.0 110.636 -179.743 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 2.9 Cg_endo -80.37 -32.06 4.23 Favored 'Cis proline' 0 C--N 1.372 1.773 0 C-N-CA 125.134 -0.778 . . . . 0.0 112.933 -0.118 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 27' ' ' TYR . . . . . . . . . . . . . 59.6 m-85 -107.24 175.06 5.62 Favored 'General case' 0 C--O 1.239 0.535 0 CA-C-N 115.785 -0.643 . . . . 0.0 111.643 -179.014 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 28' ' ' GLY . . . . . 0.723 ' O ' ' HA ' ' A' ' 7' ' ' GLN . . . -175.7 -161.18 24.59 Favored Glycine 0 CA--C 1.504 -0.609 0 CA-C-N 115.734 -0.666 . . . . 0.0 112.574 178.468 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 29' ' ' ILE . . . . . 0.541 ' HB ' ' CE2' ' A' ' 31' ' ' TYR . 2.7 mm -115.83 150.04 17.9 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 O-C-N 123.801 0.354 . . . . 0.0 110.067 -179.738 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 30' ' ' CYS . . . . . 0.525 ' HA ' ' O ' ' A' ' 20' ' ' THR . 23.7 m -79.88 104.99 10.83 Favored 'General case' 0 CA--C 1.535 0.402 0 CA-C-O 121.319 0.581 . . . . 0.0 111.303 -179.767 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 31' ' ' TYR . . . . . 0.703 ' HB2' HD12 ' A' ' 22' ' ' ILE . 36.7 m-85 -129.25 168.08 16.72 Favored 'General case' 0 C--O 1.233 0.197 0 CA-C-N 114.889 -1.051 . . . . 0.0 111.019 -179.465 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 2.7 tp -100.29 130.9 48.79 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.627 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.277 179.449 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 33' ' ' ILE . . . . . 0.49 HG23 HD11 ' A' ' 22' ' ' ILE . 1.9 pp . . . . . 0 C--O 1.249 1.061 0 CA-C-O 118.328 -0.844 . . . . 0.0 111.479 179.865 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 2' ' ' PRO . . . . . 0.584 ' HD2' ' O ' ' A' ' 14' ' ' PRO . 73.4 Cg_endo . . . . . 0 N--CA 1.488 1.191 0 N-CA-C 113.9 0.692 . . . . 0.0 113.9 . . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -142.76 -159.52 7.98 Favored Glycine 0 C--N 1.342 0.888 0 O-C-N 123.544 0.528 . . . . 0.0 112.487 179.832 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 17.4 tt0 -68.42 122.51 18.57 Favored 'General case' 0 N--CA 1.474 0.73 0 C-N-CA 122.816 0.447 . . . . 0.0 111.515 -179.925 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 92.41 14.54 55.52 Favored Glycine 0 C--N 1.341 0.82 0 CA-C-N 115.578 -0.737 . . . . 0.0 113.243 -179.882 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 43.1 mt-10 -127.42 165.64 19.41 Favored 'General case' 0 C--O 1.239 0.546 0 C-N-CA 122.438 0.295 . . . . 0.0 110.946 179.962 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 7' ' ' GLN . . . . . 0.51 ' HA ' ' O ' ' A' ' 28' ' ' GLY . 0.9 OUTLIER -83.46 145.55 28.89 Favored 'General case' 0 N--CA 1.469 0.478 0 CA-C-N 116.357 -0.383 . . . . 0.0 111.372 179.886 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 8.1 p -139.18 155.38 47.87 Favored 'General case' 0 C--O 1.237 0.44 0 CA-C-N 115.544 -0.753 . . . . 0.0 111.317 -179.786 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 6.9 t70 -118.87 153.13 35.03 Favored 'General case' 0 C--O 1.236 0.364 0 CA-C-N 115.42 -0.809 . . . . 0.0 109.652 179.045 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 14.9 m -101.86 20.89 2.47 Favored 'Isoleucine or valine' 0 CA--C 1.544 0.746 0 CA-C-N 116.296 -0.411 . . . . 0.0 111.99 -179.404 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 44.6 mt-10 -117.8 -53.03 2.42 Favored 'General case' 0 N--CA 1.465 0.32 0 N-CA-C 112.319 0.489 . . . . 0.0 112.319 -179.252 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 12' ' ' PHE . . . . . . . . . . . . . 15.7 t80 -138.96 -7.28 1.4 Allowed 'General case' 0 N--CA 1.47 0.574 0 N-CA-C 112.58 0.585 . . . . 0.0 112.58 -178.771 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 13' ' ' ASN . . . . . . . . . . . . . 8.3 t-20 -129.44 63.47 67.83 Favored Pre-proline 0 CA--C 1.551 1.006 0 N-CA-C 111.369 0.137 . . . . 0.0 111.369 -179.093 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 14' ' ' PRO . . . . . 0.584 ' O ' ' HD2' ' A' ' 2' ' ' PRO . 15.8 Cg_exo -69.08 177.7 4.86 Favored 'Trans proline' 0 C--N 1.372 1.812 0 C-N-CA 122.733 2.288 . . . . 0.0 112.253 179.282 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 1.5 m -79.45 119.6 22.68 Favored 'General case' 0 N--CA 1.471 0.577 0 C-N-CA 122.382 0.273 . . . . 0.0 111.352 -179.848 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 16' ' ' CYS . . . . . 0.573 ' HB2' ' O ' ' A' ' 2' ' ' PRO . 0.0 OUTLIER -57.36 -53.2 67.98 Favored Pre-proline 0 N--CA 1.481 1.112 0 CA-C-N 115.971 -0.559 . . . . 0.0 111.518 179.548 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 17' ' ' PRO . . . . . 0.479 ' HG2' HD12 ' A' ' 19' ' ' LEU . 57.7 Cg_endo -72.72 169.34 22.21 Favored 'Trans proline' 0 C--N 1.38 2.205 0 C-N-CA 122.042 1.828 . . . . 0.0 111.8 178.168 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 55.8 Cg_endo -72.21 44.54 0.7 Allowed 'Trans proline' 0 C--N 1.371 1.759 0 C-N-CA 122.034 1.823 . . . . 0.0 112.956 178.86 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 19' ' ' LEU . . . . . 0.479 HD12 ' HG2' ' A' ' 17' ' ' PRO . 12.9 mt -104.43 172.78 6.61 Favored 'General case' 0 CA--C 1.534 0.336 0 CA-C-N 115.875 -0.602 . . . . 0.0 110.917 -179.634 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 25.5 m -103.38 150.2 24.04 Favored 'General case' 0 CA--C 1.534 0.335 0 CA-C-N 115.934 -0.575 . . . . 0.0 111.034 -178.793 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 5.5 t -100.32 103.13 14.53 Favored 'General case' 0 C--O 1.237 0.427 0 CA-C-N 115.874 -0.603 . . . . 0.0 109.381 178.491 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 22' ' ' ILE . . . . . 0.716 HD12 ' HB2' ' A' ' 31' ' ' TYR . 2.5 mt -127.36 129.27 23.91 Favored Pre-proline 0 CA--C 1.543 0.697 0 CA-C-N 115.825 -0.625 . . . . 0.0 110.72 -178.462 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 38.0 Cg_endo -67.94 -48.55 0.25 Allowed 'Cis proline' 0 C--N 1.374 1.902 0 C-N-CA 124.77 -0.929 . . . . 0.0 113.71 -0.441 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 79.67 37.13 24.11 Favored Glycine 0 C--N 1.346 1.137 0 C-N-CA 121.39 -0.434 . . . . 0.0 112.835 179.954 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 8.4 m-20 -140.31 81.25 18.24 Favored Pre-proline 0 CA--C 1.544 0.721 0 C-N-CA 122.477 0.311 . . . . 0.0 110.837 -179.694 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 2.2 Cg_endo -81.62 -32.17 3.85 Favored 'Cis proline' 0 C--N 1.372 1.787 0 C-N-CA 125.027 -0.822 . . . . 0.0 112.928 -0.166 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 27' ' ' TYR . . . . . . . . . . . . . 66.7 m-85 -102.35 173.29 6.43 Favored 'General case' 0 C--O 1.238 0.496 0 CA-C-N 115.77 -0.65 . . . . 0.0 111.561 -179.125 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 28' ' ' GLY . . . . . 0.51 ' O ' ' HA ' ' A' ' 7' ' ' GLN . . . -175.59 -159.31 21.32 Favored Glycine 0 C--N 1.338 0.658 0 CA-C-N 115.75 -0.659 . . . . 0.0 112.451 178.974 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 29' ' ' ILE . . . . . 0.56 ' HB ' ' CE2' ' A' ' 31' ' ' TYR . 1.3 mm -123.17 152.13 27.85 Favored 'Isoleucine or valine' 0 C--O 1.235 0.332 0 N-CA-C 109.882 -0.414 . . . . 0.0 109.882 179.713 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 30' ' ' CYS . . . . . 0.443 ' SG ' ' HB2' ' A' ' 19' ' ' LEU . 0.5 OUTLIER -80.07 106.92 12.44 Favored 'General case' 0 C--O 1.238 0.472 0 CA-C-N 116.029 -0.532 . . . . 0.0 110.923 -179.975 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 31' ' ' TYR . . . . . 0.716 ' HB2' HD12 ' A' ' 22' ' ' ILE . 36.2 m-85 -132.11 167.04 20.43 Favored 'General case' 0 N--CA 1.466 0.334 0 CA-C-N 115.534 -0.757 . . . . 0.0 111.088 -179.251 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 2.8 tp -101.88 131.8 49.09 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.614 0 CA-C-N 116.081 -0.509 . . . . 0.0 110.347 179.458 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 33' ' ' ILE . . . . . 0.465 ' H ' HG13 ' A' ' 33' ' ' ILE . 1.9 pp . . . . . 0 C--O 1.247 0.961 0 CA-C-O 118.357 -0.83 . . . . 0.0 111.399 179.976 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 2' ' ' PRO . . . . . . . . . . . . . 95.6 Cg_endo . . . . . 0 CA--C 1.545 1.043 0 N-CA-C 112.937 0.322 . . . . 0.0 112.937 . . . . . . . . . 0 0 . 1 . 010 nuclear build core ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -145.39 -154.0 6.03 Favored Glycine 0 C--N 1.339 0.711 0 N-CA-C 111.813 -0.515 . . . . 0.0 111.813 179.493 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 18.5 tt0 -73.27 129.68 38.55 Favored 'General case' 0 N--CA 1.472 0.667 0 C-N-CA 122.68 0.392 . . . . 0.0 111.319 179.596 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 85.92 15.45 65.2 Favored Glycine 0 C--N 1.34 0.754 0 CA-C-N 115.793 -0.639 . . . . 0.0 113.554 -179.984 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 12.7 tt0 -126.87 161.9 27.18 Favored 'General case' 0 C--O 1.238 0.462 0 CA-C-N 116.604 0.202 . . . . 0.0 110.656 -179.842 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 7' ' ' GLN . . . . . 0.682 ' HA ' ' O ' ' A' ' 28' ' ' GLY . 18.6 tt0 -86.81 136.35 33.01 Favored 'General case' 0 C--N 1.344 0.331 0 CA-C-O 121.218 0.533 . . . . 0.0 111.407 179.962 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 8' ' ' CYS . . . . . 0.405 ' SG ' ' SG ' ' A' ' 30' ' ' CYS . 2.6 p -130.65 161.34 31.83 Favored 'General case' 0 C--O 1.239 0.517 0 CA-C-N 114.465 -1.243 . . . . 0.0 111.023 -179.58 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 9' ' ' ASP . . . . . 0.59 ' OD1' ' HB3' ' A' ' 13' ' ' ASN . 0.7 OUTLIER -120.52 143.54 48.52 Favored 'General case' 0 N--CA 1.465 0.276 0 CA-C-N 115.687 -0.688 . . . . 0.0 110.09 178.494 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 22.3 m -92.02 14.63 1.69 Allowed 'Isoleucine or valine' 0 CA--C 1.542 0.655 0 CA-C-N 116.083 -0.508 . . . . 0.0 111.509 -179.245 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 9.9 mm-40 -98.68 -51.56 3.88 Favored 'General case' 0 C--O 1.234 0.283 0 CA-C-N 116.159 -0.473 . . . . 0.0 112.085 -178.789 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 12' ' ' PHE . . . . . . . . . . . . . 6.9 t80 -144.09 -22.84 0.56 Allowed 'General case' 0 N--CA 1.472 0.67 0 N-CA-C 112.698 0.629 . . . . 0.0 112.698 -178.877 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 13' ' ' ASN . . . . . 0.59 ' HB3' ' OD1' ' A' ' 9' ' ' ASP . 13.7 t-20 -119.32 75.74 16.64 Favored Pre-proline 0 CA--C 1.548 0.901 0 CA-C-N 117.539 0.154 . . . . 0.0 111.355 -178.969 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 61.7 Cg_endo -76.77 -176.09 2.97 Favored 'Trans proline' 0 C--N 1.372 1.763 0 C-N-CA 122.542 2.162 . . . . 0.0 112.22 178.676 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 0.9 OUTLIER -79.94 121.76 25.85 Favored 'General case' 0 N--CA 1.471 0.609 0 CA-C-O 120.454 0.168 . . . . 0.0 111.252 179.95 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER -58.38 -53.76 62.79 Favored Pre-proline 0 N--CA 1.478 0.949 0 CA-C-N 116.124 -0.489 . . . . 0.0 111.552 179.115 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 44.0 Cg_endo -67.8 169.79 15.41 Favored 'Trans proline' 0 C--N 1.379 2.171 0 C-N-CA 122.187 1.925 . . . . 0.0 111.851 178.21 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 55.5 Cg_endo -72.08 47.46 1.03 Allowed 'Trans proline' 0 C--N 1.371 1.724 0 C-N-CA 122.027 1.818 . . . . 0.0 112.792 178.839 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 42.9 mt -108.68 166.3 10.9 Favored 'General case' 0 C--O 1.234 0.266 0 CA-C-N 115.926 -0.579 . . . . 0.0 111.201 -179.588 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 20' ' ' THR . . . . . 0.522 ' O ' ' HA ' ' A' ' 30' ' ' CYS . 33.5 m -103.58 152.74 21.38 Favored 'General case' 0 CA--C 1.532 0.287 0 CA-C-N 115.503 -0.771 . . . . 0.0 110.962 -178.848 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 2.3 t -102.44 99.93 10.02 Favored 'General case' 0 C--O 1.239 0.535 0 CA-C-N 115.725 -0.67 . . . . 0.0 109.601 178.841 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 22' ' ' ILE . . . . . 0.707 HD12 ' HB2' ' A' ' 31' ' ' TYR . 3.0 mt -121.04 128.7 25.62 Favored Pre-proline 0 CA--C 1.541 0.622 0 CA-C-N 115.783 -0.644 . . . . 0.0 110.424 -178.976 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 37.1 Cg_endo -66.89 -47.47 0.26 Allowed 'Cis proline' 0 C--N 1.375 1.958 0 C-N-CA 124.69 -0.962 . . . . 0.0 113.874 -0.187 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 78.92 34.4 34.1 Favored Glycine 0 C--N 1.346 1.131 0 C-N-CA 121.379 -0.438 . . . . 0.0 112.942 179.977 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 4.6 t70 -139.91 83.05 16.69 Favored Pre-proline 0 CA--C 1.546 0.823 0 C-N-CA 122.607 0.363 . . . . 0.0 110.345 -179.68 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 3.2 Cg_exo -80.86 -32.02 4.15 Favored 'Cis proline' 0 C--N 1.371 1.743 0 C-N-CA 125.095 -0.794 . . . . 0.0 112.895 0.036 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 27' ' ' TYR . . . . . 0.558 ' CD2' ' HB3' ' A' ' 9' ' ' ASP . 63.6 m-85 -106.91 172.68 6.69 Favored 'General case' 0 CA--C 1.537 0.448 0 CA-C-N 115.838 -0.619 . . . . 0.0 111.592 -178.892 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 28' ' ' GLY . . . . . 0.682 ' O ' ' HA ' ' A' ' 7' ' ' GLN . . . -176.53 -163.88 29.64 Favored Glycine 0 C--N 1.339 0.716 0 CA-C-N 115.629 -0.714 . . . . 0.0 112.636 178.558 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 29' ' ' ILE . . . . . 0.541 ' HB ' ' CE2' ' A' ' 31' ' ' TYR . 2.5 mm -114.68 151.15 16.47 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 O-C-N 123.748 0.322 . . . . 0.0 110.259 -179.898 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 30' ' ' CYS . . . . . 0.522 ' HA ' ' O ' ' A' ' 20' ' ' THR . 33.9 m -79.88 105.42 11.15 Favored 'General case' 0 CA--C 1.535 0.392 0 CA-C-O 121.328 0.585 . . . . 0.0 111.365 -179.717 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 31' ' ' TYR . . . . . 0.707 ' HB2' HD12 ' A' ' 22' ' ' ILE . 37.1 m-85 -130.28 166.88 19.43 Favored 'General case' 0 C--O 1.233 0.193 0 CA-C-N 114.917 -1.038 . . . . 0.0 111.02 -179.472 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 2.9 tp -99.59 130.24 48.93 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.604 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.372 179.496 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 33' ' ' ILE . . . . . 0.485 HG23 HD11 ' A' ' 22' ' ' ILE . 1.4 pt . . . . . 0 C--O 1.249 1.045 0 CA-C-O 118.136 -0.935 . . . . 0.0 111.463 179.883 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 2' ' ' PRO . . . . . 0.4 ' HD2' ' O ' ' A' ' 14' ' ' PRO . 95.1 Cg_endo . . . . . 0 CA--C 1.543 0.933 0 N-CA-C 112.827 0.28 . . . . 0.0 112.827 . . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -147.3 -161.39 9.38 Favored Glycine 0 C--N 1.337 0.632 0 N-CA-C 111.593 -0.603 . . . . 0.0 111.593 179.216 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 19.0 tt0 -68.33 124.06 22.46 Favored 'General case' 0 N--CA 1.473 0.679 0 C-N-CA 122.548 0.339 . . . . 0.0 111.183 179.851 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 91.28 14.69 56.99 Favored Glycine 0 C--N 1.338 0.682 0 CA-C-N 115.646 -0.706 . . . . 0.0 113.228 -179.699 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 6' ' ' GLU . . . . . 0.453 ' HG2' ' NE2' ' A' ' 7' ' ' GLN . 13.9 tt0 -129.0 166.18 19.7 Favored 'General case' 0 C--O 1.238 0.479 0 C-N-CA 122.287 0.235 . . . . 0.0 110.599 -179.933 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 7' ' ' GLN . . . . . 0.453 ' NE2' ' HG2' ' A' ' 6' ' ' GLU . 0.2 OUTLIER -82.07 153.3 26.18 Favored 'General case' 0 C--N 1.346 0.433 0 O-C-N 123.288 0.367 . . . . 0.0 110.929 -179.876 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 3.3 p -142.64 151.8 41.81 Favored 'General case' 0 C--O 1.235 0.306 0 CA-C-N 115.817 -0.629 . . . . 0.0 111.297 -179.4 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -110.23 139.8 45.02 Favored 'General case' 0 C--O 1.234 0.253 0 CA-C-N 115.765 -0.652 . . . . 0.0 109.559 179.348 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 10' ' ' VAL . . . . . 0.489 HG22 ' O ' ' A' ' 26' ' ' PRO . 7.7 m -94.89 26.65 0.48 Allowed 'Isoleucine or valine' 0 CA--C 1.543 0.702 0 O-C-N 123.31 0.381 . . . . 0.0 111.635 -179.842 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 42.6 mt-10 -124.2 -52.26 1.75 Allowed 'General case' 0 N--CA 1.465 0.291 0 N-CA-C 112.251 0.464 . . . . 0.0 112.251 -179.135 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 12' ' ' PHE . . . . . . . . . . . . . 11.5 t80 -138.51 -10.38 1.41 Allowed 'General case' 0 N--CA 1.471 0.617 0 N-CA-C 112.833 0.679 . . . . 0.0 112.833 -178.627 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 13' ' ' ASN . . . . . 0.4 ' OD1' ' HD3' ' A' ' 2' ' ' PRO . 5.2 t-20 -129.88 64.86 73.62 Favored Pre-proline 0 CA--C 1.549 0.928 0 CA-C-N 117.458 0.117 . . . . 0.0 111.206 -179.151 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 14' ' ' PRO . . . . . 0.4 ' O ' ' HD2' ' A' ' 2' ' ' PRO . 16.4 Cg_exo -68.86 179.81 2.98 Favored 'Trans proline' 0 C--N 1.373 1.843 0 C-N-CA 122.948 2.432 . . . . 0.0 112.22 179.141 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 15' ' ' CYS . . . . . 0.519 ' SG ' ' HB2' ' A' ' 19' ' ' LEU . 3.8 t -79.71 122.0 26.03 Favored 'General case' 0 N--CA 1.471 0.603 0 O-C-N 123.102 0.251 . . . . 0.0 111.247 -179.786 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER -60.85 -54.16 57.16 Favored Pre-proline 0 N--CA 1.476 0.855 0 CA-C-O 119.023 -0.513 . . . . 0.0 111.443 179.298 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 56.3 Cg_endo -70.95 169.27 20.84 Favored 'Trans proline' 0 C--N 1.379 2.176 0 C-N-CA 122.115 1.877 . . . . 0.0 111.702 178.173 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 49.7 Cg_endo -70.76 58.09 2.0 Allowed 'Trans proline' 0 C--N 1.371 1.748 0 C-N-CA 121.975 1.784 . . . . 0.0 112.909 179.01 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 19' ' ' LEU . . . . . 0.519 ' HB2' ' SG ' ' A' ' 15' ' ' CYS . 93.8 mt -118.19 167.8 11.17 Favored 'General case' 0 C--O 1.235 0.331 0 CA-C-N 115.704 -0.68 . . . . 0.0 111.24 -179.876 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 89.3 m -106.99 150.84 26.07 Favored 'General case' 0 CA--C 1.533 0.303 0 CA-C-N 115.315 -0.857 . . . . 0.0 110.94 -179.277 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 21' ' ' CYS . . . . . 0.505 ' HA ' ' O ' ' A' ' 29' ' ' ILE . 1.9 t -97.3 106.71 19.09 Favored 'General case' 0 C--O 1.238 0.476 0 CA-C-N 115.732 -0.667 . . . . 0.0 110.029 178.949 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 22' ' ' ILE . . . . . 0.723 HD12 ' HB2' ' A' ' 31' ' ' TYR . 5.7 mt -125.32 128.69 24.68 Favored Pre-proline 0 CA--C 1.543 0.697 0 CA-C-N 115.807 -0.633 . . . . 0.0 110.564 -179.16 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 37.3 Cg_endo -67.24 -47.78 0.26 Allowed 'Cis proline' 0 C--N 1.376 2.009 0 C-N-CA 124.681 -0.966 . . . . 0.0 113.81 -0.223 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 81.66 38.11 15.04 Favored Glycine 0 C--N 1.347 1.144 0 C-N-CA 121.332 -0.461 . . . . 0.0 112.88 179.822 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 8.0 m-20 -142.58 80.64 14.19 Favored Pre-proline 0 CA--C 1.546 0.817 0 C-N-CA 122.445 0.298 . . . . 0.0 111.052 -179.565 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 26' ' ' PRO . . . . . 0.489 ' O ' HG22 ' A' ' 10' ' ' VAL . 67.9 Cg_endo -84.08 -29.38 5.12 Favored 'Cis proline' 0 C--N 1.372 1.788 0 C-N-CA 124.698 -0.959 . . . . 0.0 113.439 -0.236 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 27' ' ' TYR . . . . . . . . . . . . . 57.0 m-85 -95.31 161.49 14.07 Favored 'General case' 0 N--CA 1.469 0.492 0 O-C-N 123.513 0.508 . . . . 0.0 111.304 -179.097 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 28' ' ' GLY . . . . . 0.433 ' O ' HD13 ' A' ' 29' ' ' ILE . . . -159.03 -161.91 11.53 Favored Glycine 0 C--N 1.341 0.842 0 C-N-CA 120.917 -0.659 . . . . 0.0 113.089 179.832 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 29' ' ' ILE . . . . . 0.505 ' O ' ' HA ' ' A' ' 21' ' ' CYS . 5.1 mm -129.95 155.17 41.31 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.238 0 N-CA-C 109.674 -0.491 . . . . 0.0 109.674 -179.932 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 30' ' ' CYS . . . . . . . . . . . . . 28.8 m -83.68 92.8 7.77 Favored 'General case' 0 CA--C 1.538 0.482 0 CA-C-O 121.368 0.604 . . . . 0.0 111.362 -179.955 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 31' ' ' TYR . . . . . 0.723 ' HB2' HD12 ' A' ' 22' ' ' ILE . 37.8 m-85 -124.33 166.81 15.28 Favored 'General case' 0 N--CA 1.464 0.26 0 CA-C-N 114.972 -1.013 . . . . 0.0 110.992 179.822 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 2.8 tp -99.76 131.49 47.05 Favored 'Isoleucine or valine' 0 CA--C 1.542 0.644 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.448 179.401 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 33' ' ' ILE . . . . . 0.472 HG23 HD11 ' A' ' 22' ' ' ILE . 1.8 pp . . . . . 0 C--O 1.249 1.056 0 CA-C-O 118.168 -0.92 . . . . 0.0 111.429 179.843 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 2' ' ' PRO . . . . . 0.598 ' HD2' ' O ' ' A' ' 14' ' ' PRO . 73.0 Cg_endo . . . . . 0 N--CA 1.488 1.192 0 N-CA-C 113.935 0.706 . . . . 0.0 113.935 . . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -143.5 -159.68 8.08 Favored Glycine 0 C--N 1.341 0.837 0 CA-C-N 116.146 -0.479 . . . . 0.0 112.477 179.83 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 16.7 tt0 -66.43 124.23 22.18 Favored 'General case' 0 N--CA 1.474 0.734 0 C-N-CA 122.841 0.456 . . . . 0.0 111.603 -179.711 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 95.03 -11.01 69.89 Favored Glycine 0 C--N 1.34 0.772 0 CA-C-N 115.641 -0.708 . . . . 0.0 113.282 -179.971 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 42.8 mt-10 -101.16 166.66 10.67 Favored 'General case' 0 C--O 1.24 0.601 0 C-N-CA 122.432 0.293 . . . . 0.0 110.967 -179.8 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 7' ' ' GLN . . . . . . . . . . . . . 0.2 OUTLIER -84.85 154.83 22.05 Favored 'General case' 0 C--N 1.346 0.446 0 CA-C-N 116.167 -0.47 . . . . 0.0 111.039 179.899 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 7.9 p -147.54 155.02 41.45 Favored 'General case' 0 N--CA 1.466 0.371 0 CA-C-N 115.886 -0.597 . . . . 0.0 111.511 -179.131 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 8.0 t70 -120.17 150.52 40.5 Favored 'General case' 0 C--O 1.234 0.275 0 CA-C-N 115.325 -0.852 . . . . 0.0 109.633 178.885 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 15.6 m -98.7 18.8 2.28 Favored 'Isoleucine or valine' 0 CA--C 1.543 0.677 0 CA-C-N 116.287 -0.415 . . . . 0.0 112.072 -179.41 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 46.2 mt-10 -110.13 -55.46 2.45 Favored 'General case' 0 N--CA 1.466 0.358 0 N-CA-C 112.11 0.411 . . . . 0.0 112.11 -179.106 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 12' ' ' PHE . . . . . . . . . . . . . 12.2 t80 -137.99 -15.2 1.34 Allowed 'General case' 0 N--CA 1.47 0.556 0 N-CA-C 112.429 0.529 . . . . 0.0 112.429 -178.939 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 13' ' ' ASN . . . . . . . . . . . . . 10.0 t-20 -120.21 73.01 19.61 Favored Pre-proline 0 CA--C 1.55 0.955 0 O-C-N 122.969 0.168 . . . . 0.0 111.161 -179.377 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 14' ' ' PRO . . . . . 0.598 ' O ' ' HD2' ' A' ' 2' ' ' PRO . 60.4 Cg_endo -76.13 178.74 7.09 Favored 'Trans proline' 0 C--N 1.371 1.744 0 C-N-CA 122.314 2.009 . . . . 0.0 112.501 179.587 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 1.4 m -79.38 118.65 21.47 Favored 'General case' 0 N--CA 1.47 0.547 0 O-C-N 123.118 0.261 . . . . 0.0 111.195 179.972 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 16' ' ' CYS . . . . . 0.573 ' HB2' ' O ' ' A' ' 2' ' ' PRO . 0.0 OUTLIER -56.58 -53.27 66.22 Favored Pre-proline 0 N--CA 1.48 1.073 0 CA-C-O 118.961 -0.542 . . . . 0.0 111.679 179.581 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 17' ' ' PRO . . . . . 0.474 ' HG2' HD12 ' A' ' 19' ' ' LEU . 57.7 Cg_endo -72.65 169.23 22.42 Favored 'Trans proline' 0 C--N 1.378 2.13 0 C-N-CA 122.028 1.819 . . . . 0.0 111.738 178.194 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 55.7 Cg_endo -72.51 45.33 0.83 Allowed 'Trans proline' 0 C--N 1.373 1.839 0 C-N-CA 122.012 1.808 . . . . 0.0 112.865 178.826 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 19' ' ' LEU . . . . . 0.474 HD12 ' HG2' ' A' ' 17' ' ' PRO . 11.8 mt -104.92 172.9 6.54 Favored 'General case' 0 C--O 1.237 0.401 0 CA-C-N 115.931 -0.577 . . . . 0.0 111.046 -179.628 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 24.5 m -103.98 149.3 25.27 Favored 'General case' 0 CA--C 1.531 0.228 0 CA-C-N 115.966 -0.561 . . . . 0.0 111.046 -178.945 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 5.9 t -99.35 102.74 14.43 Favored 'General case' 0 C--O 1.237 0.444 0 CA-C-N 115.856 -0.611 . . . . 0.0 109.39 178.467 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 22' ' ' ILE . . . . . 0.723 HD12 ' HB2' ' A' ' 31' ' ' TYR . 2.5 mt -126.78 129.65 24.0 Favored Pre-proline 0 CA--C 1.543 0.679 0 CA-C-N 115.787 -0.642 . . . . 0.0 110.68 -178.571 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 37.5 Cg_endo -67.65 -48.13 0.26 Allowed 'Cis proline' 0 C--N 1.374 1.885 0 C-N-CA 124.699 -0.959 . . . . 0.0 113.814 -0.434 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 78.57 37.61 26.6 Favored Glycine 0 C--N 1.348 1.242 0 C-N-CA 121.308 -0.472 . . . . 0.0 113.013 -179.962 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 4.5 t70 -140.55 80.7 18.28 Favored Pre-proline 0 CA--C 1.548 0.884 0 C-N-CA 122.372 0.269 . . . . 0.0 110.533 -179.614 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 1.9 Cg_endo -82.07 -31.81 3.98 Favored 'Cis proline' 0 C--N 1.372 1.787 0 C-N-CA 125.058 -0.809 . . . . 0.0 112.956 -0.2 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 27' ' ' TYR . . . . . . . . . . . . . 70.0 m-85 -102.0 172.55 6.85 Favored 'General case' 0 C--O 1.237 0.434 0 CA-C-N 115.822 -0.626 . . . . 0.0 111.578 -179.033 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -175.95 -160.57 23.67 Favored Glycine 0 C--N 1.337 0.634 0 CA-C-N 115.657 -0.701 . . . . 0.0 112.207 179.071 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 29' ' ' ILE . . . . . 0.559 ' HB ' ' CE2' ' A' ' 31' ' ' TYR . 1.8 mm -122.6 153.04 27.23 Favored 'Isoleucine or valine' 0 C--O 1.236 0.36 0 N-CA-C 109.87 -0.418 . . . . 0.0 109.87 179.691 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 30' ' ' CYS . . . . . 0.438 ' SG ' ' HB2' ' A' ' 19' ' ' LEU . 0.5 OUTLIER -79.92 106.72 12.15 Favored 'General case' 0 CA--C 1.539 0.521 0 CA-C-N 116.018 -0.537 . . . . 0.0 110.916 -179.919 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 31' ' ' TYR . . . . . 0.723 ' HB2' HD12 ' A' ' 22' ' ' ILE . 39.1 m-85 -131.34 166.68 20.71 Favored 'General case' 0 N--CA 1.463 0.216 0 CA-C-N 115.479 -0.782 . . . . 0.0 111.201 -179.314 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 2.7 tp -101.76 132.04 48.48 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.582 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.437 179.434 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 33' ' ' ILE . . . . . 0.477 ' H ' HG13 ' A' ' 33' ' ' ILE . 1.9 pp . . . . . 0 C--O 1.249 1.078 0 CA-C-O 118.346 -0.835 . . . . 0.0 111.504 179.945 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 2' ' ' PRO . . . . . . . . . . . . . 95.3 Cg_endo . . . . . 0 CA--C 1.545 1.04 0 N-CA-C 112.969 0.334 . . . . 0.0 112.969 . . . . . . . . . 0 0 . 1 . 013 nuclear build core ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -145.39 -155.44 6.47 Favored Glycine 0 C--N 1.339 0.727 0 N-CA-C 111.687 -0.565 . . . . 0.0 111.687 179.45 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 18.0 tt0 -73.24 129.16 37.43 Favored 'General case' 0 N--CA 1.47 0.55 0 C-N-CA 122.575 0.35 . . . . 0.0 111.221 179.74 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 85.68 16.25 64.14 Favored Glycine 0 C--N 1.339 0.738 0 CA-C-N 115.832 -0.622 . . . . 0.0 113.294 -179.844 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 12.9 tt0 -127.86 162.52 26.5 Favored 'General case' 0 C--O 1.236 0.39 0 C-N-CA 122.176 0.19 . . . . 0.0 110.488 -179.865 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 7' ' ' GLN . . . . . 0.719 ' HA ' ' O ' ' A' ' 28' ' ' GLY . 18.6 tt0 -85.35 134.76 34.08 Favored 'General case' 0 C--N 1.345 0.386 0 CA-C-O 121.298 0.571 . . . . 0.0 111.239 -179.994 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 8' ' ' CYS . . . . . 0.412 ' SG ' ' SG ' ' A' ' 30' ' ' CYS . 3.6 p -127.77 160.2 32.46 Favored 'General case' 0 C--O 1.239 0.508 0 CA-C-N 114.545 -1.207 . . . . 0.0 111.098 -179.396 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 9' ' ' ASP . . . . . 0.432 ' OD2' ' HB2' ' A' ' 11' ' ' GLU . 16.8 t70 -114.86 150.52 35.43 Favored 'General case' 0 CA--C 1.532 0.272 0 CA-C-N 115.542 -0.754 . . . . 0.0 109.477 178.766 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 15.5 m -100.91 20.12 2.47 Favored 'Isoleucine or valine' 0 CA--C 1.543 0.689 0 CA-C-N 116.22 -0.446 . . . . 0.0 112.008 -179.465 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 11' ' ' GLU . . . . . 0.432 ' HB2' ' OD2' ' A' ' 9' ' ' ASP . 44.7 mt-10 -117.51 -52.46 2.47 Favored 'General case' 0 N--CA 1.465 0.313 0 N-CA-C 112.224 0.453 . . . . 0.0 112.224 -178.969 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 12' ' ' PHE . . . . . . . . . . . . . 14.6 t80 -138.42 -8.43 1.49 Allowed 'General case' 0 N--CA 1.472 0.652 0 N-CA-C 112.596 0.591 . . . . 0.0 112.596 -178.689 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 13' ' ' ASN . . . . . . . . . . . . . 6.6 t-20 -129.6 63.79 69.26 Favored Pre-proline 0 CA--C 1.55 0.959 0 N-CA-C 111.552 0.205 . . . . 0.0 111.552 -179.091 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 14.0 Cg_exo -70.09 177.12 6.13 Favored 'Trans proline' 0 C--N 1.371 1.744 0 C-N-CA 122.86 2.373 . . . . 0.0 112.002 178.885 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 1.1 t -79.9 121.02 24.92 Favored 'General case' 0 N--CA 1.471 0.58 0 CA-C-O 120.503 0.192 . . . . 0.0 111.052 -179.983 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER -57.57 -53.09 69.18 Favored Pre-proline 0 N--CA 1.478 0.943 0 CA-C-O 119.069 -0.491 . . . . 0.0 111.541 179.282 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 17' ' ' PRO . . . . . 0.511 ' HG2' HD12 ' A' ' 19' ' ' LEU . 44.4 Cg_endo -68.81 169.44 17.66 Favored 'Trans proline' 0 C--N 1.38 2.199 0 C-N-CA 122.159 1.906 . . . . 0.0 111.782 178.059 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 55.5 Cg_endo -72.22 49.33 1.34 Allowed 'Trans proline' 0 C--N 1.373 1.833 0 C-N-CA 122.044 1.829 . . . . 0.0 112.589 178.799 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 19' ' ' LEU . . . . . 0.511 HD12 ' HG2' ' A' ' 17' ' ' PRO . 20.9 mt -110.1 168.24 9.58 Favored 'General case' 0 C--O 1.236 0.372 0 CA-C-N 115.741 -0.663 . . . . 0.0 111.34 -179.337 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 20' ' ' THR . . . . . 0.537 ' O ' ' HA ' ' A' ' 30' ' ' CYS . 29.3 m -105.31 153.82 21.11 Favored 'General case' 0 CA--C 1.533 0.31 0 CA-C-N 115.624 -0.716 . . . . 0.0 111.056 -178.804 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 2.0 t -103.42 103.89 13.93 Favored 'General case' 0 C--O 1.238 0.493 0 CA-C-N 115.678 -0.692 . . . . 0.0 109.666 178.869 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 22' ' ' ILE . . . . . 0.71 HD12 ' HB2' ' A' ' 31' ' ' TYR . 2.9 mt -125.9 129.11 24.39 Favored Pre-proline 0 CA--C 1.541 0.634 0 CA-C-N 115.768 -0.651 . . . . 0.0 110.223 -179.157 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 38.4 Cg_endo -67.77 -48.26 0.25 Allowed 'Cis proline' 0 C--N 1.375 1.941 0 C-N-CA 124.679 -0.967 . . . . 0.0 113.941 -0.155 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 81.92 36.83 17.63 Favored Glycine 0 C--N 1.348 1.229 0 C-N-CA 121.108 -0.568 . . . . 0.0 112.852 -179.977 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 8.3 m-20 -139.99 82.58 17.18 Favored Pre-proline 0 CA--C 1.543 0.701 0 C-N-CA 122.53 0.332 . . . . 0.0 110.701 -179.91 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 3.0 Cg_endo -80.54 -32.07 4.18 Favored 'Cis proline' 0 C--N 1.372 1.795 0 C-N-CA 125.191 -0.754 . . . . 0.0 112.923 0.077 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 27' ' ' TYR . . . . . . . . . . . . . 59.3 m-85 -106.96 175.07 5.62 Favored 'General case' 0 C--O 1.238 0.466 0 CA-C-N 115.68 -0.691 . . . . 0.0 111.532 -179.001 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 28' ' ' GLY . . . . . 0.719 ' O ' ' HA ' ' A' ' 7' ' ' GLN . . . -175.52 -161.26 24.65 Favored Glycine 0 C--N 1.339 0.701 0 CA-C-N 115.626 -0.715 . . . . 0.0 112.618 178.49 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 29' ' ' ILE . . . . . 0.527 ' HB ' ' CE2' ' A' ' 31' ' ' TYR . 2.8 mm -115.6 149.76 17.74 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 N-CA-C 110.084 -0.339 . . . . 0.0 110.084 -179.814 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 30' ' ' CYS . . . . . 0.537 ' HA ' ' O ' ' A' ' 20' ' ' THR . 26.8 m -79.85 105.1 10.89 Favored 'General case' 0 C--O 1.238 0.464 0 CA-C-N 115.955 -0.566 . . . . 0.0 111.35 -179.802 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 31' ' ' TYR . . . . . 0.71 ' HB2' HD12 ' A' ' 22' ' ' ILE . 36.9 m-85 -128.74 168.46 15.81 Favored 'General case' 0 C--O 1.233 0.205 0 CA-C-N 115.087 -0.961 . . . . 0.0 111.099 -179.552 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 1.8 tt -101.06 130.33 50.64 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.585 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.363 179.651 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 33' ' ' ILE . . . . . 0.458 ' H ' HG13 ' A' ' 33' ' ' ILE . 1.6 pp . . . . . 0 C--O 1.248 0.986 0 CA-C-O 118.386 -0.816 . . . . 0.0 111.525 179.881 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 2' ' ' PRO . . . . . 0.576 ' HD2' ' O ' ' A' ' 14' ' ' PRO . 73.7 Cg_endo . . . . . 0 N--CA 1.488 1.152 0 N-CA-C 113.949 0.711 . . . . 0.0 113.949 . . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -143.5 -159.09 7.83 Favored Glycine 0 C--N 1.34 0.778 0 O-C-N 123.511 0.507 . . . . 0.0 112.543 179.877 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 16.6 tt0 -68.39 122.93 19.43 Favored 'General case' 0 N--CA 1.472 0.642 0 C-N-CA 122.849 0.46 . . . . 0.0 111.524 -179.893 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 92.12 14.47 56.05 Favored Glycine 0 C--N 1.339 0.736 0 CA-C-N 115.681 -0.691 . . . . 0.0 113.242 -179.864 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 43.0 mt-10 -127.9 165.83 19.46 Favored 'General case' 0 C--O 1.239 0.535 0 C-N-CA 122.447 0.299 . . . . 0.0 110.813 179.942 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 7' ' ' GLN . . . . . 0.526 ' HA ' ' O ' ' A' ' 28' ' ' GLY . 15.6 mt-30 -85.11 145.15 27.79 Favored 'General case' 0 C--N 1.346 0.415 0 CA-C-N 116.371 -0.377 . . . . 0.0 111.515 179.966 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 7.4 p -138.26 155.59 48.48 Favored 'General case' 0 C--O 1.236 0.385 0 CA-C-N 115.274 -0.876 . . . . 0.0 111.292 -179.51 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 6.1 t70 -118.25 152.46 35.68 Favored 'General case' 0 C--O 1.235 0.335 0 CA-C-N 115.35 -0.841 . . . . 0.0 109.668 179.003 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 14.4 m -101.1 21.63 1.97 Allowed 'Isoleucine or valine' 0 CA--C 1.541 0.624 0 CA-C-N 116.18 -0.464 . . . . 0.0 112.058 -179.466 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 44.5 mt-10 -118.51 -53.0 2.34 Favored 'General case' 0 N--CA 1.465 0.319 0 N-CA-C 112.196 0.443 . . . . 0.0 112.196 -179.18 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 12' ' ' PHE . . . . . . . . . . . . . 15.1 t80 -139.01 -7.49 1.39 Allowed 'General case' 0 N--CA 1.47 0.564 0 N-CA-C 112.534 0.568 . . . . 0.0 112.534 -178.784 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 13' ' ' ASN . . . . . . . . . . . . . 8.2 t-20 -129.34 63.22 66.74 Favored Pre-proline 0 CA--C 1.55 0.943 0 N-CA-C 111.415 0.154 . . . . 0.0 111.415 -179.144 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 14' ' ' PRO . . . . . 0.576 ' O ' ' HD2' ' A' ' 2' ' ' PRO . 15.6 Cg_exo -68.93 178.03 4.44 Favored 'Trans proline' 0 C--N 1.373 1.865 0 C-N-CA 122.828 2.352 . . . . 0.0 112.372 179.235 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 1.5 m -79.54 119.45 22.54 Favored 'General case' 0 N--CA 1.471 0.605 0 O-C-N 123.144 0.278 . . . . 0.0 111.315 -179.86 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 16' ' ' CYS . . . . . 0.576 ' HB2' ' O ' ' A' ' 2' ' ' PRO . 0.0 OUTLIER -57.13 -53.18 67.97 Favored Pre-proline 0 N--CA 1.483 1.182 0 CA-C-N 115.923 -0.581 . . . . 0.0 111.554 179.489 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 17' ' ' PRO . . . . . 0.48 ' HG2' HD12 ' A' ' 19' ' ' LEU . 57.9 Cg_endo -72.71 169.28 22.35 Favored 'Trans proline' 0 C--N 1.38 2.191 0 C-N-CA 121.994 1.796 . . . . 0.0 111.815 178.178 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 55.9 Cg_endo -72.27 44.69 0.72 Allowed 'Trans proline' 0 C--N 1.371 1.76 0 C-N-CA 122.012 1.808 . . . . 0.0 113.062 178.778 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 19' ' ' LEU . . . . . 0.48 HD12 ' HG2' ' A' ' 17' ' ' PRO . 12.2 mt -104.39 172.74 6.63 Favored 'General case' 0 C--O 1.236 0.361 0 CA-C-N 115.911 -0.586 . . . . 0.0 110.996 -179.761 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 25.4 m -103.32 150.19 24.01 Favored 'General case' 0 CA--C 1.534 0.335 0 CA-C-N 115.987 -0.551 . . . . 0.0 110.982 -178.903 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 5.1 t -100.38 103.03 14.4 Favored 'General case' 0 C--O 1.238 0.453 0 CA-C-N 115.724 -0.671 . . . . 0.0 109.407 178.412 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 22' ' ' ILE . . . . . 0.715 HD12 ' HB2' ' A' ' 31' ' ' TYR . 2.5 mt -127.16 129.04 24.02 Favored Pre-proline 0 CA--C 1.541 0.629 0 CA-C-N 115.803 -0.635 . . . . 0.0 110.826 -178.457 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 37.6 Cg_endo -67.99 -48.52 0.25 Allowed 'Cis proline' 0 C--N 1.375 1.938 0 C-N-CA 124.674 -0.969 . . . . 0.0 113.726 -0.261 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 79.12 37.79 24.14 Favored Glycine 0 C--N 1.347 1.19 0 C-N-CA 121.456 -0.402 . . . . 0.0 112.883 -179.991 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 4.6 t70 -140.12 80.57 19.92 Favored Pre-proline 0 CA--C 1.549 0.912 0 C-N-CA 122.338 0.255 . . . . 0.0 110.461 -179.686 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 1.9 Cg_endo -82.24 -31.71 4.0 Favored 'Cis proline' 0 C--N 1.372 1.774 0 C-N-CA 125.112 -0.787 . . . . 0.0 112.973 -0.134 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 27' ' ' TYR . . . . . . . . . . . . . 66.8 m-85 -101.7 171.98 7.22 Favored 'General case' 0 C--O 1.237 0.424 0 CA-C-N 115.796 -0.638 . . . . 0.0 111.591 -179.146 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 28' ' ' GLY . . . . . 0.526 ' O ' ' HA ' ' A' ' 7' ' ' GLN . . . -174.93 -160.26 22.6 Favored Glycine 0 C--N 1.337 0.621 0 CA-C-N 115.667 -0.697 . . . . 0.0 112.409 178.905 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 29' ' ' ILE . . . . . 0.56 ' HB ' ' CE2' ' A' ' 31' ' ' TYR . 1.4 mm -122.37 152.14 26.48 Favored 'Isoleucine or valine' 0 C--O 1.233 0.191 0 N-CA-C 109.807 -0.442 . . . . 0.0 109.807 179.609 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 30' ' ' CYS . . . . . 0.443 ' SG ' ' HB2' ' A' ' 19' ' ' LEU . 0.5 OUTLIER -80.02 106.92 12.4 Favored 'General case' 0 CA--C 1.537 0.467 0 CA-C-N 115.961 -0.563 . . . . 0.0 110.919 -179.986 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 31' ' ' TYR . . . . . 0.715 ' HB2' HD12 ' A' ' 22' ' ' ILE . 36.3 m-85 -132.15 167.17 20.24 Favored 'General case' 0 N--CA 1.463 0.222 0 CA-C-N 115.449 -0.796 . . . . 0.0 111.155 -179.332 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 2.7 tp -101.82 131.67 49.28 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.611 0 CA-C-N 116.081 -0.509 . . . . 0.0 110.412 179.493 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 33' ' ' ILE . . . . . 0.466 ' H ' HG13 ' A' ' 33' ' ' ILE . 1.9 pp . . . . . 0 C--O 1.249 1.04 0 CA-C-O 118.133 -0.937 . . . . 0.0 111.568 179.873 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 2' ' ' PRO . . . . . . . . . . . . . 81.2 Cg_endo . . . . . 0 CA--C 1.543 0.964 0 N-CA-C 112.886 0.302 . . . . 0.0 112.886 . . . . . . . . . 0 0 . 1 . 015 nuclear build core ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -145.28 -156.63 6.92 Favored Glycine 0 C--N 1.34 0.767 0 N-CA-C 111.562 -0.615 . . . . 0.0 111.562 179.151 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 18.1 tt0 -73.43 129.49 38.11 Favored 'General case' 0 N--CA 1.471 0.624 0 C-N-CA 122.445 0.298 . . . . 0.0 111.208 179.595 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 88.13 14.14 62.89 Favored Glycine 0 C--N 1.34 0.778 0 CA-C-N 115.765 -0.652 . . . . 0.0 113.274 -179.845 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 43.2 mt-10 -129.81 162.19 29.04 Favored 'General case' 0 C--O 1.237 0.404 0 C-N-CA 122.277 0.231 . . . . 0.0 110.733 -179.897 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 7' ' ' GLN . . . . . 0.496 ' HA ' ' O ' ' A' ' 28' ' ' GLY . 9.4 tt0 -83.82 136.77 34.01 Favored 'General case' 0 C--N 1.345 0.374 0 CA-C-O 121.305 0.574 . . . . 0.0 111.296 179.815 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 4.0 p -125.57 160.25 30.06 Favored 'General case' 0 C--O 1.243 0.712 0 CA-C-N 114.471 -1.241 . . . . 0.0 110.89 -179.554 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 9' ' ' ASP . . . . . 0.444 ' OD1' ' HD2' ' A' ' 27' ' ' TYR . 2.5 m-20 -114.58 150.11 35.51 Favored 'General case' 0 C--O 1.235 0.313 0 CA-C-N 115.58 -0.736 . . . . 0.0 109.684 179.432 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 11.2 m -103.24 16.78 5.1 Favored 'Isoleucine or valine' 0 CA--C 1.542 0.64 0 CA-C-N 116.398 -0.364 . . . . 0.0 111.766 -179.686 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 9.6 mm-40 -110.73 -52.53 2.78 Favored 'General case' 0 C--O 1.235 0.312 0 N-CA-C 112.118 0.414 . . . . 0.0 112.118 -178.937 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 12' ' ' PHE . . . . . . . . . . . . . 17.2 t80 -142.01 -7.84 0.93 Allowed 'General case' 0 N--CA 1.472 0.663 0 N-CA-C 112.569 0.581 . . . . 0.0 112.569 -178.788 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 13' ' ' ASN . . . . . . . . . . . . . 5.4 t-20 -129.58 64.37 71.38 Favored Pre-proline 0 CA--C 1.55 0.952 0 N-CA-C 111.559 0.207 . . . . 0.0 111.559 -179.075 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 15.0 Cg_exo -69.64 179.95 3.28 Favored 'Trans proline' 0 C--N 1.372 1.792 0 C-N-CA 122.888 2.392 . . . . 0.0 111.993 178.947 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 1.3 t -79.76 121.25 25.12 Favored 'General case' 0 N--CA 1.47 0.573 0 CA-C-O 120.519 0.2 . . . . 0.0 111.142 -179.951 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER -57.88 -53.61 63.96 Favored Pre-proline 0 N--CA 1.478 0.952 0 CA-C-O 118.992 -0.528 . . . . 0.0 111.573 179.325 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 17' ' ' PRO . . . . . 0.552 ' HG2' HD12 ' A' ' 19' ' ' LEU . 45.1 Cg_endo -69.06 169.61 17.63 Favored 'Trans proline' 0 C--N 1.378 2.099 0 C-N-CA 122.12 1.88 . . . . 0.0 111.725 178.181 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -71.8 49.67 1.27 Allowed 'Trans proline' 0 C--N 1.372 1.794 0 C-N-CA 121.957 1.771 . . . . 0.0 112.688 178.794 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 19' ' ' LEU . . . . . 0.552 HD12 ' HG2' ' A' ' 17' ' ' PRO . 22.0 mt -110.08 168.32 9.52 Favored 'General case' 0 C--O 1.236 0.389 0 CA-C-N 115.703 -0.681 . . . . 0.0 111.284 -179.363 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 20' ' ' THR . . . . . 0.519 ' O ' ' HA ' ' A' ' 30' ' ' CYS . 27.9 m -105.19 154.48 20.14 Favored 'General case' 0 CA--C 1.533 0.304 0 CA-C-N 115.641 -0.709 . . . . 0.0 111.191 -178.71 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 1.8 t -103.78 102.37 12.19 Favored 'General case' 0 C--O 1.238 0.453 0 CA-C-N 115.594 -0.73 . . . . 0.0 109.626 178.817 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 22' ' ' ILE . . . . . 0.711 HD12 ' HB2' ' A' ' 31' ' ' TYR . 2.8 mt -125.31 129.86 24.33 Favored Pre-proline 0 CA--C 1.542 0.665 0 CA-C-N 115.655 -0.702 . . . . 0.0 110.308 -179.071 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 35.3 Cg_endo -65.93 -48.9 0.21 Allowed 'Cis proline' 0 C--N 1.375 1.922 0 C-N-CA 124.723 -0.949 . . . . 0.0 113.817 -0.21 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 77.97 33.62 40.67 Favored Glycine 0 C--N 1.347 1.179 0 C-N-CA 121.256 -0.497 . . . . 0.0 112.901 179.872 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 4.6 t70 -139.49 82.84 17.92 Favored Pre-proline 0 CA--C 1.546 0.794 0 C-N-CA 122.556 0.343 . . . . 0.0 110.166 -179.641 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 2.5 Cg_endo -81.52 -32.54 3.61 Favored 'Cis proline' 0 C--N 1.37 1.7 0 C-N-CA 125.146 -0.772 . . . . 0.0 113.048 -0.028 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 27' ' ' TYR . . . . . 0.444 ' HD2' ' OD1' ' A' ' 9' ' ' ASP . 46.4 m-85 -103.46 167.59 9.71 Favored 'General case' 0 C--O 1.239 0.5 0 O-C-N 123.669 0.606 . . . . 0.0 111.476 -178.889 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 28' ' ' GLY . . . . . 0.496 ' O ' ' HA ' ' A' ' 7' ' ' GLN . . . -170.0 -163.14 23.54 Favored Glycine 0 C--N 1.342 0.899 0 C-N-CA 120.853 -0.689 . . . . 0.0 113.327 178.543 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 29' ' ' ILE . . . . . 0.501 ' HB ' ' CE2' ' A' ' 31' ' ' TYR . 2.7 mm -118.21 154.86 20.28 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.284 0 O-C-N 124.108 0.534 . . . . 0.0 110.149 -179.931 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 30' ' ' CYS . . . . . 0.519 ' HA ' ' O ' ' A' ' 20' ' ' THR . 24.5 m -83.29 103.48 12.71 Favored 'General case' 0 C--O 1.237 0.431 0 CA-C-N 115.941 -0.572 . . . . 0.0 111.22 -179.961 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 31' ' ' TYR . . . . . 0.711 ' HB2' HD12 ' A' ' 22' ' ' ILE . 38.6 m-85 -129.55 167.37 18.01 Favored 'General case' 0 CA--C 1.531 0.212 0 CA-C-N 115.01 -0.996 . . . . 0.0 111.074 -179.586 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 2.8 tp -100.43 131.11 48.6 Favored 'Isoleucine or valine' 0 CA--C 1.542 0.639 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.271 179.534 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 33' ' ' ILE . . . . . 0.496 HG23 HD11 ' A' ' 22' ' ' ILE . 1.9 pp . . . . . 0 C--O 1.248 0.988 0 CA-C-O 118.387 -0.816 . . . . 0.0 111.48 179.866 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 2' ' ' PRO . . . . . 0.405 ' HD2' ' O ' ' A' ' 14' ' ' PRO . 84.7 Cg_endo . . . . . 0 CA--C 1.543 0.957 0 N-CA-C 112.926 0.318 . . . . 0.0 112.926 . . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -148.23 -158.42 7.96 Favored Glycine 0 C--N 1.338 0.671 0 N-CA-C 111.63 -0.588 . . . . 0.0 111.63 179.276 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 17.9 tt0 -70.32 123.83 22.68 Favored 'General case' 0 N--CA 1.473 0.702 0 C-N-CA 122.489 0.316 . . . . 0.0 111.516 179.891 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 98.42 -11.19 63.34 Favored Glycine 0 C--N 1.34 0.799 0 CA-C-N 115.748 -0.66 . . . . 0.0 113.58 179.809 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 43.0 mt-10 -105.34 166.02 10.71 Favored 'General case' 0 C--O 1.238 0.465 0 CA-C-N 116.705 0.253 . . . . 0.0 111.01 -179.735 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 7' ' ' GLN . . . . . 0.457 ' HA ' ' HA ' ' A' ' 29' ' ' ILE . 6.5 tt0 -86.73 140.39 29.81 Favored 'General case' 0 C--N 1.347 0.466 0 CA-C-O 121.113 0.482 . . . . 0.0 111.132 179.744 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 8' ' ' CYS . . . . . 0.421 ' SG ' ' SG ' ' A' ' 15' ' ' CYS . 5.8 p -127.02 158.49 36.8 Favored 'General case' 0 C--O 1.239 0.53 0 CA-C-N 114.696 -1.138 . . . . 0.0 111.128 -179.599 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -114.92 149.73 36.78 Favored 'General case' 0 C--O 1.234 0.27 0 CA-C-N 115.377 -0.829 . . . . 0.0 109.711 179.348 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 10' ' ' VAL . . . . . 0.525 HG22 ' O ' ' A' ' 26' ' ' PRO . 10.4 m -103.83 17.87 4.78 Favored 'Isoleucine or valine' 0 CA--C 1.542 0.661 0 O-C-N 123.31 0.381 . . . . 0.0 111.621 179.926 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 9.7 mm-40 -109.45 -53.08 2.7 Favored 'General case' 0 C--O 1.234 0.287 0 CA-C-N 116.347 -0.388 . . . . 0.0 111.997 -179.186 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 12' ' ' PHE . . . . . . . . . . . . . 12.2 t80 -139.74 -18.05 0.96 Allowed 'General case' 0 N--CA 1.471 0.62 0 N-CA-C 112.423 0.527 . . . . 0.0 112.423 -179.04 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 13' ' ' ASN . . . . . . . . . . . . . 5.4 t-20 -118.7 74.67 12.46 Favored Pre-proline 0 CA--C 1.549 0.929 0 O-C-N 122.977 0.173 . . . . 0.0 111.222 -179.25 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 14' ' ' PRO . . . . . 0.405 ' O ' ' HD2' ' A' ' 2' ' ' PRO . 60.0 Cg_endo -75.48 178.11 7.78 Favored 'Trans proline' 0 C--N 1.372 1.768 0 C-N-CA 122.421 2.081 . . . . 0.0 112.649 179.201 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 15' ' ' CYS . . . . . 0.421 ' SG ' ' SG ' ' A' ' 8' ' ' CYS . 1.6 m -79.66 119.83 23.14 Favored 'General case' 0 N--CA 1.471 0.596 0 O-C-N 123.151 0.282 . . . . 0.0 111.623 179.983 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER -58.91 -54.27 58.11 Favored Pre-proline 0 N--CA 1.477 0.908 0 CA-C-N 115.91 -0.586 . . . . 0.0 111.598 179.667 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 48.0 Cg_endo -68.95 169.02 18.82 Favored 'Trans proline' 0 C--N 1.38 2.207 0 C-N-CA 121.965 1.777 . . . . 0.0 111.687 178.382 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 56.1 Cg_endo -72.43 45.89 0.9 Allowed 'Trans proline' 0 C--N 1.37 1.702 0 C-N-CA 121.929 1.752 . . . . 0.0 112.939 179.048 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 19' ' ' LEU . . . . . 0.506 ' HB2' ' SG ' ' A' ' 30' ' ' CYS . 44.4 mt -106.44 169.83 8.28 Favored 'General case' 0 C--O 1.236 0.358 0 CA-C-N 116.118 -0.492 . . . . 0.0 111.038 -179.632 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 32.6 m -104.12 149.89 24.83 Favored 'General case' 0 CA--C 1.533 0.31 0 CA-C-N 115.737 -0.665 . . . . 0.0 111.095 -178.904 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 2.7 t -98.44 102.54 14.32 Favored 'General case' 0 C--O 1.238 0.464 0 CA-C-N 115.88 -0.6 . . . . 0.0 109.555 178.545 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 22' ' ' ILE . . . . . 0.723 HD12 ' HB2' ' A' ' 31' ' ' TYR . 2.4 mt -126.64 130.68 23.8 Favored Pre-proline 0 CA--C 1.542 0.671 0 CA-C-N 115.704 -0.68 . . . . 0.0 110.457 -178.728 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 36.8 Cg_endo -66.88 -48.22 0.24 Allowed 'Cis proline' 0 C--N 1.374 1.917 0 C-N-CA 124.833 -0.903 . . . . 0.0 113.784 -0.088 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 75.31 41.23 31.5 Favored Glycine 0 C--N 1.348 1.246 0 C-N-CA 121.31 -0.471 . . . . 0.0 112.811 -179.948 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 8.1 m-20 -136.24 75.36 53.13 Favored Pre-proline 0 CA--C 1.545 0.761 0 C-N-CA 122.428 0.291 . . . . 0.0 110.863 -179.627 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 26' ' ' PRO . . . . . 0.525 ' O ' HG22 ' A' ' 10' ' ' VAL . 56.8 Cg_endo -88.49 -16.91 22.33 Favored 'Cis proline' 0 C--N 1.37 1.708 0 C-N-CA 124.79 -0.921 . . . . 0.0 113.773 -0.088 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 27' ' ' TYR . . . . . 0.475 ' CE2' ' HG2' ' A' ' 26' ' ' PRO . 21.0 m-85 -106.82 163.97 12.5 Favored 'General case' 0 C--O 1.238 0.497 0 CA-C-N 116.276 -0.42 . . . . 0.0 111.457 -179.026 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 28' ' ' GLY . . . . . 0.403 ' O ' ' HA ' ' A' ' 7' ' ' GLN . . . -173.64 -162.18 25.08 Favored Glycine 0 C--N 1.341 0.846 0 C-N-CA 120.889 -0.672 . . . . 0.0 113.291 178.493 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 29' ' ' ILE . . . . . 0.549 ' HB ' ' CE2' ' A' ' 31' ' ' TYR . 1.9 mm -118.51 154.68 20.68 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.232 0 O-C-N 124.031 0.489 . . . . 0.0 110.049 -179.912 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 30' ' ' CYS . . . . . 0.506 ' SG ' ' HB2' ' A' ' 19' ' ' LEU . 0.5 OUTLIER -81.97 105.49 13.12 Favored 'General case' 0 CA--C 1.537 0.464 0 CA-C-N 115.893 -0.594 . . . . 0.0 110.986 179.974 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 31' ' ' TYR . . . . . 0.723 ' HB2' HD12 ' A' ' 22' ' ' ILE . 38.4 m-85 -131.04 165.44 23.22 Favored 'General case' 0 N--CA 1.464 0.23 0 CA-C-N 115.406 -0.815 . . . . 0.0 111.205 -179.415 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 2.9 tp -100.08 131.3 47.8 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.592 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.461 179.571 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 33' ' ' ILE . . . . . 0.476 ' H ' HG13 ' A' ' 33' ' ' ILE . 1.9 pp . . . . . 0 C--O 1.249 1.033 0 CA-C-O 118.191 -0.909 . . . . 0.0 111.468 179.956 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 2' ' ' PRO . . . . . 0.581 ' O ' ' HB2' ' A' ' 16' ' ' CYS . 87.5 Cg_endo . . . . . 0 N--CA 1.489 1.253 0 N-CA-C 113.854 0.675 . . . . 0.0 113.854 . . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -134.49 -154.56 7.23 Favored Glycine 0 C--N 1.342 0.895 0 CA-C-N 116.09 -0.504 . . . . 0.0 112.287 179.979 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 16.1 tt0 -73.72 137.67 44.17 Favored 'General case' 0 N--CA 1.472 0.637 0 C-N-CA 122.845 0.458 . . . . 0.0 111.407 -179.854 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 82.61 12.92 79.37 Favored Glycine 0 C--N 1.341 0.832 0 CA-C-N 115.689 -0.687 . . . . 0.0 113.277 -179.771 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 43.1 mt-10 -125.95 161.53 27.29 Favored 'General case' 0 C--O 1.237 0.421 0 C-N-CA 122.346 0.258 . . . . 0.0 110.935 -179.875 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 7' ' ' GLN . . . . . 0.722 ' HA ' ' O ' ' A' ' 28' ' ' GLY . 21.0 tt0 -88.54 133.96 34.0 Favored 'General case' 0 C--N 1.344 0.363 0 CA-C-O 121.216 0.532 . . . . 0.0 111.275 179.872 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 2.0 p -128.73 161.64 29.24 Favored 'General case' 0 C--O 1.239 0.54 0 CA-C-N 114.557 -1.201 . . . . 0.0 111.149 -179.738 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 12.2 t70 -117.1 147.02 42.76 Favored 'General case' 0 C--O 1.234 0.254 0 CA-C-N 115.677 -0.692 . . . . 0.0 109.562 178.769 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 15.8 m -93.73 24.98 0.52 Allowed 'Isoleucine or valine' 0 CA--C 1.544 0.74 0 CA-C-N 116.268 -0.423 . . . . 0.0 111.805 -179.43 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 43.7 mt-10 -121.51 -52.79 2.02 Favored 'General case' 0 CA--C 1.533 0.293 0 N-CA-C 112.268 0.47 . . . . 0.0 112.268 -178.98 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 12' ' ' PHE . . . . . . . . . . . . . 9.9 t80 -138.27 -10.59 1.46 Allowed 'General case' 0 N--CA 1.47 0.546 0 N-CA-C 112.812 0.671 . . . . 0.0 112.812 -178.622 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 13' ' ' ASN . . . . . . . . . . . . . 7.5 t-20 -129.57 62.79 65.19 Favored Pre-proline 0 CA--C 1.55 0.953 0 N-CA-C 111.655 0.243 . . . . 0.0 111.655 -179.277 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 14' ' ' PRO . . . . . 0.558 ' O ' ' HD2' ' A' ' 2' ' ' PRO . 13.5 Cg_exo -70.1 -179.97 3.45 Favored 'Trans proline' 0 C--N 1.374 1.878 0 C-N-CA 122.649 2.233 . . . . 0.0 111.962 178.985 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 1.8 t -79.57 120.83 24.48 Favored 'General case' 0 N--CA 1.47 0.541 0 C-N-CA 121.989 0.116 . . . . 0.0 110.849 -179.947 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 16' ' ' CYS . . . . . 0.581 ' HB2' ' O ' ' A' ' 2' ' ' PRO . 0.0 OUTLIER -55.66 -52.56 71.05 Favored Pre-proline 0 N--CA 1.483 1.214 0 CA-C-O 118.952 -0.547 . . . . 0.0 111.643 179.572 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 17' ' ' PRO . . . . . 0.554 ' HG2' HD12 ' A' ' 19' ' ' LEU . 56.5 Cg_endo -71.98 169.84 20.36 Favored 'Trans proline' 0 C--N 1.378 2.13 0 C-N-CA 122.155 1.903 . . . . 0.0 111.667 178.111 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 55.2 Cg_endo -71.91 48.55 1.13 Allowed 'Trans proline' 0 C--N 1.373 1.861 0 C-N-CA 121.976 1.784 . . . . 0.0 112.928 178.857 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 19' ' ' LEU . . . . . 0.554 HD12 ' HG2' ' A' ' 17' ' ' PRO . 28.2 mt -108.32 171.06 7.63 Favored 'General case' 0 C--O 1.236 0.383 0 CA-C-N 115.679 -0.691 . . . . 0.0 111.271 -179.655 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 20' ' ' THR . . . . . 0.527 ' O ' ' HA ' ' A' ' 30' ' ' CYS . 20.0 m -105.07 153.56 21.32 Favored 'General case' 0 CA--C 1.533 0.294 0 CA-C-N 115.927 -0.579 . . . . 0.0 111.044 -178.879 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 2.7 t -105.58 99.5 9.1 Favored 'General case' 0 C--O 1.236 0.367 0 CA-C-N 115.646 -0.706 . . . . 0.0 109.366 178.776 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 22' ' ' ILE . . . . . 0.727 HD12 ' HB2' ' A' ' 31' ' ' TYR . 3.6 mt -120.71 129.92 25.09 Favored Pre-proline 0 CA--C 1.543 0.682 0 CA-C-N 115.595 -0.729 . . . . 0.0 110.345 -178.782 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 36.8 Cg_endo -66.78 -47.01 0.27 Allowed 'Cis proline' 0 C--N 1.375 1.93 0 C-N-CA 124.647 -0.981 . . . . 0.0 113.965 -0.069 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 79.51 33.43 34.84 Favored Glycine 0 C--N 1.346 1.09 0 C-N-CA 121.223 -0.513 . . . . 0.0 112.957 179.8 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 8.3 m-20 -139.26 83.97 17.06 Favored Pre-proline 0 CA--C 1.544 0.735 0 C-N-CA 122.523 0.329 . . . . 0.0 110.588 -179.762 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 2.9 Cg_endo -80.25 -31.67 4.54 Favored 'Cis proline' 0 C--N 1.37 1.697 0 C-N-CA 125.074 -0.803 . . . . 0.0 112.907 -0.044 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 27' ' ' TYR . . . . . . . . . . . . . 59.8 m-85 -108.22 173.16 6.44 Favored 'General case' 0 C--O 1.239 0.541 0 CA-C-N 115.824 -0.625 . . . . 0.0 111.701 -179.053 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 28' ' ' GLY . . . . . 0.722 ' O ' ' HA ' ' A' ' 7' ' ' GLN . . . -175.54 -164.32 29.82 Favored Glycine 0 C--N 1.338 0.685 0 CA-C-N 115.694 -0.685 . . . . 0.0 112.491 178.495 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 29' ' ' ILE . . . . . 0.549 ' HB ' ' CE2' ' A' ' 31' ' ' TYR . 2.3 mm -113.99 152.82 15.61 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 O-C-N 123.654 0.267 . . . . 0.0 110.282 -179.825 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 30' ' ' CYS . . . . . 0.527 ' HA ' ' O ' ' A' ' 20' ' ' THR . 33.9 m -79.73 106.02 11.44 Favored 'General case' 0 C--O 1.237 0.409 0 CA-C-N 115.918 -0.583 . . . . 0.0 111.432 -179.874 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 31' ' ' TYR . . . . . 0.727 ' HB2' HD12 ' A' ' 22' ' ' ILE . 38.6 m-85 -130.51 167.83 18.03 Favored 'General case' 0 C--O 1.233 0.187 0 CA-C-N 115.081 -0.963 . . . . 0.0 111.113 -179.463 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 2.8 tp -101.21 131.13 49.54 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.551 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.31 179.514 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 33' ' ' ILE . . . . . 0.489 HG23 HD11 ' A' ' 22' ' ' ILE . 1.8 pp . . . . . 0 C--O 1.249 1.074 0 CA-C-O 118.158 -0.925 . . . . 0.0 111.443 179.913 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 2' ' ' PRO . . . . . 0.584 ' HD2' ' O ' ' A' ' 14' ' ' PRO . 91.6 Cg_endo . . . . . 0 N--CA 1.488 1.205 0 N-CA-C 113.961 0.716 . . . . 0.0 113.961 . . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -135.86 -157.74 7.96 Favored Glycine 0 C--N 1.341 0.817 0 CA-C-N 115.977 -0.556 . . . . 0.0 112.053 179.778 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 18.0 tt0 -73.07 135.46 44.82 Favored 'General case' 0 N--CA 1.471 0.608 0 C-N-CA 122.721 0.408 . . . . 0.0 111.345 -179.957 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 88.31 9.44 69.86 Favored Glycine 0 C--N 1.34 0.797 0 CA-C-N 115.797 -0.638 . . . . 0.0 113.396 -179.707 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 42.6 mt-10 -128.6 166.62 18.52 Favored 'General case' 0 C--O 1.239 0.505 0 C-N-CA 122.298 0.239 . . . . 0.0 110.883 -179.963 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 7' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER -81.74 152.48 27.0 Favored 'General case' 0 C--N 1.347 0.483 0 CA-C-N 116.581 -0.281 . . . . 0.0 110.867 179.909 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 4.9 p -140.48 150.58 43.95 Favored 'General case' 0 C--O 1.235 0.327 0 CA-C-N 115.852 -0.613 . . . . 0.0 111.116 -179.283 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -111.01 141.87 43.91 Favored 'General case' 0 C--O 1.234 0.277 0 CA-C-N 115.4 -0.818 . . . . 0.0 109.59 179.671 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 10' ' ' VAL . . . . . 0.45 HG22 ' O ' ' A' ' 26' ' ' PRO . 6.8 m -96.09 22.58 0.92 Allowed 'Isoleucine or valine' 0 CA--C 1.541 0.611 0 CA-C-N 116.559 -0.291 . . . . 0.0 111.651 -179.926 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 45.3 mt-10 -115.29 -54.34 2.55 Favored 'General case' 0 C--O 1.235 0.305 0 N-CA-C 112.079 0.4 . . . . 0.0 112.079 -179.067 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 12' ' ' PHE . . . . . . . . . . . . . 11.9 t80 -141.53 -9.17 0.95 Allowed 'General case' 0 N--CA 1.473 0.676 0 N-CA-C 112.548 0.573 . . . . 0.0 112.548 -178.791 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 13' ' ' ASN . . . . . . . . . . . . . 6.8 t-20 -129.94 63.53 68.91 Favored Pre-proline 0 CA--C 1.551 0.981 0 N-CA-C 111.369 0.137 . . . . 0.0 111.369 -179.19 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 14' ' ' PRO . . . . . 0.584 ' O ' ' HD2' ' A' ' 2' ' ' PRO . 13.3 Cg_exo -70.37 -174.54 1.05 Allowed 'Trans proline' 0 C--N 1.375 1.922 0 C-N-CA 122.784 2.322 . . . . 0.0 112.039 179.118 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 2.1 t -79.27 120.61 23.98 Favored 'General case' 0 N--CA 1.472 0.627 0 O-C-N 122.909 0.131 . . . . 0.0 110.991 -179.902 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 16' ' ' CYS . . . . . 0.572 ' HB2' ' O ' ' A' ' 2' ' ' PRO . 0.0 OUTLIER -57.03 -52.5 73.67 Favored Pre-proline 0 N--CA 1.483 1.198 0 CA-C-O 119.073 -0.489 . . . . 0.0 111.551 179.458 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 17' ' ' PRO . . . . . 0.591 ' HG2' HD12 ' A' ' 19' ' ' LEU . 56.9 Cg_endo -72.29 169.95 20.36 Favored 'Trans proline' 0 C--N 1.38 2.205 0 C-N-CA 122.1 1.867 . . . . 0.0 111.712 178.013 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 53.1 Cg_endo -71.45 49.86 1.19 Allowed 'Trans proline' 0 C--N 1.373 1.861 0 C-N-CA 121.978 1.785 . . . . 0.0 112.852 178.871 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 19' ' ' LEU . . . . . 0.591 HD12 ' HG2' ' A' ' 17' ' ' PRO . 32.9 mt -108.7 172.5 6.81 Favored 'General case' 0 CA--C 1.533 0.321 0 CA-C-N 115.722 -0.672 . . . . 0.0 111.235 -179.574 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 20' ' ' THR . . . . . 0.424 ' O ' ' HA ' ' A' ' 30' ' ' CYS . 25.0 m -106.63 153.96 21.61 Favored 'General case' 0 CA--C 1.533 0.308 0 CA-C-N 115.811 -0.631 . . . . 0.0 111.462 -178.497 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 3.5 t -103.57 104.18 14.2 Favored 'General case' 0 C--O 1.236 0.392 0 CA-C-N 115.512 -0.767 . . . . 0.0 109.474 178.568 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 22' ' ' ILE . . . . . 0.721 HD12 ' HB2' ' A' ' 31' ' ' TYR . 4.8 mt -125.56 129.66 24.33 Favored Pre-proline 0 CA--C 1.543 0.703 0 CA-C-N 115.757 -0.656 . . . . 0.0 110.665 -178.914 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 35.6 Cg_endo -66.45 -48.11 0.24 Allowed 'Cis proline' 0 C--N 1.376 1.998 0 C-N-CA 124.683 -0.965 . . . . 0.0 113.801 -0.207 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 80.46 34.4 28.86 Favored Glycine 0 C--N 1.347 1.141 0 C-N-CA 121.253 -0.498 . . . . 0.0 112.904 179.877 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 8.0 m-20 -142.81 84.27 10.87 Favored Pre-proline 0 CA--C 1.544 0.719 0 C-N-CA 122.525 0.33 . . . . 0.0 110.542 -179.604 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 26' ' ' PRO . . . . . 0.45 ' O ' HG22 ' A' ' 10' ' ' VAL . 1.1 Cg_endo -81.77 -31.73 4.12 Favored 'Cis proline' 0 C--N 1.373 1.821 0 C-N-CA 125.075 -0.802 . . . . 0.0 113.06 -0.098 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 27' ' ' TYR . . . . . . . . . . . . . 41.2 m-85 -101.26 167.56 10.12 Favored 'General case' 0 C--O 1.239 0.532 0 CA-C-N 115.797 -0.638 . . . . 0.0 111.158 -178.981 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -164.88 -161.21 13.37 Favored Glycine 0 C--N 1.34 0.799 0 C-N-CA 120.839 -0.696 . . . . 0.0 113.264 179.619 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 29' ' ' ILE . . . . . 0.489 ' HB ' ' CE2' ' A' ' 31' ' ' TYR . 3.9 mm -127.93 155.26 39.32 Favored 'Isoleucine or valine' 0 C--O 1.234 0.268 0 CA-C-N 115.175 -0.512 . . . . 0.0 109.877 179.944 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 30' ' ' CYS . . . . . 0.424 ' HA ' ' O ' ' A' ' 20' ' ' THR . 23.7 m -81.96 100.61 9.77 Favored 'General case' 0 CA--C 1.536 0.435 0 CA-C-O 121.278 0.561 . . . . 0.0 111.446 -179.911 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 31' ' ' TYR . . . . . 0.721 ' HB2' HD12 ' A' ' 22' ' ' ILE . 38.4 m-85 -130.04 166.16 20.72 Favored 'General case' 0 N--CA 1.464 0.246 0 CA-C-N 115.12 -0.946 . . . . 0.0 110.937 -179.872 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 2.9 tp -101.0 131.71 48.15 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.546 0 CA-C-N 116.077 -0.511 . . . . 0.0 110.367 179.558 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 33' ' ' ILE . . . . . 0.496 HG23 HD11 ' A' ' 22' ' ' ILE . 1.8 pp . . . . . 0 C--O 1.25 1.097 0 CA-C-O 118.241 -0.885 . . . . 0.0 111.486 179.876 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 2' ' ' PRO . . . . . 0.579 ' O ' ' HB2' ' A' ' 16' ' ' CYS . 92.3 Cg_endo . . . . . 0 N--CA 1.488 1.195 0 N-CA-C 113.907 0.695 . . . . 0.0 113.907 . . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -135.79 -156.54 7.59 Favored Glycine 0 C--N 1.342 0.894 0 CA-C-N 116.027 -0.533 . . . . 0.0 112.387 179.829 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 16.0 tt0 -74.31 138.78 43.76 Favored 'General case' 0 N--CA 1.471 0.593 0 C-N-CA 122.693 0.397 . . . . 0.0 111.377 -179.707 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 84.53 10.62 79.27 Favored Glycine 0 C--N 1.34 0.754 0 CA-C-N 115.809 -0.632 . . . . 0.0 113.333 179.99 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 43.1 mt-10 -129.16 160.98 31.17 Favored 'General case' 0 N--CA 1.467 0.4 0 C-N-CA 122.206 0.202 . . . . 0.0 110.846 -179.841 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 7' ' ' GLN . . . . . 0.516 ' HA ' ' O ' ' A' ' 28' ' ' GLY . 7.5 tt0 -84.85 133.65 34.31 Favored 'General case' 0 C--N 1.344 0.366 0 CA-C-O 121.331 0.586 . . . . 0.0 111.215 179.765 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 3.3 p -122.85 161.75 23.48 Favored 'General case' 0 C--O 1.241 0.615 0 CA-C-N 114.44 -1.254 . . . . 0.0 110.824 -179.638 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 9' ' ' ASP . . . . . 0.452 ' OD1' ' HD2' ' A' ' 27' ' ' TYR . 1.8 m-20 -114.91 152.01 33.04 Favored 'General case' 0 C--O 1.235 0.31 0 CA-C-N 115.511 -0.768 . . . . 0.0 109.77 179.41 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 10.1 m -103.79 13.03 7.44 Favored 'Isoleucine or valine' 0 CA--C 1.542 0.651 0 O-C-N 123.254 0.346 . . . . 0.0 111.801 -179.818 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 45.9 mt-10 -100.95 -55.67 2.51 Favored 'General case' 0 C--O 1.235 0.304 0 N-CA-C 111.812 0.301 . . . . 0.0 111.812 -179.073 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 12' ' ' PHE . . . . . . . . . . . . . 12.6 t80 -141.25 -14.23 0.89 Allowed 'General case' 0 N--CA 1.47 0.564 0 N-CA-C 112.218 0.451 . . . . 0.0 112.218 -179.251 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 13' ' ' ASN . . . . . . . . . . . . . 12.8 t-20 -120.47 72.91 21.09 Favored Pre-proline 0 CA--C 1.55 0.955 0 O-C-N 122.903 0.127 . . . . 0.0 111.184 -179.406 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 14' ' ' PRO . . . . . 0.575 ' O ' ' HD2' ' A' ' 2' ' ' PRO . 60.8 Cg_endo -76.44 -176.4 3.08 Favored 'Trans proline' 0 C--N 1.371 1.735 0 C-N-CA 122.367 2.044 . . . . 0.0 112.207 179.245 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 2.0 t -79.34 119.64 22.67 Favored 'General case' 0 N--CA 1.473 0.71 0 O-C-N 123.017 0.198 . . . . 0.0 110.642 179.861 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 16' ' ' CYS . . . . . 0.579 ' HB2' ' O ' ' A' ' 2' ' ' PRO . 0.0 OUTLIER -54.94 -52.48 70.49 Favored Pre-proline 0 N--CA 1.483 1.178 0 CA-C-O 119.005 -0.521 . . . . 0.0 111.664 179.715 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 17' ' ' PRO . . . . . 0.561 ' HG2' HD12 ' A' ' 19' ' ' LEU . 57.6 Cg_endo -72.39 169.79 20.83 Favored 'Trans proline' 0 C--N 1.378 2.126 0 C-N-CA 122.06 1.84 . . . . 0.0 111.789 178.021 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 55.1 Cg_endo -71.87 50.28 1.4 Allowed 'Trans proline' 0 C--N 1.374 1.895 0 C-N-CA 122.065 1.844 . . . . 0.0 112.742 178.808 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 19' ' ' LEU . . . . . 0.561 HD12 ' HG2' ' A' ' 17' ' ' PRO . 32.4 mt -110.03 172.13 7.04 Favored 'General case' 0 CA--C 1.533 0.323 0 CA-C-N 115.666 -0.697 . . . . 0.0 111.311 -179.33 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 20' ' ' THR . . . . . 0.497 ' O ' ' HA ' ' A' ' 30' ' ' CYS . 21.2 m -106.04 154.38 20.71 Favored 'General case' 0 CA--C 1.533 0.293 0 CA-C-N 115.606 -0.724 . . . . 0.0 111.002 -178.948 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 2.0 t -105.35 99.7 9.3 Favored 'General case' 0 C--O 1.237 0.398 0 CA-C-N 115.644 -0.707 . . . . 0.0 109.363 178.597 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 22' ' ' ILE . . . . . 0.73 HD12 ' HB2' ' A' ' 31' ' ' TYR . 3.0 mt -122.53 130.53 24.62 Favored Pre-proline 0 CA--C 1.542 0.658 0 CA-C-N 115.559 -0.746 . . . . 0.0 110.382 -178.713 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 32.5 Cg_endo -65.07 -48.47 0.21 Allowed 'Cis proline' 0 C--N 1.375 1.944 0 C-N-CA 124.76 -0.933 . . . . 0.0 113.942 -0.226 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 77.19 31.36 52.51 Favored Glycine 0 C--N 1.348 1.215 0 C-N-CA 121.165 -0.54 . . . . 0.0 113.004 179.725 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 8.3 m-20 -138.86 83.71 18.56 Favored Pre-proline 0 CA--C 1.544 0.717 0 C-N-CA 122.49 0.316 . . . . 0.0 110.432 -179.771 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 3.0 Cg_exo -81.17 -32.34 3.83 Favored 'Cis proline' 0 C--N 1.372 1.772 0 C-N-CA 125.101 -0.791 . . . . 0.0 113.07 -0.08 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 27' ' ' TYR . . . . . 0.452 ' HD2' ' OD1' ' A' ' 9' ' ' ASP . 45.4 m-85 -104.4 166.76 10.19 Favored 'General case' 0 N--CA 1.469 0.485 0 CA-C-N 115.864 -0.607 . . . . 0.0 111.465 -178.884 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 28' ' ' GLY . . . . . 0.516 ' O ' ' HA ' ' A' ' 7' ' ' GLN . . . -169.95 -164.85 26.36 Favored Glycine 0 C--N 1.341 0.842 0 C-N-CA 120.93 -0.652 . . . . 0.0 113.356 178.492 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 29' ' ' ILE . . . . . 0.536 ' HB ' ' CE2' ' A' ' 31' ' ' TYR . 1.9 mm -117.38 153.07 19.22 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.225 0 O-C-N 124.045 0.497 . . . . 0.0 110.22 -179.938 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 30' ' ' CYS . . . . . 0.497 ' HA ' ' O ' ' A' ' 20' ' ' THR . 20.5 m -80.06 104.66 10.78 Favored 'General case' 0 CA--C 1.536 0.42 0 CA-C-N 115.923 -0.581 . . . . 0.0 111.21 -179.866 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 31' ' ' TYR . . . . . 0.73 ' HB2' HD12 ' A' ' 22' ' ' ILE . 39.7 m-85 -130.12 167.51 18.24 Favored 'General case' 0 C--O 1.233 0.223 0 CA-C-N 115.098 -0.956 . . . . 0.0 111.044 -179.54 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 2.6 tp -100.95 131.84 47.82 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.524 0 CA-C-N 116.056 -0.52 . . . . 0.0 110.426 179.486 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 33' ' ' ILE . . . . . 0.451 ' O ' HD12 ' A' ' 33' ' ' ILE . 1.7 pp . . . . . 0 C--O 1.248 0.998 0 CA-C-O 118.383 -0.818 . . . . 0.0 111.522 179.856 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 2' ' ' PRO . . . . . 0.594 ' HD2' ' O ' ' A' ' 14' ' ' PRO . 94.6 Cg_endo . . . . . 0 N--CA 1.489 1.243 0 N-CA-C 113.801 0.654 . . . . 0.0 113.801 . . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -136.4 -158.1 7.97 Favored Glycine 0 C--N 1.342 0.89 0 CA-C-N 115.852 -0.613 . . . . 0.0 112.232 179.749 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 18.3 tt0 -73.52 136.51 44.11 Favored 'General case' 0 N--CA 1.472 0.625 0 C-N-CA 122.717 0.407 . . . . 0.0 111.382 -179.978 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 87.85 9.23 71.61 Favored Glycine 0 C--N 1.339 0.703 0 O-C-N 123.775 0.672 . . . . 0.0 113.398 -179.796 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 3.2 tp10 -129.0 166.49 19.09 Favored 'General case' 0 C--O 1.239 0.53 0 C-N-CA 122.218 0.207 . . . . 0.0 110.576 -179.816 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 7' ' ' GLN . . . . . . . . . . . . . 0.2 OUTLIER -80.6 152.81 28.36 Favored 'General case' 0 C--N 1.347 0.483 0 CA-C-N 116.517 -0.31 . . . . 0.0 110.822 179.782 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 6.2 p -140.85 152.24 44.97 Favored 'General case' 0 C--O 1.234 0.245 0 CA-C-N 115.958 -0.565 . . . . 0.0 111.163 -179.12 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -112.41 146.12 38.92 Favored 'General case' 0 C--O 1.235 0.337 0 CA-C-N 115.397 -0.82 . . . . 0.0 109.626 179.498 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 10' ' ' VAL . . . . . 0.452 HG22 ' O ' ' A' ' 26' ' ' PRO . 6.5 m -101.26 17.91 3.63 Favored 'Isoleucine or valine' 0 CA--C 1.543 0.674 0 CA-C-N 116.46 -0.336 . . . . 0.0 111.604 179.988 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 47.0 mt-10 -107.55 -55.01 2.41 Favored 'General case' 0 N--CA 1.467 0.383 0 CA-C-N 116.346 -0.388 . . . . 0.0 111.873 -179.155 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 12' ' ' PHE . . . . . . . . . . . . . 10.8 t80 -140.35 -16.77 0.92 Allowed 'General case' 0 N--CA 1.471 0.596 0 N-CA-C 112.31 0.485 . . . . 0.0 112.31 -179.193 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 13' ' ' ASN . . . . . . . . . . . . . 8.3 t-20 -120.56 72.98 21.76 Favored Pre-proline 0 CA--C 1.548 0.899 0 O-C-N 122.937 0.148 . . . . 0.0 111.139 -179.337 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 14' ' ' PRO . . . . . 0.594 ' O ' ' HD2' ' A' ' 2' ' ' PRO . 62.4 Cg_endo -76.71 -175.13 2.44 Favored 'Trans proline' 0 C--N 1.372 1.806 0 C-N-CA 122.484 2.123 . . . . 0.0 112.347 179.318 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 2.2 t -79.48 119.59 22.68 Favored 'General case' 0 N--CA 1.472 0.651 0 CA-C-O 120.452 0.168 . . . . 0.0 110.727 179.932 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 16' ' ' CYS . . . . . 0.579 ' HB2' ' O ' ' A' ' 2' ' ' PRO . 0.0 OUTLIER -56.25 -52.59 71.8 Favored Pre-proline 0 N--CA 1.481 1.101 0 CA-C-O 119.005 -0.521 . . . . 0.0 111.712 179.611 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 17' ' ' PRO . . . . . 0.582 ' HG2' HD12 ' A' ' 19' ' ' LEU . 56.9 Cg_endo -72.36 169.67 21.1 Favored 'Trans proline' 0 C--N 1.38 2.205 0 C-N-CA 122.065 1.844 . . . . 0.0 111.721 177.969 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -71.69 51.87 1.6 Allowed 'Trans proline' 0 C--N 1.373 1.859 0 C-N-CA 121.963 1.776 . . . . 0.0 112.769 178.79 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 19' ' ' LEU . . . . . 0.582 HD12 ' HG2' ' A' ' 17' ' ' PRO . 37.5 mt -110.6 173.12 6.48 Favored 'General case' 0 C--O 1.236 0.37 0 CA-C-N 115.58 -0.736 . . . . 0.0 111.333 -179.565 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 28.8 m -107.92 152.88 23.85 Favored 'General case' 0 CA--C 1.533 0.318 0 CA-C-N 115.874 -0.603 . . . . 0.0 111.346 -178.565 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 3.9 t -101.82 104.25 15.0 Favored 'General case' 0 C--O 1.238 0.471 0 CA-C-N 115.437 -0.801 . . . . 0.0 109.622 178.463 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 22' ' ' ILE . . . . . 0.726 HD12 ' HB2' ' A' ' 31' ' ' TYR . 4.5 mt -125.92 129.75 24.2 Favored Pre-proline 0 CA--C 1.544 0.717 0 CA-C-N 115.918 -0.583 . . . . 0.0 110.544 -178.775 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 23' ' ' PRO . . . . . 0.48 ' HB2' ' OD2' ' A' ' 25' ' ' ASP . 35.2 Cg_endo -66.01 -48.76 0.21 Allowed 'Cis proline' 0 C--N 1.376 1.979 0 C-N-CA 124.71 -0.954 . . . . 0.0 113.807 -0.354 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 80.55 35.61 25.38 Favored Glycine 0 C--N 1.347 1.156 0 C-N-CA 121.299 -0.477 . . . . 0.0 112.91 179.826 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 25' ' ' ASP . . . . . 0.48 ' OD2' ' HB2' ' A' ' 23' ' ' PRO . 2.5 p30 -143.72 84.1 10.11 Favored Pre-proline 0 CA--C 1.548 0.898 0 C-N-CA 122.551 0.34 . . . . 0.0 110.759 -179.789 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 26' ' ' PRO . . . . . 0.452 ' O ' HG22 ' A' ' 10' ' ' VAL . 1.2 Cg_endo -81.41 -32.1 3.95 Favored 'Cis proline' 0 C--N 1.371 1.712 0 C-N-CA 125.15 -0.771 . . . . 0.0 113.087 0.011 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 27' ' ' TYR . . . . . . . . . . . . . 40.1 m-85 -101.79 169.69 8.64 Favored 'General case' 0 C--O 1.239 0.533 0 CA-C-N 115.754 -0.657 . . . . 0.0 111.213 -178.888 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -167.49 -159.42 13.04 Favored Glycine 0 C--N 1.341 0.815 0 C-N-CA 120.888 -0.672 . . . . 0.0 113.243 179.517 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 29' ' ' ILE . . . . . 0.493 ' HB ' ' CE2' ' A' ' 31' ' ' TYR . 4.2 mm -128.17 154.4 38.78 Favored 'Isoleucine or valine' 0 C--O 1.233 0.193 0 CA-C-N 115.276 -0.462 . . . . 0.0 109.853 179.969 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 30' ' ' CYS . . . . . . . . . . . . . 18.2 m -81.55 101.48 9.99 Favored 'General case' 0 CA--C 1.536 0.42 0 CA-C-N 116.02 -0.536 . . . . 0.0 111.395 179.989 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 31' ' ' TYR . . . . . 0.726 ' HB2' HD12 ' A' ' 22' ' ' ILE . 38.4 m-85 -130.0 166.53 19.9 Favored 'General case' 0 N--CA 1.464 0.228 0 CA-C-N 115.145 -0.934 . . . . 0.0 110.995 -179.714 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 2.8 tp -101.5 131.96 48.29 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.624 0 CA-C-N 116.141 -0.482 . . . . 0.0 110.377 179.51 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 33' ' ' ILE . . . . . 0.488 ' H ' HG13 ' A' ' 33' ' ' ILE . 1.8 pp . . . . . 0 C--O 1.249 1.057 0 CA-C-O 118.382 -0.818 . . . . 0.0 111.521 179.945 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 5.8 p . . . . . 0 N--CA 1.485 1.311 0 CA-C-O 119.724 -0.179 . . . . 0.0 111.279 . . . . . . . . . 0 0 . 1 . 001 nuclear build full ' A' A ' 2' ' ' PRO . . . . . 0.415 ' HD2' ' O ' ' A' ' 14' ' ' PRO . 81.1 Cg_endo -83.07 -172.88 1.5 Allowed 'Trans proline' 0 C--N 1.368 1.556 0 C-N-CA 122.59 2.194 . . . . 0.0 112.942 179.631 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -145.77 -159.22 8.06 Favored Glycine 0 C--N 1.337 0.632 0 N-CA-C 111.547 -0.621 . . . . 0.0 111.547 179.189 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 19.7 tt0 -71.3 125.84 28.05 Favored 'General case' 0 N--CA 1.472 0.668 0 CA-C-N 116.901 0.35 . . . . 0.0 111.072 179.631 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 88.22 16.65 58.8 Favored Glycine 0 C--N 1.339 0.724 0 CA-C-N 115.659 -0.7 . . . . 0.0 113.097 -179.541 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 43.1 mt-10 -127.95 166.91 17.43 Favored 'General case' 0 C--O 1.237 0.433 0 C-N-CA 122.333 0.253 . . . . 0.0 110.719 -179.775 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 7' ' ' GLN . . . . . 0.459 ' HA ' ' O ' ' A' ' 28' ' ' GLY . 0.2 OUTLIER -81.05 152.04 28.08 Favored 'General case' 0 C--N 1.346 0.436 0 CA-C-N 116.502 -0.317 . . . . 0.0 110.974 179.89 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 6.3 p -147.12 156.24 42.83 Favored 'General case' 0 C--O 1.235 0.307 0 CA-C-N 115.963 -0.562 . . . . 0.0 111.583 -178.965 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 4.8 t70 -117.36 149.13 41.01 Favored 'General case' 0 C--O 1.234 0.263 0 CA-C-N 115.452 -0.794 . . . . 0.0 109.589 178.918 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 15.7 m -102.38 24.49 1.48 Allowed 'Isoleucine or valine' 0 CA--C 1.542 0.655 0 CA-C-N 116.225 -0.443 . . . . 0.0 111.905 -179.493 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 43.9 mt-10 -120.63 -50.89 2.18 Favored 'General case' 0 N--CA 1.466 0.333 0 N-CA-C 112.063 0.394 . . . . 0.0 112.063 -179.044 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 12' ' ' PHE . . . . . . . . . . . . . 13.7 m-85 -133.35 -27.23 1.59 Allowed 'General case' 0 N--CA 1.47 0.541 0 N-CA-C 112.181 0.437 . . . . 0.0 112.181 -178.706 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 13' ' ' ASN . . . . . . . . . . . . . 3.6 t-20 -116.03 73.91 5.11 Favored Pre-proline 0 CA--C 1.549 0.934 0 O-C-N 123.435 0.459 . . . . 0.0 112.174 -177.467 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 14' ' ' PRO . . . . . 0.415 ' O ' ' HD2' ' A' ' 2' ' ' PRO . 60.8 Cg_endo -76.1 179.09 6.67 Favored 'Trans proline' 0 C--N 1.372 1.777 0 C-N-CA 122.43 2.087 . . . . 0.0 112.125 178.746 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 1.9 t -79.67 119.9 23.24 Favored 'General case' 0 N--CA 1.47 0.566 0 CA-C-O 120.499 0.19 . . . . 0.0 110.938 179.75 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER -57.86 -54.07 59.23 Favored Pre-proline 0 N--CA 1.477 0.915 0 CA-C-O 118.973 -0.537 . . . . 0.0 111.757 179.651 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 17' ' ' PRO . . . . . 0.621 ' HG2' HD12 ' A' ' 19' ' ' LEU . 51.9 Cg_endo -70.39 168.19 23.08 Favored 'Trans proline' 0 C--N 1.378 2.118 0 C-N-CA 122.025 1.817 . . . . 0.0 111.8 178.25 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 49.8 Cg_endo -71.01 60.88 2.39 Favored 'Trans proline' 0 C--N 1.372 1.796 0 C-N-CA 121.945 1.763 . . . . 0.0 112.427 178.807 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 19' ' ' LEU . . . . . 0.621 HD12 ' HG2' ' A' ' 17' ' ' PRO . 22.6 mt -122.42 171.58 8.97 Favored 'General case' 0 C--O 1.235 0.325 0 CA-C-N 115.411 -0.813 . . . . 0.0 111.421 -179.269 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 20' ' ' THR . . . . . 0.492 ' O ' ' HA ' ' A' ' 30' ' ' CYS . 28.5 m -107.72 153.69 22.58 Favored 'General case' 0 CA--C 1.533 0.306 0 CA-C-N 115.676 -0.693 . . . . 0.0 111.227 -178.676 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 4.8 t -103.06 104.97 15.19 Favored 'General case' 0 C--O 1.237 0.426 0 CA-C-N 115.593 -0.731 . . . . 0.0 109.553 178.626 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 22' ' ' ILE . . . . . 0.712 HD12 ' HB2' ' A' ' 31' ' ' TYR . 3.4 mt -127.12 129.34 23.97 Favored Pre-proline 0 CA--C 1.543 0.686 0 CA-C-N 115.874 -0.603 . . . . 0.0 110.47 -178.805 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 37.6 Cg_endo -67.46 -48.69 0.23 Allowed 'Cis proline' 0 C--N 1.374 1.913 0 C-N-CA 124.713 -0.953 . . . . 0.0 113.848 -0.294 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 80.5 40.74 12.35 Favored Glycine 0 C--N 1.347 1.145 0 C-N-CA 121.264 -0.493 . . . . 0.0 112.761 -179.891 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 8.2 m-20 -141.6 79.31 17.21 Favored Pre-proline 0 CA--C 1.544 0.744 0 C-N-CA 122.443 0.297 . . . . 0.0 110.837 -179.709 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 1.5 Cg_endo -82.49 -32.72 3.29 Favored 'Cis proline' 0 C--N 1.371 1.746 0 C-N-CA 125.074 -0.803 . . . . 0.0 113.028 -0.125 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 27' ' ' TYR . . . . . . . . . . . . . 71.7 m-85 -98.11 171.43 8.25 Favored 'General case' 0 C--O 1.24 0.563 0 CA-C-N 115.913 -0.585 . . . . 0.0 111.568 -178.973 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 28' ' ' GLY . . . . . 0.459 ' O ' ' HA ' ' A' ' 7' ' ' GLN . . . -173.03 -159.84 20.44 Favored Glycine 0 C--N 1.338 0.653 0 CA-C-N 115.784 -0.644 . . . . 0.0 112.365 179.301 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 29' ' ' ILE . . . . . 0.518 ' HB ' ' CE2' ' A' ' 31' ' ' TYR . 2.9 mm -124.21 151.18 29.13 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 N-CA-C 109.735 -0.468 . . . . 0.0 109.735 179.737 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 30' ' ' CYS . . . . . 0.492 ' HA ' ' O ' ' A' ' 20' ' ' THR . 23.4 m -79.94 103.24 9.69 Favored 'General case' 0 CA--C 1.536 0.412 0 CA-C-O 121.225 0.536 . . . . 0.0 111.432 -179.812 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 31' ' ' TYR . . . . . 0.712 ' HB2' HD12 ' A' ' 22' ' ' ILE . 38.2 m-85 -129.07 167.77 17.04 Favored 'General case' 0 C--O 1.233 0.211 0 CA-C-N 115.014 -0.993 . . . . 0.0 110.923 -179.623 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 2.7 tp -100.95 131.43 48.62 Favored 'Isoleucine or valine' 0 CA--C 1.542 0.645 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.315 179.411 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 33' ' ' ILE . . . . . 0.498 HG23 HD11 ' A' ' 22' ' ' ILE . 1.9 pp . . . . . 0 C--O 1.249 1.051 0 CA-C-O 118.395 -0.812 . . . . 0.0 111.413 179.954 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 6.7 p . . . . . 0 N--CA 1.485 1.283 0 CA-C-O 119.778 -0.153 . . . . 0.0 111.161 . . . . . . . . . 0 0 . 1 . 002 nuclear build full ' A' A ' 2' ' ' PRO . . . . . 0.425 ' HD2' ' O ' ' A' ' 14' ' ' PRO . 88.6 Cg_endo -82.31 -172.69 1.5 Allowed 'Trans proline' 0 C--N 1.368 1.553 0 C-N-CA 122.57 2.18 . . . . 0.0 112.963 179.437 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -149.46 -159.58 8.7 Favored Glycine 0 C--N 1.338 0.67 0 N-CA-C 111.623 -0.591 . . . . 0.0 111.623 179.229 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 17.2 tt0 -70.05 121.29 17.17 Favored 'General case' 0 N--CA 1.474 0.73 0 CA-C-O 120.763 0.315 . . . . 0.0 111.241 179.811 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 93.37 15.15 51.99 Favored Glycine 0 C--N 1.34 0.782 0 CA-C-N 115.614 -0.721 . . . . 0.0 113.164 -179.776 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 43.1 mt-10 -128.75 166.63 18.62 Favored 'General case' 0 C--O 1.24 0.56 0 C-N-CA 122.514 0.326 . . . . 0.0 110.816 179.959 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 7' ' ' GLN . . . . . 0.443 ' HA ' ' O ' ' A' ' 28' ' ' GLY . 0.2 OUTLIER -81.43 152.55 27.35 Favored 'General case' 0 C--N 1.346 0.435 0 O-C-N 123.195 0.309 . . . . 0.0 111.137 -179.88 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 7.9 p -145.84 154.53 42.1 Favored 'General case' 0 N--CA 1.466 0.354 0 CA-C-N 115.957 -0.565 . . . . 0.0 111.502 -179.12 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 6.2 t70 -118.12 153.82 33.15 Favored 'General case' 0 C--O 1.236 0.345 0 CA-C-N 115.393 -0.821 . . . . 0.0 109.898 179.139 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 13.5 m -105.33 17.92 5.44 Favored 'Isoleucine or valine' 0 CA--C 1.542 0.661 0 CA-C-N 116.286 -0.416 . . . . 0.0 112.033 -179.422 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 46.3 mt-10 -110.74 -52.9 2.75 Favored 'General case' 0 N--CA 1.466 0.36 0 N-CA-C 111.898 0.332 . . . . 0.0 111.898 -179.149 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 12' ' ' PHE . . . . . . . . . . . . . 13.4 t80 -138.76 -15.66 1.17 Allowed 'General case' 0 N--CA 1.469 0.493 0 N-CA-C 112.406 0.521 . . . . 0.0 112.406 -178.945 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 13' ' ' ASN . . . . . . . . . . . . . 5.8 t-20 -120.62 73.35 22.73 Favored Pre-proline 0 CA--C 1.549 0.929 0 O-C-N 122.935 0.147 . . . . 0.0 111.343 -179.204 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 14' ' ' PRO . . . . . 0.425 ' O ' ' HD2' ' A' ' 2' ' ' PRO . 60.5 Cg_endo -76.43 176.56 9.92 Favored 'Trans proline' 0 C--N 1.371 1.75 0 C-N-CA 122.428 2.085 . . . . 0.0 112.48 179.342 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 1.4 m -79.67 118.9 21.91 Favored 'General case' 0 N--CA 1.469 0.488 0 O-C-N 123.199 0.312 . . . . 0.0 111.422 179.923 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER -58.03 -53.87 61.43 Favored Pre-proline 0 N--CA 1.477 0.906 0 CA-C-N 115.865 -0.607 . . . . 0.0 111.776 179.81 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 17' ' ' PRO . . . . . 0.459 ' HG2' HD12 ' A' ' 19' ' ' LEU . 53.3 Cg_endo -70.28 168.65 21.61 Favored 'Trans proline' 0 C--N 1.379 2.132 0 C-N-CA 121.983 1.789 . . . . 0.0 111.736 178.351 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 56.0 Cg_endo -72.4 47.34 1.09 Allowed 'Trans proline' 0 C--N 1.37 1.673 0 C-N-CA 121.872 1.714 . . . . 0.0 112.855 178.987 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 19' ' ' LEU . . . . . 0.462 ' HB2' ' SG ' ' A' ' 30' ' ' CYS . 13.0 mt -107.58 171.08 7.59 Favored 'General case' 0 CA--C 1.533 0.32 0 CA-C-N 115.921 -0.582 . . . . 0.0 110.955 -179.537 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 28.6 m -104.43 148.84 25.98 Favored 'General case' 0 CA--C 1.531 0.25 0 CA-C-N 115.829 -0.623 . . . . 0.0 111.108 -178.76 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 5.9 t -98.49 103.03 14.95 Favored 'General case' 0 C--O 1.238 0.499 0 N-CA-C 109.421 -0.585 . . . . 0.0 109.421 178.384 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 22' ' ' ILE . . . . . 0.715 HD12 ' HB2' ' A' ' 31' ' ' TYR . 2.5 mt -126.62 129.02 24.19 Favored Pre-proline 0 CA--C 1.543 0.703 0 CA-C-N 115.817 -0.629 . . . . 0.0 110.742 -178.547 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 37.4 Cg_endo -67.67 -48.55 0.24 Allowed 'Cis proline' 0 C--N 1.374 1.908 0 C-N-CA 124.719 -0.95 . . . . 0.0 113.782 -0.262 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 79.38 38.7 20.79 Favored Glycine 0 C--N 1.348 1.227 0 C-N-CA 121.37 -0.443 . . . . 0.0 112.894 -179.991 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 8.4 m-20 -140.71 79.99 18.72 Favored Pre-proline 0 CA--C 1.544 0.735 0 C-N-CA 122.447 0.299 . . . . 0.0 110.869 -179.728 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 1.8 Cg_endo -82.23 -32.63 3.41 Favored 'Cis proline' 0 C--N 1.372 1.811 0 C-N-CA 125.15 -0.771 . . . . 0.0 112.945 -0.127 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 27' ' ' TYR . . . . . . . . . . . . . 68.0 m-85 -99.37 171.64 7.84 Favored 'General case' 0 C--O 1.238 0.482 0 CA-C-N 115.786 -0.643 . . . . 0.0 111.652 -179.096 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 28' ' ' GLY . . . . . 0.443 ' O ' ' HA ' ' A' ' 7' ' ' GLN . . . -174.64 -159.79 21.56 Favored Glycine 0 C--N 1.337 0.62 0 CA-C-N 115.801 -0.636 . . . . 0.0 112.268 179.185 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 29' ' ' ILE . . . . . 0.556 ' HB ' ' CE2' ' A' ' 31' ' ' TYR . 1.8 mm -124.12 152.1 29.57 Favored 'Isoleucine or valine' 0 C--O 1.233 0.236 0 N-CA-C 109.755 -0.461 . . . . 0.0 109.755 179.627 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 30' ' ' CYS . . . . . 0.462 ' SG ' ' HB2' ' A' ' 19' ' ' LEU . 0.5 OUTLIER -80.12 104.49 10.71 Favored 'General case' 0 C--O 1.238 0.454 0 CA-C-N 115.974 -0.557 . . . . 0.0 110.99 -179.856 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 31' ' ' TYR . . . . . 0.715 ' HB2' HD12 ' A' ' 22' ' ' ILE . 36.1 m-85 -130.22 166.62 19.92 Favored 'General case' 0 C--O 1.233 0.189 0 CA-C-N 115.431 -0.804 . . . . 0.0 111.141 -179.501 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 2.8 tp -100.93 131.42 48.61 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.547 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.438 179.431 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 33' ' ' ILE . . . . . 0.47 ' H ' HG13 ' A' ' 33' ' ' ILE . 1.9 pp . . . . . 0 C--O 1.249 1.042 0 CA-C-O 118.28 -0.866 . . . . 0.0 111.518 179.903 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 5.9 p . . . . . 0 N--CA 1.487 1.375 0 CA-C-O 119.766 -0.159 . . . . 0.0 111.226 . . . . . . . . . 0 0 . 1 . 003 nuclear build full ' A' A ' 2' ' ' PRO . . . . . 0.424 ' HD2' ' O ' ' A' ' 14' ' ' PRO . 84.1 Cg_endo -82.63 -172.51 1.43 Allowed 'Trans proline' 0 C--N 1.367 1.531 0 C-N-CA 122.593 2.195 . . . . 0.0 112.845 179.554 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -147.12 -161.71 9.54 Favored Glycine 0 C--N 1.338 0.665 0 N-CA-C 111.696 -0.562 . . . . 0.0 111.696 179.194 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 19.4 tt0 -67.8 124.03 22.17 Favored 'General case' 0 N--CA 1.474 0.747 0 C-N-CA 122.488 0.315 . . . . 0.0 111.212 179.68 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 91.07 15.08 56.76 Favored Glycine 0 C--N 1.338 0.681 0 CA-C-N 115.66 -0.7 . . . . 0.0 113.125 -179.718 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 43.1 mt-10 -129.06 165.22 21.62 Favored 'General case' 0 C--O 1.237 0.414 0 C-N-CA 122.29 0.236 . . . . 0.0 110.802 -179.942 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 7' ' ' GLN . . . . . . . . . . . . . 0.2 OUTLIER -81.55 152.98 27.0 Favored 'General case' 0 C--N 1.346 0.454 0 CA-C-N 116.43 -0.35 . . . . 0.0 110.936 179.915 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 3.2 p -142.23 152.07 42.72 Favored 'General case' 0 C--O 1.234 0.249 0 CA-C-N 115.821 -0.627 . . . . 0.0 111.208 -179.255 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -110.04 141.32 43.02 Favored 'General case' 0 C--O 1.232 0.163 0 CA-C-N 115.541 -0.754 . . . . 0.0 109.492 179.38 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 8.8 m -96.59 21.5 1.15 Allowed 'Isoleucine or valine' 0 CA--C 1.543 0.675 0 CA-C-N 116.326 -0.397 . . . . 0.0 111.566 -179.984 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 45.5 mt-10 -113.81 -54.83 2.57 Favored 'General case' 0 C--O 1.236 0.351 0 N-CA-C 112.048 0.388 . . . . 0.0 112.048 -179.042 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 12' ' ' PHE . . . . . . . . . . . . . 10.5 t80 -137.62 -18.56 1.24 Allowed 'General case' 0 N--CA 1.471 0.625 0 N-CA-C 112.516 0.561 . . . . 0.0 112.516 -178.891 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 13' ' ' ASN . . . . . . . . . . . . . 6.7 t-20 -119.2 73.83 14.06 Favored Pre-proline 0 CA--C 1.55 0.954 0 O-C-N 122.918 0.136 . . . . 0.0 111.118 -179.332 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 14' ' ' PRO . . . . . 0.424 ' O ' ' HD2' ' A' ' 2' ' ' PRO . 60.5 Cg_endo -75.69 -178.84 4.6 Favored 'Trans proline' 0 C--N 1.371 1.745 0 C-N-CA 122.443 2.095 . . . . 0.0 112.506 179.481 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 15' ' ' CYS . . . . . 0.531 ' SG ' ' HB2' ' A' ' 19' ' ' LEU . 4.3 t -79.47 120.48 23.93 Favored 'General case' 0 N--CA 1.471 0.623 0 O-C-N 123.079 0.237 . . . . 0.0 111.095 179.981 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER -60.27 -54.49 54.63 Favored Pre-proline 0 N--CA 1.476 0.847 0 CA-C-O 119.062 -0.494 . . . . 0.0 111.577 179.45 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 56.7 Cg_endo -71.22 168.81 22.28 Favored 'Trans proline' 0 C--N 1.381 2.241 0 C-N-CA 122.096 1.864 . . . . 0.0 111.614 178.123 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 48.4 Cg_endo -70.48 61.29 2.12 Favored 'Trans proline' 0 C--N 1.37 1.677 0 C-N-CA 121.918 1.745 . . . . 0.0 112.78 179.048 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 19' ' ' LEU . . . . . 0.531 ' HB2' ' SG ' ' A' ' 15' ' ' CYS . 90.7 mt -122.2 166.62 14.31 Favored 'General case' 0 C--O 1.235 0.331 0 CA-C-N 115.713 -0.676 . . . . 0.0 111.189 -179.869 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 20' ' ' THR . . . . . 0.471 ' OG1' HG12 ' A' ' 33' ' ' ILE . 89.5 m -106.32 149.65 26.73 Favored 'General case' 0 CA--C 1.533 0.302 0 CA-C-N 115.305 -0.861 . . . . 0.0 110.947 -179.3 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 21' ' ' CYS . . . . . 0.503 ' HA ' ' O ' ' A' ' 29' ' ' ILE . 1.9 t -95.25 106.94 19.02 Favored 'General case' 0 C--O 1.24 0.555 0 CA-C-N 115.726 -0.67 . . . . 0.0 110.244 178.917 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 22' ' ' ILE . . . . . 0.72 HD12 ' HB2' ' A' ' 31' ' ' TYR . 5.9 mt -125.47 128.5 24.67 Favored Pre-proline 0 CA--C 1.544 0.717 0 CA-C-N 115.928 -0.578 . . . . 0.0 110.531 -179.185 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 37.4 Cg_endo -67.19 -48.0 0.25 Allowed 'Cis proline' 0 C--N 1.375 1.963 0 C-N-CA 124.685 -0.964 . . . . 0.0 113.757 -0.35 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 83.07 35.75 17.29 Favored Glycine 0 C--N 1.345 1.07 0 C-N-CA 121.433 -0.413 . . . . 0.0 112.918 179.781 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 7.6 m-20 -143.91 83.6 10.27 Favored Pre-proline 0 CA--C 1.546 0.819 0 C-N-CA 122.478 0.311 . . . . 0.0 111.04 -179.661 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 69.7 Cg_endo -82.15 -31.73 4.01 Favored 'Cis proline' 0 C--N 1.372 1.813 0 C-N-CA 124.814 -0.911 . . . . 0.0 113.479 -0.218 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 27' ' ' TYR . . . . . . . . . . . . . 59.8 m-85 -96.92 163.32 13.01 Favored 'General case' 0 N--CA 1.47 0.548 0 CA-C-N 115.956 -0.565 . . . . 0.0 111.208 -179.16 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 28' ' ' GLY . . . . . 0.443 ' O ' HD13 ' A' ' 29' ' ' ILE . . . -157.89 -162.01 11.39 Favored Glycine 0 C--N 1.339 0.746 0 C-N-CA 120.92 -0.657 . . . . 0.0 113.098 179.815 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 29' ' ' ILE . . . . . 0.503 ' O ' ' HA ' ' A' ' 21' ' ' CYS . 5.0 mm -130.53 154.81 41.14 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.222 0 N-CA-C 109.709 -0.478 . . . . 0.0 109.709 179.948 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 30' ' ' CYS . . . . . . . . . . . . . 26.2 m -83.72 92.81 7.8 Favored 'General case' 0 C--O 1.238 0.489 0 CA-C-O 121.483 0.659 . . . . 0.0 111.403 -179.968 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 31' ' ' TYR . . . . . 0.72 ' HB2' HD12 ' A' ' 22' ' ' ILE . 37.1 m-85 -124.26 167.26 14.56 Favored 'General case' 0 N--CA 1.464 0.241 0 CA-C-N 114.962 -1.017 . . . . 0.0 110.902 179.945 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 2.8 tp -99.98 131.66 46.99 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.605 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.449 179.378 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 33' ' ' ILE . . . . . 0.471 HG12 ' OG1' ' A' ' 20' ' ' THR . 1.3 pt . . . . . 0 C--O 1.249 1.048 0 CA-C-O 118.142 -0.932 . . . . 0.0 111.416 179.832 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 5.8 p . . . . . 0 N--CA 1.486 1.347 0 CA-C-O 119.823 -0.132 . . . . 0.0 111.199 . . . . . . . . . 0 0 . 1 . 004 nuclear build full ' A' A ' 2' ' ' PRO . . . . . 0.402 ' HD3' ' OD1' ' A' ' 13' ' ' ASN . 85.2 Cg_endo -82.82 -172.57 1.44 Allowed 'Trans proline' 0 C--N 1.366 1.497 0 C-N-CA 122.598 2.199 . . . . 0.0 112.832 179.514 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -146.59 -160.92 9.01 Favored Glycine 0 C--N 1.337 0.603 0 N-CA-C 111.661 -0.576 . . . . 0.0 111.661 179.141 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 19.6 tt0 -68.21 124.5 23.65 Favored 'General case' 0 N--CA 1.475 0.824 0 CA-C-N 116.816 0.308 . . . . 0.0 111.145 179.673 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 90.73 15.07 57.27 Favored Glycine 0 C--N 1.338 0.667 0 CA-C-N 115.663 -0.699 . . . . 0.0 113.143 -179.692 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 43.1 mt-10 -129.02 165.11 21.8 Favored 'General case' 0 C--O 1.239 0.53 0 C-N-CA 122.339 0.256 . . . . 0.0 110.807 -179.891 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 7' ' ' GLN . . . . . . . . . . . . . 0.2 OUTLIER -81.65 152.9 26.91 Favored 'General case' 0 C--N 1.346 0.433 0 O-C-N 123.179 0.3 . . . . 0.0 110.895 179.874 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 3.2 p -141.68 151.79 43.33 Favored 'General case' 0 C--O 1.234 0.242 0 CA-C-N 115.8 -0.636 . . . . 0.0 111.099 -179.272 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -110.34 143.56 40.38 Favored 'General case' 0 C--O 1.234 0.26 0 CA-C-N 115.481 -0.782 . . . . 0.0 109.532 179.423 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 10' ' ' VAL . . . . . 0.428 HG22 ' O ' ' A' ' 26' ' ' PRO . 6.1 m -98.28 21.06 1.52 Allowed 'Isoleucine or valine' 0 CA--C 1.541 0.606 0 O-C-N 123.238 0.336 . . . . 0.0 111.514 -179.899 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 8.5 mm-40 -115.53 -52.48 2.64 Favored 'General case' 0 C--O 1.235 0.304 0 N-CA-C 112.252 0.464 . . . . 0.0 112.252 -179.125 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 12' ' ' PHE . . . . . . . . . . . . . 13.0 t80 -141.04 -9.21 1.01 Allowed 'General case' 0 N--CA 1.473 0.709 0 N-CA-C 112.722 0.638 . . . . 0.0 112.722 -178.666 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 13' ' ' ASN . . . . . 0.402 ' OD1' ' HD3' ' A' ' 2' ' ' PRO . 6.2 t-20 -129.64 64.94 73.55 Favored Pre-proline 0 CA--C 1.551 0.986 0 CA-C-N 117.496 0.135 . . . . 0.0 111.25 -179.075 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 14' ' ' PRO . . . . . 0.401 ' O ' ' HD2' ' A' ' 2' ' ' PRO . 15.8 Cg_exo -69.04 -178.66 2.16 Favored 'Trans proline' 0 C--N 1.372 1.808 0 C-N-CA 122.957 2.438 . . . . 0.0 112.266 179.009 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 15' ' ' CYS . . . . . 0.53 ' SG ' ' HB2' ' A' ' 19' ' ' LEU . 4.0 t -79.65 121.79 25.73 Favored 'General case' 0 N--CA 1.472 0.64 0 O-C-N 123.135 0.272 . . . . 0.0 111.331 -179.781 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER -61.35 -54.32 54.04 Favored Pre-proline 0 CA--C 1.547 0.845 0 CA-C-O 119.024 -0.512 . . . . 0.0 111.43 179.22 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 56.7 Cg_endo -71.19 169.21 21.22 Favored 'Trans proline' 0 C--N 1.38 2.225 0 C-N-CA 121.96 1.773 . . . . 0.0 111.719 178.193 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 49.0 Cg_endo -70.56 59.12 2.0 Favored 'Trans proline' 0 C--N 1.372 1.795 0 C-N-CA 121.918 1.746 . . . . 0.0 112.896 179.071 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 19' ' ' LEU . . . . . 0.53 ' HB2' ' SG ' ' A' ' 15' ' ' CYS . 92.2 mt -119.99 165.2 14.98 Favored 'General case' 0 C--O 1.235 0.31 0 CA-C-N 115.751 -0.659 . . . . 0.0 111.176 -179.95 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 87.5 m -104.08 150.58 24.17 Favored 'General case' 0 CA--C 1.532 0.285 0 CA-C-N 115.327 -0.851 . . . . 0.0 110.978 -179.464 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 21' ' ' CYS . . . . . 0.499 ' HA ' ' O ' ' A' ' 29' ' ' ILE . 1.9 t -96.57 104.55 16.54 Favored 'General case' 0 C--O 1.238 0.464 0 CA-C-N 115.669 -0.696 . . . . 0.0 109.98 178.94 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 22' ' ' ILE . . . . . 0.72 HD12 ' HB2' ' A' ' 31' ' ' TYR . 6.1 mt -122.83 128.01 25.53 Favored Pre-proline 0 CA--C 1.543 0.705 0 CA-C-N 115.865 -0.607 . . . . 0.0 110.546 -179.178 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 36.8 Cg_endo -66.96 -47.57 0.26 Allowed 'Cis proline' 0 C--N 1.376 1.977 0 C-N-CA 124.632 -0.987 . . . . 0.0 113.801 -0.302 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 83.73 32.85 23.29 Favored Glycine 0 C--N 1.345 1.081 0 C-N-CA 121.305 -0.474 . . . . 0.0 113.021 179.719 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 7.7 m-20 -144.18 86.57 8.27 Favored Pre-proline 0 CA--C 1.545 0.772 0 C-N-CA 122.56 0.344 . . . . 0.0 110.532 -179.654 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 26' ' ' PRO . . . . . 0.428 ' O ' HG22 ' A' ' 10' ' ' VAL . 1.1 Cg_endo -81.47 -31.34 4.49 Favored 'Cis proline' 0 C--N 1.371 1.733 0 C-N-CA 125.164 -0.765 . . . . 0.0 112.888 0.018 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 27' ' ' TYR . . . . . . . . . . . . . 41.3 m-85 -101.76 166.56 10.61 Favored 'General case' 0 C--O 1.237 0.398 0 CA-C-N 115.712 -0.676 . . . . 0.0 111.104 -179.137 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 28' ' ' GLY . . . . . 0.428 ' O ' HD13 ' A' ' 29' ' ' ILE . . . -160.63 -160.82 10.93 Favored Glycine 0 C--N 1.341 0.807 0 C-N-CA 120.911 -0.661 . . . . 0.0 113.21 179.999 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 29' ' ' ILE . . . . . 0.499 ' O ' ' HA ' ' A' ' 21' ' ' CYS . 4.8 mm -129.76 155.29 41.3 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.255 0 CA-C-N 115.273 -0.464 . . . . 0.0 109.887 -179.995 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 30' ' ' CYS . . . . . . . . . . . . . 30.1 m -84.04 93.78 8.17 Favored 'General case' 0 C--O 1.237 0.433 0 CA-C-O 121.39 0.614 . . . . 0.0 111.302 179.926 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 31' ' ' TYR . . . . . 0.72 ' HB2' HD12 ' A' ' 22' ' ' ILE . 35.4 m-85 -124.37 168.4 13.07 Favored 'General case' 0 N--CA 1.464 0.255 0 CA-C-N 115.012 -0.994 . . . . 0.0 111.14 -179.863 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 2.6 tp -100.68 133.48 43.7 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.598 0 CA-C-N 116.082 -0.508 . . . . 0.0 110.343 179.391 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 33' ' ' ILE . . . . . 0.436 ' OXT' HD12 ' A' ' 33' ' ' ILE . 1.6 pp . . . . . 0 C--O 1.249 1.031 0 CA-C-O 118.081 -0.961 . . . . 0.0 111.519 179.888 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 3.9 p . . . . . 0 N--CA 1.486 1.327 0 CA-C-O 119.818 -0.134 . . . . 0.0 111.329 . . . . . . . . . 0 0 . 1 . 005 nuclear build full ' A' A ' 2' ' ' PRO . . . . . . . . . . . . . 94.5 Cg_endo -83.96 -171.88 1.16 Allowed 'Trans proline' 0 C--N 1.368 1.588 0 C-N-CA 122.541 2.161 . . . . 0.0 112.937 179.71 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -143.95 -153.53 5.9 Favored Glycine 0 C--N 1.339 0.724 0 N-CA-C 111.669 -0.573 . . . . 0.0 111.669 179.381 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 17.7 tt0 -73.92 130.26 39.52 Favored 'General case' 0 N--CA 1.472 0.668 0 C-N-CA 122.546 0.338 . . . . 0.0 111.265 179.578 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 85.81 15.35 65.64 Favored Glycine 0 C--N 1.339 0.709 0 CA-C-N 115.921 -0.582 . . . . 0.0 113.452 -179.756 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 43.1 mt-10 -126.02 161.13 28.26 Favored 'General case' 0 C--O 1.237 0.406 0 C-N-CA 122.243 0.217 . . . . 0.0 110.849 -179.829 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 7' ' ' GLN . . . . . 0.69 ' HA ' ' O ' ' A' ' 28' ' ' GLY . 18.9 tt0 -87.01 134.81 33.45 Favored 'General case' 0 C--N 1.346 0.422 0 CA-C-O 121.176 0.512 . . . . 0.0 111.311 179.89 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 8' ' ' CYS . . . . . 0.401 ' SG ' ' SG ' ' A' ' 30' ' ' CYS . 2.5 p -129.3 161.41 30.29 Favored 'General case' 0 C--O 1.239 0.522 0 CA-C-N 114.538 -1.21 . . . . 0.0 110.989 -179.528 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 9' ' ' ASP . . . . . 0.591 ' OD1' ' HB3' ' A' ' 13' ' ' ASN . 0.7 OUTLIER -120.69 142.68 49.26 Favored 'General case' 0 N--CA 1.463 0.222 0 CA-C-N 115.725 -0.67 . . . . 0.0 110.042 178.528 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 23.2 m -90.78 13.85 1.59 Allowed 'Isoleucine or valine' 0 CA--C 1.543 0.697 0 CA-C-N 115.994 -0.548 . . . . 0.0 111.593 -179.398 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 45.9 mt-10 -97.05 -51.96 4.03 Favored 'General case' 0 C--O 1.235 0.304 0 CA-C-N 116.029 -0.532 . . . . 0.0 111.938 -178.804 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 12' ' ' PHE . . . . . . . . . . . . . 7.2 t80 -144.97 -21.56 0.5 Allowed 'General case' 0 N--CA 1.473 0.691 0 N-CA-C 112.657 0.614 . . . . 0.0 112.657 -178.771 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 13' ' ' ASN . . . . . 0.591 ' HB3' ' OD1' ' A' ' 9' ' ' ASP . 13.2 t-20 -120.03 75.13 21.32 Favored Pre-proline 0 CA--C 1.548 0.88 0 CA-C-N 117.521 0.146 . . . . 0.0 111.324 -178.889 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 61.4 Cg_endo -76.84 -175.89 2.87 Favored 'Trans proline' 0 C--N 1.372 1.774 0 C-N-CA 122.57 2.18 . . . . 0.0 112.16 178.731 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 0.8 OUTLIER -79.99 121.61 25.7 Favored 'General case' 0 N--CA 1.472 0.633 0 O-C-N 123.02 0.2 . . . . 0.0 111.189 179.879 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER -58.16 -53.56 64.69 Favored Pre-proline 0 N--CA 1.478 0.965 0 CA-C-N 116.137 -0.483 . . . . 0.0 111.593 179.106 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 17' ' ' PRO . . . . . 0.501 ' HG2' HD12 ' A' ' 19' ' ' LEU . 41.5 Cg_endo -67.72 169.65 15.59 Favored 'Trans proline' 0 C--N 1.379 2.172 0 C-N-CA 122.148 1.899 . . . . 0.0 111.852 178.165 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 55.2 Cg_endo -71.84 47.8 1.01 Allowed 'Trans proline' 0 C--N 1.371 1.753 0 C-N-CA 122.007 1.805 . . . . 0.0 112.755 178.658 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 19' ' ' LEU . . . . . 0.501 HD12 ' HG2' ' A' ' 17' ' ' PRO . 19.5 mt -108.8 165.4 11.59 Favored 'General case' 0 C--O 1.236 0.375 0 CA-C-N 115.7 -0.682 . . . . 0.0 111.285 -179.451 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 20' ' ' THR . . . . . 0.529 ' O ' ' HA ' ' A' ' 30' ' ' CYS . 30.7 m -103.24 152.53 21.39 Favored 'General case' 0 CA--C 1.531 0.227 0 CA-C-N 115.569 -0.742 . . . . 0.0 111.038 -178.833 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 2.2 t -102.64 99.75 9.76 Favored 'General case' 0 C--O 1.237 0.435 0 CA-C-N 115.753 -0.658 . . . . 0.0 109.594 178.902 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 22' ' ' ILE . . . . . 0.705 HD12 ' HB2' ' A' ' 31' ' ' TYR . 2.9 mt -120.88 128.78 25.6 Favored Pre-proline 0 CA--C 1.542 0.652 0 CA-C-N 115.637 -0.71 . . . . 0.0 110.372 -178.973 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 37.0 Cg_endo -66.81 -47.5 0.26 Allowed 'Cis proline' 0 C--N 1.375 1.936 0 C-N-CA 124.77 -0.929 . . . . 0.0 113.867 -0.232 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 79.11 34.03 34.48 Favored Glycine 0 C--N 1.347 1.173 0 C-N-CA 121.277 -0.487 . . . . 0.0 112.894 179.969 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 8.3 m-20 -139.73 83.26 16.85 Favored Pre-proline 0 CA--C 1.543 0.686 0 C-N-CA 122.561 0.344 . . . . 0.0 110.538 -179.712 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 3.1 Cg_exo -80.61 -32.05 4.18 Favored 'Cis proline' 0 C--N 1.371 1.746 0 C-N-CA 125.095 -0.794 . . . . 0.0 112.948 -0.099 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 27' ' ' TYR . . . . . 0.561 ' CD2' ' HB3' ' A' ' 9' ' ' ASP . 62.6 m-85 -106.85 172.67 6.69 Favored 'General case' 0 C--O 1.239 0.552 0 CA-C-N 115.753 -0.658 . . . . 0.0 111.751 -178.95 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 28' ' ' GLY . . . . . 0.69 ' O ' ' HA ' ' A' ' 7' ' ' GLN . . . -176.53 -164.08 29.95 Favored Glycine 0 C--N 1.338 0.693 0 CA-C-N 115.732 -0.667 . . . . 0.0 112.655 178.452 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 29' ' ' ILE . . . . . 0.544 ' HB ' ' CE2' ' A' ' 31' ' ' TYR . 2.6 mm -114.72 151.3 16.49 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 N-CA-C 110.082 -0.34 . . . . 0.0 110.082 -179.718 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 30' ' ' CYS . . . . . 0.529 ' HA ' ' O ' ' A' ' 20' ' ' THR . 40.7 m -79.87 105.74 11.38 Favored 'General case' 0 C--O 1.237 0.395 0 CA-C-N 115.843 -0.617 . . . . 0.0 111.482 -179.801 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 31' ' ' TYR . . . . . 0.705 ' HB2' HD12 ' A' ' 22' ' ' ILE . 36.6 m-85 -130.42 167.1 19.14 Favored 'General case' 0 C--O 1.233 0.205 0 CA-C-N 114.938 -1.028 . . . . 0.0 111.011 -179.406 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 2.9 tp -99.64 130.28 48.94 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.607 0 CA-C-N 116.27 -0.423 . . . . 0.0 110.348 179.436 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 33' ' ' ILE . . . . . 0.499 HG23 HD11 ' A' ' 22' ' ' ILE . 1.9 pp . . . . . 0 C--O 1.248 0.993 0 CA-C-O 118.335 -0.84 . . . . 0.0 111.528 179.879 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 3.9 p . . . . . 0 N--CA 1.486 1.329 0 CA-C-O 119.766 -0.159 . . . . 0.0 111.325 . . . . . . . . . 0 0 . 1 . 006 nuclear build full ' A' A ' 2' ' ' PRO . . . . . . . . . . . . . 92.2 Cg_endo -83.96 -171.93 1.17 Allowed 'Trans proline' 0 C--N 1.368 1.588 0 C-N-CA 122.527 2.151 . . . . 0.0 112.953 179.641 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -143.83 -153.45 5.88 Favored Glycine 0 C--N 1.339 0.701 0 N-CA-C 111.821 -0.512 . . . . 0.0 111.821 179.383 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 17.7 tt0 -74.04 130.17 39.3 Favored 'General case' 0 N--CA 1.473 0.702 0 C-N-CA 122.702 0.401 . . . . 0.0 111.134 179.586 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 85.76 15.54 65.38 Favored Glycine 0 C--N 1.339 0.705 0 O-C-N 123.712 0.632 . . . . 0.0 113.386 -179.85 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 43.0 mt-10 -126.11 161.25 28.06 Favored 'General case' 0 C--O 1.238 0.474 0 C-N-CA 122.276 0.23 . . . . 0.0 110.85 -179.915 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 7' ' ' GLN . . . . . 0.691 ' HA ' ' O ' ' A' ' 28' ' ' GLY . 18.6 tt0 -87.1 134.81 33.47 Favored 'General case' 0 C--N 1.344 0.363 0 CA-C-O 121.258 0.552 . . . . 0.0 111.241 179.915 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 8' ' ' CYS . . . . . 0.401 ' SG ' ' SG ' ' A' ' 30' ' ' CYS . 2.5 p -129.3 161.42 30.27 Favored 'General case' 0 C--O 1.238 0.488 0 CA-C-N 114.511 -1.222 . . . . 0.0 111.017 -179.589 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 9' ' ' ASP . . . . . 0.591 ' OD1' ' HB3' ' A' ' 13' ' ' ASN . 0.7 OUTLIER -120.7 142.86 49.11 Favored 'General case' 0 N--CA 1.464 0.269 0 CA-C-N 115.693 -0.685 . . . . 0.0 109.992 178.557 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 22.5 m -90.89 13.76 1.63 Allowed 'Isoleucine or valine' 0 CA--C 1.543 0.677 0 CA-C-N 115.924 -0.58 . . . . 0.0 111.501 -179.337 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 46.0 mt-10 -96.94 -51.91 4.07 Favored 'General case' 0 C--O 1.235 0.327 0 CA-C-N 116.158 -0.474 . . . . 0.0 111.986 -178.802 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 12' ' ' PHE . . . . . . . . . . . . . 6.8 t80 -145.16 -21.49 0.49 Allowed 'General case' 0 N--CA 1.472 0.639 0 N-CA-C 112.671 0.619 . . . . 0.0 112.671 -178.845 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 13' ' ' ASN . . . . . 0.591 ' HB3' ' OD1' ' A' ' 9' ' ' ASP . 13.3 t-20 -119.91 75.19 20.52 Favored Pre-proline 0 CA--C 1.548 0.887 0 CA-C-N 117.557 0.162 . . . . 0.0 111.336 -179.017 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 62.7 Cg_endo -76.85 -175.87 2.86 Favored 'Trans proline' 0 C--N 1.37 1.679 0 C-N-CA 122.663 2.242 . . . . 0.0 112.204 178.672 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 0.8 OUTLIER -79.99 121.56 25.64 Favored 'General case' 0 N--CA 1.471 0.603 0 CA-C-O 120.462 0.172 . . . . 0.0 111.168 179.9 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER -58.17 -53.52 65.15 Favored Pre-proline 0 N--CA 1.479 0.978 0 CA-C-O 119.049 -0.501 . . . . 0.0 111.568 179.117 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 17' ' ' PRO . . . . . 0.501 ' HG2' HD12 ' A' ' 19' ' ' LEU . 41.7 Cg_endo -67.75 169.69 15.56 Favored 'Trans proline' 0 C--N 1.38 2.22 0 C-N-CA 122.104 1.869 . . . . 0.0 111.865 178.202 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 55.3 Cg_endo -71.77 47.69 0.98 Allowed 'Trans proline' 0 C--N 1.373 1.818 0 C-N-CA 121.981 1.787 . . . . 0.0 112.735 178.731 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 19' ' ' LEU . . . . . 0.501 HD12 ' HG2' ' A' ' 17' ' ' PRO . 19.4 mt -108.78 165.38 11.6 Favored 'General case' 0 C--O 1.235 0.332 0 CA-C-N 115.681 -0.691 . . . . 0.0 111.272 -179.359 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 20' ' ' THR . . . . . 0.528 ' O ' ' HA ' ' A' ' 30' ' ' CYS . 30.5 m -103.19 152.37 21.54 Favored 'General case' 0 CA--C 1.531 0.227 0 CA-C-N 115.623 -0.717 . . . . 0.0 111.084 -178.902 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 2.2 t -102.45 99.75 9.82 Favored 'General case' 0 C--O 1.237 0.445 0 CA-C-N 115.719 -0.673 . . . . 0.0 109.6 178.837 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 22' ' ' ILE . . . . . 0.705 HD12 ' HB2' ' A' ' 31' ' ' TYR . 2.9 mt -120.91 128.73 25.63 Favored Pre-proline 0 CA--C 1.541 0.615 0 CA-C-N 115.677 -0.692 . . . . 0.0 110.4 -179.026 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 37.1 Cg_endo -66.92 -47.36 0.26 Allowed 'Cis proline' 0 C--N 1.374 1.919 0 C-N-CA 124.636 -0.985 . . . . 0.0 113.859 -0.112 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 79.03 33.99 34.89 Favored Glycine 0 C--N 1.348 1.196 0 C-N-CA 121.228 -0.51 . . . . 0.0 112.916 179.961 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 8.3 m-20 -139.68 83.24 16.99 Favored Pre-proline 0 CA--C 1.544 0.721 0 C-N-CA 122.576 0.35 . . . . 0.0 110.647 -179.793 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 3.2 Cg_exo -80.7 -31.92 4.26 Favored 'Cis proline' 0 C--N 1.371 1.729 0 C-N-CA 125.102 -0.791 . . . . 0.0 112.957 -0.005 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 27' ' ' TYR . . . . . 0.562 ' CD2' ' HB3' ' A' ' 9' ' ' ASP . 62.6 m-85 -106.96 172.66 6.7 Favored 'General case' 0 C--O 1.238 0.49 0 CA-C-N 115.737 -0.665 . . . . 0.0 111.705 -178.957 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 28' ' ' GLY . . . . . 0.691 ' O ' ' HA ' ' A' ' 7' ' ' GLN . . . -176.45 -164.17 30.06 Favored Glycine 0 C--N 1.34 0.771 0 CA-C-N 115.74 -0.664 . . . . 0.0 112.559 178.474 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 29' ' ' ILE . . . . . 0.543 ' HB ' ' CE2' ' A' ' 31' ' ' TYR . 2.6 mm -114.68 151.35 16.44 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 O-C-N 123.75 0.324 . . . . 0.0 110.155 -179.733 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 30' ' ' CYS . . . . . 0.528 ' HA ' ' O ' ' A' ' 20' ' ' THR . 41.4 m -79.82 105.72 11.31 Favored 'General case' 0 C--O 1.237 0.425 0 CA-C-N 115.981 -0.554 . . . . 0.0 111.399 -179.729 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 31' ' ' TYR . . . . . 0.705 ' HB2' HD12 ' A' ' 22' ' ' ILE . 37.1 m-85 -130.48 167.18 19.04 Favored 'General case' 0 C--O 1.233 0.205 0 CA-C-N 114.989 -1.005 . . . . 0.0 111.018 -179.566 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 2.9 tp -99.63 130.2 49.04 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.584 0 CA-C-N 116.121 -0.491 . . . . 0.0 110.343 179.562 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 33' ' ' ILE . . . . . 0.502 HG23 HD11 ' A' ' 22' ' ' ILE . 1.9 pp . . . . . 0 C--O 1.249 1.051 0 CA-C-O 118.331 -0.843 . . . . 0.0 111.521 179.858 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 4.3 p . . . . . 0 N--CA 1.486 1.373 0 CA-C-O 119.801 -0.142 . . . . 0.0 111.233 . . . . . . . . . 0 0 . 1 . 007 nuclear build full ' A' A ' 2' ' ' PRO . . . . . . . . . . . . . 97.6 Cg_endo -82.43 -172.27 1.38 Allowed 'Trans proline' 0 C--N 1.367 1.53 0 C-N-CA 122.577 2.185 . . . . 0.0 112.965 179.596 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -145.12 -154.99 6.29 Favored Glycine 0 C--N 1.339 0.727 0 N-CA-C 111.78 -0.528 . . . . 0.0 111.78 179.393 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 17.9 tt0 -73.3 128.85 36.66 Favored 'General case' 0 N--CA 1.472 0.674 0 C-N-CA 122.565 0.346 . . . . 0.0 111.186 179.581 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 86.31 16.06 63.2 Favored Glycine 0 C--N 1.34 0.789 0 CA-C-N 115.784 -0.643 . . . . 0.0 113.184 -179.862 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 43.0 mt-10 -127.42 161.69 28.1 Favored 'General case' 0 N--CA 1.466 0.367 0 C-N-CA 122.312 0.245 . . . . 0.0 110.804 -179.859 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 7' ' ' GLN . . . . . 0.715 ' HA ' ' O ' ' A' ' 28' ' ' GLY . 19.3 tt0 -85.36 134.53 34.09 Favored 'General case' 0 C--N 1.346 0.415 0 CA-C-O 121.166 0.507 . . . . 0.0 111.256 179.978 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 8' ' ' CYS . . . . . 0.404 ' SG ' ' SG ' ' A' ' 30' ' ' CYS . 3.1 p -127.72 160.24 32.28 Favored 'General case' 0 C--O 1.237 0.447 0 CA-C-N 114.593 -1.185 . . . . 0.0 111.036 -179.553 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 9' ' ' ASP . . . . . 0.437 ' OD2' ' HB2' ' A' ' 11' ' ' GLU . 15.8 t70 -115.42 147.64 40.33 Favored 'General case' 0 C--O 1.234 0.26 0 CA-C-N 115.475 -0.784 . . . . 0.0 109.53 178.762 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 15.5 m -97.45 22.23 1.16 Allowed 'Isoleucine or valine' 0 CA--C 1.543 0.689 0 CA-C-N 116.312 -0.404 . . . . 0.0 111.963 -179.451 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 11' ' ' GLU . . . . . 0.437 ' HB2' ' OD2' ' A' ' 9' ' ' ASP . 44.1 mt-10 -119.68 -52.68 2.23 Favored 'General case' 0 N--CA 1.466 0.371 0 N-CA-C 112.372 0.508 . . . . 0.0 112.372 -179.068 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 12' ' ' PHE . . . . . . . . . . . . . 13.6 t80 -137.83 -8.98 1.6 Allowed 'General case' 0 N--CA 1.47 0.559 0 N-CA-C 112.649 0.611 . . . . 0.0 112.649 -178.659 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 13' ' ' ASN . . . . . . . . . . . . . 6.4 t-20 -129.65 63.81 69.45 Favored Pre-proline 0 CA--C 1.548 0.904 0 N-CA-C 111.579 0.214 . . . . 0.0 111.579 -179.195 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 13.6 Cg_exo -70.23 176.78 6.67 Favored 'Trans proline' 0 C--N 1.372 1.767 0 C-N-CA 122.801 2.334 . . . . 0.0 112.06 178.914 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 1.0 OUTLIER -79.84 121.04 24.91 Favored 'General case' 0 N--CA 1.469 0.499 0 CA-C-O 120.453 0.168 . . . . 0.0 111.155 179.983 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER -57.75 -53.01 70.18 Favored Pre-proline 0 N--CA 1.477 0.924 0 CA-C-O 118.985 -0.531 . . . . 0.0 111.535 179.316 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 17' ' ' PRO . . . . . 0.506 ' HG2' HD12 ' A' ' 19' ' ' LEU . 44.8 Cg_endo -68.67 169.53 17.25 Favored 'Trans proline' 0 C--N 1.379 2.133 0 C-N-CA 122.102 1.868 . . . . 0.0 111.747 178.008 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 55.7 Cg_endo -72.27 48.81 1.27 Allowed 'Trans proline' 0 C--N 1.372 1.785 0 C-N-CA 122.011 1.808 . . . . 0.0 112.701 178.759 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 19' ' ' LEU . . . . . 0.506 HD12 ' HG2' ' A' ' 17' ' ' PRO . 20.5 mt -109.61 167.6 10.02 Favored 'General case' 0 C--O 1.236 0.356 0 CA-C-N 115.692 -0.685 . . . . 0.0 111.316 -179.309 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 20' ' ' THR . . . . . 0.529 ' O ' ' HA ' ' A' ' 30' ' ' CYS . 32.6 m -105.03 153.37 21.55 Favored 'General case' 0 CA--C 1.532 0.279 0 CA-C-N 115.622 -0.717 . . . . 0.0 111.059 -178.794 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 1.9 t -102.71 103.27 13.5 Favored 'General case' 0 C--O 1.238 0.487 0 CA-C-N 115.672 -0.694 . . . . 0.0 109.672 178.861 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 22' ' ' ILE . . . . . 0.709 HD12 ' HB2' ' A' ' 31' ' ' TYR . 2.8 mt -125.33 129.1 24.57 Favored Pre-proline 0 CA--C 1.542 0.646 0 CA-C-N 115.774 -0.648 . . . . 0.0 110.24 -179.094 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 38.1 Cg_endo -67.43 -48.47 0.24 Allowed 'Cis proline' 0 C--N 1.374 1.897 0 C-N-CA 124.74 -0.942 . . . . 0.0 113.895 -0.113 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 81.26 36.86 19.79 Favored Glycine 0 C--N 1.347 1.141 0 C-N-CA 121.192 -0.528 . . . . 0.0 112.959 -179.927 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 4.6 t70 -139.78 82.23 18.22 Favored Pre-proline 0 CA--C 1.548 0.884 0 C-N-CA 122.454 0.301 . . . . 0.0 110.376 -179.818 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 2.6 Cg_endo -81.06 -31.72 4.33 Favored 'Cis proline' 0 C--N 1.371 1.761 0 C-N-CA 125.113 -0.786 . . . . 0.0 112.951 0.104 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 27' ' ' TYR . . . . . . . . . . . . . 60.3 m-85 -106.55 174.12 6.02 Favored 'General case' 0 C--O 1.238 0.475 0 CA-C-N 115.748 -0.66 . . . . 0.0 111.558 -179.037 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 28' ' ' GLY . . . . . 0.715 ' O ' ' HA ' ' A' ' 7' ' ' GLN . . . -175.22 -162.08 25.91 Favored Glycine 0 CA--C 1.502 -0.737 0 CA-C-N 115.627 -0.715 . . . . 0.0 112.561 178.397 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 29' ' ' ILE . . . . . 0.537 ' HB ' ' CE2' ' A' ' 31' ' ' TYR . 2.7 mm -115.35 150.36 17.32 Favored 'Isoleucine or valine' 0 C--O 1.234 0.257 0 N-CA-C 110.059 -0.349 . . . . 0.0 110.059 -179.86 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 30' ' ' CYS . . . . . 0.529 ' HA ' ' O ' ' A' ' 20' ' ' THR . 32.2 m -79.9 105.18 10.99 Favored 'General case' 0 C--O 1.236 0.372 0 CA-C-O 121.372 0.606 . . . . 0.0 111.408 -179.745 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 31' ' ' TYR . . . . . 0.709 ' HB2' HD12 ' A' ' 22' ' ' ILE . 37.1 m-85 -129.57 167.93 17.18 Favored 'General case' 0 C--O 1.234 0.28 0 CA-C-N 114.922 -1.036 . . . . 0.0 111.085 -179.466 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 2.7 tp -100.25 130.71 49.04 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.617 0 CA-C-N 116.275 -0.421 . . . . 0.0 110.317 179.402 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 33' ' ' ILE . . . . . 0.5 HG23 HD11 ' A' ' 22' ' ' ILE . 1.9 pp . . . . . 0 C--O 1.249 1.031 0 CA-C-O 118.206 -0.902 . . . . 0.0 111.454 179.911 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 4.4 p . . . . . 0 N--CA 1.486 1.36 0 CA-C-O 119.752 -0.166 . . . . 0.0 111.294 . . . . . . . . . 0 0 . 1 . 008 nuclear build full ' A' A ' 2' ' ' PRO . . . . . . . . . . . . . 98.3 Cg_endo -82.49 -172.16 1.35 Allowed 'Trans proline' 0 C--N 1.366 1.478 0 C-N-CA 122.594 2.196 . . . . 0.0 112.939 179.646 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -145.7 -155.47 6.5 Favored Glycine 0 C--N 1.338 0.676 0 N-CA-C 111.901 -0.48 . . . . 0.0 111.901 179.386 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 18.0 tt0 -73.35 129.52 38.19 Favored 'General case' 0 N--CA 1.474 0.738 0 C-N-CA 122.536 0.334 . . . . 0.0 111.198 179.658 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 85.6 16.28 64.25 Favored Glycine 0 C--N 1.339 0.748 0 CA-C-N 115.741 -0.663 . . . . 0.0 113.196 -179.849 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 43.1 mt-10 -127.61 161.49 28.73 Favored 'General case' 0 C--O 1.237 0.447 0 C-N-CA 122.188 0.195 . . . . 0.0 110.824 -179.862 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 7' ' ' GLN . . . . . 0.723 ' HA ' ' O ' ' A' ' 28' ' ' GLY . 18.7 tt0 -84.94 134.24 34.26 Favored 'General case' 0 C--N 1.345 0.381 0 CA-C-O 121.228 0.537 . . . . 0.0 111.293 179.804 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 8' ' ' CYS . . . . . 0.411 ' SG ' ' SG ' ' A' ' 30' ' ' CYS . 3.7 p -127.99 160.62 31.34 Favored 'General case' 0 C--O 1.237 0.447 0 CA-C-N 114.584 -1.189 . . . . 0.0 111.116 -179.383 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 9' ' ' ASP . . . . . 0.431 ' OD2' ' HB2' ' A' ' 11' ' ' GLU . 15.7 t70 -114.7 151.72 33.17 Favored 'General case' 0 C--O 1.236 0.352 0 CA-C-N 115.496 -0.774 . . . . 0.0 109.497 178.623 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 15.6 m -102.37 16.8 4.69 Favored 'Isoleucine or valine' 0 CA--C 1.544 0.717 0 N-CA-C 111.912 0.338 . . . . 0.0 111.912 -179.339 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 11' ' ' GLU . . . . . 0.431 ' HB2' ' OD2' ' A' ' 9' ' ' ASP . 9.5 mm-40 -110.34 -52.49 2.78 Favored 'General case' 0 N--CA 1.466 0.326 0 N-CA-C 112.082 0.401 . . . . 0.0 112.082 -178.979 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 12' ' ' PHE . . . . . . . . . . . . . 10.9 t80 -137.74 -17.51 1.26 Allowed 'General case' 0 N--CA 1.469 0.52 0 N-CA-C 112.589 0.588 . . . . 0.0 112.589 -178.812 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 13' ' ' ASN . . . . . . . . . . . . . 6.8 t-20 -120.21 73.43 20.23 Favored Pre-proline 0 CA--C 1.547 0.851 0 N-CA-C 111.373 0.138 . . . . 0.0 111.373 -179.184 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 60.4 Cg_endo -76.79 177.6 8.65 Favored 'Trans proline' 0 C--N 1.371 1.729 0 C-N-CA 122.352 2.035 . . . . 0.0 112.314 179.027 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 1.3 t -79.79 120.2 23.72 Favored 'General case' 0 N--CA 1.471 0.605 0 CA-C-O 120.508 0.194 . . . . 0.0 110.911 179.895 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER -56.94 -53.44 65.11 Favored Pre-proline 0 N--CA 1.477 0.89 0 CA-C-O 119.09 -0.481 . . . . 0.0 111.634 179.425 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 17' ' ' PRO . . . . . 0.519 ' HG2' HD12 ' A' ' 19' ' ' LEU . 44.8 Cg_endo -68.62 169.25 17.79 Favored 'Trans proline' 0 C--N 1.379 2.163 0 C-N-CA 122.152 1.901 . . . . 0.0 111.789 178.057 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 55.6 Cg_endo -72.3 50.46 1.57 Allowed 'Trans proline' 0 C--N 1.371 1.755 0 C-N-CA 122.085 1.857 . . . . 0.0 112.538 178.728 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 19' ' ' LEU . . . . . 0.519 HD12 ' HG2' ' A' ' 17' ' ' PRO . 20.9 mt -111.41 167.92 9.93 Favored 'General case' 0 C--O 1.235 0.317 0 CA-C-N 115.626 -0.716 . . . . 0.0 111.383 -179.386 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 20' ' ' THR . . . . . 0.525 ' O ' ' HA ' ' A' ' 30' ' ' CYS . 33.5 m -105.6 153.47 21.74 Favored 'General case' 0 CA--C 1.533 0.291 0 CA-C-N 115.622 -0.717 . . . . 0.0 110.995 -178.774 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 2.0 t -102.77 103.36 13.57 Favored 'General case' 0 C--O 1.236 0.389 0 CA-C-N 115.709 -0.678 . . . . 0.0 109.676 178.932 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 22' ' ' ILE . . . . . 0.703 HD12 ' HB2' ' A' ' 31' ' ' TYR . 2.8 mt -125.43 129.13 24.53 Favored Pre-proline 0 CA--C 1.542 0.635 0 CA-C-N 115.754 -0.657 . . . . 0.0 110.259 -178.99 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 38.1 Cg_endo -67.69 -48.15 0.26 Allowed 'Cis proline' 0 C--N 1.375 1.933 0 C-N-CA 124.688 -0.963 . . . . 0.0 113.906 0.056 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 81.58 36.45 19.84 Favored Glycine 0 C--N 1.348 1.202 0 C-N-CA 121.153 -0.546 . . . . 0.0 112.899 -179.968 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 8.4 m-20 -139.91 82.73 17.16 Favored Pre-proline 0 CA--C 1.544 0.726 0 C-N-CA 122.587 0.355 . . . . 0.0 110.636 -179.743 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 2.9 Cg_endo -80.37 -32.06 4.23 Favored 'Cis proline' 0 C--N 1.372 1.773 0 C-N-CA 125.134 -0.778 . . . . 0.0 112.933 -0.118 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 27' ' ' TYR . . . . . . . . . . . . . 59.6 m-85 -107.24 175.06 5.62 Favored 'General case' 0 C--O 1.239 0.535 0 CA-C-N 115.785 -0.643 . . . . 0.0 111.643 -179.014 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 28' ' ' GLY . . . . . 0.723 ' O ' ' HA ' ' A' ' 7' ' ' GLN . . . -175.7 -161.18 24.59 Favored Glycine 0 CA--C 1.504 -0.609 0 CA-C-N 115.734 -0.666 . . . . 0.0 112.574 178.468 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 29' ' ' ILE . . . . . 0.541 ' HB ' ' CE2' ' A' ' 31' ' ' TYR . 2.7 mm -115.83 150.04 17.9 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 O-C-N 123.801 0.354 . . . . 0.0 110.067 -179.738 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 30' ' ' CYS . . . . . 0.525 ' HA ' ' O ' ' A' ' 20' ' ' THR . 23.7 m -79.88 104.99 10.83 Favored 'General case' 0 CA--C 1.535 0.402 0 CA-C-O 121.319 0.581 . . . . 0.0 111.303 -179.767 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 31' ' ' TYR . . . . . 0.703 ' HB2' HD12 ' A' ' 22' ' ' ILE . 36.7 m-85 -129.25 168.08 16.72 Favored 'General case' 0 C--O 1.233 0.197 0 CA-C-N 114.889 -1.051 . . . . 0.0 111.019 -179.465 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 2.7 tp -100.29 130.9 48.79 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.627 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.277 179.449 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 33' ' ' ILE . . . . . 0.49 HG23 HD11 ' A' ' 22' ' ' ILE . 1.9 pp . . . . . 0 C--O 1.249 1.061 0 CA-C-O 118.328 -0.844 . . . . 0.0 111.479 179.865 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 N--CA 1.486 1.353 0 CA-C-O 119.629 -0.224 . . . . 0.0 111.081 . . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 2' ' ' PRO . . . . . 0.584 ' HD2' ' O ' ' A' ' 14' ' ' PRO . 73.4 Cg_endo -69.49 -170.78 0.39 Allowed 'Trans proline' 0 C--N 1.374 1.902 0 C-N-CA 123.184 2.589 . . . . 0.0 113.9 -178.918 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -142.76 -159.52 7.98 Favored Glycine 0 C--N 1.342 0.888 0 O-C-N 123.544 0.528 . . . . 0.0 112.487 179.832 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 17.4 tt0 -68.42 122.51 18.57 Favored 'General case' 0 N--CA 1.474 0.73 0 C-N-CA 122.816 0.447 . . . . 0.0 111.515 -179.925 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 92.41 14.54 55.52 Favored Glycine 0 C--N 1.341 0.82 0 CA-C-N 115.578 -0.737 . . . . 0.0 113.243 -179.882 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 43.1 mt-10 -127.42 165.64 19.41 Favored 'General case' 0 C--O 1.239 0.546 0 C-N-CA 122.438 0.295 . . . . 0.0 110.946 179.962 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 7' ' ' GLN . . . . . 0.51 ' HA ' ' O ' ' A' ' 28' ' ' GLY . 0.9 OUTLIER -83.46 145.55 28.89 Favored 'General case' 0 N--CA 1.469 0.478 0 CA-C-N 116.357 -0.383 . . . . 0.0 111.372 179.886 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 8.1 p -139.18 155.38 47.87 Favored 'General case' 0 C--O 1.237 0.44 0 CA-C-N 115.544 -0.753 . . . . 0.0 111.317 -179.786 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 6.9 t70 -118.87 153.13 35.03 Favored 'General case' 0 C--O 1.236 0.364 0 CA-C-N 115.42 -0.809 . . . . 0.0 109.652 179.045 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 14.9 m -101.86 20.89 2.47 Favored 'Isoleucine or valine' 0 CA--C 1.544 0.746 0 CA-C-N 116.296 -0.411 . . . . 0.0 111.99 -179.404 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 44.6 mt-10 -117.8 -53.03 2.42 Favored 'General case' 0 N--CA 1.465 0.32 0 N-CA-C 112.319 0.489 . . . . 0.0 112.319 -179.252 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 12' ' ' PHE . . . . . . . . . . . . . 15.7 t80 -138.96 -7.28 1.4 Allowed 'General case' 0 N--CA 1.47 0.574 0 N-CA-C 112.58 0.585 . . . . 0.0 112.58 -178.771 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 13' ' ' ASN . . . . . . . . . . . . . 8.3 t-20 -129.44 63.47 67.83 Favored Pre-proline 0 CA--C 1.551 1.006 0 N-CA-C 111.369 0.137 . . . . 0.0 111.369 -179.093 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 14' ' ' PRO . . . . . 0.584 ' O ' ' HD2' ' A' ' 2' ' ' PRO . 15.8 Cg_exo -69.08 177.7 4.86 Favored 'Trans proline' 0 C--N 1.372 1.812 0 C-N-CA 122.733 2.288 . . . . 0.0 112.253 179.282 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 1.5 m -79.45 119.6 22.68 Favored 'General case' 0 N--CA 1.471 0.577 0 C-N-CA 122.382 0.273 . . . . 0.0 111.352 -179.848 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 16' ' ' CYS . . . . . 0.573 ' HB2' ' O ' ' A' ' 2' ' ' PRO . 0.0 OUTLIER -57.36 -53.2 67.98 Favored Pre-proline 0 N--CA 1.481 1.112 0 CA-C-N 115.971 -0.559 . . . . 0.0 111.518 179.548 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 17' ' ' PRO . . . . . 0.479 ' HG2' HD12 ' A' ' 19' ' ' LEU . 57.7 Cg_endo -72.72 169.34 22.21 Favored 'Trans proline' 0 C--N 1.38 2.205 0 C-N-CA 122.042 1.828 . . . . 0.0 111.8 178.168 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 55.8 Cg_endo -72.21 44.54 0.7 Allowed 'Trans proline' 0 C--N 1.371 1.759 0 C-N-CA 122.034 1.823 . . . . 0.0 112.956 178.86 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 19' ' ' LEU . . . . . 0.479 HD12 ' HG2' ' A' ' 17' ' ' PRO . 12.9 mt -104.43 172.78 6.61 Favored 'General case' 0 CA--C 1.534 0.336 0 CA-C-N 115.875 -0.602 . . . . 0.0 110.917 -179.634 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 25.5 m -103.38 150.2 24.04 Favored 'General case' 0 CA--C 1.534 0.335 0 CA-C-N 115.934 -0.575 . . . . 0.0 111.034 -178.793 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 5.5 t -100.32 103.13 14.53 Favored 'General case' 0 C--O 1.237 0.427 0 CA-C-N 115.874 -0.603 . . . . 0.0 109.381 178.491 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 22' ' ' ILE . . . . . 0.716 HD12 ' HB2' ' A' ' 31' ' ' TYR . 2.5 mt -127.36 129.27 23.91 Favored Pre-proline 0 CA--C 1.543 0.697 0 CA-C-N 115.825 -0.625 . . . . 0.0 110.72 -178.462 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 38.0 Cg_endo -67.94 -48.55 0.25 Allowed 'Cis proline' 0 C--N 1.374 1.902 0 C-N-CA 124.77 -0.929 . . . . 0.0 113.71 -0.441 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 79.67 37.13 24.11 Favored Glycine 0 C--N 1.346 1.137 0 C-N-CA 121.39 -0.434 . . . . 0.0 112.835 179.954 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 8.4 m-20 -140.31 81.25 18.24 Favored Pre-proline 0 CA--C 1.544 0.721 0 C-N-CA 122.477 0.311 . . . . 0.0 110.837 -179.694 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 2.2 Cg_endo -81.62 -32.17 3.85 Favored 'Cis proline' 0 C--N 1.372 1.787 0 C-N-CA 125.027 -0.822 . . . . 0.0 112.928 -0.166 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 27' ' ' TYR . . . . . . . . . . . . . 66.7 m-85 -102.35 173.29 6.43 Favored 'General case' 0 C--O 1.238 0.496 0 CA-C-N 115.77 -0.65 . . . . 0.0 111.561 -179.125 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 28' ' ' GLY . . . . . 0.51 ' O ' ' HA ' ' A' ' 7' ' ' GLN . . . -175.59 -159.31 21.32 Favored Glycine 0 C--N 1.338 0.658 0 CA-C-N 115.75 -0.659 . . . . 0.0 112.451 178.974 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 29' ' ' ILE . . . . . 0.56 ' HB ' ' CE2' ' A' ' 31' ' ' TYR . 1.3 mm -123.17 152.13 27.85 Favored 'Isoleucine or valine' 0 C--O 1.235 0.332 0 N-CA-C 109.882 -0.414 . . . . 0.0 109.882 179.713 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 30' ' ' CYS . . . . . 0.443 ' SG ' ' HB2' ' A' ' 19' ' ' LEU . 0.5 OUTLIER -80.07 106.92 12.44 Favored 'General case' 0 C--O 1.238 0.472 0 CA-C-N 116.029 -0.532 . . . . 0.0 110.923 -179.975 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 31' ' ' TYR . . . . . 0.716 ' HB2' HD12 ' A' ' 22' ' ' ILE . 36.2 m-85 -132.11 167.04 20.43 Favored 'General case' 0 N--CA 1.466 0.334 0 CA-C-N 115.534 -0.757 . . . . 0.0 111.088 -179.251 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 2.8 tp -101.88 131.8 49.09 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.614 0 CA-C-N 116.081 -0.509 . . . . 0.0 110.347 179.458 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 33' ' ' ILE . . . . . 0.465 ' H ' HG13 ' A' ' 33' ' ' ILE . 1.9 pp . . . . . 0 C--O 1.247 0.961 0 CA-C-O 118.357 -0.83 . . . . 0.0 111.399 179.976 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 3.7 p . . . . . 0 N--CA 1.486 1.332 0 CA-C-O 119.71 -0.186 . . . . 0.0 111.323 . . . . . . . . . 0 0 . 1 . 010 nuclear build full ' A' A ' 2' ' ' PRO . . . . . . . . . . . . . 95.6 Cg_endo -83.52 -171.8 1.18 Allowed 'Trans proline' 0 C--N 1.368 1.567 0 C-N-CA 122.562 2.175 . . . . 0.0 112.937 179.634 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -145.39 -154.0 6.03 Favored Glycine 0 C--N 1.339 0.711 0 N-CA-C 111.813 -0.515 . . . . 0.0 111.813 179.493 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 18.5 tt0 -73.27 129.68 38.55 Favored 'General case' 0 N--CA 1.472 0.667 0 C-N-CA 122.68 0.392 . . . . 0.0 111.319 179.596 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 85.92 15.45 65.2 Favored Glycine 0 C--N 1.34 0.754 0 CA-C-N 115.793 -0.639 . . . . 0.0 113.554 -179.984 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 12.7 tt0 -126.87 161.9 27.18 Favored 'General case' 0 C--O 1.238 0.462 0 CA-C-N 116.604 0.202 . . . . 0.0 110.656 -179.842 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 7' ' ' GLN . . . . . 0.682 ' HA ' ' O ' ' A' ' 28' ' ' GLY . 18.6 tt0 -86.81 136.35 33.01 Favored 'General case' 0 C--N 1.344 0.331 0 CA-C-O 121.218 0.533 . . . . 0.0 111.407 179.962 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 8' ' ' CYS . . . . . 0.405 ' SG ' ' SG ' ' A' ' 30' ' ' CYS . 2.6 p -130.65 161.34 31.83 Favored 'General case' 0 C--O 1.239 0.517 0 CA-C-N 114.465 -1.243 . . . . 0.0 111.023 -179.58 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 9' ' ' ASP . . . . . 0.59 ' OD1' ' HB3' ' A' ' 13' ' ' ASN . 0.7 OUTLIER -120.52 143.54 48.52 Favored 'General case' 0 N--CA 1.465 0.276 0 CA-C-N 115.687 -0.688 . . . . 0.0 110.09 178.494 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 22.3 m -92.02 14.63 1.69 Allowed 'Isoleucine or valine' 0 CA--C 1.542 0.655 0 CA-C-N 116.083 -0.508 . . . . 0.0 111.509 -179.245 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 9.9 mm-40 -98.68 -51.56 3.88 Favored 'General case' 0 C--O 1.234 0.283 0 CA-C-N 116.159 -0.473 . . . . 0.0 112.085 -178.789 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 12' ' ' PHE . . . . . . . . . . . . . 6.9 t80 -144.09 -22.84 0.56 Allowed 'General case' 0 N--CA 1.472 0.67 0 N-CA-C 112.698 0.629 . . . . 0.0 112.698 -178.877 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 13' ' ' ASN . . . . . 0.59 ' HB3' ' OD1' ' A' ' 9' ' ' ASP . 13.7 t-20 -119.32 75.74 16.64 Favored Pre-proline 0 CA--C 1.548 0.901 0 CA-C-N 117.539 0.154 . . . . 0.0 111.355 -178.969 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 61.7 Cg_endo -76.77 -176.09 2.97 Favored 'Trans proline' 0 C--N 1.372 1.763 0 C-N-CA 122.542 2.162 . . . . 0.0 112.22 178.676 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 0.9 OUTLIER -79.94 121.76 25.85 Favored 'General case' 0 N--CA 1.471 0.609 0 CA-C-O 120.454 0.168 . . . . 0.0 111.252 179.95 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER -58.38 -53.76 62.79 Favored Pre-proline 0 N--CA 1.478 0.949 0 CA-C-N 116.124 -0.489 . . . . 0.0 111.552 179.115 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 44.0 Cg_endo -67.8 169.79 15.41 Favored 'Trans proline' 0 C--N 1.379 2.171 0 C-N-CA 122.187 1.925 . . . . 0.0 111.851 178.21 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 55.5 Cg_endo -72.08 47.46 1.03 Allowed 'Trans proline' 0 C--N 1.371 1.724 0 C-N-CA 122.027 1.818 . . . . 0.0 112.792 178.839 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 42.9 mt -108.68 166.3 10.9 Favored 'General case' 0 C--O 1.234 0.266 0 CA-C-N 115.926 -0.579 . . . . 0.0 111.201 -179.588 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 20' ' ' THR . . . . . 0.522 ' O ' ' HA ' ' A' ' 30' ' ' CYS . 33.5 m -103.58 152.74 21.38 Favored 'General case' 0 CA--C 1.532 0.287 0 CA-C-N 115.503 -0.771 . . . . 0.0 110.962 -178.848 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 2.3 t -102.44 99.93 10.02 Favored 'General case' 0 C--O 1.239 0.535 0 CA-C-N 115.725 -0.67 . . . . 0.0 109.601 178.841 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 22' ' ' ILE . . . . . 0.707 HD12 ' HB2' ' A' ' 31' ' ' TYR . 3.0 mt -121.04 128.7 25.62 Favored Pre-proline 0 CA--C 1.541 0.622 0 CA-C-N 115.783 -0.644 . . . . 0.0 110.424 -178.976 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 37.1 Cg_endo -66.89 -47.47 0.26 Allowed 'Cis proline' 0 C--N 1.375 1.958 0 C-N-CA 124.69 -0.962 . . . . 0.0 113.874 -0.187 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 78.92 34.4 34.1 Favored Glycine 0 C--N 1.346 1.131 0 C-N-CA 121.379 -0.438 . . . . 0.0 112.942 179.977 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 4.6 t70 -139.91 83.05 16.69 Favored Pre-proline 0 CA--C 1.546 0.823 0 C-N-CA 122.607 0.363 . . . . 0.0 110.345 -179.68 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 3.2 Cg_exo -80.86 -32.02 4.15 Favored 'Cis proline' 0 C--N 1.371 1.743 0 C-N-CA 125.095 -0.794 . . . . 0.0 112.895 0.036 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 27' ' ' TYR . . . . . 0.558 ' CD2' ' HB3' ' A' ' 9' ' ' ASP . 63.6 m-85 -106.91 172.68 6.69 Favored 'General case' 0 CA--C 1.537 0.448 0 CA-C-N 115.838 -0.619 . . . . 0.0 111.592 -178.892 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 28' ' ' GLY . . . . . 0.682 ' O ' ' HA ' ' A' ' 7' ' ' GLN . . . -176.53 -163.88 29.64 Favored Glycine 0 C--N 1.339 0.716 0 CA-C-N 115.629 -0.714 . . . . 0.0 112.636 178.558 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 29' ' ' ILE . . . . . 0.541 ' HB ' ' CE2' ' A' ' 31' ' ' TYR . 2.5 mm -114.68 151.15 16.47 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 O-C-N 123.748 0.322 . . . . 0.0 110.259 -179.898 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 30' ' ' CYS . . . . . 0.522 ' HA ' ' O ' ' A' ' 20' ' ' THR . 33.9 m -79.88 105.42 11.15 Favored 'General case' 0 CA--C 1.535 0.392 0 CA-C-O 121.328 0.585 . . . . 0.0 111.365 -179.717 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 31' ' ' TYR . . . . . 0.707 ' HB2' HD12 ' A' ' 22' ' ' ILE . 37.1 m-85 -130.28 166.88 19.43 Favored 'General case' 0 C--O 1.233 0.193 0 CA-C-N 114.917 -1.038 . . . . 0.0 111.02 -179.472 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 2.9 tp -99.59 130.24 48.93 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.604 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.372 179.496 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 33' ' ' ILE . . . . . 0.485 HG23 HD11 ' A' ' 22' ' ' ILE . 1.4 pt . . . . . 0 C--O 1.249 1.045 0 CA-C-O 118.136 -0.935 . . . . 0.0 111.463 179.883 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 5.7 p . . . . . 0 N--CA 1.486 1.345 0 CA-C-O 119.716 -0.183 . . . . 0.0 111.253 . . . . . . . . . 0 0 . 1 . 011 nuclear build full ' A' A ' 2' ' ' PRO . . . . . 0.4 ' HD2' ' O ' ' A' ' 14' ' ' PRO . 95.1 Cg_endo -82.24 -172.34 1.41 Allowed 'Trans proline' 0 C--N 1.367 1.529 0 C-N-CA 122.581 2.187 . . . . 0.0 112.827 179.498 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -147.3 -161.39 9.38 Favored Glycine 0 C--N 1.337 0.632 0 N-CA-C 111.593 -0.603 . . . . 0.0 111.593 179.216 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 19.0 tt0 -68.33 124.06 22.46 Favored 'General case' 0 N--CA 1.473 0.679 0 C-N-CA 122.548 0.339 . . . . 0.0 111.183 179.851 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 91.28 14.69 56.99 Favored Glycine 0 C--N 1.338 0.682 0 CA-C-N 115.646 -0.706 . . . . 0.0 113.228 -179.699 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 6' ' ' GLU . . . . . 0.453 ' HG2' ' NE2' ' A' ' 7' ' ' GLN . 13.9 tt0 -129.0 166.18 19.7 Favored 'General case' 0 C--O 1.238 0.479 0 C-N-CA 122.287 0.235 . . . . 0.0 110.599 -179.933 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 7' ' ' GLN . . . . . 0.453 ' NE2' ' HG2' ' A' ' 6' ' ' GLU . 0.2 OUTLIER -82.07 153.3 26.18 Favored 'General case' 0 C--N 1.346 0.433 0 O-C-N 123.288 0.367 . . . . 0.0 110.929 -179.876 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 3.3 p -142.64 151.8 41.81 Favored 'General case' 0 C--O 1.235 0.306 0 CA-C-N 115.817 -0.629 . . . . 0.0 111.297 -179.4 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -110.23 139.8 45.02 Favored 'General case' 0 C--O 1.234 0.253 0 CA-C-N 115.765 -0.652 . . . . 0.0 109.559 179.348 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 10' ' ' VAL . . . . . 0.489 HG22 ' O ' ' A' ' 26' ' ' PRO . 7.7 m -94.89 26.65 0.48 Allowed 'Isoleucine or valine' 0 CA--C 1.543 0.702 0 O-C-N 123.31 0.381 . . . . 0.0 111.635 -179.842 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 42.6 mt-10 -124.2 -52.26 1.75 Allowed 'General case' 0 N--CA 1.465 0.291 0 N-CA-C 112.251 0.464 . . . . 0.0 112.251 -179.135 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 12' ' ' PHE . . . . . . . . . . . . . 11.5 t80 -138.51 -10.38 1.41 Allowed 'General case' 0 N--CA 1.471 0.617 0 N-CA-C 112.833 0.679 . . . . 0.0 112.833 -178.627 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 13' ' ' ASN . . . . . 0.4 ' OD1' ' HD3' ' A' ' 2' ' ' PRO . 5.2 t-20 -129.88 64.86 73.62 Favored Pre-proline 0 CA--C 1.549 0.928 0 CA-C-N 117.458 0.117 . . . . 0.0 111.206 -179.151 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 14' ' ' PRO . . . . . 0.4 ' O ' ' HD2' ' A' ' 2' ' ' PRO . 16.4 Cg_exo -68.86 179.81 2.98 Favored 'Trans proline' 0 C--N 1.373 1.843 0 C-N-CA 122.948 2.432 . . . . 0.0 112.22 179.141 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 15' ' ' CYS . . . . . 0.519 ' SG ' ' HB2' ' A' ' 19' ' ' LEU . 3.8 t -79.71 122.0 26.03 Favored 'General case' 0 N--CA 1.471 0.603 0 O-C-N 123.102 0.251 . . . . 0.0 111.247 -179.786 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER -60.85 -54.16 57.16 Favored Pre-proline 0 N--CA 1.476 0.855 0 CA-C-O 119.023 -0.513 . . . . 0.0 111.443 179.298 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 56.3 Cg_endo -70.95 169.27 20.84 Favored 'Trans proline' 0 C--N 1.379 2.176 0 C-N-CA 122.115 1.877 . . . . 0.0 111.702 178.173 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 49.7 Cg_endo -70.76 58.09 2.0 Allowed 'Trans proline' 0 C--N 1.371 1.748 0 C-N-CA 121.975 1.784 . . . . 0.0 112.909 179.01 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 19' ' ' LEU . . . . . 0.519 ' HB2' ' SG ' ' A' ' 15' ' ' CYS . 93.8 mt -118.19 167.8 11.17 Favored 'General case' 0 C--O 1.235 0.331 0 CA-C-N 115.704 -0.68 . . . . 0.0 111.24 -179.876 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 89.3 m -106.99 150.84 26.07 Favored 'General case' 0 CA--C 1.533 0.303 0 CA-C-N 115.315 -0.857 . . . . 0.0 110.94 -179.277 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 21' ' ' CYS . . . . . 0.505 ' HA ' ' O ' ' A' ' 29' ' ' ILE . 1.9 t -97.3 106.71 19.09 Favored 'General case' 0 C--O 1.238 0.476 0 CA-C-N 115.732 -0.667 . . . . 0.0 110.029 178.949 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 22' ' ' ILE . . . . . 0.723 HD12 ' HB2' ' A' ' 31' ' ' TYR . 5.7 mt -125.32 128.69 24.68 Favored Pre-proline 0 CA--C 1.543 0.697 0 CA-C-N 115.807 -0.633 . . . . 0.0 110.564 -179.16 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 37.3 Cg_endo -67.24 -47.78 0.26 Allowed 'Cis proline' 0 C--N 1.376 2.009 0 C-N-CA 124.681 -0.966 . . . . 0.0 113.81 -0.223 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 81.66 38.11 15.04 Favored Glycine 0 C--N 1.347 1.144 0 C-N-CA 121.332 -0.461 . . . . 0.0 112.88 179.822 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 8.0 m-20 -142.58 80.64 14.19 Favored Pre-proline 0 CA--C 1.546 0.817 0 C-N-CA 122.445 0.298 . . . . 0.0 111.052 -179.565 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 26' ' ' PRO . . . . . 0.489 ' O ' HG22 ' A' ' 10' ' ' VAL . 67.9 Cg_endo -84.08 -29.38 5.12 Favored 'Cis proline' 0 C--N 1.372 1.788 0 C-N-CA 124.698 -0.959 . . . . 0.0 113.439 -0.236 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 27' ' ' TYR . . . . . . . . . . . . . 57.0 m-85 -95.31 161.49 14.07 Favored 'General case' 0 N--CA 1.469 0.492 0 O-C-N 123.513 0.508 . . . . 0.0 111.304 -179.097 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 28' ' ' GLY . . . . . 0.433 ' O ' HD13 ' A' ' 29' ' ' ILE . . . -159.03 -161.91 11.53 Favored Glycine 0 C--N 1.341 0.842 0 C-N-CA 120.917 -0.659 . . . . 0.0 113.089 179.832 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 29' ' ' ILE . . . . . 0.505 ' O ' ' HA ' ' A' ' 21' ' ' CYS . 5.1 mm -129.95 155.17 41.31 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.238 0 N-CA-C 109.674 -0.491 . . . . 0.0 109.674 -179.932 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 30' ' ' CYS . . . . . . . . . . . . . 28.8 m -83.68 92.8 7.77 Favored 'General case' 0 CA--C 1.538 0.482 0 CA-C-O 121.368 0.604 . . . . 0.0 111.362 -179.955 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 31' ' ' TYR . . . . . 0.723 ' HB2' HD12 ' A' ' 22' ' ' ILE . 37.8 m-85 -124.33 166.81 15.28 Favored 'General case' 0 N--CA 1.464 0.26 0 CA-C-N 114.972 -1.013 . . . . 0.0 110.992 179.822 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 2.8 tp -99.76 131.49 47.05 Favored 'Isoleucine or valine' 0 CA--C 1.542 0.644 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.448 179.401 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 33' ' ' ILE . . . . . 0.472 HG23 HD11 ' A' ' 22' ' ' ILE . 1.8 pp . . . . . 0 C--O 1.249 1.056 0 CA-C-O 118.168 -0.92 . . . . 0.0 111.429 179.843 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 N--CA 1.487 1.385 0 CA-C-O 119.771 -0.157 . . . . 0.0 111.093 . . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 2' ' ' PRO . . . . . 0.598 ' HD2' ' O ' ' A' ' 14' ' ' PRO . 73.0 Cg_endo -69.33 -170.71 0.38 Allowed 'Trans proline' 0 C--N 1.376 1.989 0 C-N-CA 123.23 2.62 . . . . 0.0 113.935 -179.044 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -143.5 -159.68 8.08 Favored Glycine 0 C--N 1.341 0.837 0 CA-C-N 116.146 -0.479 . . . . 0.0 112.477 179.83 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 16.7 tt0 -66.43 124.23 22.18 Favored 'General case' 0 N--CA 1.474 0.734 0 C-N-CA 122.841 0.456 . . . . 0.0 111.603 -179.711 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 95.03 -11.01 69.89 Favored Glycine 0 C--N 1.34 0.772 0 CA-C-N 115.641 -0.708 . . . . 0.0 113.282 -179.971 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 42.8 mt-10 -101.16 166.66 10.67 Favored 'General case' 0 C--O 1.24 0.601 0 C-N-CA 122.432 0.293 . . . . 0.0 110.967 -179.8 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 7' ' ' GLN . . . . . . . . . . . . . 0.2 OUTLIER -84.85 154.83 22.05 Favored 'General case' 0 C--N 1.346 0.446 0 CA-C-N 116.167 -0.47 . . . . 0.0 111.039 179.899 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 7.9 p -147.54 155.02 41.45 Favored 'General case' 0 N--CA 1.466 0.371 0 CA-C-N 115.886 -0.597 . . . . 0.0 111.511 -179.131 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 8.0 t70 -120.17 150.52 40.5 Favored 'General case' 0 C--O 1.234 0.275 0 CA-C-N 115.325 -0.852 . . . . 0.0 109.633 178.885 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 15.6 m -98.7 18.8 2.28 Favored 'Isoleucine or valine' 0 CA--C 1.543 0.677 0 CA-C-N 116.287 -0.415 . . . . 0.0 112.072 -179.41 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 46.2 mt-10 -110.13 -55.46 2.45 Favored 'General case' 0 N--CA 1.466 0.358 0 N-CA-C 112.11 0.411 . . . . 0.0 112.11 -179.106 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 12' ' ' PHE . . . . . . . . . . . . . 12.2 t80 -137.99 -15.2 1.34 Allowed 'General case' 0 N--CA 1.47 0.556 0 N-CA-C 112.429 0.529 . . . . 0.0 112.429 -178.939 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 13' ' ' ASN . . . . . . . . . . . . . 10.0 t-20 -120.21 73.01 19.61 Favored Pre-proline 0 CA--C 1.55 0.955 0 O-C-N 122.969 0.168 . . . . 0.0 111.161 -179.377 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 14' ' ' PRO . . . . . 0.598 ' O ' ' HD2' ' A' ' 2' ' ' PRO . 60.4 Cg_endo -76.13 178.74 7.09 Favored 'Trans proline' 0 C--N 1.371 1.744 0 C-N-CA 122.314 2.009 . . . . 0.0 112.501 179.587 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 1.4 m -79.38 118.65 21.47 Favored 'General case' 0 N--CA 1.47 0.547 0 O-C-N 123.118 0.261 . . . . 0.0 111.195 179.972 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 16' ' ' CYS . . . . . 0.573 ' HB2' ' O ' ' A' ' 2' ' ' PRO . 0.0 OUTLIER -56.58 -53.27 66.22 Favored Pre-proline 0 N--CA 1.48 1.073 0 CA-C-O 118.961 -0.542 . . . . 0.0 111.679 179.581 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 17' ' ' PRO . . . . . 0.474 ' HG2' HD12 ' A' ' 19' ' ' LEU . 57.7 Cg_endo -72.65 169.23 22.42 Favored 'Trans proline' 0 C--N 1.378 2.13 0 C-N-CA 122.028 1.819 . . . . 0.0 111.738 178.194 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 55.7 Cg_endo -72.51 45.33 0.83 Allowed 'Trans proline' 0 C--N 1.373 1.839 0 C-N-CA 122.012 1.808 . . . . 0.0 112.865 178.826 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 19' ' ' LEU . . . . . 0.474 HD12 ' HG2' ' A' ' 17' ' ' PRO . 11.8 mt -104.92 172.9 6.54 Favored 'General case' 0 C--O 1.237 0.401 0 CA-C-N 115.931 -0.577 . . . . 0.0 111.046 -179.628 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 24.5 m -103.98 149.3 25.27 Favored 'General case' 0 CA--C 1.531 0.228 0 CA-C-N 115.966 -0.561 . . . . 0.0 111.046 -178.945 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 5.9 t -99.35 102.74 14.43 Favored 'General case' 0 C--O 1.237 0.444 0 CA-C-N 115.856 -0.611 . . . . 0.0 109.39 178.467 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 22' ' ' ILE . . . . . 0.723 HD12 ' HB2' ' A' ' 31' ' ' TYR . 2.5 mt -126.78 129.65 24.0 Favored Pre-proline 0 CA--C 1.543 0.679 0 CA-C-N 115.787 -0.642 . . . . 0.0 110.68 -178.571 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 37.5 Cg_endo -67.65 -48.13 0.26 Allowed 'Cis proline' 0 C--N 1.374 1.885 0 C-N-CA 124.699 -0.959 . . . . 0.0 113.814 -0.434 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 78.57 37.61 26.6 Favored Glycine 0 C--N 1.348 1.242 0 C-N-CA 121.308 -0.472 . . . . 0.0 113.013 -179.962 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 4.5 t70 -140.55 80.7 18.28 Favored Pre-proline 0 CA--C 1.548 0.884 0 C-N-CA 122.372 0.269 . . . . 0.0 110.533 -179.614 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 1.9 Cg_endo -82.07 -31.81 3.98 Favored 'Cis proline' 0 C--N 1.372 1.787 0 C-N-CA 125.058 -0.809 . . . . 0.0 112.956 -0.2 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 27' ' ' TYR . . . . . . . . . . . . . 70.0 m-85 -102.0 172.55 6.85 Favored 'General case' 0 C--O 1.237 0.434 0 CA-C-N 115.822 -0.626 . . . . 0.0 111.578 -179.033 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -175.95 -160.57 23.67 Favored Glycine 0 C--N 1.337 0.634 0 CA-C-N 115.657 -0.701 . . . . 0.0 112.207 179.071 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 29' ' ' ILE . . . . . 0.559 ' HB ' ' CE2' ' A' ' 31' ' ' TYR . 1.8 mm -122.6 153.04 27.23 Favored 'Isoleucine or valine' 0 C--O 1.236 0.36 0 N-CA-C 109.87 -0.418 . . . . 0.0 109.87 179.691 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 30' ' ' CYS . . . . . 0.438 ' SG ' ' HB2' ' A' ' 19' ' ' LEU . 0.5 OUTLIER -79.92 106.72 12.15 Favored 'General case' 0 CA--C 1.539 0.521 0 CA-C-N 116.018 -0.537 . . . . 0.0 110.916 -179.919 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 31' ' ' TYR . . . . . 0.723 ' HB2' HD12 ' A' ' 22' ' ' ILE . 39.1 m-85 -131.34 166.68 20.71 Favored 'General case' 0 N--CA 1.463 0.216 0 CA-C-N 115.479 -0.782 . . . . 0.0 111.201 -179.314 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 2.7 tp -101.76 132.04 48.48 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.582 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.437 179.434 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 33' ' ' ILE . . . . . 0.477 ' H ' HG13 ' A' ' 33' ' ' ILE . 1.9 pp . . . . . 0 C--O 1.249 1.078 0 CA-C-O 118.346 -0.835 . . . . 0.0 111.504 179.945 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 4.5 p . . . . . 0 N--CA 1.486 1.346 0 CA-C-O 119.746 -0.169 . . . . 0.0 111.272 . . . . . . . . . 0 0 . 1 . 013 nuclear build full ' A' A ' 2' ' ' PRO . . . . . . . . . . . . . 95.3 Cg_endo -82.36 -172.35 1.41 Allowed 'Trans proline' 0 C--N 1.367 1.539 0 C-N-CA 122.598 2.199 . . . . 0.0 112.969 179.474 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -145.39 -155.44 6.47 Favored Glycine 0 C--N 1.339 0.727 0 N-CA-C 111.687 -0.565 . . . . 0.0 111.687 179.45 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 18.0 tt0 -73.24 129.16 37.43 Favored 'General case' 0 N--CA 1.47 0.55 0 C-N-CA 122.575 0.35 . . . . 0.0 111.221 179.74 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 85.68 16.25 64.14 Favored Glycine 0 C--N 1.339 0.738 0 CA-C-N 115.832 -0.622 . . . . 0.0 113.294 -179.844 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 12.9 tt0 -127.86 162.52 26.5 Favored 'General case' 0 C--O 1.236 0.39 0 C-N-CA 122.176 0.19 . . . . 0.0 110.488 -179.865 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 7' ' ' GLN . . . . . 0.719 ' HA ' ' O ' ' A' ' 28' ' ' GLY . 18.6 tt0 -85.35 134.76 34.08 Favored 'General case' 0 C--N 1.345 0.386 0 CA-C-O 121.298 0.571 . . . . 0.0 111.239 -179.994 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 8' ' ' CYS . . . . . 0.412 ' SG ' ' SG ' ' A' ' 30' ' ' CYS . 3.6 p -127.77 160.2 32.46 Favored 'General case' 0 C--O 1.239 0.508 0 CA-C-N 114.545 -1.207 . . . . 0.0 111.098 -179.396 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 9' ' ' ASP . . . . . 0.432 ' OD2' ' HB2' ' A' ' 11' ' ' GLU . 16.8 t70 -114.86 150.52 35.43 Favored 'General case' 0 CA--C 1.532 0.272 0 CA-C-N 115.542 -0.754 . . . . 0.0 109.477 178.766 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 15.5 m -100.91 20.12 2.47 Favored 'Isoleucine or valine' 0 CA--C 1.543 0.689 0 CA-C-N 116.22 -0.446 . . . . 0.0 112.008 -179.465 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 11' ' ' GLU . . . . . 0.432 ' HB2' ' OD2' ' A' ' 9' ' ' ASP . 44.7 mt-10 -117.51 -52.46 2.47 Favored 'General case' 0 N--CA 1.465 0.313 0 N-CA-C 112.224 0.453 . . . . 0.0 112.224 -178.969 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 12' ' ' PHE . . . . . . . . . . . . . 14.6 t80 -138.42 -8.43 1.49 Allowed 'General case' 0 N--CA 1.472 0.652 0 N-CA-C 112.596 0.591 . . . . 0.0 112.596 -178.689 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 13' ' ' ASN . . . . . . . . . . . . . 6.6 t-20 -129.6 63.79 69.26 Favored Pre-proline 0 CA--C 1.55 0.959 0 N-CA-C 111.552 0.205 . . . . 0.0 111.552 -179.091 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 14.0 Cg_exo -70.09 177.12 6.13 Favored 'Trans proline' 0 C--N 1.371 1.744 0 C-N-CA 122.86 2.373 . . . . 0.0 112.002 178.885 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 1.1 t -79.9 121.02 24.92 Favored 'General case' 0 N--CA 1.471 0.58 0 CA-C-O 120.503 0.192 . . . . 0.0 111.052 -179.983 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER -57.57 -53.09 69.18 Favored Pre-proline 0 N--CA 1.478 0.943 0 CA-C-O 119.069 -0.491 . . . . 0.0 111.541 179.282 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 17' ' ' PRO . . . . . 0.511 ' HG2' HD12 ' A' ' 19' ' ' LEU . 44.4 Cg_endo -68.81 169.44 17.66 Favored 'Trans proline' 0 C--N 1.38 2.199 0 C-N-CA 122.159 1.906 . . . . 0.0 111.782 178.059 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 55.5 Cg_endo -72.22 49.33 1.34 Allowed 'Trans proline' 0 C--N 1.373 1.833 0 C-N-CA 122.044 1.829 . . . . 0.0 112.589 178.799 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 19' ' ' LEU . . . . . 0.511 HD12 ' HG2' ' A' ' 17' ' ' PRO . 20.9 mt -110.1 168.24 9.58 Favored 'General case' 0 C--O 1.236 0.372 0 CA-C-N 115.741 -0.663 . . . . 0.0 111.34 -179.337 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 20' ' ' THR . . . . . 0.537 ' O ' ' HA ' ' A' ' 30' ' ' CYS . 29.3 m -105.31 153.82 21.11 Favored 'General case' 0 CA--C 1.533 0.31 0 CA-C-N 115.624 -0.716 . . . . 0.0 111.056 -178.804 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 2.0 t -103.42 103.89 13.93 Favored 'General case' 0 C--O 1.238 0.493 0 CA-C-N 115.678 -0.692 . . . . 0.0 109.666 178.869 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 22' ' ' ILE . . . . . 0.71 HD12 ' HB2' ' A' ' 31' ' ' TYR . 2.9 mt -125.9 129.11 24.39 Favored Pre-proline 0 CA--C 1.541 0.634 0 CA-C-N 115.768 -0.651 . . . . 0.0 110.223 -179.157 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 38.4 Cg_endo -67.77 -48.26 0.25 Allowed 'Cis proline' 0 C--N 1.375 1.941 0 C-N-CA 124.679 -0.967 . . . . 0.0 113.941 -0.155 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 81.92 36.83 17.63 Favored Glycine 0 C--N 1.348 1.229 0 C-N-CA 121.108 -0.568 . . . . 0.0 112.852 -179.977 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 8.3 m-20 -139.99 82.58 17.18 Favored Pre-proline 0 CA--C 1.543 0.701 0 C-N-CA 122.53 0.332 . . . . 0.0 110.701 -179.91 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 3.0 Cg_endo -80.54 -32.07 4.18 Favored 'Cis proline' 0 C--N 1.372 1.795 0 C-N-CA 125.191 -0.754 . . . . 0.0 112.923 0.077 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 27' ' ' TYR . . . . . . . . . . . . . 59.3 m-85 -106.96 175.07 5.62 Favored 'General case' 0 C--O 1.238 0.466 0 CA-C-N 115.68 -0.691 . . . . 0.0 111.532 -179.001 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 28' ' ' GLY . . . . . 0.719 ' O ' ' HA ' ' A' ' 7' ' ' GLN . . . -175.52 -161.26 24.65 Favored Glycine 0 C--N 1.339 0.701 0 CA-C-N 115.626 -0.715 . . . . 0.0 112.618 178.49 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 29' ' ' ILE . . . . . 0.527 ' HB ' ' CE2' ' A' ' 31' ' ' TYR . 2.8 mm -115.6 149.76 17.74 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 N-CA-C 110.084 -0.339 . . . . 0.0 110.084 -179.814 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 30' ' ' CYS . . . . . 0.537 ' HA ' ' O ' ' A' ' 20' ' ' THR . 26.8 m -79.85 105.1 10.89 Favored 'General case' 0 C--O 1.238 0.464 0 CA-C-N 115.955 -0.566 . . . . 0.0 111.35 -179.802 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 31' ' ' TYR . . . . . 0.71 ' HB2' HD12 ' A' ' 22' ' ' ILE . 36.9 m-85 -128.74 168.46 15.81 Favored 'General case' 0 C--O 1.233 0.205 0 CA-C-N 115.087 -0.961 . . . . 0.0 111.099 -179.552 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 1.8 tt -101.06 130.33 50.64 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.585 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.363 179.651 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 33' ' ' ILE . . . . . 0.458 ' H ' HG13 ' A' ' 33' ' ' ILE . 1.6 pp . . . . . 0 C--O 1.248 0.986 0 CA-C-O 118.386 -0.816 . . . . 0.0 111.525 179.881 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 N--CA 1.488 1.455 0 CA-C-O 119.757 -0.163 . . . . 0.0 111.045 . . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 2' ' ' PRO . . . . . 0.576 ' HD2' ' O ' ' A' ' 14' ' ' PRO . 73.7 Cg_endo -69.22 -170.6 0.36 Allowed 'Trans proline' 0 C--N 1.376 1.991 0 C-N-CA 123.204 2.603 . . . . 0.0 113.949 -178.955 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -143.5 -159.09 7.83 Favored Glycine 0 C--N 1.34 0.778 0 O-C-N 123.511 0.507 . . . . 0.0 112.543 179.877 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 16.6 tt0 -68.39 122.93 19.43 Favored 'General case' 0 N--CA 1.472 0.642 0 C-N-CA 122.849 0.46 . . . . 0.0 111.524 -179.893 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 92.12 14.47 56.05 Favored Glycine 0 C--N 1.339 0.736 0 CA-C-N 115.681 -0.691 . . . . 0.0 113.242 -179.864 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 43.0 mt-10 -127.9 165.83 19.46 Favored 'General case' 0 C--O 1.239 0.535 0 C-N-CA 122.447 0.299 . . . . 0.0 110.813 179.942 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 7' ' ' GLN . . . . . 0.526 ' HA ' ' O ' ' A' ' 28' ' ' GLY . 15.6 mt-30 -85.11 145.15 27.79 Favored 'General case' 0 C--N 1.346 0.415 0 CA-C-N 116.371 -0.377 . . . . 0.0 111.515 179.966 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 7.4 p -138.26 155.59 48.48 Favored 'General case' 0 C--O 1.236 0.385 0 CA-C-N 115.274 -0.876 . . . . 0.0 111.292 -179.51 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 6.1 t70 -118.25 152.46 35.68 Favored 'General case' 0 C--O 1.235 0.335 0 CA-C-N 115.35 -0.841 . . . . 0.0 109.668 179.003 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 14.4 m -101.1 21.63 1.97 Allowed 'Isoleucine or valine' 0 CA--C 1.541 0.624 0 CA-C-N 116.18 -0.464 . . . . 0.0 112.058 -179.466 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 44.5 mt-10 -118.51 -53.0 2.34 Favored 'General case' 0 N--CA 1.465 0.319 0 N-CA-C 112.196 0.443 . . . . 0.0 112.196 -179.18 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 12' ' ' PHE . . . . . . . . . . . . . 15.1 t80 -139.01 -7.49 1.39 Allowed 'General case' 0 N--CA 1.47 0.564 0 N-CA-C 112.534 0.568 . . . . 0.0 112.534 -178.784 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 13' ' ' ASN . . . . . . . . . . . . . 8.2 t-20 -129.34 63.22 66.74 Favored Pre-proline 0 CA--C 1.55 0.943 0 N-CA-C 111.415 0.154 . . . . 0.0 111.415 -179.144 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 14' ' ' PRO . . . . . 0.576 ' O ' ' HD2' ' A' ' 2' ' ' PRO . 15.6 Cg_exo -68.93 178.03 4.44 Favored 'Trans proline' 0 C--N 1.373 1.865 0 C-N-CA 122.828 2.352 . . . . 0.0 112.372 179.235 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 1.5 m -79.54 119.45 22.54 Favored 'General case' 0 N--CA 1.471 0.605 0 O-C-N 123.144 0.278 . . . . 0.0 111.315 -179.86 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 16' ' ' CYS . . . . . 0.576 ' HB2' ' O ' ' A' ' 2' ' ' PRO . 0.0 OUTLIER -57.13 -53.18 67.97 Favored Pre-proline 0 N--CA 1.483 1.182 0 CA-C-N 115.923 -0.581 . . . . 0.0 111.554 179.489 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 17' ' ' PRO . . . . . 0.48 ' HG2' HD12 ' A' ' 19' ' ' LEU . 57.9 Cg_endo -72.71 169.28 22.35 Favored 'Trans proline' 0 C--N 1.38 2.191 0 C-N-CA 121.994 1.796 . . . . 0.0 111.815 178.178 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 55.9 Cg_endo -72.27 44.69 0.72 Allowed 'Trans proline' 0 C--N 1.371 1.76 0 C-N-CA 122.012 1.808 . . . . 0.0 113.062 178.778 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 19' ' ' LEU . . . . . 0.48 HD12 ' HG2' ' A' ' 17' ' ' PRO . 12.2 mt -104.39 172.74 6.63 Favored 'General case' 0 C--O 1.236 0.361 0 CA-C-N 115.911 -0.586 . . . . 0.0 110.996 -179.761 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 25.4 m -103.32 150.19 24.01 Favored 'General case' 0 CA--C 1.534 0.335 0 CA-C-N 115.987 -0.551 . . . . 0.0 110.982 -178.903 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 5.1 t -100.38 103.03 14.4 Favored 'General case' 0 C--O 1.238 0.453 0 CA-C-N 115.724 -0.671 . . . . 0.0 109.407 178.412 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 22' ' ' ILE . . . . . 0.715 HD12 ' HB2' ' A' ' 31' ' ' TYR . 2.5 mt -127.16 129.04 24.02 Favored Pre-proline 0 CA--C 1.541 0.629 0 CA-C-N 115.803 -0.635 . . . . 0.0 110.826 -178.457 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 37.6 Cg_endo -67.99 -48.52 0.25 Allowed 'Cis proline' 0 C--N 1.375 1.938 0 C-N-CA 124.674 -0.969 . . . . 0.0 113.726 -0.261 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 79.12 37.79 24.14 Favored Glycine 0 C--N 1.347 1.19 0 C-N-CA 121.456 -0.402 . . . . 0.0 112.883 -179.991 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 4.6 t70 -140.12 80.57 19.92 Favored Pre-proline 0 CA--C 1.549 0.912 0 C-N-CA 122.338 0.255 . . . . 0.0 110.461 -179.686 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 1.9 Cg_endo -82.24 -31.71 4.0 Favored 'Cis proline' 0 C--N 1.372 1.774 0 C-N-CA 125.112 -0.787 . . . . 0.0 112.973 -0.134 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 27' ' ' TYR . . . . . . . . . . . . . 66.8 m-85 -101.7 171.98 7.22 Favored 'General case' 0 C--O 1.237 0.424 0 CA-C-N 115.796 -0.638 . . . . 0.0 111.591 -179.146 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 28' ' ' GLY . . . . . 0.526 ' O ' ' HA ' ' A' ' 7' ' ' GLN . . . -174.93 -160.26 22.6 Favored Glycine 0 C--N 1.337 0.621 0 CA-C-N 115.667 -0.697 . . . . 0.0 112.409 178.905 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 29' ' ' ILE . . . . . 0.56 ' HB ' ' CE2' ' A' ' 31' ' ' TYR . 1.4 mm -122.37 152.14 26.48 Favored 'Isoleucine or valine' 0 C--O 1.233 0.191 0 N-CA-C 109.807 -0.442 . . . . 0.0 109.807 179.609 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 30' ' ' CYS . . . . . 0.443 ' SG ' ' HB2' ' A' ' 19' ' ' LEU . 0.5 OUTLIER -80.02 106.92 12.4 Favored 'General case' 0 CA--C 1.537 0.467 0 CA-C-N 115.961 -0.563 . . . . 0.0 110.919 -179.986 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 31' ' ' TYR . . . . . 0.715 ' HB2' HD12 ' A' ' 22' ' ' ILE . 36.3 m-85 -132.15 167.17 20.24 Favored 'General case' 0 N--CA 1.463 0.222 0 CA-C-N 115.449 -0.796 . . . . 0.0 111.155 -179.332 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 2.7 tp -101.82 131.67 49.28 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.611 0 CA-C-N 116.081 -0.509 . . . . 0.0 110.412 179.493 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 33' ' ' ILE . . . . . 0.466 ' H ' HG13 ' A' ' 33' ' ' ILE . 1.9 pp . . . . . 0 C--O 1.249 1.04 0 CA-C-O 118.133 -0.937 . . . . 0.0 111.568 179.873 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 4.8 p . . . . . 0 N--CA 1.485 1.313 0 CA-C-O 119.719 -0.182 . . . . 0.0 111.263 . . . . . . . . . 0 0 . 1 . 015 nuclear build full ' A' A ' 2' ' ' PRO . . . . . . . . . . . . . 81.2 Cg_endo -82.88 -172.65 1.45 Allowed 'Trans proline' 0 C--N 1.367 1.508 0 C-N-CA 122.619 2.213 . . . . 0.0 112.886 179.59 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -145.28 -156.63 6.92 Favored Glycine 0 C--N 1.34 0.767 0 N-CA-C 111.562 -0.615 . . . . 0.0 111.562 179.151 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 18.1 tt0 -73.43 129.49 38.11 Favored 'General case' 0 N--CA 1.471 0.624 0 C-N-CA 122.445 0.298 . . . . 0.0 111.208 179.595 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 88.13 14.14 62.89 Favored Glycine 0 C--N 1.34 0.778 0 CA-C-N 115.765 -0.652 . . . . 0.0 113.274 -179.845 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 43.2 mt-10 -129.81 162.19 29.04 Favored 'General case' 0 C--O 1.237 0.404 0 C-N-CA 122.277 0.231 . . . . 0.0 110.733 -179.897 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 7' ' ' GLN . . . . . 0.496 ' HA ' ' O ' ' A' ' 28' ' ' GLY . 9.4 tt0 -83.82 136.77 34.01 Favored 'General case' 0 C--N 1.345 0.374 0 CA-C-O 121.305 0.574 . . . . 0.0 111.296 179.815 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 4.0 p -125.57 160.25 30.06 Favored 'General case' 0 C--O 1.243 0.712 0 CA-C-N 114.471 -1.241 . . . . 0.0 110.89 -179.554 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 9' ' ' ASP . . . . . 0.444 ' OD1' ' HD2' ' A' ' 27' ' ' TYR . 2.5 m-20 -114.58 150.11 35.51 Favored 'General case' 0 C--O 1.235 0.313 0 CA-C-N 115.58 -0.736 . . . . 0.0 109.684 179.432 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 11.2 m -103.24 16.78 5.1 Favored 'Isoleucine or valine' 0 CA--C 1.542 0.64 0 CA-C-N 116.398 -0.364 . . . . 0.0 111.766 -179.686 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 9.6 mm-40 -110.73 -52.53 2.78 Favored 'General case' 0 C--O 1.235 0.312 0 N-CA-C 112.118 0.414 . . . . 0.0 112.118 -178.937 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 12' ' ' PHE . . . . . . . . . . . . . 17.2 t80 -142.01 -7.84 0.93 Allowed 'General case' 0 N--CA 1.472 0.663 0 N-CA-C 112.569 0.581 . . . . 0.0 112.569 -178.788 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 13' ' ' ASN . . . . . . . . . . . . . 5.4 t-20 -129.58 64.37 71.38 Favored Pre-proline 0 CA--C 1.55 0.952 0 N-CA-C 111.559 0.207 . . . . 0.0 111.559 -179.075 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 15.0 Cg_exo -69.64 179.95 3.28 Favored 'Trans proline' 0 C--N 1.372 1.792 0 C-N-CA 122.888 2.392 . . . . 0.0 111.993 178.947 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 1.3 t -79.76 121.25 25.12 Favored 'General case' 0 N--CA 1.47 0.573 0 CA-C-O 120.519 0.2 . . . . 0.0 111.142 -179.951 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER -57.88 -53.61 63.96 Favored Pre-proline 0 N--CA 1.478 0.952 0 CA-C-O 118.992 -0.528 . . . . 0.0 111.573 179.325 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 17' ' ' PRO . . . . . 0.552 ' HG2' HD12 ' A' ' 19' ' ' LEU . 45.1 Cg_endo -69.06 169.61 17.63 Favored 'Trans proline' 0 C--N 1.378 2.099 0 C-N-CA 122.12 1.88 . . . . 0.0 111.725 178.181 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -71.8 49.67 1.27 Allowed 'Trans proline' 0 C--N 1.372 1.794 0 C-N-CA 121.957 1.771 . . . . 0.0 112.688 178.794 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 19' ' ' LEU . . . . . 0.552 HD12 ' HG2' ' A' ' 17' ' ' PRO . 22.0 mt -110.08 168.32 9.52 Favored 'General case' 0 C--O 1.236 0.389 0 CA-C-N 115.703 -0.681 . . . . 0.0 111.284 -179.363 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 20' ' ' THR . . . . . 0.519 ' O ' ' HA ' ' A' ' 30' ' ' CYS . 27.9 m -105.19 154.48 20.14 Favored 'General case' 0 CA--C 1.533 0.304 0 CA-C-N 115.641 -0.709 . . . . 0.0 111.191 -178.71 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 1.8 t -103.78 102.37 12.19 Favored 'General case' 0 C--O 1.238 0.453 0 CA-C-N 115.594 -0.73 . . . . 0.0 109.626 178.817 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 22' ' ' ILE . . . . . 0.711 HD12 ' HB2' ' A' ' 31' ' ' TYR . 2.8 mt -125.31 129.86 24.33 Favored Pre-proline 0 CA--C 1.542 0.665 0 CA-C-N 115.655 -0.702 . . . . 0.0 110.308 -179.071 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 35.3 Cg_endo -65.93 -48.9 0.21 Allowed 'Cis proline' 0 C--N 1.375 1.922 0 C-N-CA 124.723 -0.949 . . . . 0.0 113.817 -0.21 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 77.97 33.62 40.67 Favored Glycine 0 C--N 1.347 1.179 0 C-N-CA 121.256 -0.497 . . . . 0.0 112.901 179.872 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 4.6 t70 -139.49 82.84 17.92 Favored Pre-proline 0 CA--C 1.546 0.794 0 C-N-CA 122.556 0.343 . . . . 0.0 110.166 -179.641 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 2.5 Cg_endo -81.52 -32.54 3.61 Favored 'Cis proline' 0 C--N 1.37 1.7 0 C-N-CA 125.146 -0.772 . . . . 0.0 113.048 -0.028 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 27' ' ' TYR . . . . . 0.444 ' HD2' ' OD1' ' A' ' 9' ' ' ASP . 46.4 m-85 -103.46 167.59 9.71 Favored 'General case' 0 C--O 1.239 0.5 0 O-C-N 123.669 0.606 . . . . 0.0 111.476 -178.889 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 28' ' ' GLY . . . . . 0.496 ' O ' ' HA ' ' A' ' 7' ' ' GLN . . . -170.0 -163.14 23.54 Favored Glycine 0 C--N 1.342 0.899 0 C-N-CA 120.853 -0.689 . . . . 0.0 113.327 178.543 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 29' ' ' ILE . . . . . 0.501 ' HB ' ' CE2' ' A' ' 31' ' ' TYR . 2.7 mm -118.21 154.86 20.28 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.284 0 O-C-N 124.108 0.534 . . . . 0.0 110.149 -179.931 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 30' ' ' CYS . . . . . 0.519 ' HA ' ' O ' ' A' ' 20' ' ' THR . 24.5 m -83.29 103.48 12.71 Favored 'General case' 0 C--O 1.237 0.431 0 CA-C-N 115.941 -0.572 . . . . 0.0 111.22 -179.961 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 31' ' ' TYR . . . . . 0.711 ' HB2' HD12 ' A' ' 22' ' ' ILE . 38.6 m-85 -129.55 167.37 18.01 Favored 'General case' 0 CA--C 1.531 0.212 0 CA-C-N 115.01 -0.996 . . . . 0.0 111.074 -179.586 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 2.8 tp -100.43 131.11 48.6 Favored 'Isoleucine or valine' 0 CA--C 1.542 0.639 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.271 179.534 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 33' ' ' ILE . . . . . 0.496 HG23 HD11 ' A' ' 22' ' ' ILE . 1.9 pp . . . . . 0 C--O 1.248 0.988 0 CA-C-O 118.387 -0.816 . . . . 0.0 111.48 179.866 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 6.0 p . . . . . 0 N--CA 1.485 1.295 0 CA-C-O 119.796 -0.145 . . . . 0.0 111.22 . . . . . . . . . 0 0 . 1 . 016 nuclear build full ' A' A ' 2' ' ' PRO . . . . . 0.405 ' HD2' ' O ' ' A' ' 14' ' ' PRO . 84.7 Cg_endo -83.12 -172.29 1.34 Allowed 'Trans proline' 0 C--N 1.367 1.528 0 C-N-CA 122.545 2.164 . . . . 0.0 112.926 179.629 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -148.23 -158.42 7.96 Favored Glycine 0 C--N 1.338 0.671 0 N-CA-C 111.63 -0.588 . . . . 0.0 111.63 179.276 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 17.9 tt0 -70.32 123.83 22.68 Favored 'General case' 0 N--CA 1.473 0.702 0 C-N-CA 122.489 0.316 . . . . 0.0 111.516 179.891 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 98.42 -11.19 63.34 Favored Glycine 0 C--N 1.34 0.799 0 CA-C-N 115.748 -0.66 . . . . 0.0 113.58 179.809 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 43.0 mt-10 -105.34 166.02 10.71 Favored 'General case' 0 C--O 1.238 0.465 0 CA-C-N 116.705 0.253 . . . . 0.0 111.01 -179.735 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 7' ' ' GLN . . . . . 0.457 ' HA ' ' HA ' ' A' ' 29' ' ' ILE . 6.5 tt0 -86.73 140.39 29.81 Favored 'General case' 0 C--N 1.347 0.466 0 CA-C-O 121.113 0.482 . . . . 0.0 111.132 179.744 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 8' ' ' CYS . . . . . 0.421 ' SG ' ' SG ' ' A' ' 15' ' ' CYS . 5.8 p -127.02 158.49 36.8 Favored 'General case' 0 C--O 1.239 0.53 0 CA-C-N 114.696 -1.138 . . . . 0.0 111.128 -179.599 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -114.92 149.73 36.78 Favored 'General case' 0 C--O 1.234 0.27 0 CA-C-N 115.377 -0.829 . . . . 0.0 109.711 179.348 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 10' ' ' VAL . . . . . 0.525 HG22 ' O ' ' A' ' 26' ' ' PRO . 10.4 m -103.83 17.87 4.78 Favored 'Isoleucine or valine' 0 CA--C 1.542 0.661 0 O-C-N 123.31 0.381 . . . . 0.0 111.621 179.926 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 9.7 mm-40 -109.45 -53.08 2.7 Favored 'General case' 0 C--O 1.234 0.287 0 CA-C-N 116.347 -0.388 . . . . 0.0 111.997 -179.186 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 12' ' ' PHE . . . . . . . . . . . . . 12.2 t80 -139.74 -18.05 0.96 Allowed 'General case' 0 N--CA 1.471 0.62 0 N-CA-C 112.423 0.527 . . . . 0.0 112.423 -179.04 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 13' ' ' ASN . . . . . . . . . . . . . 5.4 t-20 -118.7 74.67 12.46 Favored Pre-proline 0 CA--C 1.549 0.929 0 O-C-N 122.977 0.173 . . . . 0.0 111.222 -179.25 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 14' ' ' PRO . . . . . 0.405 ' O ' ' HD2' ' A' ' 2' ' ' PRO . 60.0 Cg_endo -75.48 178.11 7.78 Favored 'Trans proline' 0 C--N 1.372 1.768 0 C-N-CA 122.421 2.081 . . . . 0.0 112.649 179.201 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 15' ' ' CYS . . . . . 0.421 ' SG ' ' SG ' ' A' ' 8' ' ' CYS . 1.6 m -79.66 119.83 23.14 Favored 'General case' 0 N--CA 1.471 0.596 0 O-C-N 123.151 0.282 . . . . 0.0 111.623 179.983 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER -58.91 -54.27 58.11 Favored Pre-proline 0 N--CA 1.477 0.908 0 CA-C-N 115.91 -0.586 . . . . 0.0 111.598 179.667 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 48.0 Cg_endo -68.95 169.02 18.82 Favored 'Trans proline' 0 C--N 1.38 2.207 0 C-N-CA 121.965 1.777 . . . . 0.0 111.687 178.382 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 56.1 Cg_endo -72.43 45.89 0.9 Allowed 'Trans proline' 0 C--N 1.37 1.702 0 C-N-CA 121.929 1.752 . . . . 0.0 112.939 179.048 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 19' ' ' LEU . . . . . 0.506 ' HB2' ' SG ' ' A' ' 30' ' ' CYS . 44.4 mt -106.44 169.83 8.28 Favored 'General case' 0 C--O 1.236 0.358 0 CA-C-N 116.118 -0.492 . . . . 0.0 111.038 -179.632 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 32.6 m -104.12 149.89 24.83 Favored 'General case' 0 CA--C 1.533 0.31 0 CA-C-N 115.737 -0.665 . . . . 0.0 111.095 -178.904 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 2.7 t -98.44 102.54 14.32 Favored 'General case' 0 C--O 1.238 0.464 0 CA-C-N 115.88 -0.6 . . . . 0.0 109.555 178.545 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 22' ' ' ILE . . . . . 0.723 HD12 ' HB2' ' A' ' 31' ' ' TYR . 2.4 mt -126.64 130.68 23.8 Favored Pre-proline 0 CA--C 1.542 0.671 0 CA-C-N 115.704 -0.68 . . . . 0.0 110.457 -178.728 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 36.8 Cg_endo -66.88 -48.22 0.24 Allowed 'Cis proline' 0 C--N 1.374 1.917 0 C-N-CA 124.833 -0.903 . . . . 0.0 113.784 -0.088 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 75.31 41.23 31.5 Favored Glycine 0 C--N 1.348 1.246 0 C-N-CA 121.31 -0.471 . . . . 0.0 112.811 -179.948 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 8.1 m-20 -136.24 75.36 53.13 Favored Pre-proline 0 CA--C 1.545 0.761 0 C-N-CA 122.428 0.291 . . . . 0.0 110.863 -179.627 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 26' ' ' PRO . . . . . 0.525 ' O ' HG22 ' A' ' 10' ' ' VAL . 56.8 Cg_endo -88.49 -16.91 22.33 Favored 'Cis proline' 0 C--N 1.37 1.708 0 C-N-CA 124.79 -0.921 . . . . 0.0 113.773 -0.088 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 27' ' ' TYR . . . . . 0.475 ' CE2' ' HG2' ' A' ' 26' ' ' PRO . 21.0 m-85 -106.82 163.97 12.5 Favored 'General case' 0 C--O 1.238 0.497 0 CA-C-N 116.276 -0.42 . . . . 0.0 111.457 -179.026 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 28' ' ' GLY . . . . . 0.403 ' O ' ' HA ' ' A' ' 7' ' ' GLN . . . -173.64 -162.18 25.08 Favored Glycine 0 C--N 1.341 0.846 0 C-N-CA 120.889 -0.672 . . . . 0.0 113.291 178.493 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 29' ' ' ILE . . . . . 0.549 ' HB ' ' CE2' ' A' ' 31' ' ' TYR . 1.9 mm -118.51 154.68 20.68 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.232 0 O-C-N 124.031 0.489 . . . . 0.0 110.049 -179.912 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 30' ' ' CYS . . . . . 0.506 ' SG ' ' HB2' ' A' ' 19' ' ' LEU . 0.5 OUTLIER -81.97 105.49 13.12 Favored 'General case' 0 CA--C 1.537 0.464 0 CA-C-N 115.893 -0.594 . . . . 0.0 110.986 179.974 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 31' ' ' TYR . . . . . 0.723 ' HB2' HD12 ' A' ' 22' ' ' ILE . 38.4 m-85 -131.04 165.44 23.22 Favored 'General case' 0 N--CA 1.464 0.23 0 CA-C-N 115.406 -0.815 . . . . 0.0 111.205 -179.415 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 2.9 tp -100.08 131.3 47.8 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.592 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.461 179.571 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 33' ' ' ILE . . . . . 0.476 ' H ' HG13 ' A' ' 33' ' ' ILE . 1.9 pp . . . . . 0 C--O 1.249 1.033 0 CA-C-O 118.191 -0.909 . . . . 0.0 111.468 179.956 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 0.3 OUTLIER . . . . . 0 N--CA 1.487 1.417 0 CA-C-O 119.794 -0.146 . . . . 0.0 111.07 . . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 2' ' ' PRO . . . . . 0.581 ' O ' ' HB2' ' A' ' 16' ' ' CYS . 87.5 Cg_endo -71.35 -172.28 0.73 Allowed 'Trans proline' 0 C--N 1.375 1.923 0 C-N-CA 123.224 2.616 . . . . 0.0 113.854 -178.885 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -134.49 -154.56 7.23 Favored Glycine 0 C--N 1.342 0.895 0 CA-C-N 116.09 -0.504 . . . . 0.0 112.287 179.979 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 16.1 tt0 -73.72 137.67 44.17 Favored 'General case' 0 N--CA 1.472 0.637 0 C-N-CA 122.845 0.458 . . . . 0.0 111.407 -179.854 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 82.61 12.92 79.37 Favored Glycine 0 C--N 1.341 0.832 0 CA-C-N 115.689 -0.687 . . . . 0.0 113.277 -179.771 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 43.1 mt-10 -125.95 161.53 27.29 Favored 'General case' 0 C--O 1.237 0.421 0 C-N-CA 122.346 0.258 . . . . 0.0 110.935 -179.875 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 7' ' ' GLN . . . . . 0.722 ' HA ' ' O ' ' A' ' 28' ' ' GLY . 21.0 tt0 -88.54 133.96 34.0 Favored 'General case' 0 C--N 1.344 0.363 0 CA-C-O 121.216 0.532 . . . . 0.0 111.275 179.872 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 2.0 p -128.73 161.64 29.24 Favored 'General case' 0 C--O 1.239 0.54 0 CA-C-N 114.557 -1.201 . . . . 0.0 111.149 -179.738 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 12.2 t70 -117.1 147.02 42.76 Favored 'General case' 0 C--O 1.234 0.254 0 CA-C-N 115.677 -0.692 . . . . 0.0 109.562 178.769 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 15.8 m -93.73 24.98 0.52 Allowed 'Isoleucine or valine' 0 CA--C 1.544 0.74 0 CA-C-N 116.268 -0.423 . . . . 0.0 111.805 -179.43 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 43.7 mt-10 -121.51 -52.79 2.02 Favored 'General case' 0 CA--C 1.533 0.293 0 N-CA-C 112.268 0.47 . . . . 0.0 112.268 -178.98 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 12' ' ' PHE . . . . . . . . . . . . . 9.9 t80 -138.27 -10.59 1.46 Allowed 'General case' 0 N--CA 1.47 0.546 0 N-CA-C 112.812 0.671 . . . . 0.0 112.812 -178.622 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 13' ' ' ASN . . . . . . . . . . . . . 7.5 t-20 -129.57 62.79 65.19 Favored Pre-proline 0 CA--C 1.55 0.953 0 N-CA-C 111.655 0.243 . . . . 0.0 111.655 -179.277 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 14' ' ' PRO . . . . . 0.558 ' O ' ' HD2' ' A' ' 2' ' ' PRO . 13.5 Cg_exo -70.1 -179.97 3.45 Favored 'Trans proline' 0 C--N 1.374 1.878 0 C-N-CA 122.649 2.233 . . . . 0.0 111.962 178.985 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 1.8 t -79.57 120.83 24.48 Favored 'General case' 0 N--CA 1.47 0.541 0 C-N-CA 121.989 0.116 . . . . 0.0 110.849 -179.947 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 16' ' ' CYS . . . . . 0.581 ' HB2' ' O ' ' A' ' 2' ' ' PRO . 0.0 OUTLIER -55.66 -52.56 71.05 Favored Pre-proline 0 N--CA 1.483 1.214 0 CA-C-O 118.952 -0.547 . . . . 0.0 111.643 179.572 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 17' ' ' PRO . . . . . 0.554 ' HG2' HD12 ' A' ' 19' ' ' LEU . 56.5 Cg_endo -71.98 169.84 20.36 Favored 'Trans proline' 0 C--N 1.378 2.13 0 C-N-CA 122.155 1.903 . . . . 0.0 111.667 178.111 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 55.2 Cg_endo -71.91 48.55 1.13 Allowed 'Trans proline' 0 C--N 1.373 1.861 0 C-N-CA 121.976 1.784 . . . . 0.0 112.928 178.857 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 19' ' ' LEU . . . . . 0.554 HD12 ' HG2' ' A' ' 17' ' ' PRO . 28.2 mt -108.32 171.06 7.63 Favored 'General case' 0 C--O 1.236 0.383 0 CA-C-N 115.679 -0.691 . . . . 0.0 111.271 -179.655 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 20' ' ' THR . . . . . 0.527 ' O ' ' HA ' ' A' ' 30' ' ' CYS . 20.0 m -105.07 153.56 21.32 Favored 'General case' 0 CA--C 1.533 0.294 0 CA-C-N 115.927 -0.579 . . . . 0.0 111.044 -178.879 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 2.7 t -105.58 99.5 9.1 Favored 'General case' 0 C--O 1.236 0.367 0 CA-C-N 115.646 -0.706 . . . . 0.0 109.366 178.776 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 22' ' ' ILE . . . . . 0.727 HD12 ' HB2' ' A' ' 31' ' ' TYR . 3.6 mt -120.71 129.92 25.09 Favored Pre-proline 0 CA--C 1.543 0.682 0 CA-C-N 115.595 -0.729 . . . . 0.0 110.345 -178.782 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 36.8 Cg_endo -66.78 -47.01 0.27 Allowed 'Cis proline' 0 C--N 1.375 1.93 0 C-N-CA 124.647 -0.981 . . . . 0.0 113.965 -0.069 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 79.51 33.43 34.84 Favored Glycine 0 C--N 1.346 1.09 0 C-N-CA 121.223 -0.513 . . . . 0.0 112.957 179.8 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 8.3 m-20 -139.26 83.97 17.06 Favored Pre-proline 0 CA--C 1.544 0.735 0 C-N-CA 122.523 0.329 . . . . 0.0 110.588 -179.762 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 2.9 Cg_endo -80.25 -31.67 4.54 Favored 'Cis proline' 0 C--N 1.37 1.697 0 C-N-CA 125.074 -0.803 . . . . 0.0 112.907 -0.044 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 27' ' ' TYR . . . . . . . . . . . . . 59.8 m-85 -108.22 173.16 6.44 Favored 'General case' 0 C--O 1.239 0.541 0 CA-C-N 115.824 -0.625 . . . . 0.0 111.701 -179.053 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 28' ' ' GLY . . . . . 0.722 ' O ' ' HA ' ' A' ' 7' ' ' GLN . . . -175.54 -164.32 29.82 Favored Glycine 0 C--N 1.338 0.685 0 CA-C-N 115.694 -0.685 . . . . 0.0 112.491 178.495 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 29' ' ' ILE . . . . . 0.549 ' HB ' ' CE2' ' A' ' 31' ' ' TYR . 2.3 mm -113.99 152.82 15.61 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 O-C-N 123.654 0.267 . . . . 0.0 110.282 -179.825 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 30' ' ' CYS . . . . . 0.527 ' HA ' ' O ' ' A' ' 20' ' ' THR . 33.9 m -79.73 106.02 11.44 Favored 'General case' 0 C--O 1.237 0.409 0 CA-C-N 115.918 -0.583 . . . . 0.0 111.432 -179.874 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 31' ' ' TYR . . . . . 0.727 ' HB2' HD12 ' A' ' 22' ' ' ILE . 38.6 m-85 -130.51 167.83 18.03 Favored 'General case' 0 C--O 1.233 0.187 0 CA-C-N 115.081 -0.963 . . . . 0.0 111.113 -179.463 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 2.8 tp -101.21 131.13 49.54 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.551 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.31 179.514 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 33' ' ' ILE . . . . . 0.489 HG23 HD11 ' A' ' 22' ' ' ILE . 1.8 pp . . . . . 0 C--O 1.249 1.074 0 CA-C-O 118.158 -0.925 . . . . 0.0 111.443 179.913 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 0.2 OUTLIER . . . . . 0 N--CA 1.487 1.418 0 CA-C-O 119.803 -0.141 . . . . 0.0 111.094 . . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 2' ' ' PRO . . . . . 0.584 ' HD2' ' O ' ' A' ' 14' ' ' PRO . 91.6 Cg_endo -71.51 -172.46 0.78 Allowed 'Trans proline' 0 C--N 1.375 1.946 0 C-N-CA 123.252 2.635 . . . . 0.0 113.961 -178.761 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -135.86 -157.74 7.96 Favored Glycine 0 C--N 1.341 0.817 0 CA-C-N 115.977 -0.556 . . . . 0.0 112.053 179.778 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 18.0 tt0 -73.07 135.46 44.82 Favored 'General case' 0 N--CA 1.471 0.608 0 C-N-CA 122.721 0.408 . . . . 0.0 111.345 -179.957 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 88.31 9.44 69.86 Favored Glycine 0 C--N 1.34 0.797 0 CA-C-N 115.797 -0.638 . . . . 0.0 113.396 -179.707 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 42.6 mt-10 -128.6 166.62 18.52 Favored 'General case' 0 C--O 1.239 0.505 0 C-N-CA 122.298 0.239 . . . . 0.0 110.883 -179.963 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 7' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER -81.74 152.48 27.0 Favored 'General case' 0 C--N 1.347 0.483 0 CA-C-N 116.581 -0.281 . . . . 0.0 110.867 179.909 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 4.9 p -140.48 150.58 43.95 Favored 'General case' 0 C--O 1.235 0.327 0 CA-C-N 115.852 -0.613 . . . . 0.0 111.116 -179.283 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -111.01 141.87 43.91 Favored 'General case' 0 C--O 1.234 0.277 0 CA-C-N 115.4 -0.818 . . . . 0.0 109.59 179.671 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 10' ' ' VAL . . . . . 0.45 HG22 ' O ' ' A' ' 26' ' ' PRO . 6.8 m -96.09 22.58 0.92 Allowed 'Isoleucine or valine' 0 CA--C 1.541 0.611 0 CA-C-N 116.559 -0.291 . . . . 0.0 111.651 -179.926 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 45.3 mt-10 -115.29 -54.34 2.55 Favored 'General case' 0 C--O 1.235 0.305 0 N-CA-C 112.079 0.4 . . . . 0.0 112.079 -179.067 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 12' ' ' PHE . . . . . . . . . . . . . 11.9 t80 -141.53 -9.17 0.95 Allowed 'General case' 0 N--CA 1.473 0.676 0 N-CA-C 112.548 0.573 . . . . 0.0 112.548 -178.791 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 13' ' ' ASN . . . . . . . . . . . . . 6.8 t-20 -129.94 63.53 68.91 Favored Pre-proline 0 CA--C 1.551 0.981 0 N-CA-C 111.369 0.137 . . . . 0.0 111.369 -179.19 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 14' ' ' PRO . . . . . 0.584 ' O ' ' HD2' ' A' ' 2' ' ' PRO . 13.3 Cg_exo -70.37 -174.54 1.05 Allowed 'Trans proline' 0 C--N 1.375 1.922 0 C-N-CA 122.784 2.322 . . . . 0.0 112.039 179.118 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 2.1 t -79.27 120.61 23.98 Favored 'General case' 0 N--CA 1.472 0.627 0 O-C-N 122.909 0.131 . . . . 0.0 110.991 -179.902 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 16' ' ' CYS . . . . . 0.572 ' HB2' ' O ' ' A' ' 2' ' ' PRO . 0.0 OUTLIER -57.03 -52.5 73.67 Favored Pre-proline 0 N--CA 1.483 1.198 0 CA-C-O 119.073 -0.489 . . . . 0.0 111.551 179.458 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 17' ' ' PRO . . . . . 0.591 ' HG2' HD12 ' A' ' 19' ' ' LEU . 56.9 Cg_endo -72.29 169.95 20.36 Favored 'Trans proline' 0 C--N 1.38 2.205 0 C-N-CA 122.1 1.867 . . . . 0.0 111.712 178.013 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 53.1 Cg_endo -71.45 49.86 1.19 Allowed 'Trans proline' 0 C--N 1.373 1.861 0 C-N-CA 121.978 1.785 . . . . 0.0 112.852 178.871 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 19' ' ' LEU . . . . . 0.591 HD12 ' HG2' ' A' ' 17' ' ' PRO . 32.9 mt -108.7 172.5 6.81 Favored 'General case' 0 CA--C 1.533 0.321 0 CA-C-N 115.722 -0.672 . . . . 0.0 111.235 -179.574 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 20' ' ' THR . . . . . 0.424 ' O ' ' HA ' ' A' ' 30' ' ' CYS . 25.0 m -106.63 153.96 21.61 Favored 'General case' 0 CA--C 1.533 0.308 0 CA-C-N 115.811 -0.631 . . . . 0.0 111.462 -178.497 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 3.5 t -103.57 104.18 14.2 Favored 'General case' 0 C--O 1.236 0.392 0 CA-C-N 115.512 -0.767 . . . . 0.0 109.474 178.568 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 22' ' ' ILE . . . . . 0.721 HD12 ' HB2' ' A' ' 31' ' ' TYR . 4.8 mt -125.56 129.66 24.33 Favored Pre-proline 0 CA--C 1.543 0.703 0 CA-C-N 115.757 -0.656 . . . . 0.0 110.665 -178.914 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 35.6 Cg_endo -66.45 -48.11 0.24 Allowed 'Cis proline' 0 C--N 1.376 1.998 0 C-N-CA 124.683 -0.965 . . . . 0.0 113.801 -0.207 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 80.46 34.4 28.86 Favored Glycine 0 C--N 1.347 1.141 0 C-N-CA 121.253 -0.498 . . . . 0.0 112.904 179.877 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 8.0 m-20 -142.81 84.27 10.87 Favored Pre-proline 0 CA--C 1.544 0.719 0 C-N-CA 122.525 0.33 . . . . 0.0 110.542 -179.604 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 26' ' ' PRO . . . . . 0.45 ' O ' HG22 ' A' ' 10' ' ' VAL . 1.1 Cg_endo -81.77 -31.73 4.12 Favored 'Cis proline' 0 C--N 1.373 1.821 0 C-N-CA 125.075 -0.802 . . . . 0.0 113.06 -0.098 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 27' ' ' TYR . . . . . . . . . . . . . 41.2 m-85 -101.26 167.56 10.12 Favored 'General case' 0 C--O 1.239 0.532 0 CA-C-N 115.797 -0.638 . . . . 0.0 111.158 -178.981 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -164.88 -161.21 13.37 Favored Glycine 0 C--N 1.34 0.799 0 C-N-CA 120.839 -0.696 . . . . 0.0 113.264 179.619 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 29' ' ' ILE . . . . . 0.489 ' HB ' ' CE2' ' A' ' 31' ' ' TYR . 3.9 mm -127.93 155.26 39.32 Favored 'Isoleucine or valine' 0 C--O 1.234 0.268 0 CA-C-N 115.175 -0.512 . . . . 0.0 109.877 179.944 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 30' ' ' CYS . . . . . 0.424 ' HA ' ' O ' ' A' ' 20' ' ' THR . 23.7 m -81.96 100.61 9.77 Favored 'General case' 0 CA--C 1.536 0.435 0 CA-C-O 121.278 0.561 . . . . 0.0 111.446 -179.911 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 31' ' ' TYR . . . . . 0.721 ' HB2' HD12 ' A' ' 22' ' ' ILE . 38.4 m-85 -130.04 166.16 20.72 Favored 'General case' 0 N--CA 1.464 0.246 0 CA-C-N 115.12 -0.946 . . . . 0.0 110.937 -179.872 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 2.9 tp -101.0 131.71 48.15 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.546 0 CA-C-N 116.077 -0.511 . . . . 0.0 110.367 179.558 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 33' ' ' ILE . . . . . 0.496 HG23 HD11 ' A' ' 22' ' ' ILE . 1.8 pp . . . . . 0 C--O 1.25 1.097 0 CA-C-O 118.241 -0.885 . . . . 0.0 111.486 179.876 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 0.2 OUTLIER . . . . . 0 N--CA 1.486 1.34 0 CA-C-O 119.777 -0.154 . . . . 0.0 111.068 . . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 2' ' ' PRO . . . . . 0.579 ' O ' ' HB2' ' A' ' 16' ' ' CYS . 92.3 Cg_endo -71.43 -172.32 0.75 Allowed 'Trans proline' 0 C--N 1.375 1.929 0 C-N-CA 123.27 2.647 . . . . 0.0 113.907 -178.842 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -135.79 -156.54 7.59 Favored Glycine 0 C--N 1.342 0.894 0 CA-C-N 116.027 -0.533 . . . . 0.0 112.387 179.829 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 16.0 tt0 -74.31 138.78 43.76 Favored 'General case' 0 N--CA 1.471 0.593 0 C-N-CA 122.693 0.397 . . . . 0.0 111.377 -179.707 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 84.53 10.62 79.27 Favored Glycine 0 C--N 1.34 0.754 0 CA-C-N 115.809 -0.632 . . . . 0.0 113.333 179.99 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 43.1 mt-10 -129.16 160.98 31.17 Favored 'General case' 0 N--CA 1.467 0.4 0 C-N-CA 122.206 0.202 . . . . 0.0 110.846 -179.841 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 7' ' ' GLN . . . . . 0.516 ' HA ' ' O ' ' A' ' 28' ' ' GLY . 7.5 tt0 -84.85 133.65 34.31 Favored 'General case' 0 C--N 1.344 0.366 0 CA-C-O 121.331 0.586 . . . . 0.0 111.215 179.765 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 3.3 p -122.85 161.75 23.48 Favored 'General case' 0 C--O 1.241 0.615 0 CA-C-N 114.44 -1.254 . . . . 0.0 110.824 -179.638 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 9' ' ' ASP . . . . . 0.452 ' OD1' ' HD2' ' A' ' 27' ' ' TYR . 1.8 m-20 -114.91 152.01 33.04 Favored 'General case' 0 C--O 1.235 0.31 0 CA-C-N 115.511 -0.768 . . . . 0.0 109.77 179.41 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 10.1 m -103.79 13.03 7.44 Favored 'Isoleucine or valine' 0 CA--C 1.542 0.651 0 O-C-N 123.254 0.346 . . . . 0.0 111.801 -179.818 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 45.9 mt-10 -100.95 -55.67 2.51 Favored 'General case' 0 C--O 1.235 0.304 0 N-CA-C 111.812 0.301 . . . . 0.0 111.812 -179.073 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 12' ' ' PHE . . . . . . . . . . . . . 12.6 t80 -141.25 -14.23 0.89 Allowed 'General case' 0 N--CA 1.47 0.564 0 N-CA-C 112.218 0.451 . . . . 0.0 112.218 -179.251 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 13' ' ' ASN . . . . . . . . . . . . . 12.8 t-20 -120.47 72.91 21.09 Favored Pre-proline 0 CA--C 1.55 0.955 0 O-C-N 122.903 0.127 . . . . 0.0 111.184 -179.406 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 14' ' ' PRO . . . . . 0.575 ' O ' ' HD2' ' A' ' 2' ' ' PRO . 60.8 Cg_endo -76.44 -176.4 3.08 Favored 'Trans proline' 0 C--N 1.371 1.735 0 C-N-CA 122.367 2.044 . . . . 0.0 112.207 179.245 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 2.0 t -79.34 119.64 22.67 Favored 'General case' 0 N--CA 1.473 0.71 0 O-C-N 123.017 0.198 . . . . 0.0 110.642 179.861 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 16' ' ' CYS . . . . . 0.579 ' HB2' ' O ' ' A' ' 2' ' ' PRO . 0.0 OUTLIER -54.94 -52.48 70.49 Favored Pre-proline 0 N--CA 1.483 1.178 0 CA-C-O 119.005 -0.521 . . . . 0.0 111.664 179.715 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 17' ' ' PRO . . . . . 0.561 ' HG2' HD12 ' A' ' 19' ' ' LEU . 57.6 Cg_endo -72.39 169.79 20.83 Favored 'Trans proline' 0 C--N 1.378 2.126 0 C-N-CA 122.06 1.84 . . . . 0.0 111.789 178.021 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 55.1 Cg_endo -71.87 50.28 1.4 Allowed 'Trans proline' 0 C--N 1.374 1.895 0 C-N-CA 122.065 1.844 . . . . 0.0 112.742 178.808 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 19' ' ' LEU . . . . . 0.561 HD12 ' HG2' ' A' ' 17' ' ' PRO . 32.4 mt -110.03 172.13 7.04 Favored 'General case' 0 CA--C 1.533 0.323 0 CA-C-N 115.666 -0.697 . . . . 0.0 111.311 -179.33 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 20' ' ' THR . . . . . 0.497 ' O ' ' HA ' ' A' ' 30' ' ' CYS . 21.2 m -106.04 154.38 20.71 Favored 'General case' 0 CA--C 1.533 0.293 0 CA-C-N 115.606 -0.724 . . . . 0.0 111.002 -178.948 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 2.0 t -105.35 99.7 9.3 Favored 'General case' 0 C--O 1.237 0.398 0 CA-C-N 115.644 -0.707 . . . . 0.0 109.363 178.597 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 22' ' ' ILE . . . . . 0.73 HD12 ' HB2' ' A' ' 31' ' ' TYR . 3.0 mt -122.53 130.53 24.62 Favored Pre-proline 0 CA--C 1.542 0.658 0 CA-C-N 115.559 -0.746 . . . . 0.0 110.382 -178.713 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 32.5 Cg_endo -65.07 -48.47 0.21 Allowed 'Cis proline' 0 C--N 1.375 1.944 0 C-N-CA 124.76 -0.933 . . . . 0.0 113.942 -0.226 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 77.19 31.36 52.51 Favored Glycine 0 C--N 1.348 1.215 0 C-N-CA 121.165 -0.54 . . . . 0.0 113.004 179.725 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 8.3 m-20 -138.86 83.71 18.56 Favored Pre-proline 0 CA--C 1.544 0.717 0 C-N-CA 122.49 0.316 . . . . 0.0 110.432 -179.771 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 3.0 Cg_exo -81.17 -32.34 3.83 Favored 'Cis proline' 0 C--N 1.372 1.772 0 C-N-CA 125.101 -0.791 . . . . 0.0 113.07 -0.08 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 27' ' ' TYR . . . . . 0.452 ' HD2' ' OD1' ' A' ' 9' ' ' ASP . 45.4 m-85 -104.4 166.76 10.19 Favored 'General case' 0 N--CA 1.469 0.485 0 CA-C-N 115.864 -0.607 . . . . 0.0 111.465 -178.884 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 28' ' ' GLY . . . . . 0.516 ' O ' ' HA ' ' A' ' 7' ' ' GLN . . . -169.95 -164.85 26.36 Favored Glycine 0 C--N 1.341 0.842 0 C-N-CA 120.93 -0.652 . . . . 0.0 113.356 178.492 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 29' ' ' ILE . . . . . 0.536 ' HB ' ' CE2' ' A' ' 31' ' ' TYR . 1.9 mm -117.38 153.07 19.22 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.225 0 O-C-N 124.045 0.497 . . . . 0.0 110.22 -179.938 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 30' ' ' CYS . . . . . 0.497 ' HA ' ' O ' ' A' ' 20' ' ' THR . 20.5 m -80.06 104.66 10.78 Favored 'General case' 0 CA--C 1.536 0.42 0 CA-C-N 115.923 -0.581 . . . . 0.0 111.21 -179.866 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 31' ' ' TYR . . . . . 0.73 ' HB2' HD12 ' A' ' 22' ' ' ILE . 39.7 m-85 -130.12 167.51 18.24 Favored 'General case' 0 C--O 1.233 0.223 0 CA-C-N 115.098 -0.956 . . . . 0.0 111.044 -179.54 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 2.6 tp -100.95 131.84 47.82 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.524 0 CA-C-N 116.056 -0.52 . . . . 0.0 110.426 179.486 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 33' ' ' ILE . . . . . 0.451 ' O ' HD12 ' A' ' 33' ' ' ILE . 1.7 pp . . . . . 0 C--O 1.248 0.998 0 CA-C-O 118.383 -0.818 . . . . 0.0 111.522 179.856 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 0.2 OUTLIER . . . . . 0 N--CA 1.487 1.402 0 CA-C-O 119.753 -0.165 . . . . 0.0 111.045 . . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 2' ' ' PRO . . . . . 0.594 ' HD2' ' O ' ' A' ' 14' ' ' PRO . 94.6 Cg_endo -71.52 -172.63 0.81 Allowed 'Trans proline' 0 C--N 1.375 1.931 0 C-N-CA 123.299 2.666 . . . . 0.0 113.801 -178.816 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -136.4 -158.1 7.97 Favored Glycine 0 C--N 1.342 0.89 0 CA-C-N 115.852 -0.613 . . . . 0.0 112.232 179.749 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 18.3 tt0 -73.52 136.51 44.11 Favored 'General case' 0 N--CA 1.472 0.625 0 C-N-CA 122.717 0.407 . . . . 0.0 111.382 -179.978 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 87.85 9.23 71.61 Favored Glycine 0 C--N 1.339 0.703 0 O-C-N 123.775 0.672 . . . . 0.0 113.398 -179.796 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 3.2 tp10 -129.0 166.49 19.09 Favored 'General case' 0 C--O 1.239 0.53 0 C-N-CA 122.218 0.207 . . . . 0.0 110.576 -179.816 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 7' ' ' GLN . . . . . . . . . . . . . 0.2 OUTLIER -80.6 152.81 28.36 Favored 'General case' 0 C--N 1.347 0.483 0 CA-C-N 116.517 -0.31 . . . . 0.0 110.822 179.782 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 6.2 p -140.85 152.24 44.97 Favored 'General case' 0 C--O 1.234 0.245 0 CA-C-N 115.958 -0.565 . . . . 0.0 111.163 -179.12 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -112.41 146.12 38.92 Favored 'General case' 0 C--O 1.235 0.337 0 CA-C-N 115.397 -0.82 . . . . 0.0 109.626 179.498 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 10' ' ' VAL . . . . . 0.452 HG22 ' O ' ' A' ' 26' ' ' PRO . 6.5 m -101.26 17.91 3.63 Favored 'Isoleucine or valine' 0 CA--C 1.543 0.674 0 CA-C-N 116.46 -0.336 . . . . 0.0 111.604 179.988 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 47.0 mt-10 -107.55 -55.01 2.41 Favored 'General case' 0 N--CA 1.467 0.383 0 CA-C-N 116.346 -0.388 . . . . 0.0 111.873 -179.155 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 12' ' ' PHE . . . . . . . . . . . . . 10.8 t80 -140.35 -16.77 0.92 Allowed 'General case' 0 N--CA 1.471 0.596 0 N-CA-C 112.31 0.485 . . . . 0.0 112.31 -179.193 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 13' ' ' ASN . . . . . . . . . . . . . 8.3 t-20 -120.56 72.98 21.76 Favored Pre-proline 0 CA--C 1.548 0.899 0 O-C-N 122.937 0.148 . . . . 0.0 111.139 -179.337 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 14' ' ' PRO . . . . . 0.594 ' O ' ' HD2' ' A' ' 2' ' ' PRO . 62.4 Cg_endo -76.71 -175.13 2.44 Favored 'Trans proline' 0 C--N 1.372 1.806 0 C-N-CA 122.484 2.123 . . . . 0.0 112.347 179.318 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 2.2 t -79.48 119.59 22.68 Favored 'General case' 0 N--CA 1.472 0.651 0 CA-C-O 120.452 0.168 . . . . 0.0 110.727 179.932 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 16' ' ' CYS . . . . . 0.579 ' HB2' ' O ' ' A' ' 2' ' ' PRO . 0.0 OUTLIER -56.25 -52.59 71.8 Favored Pre-proline 0 N--CA 1.481 1.101 0 CA-C-O 119.005 -0.521 . . . . 0.0 111.712 179.611 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 17' ' ' PRO . . . . . 0.582 ' HG2' HD12 ' A' ' 19' ' ' LEU . 56.9 Cg_endo -72.36 169.67 21.1 Favored 'Trans proline' 0 C--N 1.38 2.205 0 C-N-CA 122.065 1.844 . . . . 0.0 111.721 177.969 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -71.69 51.87 1.6 Allowed 'Trans proline' 0 C--N 1.373 1.859 0 C-N-CA 121.963 1.776 . . . . 0.0 112.769 178.79 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 19' ' ' LEU . . . . . 0.582 HD12 ' HG2' ' A' ' 17' ' ' PRO . 37.5 mt -110.6 173.12 6.48 Favored 'General case' 0 C--O 1.236 0.37 0 CA-C-N 115.58 -0.736 . . . . 0.0 111.333 -179.565 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 28.8 m -107.92 152.88 23.85 Favored 'General case' 0 CA--C 1.533 0.318 0 CA-C-N 115.874 -0.603 . . . . 0.0 111.346 -178.565 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 3.9 t -101.82 104.25 15.0 Favored 'General case' 0 C--O 1.238 0.471 0 CA-C-N 115.437 -0.801 . . . . 0.0 109.622 178.463 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 22' ' ' ILE . . . . . 0.726 HD12 ' HB2' ' A' ' 31' ' ' TYR . 4.5 mt -125.92 129.75 24.2 Favored Pre-proline 0 CA--C 1.544 0.717 0 CA-C-N 115.918 -0.583 . . . . 0.0 110.544 -178.775 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 23' ' ' PRO . . . . . 0.48 ' HB2' ' OD2' ' A' ' 25' ' ' ASP . 35.2 Cg_endo -66.01 -48.76 0.21 Allowed 'Cis proline' 0 C--N 1.376 1.979 0 C-N-CA 124.71 -0.954 . . . . 0.0 113.807 -0.354 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 80.55 35.61 25.38 Favored Glycine 0 C--N 1.347 1.156 0 C-N-CA 121.299 -0.477 . . . . 0.0 112.91 179.826 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 25' ' ' ASP . . . . . 0.48 ' OD2' ' HB2' ' A' ' 23' ' ' PRO . 2.5 p30 -143.72 84.1 10.11 Favored Pre-proline 0 CA--C 1.548 0.898 0 C-N-CA 122.551 0.34 . . . . 0.0 110.759 -179.789 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 26' ' ' PRO . . . . . 0.452 ' O ' HG22 ' A' ' 10' ' ' VAL . 1.2 Cg_endo -81.41 -32.1 3.95 Favored 'Cis proline' 0 C--N 1.371 1.712 0 C-N-CA 125.15 -0.771 . . . . 0.0 113.087 0.011 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 27' ' ' TYR . . . . . . . . . . . . . 40.1 m-85 -101.79 169.69 8.64 Favored 'General case' 0 C--O 1.239 0.533 0 CA-C-N 115.754 -0.657 . . . . 0.0 111.213 -178.888 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -167.49 -159.42 13.04 Favored Glycine 0 C--N 1.341 0.815 0 C-N-CA 120.888 -0.672 . . . . 0.0 113.243 179.517 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 29' ' ' ILE . . . . . 0.493 ' HB ' ' CE2' ' A' ' 31' ' ' TYR . 4.2 mm -128.17 154.4 38.78 Favored 'Isoleucine or valine' 0 C--O 1.233 0.193 0 CA-C-N 115.276 -0.462 . . . . 0.0 109.853 179.969 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 30' ' ' CYS . . . . . . . . . . . . . 18.2 m -81.55 101.48 9.99 Favored 'General case' 0 CA--C 1.536 0.42 0 CA-C-N 116.02 -0.536 . . . . 0.0 111.395 179.989 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 31' ' ' TYR . . . . . 0.726 ' HB2' HD12 ' A' ' 22' ' ' ILE . 38.4 m-85 -130.0 166.53 19.9 Favored 'General case' 0 N--CA 1.464 0.228 0 CA-C-N 115.145 -0.934 . . . . 0.0 110.995 -179.714 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 2.8 tp -101.5 131.96 48.29 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.624 0 CA-C-N 116.141 -0.482 . . . . 0.0 110.377 179.51 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 33' ' ' ILE . . . . . 0.488 ' H ' HG13 ' A' ' 33' ' ' ILE . 1.8 pp . . . . . 0 C--O 1.249 1.057 0 CA-C-O 118.382 -0.818 . . . . 0.0 111.521 179.945 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 2' ' ' PRO . . . . . 0.539 ' HD3' ' ND2' ' A' ' 13' ' ' ASN . 81.1 Cg_endo . . . . . 0 CA--C 1.545 1.034 0 N-CA-C 112.942 0.324 . . . . 0.0 112.942 . . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -145.77 -159.22 8.06 Favored Glycine 0 C--N 1.337 0.632 0 N-CA-C 111.547 -0.621 . . . . 0.0 111.547 179.189 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 19.7 tt0 -71.3 125.84 28.05 Favored 'General case' 0 N--CA 1.472 0.668 0 CA-C-N 116.901 0.35 . . . . 0.0 111.072 179.631 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 88.22 16.65 58.8 Favored Glycine 0 C--N 1.339 0.724 0 CA-C-N 115.659 -0.7 . . . . 0.0 113.097 -179.541 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 43.1 mt-10 -127.95 166.91 17.43 Favored 'General case' 0 C--O 1.237 0.433 0 C-N-CA 122.333 0.253 . . . . 0.0 110.719 -179.775 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 7' ' ' GLN . . . . . 0.459 ' HA ' ' O ' ' A' ' 28' ' ' GLY . 0.2 OUTLIER -81.05 152.04 28.08 Favored 'General case' 0 C--N 1.346 0.436 0 CA-C-N 116.502 -0.317 . . . . 0.0 110.974 179.89 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 6.3 p -147.12 156.24 42.83 Favored 'General case' 0 C--O 1.235 0.307 0 CA-C-N 115.963 -0.562 . . . . 0.0 111.583 -178.965 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 4.8 t70 -117.36 149.13 41.01 Favored 'General case' 0 C--O 1.234 0.263 0 CA-C-N 115.452 -0.794 . . . . 0.0 109.589 178.918 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 15.7 m -102.38 24.49 1.48 Allowed 'Isoleucine or valine' 0 CA--C 1.542 0.655 0 CA-C-N 116.225 -0.443 . . . . 0.0 111.905 -179.493 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 43.9 mt-10 -120.63 -50.89 2.18 Favored 'General case' 0 N--CA 1.466 0.333 0 N-CA-C 112.063 0.394 . . . . 0.0 112.063 -179.044 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 12' ' ' PHE . . . . . . . . . . . . . 13.7 m-85 -133.35 -27.23 1.59 Allowed 'General case' 0 N--CA 1.47 0.541 0 N-CA-C 112.181 0.437 . . . . 0.0 112.181 -178.706 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 13' ' ' ASN . . . . . 0.539 ' ND2' ' HD3' ' A' ' 2' ' ' PRO . 6.3 t30 -116.03 73.91 5.11 Favored Pre-proline 0 CA--C 1.549 0.934 0 O-C-N 123.435 0.459 . . . . 0.0 112.174 -177.467 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 14' ' ' PRO . . . . . 0.415 ' O ' ' HD2' ' A' ' 2' ' ' PRO . 60.8 Cg_endo -76.1 179.09 6.67 Favored 'Trans proline' 0 C--N 1.372 1.777 0 C-N-CA 122.43 2.087 . . . . 0.0 112.125 178.746 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 1.9 t -79.67 119.9 23.24 Favored 'General case' 0 N--CA 1.47 0.566 0 CA-C-O 120.499 0.19 . . . . 0.0 110.938 179.75 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER -57.86 -54.07 59.23 Favored Pre-proline 0 N--CA 1.477 0.915 0 CA-C-O 118.973 -0.537 . . . . 0.0 111.757 179.651 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 17' ' ' PRO . . . . . 0.621 ' HG2' HD12 ' A' ' 19' ' ' LEU . 51.9 Cg_endo -70.39 168.19 23.08 Favored 'Trans proline' 0 C--N 1.378 2.118 0 C-N-CA 122.025 1.817 . . . . 0.0 111.8 178.25 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 49.8 Cg_endo -71.01 60.88 2.39 Favored 'Trans proline' 0 C--N 1.372 1.796 0 C-N-CA 121.945 1.763 . . . . 0.0 112.427 178.807 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 19' ' ' LEU . . . . . 0.621 HD12 ' HG2' ' A' ' 17' ' ' PRO . 22.6 mt -122.42 171.58 8.97 Favored 'General case' 0 C--O 1.235 0.325 0 CA-C-N 115.411 -0.813 . . . . 0.0 111.421 -179.269 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 20' ' ' THR . . . . . 0.492 ' O ' ' HA ' ' A' ' 30' ' ' CYS . 28.5 m -107.72 153.69 22.58 Favored 'General case' 0 CA--C 1.533 0.306 0 CA-C-N 115.676 -0.693 . . . . 0.0 111.227 -178.676 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 4.8 t -103.06 104.97 15.19 Favored 'General case' 0 C--O 1.237 0.426 0 CA-C-N 115.593 -0.731 . . . . 0.0 109.553 178.626 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 22' ' ' ILE . . . . . 0.712 HD12 ' HB2' ' A' ' 31' ' ' TYR . 3.4 mt -127.12 129.34 23.97 Favored Pre-proline 0 CA--C 1.543 0.686 0 CA-C-N 115.874 -0.603 . . . . 0.0 110.47 -178.805 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 37.6 Cg_endo -67.46 -48.69 0.23 Allowed 'Cis proline' 0 C--N 1.374 1.913 0 C-N-CA 124.713 -0.953 . . . . 0.0 113.848 -0.294 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 80.5 40.74 12.35 Favored Glycine 0 C--N 1.347 1.145 0 C-N-CA 121.264 -0.493 . . . . 0.0 112.761 -179.891 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 8.2 m-20 -141.6 79.31 17.21 Favored Pre-proline 0 CA--C 1.544 0.744 0 C-N-CA 122.443 0.297 . . . . 0.0 110.837 -179.709 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 1.5 Cg_endo -82.49 -32.72 3.29 Favored 'Cis proline' 0 C--N 1.371 1.746 0 C-N-CA 125.074 -0.803 . . . . 0.0 113.028 -0.125 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 27' ' ' TYR . . . . . . . . . . . . . 71.7 m-85 -98.11 171.43 8.25 Favored 'General case' 0 C--O 1.24 0.563 0 CA-C-N 115.913 -0.585 . . . . 0.0 111.568 -178.973 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 28' ' ' GLY . . . . . 0.459 ' O ' ' HA ' ' A' ' 7' ' ' GLN . . . -173.03 -159.84 20.44 Favored Glycine 0 C--N 1.338 0.653 0 CA-C-N 115.784 -0.644 . . . . 0.0 112.365 179.301 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 29' ' ' ILE . . . . . 0.518 ' HB ' ' CE2' ' A' ' 31' ' ' TYR . 2.9 mm -124.21 151.18 29.13 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 N-CA-C 109.735 -0.468 . . . . 0.0 109.735 179.737 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 30' ' ' CYS . . . . . 0.492 ' HA ' ' O ' ' A' ' 20' ' ' THR . 23.4 m -79.94 103.24 9.69 Favored 'General case' 0 CA--C 1.536 0.412 0 CA-C-O 121.225 0.536 . . . . 0.0 111.432 -179.812 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 31' ' ' TYR . . . . . 0.712 ' HB2' HD12 ' A' ' 22' ' ' ILE . 38.2 m-85 -129.07 167.77 17.04 Favored 'General case' 0 C--O 1.233 0.211 0 CA-C-N 115.014 -0.993 . . . . 0.0 110.923 -179.623 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 2.7 tp -100.95 131.43 48.62 Favored 'Isoleucine or valine' 0 CA--C 1.542 0.645 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.315 179.411 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 33' ' ' ILE . . . . . 0.498 HG23 HD11 ' A' ' 22' ' ' ILE . 1.9 pp . . . . . 0 C--O 1.249 1.051 0 CA-C-O 118.395 -0.812 . . . . 0.0 111.413 179.954 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 2' ' ' PRO . . . . . 0.488 ' HD3' ' ND2' ' A' ' 13' ' ' ASN . 88.6 Cg_endo . . . . . 0 CA--C 1.543 0.926 0 N-CA-C 112.963 0.332 . . . . 0.0 112.963 . . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -149.46 -159.58 8.7 Favored Glycine 0 C--N 1.338 0.67 0 N-CA-C 111.623 -0.591 . . . . 0.0 111.623 179.229 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 17.2 tt0 -70.05 121.29 17.17 Favored 'General case' 0 N--CA 1.474 0.73 0 CA-C-O 120.763 0.315 . . . . 0.0 111.241 179.811 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 93.37 15.15 51.99 Favored Glycine 0 C--N 1.34 0.782 0 CA-C-N 115.614 -0.721 . . . . 0.0 113.164 -179.776 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 43.1 mt-10 -128.75 166.63 18.62 Favored 'General case' 0 C--O 1.24 0.56 0 C-N-CA 122.514 0.326 . . . . 0.0 110.816 179.959 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 7' ' ' GLN . . . . . 0.443 ' HA ' ' O ' ' A' ' 28' ' ' GLY . 0.2 OUTLIER -81.43 152.55 27.35 Favored 'General case' 0 C--N 1.346 0.435 0 O-C-N 123.195 0.309 . . . . 0.0 111.137 -179.88 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 7.9 p -145.84 154.53 42.1 Favored 'General case' 0 N--CA 1.466 0.354 0 CA-C-N 115.957 -0.565 . . . . 0.0 111.502 -179.12 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 6.2 t70 -118.12 153.82 33.15 Favored 'General case' 0 C--O 1.236 0.345 0 CA-C-N 115.393 -0.821 . . . . 0.0 109.898 179.139 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 13.5 m -105.33 17.92 5.44 Favored 'Isoleucine or valine' 0 CA--C 1.542 0.661 0 CA-C-N 116.286 -0.416 . . . . 0.0 112.033 -179.422 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 46.3 mt-10 -110.74 -52.9 2.75 Favored 'General case' 0 N--CA 1.466 0.36 0 N-CA-C 111.898 0.332 . . . . 0.0 111.898 -179.149 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 12' ' ' PHE . . . . . . . . . . . . . 13.4 t80 -138.76 -15.66 1.17 Allowed 'General case' 0 N--CA 1.469 0.493 0 N-CA-C 112.406 0.521 . . . . 0.0 112.406 -178.945 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 13' ' ' ASN . . . . . 0.488 ' ND2' ' HD3' ' A' ' 2' ' ' PRO . 7.4 t30 -120.62 73.35 22.73 Favored Pre-proline 0 CA--C 1.549 0.929 0 O-C-N 122.935 0.147 . . . . 0.0 111.343 -179.204 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 14' ' ' PRO . . . . . 0.425 ' O ' ' HD2' ' A' ' 2' ' ' PRO . 60.5 Cg_endo -76.43 176.56 9.92 Favored 'Trans proline' 0 C--N 1.371 1.75 0 C-N-CA 122.428 2.085 . . . . 0.0 112.48 179.342 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 1.4 m -79.67 118.9 21.91 Favored 'General case' 0 N--CA 1.469 0.488 0 O-C-N 123.199 0.312 . . . . 0.0 111.422 179.923 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER -58.03 -53.87 61.43 Favored Pre-proline 0 N--CA 1.477 0.906 0 CA-C-N 115.865 -0.607 . . . . 0.0 111.776 179.81 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 17' ' ' PRO . . . . . 0.459 ' HG2' HD12 ' A' ' 19' ' ' LEU . 53.3 Cg_endo -70.28 168.65 21.61 Favored 'Trans proline' 0 C--N 1.379 2.132 0 C-N-CA 121.983 1.789 . . . . 0.0 111.736 178.351 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 56.0 Cg_endo -72.4 47.34 1.09 Allowed 'Trans proline' 0 C--N 1.37 1.673 0 C-N-CA 121.872 1.714 . . . . 0.0 112.855 178.987 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 19' ' ' LEU . . . . . 0.462 ' HB2' ' SG ' ' A' ' 30' ' ' CYS . 13.0 mt -107.58 171.08 7.59 Favored 'General case' 0 CA--C 1.533 0.32 0 CA-C-N 115.921 -0.582 . . . . 0.0 110.955 -179.537 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 28.6 m -104.43 148.84 25.98 Favored 'General case' 0 CA--C 1.531 0.25 0 CA-C-N 115.829 -0.623 . . . . 0.0 111.108 -178.76 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 5.9 t -98.49 103.03 14.95 Favored 'General case' 0 C--O 1.238 0.499 0 N-CA-C 109.421 -0.585 . . . . 0.0 109.421 178.384 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 22' ' ' ILE . . . . . 0.715 HD12 ' HB2' ' A' ' 31' ' ' TYR . 2.5 mt -126.62 129.02 24.19 Favored Pre-proline 0 CA--C 1.543 0.703 0 CA-C-N 115.817 -0.629 . . . . 0.0 110.742 -178.547 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 37.4 Cg_endo -67.67 -48.55 0.24 Allowed 'Cis proline' 0 C--N 1.374 1.908 0 C-N-CA 124.719 -0.95 . . . . 0.0 113.782 -0.262 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 79.38 38.7 20.79 Favored Glycine 0 C--N 1.348 1.227 0 C-N-CA 121.37 -0.443 . . . . 0.0 112.894 -179.991 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 8.4 m-20 -140.71 79.99 18.72 Favored Pre-proline 0 CA--C 1.544 0.735 0 C-N-CA 122.447 0.299 . . . . 0.0 110.869 -179.728 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 1.8 Cg_endo -82.23 -32.63 3.41 Favored 'Cis proline' 0 C--N 1.372 1.811 0 C-N-CA 125.15 -0.771 . . . . 0.0 112.945 -0.127 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 27' ' ' TYR . . . . . . . . . . . . . 68.0 m-85 -99.37 171.64 7.84 Favored 'General case' 0 C--O 1.238 0.482 0 CA-C-N 115.786 -0.643 . . . . 0.0 111.652 -179.096 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 28' ' ' GLY . . . . . 0.443 ' O ' ' HA ' ' A' ' 7' ' ' GLN . . . -174.64 -159.79 21.56 Favored Glycine 0 C--N 1.337 0.62 0 CA-C-N 115.801 -0.636 . . . . 0.0 112.268 179.185 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 29' ' ' ILE . . . . . 0.556 ' HB ' ' CE2' ' A' ' 31' ' ' TYR . 1.8 mm -124.12 152.1 29.57 Favored 'Isoleucine or valine' 0 C--O 1.233 0.236 0 N-CA-C 109.755 -0.461 . . . . 0.0 109.755 179.627 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 30' ' ' CYS . . . . . 0.462 ' SG ' ' HB2' ' A' ' 19' ' ' LEU . 0.5 OUTLIER -80.12 104.49 10.71 Favored 'General case' 0 C--O 1.238 0.454 0 CA-C-N 115.974 -0.557 . . . . 0.0 110.99 -179.856 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 31' ' ' TYR . . . . . 0.715 ' HB2' HD12 ' A' ' 22' ' ' ILE . 36.1 m-85 -130.22 166.62 19.92 Favored 'General case' 0 C--O 1.233 0.189 0 CA-C-N 115.431 -0.804 . . . . 0.0 111.141 -179.501 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 2.8 tp -100.93 131.42 48.61 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.547 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.438 179.431 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 33' ' ' ILE . . . . . 0.47 ' H ' HG13 ' A' ' 33' ' ' ILE . 1.9 pp . . . . . 0 C--O 1.249 1.042 0 CA-C-O 118.28 -0.866 . . . . 0.0 111.518 179.903 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 2' ' ' PRO . . . . . 0.537 ' HD3' ' ND2' ' A' ' 13' ' ' ASN . 84.1 Cg_endo . . . . . 0 CA--C 1.543 0.933 0 N-CA-C 112.845 0.287 . . . . 0.0 112.845 . . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -147.12 -161.71 9.54 Favored Glycine 0 C--N 1.338 0.665 0 N-CA-C 111.696 -0.562 . . . . 0.0 111.696 179.194 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 19.4 tt0 -67.8 124.03 22.17 Favored 'General case' 0 N--CA 1.474 0.747 0 C-N-CA 122.488 0.315 . . . . 0.0 111.212 179.68 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 91.07 15.08 56.76 Favored Glycine 0 C--N 1.338 0.681 0 CA-C-N 115.66 -0.7 . . . . 0.0 113.125 -179.718 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 43.1 mt-10 -129.06 165.22 21.62 Favored 'General case' 0 C--O 1.237 0.414 0 C-N-CA 122.29 0.236 . . . . 0.0 110.802 -179.942 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 7' ' ' GLN . . . . . . . . . . . . . 0.2 OUTLIER -81.55 152.98 27.0 Favored 'General case' 0 C--N 1.346 0.454 0 CA-C-N 116.43 -0.35 . . . . 0.0 110.936 179.915 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 3.2 p -142.23 152.07 42.72 Favored 'General case' 0 C--O 1.234 0.249 0 CA-C-N 115.821 -0.627 . . . . 0.0 111.208 -179.255 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -110.04 141.32 43.02 Favored 'General case' 0 C--O 1.232 0.163 0 CA-C-N 115.541 -0.754 . . . . 0.0 109.492 179.38 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 8.8 m -96.59 21.5 1.15 Allowed 'Isoleucine or valine' 0 CA--C 1.543 0.675 0 CA-C-N 116.326 -0.397 . . . . 0.0 111.566 -179.984 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 45.5 mt-10 -113.81 -54.83 2.57 Favored 'General case' 0 C--O 1.236 0.351 0 N-CA-C 112.048 0.388 . . . . 0.0 112.048 -179.042 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 12' ' ' PHE . . . . . . . . . . . . . 10.5 t80 -137.62 -18.56 1.24 Allowed 'General case' 0 N--CA 1.471 0.625 0 N-CA-C 112.516 0.561 . . . . 0.0 112.516 -178.891 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 13' ' ' ASN . . . . . 0.537 ' ND2' ' HD3' ' A' ' 2' ' ' PRO . 9.2 t30 -119.2 73.83 14.06 Favored Pre-proline 0 CA--C 1.55 0.954 0 O-C-N 122.918 0.136 . . . . 0.0 111.118 -179.332 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 14' ' ' PRO . . . . . 0.424 ' O ' ' HD2' ' A' ' 2' ' ' PRO . 60.5 Cg_endo -75.69 -178.84 4.6 Favored 'Trans proline' 0 C--N 1.371 1.745 0 C-N-CA 122.443 2.095 . . . . 0.0 112.506 179.481 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 15' ' ' CYS . . . . . 0.531 ' SG ' ' HB2' ' A' ' 19' ' ' LEU . 4.3 t -79.47 120.48 23.93 Favored 'General case' 0 N--CA 1.471 0.623 0 O-C-N 123.079 0.237 . . . . 0.0 111.095 179.981 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER -60.27 -54.49 54.63 Favored Pre-proline 0 N--CA 1.476 0.847 0 CA-C-O 119.062 -0.494 . . . . 0.0 111.577 179.45 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 56.7 Cg_endo -71.22 168.81 22.28 Favored 'Trans proline' 0 C--N 1.381 2.241 0 C-N-CA 122.096 1.864 . . . . 0.0 111.614 178.123 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 48.4 Cg_endo -70.48 61.29 2.12 Favored 'Trans proline' 0 C--N 1.37 1.677 0 C-N-CA 121.918 1.745 . . . . 0.0 112.78 179.048 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 19' ' ' LEU . . . . . 0.531 ' HB2' ' SG ' ' A' ' 15' ' ' CYS . 90.7 mt -122.2 166.62 14.31 Favored 'General case' 0 C--O 1.235 0.331 0 CA-C-N 115.713 -0.676 . . . . 0.0 111.189 -179.869 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 20' ' ' THR . . . . . 0.471 ' OG1' HG12 ' A' ' 33' ' ' ILE . 89.5 m -106.32 149.65 26.73 Favored 'General case' 0 CA--C 1.533 0.302 0 CA-C-N 115.305 -0.861 . . . . 0.0 110.947 -179.3 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 21' ' ' CYS . . . . . 0.503 ' HA ' ' O ' ' A' ' 29' ' ' ILE . 1.9 t -95.25 106.94 19.02 Favored 'General case' 0 C--O 1.24 0.555 0 CA-C-N 115.726 -0.67 . . . . 0.0 110.244 178.917 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 22' ' ' ILE . . . . . 0.72 HD12 ' HB2' ' A' ' 31' ' ' TYR . 5.9 mt -125.47 128.5 24.67 Favored Pre-proline 0 CA--C 1.544 0.717 0 CA-C-N 115.928 -0.578 . . . . 0.0 110.531 -179.185 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 37.4 Cg_endo -67.19 -48.0 0.25 Allowed 'Cis proline' 0 C--N 1.375 1.963 0 C-N-CA 124.685 -0.964 . . . . 0.0 113.757 -0.35 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 83.07 35.75 17.29 Favored Glycine 0 C--N 1.345 1.07 0 C-N-CA 121.433 -0.413 . . . . 0.0 112.918 179.781 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 7.6 m-20 -143.91 83.6 10.27 Favored Pre-proline 0 CA--C 1.546 0.819 0 C-N-CA 122.478 0.311 . . . . 0.0 111.04 -179.661 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 69.7 Cg_endo -82.15 -31.73 4.01 Favored 'Cis proline' 0 C--N 1.372 1.813 0 C-N-CA 124.814 -0.911 . . . . 0.0 113.479 -0.218 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 27' ' ' TYR . . . . . . . . . . . . . 59.8 m-85 -96.92 163.32 13.01 Favored 'General case' 0 N--CA 1.47 0.548 0 CA-C-N 115.956 -0.565 . . . . 0.0 111.208 -179.16 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 28' ' ' GLY . . . . . 0.443 ' O ' HD13 ' A' ' 29' ' ' ILE . . . -157.89 -162.01 11.39 Favored Glycine 0 C--N 1.339 0.746 0 C-N-CA 120.92 -0.657 . . . . 0.0 113.098 179.815 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 29' ' ' ILE . . . . . 0.503 ' O ' ' HA ' ' A' ' 21' ' ' CYS . 5.0 mm -130.53 154.81 41.14 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.222 0 N-CA-C 109.709 -0.478 . . . . 0.0 109.709 179.948 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 30' ' ' CYS . . . . . . . . . . . . . 26.2 m -83.72 92.81 7.8 Favored 'General case' 0 C--O 1.238 0.489 0 CA-C-O 121.483 0.659 . . . . 0.0 111.403 -179.968 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 31' ' ' TYR . . . . . 0.72 ' HB2' HD12 ' A' ' 22' ' ' ILE . 37.1 m-85 -124.26 167.26 14.56 Favored 'General case' 0 N--CA 1.464 0.241 0 CA-C-N 114.962 -1.017 . . . . 0.0 110.902 179.945 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 2.8 tp -99.98 131.66 46.99 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.605 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.449 179.378 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 33' ' ' ILE . . . . . 0.471 HG12 ' OG1' ' A' ' 20' ' ' THR . 1.3 pt . . . . . 0 C--O 1.249 1.048 0 CA-C-O 118.142 -0.932 . . . . 0.0 111.416 179.832 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 2' ' ' PRO . . . . . 0.549 ' HD3' ' ND2' ' A' ' 13' ' ' ASN . 85.2 Cg_endo . . . . . 0 CA--C 1.543 0.954 0 N-CA-C 112.832 0.282 . . . . 0.0 112.832 . . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -146.59 -160.92 9.01 Favored Glycine 0 C--N 1.337 0.603 0 N-CA-C 111.661 -0.576 . . . . 0.0 111.661 179.141 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 19.6 tt0 -68.21 124.5 23.65 Favored 'General case' 0 N--CA 1.475 0.824 0 CA-C-N 116.816 0.308 . . . . 0.0 111.145 179.673 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 90.73 15.07 57.27 Favored Glycine 0 C--N 1.338 0.667 0 CA-C-N 115.663 -0.699 . . . . 0.0 113.143 -179.692 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 43.1 mt-10 -129.02 165.11 21.8 Favored 'General case' 0 C--O 1.239 0.53 0 C-N-CA 122.339 0.256 . . . . 0.0 110.807 -179.891 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 7' ' ' GLN . . . . . . . . . . . . . 0.2 OUTLIER -81.65 152.9 26.91 Favored 'General case' 0 C--N 1.346 0.433 0 O-C-N 123.179 0.3 . . . . 0.0 110.895 179.874 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 3.2 p -141.68 151.79 43.33 Favored 'General case' 0 C--O 1.234 0.242 0 CA-C-N 115.8 -0.636 . . . . 0.0 111.099 -179.272 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -110.34 143.56 40.38 Favored 'General case' 0 C--O 1.234 0.26 0 CA-C-N 115.481 -0.782 . . . . 0.0 109.532 179.423 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 10' ' ' VAL . . . . . 0.428 HG22 ' O ' ' A' ' 26' ' ' PRO . 6.1 m -98.28 21.06 1.52 Allowed 'Isoleucine or valine' 0 CA--C 1.541 0.606 0 O-C-N 123.238 0.336 . . . . 0.0 111.514 -179.899 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 8.5 mm-40 -115.53 -52.48 2.64 Favored 'General case' 0 C--O 1.235 0.304 0 N-CA-C 112.252 0.464 . . . . 0.0 112.252 -179.125 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 12' ' ' PHE . . . . . . . . . . . . . 13.0 t80 -141.04 -9.21 1.01 Allowed 'General case' 0 N--CA 1.473 0.709 0 N-CA-C 112.722 0.638 . . . . 0.0 112.722 -178.666 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 13' ' ' ASN . . . . . 0.549 ' ND2' ' HD3' ' A' ' 2' ' ' PRO . 7.6 t30 -129.64 64.94 73.55 Favored Pre-proline 0 CA--C 1.551 0.986 0 CA-C-N 117.496 0.135 . . . . 0.0 111.25 -179.075 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 14' ' ' PRO . . . . . 0.401 ' O ' ' HD2' ' A' ' 2' ' ' PRO . 15.8 Cg_exo -69.04 -178.66 2.16 Favored 'Trans proline' 0 C--N 1.372 1.808 0 C-N-CA 122.957 2.438 . . . . 0.0 112.266 179.009 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 15' ' ' CYS . . . . . 0.53 ' SG ' ' HB2' ' A' ' 19' ' ' LEU . 4.0 t -79.65 121.79 25.73 Favored 'General case' 0 N--CA 1.472 0.64 0 O-C-N 123.135 0.272 . . . . 0.0 111.331 -179.781 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER -61.35 -54.32 54.04 Favored Pre-proline 0 CA--C 1.547 0.845 0 CA-C-O 119.024 -0.512 . . . . 0.0 111.43 179.22 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 56.7 Cg_endo -71.19 169.21 21.22 Favored 'Trans proline' 0 C--N 1.38 2.225 0 C-N-CA 121.96 1.773 . . . . 0.0 111.719 178.193 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 49.0 Cg_endo -70.56 59.12 2.0 Favored 'Trans proline' 0 C--N 1.372 1.795 0 C-N-CA 121.918 1.746 . . . . 0.0 112.896 179.071 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 19' ' ' LEU . . . . . 0.53 ' HB2' ' SG ' ' A' ' 15' ' ' CYS . 92.2 mt -119.99 165.2 14.98 Favored 'General case' 0 C--O 1.235 0.31 0 CA-C-N 115.751 -0.659 . . . . 0.0 111.176 -179.95 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 87.5 m -104.08 150.58 24.17 Favored 'General case' 0 CA--C 1.532 0.285 0 CA-C-N 115.327 -0.851 . . . . 0.0 110.978 -179.464 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 21' ' ' CYS . . . . . 0.499 ' HA ' ' O ' ' A' ' 29' ' ' ILE . 1.9 t -96.57 104.55 16.54 Favored 'General case' 0 C--O 1.238 0.464 0 CA-C-N 115.669 -0.696 . . . . 0.0 109.98 178.94 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 22' ' ' ILE . . . . . 0.72 HD12 ' HB2' ' A' ' 31' ' ' TYR . 6.1 mt -122.83 128.01 25.53 Favored Pre-proline 0 CA--C 1.543 0.705 0 CA-C-N 115.865 -0.607 . . . . 0.0 110.546 -179.178 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 36.8 Cg_endo -66.96 -47.57 0.26 Allowed 'Cis proline' 0 C--N 1.376 1.977 0 C-N-CA 124.632 -0.987 . . . . 0.0 113.801 -0.302 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 83.73 32.85 23.29 Favored Glycine 0 C--N 1.345 1.081 0 C-N-CA 121.305 -0.474 . . . . 0.0 113.021 179.719 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 7.7 m-20 -144.18 86.57 8.27 Favored Pre-proline 0 CA--C 1.545 0.772 0 C-N-CA 122.56 0.344 . . . . 0.0 110.532 -179.654 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 26' ' ' PRO . . . . . 0.428 ' O ' HG22 ' A' ' 10' ' ' VAL . 1.1 Cg_endo -81.47 -31.34 4.49 Favored 'Cis proline' 0 C--N 1.371 1.733 0 C-N-CA 125.164 -0.765 . . . . 0.0 112.888 0.018 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 27' ' ' TYR . . . . . . . . . . . . . 41.3 m-85 -101.76 166.56 10.61 Favored 'General case' 0 C--O 1.237 0.398 0 CA-C-N 115.712 -0.676 . . . . 0.0 111.104 -179.137 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 28' ' ' GLY . . . . . 0.428 ' O ' HD13 ' A' ' 29' ' ' ILE . . . -160.63 -160.82 10.93 Favored Glycine 0 C--N 1.341 0.807 0 C-N-CA 120.911 -0.661 . . . . 0.0 113.21 179.999 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 29' ' ' ILE . . . . . 0.499 ' O ' ' HA ' ' A' ' 21' ' ' CYS . 4.8 mm -129.76 155.29 41.3 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.255 0 CA-C-N 115.273 -0.464 . . . . 0.0 109.887 -179.995 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 30' ' ' CYS . . . . . . . . . . . . . 30.1 m -84.04 93.78 8.17 Favored 'General case' 0 C--O 1.237 0.433 0 CA-C-O 121.39 0.614 . . . . 0.0 111.302 179.926 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 31' ' ' TYR . . . . . 0.72 ' HB2' HD12 ' A' ' 22' ' ' ILE . 35.4 m-85 -124.37 168.4 13.07 Favored 'General case' 0 N--CA 1.464 0.255 0 CA-C-N 115.012 -0.994 . . . . 0.0 111.14 -179.863 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 2.6 tp -100.68 133.48 43.7 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.598 0 CA-C-N 116.082 -0.508 . . . . 0.0 110.343 179.391 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 33' ' ' ILE . . . . . 0.436 ' OXT' HD12 ' A' ' 33' ' ' ILE . 1.6 pp . . . . . 0 C--O 1.249 1.031 0 CA-C-O 118.081 -0.961 . . . . 0.0 111.519 179.888 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 2' ' ' PRO . . . . . 0.486 ' HD3' HD21 ' A' ' 13' ' ' ASN . 94.5 Cg_endo . . . . . 0 CA--C 1.545 1.032 0 N-CA-C 112.937 0.322 . . . . 0.0 112.937 . . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -143.95 -153.53 5.9 Favored Glycine 0 C--N 1.339 0.724 0 N-CA-C 111.669 -0.573 . . . . 0.0 111.669 179.381 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 17.7 tt0 -73.92 130.26 39.52 Favored 'General case' 0 N--CA 1.472 0.668 0 C-N-CA 122.546 0.338 . . . . 0.0 111.265 179.578 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 85.81 15.35 65.64 Favored Glycine 0 C--N 1.339 0.709 0 CA-C-N 115.921 -0.582 . . . . 0.0 113.452 -179.756 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 43.1 mt-10 -126.02 161.13 28.26 Favored 'General case' 0 C--O 1.237 0.406 0 C-N-CA 122.243 0.217 . . . . 0.0 110.849 -179.829 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 7' ' ' GLN . . . . . 0.69 ' HA ' ' O ' ' A' ' 28' ' ' GLY . 18.9 tt0 -87.01 134.81 33.45 Favored 'General case' 0 C--N 1.346 0.422 0 CA-C-O 121.176 0.512 . . . . 0.0 111.311 179.89 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 8' ' ' CYS . . . . . 0.401 ' SG ' ' SG ' ' A' ' 30' ' ' CYS . 2.5 p -129.3 161.41 30.29 Favored 'General case' 0 C--O 1.239 0.522 0 CA-C-N 114.538 -1.21 . . . . 0.0 110.989 -179.528 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 9' ' ' ASP . . . . . 0.591 ' OD1' ' HB3' ' A' ' 13' ' ' ASN . 0.7 OUTLIER -120.69 142.68 49.26 Favored 'General case' 0 N--CA 1.463 0.222 0 CA-C-N 115.725 -0.67 . . . . 0.0 110.042 178.528 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 23.2 m -90.78 13.85 1.59 Allowed 'Isoleucine or valine' 0 CA--C 1.543 0.697 0 CA-C-N 115.994 -0.548 . . . . 0.0 111.593 -179.398 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 45.9 mt-10 -97.05 -51.96 4.03 Favored 'General case' 0 C--O 1.235 0.304 0 CA-C-N 116.029 -0.532 . . . . 0.0 111.938 -178.804 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 12' ' ' PHE . . . . . . . . . . . . . 7.2 t80 -144.97 -21.56 0.5 Allowed 'General case' 0 N--CA 1.473 0.691 0 N-CA-C 112.657 0.614 . . . . 0.0 112.657 -178.771 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 13' ' ' ASN . . . . . 0.591 ' HB3' ' OD1' ' A' ' 9' ' ' ASP . 13.2 t30 -120.03 75.13 21.32 Favored Pre-proline 0 CA--C 1.548 0.88 0 CA-C-N 117.521 0.146 . . . . 0.0 111.324 -178.889 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 61.4 Cg_endo -76.84 -175.89 2.87 Favored 'Trans proline' 0 C--N 1.372 1.774 0 C-N-CA 122.57 2.18 . . . . 0.0 112.16 178.731 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 0.8 OUTLIER -79.99 121.61 25.7 Favored 'General case' 0 N--CA 1.472 0.633 0 O-C-N 123.02 0.2 . . . . 0.0 111.189 179.879 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER -58.16 -53.56 64.69 Favored Pre-proline 0 N--CA 1.478 0.965 0 CA-C-N 116.137 -0.483 . . . . 0.0 111.593 179.106 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 17' ' ' PRO . . . . . 0.501 ' HG2' HD12 ' A' ' 19' ' ' LEU . 41.5 Cg_endo -67.72 169.65 15.59 Favored 'Trans proline' 0 C--N 1.379 2.172 0 C-N-CA 122.148 1.899 . . . . 0.0 111.852 178.165 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 55.2 Cg_endo -71.84 47.8 1.01 Allowed 'Trans proline' 0 C--N 1.371 1.753 0 C-N-CA 122.007 1.805 . . . . 0.0 112.755 178.658 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 19' ' ' LEU . . . . . 0.501 HD12 ' HG2' ' A' ' 17' ' ' PRO . 19.5 mt -108.8 165.4 11.59 Favored 'General case' 0 C--O 1.236 0.375 0 CA-C-N 115.7 -0.682 . . . . 0.0 111.285 -179.451 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 20' ' ' THR . . . . . 0.529 ' O ' ' HA ' ' A' ' 30' ' ' CYS . 30.7 m -103.24 152.53 21.39 Favored 'General case' 0 CA--C 1.531 0.227 0 CA-C-N 115.569 -0.742 . . . . 0.0 111.038 -178.833 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 2.2 t -102.64 99.75 9.76 Favored 'General case' 0 C--O 1.237 0.435 0 CA-C-N 115.753 -0.658 . . . . 0.0 109.594 178.902 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 22' ' ' ILE . . . . . 0.705 HD12 ' HB2' ' A' ' 31' ' ' TYR . 2.9 mt -120.88 128.78 25.6 Favored Pre-proline 0 CA--C 1.542 0.652 0 CA-C-N 115.637 -0.71 . . . . 0.0 110.372 -178.973 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 37.0 Cg_endo -66.81 -47.5 0.26 Allowed 'Cis proline' 0 C--N 1.375 1.936 0 C-N-CA 124.77 -0.929 . . . . 0.0 113.867 -0.232 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 79.11 34.03 34.48 Favored Glycine 0 C--N 1.347 1.173 0 C-N-CA 121.277 -0.487 . . . . 0.0 112.894 179.969 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 8.3 m-20 -139.73 83.26 16.85 Favored Pre-proline 0 CA--C 1.543 0.686 0 C-N-CA 122.561 0.344 . . . . 0.0 110.538 -179.712 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 3.1 Cg_exo -80.61 -32.05 4.18 Favored 'Cis proline' 0 C--N 1.371 1.746 0 C-N-CA 125.095 -0.794 . . . . 0.0 112.948 -0.099 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 27' ' ' TYR . . . . . 0.561 ' CD2' ' HB3' ' A' ' 9' ' ' ASP . 62.6 m-85 -106.85 172.67 6.69 Favored 'General case' 0 C--O 1.239 0.552 0 CA-C-N 115.753 -0.658 . . . . 0.0 111.751 -178.95 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 28' ' ' GLY . . . . . 0.69 ' O ' ' HA ' ' A' ' 7' ' ' GLN . . . -176.53 -164.08 29.95 Favored Glycine 0 C--N 1.338 0.693 0 CA-C-N 115.732 -0.667 . . . . 0.0 112.655 178.452 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 29' ' ' ILE . . . . . 0.544 ' HB ' ' CE2' ' A' ' 31' ' ' TYR . 2.6 mm -114.72 151.3 16.49 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 N-CA-C 110.082 -0.34 . . . . 0.0 110.082 -179.718 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 30' ' ' CYS . . . . . 0.529 ' HA ' ' O ' ' A' ' 20' ' ' THR . 40.7 m -79.87 105.74 11.38 Favored 'General case' 0 C--O 1.237 0.395 0 CA-C-N 115.843 -0.617 . . . . 0.0 111.482 -179.801 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 31' ' ' TYR . . . . . 0.705 ' HB2' HD12 ' A' ' 22' ' ' ILE . 36.6 m-85 -130.42 167.1 19.14 Favored 'General case' 0 C--O 1.233 0.205 0 CA-C-N 114.938 -1.028 . . . . 0.0 111.011 -179.406 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 2.9 tp -99.64 130.28 48.94 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.607 0 CA-C-N 116.27 -0.423 . . . . 0.0 110.348 179.436 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 33' ' ' ILE . . . . . 0.499 HG23 HD11 ' A' ' 22' ' ' ILE . 1.9 pp . . . . . 0 C--O 1.248 0.993 0 CA-C-O 118.335 -0.84 . . . . 0.0 111.528 179.879 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 2' ' ' PRO . . . . . 0.49 ' HD3' HD21 ' A' ' 13' ' ' ASN . 92.2 Cg_endo . . . . . 0 CA--C 1.543 0.975 0 N-CA-C 112.953 0.328 . . . . 0.0 112.953 . . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -143.83 -153.45 5.88 Favored Glycine 0 C--N 1.339 0.701 0 N-CA-C 111.821 -0.512 . . . . 0.0 111.821 179.383 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 17.7 tt0 -74.04 130.17 39.3 Favored 'General case' 0 N--CA 1.473 0.702 0 C-N-CA 122.702 0.401 . . . . 0.0 111.134 179.586 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 85.76 15.54 65.38 Favored Glycine 0 C--N 1.339 0.705 0 O-C-N 123.712 0.632 . . . . 0.0 113.386 -179.85 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 43.0 mt-10 -126.11 161.25 28.06 Favored 'General case' 0 C--O 1.238 0.474 0 C-N-CA 122.276 0.23 . . . . 0.0 110.85 -179.915 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 7' ' ' GLN . . . . . 0.691 ' HA ' ' O ' ' A' ' 28' ' ' GLY . 18.6 tt0 -87.1 134.81 33.47 Favored 'General case' 0 C--N 1.344 0.363 0 CA-C-O 121.258 0.552 . . . . 0.0 111.241 179.915 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 8' ' ' CYS . . . . . 0.401 ' SG ' ' SG ' ' A' ' 30' ' ' CYS . 2.5 p -129.3 161.42 30.27 Favored 'General case' 0 C--O 1.238 0.488 0 CA-C-N 114.511 -1.222 . . . . 0.0 111.017 -179.589 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 9' ' ' ASP . . . . . 0.591 ' OD1' ' HB3' ' A' ' 13' ' ' ASN . 0.7 OUTLIER -120.7 142.86 49.11 Favored 'General case' 0 N--CA 1.464 0.269 0 CA-C-N 115.693 -0.685 . . . . 0.0 109.992 178.557 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 22.5 m -90.89 13.76 1.63 Allowed 'Isoleucine or valine' 0 CA--C 1.543 0.677 0 CA-C-N 115.924 -0.58 . . . . 0.0 111.501 -179.337 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 46.0 mt-10 -96.94 -51.91 4.07 Favored 'General case' 0 C--O 1.235 0.327 0 CA-C-N 116.158 -0.474 . . . . 0.0 111.986 -178.802 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 12' ' ' PHE . . . . . . . . . . . . . 6.8 t80 -145.16 -21.49 0.49 Allowed 'General case' 0 N--CA 1.472 0.639 0 N-CA-C 112.671 0.619 . . . . 0.0 112.671 -178.845 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 13' ' ' ASN . . . . . 0.591 ' HB3' ' OD1' ' A' ' 9' ' ' ASP . 13.3 t30 -119.91 75.19 20.52 Favored Pre-proline 0 CA--C 1.548 0.887 0 CA-C-N 117.557 0.162 . . . . 0.0 111.336 -179.017 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 62.7 Cg_endo -76.85 -175.87 2.86 Favored 'Trans proline' 0 C--N 1.37 1.679 0 C-N-CA 122.663 2.242 . . . . 0.0 112.204 178.672 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 0.8 OUTLIER -79.99 121.56 25.64 Favored 'General case' 0 N--CA 1.471 0.603 0 CA-C-O 120.462 0.172 . . . . 0.0 111.168 179.9 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER -58.17 -53.52 65.15 Favored Pre-proline 0 N--CA 1.479 0.978 0 CA-C-O 119.049 -0.501 . . . . 0.0 111.568 179.117 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 17' ' ' PRO . . . . . 0.501 ' HG2' HD12 ' A' ' 19' ' ' LEU . 41.7 Cg_endo -67.75 169.69 15.56 Favored 'Trans proline' 0 C--N 1.38 2.22 0 C-N-CA 122.104 1.869 . . . . 0.0 111.865 178.202 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 55.3 Cg_endo -71.77 47.69 0.98 Allowed 'Trans proline' 0 C--N 1.373 1.818 0 C-N-CA 121.981 1.787 . . . . 0.0 112.735 178.731 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 19' ' ' LEU . . . . . 0.501 HD12 ' HG2' ' A' ' 17' ' ' PRO . 19.4 mt -108.78 165.38 11.6 Favored 'General case' 0 C--O 1.235 0.332 0 CA-C-N 115.681 -0.691 . . . . 0.0 111.272 -179.359 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 20' ' ' THR . . . . . 0.528 ' O ' ' HA ' ' A' ' 30' ' ' CYS . 30.5 m -103.19 152.37 21.54 Favored 'General case' 0 CA--C 1.531 0.227 0 CA-C-N 115.623 -0.717 . . . . 0.0 111.084 -178.902 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 2.2 t -102.45 99.75 9.82 Favored 'General case' 0 C--O 1.237 0.445 0 CA-C-N 115.719 -0.673 . . . . 0.0 109.6 178.837 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 22' ' ' ILE . . . . . 0.705 HD12 ' HB2' ' A' ' 31' ' ' TYR . 2.9 mt -120.91 128.73 25.63 Favored Pre-proline 0 CA--C 1.541 0.615 0 CA-C-N 115.677 -0.692 . . . . 0.0 110.4 -179.026 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 37.1 Cg_endo -66.92 -47.36 0.26 Allowed 'Cis proline' 0 C--N 1.374 1.919 0 C-N-CA 124.636 -0.985 . . . . 0.0 113.859 -0.112 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 79.03 33.99 34.89 Favored Glycine 0 C--N 1.348 1.196 0 C-N-CA 121.228 -0.51 . . . . 0.0 112.916 179.961 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 8.3 m-20 -139.68 83.24 16.99 Favored Pre-proline 0 CA--C 1.544 0.721 0 C-N-CA 122.576 0.35 . . . . 0.0 110.647 -179.793 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 3.2 Cg_exo -80.7 -31.92 4.26 Favored 'Cis proline' 0 C--N 1.371 1.729 0 C-N-CA 125.102 -0.791 . . . . 0.0 112.957 -0.005 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 27' ' ' TYR . . . . . 0.562 ' CD2' ' HB3' ' A' ' 9' ' ' ASP . 62.6 m-85 -106.96 172.66 6.7 Favored 'General case' 0 C--O 1.238 0.49 0 CA-C-N 115.737 -0.665 . . . . 0.0 111.705 -178.957 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 28' ' ' GLY . . . . . 0.691 ' O ' ' HA ' ' A' ' 7' ' ' GLN . . . -176.45 -164.17 30.06 Favored Glycine 0 C--N 1.34 0.771 0 CA-C-N 115.74 -0.664 . . . . 0.0 112.559 178.474 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 29' ' ' ILE . . . . . 0.543 ' HB ' ' CE2' ' A' ' 31' ' ' TYR . 2.6 mm -114.68 151.35 16.44 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 O-C-N 123.75 0.324 . . . . 0.0 110.155 -179.733 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 30' ' ' CYS . . . . . 0.528 ' HA ' ' O ' ' A' ' 20' ' ' THR . 41.4 m -79.82 105.72 11.31 Favored 'General case' 0 C--O 1.237 0.425 0 CA-C-N 115.981 -0.554 . . . . 0.0 111.399 -179.729 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 31' ' ' TYR . . . . . 0.705 ' HB2' HD12 ' A' ' 22' ' ' ILE . 37.1 m-85 -130.48 167.18 19.04 Favored 'General case' 0 C--O 1.233 0.205 0 CA-C-N 114.989 -1.005 . . . . 0.0 111.018 -179.566 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 2.9 tp -99.63 130.2 49.04 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.584 0 CA-C-N 116.121 -0.491 . . . . 0.0 110.343 179.562 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 33' ' ' ILE . . . . . 0.502 HG23 HD11 ' A' ' 22' ' ' ILE . 1.9 pp . . . . . 0 C--O 1.249 1.051 0 CA-C-O 118.331 -0.843 . . . . 0.0 111.521 179.858 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 2' ' ' PRO . . . . . 0.43 ' HD3' ' ND2' ' A' ' 13' ' ' ASN . 97.6 Cg_endo . . . . . 0 CA--C 1.544 1.013 0 N-CA-C 112.965 0.333 . . . . 0.0 112.965 . . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -145.12 -154.99 6.29 Favored Glycine 0 C--N 1.339 0.727 0 N-CA-C 111.78 -0.528 . . . . 0.0 111.78 179.393 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 17.9 tt0 -73.3 128.85 36.66 Favored 'General case' 0 N--CA 1.472 0.674 0 C-N-CA 122.565 0.346 . . . . 0.0 111.186 179.581 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 86.31 16.06 63.2 Favored Glycine 0 C--N 1.34 0.789 0 CA-C-N 115.784 -0.643 . . . . 0.0 113.184 -179.862 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 43.0 mt-10 -127.42 161.69 28.1 Favored 'General case' 0 N--CA 1.466 0.367 0 C-N-CA 122.312 0.245 . . . . 0.0 110.804 -179.859 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 7' ' ' GLN . . . . . 0.715 ' HA ' ' O ' ' A' ' 28' ' ' GLY . 19.3 tt0 -85.36 134.53 34.09 Favored 'General case' 0 C--N 1.346 0.415 0 CA-C-O 121.166 0.507 . . . . 0.0 111.256 179.978 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 8' ' ' CYS . . . . . 0.404 ' SG ' ' SG ' ' A' ' 30' ' ' CYS . 3.1 p -127.72 160.24 32.28 Favored 'General case' 0 C--O 1.237 0.447 0 CA-C-N 114.593 -1.185 . . . . 0.0 111.036 -179.553 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 9' ' ' ASP . . . . . 0.437 ' OD2' ' HB2' ' A' ' 11' ' ' GLU . 15.8 t70 -115.42 147.64 40.33 Favored 'General case' 0 C--O 1.234 0.26 0 CA-C-N 115.475 -0.784 . . . . 0.0 109.53 178.762 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 15.5 m -97.45 22.23 1.16 Allowed 'Isoleucine or valine' 0 CA--C 1.543 0.689 0 CA-C-N 116.312 -0.404 . . . . 0.0 111.963 -179.451 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 11' ' ' GLU . . . . . 0.437 ' HB2' ' OD2' ' A' ' 9' ' ' ASP . 44.1 mt-10 -119.68 -52.68 2.23 Favored 'General case' 0 N--CA 1.466 0.371 0 N-CA-C 112.372 0.508 . . . . 0.0 112.372 -179.068 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 12' ' ' PHE . . . . . . . . . . . . . 13.6 t80 -137.83 -8.98 1.6 Allowed 'General case' 0 N--CA 1.47 0.559 0 N-CA-C 112.649 0.611 . . . . 0.0 112.649 -178.659 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 13' ' ' ASN . . . . . 0.43 ' ND2' ' HD3' ' A' ' 2' ' ' PRO . 6.0 t30 -129.65 63.81 69.45 Favored Pre-proline 0 CA--C 1.548 0.904 0 N-CA-C 111.579 0.214 . . . . 0.0 111.579 -179.195 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 13.6 Cg_exo -70.23 176.78 6.67 Favored 'Trans proline' 0 C--N 1.372 1.767 0 C-N-CA 122.801 2.334 . . . . 0.0 112.06 178.914 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 1.0 OUTLIER -79.84 121.04 24.91 Favored 'General case' 0 N--CA 1.469 0.499 0 CA-C-O 120.453 0.168 . . . . 0.0 111.155 179.983 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER -57.75 -53.01 70.18 Favored Pre-proline 0 N--CA 1.477 0.924 0 CA-C-O 118.985 -0.531 . . . . 0.0 111.535 179.316 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 17' ' ' PRO . . . . . 0.506 ' HG2' HD12 ' A' ' 19' ' ' LEU . 44.8 Cg_endo -68.67 169.53 17.25 Favored 'Trans proline' 0 C--N 1.379 2.133 0 C-N-CA 122.102 1.868 . . . . 0.0 111.747 178.008 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 55.7 Cg_endo -72.27 48.81 1.27 Allowed 'Trans proline' 0 C--N 1.372 1.785 0 C-N-CA 122.011 1.808 . . . . 0.0 112.701 178.759 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 19' ' ' LEU . . . . . 0.506 HD12 ' HG2' ' A' ' 17' ' ' PRO . 20.5 mt -109.61 167.6 10.02 Favored 'General case' 0 C--O 1.236 0.356 0 CA-C-N 115.692 -0.685 . . . . 0.0 111.316 -179.309 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 20' ' ' THR . . . . . 0.529 ' O ' ' HA ' ' A' ' 30' ' ' CYS . 32.6 m -105.03 153.37 21.55 Favored 'General case' 0 CA--C 1.532 0.279 0 CA-C-N 115.622 -0.717 . . . . 0.0 111.059 -178.794 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 1.9 t -102.71 103.27 13.5 Favored 'General case' 0 C--O 1.238 0.487 0 CA-C-N 115.672 -0.694 . . . . 0.0 109.672 178.861 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 22' ' ' ILE . . . . . 0.709 HD12 ' HB2' ' A' ' 31' ' ' TYR . 2.8 mt -125.33 129.1 24.57 Favored Pre-proline 0 CA--C 1.542 0.646 0 CA-C-N 115.774 -0.648 . . . . 0.0 110.24 -179.094 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 38.1 Cg_endo -67.43 -48.47 0.24 Allowed 'Cis proline' 0 C--N 1.374 1.897 0 C-N-CA 124.74 -0.942 . . . . 0.0 113.895 -0.113 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 81.26 36.86 19.79 Favored Glycine 0 C--N 1.347 1.141 0 C-N-CA 121.192 -0.528 . . . . 0.0 112.959 -179.927 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 4.6 t70 -139.78 82.23 18.22 Favored Pre-proline 0 CA--C 1.548 0.884 0 C-N-CA 122.454 0.301 . . . . 0.0 110.376 -179.818 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 2.6 Cg_endo -81.06 -31.72 4.33 Favored 'Cis proline' 0 C--N 1.371 1.761 0 C-N-CA 125.113 -0.786 . . . . 0.0 112.951 0.104 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 27' ' ' TYR . . . . . . . . . . . . . 60.3 m-85 -106.55 174.12 6.02 Favored 'General case' 0 C--O 1.238 0.475 0 CA-C-N 115.748 -0.66 . . . . 0.0 111.558 -179.037 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 28' ' ' GLY . . . . . 0.715 ' O ' ' HA ' ' A' ' 7' ' ' GLN . . . -175.22 -162.08 25.91 Favored Glycine 0 CA--C 1.502 -0.737 0 CA-C-N 115.627 -0.715 . . . . 0.0 112.561 178.397 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 29' ' ' ILE . . . . . 0.537 ' HB ' ' CE2' ' A' ' 31' ' ' TYR . 2.7 mm -115.35 150.36 17.32 Favored 'Isoleucine or valine' 0 C--O 1.234 0.257 0 N-CA-C 110.059 -0.349 . . . . 0.0 110.059 -179.86 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 30' ' ' CYS . . . . . 0.529 ' HA ' ' O ' ' A' ' 20' ' ' THR . 32.2 m -79.9 105.18 10.99 Favored 'General case' 0 C--O 1.236 0.372 0 CA-C-O 121.372 0.606 . . . . 0.0 111.408 -179.745 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 31' ' ' TYR . . . . . 0.709 ' HB2' HD12 ' A' ' 22' ' ' ILE . 37.1 m-85 -129.57 167.93 17.18 Favored 'General case' 0 C--O 1.234 0.28 0 CA-C-N 114.922 -1.036 . . . . 0.0 111.085 -179.466 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 2.7 tp -100.25 130.71 49.04 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.617 0 CA-C-N 116.275 -0.421 . . . . 0.0 110.317 179.402 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 33' ' ' ILE . . . . . 0.5 HG23 HD11 ' A' ' 22' ' ' ILE . 1.9 pp . . . . . 0 C--O 1.249 1.031 0 CA-C-O 118.206 -0.902 . . . . 0.0 111.454 179.911 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 2' ' ' PRO . . . . . 0.433 ' HD3' ' ND2' ' A' ' 13' ' ' ASN . 98.3 Cg_endo . . . . . 0 CA--C 1.545 1.045 0 N-CA-C 112.939 0.323 . . . . 0.0 112.939 . . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -145.7 -155.47 6.5 Favored Glycine 0 C--N 1.338 0.676 0 N-CA-C 111.901 -0.48 . . . . 0.0 111.901 179.386 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 18.0 tt0 -73.35 129.52 38.19 Favored 'General case' 0 N--CA 1.474 0.738 0 C-N-CA 122.536 0.334 . . . . 0.0 111.198 179.658 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 85.6 16.28 64.25 Favored Glycine 0 C--N 1.339 0.748 0 CA-C-N 115.741 -0.663 . . . . 0.0 113.196 -179.849 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 43.1 mt-10 -127.61 161.49 28.73 Favored 'General case' 0 C--O 1.237 0.447 0 C-N-CA 122.188 0.195 . . . . 0.0 110.824 -179.862 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 7' ' ' GLN . . . . . 0.723 ' HA ' ' O ' ' A' ' 28' ' ' GLY . 18.7 tt0 -84.94 134.24 34.26 Favored 'General case' 0 C--N 1.345 0.381 0 CA-C-O 121.228 0.537 . . . . 0.0 111.293 179.804 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 8' ' ' CYS . . . . . 0.411 ' SG ' ' SG ' ' A' ' 30' ' ' CYS . 3.7 p -127.99 160.62 31.34 Favored 'General case' 0 C--O 1.237 0.447 0 CA-C-N 114.584 -1.189 . . . . 0.0 111.116 -179.383 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 9' ' ' ASP . . . . . 0.431 ' OD2' ' HB2' ' A' ' 11' ' ' GLU . 15.7 t70 -114.7 151.72 33.17 Favored 'General case' 0 C--O 1.236 0.352 0 CA-C-N 115.496 -0.774 . . . . 0.0 109.497 178.623 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 15.6 m -102.37 16.8 4.69 Favored 'Isoleucine or valine' 0 CA--C 1.544 0.717 0 N-CA-C 111.912 0.338 . . . . 0.0 111.912 -179.339 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 11' ' ' GLU . . . . . 0.431 ' HB2' ' OD2' ' A' ' 9' ' ' ASP . 9.5 mm-40 -110.34 -52.49 2.78 Favored 'General case' 0 N--CA 1.466 0.326 0 N-CA-C 112.082 0.401 . . . . 0.0 112.082 -178.979 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 12' ' ' PHE . . . . . . . . . . . . . 10.9 t80 -137.74 -17.51 1.26 Allowed 'General case' 0 N--CA 1.469 0.52 0 N-CA-C 112.589 0.588 . . . . 0.0 112.589 -178.812 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 13' ' ' ASN . . . . . 0.433 ' ND2' ' HD3' ' A' ' 2' ' ' PRO . 7.9 t30 -120.21 73.43 20.23 Favored Pre-proline 0 CA--C 1.547 0.851 0 N-CA-C 111.373 0.138 . . . . 0.0 111.373 -179.184 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 60.4 Cg_endo -76.79 177.6 8.65 Favored 'Trans proline' 0 C--N 1.371 1.729 0 C-N-CA 122.352 2.035 . . . . 0.0 112.314 179.027 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 1.3 t -79.79 120.2 23.72 Favored 'General case' 0 N--CA 1.471 0.605 0 CA-C-O 120.508 0.194 . . . . 0.0 110.911 179.895 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER -56.94 -53.44 65.11 Favored Pre-proline 0 N--CA 1.477 0.89 0 CA-C-O 119.09 -0.481 . . . . 0.0 111.634 179.425 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 17' ' ' PRO . . . . . 0.519 ' HG2' HD12 ' A' ' 19' ' ' LEU . 44.8 Cg_endo -68.62 169.25 17.79 Favored 'Trans proline' 0 C--N 1.379 2.163 0 C-N-CA 122.152 1.901 . . . . 0.0 111.789 178.057 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 55.6 Cg_endo -72.3 50.46 1.57 Allowed 'Trans proline' 0 C--N 1.371 1.755 0 C-N-CA 122.085 1.857 . . . . 0.0 112.538 178.728 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 19' ' ' LEU . . . . . 0.519 HD12 ' HG2' ' A' ' 17' ' ' PRO . 20.9 mt -111.41 167.92 9.93 Favored 'General case' 0 C--O 1.235 0.317 0 CA-C-N 115.626 -0.716 . . . . 0.0 111.383 -179.386 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 20' ' ' THR . . . . . 0.525 ' O ' ' HA ' ' A' ' 30' ' ' CYS . 33.5 m -105.6 153.47 21.74 Favored 'General case' 0 CA--C 1.533 0.291 0 CA-C-N 115.622 -0.717 . . . . 0.0 110.995 -178.774 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 2.0 t -102.77 103.36 13.57 Favored 'General case' 0 C--O 1.236 0.389 0 CA-C-N 115.709 -0.678 . . . . 0.0 109.676 178.932 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 22' ' ' ILE . . . . . 0.703 HD12 ' HB2' ' A' ' 31' ' ' TYR . 2.8 mt -125.43 129.13 24.53 Favored Pre-proline 0 CA--C 1.542 0.635 0 CA-C-N 115.754 -0.657 . . . . 0.0 110.259 -178.99 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 38.1 Cg_endo -67.69 -48.15 0.26 Allowed 'Cis proline' 0 C--N 1.375 1.933 0 C-N-CA 124.688 -0.963 . . . . 0.0 113.906 0.056 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 81.58 36.45 19.84 Favored Glycine 0 C--N 1.348 1.202 0 C-N-CA 121.153 -0.546 . . . . 0.0 112.899 -179.968 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 8.4 m-20 -139.91 82.73 17.16 Favored Pre-proline 0 CA--C 1.544 0.726 0 C-N-CA 122.587 0.355 . . . . 0.0 110.636 -179.743 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 2.9 Cg_endo -80.37 -32.06 4.23 Favored 'Cis proline' 0 C--N 1.372 1.773 0 C-N-CA 125.134 -0.778 . . . . 0.0 112.933 -0.118 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 27' ' ' TYR . . . . . . . . . . . . . 59.6 m-85 -107.24 175.06 5.62 Favored 'General case' 0 C--O 1.239 0.535 0 CA-C-N 115.785 -0.643 . . . . 0.0 111.643 -179.014 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 28' ' ' GLY . . . . . 0.723 ' O ' ' HA ' ' A' ' 7' ' ' GLN . . . -175.7 -161.18 24.59 Favored Glycine 0 CA--C 1.504 -0.609 0 CA-C-N 115.734 -0.666 . . . . 0.0 112.574 178.468 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 29' ' ' ILE . . . . . 0.541 ' HB ' ' CE2' ' A' ' 31' ' ' TYR . 2.7 mm -115.83 150.04 17.9 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 O-C-N 123.801 0.354 . . . . 0.0 110.067 -179.738 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 30' ' ' CYS . . . . . 0.525 ' HA ' ' O ' ' A' ' 20' ' ' THR . 23.7 m -79.88 104.99 10.83 Favored 'General case' 0 CA--C 1.535 0.402 0 CA-C-O 121.319 0.581 . . . . 0.0 111.303 -179.767 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 31' ' ' TYR . . . . . 0.703 ' HB2' HD12 ' A' ' 22' ' ' ILE . 36.7 m-85 -129.25 168.08 16.72 Favored 'General case' 0 C--O 1.233 0.197 0 CA-C-N 114.889 -1.051 . . . . 0.0 111.019 -179.465 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 2.7 tp -100.29 130.9 48.79 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.627 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.277 179.449 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 33' ' ' ILE . . . . . 0.49 HG23 HD11 ' A' ' 22' ' ' ILE . 1.9 pp . . . . . 0 C--O 1.249 1.061 0 CA-C-O 118.328 -0.844 . . . . 0.0 111.479 179.865 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 2' ' ' PRO . . . . . 0.584 ' HD2' ' O ' ' A' ' 14' ' ' PRO . 73.4 Cg_endo . . . . . 0 N--CA 1.488 1.191 0 N-CA-C 113.9 0.692 . . . . 0.0 113.9 . . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -142.76 -159.52 7.98 Favored Glycine 0 C--N 1.342 0.888 0 O-C-N 123.544 0.528 . . . . 0.0 112.487 179.832 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 17.4 tt0 -68.42 122.51 18.57 Favored 'General case' 0 N--CA 1.474 0.73 0 C-N-CA 122.816 0.447 . . . . 0.0 111.515 -179.925 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 92.41 14.54 55.52 Favored Glycine 0 C--N 1.341 0.82 0 CA-C-N 115.578 -0.737 . . . . 0.0 113.243 -179.882 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 43.1 mt-10 -127.42 165.64 19.41 Favored 'General case' 0 C--O 1.239 0.546 0 C-N-CA 122.438 0.295 . . . . 0.0 110.946 179.962 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 7' ' ' GLN . . . . . 0.51 ' HA ' ' O ' ' A' ' 28' ' ' GLY . 0.9 OUTLIER -83.46 145.55 28.89 Favored 'General case' 0 N--CA 1.469 0.478 0 CA-C-N 116.357 -0.383 . . . . 0.0 111.372 179.886 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 8.1 p -139.18 155.38 47.87 Favored 'General case' 0 C--O 1.237 0.44 0 CA-C-N 115.544 -0.753 . . . . 0.0 111.317 -179.786 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 6.9 t70 -118.87 153.13 35.03 Favored 'General case' 0 C--O 1.236 0.364 0 CA-C-N 115.42 -0.809 . . . . 0.0 109.652 179.045 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 14.9 m -101.86 20.89 2.47 Favored 'Isoleucine or valine' 0 CA--C 1.544 0.746 0 CA-C-N 116.296 -0.411 . . . . 0.0 111.99 -179.404 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 44.6 mt-10 -117.8 -53.03 2.42 Favored 'General case' 0 N--CA 1.465 0.32 0 N-CA-C 112.319 0.489 . . . . 0.0 112.319 -179.252 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 12' ' ' PHE . . . . . . . . . . . . . 15.7 t80 -138.96 -7.28 1.4 Allowed 'General case' 0 N--CA 1.47 0.574 0 N-CA-C 112.58 0.585 . . . . 0.0 112.58 -178.771 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 13' ' ' ASN . . . . . . . . . . . . . 8.6 t30 -129.44 63.47 67.83 Favored Pre-proline 0 CA--C 1.551 1.006 0 N-CA-C 111.369 0.137 . . . . 0.0 111.369 -179.093 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 14' ' ' PRO . . . . . 0.584 ' O ' ' HD2' ' A' ' 2' ' ' PRO . 15.8 Cg_exo -69.08 177.7 4.86 Favored 'Trans proline' 0 C--N 1.372 1.812 0 C-N-CA 122.733 2.288 . . . . 0.0 112.253 179.282 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 1.5 m -79.45 119.6 22.68 Favored 'General case' 0 N--CA 1.471 0.577 0 C-N-CA 122.382 0.273 . . . . 0.0 111.352 -179.848 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 16' ' ' CYS . . . . . 0.573 ' HB2' ' O ' ' A' ' 2' ' ' PRO . 0.0 OUTLIER -57.36 -53.2 67.98 Favored Pre-proline 0 N--CA 1.481 1.112 0 CA-C-N 115.971 -0.559 . . . . 0.0 111.518 179.548 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 17' ' ' PRO . . . . . 0.479 ' HG2' HD12 ' A' ' 19' ' ' LEU . 57.7 Cg_endo -72.72 169.34 22.21 Favored 'Trans proline' 0 C--N 1.38 2.205 0 C-N-CA 122.042 1.828 . . . . 0.0 111.8 178.168 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 55.8 Cg_endo -72.21 44.54 0.7 Allowed 'Trans proline' 0 C--N 1.371 1.759 0 C-N-CA 122.034 1.823 . . . . 0.0 112.956 178.86 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 19' ' ' LEU . . . . . 0.479 HD12 ' HG2' ' A' ' 17' ' ' PRO . 12.9 mt -104.43 172.78 6.61 Favored 'General case' 0 CA--C 1.534 0.336 0 CA-C-N 115.875 -0.602 . . . . 0.0 110.917 -179.634 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 25.5 m -103.38 150.2 24.04 Favored 'General case' 0 CA--C 1.534 0.335 0 CA-C-N 115.934 -0.575 . . . . 0.0 111.034 -178.793 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 5.5 t -100.32 103.13 14.53 Favored 'General case' 0 C--O 1.237 0.427 0 CA-C-N 115.874 -0.603 . . . . 0.0 109.381 178.491 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 22' ' ' ILE . . . . . 0.716 HD12 ' HB2' ' A' ' 31' ' ' TYR . 2.5 mt -127.36 129.27 23.91 Favored Pre-proline 0 CA--C 1.543 0.697 0 CA-C-N 115.825 -0.625 . . . . 0.0 110.72 -178.462 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 38.0 Cg_endo -67.94 -48.55 0.25 Allowed 'Cis proline' 0 C--N 1.374 1.902 0 C-N-CA 124.77 -0.929 . . . . 0.0 113.71 -0.441 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 79.67 37.13 24.11 Favored Glycine 0 C--N 1.346 1.137 0 C-N-CA 121.39 -0.434 . . . . 0.0 112.835 179.954 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 8.4 m-20 -140.31 81.25 18.24 Favored Pre-proline 0 CA--C 1.544 0.721 0 C-N-CA 122.477 0.311 . . . . 0.0 110.837 -179.694 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 2.2 Cg_endo -81.62 -32.17 3.85 Favored 'Cis proline' 0 C--N 1.372 1.787 0 C-N-CA 125.027 -0.822 . . . . 0.0 112.928 -0.166 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 27' ' ' TYR . . . . . . . . . . . . . 66.7 m-85 -102.35 173.29 6.43 Favored 'General case' 0 C--O 1.238 0.496 0 CA-C-N 115.77 -0.65 . . . . 0.0 111.561 -179.125 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 28' ' ' GLY . . . . . 0.51 ' O ' ' HA ' ' A' ' 7' ' ' GLN . . . -175.59 -159.31 21.32 Favored Glycine 0 C--N 1.338 0.658 0 CA-C-N 115.75 -0.659 . . . . 0.0 112.451 178.974 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 29' ' ' ILE . . . . . 0.56 ' HB ' ' CE2' ' A' ' 31' ' ' TYR . 1.3 mm -123.17 152.13 27.85 Favored 'Isoleucine or valine' 0 C--O 1.235 0.332 0 N-CA-C 109.882 -0.414 . . . . 0.0 109.882 179.713 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 30' ' ' CYS . . . . . 0.443 ' SG ' ' HB2' ' A' ' 19' ' ' LEU . 0.5 OUTLIER -80.07 106.92 12.44 Favored 'General case' 0 C--O 1.238 0.472 0 CA-C-N 116.029 -0.532 . . . . 0.0 110.923 -179.975 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 31' ' ' TYR . . . . . 0.716 ' HB2' HD12 ' A' ' 22' ' ' ILE . 36.2 m-85 -132.11 167.04 20.43 Favored 'General case' 0 N--CA 1.466 0.334 0 CA-C-N 115.534 -0.757 . . . . 0.0 111.088 -179.251 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 2.8 tp -101.88 131.8 49.09 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.614 0 CA-C-N 116.081 -0.509 . . . . 0.0 110.347 179.458 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 33' ' ' ILE . . . . . 0.465 ' H ' HG13 ' A' ' 33' ' ' ILE . 1.9 pp . . . . . 0 C--O 1.247 0.961 0 CA-C-O 118.357 -0.83 . . . . 0.0 111.399 179.976 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 2' ' ' PRO . . . . . 0.494 ' HD3' HD21 ' A' ' 13' ' ' ASN . 95.6 Cg_endo . . . . . 0 CA--C 1.545 1.043 0 N-CA-C 112.937 0.322 . . . . 0.0 112.937 . . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -145.39 -154.0 6.03 Favored Glycine 0 C--N 1.339 0.711 0 N-CA-C 111.813 -0.515 . . . . 0.0 111.813 179.493 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 18.5 tt0 -73.27 129.68 38.55 Favored 'General case' 0 N--CA 1.472 0.667 0 C-N-CA 122.68 0.392 . . . . 0.0 111.319 179.596 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 85.92 15.45 65.2 Favored Glycine 0 C--N 1.34 0.754 0 CA-C-N 115.793 -0.639 . . . . 0.0 113.554 -179.984 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 12.7 tt0 -126.87 161.9 27.18 Favored 'General case' 0 C--O 1.238 0.462 0 CA-C-N 116.604 0.202 . . . . 0.0 110.656 -179.842 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 7' ' ' GLN . . . . . 0.682 ' HA ' ' O ' ' A' ' 28' ' ' GLY . 18.6 tt0 -86.81 136.35 33.01 Favored 'General case' 0 C--N 1.344 0.331 0 CA-C-O 121.218 0.533 . . . . 0.0 111.407 179.962 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 8' ' ' CYS . . . . . 0.405 ' SG ' ' SG ' ' A' ' 30' ' ' CYS . 2.6 p -130.65 161.34 31.83 Favored 'General case' 0 C--O 1.239 0.517 0 CA-C-N 114.465 -1.243 . . . . 0.0 111.023 -179.58 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 9' ' ' ASP . . . . . 0.59 ' OD1' ' HB3' ' A' ' 13' ' ' ASN . 0.7 OUTLIER -120.52 143.54 48.52 Favored 'General case' 0 N--CA 1.465 0.276 0 CA-C-N 115.687 -0.688 . . . . 0.0 110.09 178.494 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 22.3 m -92.02 14.63 1.69 Allowed 'Isoleucine or valine' 0 CA--C 1.542 0.655 0 CA-C-N 116.083 -0.508 . . . . 0.0 111.509 -179.245 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 9.9 mm-40 -98.68 -51.56 3.88 Favored 'General case' 0 C--O 1.234 0.283 0 CA-C-N 116.159 -0.473 . . . . 0.0 112.085 -178.789 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 12' ' ' PHE . . . . . . . . . . . . . 6.9 t80 -144.09 -22.84 0.56 Allowed 'General case' 0 N--CA 1.472 0.67 0 N-CA-C 112.698 0.629 . . . . 0.0 112.698 -178.877 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 13' ' ' ASN . . . . . 0.59 ' HB3' ' OD1' ' A' ' 9' ' ' ASP . 13.9 t30 -119.32 75.74 16.64 Favored Pre-proline 0 CA--C 1.548 0.901 0 CA-C-N 117.539 0.154 . . . . 0.0 111.355 -178.969 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 61.7 Cg_endo -76.77 -176.09 2.97 Favored 'Trans proline' 0 C--N 1.372 1.763 0 C-N-CA 122.542 2.162 . . . . 0.0 112.22 178.676 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 0.9 OUTLIER -79.94 121.76 25.85 Favored 'General case' 0 N--CA 1.471 0.609 0 CA-C-O 120.454 0.168 . . . . 0.0 111.252 179.95 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER -58.38 -53.76 62.79 Favored Pre-proline 0 N--CA 1.478 0.949 0 CA-C-N 116.124 -0.489 . . . . 0.0 111.552 179.115 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 44.0 Cg_endo -67.8 169.79 15.41 Favored 'Trans proline' 0 C--N 1.379 2.171 0 C-N-CA 122.187 1.925 . . . . 0.0 111.851 178.21 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 55.5 Cg_endo -72.08 47.46 1.03 Allowed 'Trans proline' 0 C--N 1.371 1.724 0 C-N-CA 122.027 1.818 . . . . 0.0 112.792 178.839 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 42.9 mt -108.68 166.3 10.9 Favored 'General case' 0 C--O 1.234 0.266 0 CA-C-N 115.926 -0.579 . . . . 0.0 111.201 -179.588 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 20' ' ' THR . . . . . 0.522 ' O ' ' HA ' ' A' ' 30' ' ' CYS . 33.5 m -103.58 152.74 21.38 Favored 'General case' 0 CA--C 1.532 0.287 0 CA-C-N 115.503 -0.771 . . . . 0.0 110.962 -178.848 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 2.3 t -102.44 99.93 10.02 Favored 'General case' 0 C--O 1.239 0.535 0 CA-C-N 115.725 -0.67 . . . . 0.0 109.601 178.841 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 22' ' ' ILE . . . . . 0.707 HD12 ' HB2' ' A' ' 31' ' ' TYR . 3.0 mt -121.04 128.7 25.62 Favored Pre-proline 0 CA--C 1.541 0.622 0 CA-C-N 115.783 -0.644 . . . . 0.0 110.424 -178.976 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 37.1 Cg_endo -66.89 -47.47 0.26 Allowed 'Cis proline' 0 C--N 1.375 1.958 0 C-N-CA 124.69 -0.962 . . . . 0.0 113.874 -0.187 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 78.92 34.4 34.1 Favored Glycine 0 C--N 1.346 1.131 0 C-N-CA 121.379 -0.438 . . . . 0.0 112.942 179.977 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 4.6 t70 -139.91 83.05 16.69 Favored Pre-proline 0 CA--C 1.546 0.823 0 C-N-CA 122.607 0.363 . . . . 0.0 110.345 -179.68 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 3.2 Cg_exo -80.86 -32.02 4.15 Favored 'Cis proline' 0 C--N 1.371 1.743 0 C-N-CA 125.095 -0.794 . . . . 0.0 112.895 0.036 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 27' ' ' TYR . . . . . 0.558 ' CD2' ' HB3' ' A' ' 9' ' ' ASP . 63.6 m-85 -106.91 172.68 6.69 Favored 'General case' 0 CA--C 1.537 0.448 0 CA-C-N 115.838 -0.619 . . . . 0.0 111.592 -178.892 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 28' ' ' GLY . . . . . 0.682 ' O ' ' HA ' ' A' ' 7' ' ' GLN . . . -176.53 -163.88 29.64 Favored Glycine 0 C--N 1.339 0.716 0 CA-C-N 115.629 -0.714 . . . . 0.0 112.636 178.558 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 29' ' ' ILE . . . . . 0.541 ' HB ' ' CE2' ' A' ' 31' ' ' TYR . 2.5 mm -114.68 151.15 16.47 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 O-C-N 123.748 0.322 . . . . 0.0 110.259 -179.898 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 30' ' ' CYS . . . . . 0.522 ' HA ' ' O ' ' A' ' 20' ' ' THR . 33.9 m -79.88 105.42 11.15 Favored 'General case' 0 CA--C 1.535 0.392 0 CA-C-O 121.328 0.585 . . . . 0.0 111.365 -179.717 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 31' ' ' TYR . . . . . 0.707 ' HB2' HD12 ' A' ' 22' ' ' ILE . 37.1 m-85 -130.28 166.88 19.43 Favored 'General case' 0 C--O 1.233 0.193 0 CA-C-N 114.917 -1.038 . . . . 0.0 111.02 -179.472 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 2.9 tp -99.59 130.24 48.93 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.604 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.372 179.496 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 33' ' ' ILE . . . . . 0.485 HG23 HD11 ' A' ' 22' ' ' ILE . 1.4 pt . . . . . 0 C--O 1.249 1.045 0 CA-C-O 118.136 -0.935 . . . . 0.0 111.463 179.883 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 2' ' ' PRO . . . . . 0.551 ' HD3' ' ND2' ' A' ' 13' ' ' ASN . 95.1 Cg_endo . . . . . 0 CA--C 1.543 0.933 0 N-CA-C 112.827 0.28 . . . . 0.0 112.827 . . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -147.3 -161.39 9.38 Favored Glycine 0 C--N 1.337 0.632 0 N-CA-C 111.593 -0.603 . . . . 0.0 111.593 179.216 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 19.0 tt0 -68.33 124.06 22.46 Favored 'General case' 0 N--CA 1.473 0.679 0 C-N-CA 122.548 0.339 . . . . 0.0 111.183 179.851 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 91.28 14.69 56.99 Favored Glycine 0 C--N 1.338 0.682 0 CA-C-N 115.646 -0.706 . . . . 0.0 113.228 -179.699 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 6' ' ' GLU . . . . . 0.453 ' HG2' ' NE2' ' A' ' 7' ' ' GLN . 13.9 tt0 -129.0 166.18 19.7 Favored 'General case' 0 C--O 1.238 0.479 0 C-N-CA 122.287 0.235 . . . . 0.0 110.599 -179.933 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 7' ' ' GLN . . . . . 0.453 ' NE2' ' HG2' ' A' ' 6' ' ' GLU . 0.2 OUTLIER -82.07 153.3 26.18 Favored 'General case' 0 C--N 1.346 0.433 0 O-C-N 123.288 0.367 . . . . 0.0 110.929 -179.876 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 3.3 p -142.64 151.8 41.81 Favored 'General case' 0 C--O 1.235 0.306 0 CA-C-N 115.817 -0.629 . . . . 0.0 111.297 -179.4 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -110.23 139.8 45.02 Favored 'General case' 0 C--O 1.234 0.253 0 CA-C-N 115.765 -0.652 . . . . 0.0 109.559 179.348 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 10' ' ' VAL . . . . . 0.489 HG22 ' O ' ' A' ' 26' ' ' PRO . 7.7 m -94.89 26.65 0.48 Allowed 'Isoleucine or valine' 0 CA--C 1.543 0.702 0 O-C-N 123.31 0.381 . . . . 0.0 111.635 -179.842 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 42.6 mt-10 -124.2 -52.26 1.75 Allowed 'General case' 0 N--CA 1.465 0.291 0 N-CA-C 112.251 0.464 . . . . 0.0 112.251 -179.135 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 12' ' ' PHE . . . . . . . . . . . . . 11.5 t80 -138.51 -10.38 1.41 Allowed 'General case' 0 N--CA 1.471 0.617 0 N-CA-C 112.833 0.679 . . . . 0.0 112.833 -178.627 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 13' ' ' ASN . . . . . 0.551 ' ND2' ' HD3' ' A' ' 2' ' ' PRO . 6.9 t30 -129.88 64.86 73.62 Favored Pre-proline 0 CA--C 1.549 0.928 0 CA-C-N 117.458 0.117 . . . . 0.0 111.206 -179.151 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 14' ' ' PRO . . . . . 0.4 ' O ' ' HD2' ' A' ' 2' ' ' PRO . 16.4 Cg_exo -68.86 179.81 2.98 Favored 'Trans proline' 0 C--N 1.373 1.843 0 C-N-CA 122.948 2.432 . . . . 0.0 112.22 179.141 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 15' ' ' CYS . . . . . 0.519 ' SG ' ' HB2' ' A' ' 19' ' ' LEU . 3.8 t -79.71 122.0 26.03 Favored 'General case' 0 N--CA 1.471 0.603 0 O-C-N 123.102 0.251 . . . . 0.0 111.247 -179.786 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER -60.85 -54.16 57.16 Favored Pre-proline 0 N--CA 1.476 0.855 0 CA-C-O 119.023 -0.513 . . . . 0.0 111.443 179.298 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 56.3 Cg_endo -70.95 169.27 20.84 Favored 'Trans proline' 0 C--N 1.379 2.176 0 C-N-CA 122.115 1.877 . . . . 0.0 111.702 178.173 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 49.7 Cg_endo -70.76 58.09 2.0 Allowed 'Trans proline' 0 C--N 1.371 1.748 0 C-N-CA 121.975 1.784 . . . . 0.0 112.909 179.01 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 19' ' ' LEU . . . . . 0.519 ' HB2' ' SG ' ' A' ' 15' ' ' CYS . 93.8 mt -118.19 167.8 11.17 Favored 'General case' 0 C--O 1.235 0.331 0 CA-C-N 115.704 -0.68 . . . . 0.0 111.24 -179.876 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 89.3 m -106.99 150.84 26.07 Favored 'General case' 0 CA--C 1.533 0.303 0 CA-C-N 115.315 -0.857 . . . . 0.0 110.94 -179.277 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 21' ' ' CYS . . . . . 0.505 ' HA ' ' O ' ' A' ' 29' ' ' ILE . 1.9 t -97.3 106.71 19.09 Favored 'General case' 0 C--O 1.238 0.476 0 CA-C-N 115.732 -0.667 . . . . 0.0 110.029 178.949 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 22' ' ' ILE . . . . . 0.723 HD12 ' HB2' ' A' ' 31' ' ' TYR . 5.7 mt -125.32 128.69 24.68 Favored Pre-proline 0 CA--C 1.543 0.697 0 CA-C-N 115.807 -0.633 . . . . 0.0 110.564 -179.16 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 37.3 Cg_endo -67.24 -47.78 0.26 Allowed 'Cis proline' 0 C--N 1.376 2.009 0 C-N-CA 124.681 -0.966 . . . . 0.0 113.81 -0.223 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 81.66 38.11 15.04 Favored Glycine 0 C--N 1.347 1.144 0 C-N-CA 121.332 -0.461 . . . . 0.0 112.88 179.822 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 8.0 m-20 -142.58 80.64 14.19 Favored Pre-proline 0 CA--C 1.546 0.817 0 C-N-CA 122.445 0.298 . . . . 0.0 111.052 -179.565 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 26' ' ' PRO . . . . . 0.489 ' O ' HG22 ' A' ' 10' ' ' VAL . 67.9 Cg_endo -84.08 -29.38 5.12 Favored 'Cis proline' 0 C--N 1.372 1.788 0 C-N-CA 124.698 -0.959 . . . . 0.0 113.439 -0.236 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 27' ' ' TYR . . . . . . . . . . . . . 57.0 m-85 -95.31 161.49 14.07 Favored 'General case' 0 N--CA 1.469 0.492 0 O-C-N 123.513 0.508 . . . . 0.0 111.304 -179.097 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 28' ' ' GLY . . . . . 0.433 ' O ' HD13 ' A' ' 29' ' ' ILE . . . -159.03 -161.91 11.53 Favored Glycine 0 C--N 1.341 0.842 0 C-N-CA 120.917 -0.659 . . . . 0.0 113.089 179.832 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 29' ' ' ILE . . . . . 0.505 ' O ' ' HA ' ' A' ' 21' ' ' CYS . 5.1 mm -129.95 155.17 41.31 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.238 0 N-CA-C 109.674 -0.491 . . . . 0.0 109.674 -179.932 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 30' ' ' CYS . . . . . . . . . . . . . 28.8 m -83.68 92.8 7.77 Favored 'General case' 0 CA--C 1.538 0.482 0 CA-C-O 121.368 0.604 . . . . 0.0 111.362 -179.955 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 31' ' ' TYR . . . . . 0.723 ' HB2' HD12 ' A' ' 22' ' ' ILE . 37.8 m-85 -124.33 166.81 15.28 Favored 'General case' 0 N--CA 1.464 0.26 0 CA-C-N 114.972 -1.013 . . . . 0.0 110.992 179.822 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 2.8 tp -99.76 131.49 47.05 Favored 'Isoleucine or valine' 0 CA--C 1.542 0.644 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.448 179.401 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 33' ' ' ILE . . . . . 0.472 HG23 HD11 ' A' ' 22' ' ' ILE . 1.8 pp . . . . . 0 C--O 1.249 1.056 0 CA-C-O 118.168 -0.92 . . . . 0.0 111.429 179.843 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 2' ' ' PRO . . . . . 0.598 ' HD2' ' O ' ' A' ' 14' ' ' PRO . 73.0 Cg_endo . . . . . 0 N--CA 1.488 1.192 0 N-CA-C 113.935 0.706 . . . . 0.0 113.935 . . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -143.5 -159.68 8.08 Favored Glycine 0 C--N 1.341 0.837 0 CA-C-N 116.146 -0.479 . . . . 0.0 112.477 179.83 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 16.7 tt0 -66.43 124.23 22.18 Favored 'General case' 0 N--CA 1.474 0.734 0 C-N-CA 122.841 0.456 . . . . 0.0 111.603 -179.711 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 95.03 -11.01 69.89 Favored Glycine 0 C--N 1.34 0.772 0 CA-C-N 115.641 -0.708 . . . . 0.0 113.282 -179.971 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 42.8 mt-10 -101.16 166.66 10.67 Favored 'General case' 0 C--O 1.24 0.601 0 C-N-CA 122.432 0.293 . . . . 0.0 110.967 -179.8 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 7' ' ' GLN . . . . . . . . . . . . . 0.2 OUTLIER -84.85 154.83 22.05 Favored 'General case' 0 C--N 1.346 0.446 0 CA-C-N 116.167 -0.47 . . . . 0.0 111.039 179.899 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 7.9 p -147.54 155.02 41.45 Favored 'General case' 0 N--CA 1.466 0.371 0 CA-C-N 115.886 -0.597 . . . . 0.0 111.511 -179.131 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 8.0 t70 -120.17 150.52 40.5 Favored 'General case' 0 C--O 1.234 0.275 0 CA-C-N 115.325 -0.852 . . . . 0.0 109.633 178.885 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 15.6 m -98.7 18.8 2.28 Favored 'Isoleucine or valine' 0 CA--C 1.543 0.677 0 CA-C-N 116.287 -0.415 . . . . 0.0 112.072 -179.41 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 46.2 mt-10 -110.13 -55.46 2.45 Favored 'General case' 0 N--CA 1.466 0.358 0 N-CA-C 112.11 0.411 . . . . 0.0 112.11 -179.106 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 12' ' ' PHE . . . . . . . . . . . . . 12.2 t80 -137.99 -15.2 1.34 Allowed 'General case' 0 N--CA 1.47 0.556 0 N-CA-C 112.429 0.529 . . . . 0.0 112.429 -178.939 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 13' ' ' ASN . . . . . 0.454 HD21 ' HD3' ' A' ' 2' ' ' PRO . 11.5 t30 -120.21 73.01 19.61 Favored Pre-proline 0 CA--C 1.55 0.955 0 O-C-N 122.969 0.168 . . . . 0.0 111.161 -179.377 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 14' ' ' PRO . . . . . 0.598 ' O ' ' HD2' ' A' ' 2' ' ' PRO . 60.4 Cg_endo -76.13 178.74 7.09 Favored 'Trans proline' 0 C--N 1.371 1.744 0 C-N-CA 122.314 2.009 . . . . 0.0 112.501 179.587 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 1.4 m -79.38 118.65 21.47 Favored 'General case' 0 N--CA 1.47 0.547 0 O-C-N 123.118 0.261 . . . . 0.0 111.195 179.972 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 16' ' ' CYS . . . . . 0.573 ' HB2' ' O ' ' A' ' 2' ' ' PRO . 0.0 OUTLIER -56.58 -53.27 66.22 Favored Pre-proline 0 N--CA 1.48 1.073 0 CA-C-O 118.961 -0.542 . . . . 0.0 111.679 179.581 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 17' ' ' PRO . . . . . 0.474 ' HG2' HD12 ' A' ' 19' ' ' LEU . 57.7 Cg_endo -72.65 169.23 22.42 Favored 'Trans proline' 0 C--N 1.378 2.13 0 C-N-CA 122.028 1.819 . . . . 0.0 111.738 178.194 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 55.7 Cg_endo -72.51 45.33 0.83 Allowed 'Trans proline' 0 C--N 1.373 1.839 0 C-N-CA 122.012 1.808 . . . . 0.0 112.865 178.826 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 19' ' ' LEU . . . . . 0.474 HD12 ' HG2' ' A' ' 17' ' ' PRO . 11.8 mt -104.92 172.9 6.54 Favored 'General case' 0 C--O 1.237 0.401 0 CA-C-N 115.931 -0.577 . . . . 0.0 111.046 -179.628 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 24.5 m -103.98 149.3 25.27 Favored 'General case' 0 CA--C 1.531 0.228 0 CA-C-N 115.966 -0.561 . . . . 0.0 111.046 -178.945 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 5.9 t -99.35 102.74 14.43 Favored 'General case' 0 C--O 1.237 0.444 0 CA-C-N 115.856 -0.611 . . . . 0.0 109.39 178.467 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 22' ' ' ILE . . . . . 0.723 HD12 ' HB2' ' A' ' 31' ' ' TYR . 2.5 mt -126.78 129.65 24.0 Favored Pre-proline 0 CA--C 1.543 0.679 0 CA-C-N 115.787 -0.642 . . . . 0.0 110.68 -178.571 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 37.5 Cg_endo -67.65 -48.13 0.26 Allowed 'Cis proline' 0 C--N 1.374 1.885 0 C-N-CA 124.699 -0.959 . . . . 0.0 113.814 -0.434 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 78.57 37.61 26.6 Favored Glycine 0 C--N 1.348 1.242 0 C-N-CA 121.308 -0.472 . . . . 0.0 113.013 -179.962 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 4.5 t70 -140.55 80.7 18.28 Favored Pre-proline 0 CA--C 1.548 0.884 0 C-N-CA 122.372 0.269 . . . . 0.0 110.533 -179.614 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 1.9 Cg_endo -82.07 -31.81 3.98 Favored 'Cis proline' 0 C--N 1.372 1.787 0 C-N-CA 125.058 -0.809 . . . . 0.0 112.956 -0.2 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 27' ' ' TYR . . . . . . . . . . . . . 70.0 m-85 -102.0 172.55 6.85 Favored 'General case' 0 C--O 1.237 0.434 0 CA-C-N 115.822 -0.626 . . . . 0.0 111.578 -179.033 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -175.95 -160.57 23.67 Favored Glycine 0 C--N 1.337 0.634 0 CA-C-N 115.657 -0.701 . . . . 0.0 112.207 179.071 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 29' ' ' ILE . . . . . 0.559 ' HB ' ' CE2' ' A' ' 31' ' ' TYR . 1.8 mm -122.6 153.04 27.23 Favored 'Isoleucine or valine' 0 C--O 1.236 0.36 0 N-CA-C 109.87 -0.418 . . . . 0.0 109.87 179.691 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 30' ' ' CYS . . . . . 0.438 ' SG ' ' HB2' ' A' ' 19' ' ' LEU . 0.5 OUTLIER -79.92 106.72 12.15 Favored 'General case' 0 CA--C 1.539 0.521 0 CA-C-N 116.018 -0.537 . . . . 0.0 110.916 -179.919 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 31' ' ' TYR . . . . . 0.723 ' HB2' HD12 ' A' ' 22' ' ' ILE . 39.1 m-85 -131.34 166.68 20.71 Favored 'General case' 0 N--CA 1.463 0.216 0 CA-C-N 115.479 -0.782 . . . . 0.0 111.201 -179.314 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 2.7 tp -101.76 132.04 48.48 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.582 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.437 179.434 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 33' ' ' ILE . . . . . 0.477 ' H ' HG13 ' A' ' 33' ' ' ILE . 1.9 pp . . . . . 0 C--O 1.249 1.078 0 CA-C-O 118.346 -0.835 . . . . 0.0 111.504 179.945 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 2' ' ' PRO . . . . . 0.435 ' HD3' ' ND2' ' A' ' 13' ' ' ASN . 95.3 Cg_endo . . . . . 0 CA--C 1.545 1.04 0 N-CA-C 112.969 0.334 . . . . 0.0 112.969 . . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -145.39 -155.44 6.47 Favored Glycine 0 C--N 1.339 0.727 0 N-CA-C 111.687 -0.565 . . . . 0.0 111.687 179.45 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 18.0 tt0 -73.24 129.16 37.43 Favored 'General case' 0 N--CA 1.47 0.55 0 C-N-CA 122.575 0.35 . . . . 0.0 111.221 179.74 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 85.68 16.25 64.14 Favored Glycine 0 C--N 1.339 0.738 0 CA-C-N 115.832 -0.622 . . . . 0.0 113.294 -179.844 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 12.9 tt0 -127.86 162.52 26.5 Favored 'General case' 0 C--O 1.236 0.39 0 C-N-CA 122.176 0.19 . . . . 0.0 110.488 -179.865 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 7' ' ' GLN . . . . . 0.719 ' HA ' ' O ' ' A' ' 28' ' ' GLY . 18.6 tt0 -85.35 134.76 34.08 Favored 'General case' 0 C--N 1.345 0.386 0 CA-C-O 121.298 0.571 . . . . 0.0 111.239 -179.994 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 8' ' ' CYS . . . . . 0.412 ' SG ' ' SG ' ' A' ' 30' ' ' CYS . 3.6 p -127.77 160.2 32.46 Favored 'General case' 0 C--O 1.239 0.508 0 CA-C-N 114.545 -1.207 . . . . 0.0 111.098 -179.396 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 9' ' ' ASP . . . . . 0.432 ' OD2' ' HB2' ' A' ' 11' ' ' GLU . 16.8 t70 -114.86 150.52 35.43 Favored 'General case' 0 CA--C 1.532 0.272 0 CA-C-N 115.542 -0.754 . . . . 0.0 109.477 178.766 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 15.5 m -100.91 20.12 2.47 Favored 'Isoleucine or valine' 0 CA--C 1.543 0.689 0 CA-C-N 116.22 -0.446 . . . . 0.0 112.008 -179.465 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 11' ' ' GLU . . . . . 0.432 ' HB2' ' OD2' ' A' ' 9' ' ' ASP . 44.7 mt-10 -117.51 -52.46 2.47 Favored 'General case' 0 N--CA 1.465 0.313 0 N-CA-C 112.224 0.453 . . . . 0.0 112.224 -178.969 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 12' ' ' PHE . . . . . . . . . . . . . 14.6 t80 -138.42 -8.43 1.49 Allowed 'General case' 0 N--CA 1.472 0.652 0 N-CA-C 112.596 0.591 . . . . 0.0 112.596 -178.689 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 13' ' ' ASN . . . . . 0.435 ' ND2' ' HD3' ' A' ' 2' ' ' PRO . 6.3 t30 -129.6 63.79 69.26 Favored Pre-proline 0 CA--C 1.55 0.959 0 N-CA-C 111.552 0.205 . . . . 0.0 111.552 -179.091 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 14.0 Cg_exo -70.09 177.12 6.13 Favored 'Trans proline' 0 C--N 1.371 1.744 0 C-N-CA 122.86 2.373 . . . . 0.0 112.002 178.885 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 1.1 t -79.9 121.02 24.92 Favored 'General case' 0 N--CA 1.471 0.58 0 CA-C-O 120.503 0.192 . . . . 0.0 111.052 -179.983 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER -57.57 -53.09 69.18 Favored Pre-proline 0 N--CA 1.478 0.943 0 CA-C-O 119.069 -0.491 . . . . 0.0 111.541 179.282 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 17' ' ' PRO . . . . . 0.511 ' HG2' HD12 ' A' ' 19' ' ' LEU . 44.4 Cg_endo -68.81 169.44 17.66 Favored 'Trans proline' 0 C--N 1.38 2.199 0 C-N-CA 122.159 1.906 . . . . 0.0 111.782 178.059 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 55.5 Cg_endo -72.22 49.33 1.34 Allowed 'Trans proline' 0 C--N 1.373 1.833 0 C-N-CA 122.044 1.829 . . . . 0.0 112.589 178.799 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 19' ' ' LEU . . . . . 0.511 HD12 ' HG2' ' A' ' 17' ' ' PRO . 20.9 mt -110.1 168.24 9.58 Favored 'General case' 0 C--O 1.236 0.372 0 CA-C-N 115.741 -0.663 . . . . 0.0 111.34 -179.337 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 20' ' ' THR . . . . . 0.537 ' O ' ' HA ' ' A' ' 30' ' ' CYS . 29.3 m -105.31 153.82 21.11 Favored 'General case' 0 CA--C 1.533 0.31 0 CA-C-N 115.624 -0.716 . . . . 0.0 111.056 -178.804 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 2.0 t -103.42 103.89 13.93 Favored 'General case' 0 C--O 1.238 0.493 0 CA-C-N 115.678 -0.692 . . . . 0.0 109.666 178.869 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 22' ' ' ILE . . . . . 0.71 HD12 ' HB2' ' A' ' 31' ' ' TYR . 2.9 mt -125.9 129.11 24.39 Favored Pre-proline 0 CA--C 1.541 0.634 0 CA-C-N 115.768 -0.651 . . . . 0.0 110.223 -179.157 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 38.4 Cg_endo -67.77 -48.26 0.25 Allowed 'Cis proline' 0 C--N 1.375 1.941 0 C-N-CA 124.679 -0.967 . . . . 0.0 113.941 -0.155 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 81.92 36.83 17.63 Favored Glycine 0 C--N 1.348 1.229 0 C-N-CA 121.108 -0.568 . . . . 0.0 112.852 -179.977 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 8.3 m-20 -139.99 82.58 17.18 Favored Pre-proline 0 CA--C 1.543 0.701 0 C-N-CA 122.53 0.332 . . . . 0.0 110.701 -179.91 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 3.0 Cg_endo -80.54 -32.07 4.18 Favored 'Cis proline' 0 C--N 1.372 1.795 0 C-N-CA 125.191 -0.754 . . . . 0.0 112.923 0.077 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 27' ' ' TYR . . . . . . . . . . . . . 59.3 m-85 -106.96 175.07 5.62 Favored 'General case' 0 C--O 1.238 0.466 0 CA-C-N 115.68 -0.691 . . . . 0.0 111.532 -179.001 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 28' ' ' GLY . . . . . 0.719 ' O ' ' HA ' ' A' ' 7' ' ' GLN . . . -175.52 -161.26 24.65 Favored Glycine 0 C--N 1.339 0.701 0 CA-C-N 115.626 -0.715 . . . . 0.0 112.618 178.49 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 29' ' ' ILE . . . . . 0.527 ' HB ' ' CE2' ' A' ' 31' ' ' TYR . 2.8 mm -115.6 149.76 17.74 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 N-CA-C 110.084 -0.339 . . . . 0.0 110.084 -179.814 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 30' ' ' CYS . . . . . 0.537 ' HA ' ' O ' ' A' ' 20' ' ' THR . 26.8 m -79.85 105.1 10.89 Favored 'General case' 0 C--O 1.238 0.464 0 CA-C-N 115.955 -0.566 . . . . 0.0 111.35 -179.802 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 31' ' ' TYR . . . . . 0.71 ' HB2' HD12 ' A' ' 22' ' ' ILE . 36.9 m-85 -128.74 168.46 15.81 Favored 'General case' 0 C--O 1.233 0.205 0 CA-C-N 115.087 -0.961 . . . . 0.0 111.099 -179.552 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 1.8 tt -101.06 130.33 50.64 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.585 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.363 179.651 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 33' ' ' ILE . . . . . 0.458 ' H ' HG13 ' A' ' 33' ' ' ILE . 1.6 pp . . . . . 0 C--O 1.248 0.986 0 CA-C-O 118.386 -0.816 . . . . 0.0 111.525 179.881 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 2' ' ' PRO . . . . . 0.576 ' HD2' ' O ' ' A' ' 14' ' ' PRO . 73.7 Cg_endo . . . . . 0 N--CA 1.488 1.152 0 N-CA-C 113.949 0.711 . . . . 0.0 113.949 . . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -143.5 -159.09 7.83 Favored Glycine 0 C--N 1.34 0.778 0 O-C-N 123.511 0.507 . . . . 0.0 112.543 179.877 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 16.6 tt0 -68.39 122.93 19.43 Favored 'General case' 0 N--CA 1.472 0.642 0 C-N-CA 122.849 0.46 . . . . 0.0 111.524 -179.893 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 92.12 14.47 56.05 Favored Glycine 0 C--N 1.339 0.736 0 CA-C-N 115.681 -0.691 . . . . 0.0 113.242 -179.864 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 43.0 mt-10 -127.9 165.83 19.46 Favored 'General case' 0 C--O 1.239 0.535 0 C-N-CA 122.447 0.299 . . . . 0.0 110.813 179.942 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 7' ' ' GLN . . . . . 0.526 ' HA ' ' O ' ' A' ' 28' ' ' GLY . 15.6 mt-30 -85.11 145.15 27.79 Favored 'General case' 0 C--N 1.346 0.415 0 CA-C-N 116.371 -0.377 . . . . 0.0 111.515 179.966 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 7.4 p -138.26 155.59 48.48 Favored 'General case' 0 C--O 1.236 0.385 0 CA-C-N 115.274 -0.876 . . . . 0.0 111.292 -179.51 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 6.1 t70 -118.25 152.46 35.68 Favored 'General case' 0 C--O 1.235 0.335 0 CA-C-N 115.35 -0.841 . . . . 0.0 109.668 179.003 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 14.4 m -101.1 21.63 1.97 Allowed 'Isoleucine or valine' 0 CA--C 1.541 0.624 0 CA-C-N 116.18 -0.464 . . . . 0.0 112.058 -179.466 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 44.5 mt-10 -118.51 -53.0 2.34 Favored 'General case' 0 N--CA 1.465 0.319 0 N-CA-C 112.196 0.443 . . . . 0.0 112.196 -179.18 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 12' ' ' PHE . . . . . . . . . . . . . 15.1 t80 -139.01 -7.49 1.39 Allowed 'General case' 0 N--CA 1.47 0.564 0 N-CA-C 112.534 0.568 . . . . 0.0 112.534 -178.784 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 13' ' ' ASN . . . . . . . . . . . . . 8.6 t30 -129.34 63.22 66.74 Favored Pre-proline 0 CA--C 1.55 0.943 0 N-CA-C 111.415 0.154 . . . . 0.0 111.415 -179.144 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 14' ' ' PRO . . . . . 0.576 ' O ' ' HD2' ' A' ' 2' ' ' PRO . 15.6 Cg_exo -68.93 178.03 4.44 Favored 'Trans proline' 0 C--N 1.373 1.865 0 C-N-CA 122.828 2.352 . . . . 0.0 112.372 179.235 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 1.5 m -79.54 119.45 22.54 Favored 'General case' 0 N--CA 1.471 0.605 0 O-C-N 123.144 0.278 . . . . 0.0 111.315 -179.86 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 16' ' ' CYS . . . . . 0.576 ' HB2' ' O ' ' A' ' 2' ' ' PRO . 0.0 OUTLIER -57.13 -53.18 67.97 Favored Pre-proline 0 N--CA 1.483 1.182 0 CA-C-N 115.923 -0.581 . . . . 0.0 111.554 179.489 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 17' ' ' PRO . . . . . 0.48 ' HG2' HD12 ' A' ' 19' ' ' LEU . 57.9 Cg_endo -72.71 169.28 22.35 Favored 'Trans proline' 0 C--N 1.38 2.191 0 C-N-CA 121.994 1.796 . . . . 0.0 111.815 178.178 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 55.9 Cg_endo -72.27 44.69 0.72 Allowed 'Trans proline' 0 C--N 1.371 1.76 0 C-N-CA 122.012 1.808 . . . . 0.0 113.062 178.778 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 19' ' ' LEU . . . . . 0.48 HD12 ' HG2' ' A' ' 17' ' ' PRO . 12.2 mt -104.39 172.74 6.63 Favored 'General case' 0 C--O 1.236 0.361 0 CA-C-N 115.911 -0.586 . . . . 0.0 110.996 -179.761 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 25.4 m -103.32 150.19 24.01 Favored 'General case' 0 CA--C 1.534 0.335 0 CA-C-N 115.987 -0.551 . . . . 0.0 110.982 -178.903 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 5.1 t -100.38 103.03 14.4 Favored 'General case' 0 C--O 1.238 0.453 0 CA-C-N 115.724 -0.671 . . . . 0.0 109.407 178.412 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 22' ' ' ILE . . . . . 0.715 HD12 ' HB2' ' A' ' 31' ' ' TYR . 2.5 mt -127.16 129.04 24.02 Favored Pre-proline 0 CA--C 1.541 0.629 0 CA-C-N 115.803 -0.635 . . . . 0.0 110.826 -178.457 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 37.6 Cg_endo -67.99 -48.52 0.25 Allowed 'Cis proline' 0 C--N 1.375 1.938 0 C-N-CA 124.674 -0.969 . . . . 0.0 113.726 -0.261 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 79.12 37.79 24.14 Favored Glycine 0 C--N 1.347 1.19 0 C-N-CA 121.456 -0.402 . . . . 0.0 112.883 -179.991 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 4.6 t70 -140.12 80.57 19.92 Favored Pre-proline 0 CA--C 1.549 0.912 0 C-N-CA 122.338 0.255 . . . . 0.0 110.461 -179.686 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 1.9 Cg_endo -82.24 -31.71 4.0 Favored 'Cis proline' 0 C--N 1.372 1.774 0 C-N-CA 125.112 -0.787 . . . . 0.0 112.973 -0.134 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 27' ' ' TYR . . . . . . . . . . . . . 66.8 m-85 -101.7 171.98 7.22 Favored 'General case' 0 C--O 1.237 0.424 0 CA-C-N 115.796 -0.638 . . . . 0.0 111.591 -179.146 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 28' ' ' GLY . . . . . 0.526 ' O ' ' HA ' ' A' ' 7' ' ' GLN . . . -174.93 -160.26 22.6 Favored Glycine 0 C--N 1.337 0.621 0 CA-C-N 115.667 -0.697 . . . . 0.0 112.409 178.905 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 29' ' ' ILE . . . . . 0.56 ' HB ' ' CE2' ' A' ' 31' ' ' TYR . 1.4 mm -122.37 152.14 26.48 Favored 'Isoleucine or valine' 0 C--O 1.233 0.191 0 N-CA-C 109.807 -0.442 . . . . 0.0 109.807 179.609 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 30' ' ' CYS . . . . . 0.443 ' SG ' ' HB2' ' A' ' 19' ' ' LEU . 0.5 OUTLIER -80.02 106.92 12.4 Favored 'General case' 0 CA--C 1.537 0.467 0 CA-C-N 115.961 -0.563 . . . . 0.0 110.919 -179.986 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 31' ' ' TYR . . . . . 0.715 ' HB2' HD12 ' A' ' 22' ' ' ILE . 36.3 m-85 -132.15 167.17 20.24 Favored 'General case' 0 N--CA 1.463 0.222 0 CA-C-N 115.449 -0.796 . . . . 0.0 111.155 -179.332 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 2.7 tp -101.82 131.67 49.28 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.611 0 CA-C-N 116.081 -0.509 . . . . 0.0 110.412 179.493 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 33' ' ' ILE . . . . . 0.466 ' H ' HG13 ' A' ' 33' ' ' ILE . 1.9 pp . . . . . 0 C--O 1.249 1.04 0 CA-C-O 118.133 -0.937 . . . . 0.0 111.568 179.873 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 2' ' ' PRO . . . . . 0.511 ' HD3' ' ND2' ' A' ' 13' ' ' ASN . 81.2 Cg_endo . . . . . 0 CA--C 1.543 0.964 0 N-CA-C 112.886 0.302 . . . . 0.0 112.886 . . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -145.28 -156.63 6.92 Favored Glycine 0 C--N 1.34 0.767 0 N-CA-C 111.562 -0.615 . . . . 0.0 111.562 179.151 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 18.1 tt0 -73.43 129.49 38.11 Favored 'General case' 0 N--CA 1.471 0.624 0 C-N-CA 122.445 0.298 . . . . 0.0 111.208 179.595 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 88.13 14.14 62.89 Favored Glycine 0 C--N 1.34 0.778 0 CA-C-N 115.765 -0.652 . . . . 0.0 113.274 -179.845 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 43.2 mt-10 -129.81 162.19 29.04 Favored 'General case' 0 C--O 1.237 0.404 0 C-N-CA 122.277 0.231 . . . . 0.0 110.733 -179.897 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 7' ' ' GLN . . . . . 0.496 ' HA ' ' O ' ' A' ' 28' ' ' GLY . 9.4 tt0 -83.82 136.77 34.01 Favored 'General case' 0 C--N 1.345 0.374 0 CA-C-O 121.305 0.574 . . . . 0.0 111.296 179.815 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 4.0 p -125.57 160.25 30.06 Favored 'General case' 0 C--O 1.243 0.712 0 CA-C-N 114.471 -1.241 . . . . 0.0 110.89 -179.554 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 9' ' ' ASP . . . . . 0.444 ' OD1' ' HD2' ' A' ' 27' ' ' TYR . 2.5 m-20 -114.58 150.11 35.51 Favored 'General case' 0 C--O 1.235 0.313 0 CA-C-N 115.58 -0.736 . . . . 0.0 109.684 179.432 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 11.2 m -103.24 16.78 5.1 Favored 'Isoleucine or valine' 0 CA--C 1.542 0.64 0 CA-C-N 116.398 -0.364 . . . . 0.0 111.766 -179.686 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 9.6 mm-40 -110.73 -52.53 2.78 Favored 'General case' 0 C--O 1.235 0.312 0 N-CA-C 112.118 0.414 . . . . 0.0 112.118 -178.937 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 12' ' ' PHE . . . . . . . . . . . . . 17.2 t80 -142.01 -7.84 0.93 Allowed 'General case' 0 N--CA 1.472 0.663 0 N-CA-C 112.569 0.581 . . . . 0.0 112.569 -178.788 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 13' ' ' ASN . . . . . 0.511 ' ND2' ' HD3' ' A' ' 2' ' ' PRO . 6.7 t30 -129.58 64.37 71.38 Favored Pre-proline 0 CA--C 1.55 0.952 0 N-CA-C 111.559 0.207 . . . . 0.0 111.559 -179.075 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 15.0 Cg_exo -69.64 179.95 3.28 Favored 'Trans proline' 0 C--N 1.372 1.792 0 C-N-CA 122.888 2.392 . . . . 0.0 111.993 178.947 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 1.3 t -79.76 121.25 25.12 Favored 'General case' 0 N--CA 1.47 0.573 0 CA-C-O 120.519 0.2 . . . . 0.0 111.142 -179.951 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER -57.88 -53.61 63.96 Favored Pre-proline 0 N--CA 1.478 0.952 0 CA-C-O 118.992 -0.528 . . . . 0.0 111.573 179.325 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 17' ' ' PRO . . . . . 0.552 ' HG2' HD12 ' A' ' 19' ' ' LEU . 45.1 Cg_endo -69.06 169.61 17.63 Favored 'Trans proline' 0 C--N 1.378 2.099 0 C-N-CA 122.12 1.88 . . . . 0.0 111.725 178.181 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -71.8 49.67 1.27 Allowed 'Trans proline' 0 C--N 1.372 1.794 0 C-N-CA 121.957 1.771 . . . . 0.0 112.688 178.794 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 19' ' ' LEU . . . . . 0.552 HD12 ' HG2' ' A' ' 17' ' ' PRO . 22.0 mt -110.08 168.32 9.52 Favored 'General case' 0 C--O 1.236 0.389 0 CA-C-N 115.703 -0.681 . . . . 0.0 111.284 -179.363 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 20' ' ' THR . . . . . 0.519 ' O ' ' HA ' ' A' ' 30' ' ' CYS . 27.9 m -105.19 154.48 20.14 Favored 'General case' 0 CA--C 1.533 0.304 0 CA-C-N 115.641 -0.709 . . . . 0.0 111.191 -178.71 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 1.8 t -103.78 102.37 12.19 Favored 'General case' 0 C--O 1.238 0.453 0 CA-C-N 115.594 -0.73 . . . . 0.0 109.626 178.817 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 22' ' ' ILE . . . . . 0.711 HD12 ' HB2' ' A' ' 31' ' ' TYR . 2.8 mt -125.31 129.86 24.33 Favored Pre-proline 0 CA--C 1.542 0.665 0 CA-C-N 115.655 -0.702 . . . . 0.0 110.308 -179.071 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 35.3 Cg_endo -65.93 -48.9 0.21 Allowed 'Cis proline' 0 C--N 1.375 1.922 0 C-N-CA 124.723 -0.949 . . . . 0.0 113.817 -0.21 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 77.97 33.62 40.67 Favored Glycine 0 C--N 1.347 1.179 0 C-N-CA 121.256 -0.497 . . . . 0.0 112.901 179.872 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 4.6 t70 -139.49 82.84 17.92 Favored Pre-proline 0 CA--C 1.546 0.794 0 C-N-CA 122.556 0.343 . . . . 0.0 110.166 -179.641 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 2.5 Cg_endo -81.52 -32.54 3.61 Favored 'Cis proline' 0 C--N 1.37 1.7 0 C-N-CA 125.146 -0.772 . . . . 0.0 113.048 -0.028 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 27' ' ' TYR . . . . . 0.444 ' HD2' ' OD1' ' A' ' 9' ' ' ASP . 46.4 m-85 -103.46 167.59 9.71 Favored 'General case' 0 C--O 1.239 0.5 0 O-C-N 123.669 0.606 . . . . 0.0 111.476 -178.889 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 28' ' ' GLY . . . . . 0.496 ' O ' ' HA ' ' A' ' 7' ' ' GLN . . . -170.0 -163.14 23.54 Favored Glycine 0 C--N 1.342 0.899 0 C-N-CA 120.853 -0.689 . . . . 0.0 113.327 178.543 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 29' ' ' ILE . . . . . 0.501 ' HB ' ' CE2' ' A' ' 31' ' ' TYR . 2.7 mm -118.21 154.86 20.28 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.284 0 O-C-N 124.108 0.534 . . . . 0.0 110.149 -179.931 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 30' ' ' CYS . . . . . 0.519 ' HA ' ' O ' ' A' ' 20' ' ' THR . 24.5 m -83.29 103.48 12.71 Favored 'General case' 0 C--O 1.237 0.431 0 CA-C-N 115.941 -0.572 . . . . 0.0 111.22 -179.961 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 31' ' ' TYR . . . . . 0.711 ' HB2' HD12 ' A' ' 22' ' ' ILE . 38.6 m-85 -129.55 167.37 18.01 Favored 'General case' 0 CA--C 1.531 0.212 0 CA-C-N 115.01 -0.996 . . . . 0.0 111.074 -179.586 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 2.8 tp -100.43 131.11 48.6 Favored 'Isoleucine or valine' 0 CA--C 1.542 0.639 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.271 179.534 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 33' ' ' ILE . . . . . 0.496 HG23 HD11 ' A' ' 22' ' ' ILE . 1.9 pp . . . . . 0 C--O 1.248 0.988 0 CA-C-O 118.387 -0.816 . . . . 0.0 111.48 179.866 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 2' ' ' PRO . . . . . 0.532 ' HD3' ' ND2' ' A' ' 13' ' ' ASN . 84.7 Cg_endo . . . . . 0 CA--C 1.543 0.957 0 N-CA-C 112.926 0.318 . . . . 0.0 112.926 . . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -148.23 -158.42 7.96 Favored Glycine 0 C--N 1.338 0.671 0 N-CA-C 111.63 -0.588 . . . . 0.0 111.63 179.276 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 17.9 tt0 -70.32 123.83 22.68 Favored 'General case' 0 N--CA 1.473 0.702 0 C-N-CA 122.489 0.316 . . . . 0.0 111.516 179.891 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 98.42 -11.19 63.34 Favored Glycine 0 C--N 1.34 0.799 0 CA-C-N 115.748 -0.66 . . . . 0.0 113.58 179.809 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 43.0 mt-10 -105.34 166.02 10.71 Favored 'General case' 0 C--O 1.238 0.465 0 CA-C-N 116.705 0.253 . . . . 0.0 111.01 -179.735 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 7' ' ' GLN . . . . . 0.457 ' HA ' ' HA ' ' A' ' 29' ' ' ILE . 6.5 tt0 -86.73 140.39 29.81 Favored 'General case' 0 C--N 1.347 0.466 0 CA-C-O 121.113 0.482 . . . . 0.0 111.132 179.744 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 8' ' ' CYS . . . . . 0.421 ' SG ' ' SG ' ' A' ' 15' ' ' CYS . 5.8 p -127.02 158.49 36.8 Favored 'General case' 0 C--O 1.239 0.53 0 CA-C-N 114.696 -1.138 . . . . 0.0 111.128 -179.599 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -114.92 149.73 36.78 Favored 'General case' 0 C--O 1.234 0.27 0 CA-C-N 115.377 -0.829 . . . . 0.0 109.711 179.348 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 10' ' ' VAL . . . . . 0.525 HG22 ' O ' ' A' ' 26' ' ' PRO . 10.4 m -103.83 17.87 4.78 Favored 'Isoleucine or valine' 0 CA--C 1.542 0.661 0 O-C-N 123.31 0.381 . . . . 0.0 111.621 179.926 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 9.7 mm-40 -109.45 -53.08 2.7 Favored 'General case' 0 C--O 1.234 0.287 0 CA-C-N 116.347 -0.388 . . . . 0.0 111.997 -179.186 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 12' ' ' PHE . . . . . . . . . . . . . 12.2 t80 -139.74 -18.05 0.96 Allowed 'General case' 0 N--CA 1.471 0.62 0 N-CA-C 112.423 0.527 . . . . 0.0 112.423 -179.04 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 13' ' ' ASN . . . . . 0.532 ' ND2' ' HD3' ' A' ' 2' ' ' PRO . 8.3 t30 -118.7 74.67 12.46 Favored Pre-proline 0 CA--C 1.549 0.929 0 O-C-N 122.977 0.173 . . . . 0.0 111.222 -179.25 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 14' ' ' PRO . . . . . 0.405 ' O ' ' HD2' ' A' ' 2' ' ' PRO . 60.0 Cg_endo -75.48 178.11 7.78 Favored 'Trans proline' 0 C--N 1.372 1.768 0 C-N-CA 122.421 2.081 . . . . 0.0 112.649 179.201 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 15' ' ' CYS . . . . . 0.421 ' SG ' ' SG ' ' A' ' 8' ' ' CYS . 1.6 m -79.66 119.83 23.14 Favored 'General case' 0 N--CA 1.471 0.596 0 O-C-N 123.151 0.282 . . . . 0.0 111.623 179.983 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER -58.91 -54.27 58.11 Favored Pre-proline 0 N--CA 1.477 0.908 0 CA-C-N 115.91 -0.586 . . . . 0.0 111.598 179.667 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 48.0 Cg_endo -68.95 169.02 18.82 Favored 'Trans proline' 0 C--N 1.38 2.207 0 C-N-CA 121.965 1.777 . . . . 0.0 111.687 178.382 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 56.1 Cg_endo -72.43 45.89 0.9 Allowed 'Trans proline' 0 C--N 1.37 1.702 0 C-N-CA 121.929 1.752 . . . . 0.0 112.939 179.048 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 19' ' ' LEU . . . . . 0.506 ' HB2' ' SG ' ' A' ' 30' ' ' CYS . 44.4 mt -106.44 169.83 8.28 Favored 'General case' 0 C--O 1.236 0.358 0 CA-C-N 116.118 -0.492 . . . . 0.0 111.038 -179.632 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 32.6 m -104.12 149.89 24.83 Favored 'General case' 0 CA--C 1.533 0.31 0 CA-C-N 115.737 -0.665 . . . . 0.0 111.095 -178.904 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 2.7 t -98.44 102.54 14.32 Favored 'General case' 0 C--O 1.238 0.464 0 CA-C-N 115.88 -0.6 . . . . 0.0 109.555 178.545 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 22' ' ' ILE . . . . . 0.723 HD12 ' HB2' ' A' ' 31' ' ' TYR . 2.4 mt -126.64 130.68 23.8 Favored Pre-proline 0 CA--C 1.542 0.671 0 CA-C-N 115.704 -0.68 . . . . 0.0 110.457 -178.728 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 36.8 Cg_endo -66.88 -48.22 0.24 Allowed 'Cis proline' 0 C--N 1.374 1.917 0 C-N-CA 124.833 -0.903 . . . . 0.0 113.784 -0.088 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 75.31 41.23 31.5 Favored Glycine 0 C--N 1.348 1.246 0 C-N-CA 121.31 -0.471 . . . . 0.0 112.811 -179.948 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 8.1 m-20 -136.24 75.36 53.13 Favored Pre-proline 0 CA--C 1.545 0.761 0 C-N-CA 122.428 0.291 . . . . 0.0 110.863 -179.627 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 26' ' ' PRO . . . . . 0.525 ' O ' HG22 ' A' ' 10' ' ' VAL . 56.8 Cg_endo -88.49 -16.91 22.33 Favored 'Cis proline' 0 C--N 1.37 1.708 0 C-N-CA 124.79 -0.921 . . . . 0.0 113.773 -0.088 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 27' ' ' TYR . . . . . 0.475 ' CE2' ' HG2' ' A' ' 26' ' ' PRO . 21.0 m-85 -106.82 163.97 12.5 Favored 'General case' 0 C--O 1.238 0.497 0 CA-C-N 116.276 -0.42 . . . . 0.0 111.457 -179.026 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 28' ' ' GLY . . . . . 0.403 ' O ' ' HA ' ' A' ' 7' ' ' GLN . . . -173.64 -162.18 25.08 Favored Glycine 0 C--N 1.341 0.846 0 C-N-CA 120.889 -0.672 . . . . 0.0 113.291 178.493 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 29' ' ' ILE . . . . . 0.549 ' HB ' ' CE2' ' A' ' 31' ' ' TYR . 1.9 mm -118.51 154.68 20.68 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.232 0 O-C-N 124.031 0.489 . . . . 0.0 110.049 -179.912 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 30' ' ' CYS . . . . . 0.506 ' SG ' ' HB2' ' A' ' 19' ' ' LEU . 0.5 OUTLIER -81.97 105.49 13.12 Favored 'General case' 0 CA--C 1.537 0.464 0 CA-C-N 115.893 -0.594 . . . . 0.0 110.986 179.974 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 31' ' ' TYR . . . . . 0.723 ' HB2' HD12 ' A' ' 22' ' ' ILE . 38.4 m-85 -131.04 165.44 23.22 Favored 'General case' 0 N--CA 1.464 0.23 0 CA-C-N 115.406 -0.815 . . . . 0.0 111.205 -179.415 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 2.9 tp -100.08 131.3 47.8 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.592 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.461 179.571 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 33' ' ' ILE . . . . . 0.476 ' H ' HG13 ' A' ' 33' ' ' ILE . 1.9 pp . . . . . 0 C--O 1.249 1.033 0 CA-C-O 118.191 -0.909 . . . . 0.0 111.468 179.956 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 2' ' ' PRO . . . . . 0.581 ' O ' ' HB2' ' A' ' 16' ' ' CYS . 87.5 Cg_endo . . . . . 0 N--CA 1.489 1.253 0 N-CA-C 113.854 0.675 . . . . 0.0 113.854 . . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -134.49 -154.56 7.23 Favored Glycine 0 C--N 1.342 0.895 0 CA-C-N 116.09 -0.504 . . . . 0.0 112.287 179.979 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 16.1 tt0 -73.72 137.67 44.17 Favored 'General case' 0 N--CA 1.472 0.637 0 C-N-CA 122.845 0.458 . . . . 0.0 111.407 -179.854 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 82.61 12.92 79.37 Favored Glycine 0 C--N 1.341 0.832 0 CA-C-N 115.689 -0.687 . . . . 0.0 113.277 -179.771 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 43.1 mt-10 -125.95 161.53 27.29 Favored 'General case' 0 C--O 1.237 0.421 0 C-N-CA 122.346 0.258 . . . . 0.0 110.935 -179.875 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 7' ' ' GLN . . . . . 0.722 ' HA ' ' O ' ' A' ' 28' ' ' GLY . 21.0 tt0 -88.54 133.96 34.0 Favored 'General case' 0 C--N 1.344 0.363 0 CA-C-O 121.216 0.532 . . . . 0.0 111.275 179.872 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 2.0 p -128.73 161.64 29.24 Favored 'General case' 0 C--O 1.239 0.54 0 CA-C-N 114.557 -1.201 . . . . 0.0 111.149 -179.738 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 12.2 t70 -117.1 147.02 42.76 Favored 'General case' 0 C--O 1.234 0.254 0 CA-C-N 115.677 -0.692 . . . . 0.0 109.562 178.769 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 15.8 m -93.73 24.98 0.52 Allowed 'Isoleucine or valine' 0 CA--C 1.544 0.74 0 CA-C-N 116.268 -0.423 . . . . 0.0 111.805 -179.43 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 43.7 mt-10 -121.51 -52.79 2.02 Favored 'General case' 0 CA--C 1.533 0.293 0 N-CA-C 112.268 0.47 . . . . 0.0 112.268 -178.98 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 12' ' ' PHE . . . . . . . . . . . . . 9.9 t80 -138.27 -10.59 1.46 Allowed 'General case' 0 N--CA 1.47 0.546 0 N-CA-C 112.812 0.671 . . . . 0.0 112.812 -178.622 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 13' ' ' ASN . . . . . . . . . . . . . 7.3 t30 -129.57 62.79 65.19 Favored Pre-proline 0 CA--C 1.55 0.953 0 N-CA-C 111.655 0.243 . . . . 0.0 111.655 -179.277 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 14' ' ' PRO . . . . . 0.558 ' O ' ' HD2' ' A' ' 2' ' ' PRO . 13.5 Cg_exo -70.1 -179.97 3.45 Favored 'Trans proline' 0 C--N 1.374 1.878 0 C-N-CA 122.649 2.233 . . . . 0.0 111.962 178.985 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 1.8 t -79.57 120.83 24.48 Favored 'General case' 0 N--CA 1.47 0.541 0 C-N-CA 121.989 0.116 . . . . 0.0 110.849 -179.947 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 16' ' ' CYS . . . . . 0.581 ' HB2' ' O ' ' A' ' 2' ' ' PRO . 0.0 OUTLIER -55.66 -52.56 71.05 Favored Pre-proline 0 N--CA 1.483 1.214 0 CA-C-O 118.952 -0.547 . . . . 0.0 111.643 179.572 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 17' ' ' PRO . . . . . 0.554 ' HG2' HD12 ' A' ' 19' ' ' LEU . 56.5 Cg_endo -71.98 169.84 20.36 Favored 'Trans proline' 0 C--N 1.378 2.13 0 C-N-CA 122.155 1.903 . . . . 0.0 111.667 178.111 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 55.2 Cg_endo -71.91 48.55 1.13 Allowed 'Trans proline' 0 C--N 1.373 1.861 0 C-N-CA 121.976 1.784 . . . . 0.0 112.928 178.857 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 19' ' ' LEU . . . . . 0.554 HD12 ' HG2' ' A' ' 17' ' ' PRO . 28.2 mt -108.32 171.06 7.63 Favored 'General case' 0 C--O 1.236 0.383 0 CA-C-N 115.679 -0.691 . . . . 0.0 111.271 -179.655 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 20' ' ' THR . . . . . 0.527 ' O ' ' HA ' ' A' ' 30' ' ' CYS . 20.0 m -105.07 153.56 21.32 Favored 'General case' 0 CA--C 1.533 0.294 0 CA-C-N 115.927 -0.579 . . . . 0.0 111.044 -178.879 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 2.7 t -105.58 99.5 9.1 Favored 'General case' 0 C--O 1.236 0.367 0 CA-C-N 115.646 -0.706 . . . . 0.0 109.366 178.776 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 22' ' ' ILE . . . . . 0.727 HD12 ' HB2' ' A' ' 31' ' ' TYR . 3.6 mt -120.71 129.92 25.09 Favored Pre-proline 0 CA--C 1.543 0.682 0 CA-C-N 115.595 -0.729 . . . . 0.0 110.345 -178.782 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 36.8 Cg_endo -66.78 -47.01 0.27 Allowed 'Cis proline' 0 C--N 1.375 1.93 0 C-N-CA 124.647 -0.981 . . . . 0.0 113.965 -0.069 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 79.51 33.43 34.84 Favored Glycine 0 C--N 1.346 1.09 0 C-N-CA 121.223 -0.513 . . . . 0.0 112.957 179.8 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 8.3 m-20 -139.26 83.97 17.06 Favored Pre-proline 0 CA--C 1.544 0.735 0 C-N-CA 122.523 0.329 . . . . 0.0 110.588 -179.762 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 2.9 Cg_endo -80.25 -31.67 4.54 Favored 'Cis proline' 0 C--N 1.37 1.697 0 C-N-CA 125.074 -0.803 . . . . 0.0 112.907 -0.044 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 27' ' ' TYR . . . . . . . . . . . . . 59.8 m-85 -108.22 173.16 6.44 Favored 'General case' 0 C--O 1.239 0.541 0 CA-C-N 115.824 -0.625 . . . . 0.0 111.701 -179.053 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 28' ' ' GLY . . . . . 0.722 ' O ' ' HA ' ' A' ' 7' ' ' GLN . . . -175.54 -164.32 29.82 Favored Glycine 0 C--N 1.338 0.685 0 CA-C-N 115.694 -0.685 . . . . 0.0 112.491 178.495 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 29' ' ' ILE . . . . . 0.549 ' HB ' ' CE2' ' A' ' 31' ' ' TYR . 2.3 mm -113.99 152.82 15.61 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 O-C-N 123.654 0.267 . . . . 0.0 110.282 -179.825 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 30' ' ' CYS . . . . . 0.527 ' HA ' ' O ' ' A' ' 20' ' ' THR . 33.9 m -79.73 106.02 11.44 Favored 'General case' 0 C--O 1.237 0.409 0 CA-C-N 115.918 -0.583 . . . . 0.0 111.432 -179.874 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 31' ' ' TYR . . . . . 0.727 ' HB2' HD12 ' A' ' 22' ' ' ILE . 38.6 m-85 -130.51 167.83 18.03 Favored 'General case' 0 C--O 1.233 0.187 0 CA-C-N 115.081 -0.963 . . . . 0.0 111.113 -179.463 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 2.8 tp -101.21 131.13 49.54 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.551 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.31 179.514 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 33' ' ' ILE . . . . . 0.489 HG23 HD11 ' A' ' 22' ' ' ILE . 1.8 pp . . . . . 0 C--O 1.249 1.074 0 CA-C-O 118.158 -0.925 . . . . 0.0 111.443 179.913 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 2' ' ' PRO . . . . . 0.584 ' HD2' ' O ' ' A' ' 14' ' ' PRO . 91.6 Cg_endo . . . . . 0 N--CA 1.488 1.205 0 N-CA-C 113.961 0.716 . . . . 0.0 113.961 . . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -135.86 -157.74 7.96 Favored Glycine 0 C--N 1.341 0.817 0 CA-C-N 115.977 -0.556 . . . . 0.0 112.053 179.778 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 18.0 tt0 -73.07 135.46 44.82 Favored 'General case' 0 N--CA 1.471 0.608 0 C-N-CA 122.721 0.408 . . . . 0.0 111.345 -179.957 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 88.31 9.44 69.86 Favored Glycine 0 C--N 1.34 0.797 0 CA-C-N 115.797 -0.638 . . . . 0.0 113.396 -179.707 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 42.6 mt-10 -128.6 166.62 18.52 Favored 'General case' 0 C--O 1.239 0.505 0 C-N-CA 122.298 0.239 . . . . 0.0 110.883 -179.963 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 7' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER -81.74 152.48 27.0 Favored 'General case' 0 C--N 1.347 0.483 0 CA-C-N 116.581 -0.281 . . . . 0.0 110.867 179.909 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 4.9 p -140.48 150.58 43.95 Favored 'General case' 0 C--O 1.235 0.327 0 CA-C-N 115.852 -0.613 . . . . 0.0 111.116 -179.283 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -111.01 141.87 43.91 Favored 'General case' 0 C--O 1.234 0.277 0 CA-C-N 115.4 -0.818 . . . . 0.0 109.59 179.671 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 10' ' ' VAL . . . . . 0.45 HG22 ' O ' ' A' ' 26' ' ' PRO . 6.8 m -96.09 22.58 0.92 Allowed 'Isoleucine or valine' 0 CA--C 1.541 0.611 0 CA-C-N 116.559 -0.291 . . . . 0.0 111.651 -179.926 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 45.3 mt-10 -115.29 -54.34 2.55 Favored 'General case' 0 C--O 1.235 0.305 0 N-CA-C 112.079 0.4 . . . . 0.0 112.079 -179.067 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 12' ' ' PHE . . . . . . . . . . . . . 11.9 t80 -141.53 -9.17 0.95 Allowed 'General case' 0 N--CA 1.473 0.676 0 N-CA-C 112.548 0.573 . . . . 0.0 112.548 -178.791 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 13' ' ' ASN . . . . . 0.456 HD21 ' HD3' ' A' ' 2' ' ' PRO . 9.9 t30 -129.94 63.53 68.91 Favored Pre-proline 0 CA--C 1.551 0.981 0 N-CA-C 111.369 0.137 . . . . 0.0 111.369 -179.19 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 14' ' ' PRO . . . . . 0.584 ' O ' ' HD2' ' A' ' 2' ' ' PRO . 13.3 Cg_exo -70.37 -174.54 1.05 Allowed 'Trans proline' 0 C--N 1.375 1.922 0 C-N-CA 122.784 2.322 . . . . 0.0 112.039 179.118 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 2.1 t -79.27 120.61 23.98 Favored 'General case' 0 N--CA 1.472 0.627 0 O-C-N 122.909 0.131 . . . . 0.0 110.991 -179.902 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 16' ' ' CYS . . . . . 0.572 ' HB2' ' O ' ' A' ' 2' ' ' PRO . 0.0 OUTLIER -57.03 -52.5 73.67 Favored Pre-proline 0 N--CA 1.483 1.198 0 CA-C-O 119.073 -0.489 . . . . 0.0 111.551 179.458 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 17' ' ' PRO . . . . . 0.591 ' HG2' HD12 ' A' ' 19' ' ' LEU . 56.9 Cg_endo -72.29 169.95 20.36 Favored 'Trans proline' 0 C--N 1.38 2.205 0 C-N-CA 122.1 1.867 . . . . 0.0 111.712 178.013 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 53.1 Cg_endo -71.45 49.86 1.19 Allowed 'Trans proline' 0 C--N 1.373 1.861 0 C-N-CA 121.978 1.785 . . . . 0.0 112.852 178.871 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 19' ' ' LEU . . . . . 0.591 HD12 ' HG2' ' A' ' 17' ' ' PRO . 32.9 mt -108.7 172.5 6.81 Favored 'General case' 0 CA--C 1.533 0.321 0 CA-C-N 115.722 -0.672 . . . . 0.0 111.235 -179.574 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 20' ' ' THR . . . . . 0.424 ' O ' ' HA ' ' A' ' 30' ' ' CYS . 25.0 m -106.63 153.96 21.61 Favored 'General case' 0 CA--C 1.533 0.308 0 CA-C-N 115.811 -0.631 . . . . 0.0 111.462 -178.497 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 3.5 t -103.57 104.18 14.2 Favored 'General case' 0 C--O 1.236 0.392 0 CA-C-N 115.512 -0.767 . . . . 0.0 109.474 178.568 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 22' ' ' ILE . . . . . 0.721 HD12 ' HB2' ' A' ' 31' ' ' TYR . 4.8 mt -125.56 129.66 24.33 Favored Pre-proline 0 CA--C 1.543 0.703 0 CA-C-N 115.757 -0.656 . . . . 0.0 110.665 -178.914 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 35.6 Cg_endo -66.45 -48.11 0.24 Allowed 'Cis proline' 0 C--N 1.376 1.998 0 C-N-CA 124.683 -0.965 . . . . 0.0 113.801 -0.207 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 80.46 34.4 28.86 Favored Glycine 0 C--N 1.347 1.141 0 C-N-CA 121.253 -0.498 . . . . 0.0 112.904 179.877 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 8.0 m-20 -142.81 84.27 10.87 Favored Pre-proline 0 CA--C 1.544 0.719 0 C-N-CA 122.525 0.33 . . . . 0.0 110.542 -179.604 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 26' ' ' PRO . . . . . 0.45 ' O ' HG22 ' A' ' 10' ' ' VAL . 1.1 Cg_endo -81.77 -31.73 4.12 Favored 'Cis proline' 0 C--N 1.373 1.821 0 C-N-CA 125.075 -0.802 . . . . 0.0 113.06 -0.098 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 27' ' ' TYR . . . . . . . . . . . . . 41.2 m-85 -101.26 167.56 10.12 Favored 'General case' 0 C--O 1.239 0.532 0 CA-C-N 115.797 -0.638 . . . . 0.0 111.158 -178.981 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -164.88 -161.21 13.37 Favored Glycine 0 C--N 1.34 0.799 0 C-N-CA 120.839 -0.696 . . . . 0.0 113.264 179.619 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 29' ' ' ILE . . . . . 0.489 ' HB ' ' CE2' ' A' ' 31' ' ' TYR . 3.9 mm -127.93 155.26 39.32 Favored 'Isoleucine or valine' 0 C--O 1.234 0.268 0 CA-C-N 115.175 -0.512 . . . . 0.0 109.877 179.944 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 30' ' ' CYS . . . . . 0.424 ' HA ' ' O ' ' A' ' 20' ' ' THR . 23.7 m -81.96 100.61 9.77 Favored 'General case' 0 CA--C 1.536 0.435 0 CA-C-O 121.278 0.561 . . . . 0.0 111.446 -179.911 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 31' ' ' TYR . . . . . 0.721 ' HB2' HD12 ' A' ' 22' ' ' ILE . 38.4 m-85 -130.04 166.16 20.72 Favored 'General case' 0 N--CA 1.464 0.246 0 CA-C-N 115.12 -0.946 . . . . 0.0 110.937 -179.872 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 2.9 tp -101.0 131.71 48.15 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.546 0 CA-C-N 116.077 -0.511 . . . . 0.0 110.367 179.558 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 33' ' ' ILE . . . . . 0.496 HG23 HD11 ' A' ' 22' ' ' ILE . 1.8 pp . . . . . 0 C--O 1.25 1.097 0 CA-C-O 118.241 -0.885 . . . . 0.0 111.486 179.876 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 2' ' ' PRO . . . . . 0.579 ' O ' ' HB2' ' A' ' 16' ' ' CYS . 92.3 Cg_endo . . . . . 0 N--CA 1.488 1.195 0 N-CA-C 113.907 0.695 . . . . 0.0 113.907 . . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -135.79 -156.54 7.59 Favored Glycine 0 C--N 1.342 0.894 0 CA-C-N 116.027 -0.533 . . . . 0.0 112.387 179.829 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 16.0 tt0 -74.31 138.78 43.76 Favored 'General case' 0 N--CA 1.471 0.593 0 C-N-CA 122.693 0.397 . . . . 0.0 111.377 -179.707 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 84.53 10.62 79.27 Favored Glycine 0 C--N 1.34 0.754 0 CA-C-N 115.809 -0.632 . . . . 0.0 113.333 179.99 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 43.1 mt-10 -129.16 160.98 31.17 Favored 'General case' 0 N--CA 1.467 0.4 0 C-N-CA 122.206 0.202 . . . . 0.0 110.846 -179.841 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 7' ' ' GLN . . . . . 0.516 ' HA ' ' O ' ' A' ' 28' ' ' GLY . 7.5 tt0 -84.85 133.65 34.31 Favored 'General case' 0 C--N 1.344 0.366 0 CA-C-O 121.331 0.586 . . . . 0.0 111.215 179.765 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 3.3 p -122.85 161.75 23.48 Favored 'General case' 0 C--O 1.241 0.615 0 CA-C-N 114.44 -1.254 . . . . 0.0 110.824 -179.638 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 9' ' ' ASP . . . . . 0.452 ' OD1' ' HD2' ' A' ' 27' ' ' TYR . 1.8 m-20 -114.91 152.01 33.04 Favored 'General case' 0 C--O 1.235 0.31 0 CA-C-N 115.511 -0.768 . . . . 0.0 109.77 179.41 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 10.1 m -103.79 13.03 7.44 Favored 'Isoleucine or valine' 0 CA--C 1.542 0.651 0 O-C-N 123.254 0.346 . . . . 0.0 111.801 -179.818 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 45.9 mt-10 -100.95 -55.67 2.51 Favored 'General case' 0 C--O 1.235 0.304 0 N-CA-C 111.812 0.301 . . . . 0.0 111.812 -179.073 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 12' ' ' PHE . . . . . . . . . . . . . 12.6 t80 -141.25 -14.23 0.89 Allowed 'General case' 0 N--CA 1.47 0.564 0 N-CA-C 112.218 0.451 . . . . 0.0 112.218 -179.251 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 13' ' ' ASN . . . . . 0.484 HD21 ' HD3' ' A' ' 2' ' ' PRO . 12.6 t30 -120.47 72.91 21.09 Favored Pre-proline 0 CA--C 1.55 0.955 0 O-C-N 122.903 0.127 . . . . 0.0 111.184 -179.406 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 14' ' ' PRO . . . . . 0.575 ' O ' ' HD2' ' A' ' 2' ' ' PRO . 60.8 Cg_endo -76.44 -176.4 3.08 Favored 'Trans proline' 0 C--N 1.371 1.735 0 C-N-CA 122.367 2.044 . . . . 0.0 112.207 179.245 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 2.0 t -79.34 119.64 22.67 Favored 'General case' 0 N--CA 1.473 0.71 0 O-C-N 123.017 0.198 . . . . 0.0 110.642 179.861 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 16' ' ' CYS . . . . . 0.579 ' HB2' ' O ' ' A' ' 2' ' ' PRO . 0.0 OUTLIER -54.94 -52.48 70.49 Favored Pre-proline 0 N--CA 1.483 1.178 0 CA-C-O 119.005 -0.521 . . . . 0.0 111.664 179.715 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 17' ' ' PRO . . . . . 0.561 ' HG2' HD12 ' A' ' 19' ' ' LEU . 57.6 Cg_endo -72.39 169.79 20.83 Favored 'Trans proline' 0 C--N 1.378 2.126 0 C-N-CA 122.06 1.84 . . . . 0.0 111.789 178.021 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 55.1 Cg_endo -71.87 50.28 1.4 Allowed 'Trans proline' 0 C--N 1.374 1.895 0 C-N-CA 122.065 1.844 . . . . 0.0 112.742 178.808 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 19' ' ' LEU . . . . . 0.561 HD12 ' HG2' ' A' ' 17' ' ' PRO . 32.4 mt -110.03 172.13 7.04 Favored 'General case' 0 CA--C 1.533 0.323 0 CA-C-N 115.666 -0.697 . . . . 0.0 111.311 -179.33 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 20' ' ' THR . . . . . 0.497 ' O ' ' HA ' ' A' ' 30' ' ' CYS . 21.2 m -106.04 154.38 20.71 Favored 'General case' 0 CA--C 1.533 0.293 0 CA-C-N 115.606 -0.724 . . . . 0.0 111.002 -178.948 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 2.0 t -105.35 99.7 9.3 Favored 'General case' 0 C--O 1.237 0.398 0 CA-C-N 115.644 -0.707 . . . . 0.0 109.363 178.597 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 22' ' ' ILE . . . . . 0.73 HD12 ' HB2' ' A' ' 31' ' ' TYR . 3.0 mt -122.53 130.53 24.62 Favored Pre-proline 0 CA--C 1.542 0.658 0 CA-C-N 115.559 -0.746 . . . . 0.0 110.382 -178.713 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 32.5 Cg_endo -65.07 -48.47 0.21 Allowed 'Cis proline' 0 C--N 1.375 1.944 0 C-N-CA 124.76 -0.933 . . . . 0.0 113.942 -0.226 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 77.19 31.36 52.51 Favored Glycine 0 C--N 1.348 1.215 0 C-N-CA 121.165 -0.54 . . . . 0.0 113.004 179.725 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 8.3 m-20 -138.86 83.71 18.56 Favored Pre-proline 0 CA--C 1.544 0.717 0 C-N-CA 122.49 0.316 . . . . 0.0 110.432 -179.771 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 3.0 Cg_exo -81.17 -32.34 3.83 Favored 'Cis proline' 0 C--N 1.372 1.772 0 C-N-CA 125.101 -0.791 . . . . 0.0 113.07 -0.08 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 27' ' ' TYR . . . . . 0.452 ' HD2' ' OD1' ' A' ' 9' ' ' ASP . 45.4 m-85 -104.4 166.76 10.19 Favored 'General case' 0 N--CA 1.469 0.485 0 CA-C-N 115.864 -0.607 . . . . 0.0 111.465 -178.884 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 28' ' ' GLY . . . . . 0.516 ' O ' ' HA ' ' A' ' 7' ' ' GLN . . . -169.95 -164.85 26.36 Favored Glycine 0 C--N 1.341 0.842 0 C-N-CA 120.93 -0.652 . . . . 0.0 113.356 178.492 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 29' ' ' ILE . . . . . 0.536 ' HB ' ' CE2' ' A' ' 31' ' ' TYR . 1.9 mm -117.38 153.07 19.22 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.225 0 O-C-N 124.045 0.497 . . . . 0.0 110.22 -179.938 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 30' ' ' CYS . . . . . 0.497 ' HA ' ' O ' ' A' ' 20' ' ' THR . 20.5 m -80.06 104.66 10.78 Favored 'General case' 0 CA--C 1.536 0.42 0 CA-C-N 115.923 -0.581 . . . . 0.0 111.21 -179.866 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 31' ' ' TYR . . . . . 0.73 ' HB2' HD12 ' A' ' 22' ' ' ILE . 39.7 m-85 -130.12 167.51 18.24 Favored 'General case' 0 C--O 1.233 0.223 0 CA-C-N 115.098 -0.956 . . . . 0.0 111.044 -179.54 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 2.6 tp -100.95 131.84 47.82 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.524 0 CA-C-N 116.056 -0.52 . . . . 0.0 110.426 179.486 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 33' ' ' ILE . . . . . 0.451 ' O ' HD12 ' A' ' 33' ' ' ILE . 1.7 pp . . . . . 0 C--O 1.248 0.998 0 CA-C-O 118.383 -0.818 . . . . 0.0 111.522 179.856 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 2' ' ' PRO . . . . . 0.594 ' HD2' ' O ' ' A' ' 14' ' ' PRO . 94.6 Cg_endo . . . . . 0 N--CA 1.489 1.243 0 N-CA-C 113.801 0.654 . . . . 0.0 113.801 . . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -136.4 -158.1 7.97 Favored Glycine 0 C--N 1.342 0.89 0 CA-C-N 115.852 -0.613 . . . . 0.0 112.232 179.749 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 18.3 tt0 -73.52 136.51 44.11 Favored 'General case' 0 N--CA 1.472 0.625 0 C-N-CA 122.717 0.407 . . . . 0.0 111.382 -179.978 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 87.85 9.23 71.61 Favored Glycine 0 C--N 1.339 0.703 0 O-C-N 123.775 0.672 . . . . 0.0 113.398 -179.796 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 3.2 tp10 -129.0 166.49 19.09 Favored 'General case' 0 C--O 1.239 0.53 0 C-N-CA 122.218 0.207 . . . . 0.0 110.576 -179.816 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 7' ' ' GLN . . . . . . . . . . . . . 0.2 OUTLIER -80.6 152.81 28.36 Favored 'General case' 0 C--N 1.347 0.483 0 CA-C-N 116.517 -0.31 . . . . 0.0 110.822 179.782 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 6.2 p -140.85 152.24 44.97 Favored 'General case' 0 C--O 1.234 0.245 0 CA-C-N 115.958 -0.565 . . . . 0.0 111.163 -179.12 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -112.41 146.12 38.92 Favored 'General case' 0 C--O 1.235 0.337 0 CA-C-N 115.397 -0.82 . . . . 0.0 109.626 179.498 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 10' ' ' VAL . . . . . 0.452 HG22 ' O ' ' A' ' 26' ' ' PRO . 6.5 m -101.26 17.91 3.63 Favored 'Isoleucine or valine' 0 CA--C 1.543 0.674 0 CA-C-N 116.46 -0.336 . . . . 0.0 111.604 179.988 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 47.0 mt-10 -107.55 -55.01 2.41 Favored 'General case' 0 N--CA 1.467 0.383 0 CA-C-N 116.346 -0.388 . . . . 0.0 111.873 -179.155 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 12' ' ' PHE . . . . . . . . . . . . . 10.8 t80 -140.35 -16.77 0.92 Allowed 'General case' 0 N--CA 1.471 0.596 0 N-CA-C 112.31 0.485 . . . . 0.0 112.31 -179.193 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 13' ' ' ASN . . . . . 0.498 HD21 ' HD3' ' A' ' 2' ' ' PRO . 13.3 t30 -120.56 72.98 21.76 Favored Pre-proline 0 CA--C 1.548 0.899 0 O-C-N 122.937 0.148 . . . . 0.0 111.139 -179.337 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 14' ' ' PRO . . . . . 0.594 ' O ' ' HD2' ' A' ' 2' ' ' PRO . 62.4 Cg_endo -76.71 -175.13 2.44 Favored 'Trans proline' 0 C--N 1.372 1.806 0 C-N-CA 122.484 2.123 . . . . 0.0 112.347 179.318 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 2.2 t -79.48 119.59 22.68 Favored 'General case' 0 N--CA 1.472 0.651 0 CA-C-O 120.452 0.168 . . . . 0.0 110.727 179.932 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 16' ' ' CYS . . . . . 0.579 ' HB2' ' O ' ' A' ' 2' ' ' PRO . 0.0 OUTLIER -56.25 -52.59 71.8 Favored Pre-proline 0 N--CA 1.481 1.101 0 CA-C-O 119.005 -0.521 . . . . 0.0 111.712 179.611 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 17' ' ' PRO . . . . . 0.582 ' HG2' HD12 ' A' ' 19' ' ' LEU . 56.9 Cg_endo -72.36 169.67 21.1 Favored 'Trans proline' 0 C--N 1.38 2.205 0 C-N-CA 122.065 1.844 . . . . 0.0 111.721 177.969 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -71.69 51.87 1.6 Allowed 'Trans proline' 0 C--N 1.373 1.859 0 C-N-CA 121.963 1.776 . . . . 0.0 112.769 178.79 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 19' ' ' LEU . . . . . 0.582 HD12 ' HG2' ' A' ' 17' ' ' PRO . 37.5 mt -110.6 173.12 6.48 Favored 'General case' 0 C--O 1.236 0.37 0 CA-C-N 115.58 -0.736 . . . . 0.0 111.333 -179.565 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 28.8 m -107.92 152.88 23.85 Favored 'General case' 0 CA--C 1.533 0.318 0 CA-C-N 115.874 -0.603 . . . . 0.0 111.346 -178.565 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 3.9 t -101.82 104.25 15.0 Favored 'General case' 0 C--O 1.238 0.471 0 CA-C-N 115.437 -0.801 . . . . 0.0 109.622 178.463 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 22' ' ' ILE . . . . . 0.726 HD12 ' HB2' ' A' ' 31' ' ' TYR . 4.5 mt -125.92 129.75 24.2 Favored Pre-proline 0 CA--C 1.544 0.717 0 CA-C-N 115.918 -0.583 . . . . 0.0 110.544 -178.775 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 23' ' ' PRO . . . . . 0.48 ' HB2' ' OD2' ' A' ' 25' ' ' ASP . 35.2 Cg_endo -66.01 -48.76 0.21 Allowed 'Cis proline' 0 C--N 1.376 1.979 0 C-N-CA 124.71 -0.954 . . . . 0.0 113.807 -0.354 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 80.55 35.61 25.38 Favored Glycine 0 C--N 1.347 1.156 0 C-N-CA 121.299 -0.477 . . . . 0.0 112.91 179.826 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 25' ' ' ASP . . . . . 0.48 ' OD2' ' HB2' ' A' ' 23' ' ' PRO . 2.5 p30 -143.72 84.1 10.11 Favored Pre-proline 0 CA--C 1.548 0.898 0 C-N-CA 122.551 0.34 . . . . 0.0 110.759 -179.789 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 26' ' ' PRO . . . . . 0.452 ' O ' HG22 ' A' ' 10' ' ' VAL . 1.2 Cg_endo -81.41 -32.1 3.95 Favored 'Cis proline' 0 C--N 1.371 1.712 0 C-N-CA 125.15 -0.771 . . . . 0.0 113.087 0.011 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 27' ' ' TYR . . . . . . . . . . . . . 40.1 m-85 -101.79 169.69 8.64 Favored 'General case' 0 C--O 1.239 0.533 0 CA-C-N 115.754 -0.657 . . . . 0.0 111.213 -178.888 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -167.49 -159.42 13.04 Favored Glycine 0 C--N 1.341 0.815 0 C-N-CA 120.888 -0.672 . . . . 0.0 113.243 179.517 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 29' ' ' ILE . . . . . 0.493 ' HB ' ' CE2' ' A' ' 31' ' ' TYR . 4.2 mm -128.17 154.4 38.78 Favored 'Isoleucine or valine' 0 C--O 1.233 0.193 0 CA-C-N 115.276 -0.462 . . . . 0.0 109.853 179.969 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 30' ' ' CYS . . . . . . . . . . . . . 18.2 m -81.55 101.48 9.99 Favored 'General case' 0 CA--C 1.536 0.42 0 CA-C-N 116.02 -0.536 . . . . 0.0 111.395 179.989 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 31' ' ' TYR . . . . . 0.726 ' HB2' HD12 ' A' ' 22' ' ' ILE . 38.4 m-85 -130.0 166.53 19.9 Favored 'General case' 0 N--CA 1.464 0.228 0 CA-C-N 115.145 -0.934 . . . . 0.0 110.995 -179.714 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 2.8 tp -101.5 131.96 48.29 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.624 0 CA-C-N 116.141 -0.482 . . . . 0.0 110.377 179.51 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 33' ' ' ILE . . . . . 0.488 ' H ' HG13 ' A' ' 33' ' ' ILE . 1.8 pp . . . . . 0 C--O 1.249 1.057 0 CA-C-O 118.382 -0.818 . . . . 0.0 111.521 179.945 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 5.8 p . . . . . 0 N--CA 1.485 1.311 0 CA-C-O 119.724 -0.179 . . . . 0.0 111.279 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' A' A ' 2' ' ' PRO . . . . . 0.539 ' HD3' ' ND2' ' A' ' 13' ' ' ASN . 81.1 Cg_endo -83.07 -172.88 1.5 Allowed 'Trans proline' 0 C--N 1.368 1.556 0 C-N-CA 122.59 2.194 . . . . 0.0 112.942 179.631 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -145.77 -159.22 8.06 Favored Glycine 0 C--N 1.337 0.632 0 N-CA-C 111.547 -0.621 . . . . 0.0 111.547 179.189 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 19.7 tt0 -71.3 125.84 28.05 Favored 'General case' 0 N--CA 1.472 0.668 0 CA-C-N 116.901 0.35 . . . . 0.0 111.072 179.631 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 88.22 16.65 58.8 Favored Glycine 0 C--N 1.339 0.724 0 CA-C-N 115.659 -0.7 . . . . 0.0 113.097 -179.541 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 43.1 mt-10 -127.95 166.91 17.43 Favored 'General case' 0 C--O 1.237 0.433 0 C-N-CA 122.333 0.253 . . . . 0.0 110.719 -179.775 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 7' ' ' GLN . . . . . 0.459 ' HA ' ' O ' ' A' ' 28' ' ' GLY . 0.2 OUTLIER -81.05 152.04 28.08 Favored 'General case' 0 C--N 1.346 0.436 0 CA-C-N 116.502 -0.317 . . . . 0.0 110.974 179.89 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 6.3 p -147.12 156.24 42.83 Favored 'General case' 0 C--O 1.235 0.307 0 CA-C-N 115.963 -0.562 . . . . 0.0 111.583 -178.965 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 4.8 t70 -117.36 149.13 41.01 Favored 'General case' 0 C--O 1.234 0.263 0 CA-C-N 115.452 -0.794 . . . . 0.0 109.589 178.918 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 15.7 m -102.38 24.49 1.48 Allowed 'Isoleucine or valine' 0 CA--C 1.542 0.655 0 CA-C-N 116.225 -0.443 . . . . 0.0 111.905 -179.493 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 43.9 mt-10 -120.63 -50.89 2.18 Favored 'General case' 0 N--CA 1.466 0.333 0 N-CA-C 112.063 0.394 . . . . 0.0 112.063 -179.044 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 12' ' ' PHE . . . . . . . . . . . . . 13.7 m-85 -133.35 -27.23 1.59 Allowed 'General case' 0 N--CA 1.47 0.541 0 N-CA-C 112.181 0.437 . . . . 0.0 112.181 -178.706 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 13' ' ' ASN . . . . . 0.539 ' ND2' ' HD3' ' A' ' 2' ' ' PRO . 6.3 t30 -116.03 73.91 5.11 Favored Pre-proline 0 CA--C 1.549 0.934 0 O-C-N 123.435 0.459 . . . . 0.0 112.174 -177.467 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 14' ' ' PRO . . . . . 0.415 ' O ' ' HD2' ' A' ' 2' ' ' PRO . 60.8 Cg_endo -76.1 179.09 6.67 Favored 'Trans proline' 0 C--N 1.372 1.777 0 C-N-CA 122.43 2.087 . . . . 0.0 112.125 178.746 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 1.9 t -79.67 119.9 23.24 Favored 'General case' 0 N--CA 1.47 0.566 0 CA-C-O 120.499 0.19 . . . . 0.0 110.938 179.75 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER -57.86 -54.07 59.23 Favored Pre-proline 0 N--CA 1.477 0.915 0 CA-C-O 118.973 -0.537 . . . . 0.0 111.757 179.651 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 17' ' ' PRO . . . . . 0.621 ' HG2' HD12 ' A' ' 19' ' ' LEU . 51.9 Cg_endo -70.39 168.19 23.08 Favored 'Trans proline' 0 C--N 1.378 2.118 0 C-N-CA 122.025 1.817 . . . . 0.0 111.8 178.25 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 49.8 Cg_endo -71.01 60.88 2.39 Favored 'Trans proline' 0 C--N 1.372 1.796 0 C-N-CA 121.945 1.763 . . . . 0.0 112.427 178.807 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 19' ' ' LEU . . . . . 0.621 HD12 ' HG2' ' A' ' 17' ' ' PRO . 22.6 mt -122.42 171.58 8.97 Favored 'General case' 0 C--O 1.235 0.325 0 CA-C-N 115.411 -0.813 . . . . 0.0 111.421 -179.269 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 20' ' ' THR . . . . . 0.492 ' O ' ' HA ' ' A' ' 30' ' ' CYS . 28.5 m -107.72 153.69 22.58 Favored 'General case' 0 CA--C 1.533 0.306 0 CA-C-N 115.676 -0.693 . . . . 0.0 111.227 -178.676 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 4.8 t -103.06 104.97 15.19 Favored 'General case' 0 C--O 1.237 0.426 0 CA-C-N 115.593 -0.731 . . . . 0.0 109.553 178.626 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 22' ' ' ILE . . . . . 0.712 HD12 ' HB2' ' A' ' 31' ' ' TYR . 3.4 mt -127.12 129.34 23.97 Favored Pre-proline 0 CA--C 1.543 0.686 0 CA-C-N 115.874 -0.603 . . . . 0.0 110.47 -178.805 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 37.6 Cg_endo -67.46 -48.69 0.23 Allowed 'Cis proline' 0 C--N 1.374 1.913 0 C-N-CA 124.713 -0.953 . . . . 0.0 113.848 -0.294 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 80.5 40.74 12.35 Favored Glycine 0 C--N 1.347 1.145 0 C-N-CA 121.264 -0.493 . . . . 0.0 112.761 -179.891 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 8.2 m-20 -141.6 79.31 17.21 Favored Pre-proline 0 CA--C 1.544 0.744 0 C-N-CA 122.443 0.297 . . . . 0.0 110.837 -179.709 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 1.5 Cg_endo -82.49 -32.72 3.29 Favored 'Cis proline' 0 C--N 1.371 1.746 0 C-N-CA 125.074 -0.803 . . . . 0.0 113.028 -0.125 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 27' ' ' TYR . . . . . . . . . . . . . 71.7 m-85 -98.11 171.43 8.25 Favored 'General case' 0 C--O 1.24 0.563 0 CA-C-N 115.913 -0.585 . . . . 0.0 111.568 -178.973 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 28' ' ' GLY . . . . . 0.459 ' O ' ' HA ' ' A' ' 7' ' ' GLN . . . -173.03 -159.84 20.44 Favored Glycine 0 C--N 1.338 0.653 0 CA-C-N 115.784 -0.644 . . . . 0.0 112.365 179.301 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 29' ' ' ILE . . . . . 0.518 ' HB ' ' CE2' ' A' ' 31' ' ' TYR . 2.9 mm -124.21 151.18 29.13 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 N-CA-C 109.735 -0.468 . . . . 0.0 109.735 179.737 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 30' ' ' CYS . . . . . 0.492 ' HA ' ' O ' ' A' ' 20' ' ' THR . 23.4 m -79.94 103.24 9.69 Favored 'General case' 0 CA--C 1.536 0.412 0 CA-C-O 121.225 0.536 . . . . 0.0 111.432 -179.812 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 31' ' ' TYR . . . . . 0.712 ' HB2' HD12 ' A' ' 22' ' ' ILE . 38.2 m-85 -129.07 167.77 17.04 Favored 'General case' 0 C--O 1.233 0.211 0 CA-C-N 115.014 -0.993 . . . . 0.0 110.923 -179.623 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 2.7 tp -100.95 131.43 48.62 Favored 'Isoleucine or valine' 0 CA--C 1.542 0.645 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.315 179.411 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 33' ' ' ILE . . . . . 0.498 HG23 HD11 ' A' ' 22' ' ' ILE . 1.9 pp . . . . . 0 C--O 1.249 1.051 0 CA-C-O 118.395 -0.812 . . . . 0.0 111.413 179.954 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 6.7 p . . . . . 0 N--CA 1.485 1.283 0 CA-C-O 119.778 -0.153 . . . . 0.0 111.161 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' A' A ' 2' ' ' PRO . . . . . 0.488 ' HD3' ' ND2' ' A' ' 13' ' ' ASN . 88.6 Cg_endo -82.31 -172.69 1.5 Allowed 'Trans proline' 0 C--N 1.368 1.553 0 C-N-CA 122.57 2.18 . . . . 0.0 112.963 179.437 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -149.46 -159.58 8.7 Favored Glycine 0 C--N 1.338 0.67 0 N-CA-C 111.623 -0.591 . . . . 0.0 111.623 179.229 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 17.2 tt0 -70.05 121.29 17.17 Favored 'General case' 0 N--CA 1.474 0.73 0 CA-C-O 120.763 0.315 . . . . 0.0 111.241 179.811 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 93.37 15.15 51.99 Favored Glycine 0 C--N 1.34 0.782 0 CA-C-N 115.614 -0.721 . . . . 0.0 113.164 -179.776 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 43.1 mt-10 -128.75 166.63 18.62 Favored 'General case' 0 C--O 1.24 0.56 0 C-N-CA 122.514 0.326 . . . . 0.0 110.816 179.959 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 7' ' ' GLN . . . . . 0.443 ' HA ' ' O ' ' A' ' 28' ' ' GLY . 0.2 OUTLIER -81.43 152.55 27.35 Favored 'General case' 0 C--N 1.346 0.435 0 O-C-N 123.195 0.309 . . . . 0.0 111.137 -179.88 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 7.9 p -145.84 154.53 42.1 Favored 'General case' 0 N--CA 1.466 0.354 0 CA-C-N 115.957 -0.565 . . . . 0.0 111.502 -179.12 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 6.2 t70 -118.12 153.82 33.15 Favored 'General case' 0 C--O 1.236 0.345 0 CA-C-N 115.393 -0.821 . . . . 0.0 109.898 179.139 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 13.5 m -105.33 17.92 5.44 Favored 'Isoleucine or valine' 0 CA--C 1.542 0.661 0 CA-C-N 116.286 -0.416 . . . . 0.0 112.033 -179.422 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 46.3 mt-10 -110.74 -52.9 2.75 Favored 'General case' 0 N--CA 1.466 0.36 0 N-CA-C 111.898 0.332 . . . . 0.0 111.898 -179.149 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 12' ' ' PHE . . . . . . . . . . . . . 13.4 t80 -138.76 -15.66 1.17 Allowed 'General case' 0 N--CA 1.469 0.493 0 N-CA-C 112.406 0.521 . . . . 0.0 112.406 -178.945 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 13' ' ' ASN . . . . . 0.488 ' ND2' ' HD3' ' A' ' 2' ' ' PRO . 7.4 t30 -120.62 73.35 22.73 Favored Pre-proline 0 CA--C 1.549 0.929 0 O-C-N 122.935 0.147 . . . . 0.0 111.343 -179.204 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 14' ' ' PRO . . . . . 0.425 ' O ' ' HD2' ' A' ' 2' ' ' PRO . 60.5 Cg_endo -76.43 176.56 9.92 Favored 'Trans proline' 0 C--N 1.371 1.75 0 C-N-CA 122.428 2.085 . . . . 0.0 112.48 179.342 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 1.4 m -79.67 118.9 21.91 Favored 'General case' 0 N--CA 1.469 0.488 0 O-C-N 123.199 0.312 . . . . 0.0 111.422 179.923 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER -58.03 -53.87 61.43 Favored Pre-proline 0 N--CA 1.477 0.906 0 CA-C-N 115.865 -0.607 . . . . 0.0 111.776 179.81 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 17' ' ' PRO . . . . . 0.459 ' HG2' HD12 ' A' ' 19' ' ' LEU . 53.3 Cg_endo -70.28 168.65 21.61 Favored 'Trans proline' 0 C--N 1.379 2.132 0 C-N-CA 121.983 1.789 . . . . 0.0 111.736 178.351 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 56.0 Cg_endo -72.4 47.34 1.09 Allowed 'Trans proline' 0 C--N 1.37 1.673 0 C-N-CA 121.872 1.714 . . . . 0.0 112.855 178.987 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 19' ' ' LEU . . . . . 0.462 ' HB2' ' SG ' ' A' ' 30' ' ' CYS . 13.0 mt -107.58 171.08 7.59 Favored 'General case' 0 CA--C 1.533 0.32 0 CA-C-N 115.921 -0.582 . . . . 0.0 110.955 -179.537 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 28.6 m -104.43 148.84 25.98 Favored 'General case' 0 CA--C 1.531 0.25 0 CA-C-N 115.829 -0.623 . . . . 0.0 111.108 -178.76 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 5.9 t -98.49 103.03 14.95 Favored 'General case' 0 C--O 1.238 0.499 0 N-CA-C 109.421 -0.585 . . . . 0.0 109.421 178.384 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 22' ' ' ILE . . . . . 0.715 HD12 ' HB2' ' A' ' 31' ' ' TYR . 2.5 mt -126.62 129.02 24.19 Favored Pre-proline 0 CA--C 1.543 0.703 0 CA-C-N 115.817 -0.629 . . . . 0.0 110.742 -178.547 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 37.4 Cg_endo -67.67 -48.55 0.24 Allowed 'Cis proline' 0 C--N 1.374 1.908 0 C-N-CA 124.719 -0.95 . . . . 0.0 113.782 -0.262 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 79.38 38.7 20.79 Favored Glycine 0 C--N 1.348 1.227 0 C-N-CA 121.37 -0.443 . . . . 0.0 112.894 -179.991 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 8.4 m-20 -140.71 79.99 18.72 Favored Pre-proline 0 CA--C 1.544 0.735 0 C-N-CA 122.447 0.299 . . . . 0.0 110.869 -179.728 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 1.8 Cg_endo -82.23 -32.63 3.41 Favored 'Cis proline' 0 C--N 1.372 1.811 0 C-N-CA 125.15 -0.771 . . . . 0.0 112.945 -0.127 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 27' ' ' TYR . . . . . . . . . . . . . 68.0 m-85 -99.37 171.64 7.84 Favored 'General case' 0 C--O 1.238 0.482 0 CA-C-N 115.786 -0.643 . . . . 0.0 111.652 -179.096 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 28' ' ' GLY . . . . . 0.443 ' O ' ' HA ' ' A' ' 7' ' ' GLN . . . -174.64 -159.79 21.56 Favored Glycine 0 C--N 1.337 0.62 0 CA-C-N 115.801 -0.636 . . . . 0.0 112.268 179.185 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 29' ' ' ILE . . . . . 0.556 ' HB ' ' CE2' ' A' ' 31' ' ' TYR . 1.8 mm -124.12 152.1 29.57 Favored 'Isoleucine or valine' 0 C--O 1.233 0.236 0 N-CA-C 109.755 -0.461 . . . . 0.0 109.755 179.627 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 30' ' ' CYS . . . . . 0.462 ' SG ' ' HB2' ' A' ' 19' ' ' LEU . 0.5 OUTLIER -80.12 104.49 10.71 Favored 'General case' 0 C--O 1.238 0.454 0 CA-C-N 115.974 -0.557 . . . . 0.0 110.99 -179.856 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 31' ' ' TYR . . . . . 0.715 ' HB2' HD12 ' A' ' 22' ' ' ILE . 36.1 m-85 -130.22 166.62 19.92 Favored 'General case' 0 C--O 1.233 0.189 0 CA-C-N 115.431 -0.804 . . . . 0.0 111.141 -179.501 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 2.8 tp -100.93 131.42 48.61 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.547 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.438 179.431 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 33' ' ' ILE . . . . . 0.47 ' H ' HG13 ' A' ' 33' ' ' ILE . 1.9 pp . . . . . 0 C--O 1.249 1.042 0 CA-C-O 118.28 -0.866 . . . . 0.0 111.518 179.903 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 5.9 p . . . . . 0 N--CA 1.487 1.375 0 CA-C-O 119.766 -0.159 . . . . 0.0 111.226 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' A' A ' 2' ' ' PRO . . . . . 0.537 ' HD3' ' ND2' ' A' ' 13' ' ' ASN . 84.1 Cg_endo -82.63 -172.51 1.43 Allowed 'Trans proline' 0 C--N 1.367 1.531 0 C-N-CA 122.593 2.195 . . . . 0.0 112.845 179.554 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -147.12 -161.71 9.54 Favored Glycine 0 C--N 1.338 0.665 0 N-CA-C 111.696 -0.562 . . . . 0.0 111.696 179.194 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 19.4 tt0 -67.8 124.03 22.17 Favored 'General case' 0 N--CA 1.474 0.747 0 C-N-CA 122.488 0.315 . . . . 0.0 111.212 179.68 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 91.07 15.08 56.76 Favored Glycine 0 C--N 1.338 0.681 0 CA-C-N 115.66 -0.7 . . . . 0.0 113.125 -179.718 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 43.1 mt-10 -129.06 165.22 21.62 Favored 'General case' 0 C--O 1.237 0.414 0 C-N-CA 122.29 0.236 . . . . 0.0 110.802 -179.942 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 7' ' ' GLN . . . . . . . . . . . . . 0.2 OUTLIER -81.55 152.98 27.0 Favored 'General case' 0 C--N 1.346 0.454 0 CA-C-N 116.43 -0.35 . . . . 0.0 110.936 179.915 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 3.2 p -142.23 152.07 42.72 Favored 'General case' 0 C--O 1.234 0.249 0 CA-C-N 115.821 -0.627 . . . . 0.0 111.208 -179.255 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -110.04 141.32 43.02 Favored 'General case' 0 C--O 1.232 0.163 0 CA-C-N 115.541 -0.754 . . . . 0.0 109.492 179.38 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 8.8 m -96.59 21.5 1.15 Allowed 'Isoleucine or valine' 0 CA--C 1.543 0.675 0 CA-C-N 116.326 -0.397 . . . . 0.0 111.566 -179.984 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 45.5 mt-10 -113.81 -54.83 2.57 Favored 'General case' 0 C--O 1.236 0.351 0 N-CA-C 112.048 0.388 . . . . 0.0 112.048 -179.042 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 12' ' ' PHE . . . . . . . . . . . . . 10.5 t80 -137.62 -18.56 1.24 Allowed 'General case' 0 N--CA 1.471 0.625 0 N-CA-C 112.516 0.561 . . . . 0.0 112.516 -178.891 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 13' ' ' ASN . . . . . 0.537 ' ND2' ' HD3' ' A' ' 2' ' ' PRO . 9.2 t30 -119.2 73.83 14.06 Favored Pre-proline 0 CA--C 1.55 0.954 0 O-C-N 122.918 0.136 . . . . 0.0 111.118 -179.332 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 14' ' ' PRO . . . . . 0.424 ' O ' ' HD2' ' A' ' 2' ' ' PRO . 60.5 Cg_endo -75.69 -178.84 4.6 Favored 'Trans proline' 0 C--N 1.371 1.745 0 C-N-CA 122.443 2.095 . . . . 0.0 112.506 179.481 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 15' ' ' CYS . . . . . 0.531 ' SG ' ' HB2' ' A' ' 19' ' ' LEU . 4.3 t -79.47 120.48 23.93 Favored 'General case' 0 N--CA 1.471 0.623 0 O-C-N 123.079 0.237 . . . . 0.0 111.095 179.981 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER -60.27 -54.49 54.63 Favored Pre-proline 0 N--CA 1.476 0.847 0 CA-C-O 119.062 -0.494 . . . . 0.0 111.577 179.45 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 56.7 Cg_endo -71.22 168.81 22.28 Favored 'Trans proline' 0 C--N 1.381 2.241 0 C-N-CA 122.096 1.864 . . . . 0.0 111.614 178.123 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 48.4 Cg_endo -70.48 61.29 2.12 Favored 'Trans proline' 0 C--N 1.37 1.677 0 C-N-CA 121.918 1.745 . . . . 0.0 112.78 179.048 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 19' ' ' LEU . . . . . 0.531 ' HB2' ' SG ' ' A' ' 15' ' ' CYS . 90.7 mt -122.2 166.62 14.31 Favored 'General case' 0 C--O 1.235 0.331 0 CA-C-N 115.713 -0.676 . . . . 0.0 111.189 -179.869 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 20' ' ' THR . . . . . 0.471 ' OG1' HG12 ' A' ' 33' ' ' ILE . 89.5 m -106.32 149.65 26.73 Favored 'General case' 0 CA--C 1.533 0.302 0 CA-C-N 115.305 -0.861 . . . . 0.0 110.947 -179.3 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 21' ' ' CYS . . . . . 0.503 ' HA ' ' O ' ' A' ' 29' ' ' ILE . 1.9 t -95.25 106.94 19.02 Favored 'General case' 0 C--O 1.24 0.555 0 CA-C-N 115.726 -0.67 . . . . 0.0 110.244 178.917 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 22' ' ' ILE . . . . . 0.72 HD12 ' HB2' ' A' ' 31' ' ' TYR . 5.9 mt -125.47 128.5 24.67 Favored Pre-proline 0 CA--C 1.544 0.717 0 CA-C-N 115.928 -0.578 . . . . 0.0 110.531 -179.185 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 37.4 Cg_endo -67.19 -48.0 0.25 Allowed 'Cis proline' 0 C--N 1.375 1.963 0 C-N-CA 124.685 -0.964 . . . . 0.0 113.757 -0.35 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 83.07 35.75 17.29 Favored Glycine 0 C--N 1.345 1.07 0 C-N-CA 121.433 -0.413 . . . . 0.0 112.918 179.781 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 7.6 m-20 -143.91 83.6 10.27 Favored Pre-proline 0 CA--C 1.546 0.819 0 C-N-CA 122.478 0.311 . . . . 0.0 111.04 -179.661 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 69.7 Cg_endo -82.15 -31.73 4.01 Favored 'Cis proline' 0 C--N 1.372 1.813 0 C-N-CA 124.814 -0.911 . . . . 0.0 113.479 -0.218 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 27' ' ' TYR . . . . . . . . . . . . . 59.8 m-85 -96.92 163.32 13.01 Favored 'General case' 0 N--CA 1.47 0.548 0 CA-C-N 115.956 -0.565 . . . . 0.0 111.208 -179.16 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 28' ' ' GLY . . . . . 0.443 ' O ' HD13 ' A' ' 29' ' ' ILE . . . -157.89 -162.01 11.39 Favored Glycine 0 C--N 1.339 0.746 0 C-N-CA 120.92 -0.657 . . . . 0.0 113.098 179.815 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 29' ' ' ILE . . . . . 0.503 ' O ' ' HA ' ' A' ' 21' ' ' CYS . 5.0 mm -130.53 154.81 41.14 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.222 0 N-CA-C 109.709 -0.478 . . . . 0.0 109.709 179.948 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 30' ' ' CYS . . . . . . . . . . . . . 26.2 m -83.72 92.81 7.8 Favored 'General case' 0 C--O 1.238 0.489 0 CA-C-O 121.483 0.659 . . . . 0.0 111.403 -179.968 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 31' ' ' TYR . . . . . 0.72 ' HB2' HD12 ' A' ' 22' ' ' ILE . 37.1 m-85 -124.26 167.26 14.56 Favored 'General case' 0 N--CA 1.464 0.241 0 CA-C-N 114.962 -1.017 . . . . 0.0 110.902 179.945 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 2.8 tp -99.98 131.66 46.99 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.605 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.449 179.378 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 33' ' ' ILE . . . . . 0.471 HG12 ' OG1' ' A' ' 20' ' ' THR . 1.3 pt . . . . . 0 C--O 1.249 1.048 0 CA-C-O 118.142 -0.932 . . . . 0.0 111.416 179.832 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 5.8 p . . . . . 0 N--CA 1.486 1.347 0 CA-C-O 119.823 -0.132 . . . . 0.0 111.199 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' A' A ' 2' ' ' PRO . . . . . 0.549 ' HD3' ' ND2' ' A' ' 13' ' ' ASN . 85.2 Cg_endo -82.82 -172.57 1.44 Allowed 'Trans proline' 0 C--N 1.366 1.497 0 C-N-CA 122.598 2.199 . . . . 0.0 112.832 179.514 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -146.59 -160.92 9.01 Favored Glycine 0 C--N 1.337 0.603 0 N-CA-C 111.661 -0.576 . . . . 0.0 111.661 179.141 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 19.6 tt0 -68.21 124.5 23.65 Favored 'General case' 0 N--CA 1.475 0.824 0 CA-C-N 116.816 0.308 . . . . 0.0 111.145 179.673 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 90.73 15.07 57.27 Favored Glycine 0 C--N 1.338 0.667 0 CA-C-N 115.663 -0.699 . . . . 0.0 113.143 -179.692 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 43.1 mt-10 -129.02 165.11 21.8 Favored 'General case' 0 C--O 1.239 0.53 0 C-N-CA 122.339 0.256 . . . . 0.0 110.807 -179.891 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 7' ' ' GLN . . . . . . . . . . . . . 0.2 OUTLIER -81.65 152.9 26.91 Favored 'General case' 0 C--N 1.346 0.433 0 O-C-N 123.179 0.3 . . . . 0.0 110.895 179.874 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 3.2 p -141.68 151.79 43.33 Favored 'General case' 0 C--O 1.234 0.242 0 CA-C-N 115.8 -0.636 . . . . 0.0 111.099 -179.272 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -110.34 143.56 40.38 Favored 'General case' 0 C--O 1.234 0.26 0 CA-C-N 115.481 -0.782 . . . . 0.0 109.532 179.423 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 10' ' ' VAL . . . . . 0.428 HG22 ' O ' ' A' ' 26' ' ' PRO . 6.1 m -98.28 21.06 1.52 Allowed 'Isoleucine or valine' 0 CA--C 1.541 0.606 0 O-C-N 123.238 0.336 . . . . 0.0 111.514 -179.899 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 8.5 mm-40 -115.53 -52.48 2.64 Favored 'General case' 0 C--O 1.235 0.304 0 N-CA-C 112.252 0.464 . . . . 0.0 112.252 -179.125 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 12' ' ' PHE . . . . . . . . . . . . . 13.0 t80 -141.04 -9.21 1.01 Allowed 'General case' 0 N--CA 1.473 0.709 0 N-CA-C 112.722 0.638 . . . . 0.0 112.722 -178.666 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 13' ' ' ASN . . . . . 0.549 ' ND2' ' HD3' ' A' ' 2' ' ' PRO . 7.6 t30 -129.64 64.94 73.55 Favored Pre-proline 0 CA--C 1.551 0.986 0 CA-C-N 117.496 0.135 . . . . 0.0 111.25 -179.075 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 14' ' ' PRO . . . . . 0.401 ' O ' ' HD2' ' A' ' 2' ' ' PRO . 15.8 Cg_exo -69.04 -178.66 2.16 Favored 'Trans proline' 0 C--N 1.372 1.808 0 C-N-CA 122.957 2.438 . . . . 0.0 112.266 179.009 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 15' ' ' CYS . . . . . 0.53 ' SG ' ' HB2' ' A' ' 19' ' ' LEU . 4.0 t -79.65 121.79 25.73 Favored 'General case' 0 N--CA 1.472 0.64 0 O-C-N 123.135 0.272 . . . . 0.0 111.331 -179.781 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER -61.35 -54.32 54.04 Favored Pre-proline 0 CA--C 1.547 0.845 0 CA-C-O 119.024 -0.512 . . . . 0.0 111.43 179.22 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 56.7 Cg_endo -71.19 169.21 21.22 Favored 'Trans proline' 0 C--N 1.38 2.225 0 C-N-CA 121.96 1.773 . . . . 0.0 111.719 178.193 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 49.0 Cg_endo -70.56 59.12 2.0 Favored 'Trans proline' 0 C--N 1.372 1.795 0 C-N-CA 121.918 1.746 . . . . 0.0 112.896 179.071 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 19' ' ' LEU . . . . . 0.53 ' HB2' ' SG ' ' A' ' 15' ' ' CYS . 92.2 mt -119.99 165.2 14.98 Favored 'General case' 0 C--O 1.235 0.31 0 CA-C-N 115.751 -0.659 . . . . 0.0 111.176 -179.95 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 87.5 m -104.08 150.58 24.17 Favored 'General case' 0 CA--C 1.532 0.285 0 CA-C-N 115.327 -0.851 . . . . 0.0 110.978 -179.464 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 21' ' ' CYS . . . . . 0.499 ' HA ' ' O ' ' A' ' 29' ' ' ILE . 1.9 t -96.57 104.55 16.54 Favored 'General case' 0 C--O 1.238 0.464 0 CA-C-N 115.669 -0.696 . . . . 0.0 109.98 178.94 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 22' ' ' ILE . . . . . 0.72 HD12 ' HB2' ' A' ' 31' ' ' TYR . 6.1 mt -122.83 128.01 25.53 Favored Pre-proline 0 CA--C 1.543 0.705 0 CA-C-N 115.865 -0.607 . . . . 0.0 110.546 -179.178 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 36.8 Cg_endo -66.96 -47.57 0.26 Allowed 'Cis proline' 0 C--N 1.376 1.977 0 C-N-CA 124.632 -0.987 . . . . 0.0 113.801 -0.302 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 83.73 32.85 23.29 Favored Glycine 0 C--N 1.345 1.081 0 C-N-CA 121.305 -0.474 . . . . 0.0 113.021 179.719 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 7.7 m-20 -144.18 86.57 8.27 Favored Pre-proline 0 CA--C 1.545 0.772 0 C-N-CA 122.56 0.344 . . . . 0.0 110.532 -179.654 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 26' ' ' PRO . . . . . 0.428 ' O ' HG22 ' A' ' 10' ' ' VAL . 1.1 Cg_endo -81.47 -31.34 4.49 Favored 'Cis proline' 0 C--N 1.371 1.733 0 C-N-CA 125.164 -0.765 . . . . 0.0 112.888 0.018 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 27' ' ' TYR . . . . . . . . . . . . . 41.3 m-85 -101.76 166.56 10.61 Favored 'General case' 0 C--O 1.237 0.398 0 CA-C-N 115.712 -0.676 . . . . 0.0 111.104 -179.137 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 28' ' ' GLY . . . . . 0.428 ' O ' HD13 ' A' ' 29' ' ' ILE . . . -160.63 -160.82 10.93 Favored Glycine 0 C--N 1.341 0.807 0 C-N-CA 120.911 -0.661 . . . . 0.0 113.21 179.999 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 29' ' ' ILE . . . . . 0.499 ' O ' ' HA ' ' A' ' 21' ' ' CYS . 4.8 mm -129.76 155.29 41.3 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.255 0 CA-C-N 115.273 -0.464 . . . . 0.0 109.887 -179.995 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 30' ' ' CYS . . . . . . . . . . . . . 30.1 m -84.04 93.78 8.17 Favored 'General case' 0 C--O 1.237 0.433 0 CA-C-O 121.39 0.614 . . . . 0.0 111.302 179.926 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 31' ' ' TYR . . . . . 0.72 ' HB2' HD12 ' A' ' 22' ' ' ILE . 35.4 m-85 -124.37 168.4 13.07 Favored 'General case' 0 N--CA 1.464 0.255 0 CA-C-N 115.012 -0.994 . . . . 0.0 111.14 -179.863 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 2.6 tp -100.68 133.48 43.7 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.598 0 CA-C-N 116.082 -0.508 . . . . 0.0 110.343 179.391 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 33' ' ' ILE . . . . . 0.436 ' OXT' HD12 ' A' ' 33' ' ' ILE . 1.6 pp . . . . . 0 C--O 1.249 1.031 0 CA-C-O 118.081 -0.961 . . . . 0.0 111.519 179.888 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 3.9 p . . . . . 0 N--CA 1.486 1.327 0 CA-C-O 119.818 -0.134 . . . . 0.0 111.329 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' A' A ' 2' ' ' PRO . . . . . 0.486 ' HD3' HD21 ' A' ' 13' ' ' ASN . 94.5 Cg_endo -83.96 -171.88 1.16 Allowed 'Trans proline' 0 C--N 1.368 1.588 0 C-N-CA 122.541 2.161 . . . . 0.0 112.937 179.71 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -143.95 -153.53 5.9 Favored Glycine 0 C--N 1.339 0.724 0 N-CA-C 111.669 -0.573 . . . . 0.0 111.669 179.381 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 17.7 tt0 -73.92 130.26 39.52 Favored 'General case' 0 N--CA 1.472 0.668 0 C-N-CA 122.546 0.338 . . . . 0.0 111.265 179.578 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 85.81 15.35 65.64 Favored Glycine 0 C--N 1.339 0.709 0 CA-C-N 115.921 -0.582 . . . . 0.0 113.452 -179.756 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 43.1 mt-10 -126.02 161.13 28.26 Favored 'General case' 0 C--O 1.237 0.406 0 C-N-CA 122.243 0.217 . . . . 0.0 110.849 -179.829 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 7' ' ' GLN . . . . . 0.69 ' HA ' ' O ' ' A' ' 28' ' ' GLY . 18.9 tt0 -87.01 134.81 33.45 Favored 'General case' 0 C--N 1.346 0.422 0 CA-C-O 121.176 0.512 . . . . 0.0 111.311 179.89 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 8' ' ' CYS . . . . . 0.401 ' SG ' ' SG ' ' A' ' 30' ' ' CYS . 2.5 p -129.3 161.41 30.29 Favored 'General case' 0 C--O 1.239 0.522 0 CA-C-N 114.538 -1.21 . . . . 0.0 110.989 -179.528 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 9' ' ' ASP . . . . . 0.591 ' OD1' ' HB3' ' A' ' 13' ' ' ASN . 0.7 OUTLIER -120.69 142.68 49.26 Favored 'General case' 0 N--CA 1.463 0.222 0 CA-C-N 115.725 -0.67 . . . . 0.0 110.042 178.528 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 23.2 m -90.78 13.85 1.59 Allowed 'Isoleucine or valine' 0 CA--C 1.543 0.697 0 CA-C-N 115.994 -0.548 . . . . 0.0 111.593 -179.398 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 45.9 mt-10 -97.05 -51.96 4.03 Favored 'General case' 0 C--O 1.235 0.304 0 CA-C-N 116.029 -0.532 . . . . 0.0 111.938 -178.804 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 12' ' ' PHE . . . . . . . . . . . . . 7.2 t80 -144.97 -21.56 0.5 Allowed 'General case' 0 N--CA 1.473 0.691 0 N-CA-C 112.657 0.614 . . . . 0.0 112.657 -178.771 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 13' ' ' ASN . . . . . 0.591 ' HB3' ' OD1' ' A' ' 9' ' ' ASP . 13.2 t30 -120.03 75.13 21.32 Favored Pre-proline 0 CA--C 1.548 0.88 0 CA-C-N 117.521 0.146 . . . . 0.0 111.324 -178.889 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 61.4 Cg_endo -76.84 -175.89 2.87 Favored 'Trans proline' 0 C--N 1.372 1.774 0 C-N-CA 122.57 2.18 . . . . 0.0 112.16 178.731 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 0.8 OUTLIER -79.99 121.61 25.7 Favored 'General case' 0 N--CA 1.472 0.633 0 O-C-N 123.02 0.2 . . . . 0.0 111.189 179.879 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER -58.16 -53.56 64.69 Favored Pre-proline 0 N--CA 1.478 0.965 0 CA-C-N 116.137 -0.483 . . . . 0.0 111.593 179.106 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 17' ' ' PRO . . . . . 0.501 ' HG2' HD12 ' A' ' 19' ' ' LEU . 41.5 Cg_endo -67.72 169.65 15.59 Favored 'Trans proline' 0 C--N 1.379 2.172 0 C-N-CA 122.148 1.899 . . . . 0.0 111.852 178.165 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 55.2 Cg_endo -71.84 47.8 1.01 Allowed 'Trans proline' 0 C--N 1.371 1.753 0 C-N-CA 122.007 1.805 . . . . 0.0 112.755 178.658 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 19' ' ' LEU . . . . . 0.501 HD12 ' HG2' ' A' ' 17' ' ' PRO . 19.5 mt -108.8 165.4 11.59 Favored 'General case' 0 C--O 1.236 0.375 0 CA-C-N 115.7 -0.682 . . . . 0.0 111.285 -179.451 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 20' ' ' THR . . . . . 0.529 ' O ' ' HA ' ' A' ' 30' ' ' CYS . 30.7 m -103.24 152.53 21.39 Favored 'General case' 0 CA--C 1.531 0.227 0 CA-C-N 115.569 -0.742 . . . . 0.0 111.038 -178.833 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 2.2 t -102.64 99.75 9.76 Favored 'General case' 0 C--O 1.237 0.435 0 CA-C-N 115.753 -0.658 . . . . 0.0 109.594 178.902 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 22' ' ' ILE . . . . . 0.705 HD12 ' HB2' ' A' ' 31' ' ' TYR . 2.9 mt -120.88 128.78 25.6 Favored Pre-proline 0 CA--C 1.542 0.652 0 CA-C-N 115.637 -0.71 . . . . 0.0 110.372 -178.973 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 37.0 Cg_endo -66.81 -47.5 0.26 Allowed 'Cis proline' 0 C--N 1.375 1.936 0 C-N-CA 124.77 -0.929 . . . . 0.0 113.867 -0.232 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 79.11 34.03 34.48 Favored Glycine 0 C--N 1.347 1.173 0 C-N-CA 121.277 -0.487 . . . . 0.0 112.894 179.969 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 8.3 m-20 -139.73 83.26 16.85 Favored Pre-proline 0 CA--C 1.543 0.686 0 C-N-CA 122.561 0.344 . . . . 0.0 110.538 -179.712 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 3.1 Cg_exo -80.61 -32.05 4.18 Favored 'Cis proline' 0 C--N 1.371 1.746 0 C-N-CA 125.095 -0.794 . . . . 0.0 112.948 -0.099 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 27' ' ' TYR . . . . . 0.561 ' CD2' ' HB3' ' A' ' 9' ' ' ASP . 62.6 m-85 -106.85 172.67 6.69 Favored 'General case' 0 C--O 1.239 0.552 0 CA-C-N 115.753 -0.658 . . . . 0.0 111.751 -178.95 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 28' ' ' GLY . . . . . 0.69 ' O ' ' HA ' ' A' ' 7' ' ' GLN . . . -176.53 -164.08 29.95 Favored Glycine 0 C--N 1.338 0.693 0 CA-C-N 115.732 -0.667 . . . . 0.0 112.655 178.452 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 29' ' ' ILE . . . . . 0.544 ' HB ' ' CE2' ' A' ' 31' ' ' TYR . 2.6 mm -114.72 151.3 16.49 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 N-CA-C 110.082 -0.34 . . . . 0.0 110.082 -179.718 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 30' ' ' CYS . . . . . 0.529 ' HA ' ' O ' ' A' ' 20' ' ' THR . 40.7 m -79.87 105.74 11.38 Favored 'General case' 0 C--O 1.237 0.395 0 CA-C-N 115.843 -0.617 . . . . 0.0 111.482 -179.801 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 31' ' ' TYR . . . . . 0.705 ' HB2' HD12 ' A' ' 22' ' ' ILE . 36.6 m-85 -130.42 167.1 19.14 Favored 'General case' 0 C--O 1.233 0.205 0 CA-C-N 114.938 -1.028 . . . . 0.0 111.011 -179.406 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 2.9 tp -99.64 130.28 48.94 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.607 0 CA-C-N 116.27 -0.423 . . . . 0.0 110.348 179.436 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 33' ' ' ILE . . . . . 0.499 HG23 HD11 ' A' ' 22' ' ' ILE . 1.9 pp . . . . . 0 C--O 1.248 0.993 0 CA-C-O 118.335 -0.84 . . . . 0.0 111.528 179.879 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 3.9 p . . . . . 0 N--CA 1.486 1.329 0 CA-C-O 119.766 -0.159 . . . . 0.0 111.325 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' A' A ' 2' ' ' PRO . . . . . 0.49 ' HD3' HD21 ' A' ' 13' ' ' ASN . 92.2 Cg_endo -83.96 -171.93 1.17 Allowed 'Trans proline' 0 C--N 1.368 1.588 0 C-N-CA 122.527 2.151 . . . . 0.0 112.953 179.641 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -143.83 -153.45 5.88 Favored Glycine 0 C--N 1.339 0.701 0 N-CA-C 111.821 -0.512 . . . . 0.0 111.821 179.383 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 17.7 tt0 -74.04 130.17 39.3 Favored 'General case' 0 N--CA 1.473 0.702 0 C-N-CA 122.702 0.401 . . . . 0.0 111.134 179.586 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 85.76 15.54 65.38 Favored Glycine 0 C--N 1.339 0.705 0 O-C-N 123.712 0.632 . . . . 0.0 113.386 -179.85 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 43.0 mt-10 -126.11 161.25 28.06 Favored 'General case' 0 C--O 1.238 0.474 0 C-N-CA 122.276 0.23 . . . . 0.0 110.85 -179.915 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 7' ' ' GLN . . . . . 0.691 ' HA ' ' O ' ' A' ' 28' ' ' GLY . 18.6 tt0 -87.1 134.81 33.47 Favored 'General case' 0 C--N 1.344 0.363 0 CA-C-O 121.258 0.552 . . . . 0.0 111.241 179.915 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 8' ' ' CYS . . . . . 0.401 ' SG ' ' SG ' ' A' ' 30' ' ' CYS . 2.5 p -129.3 161.42 30.27 Favored 'General case' 0 C--O 1.238 0.488 0 CA-C-N 114.511 -1.222 . . . . 0.0 111.017 -179.589 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 9' ' ' ASP . . . . . 0.591 ' OD1' ' HB3' ' A' ' 13' ' ' ASN . 0.7 OUTLIER -120.7 142.86 49.11 Favored 'General case' 0 N--CA 1.464 0.269 0 CA-C-N 115.693 -0.685 . . . . 0.0 109.992 178.557 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 22.5 m -90.89 13.76 1.63 Allowed 'Isoleucine or valine' 0 CA--C 1.543 0.677 0 CA-C-N 115.924 -0.58 . . . . 0.0 111.501 -179.337 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 46.0 mt-10 -96.94 -51.91 4.07 Favored 'General case' 0 C--O 1.235 0.327 0 CA-C-N 116.158 -0.474 . . . . 0.0 111.986 -178.802 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 12' ' ' PHE . . . . . . . . . . . . . 6.8 t80 -145.16 -21.49 0.49 Allowed 'General case' 0 N--CA 1.472 0.639 0 N-CA-C 112.671 0.619 . . . . 0.0 112.671 -178.845 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 13' ' ' ASN . . . . . 0.591 ' HB3' ' OD1' ' A' ' 9' ' ' ASP . 13.3 t30 -119.91 75.19 20.52 Favored Pre-proline 0 CA--C 1.548 0.887 0 CA-C-N 117.557 0.162 . . . . 0.0 111.336 -179.017 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 62.7 Cg_endo -76.85 -175.87 2.86 Favored 'Trans proline' 0 C--N 1.37 1.679 0 C-N-CA 122.663 2.242 . . . . 0.0 112.204 178.672 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 0.8 OUTLIER -79.99 121.56 25.64 Favored 'General case' 0 N--CA 1.471 0.603 0 CA-C-O 120.462 0.172 . . . . 0.0 111.168 179.9 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER -58.17 -53.52 65.15 Favored Pre-proline 0 N--CA 1.479 0.978 0 CA-C-O 119.049 -0.501 . . . . 0.0 111.568 179.117 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 17' ' ' PRO . . . . . 0.501 ' HG2' HD12 ' A' ' 19' ' ' LEU . 41.7 Cg_endo -67.75 169.69 15.56 Favored 'Trans proline' 0 C--N 1.38 2.22 0 C-N-CA 122.104 1.869 . . . . 0.0 111.865 178.202 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 55.3 Cg_endo -71.77 47.69 0.98 Allowed 'Trans proline' 0 C--N 1.373 1.818 0 C-N-CA 121.981 1.787 . . . . 0.0 112.735 178.731 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 19' ' ' LEU . . . . . 0.501 HD12 ' HG2' ' A' ' 17' ' ' PRO . 19.4 mt -108.78 165.38 11.6 Favored 'General case' 0 C--O 1.235 0.332 0 CA-C-N 115.681 -0.691 . . . . 0.0 111.272 -179.359 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 20' ' ' THR . . . . . 0.528 ' O ' ' HA ' ' A' ' 30' ' ' CYS . 30.5 m -103.19 152.37 21.54 Favored 'General case' 0 CA--C 1.531 0.227 0 CA-C-N 115.623 -0.717 . . . . 0.0 111.084 -178.902 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 2.2 t -102.45 99.75 9.82 Favored 'General case' 0 C--O 1.237 0.445 0 CA-C-N 115.719 -0.673 . . . . 0.0 109.6 178.837 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 22' ' ' ILE . . . . . 0.705 HD12 ' HB2' ' A' ' 31' ' ' TYR . 2.9 mt -120.91 128.73 25.63 Favored Pre-proline 0 CA--C 1.541 0.615 0 CA-C-N 115.677 -0.692 . . . . 0.0 110.4 -179.026 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 37.1 Cg_endo -66.92 -47.36 0.26 Allowed 'Cis proline' 0 C--N 1.374 1.919 0 C-N-CA 124.636 -0.985 . . . . 0.0 113.859 -0.112 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 79.03 33.99 34.89 Favored Glycine 0 C--N 1.348 1.196 0 C-N-CA 121.228 -0.51 . . . . 0.0 112.916 179.961 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 8.3 m-20 -139.68 83.24 16.99 Favored Pre-proline 0 CA--C 1.544 0.721 0 C-N-CA 122.576 0.35 . . . . 0.0 110.647 -179.793 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 3.2 Cg_exo -80.7 -31.92 4.26 Favored 'Cis proline' 0 C--N 1.371 1.729 0 C-N-CA 125.102 -0.791 . . . . 0.0 112.957 -0.005 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 27' ' ' TYR . . . . . 0.562 ' CD2' ' HB3' ' A' ' 9' ' ' ASP . 62.6 m-85 -106.96 172.66 6.7 Favored 'General case' 0 C--O 1.238 0.49 0 CA-C-N 115.737 -0.665 . . . . 0.0 111.705 -178.957 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 28' ' ' GLY . . . . . 0.691 ' O ' ' HA ' ' A' ' 7' ' ' GLN . . . -176.45 -164.17 30.06 Favored Glycine 0 C--N 1.34 0.771 0 CA-C-N 115.74 -0.664 . . . . 0.0 112.559 178.474 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 29' ' ' ILE . . . . . 0.543 ' HB ' ' CE2' ' A' ' 31' ' ' TYR . 2.6 mm -114.68 151.35 16.44 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 O-C-N 123.75 0.324 . . . . 0.0 110.155 -179.733 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 30' ' ' CYS . . . . . 0.528 ' HA ' ' O ' ' A' ' 20' ' ' THR . 41.4 m -79.82 105.72 11.31 Favored 'General case' 0 C--O 1.237 0.425 0 CA-C-N 115.981 -0.554 . . . . 0.0 111.399 -179.729 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 31' ' ' TYR . . . . . 0.705 ' HB2' HD12 ' A' ' 22' ' ' ILE . 37.1 m-85 -130.48 167.18 19.04 Favored 'General case' 0 C--O 1.233 0.205 0 CA-C-N 114.989 -1.005 . . . . 0.0 111.018 -179.566 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 2.9 tp -99.63 130.2 49.04 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.584 0 CA-C-N 116.121 -0.491 . . . . 0.0 110.343 179.562 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 33' ' ' ILE . . . . . 0.502 HG23 HD11 ' A' ' 22' ' ' ILE . 1.9 pp . . . . . 0 C--O 1.249 1.051 0 CA-C-O 118.331 -0.843 . . . . 0.0 111.521 179.858 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 4.3 p . . . . . 0 N--CA 1.486 1.373 0 CA-C-O 119.801 -0.142 . . . . 0.0 111.233 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' A' A ' 2' ' ' PRO . . . . . 0.43 ' HD3' ' ND2' ' A' ' 13' ' ' ASN . 97.6 Cg_endo -82.43 -172.27 1.38 Allowed 'Trans proline' 0 C--N 1.367 1.53 0 C-N-CA 122.577 2.185 . . . . 0.0 112.965 179.596 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -145.12 -154.99 6.29 Favored Glycine 0 C--N 1.339 0.727 0 N-CA-C 111.78 -0.528 . . . . 0.0 111.78 179.393 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 17.9 tt0 -73.3 128.85 36.66 Favored 'General case' 0 N--CA 1.472 0.674 0 C-N-CA 122.565 0.346 . . . . 0.0 111.186 179.581 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 86.31 16.06 63.2 Favored Glycine 0 C--N 1.34 0.789 0 CA-C-N 115.784 -0.643 . . . . 0.0 113.184 -179.862 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 43.0 mt-10 -127.42 161.69 28.1 Favored 'General case' 0 N--CA 1.466 0.367 0 C-N-CA 122.312 0.245 . . . . 0.0 110.804 -179.859 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 7' ' ' GLN . . . . . 0.715 ' HA ' ' O ' ' A' ' 28' ' ' GLY . 19.3 tt0 -85.36 134.53 34.09 Favored 'General case' 0 C--N 1.346 0.415 0 CA-C-O 121.166 0.507 . . . . 0.0 111.256 179.978 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 8' ' ' CYS . . . . . 0.404 ' SG ' ' SG ' ' A' ' 30' ' ' CYS . 3.1 p -127.72 160.24 32.28 Favored 'General case' 0 C--O 1.237 0.447 0 CA-C-N 114.593 -1.185 . . . . 0.0 111.036 -179.553 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 9' ' ' ASP . . . . . 0.437 ' OD2' ' HB2' ' A' ' 11' ' ' GLU . 15.8 t70 -115.42 147.64 40.33 Favored 'General case' 0 C--O 1.234 0.26 0 CA-C-N 115.475 -0.784 . . . . 0.0 109.53 178.762 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 15.5 m -97.45 22.23 1.16 Allowed 'Isoleucine or valine' 0 CA--C 1.543 0.689 0 CA-C-N 116.312 -0.404 . . . . 0.0 111.963 -179.451 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 11' ' ' GLU . . . . . 0.437 ' HB2' ' OD2' ' A' ' 9' ' ' ASP . 44.1 mt-10 -119.68 -52.68 2.23 Favored 'General case' 0 N--CA 1.466 0.371 0 N-CA-C 112.372 0.508 . . . . 0.0 112.372 -179.068 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 12' ' ' PHE . . . . . . . . . . . . . 13.6 t80 -137.83 -8.98 1.6 Allowed 'General case' 0 N--CA 1.47 0.559 0 N-CA-C 112.649 0.611 . . . . 0.0 112.649 -178.659 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 13' ' ' ASN . . . . . 0.43 ' ND2' ' HD3' ' A' ' 2' ' ' PRO . 6.0 t30 -129.65 63.81 69.45 Favored Pre-proline 0 CA--C 1.548 0.904 0 N-CA-C 111.579 0.214 . . . . 0.0 111.579 -179.195 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 13.6 Cg_exo -70.23 176.78 6.67 Favored 'Trans proline' 0 C--N 1.372 1.767 0 C-N-CA 122.801 2.334 . . . . 0.0 112.06 178.914 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 1.0 OUTLIER -79.84 121.04 24.91 Favored 'General case' 0 N--CA 1.469 0.499 0 CA-C-O 120.453 0.168 . . . . 0.0 111.155 179.983 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER -57.75 -53.01 70.18 Favored Pre-proline 0 N--CA 1.477 0.924 0 CA-C-O 118.985 -0.531 . . . . 0.0 111.535 179.316 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 17' ' ' PRO . . . . . 0.506 ' HG2' HD12 ' A' ' 19' ' ' LEU . 44.8 Cg_endo -68.67 169.53 17.25 Favored 'Trans proline' 0 C--N 1.379 2.133 0 C-N-CA 122.102 1.868 . . . . 0.0 111.747 178.008 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 55.7 Cg_endo -72.27 48.81 1.27 Allowed 'Trans proline' 0 C--N 1.372 1.785 0 C-N-CA 122.011 1.808 . . . . 0.0 112.701 178.759 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 19' ' ' LEU . . . . . 0.506 HD12 ' HG2' ' A' ' 17' ' ' PRO . 20.5 mt -109.61 167.6 10.02 Favored 'General case' 0 C--O 1.236 0.356 0 CA-C-N 115.692 -0.685 . . . . 0.0 111.316 -179.309 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 20' ' ' THR . . . . . 0.529 ' O ' ' HA ' ' A' ' 30' ' ' CYS . 32.6 m -105.03 153.37 21.55 Favored 'General case' 0 CA--C 1.532 0.279 0 CA-C-N 115.622 -0.717 . . . . 0.0 111.059 -178.794 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 1.9 t -102.71 103.27 13.5 Favored 'General case' 0 C--O 1.238 0.487 0 CA-C-N 115.672 -0.694 . . . . 0.0 109.672 178.861 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 22' ' ' ILE . . . . . 0.709 HD12 ' HB2' ' A' ' 31' ' ' TYR . 2.8 mt -125.33 129.1 24.57 Favored Pre-proline 0 CA--C 1.542 0.646 0 CA-C-N 115.774 -0.648 . . . . 0.0 110.24 -179.094 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 38.1 Cg_endo -67.43 -48.47 0.24 Allowed 'Cis proline' 0 C--N 1.374 1.897 0 C-N-CA 124.74 -0.942 . . . . 0.0 113.895 -0.113 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 81.26 36.86 19.79 Favored Glycine 0 C--N 1.347 1.141 0 C-N-CA 121.192 -0.528 . . . . 0.0 112.959 -179.927 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 4.6 t70 -139.78 82.23 18.22 Favored Pre-proline 0 CA--C 1.548 0.884 0 C-N-CA 122.454 0.301 . . . . 0.0 110.376 -179.818 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 2.6 Cg_endo -81.06 -31.72 4.33 Favored 'Cis proline' 0 C--N 1.371 1.761 0 C-N-CA 125.113 -0.786 . . . . 0.0 112.951 0.104 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 27' ' ' TYR . . . . . . . . . . . . . 60.3 m-85 -106.55 174.12 6.02 Favored 'General case' 0 C--O 1.238 0.475 0 CA-C-N 115.748 -0.66 . . . . 0.0 111.558 -179.037 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 28' ' ' GLY . . . . . 0.715 ' O ' ' HA ' ' A' ' 7' ' ' GLN . . . -175.22 -162.08 25.91 Favored Glycine 0 CA--C 1.502 -0.737 0 CA-C-N 115.627 -0.715 . . . . 0.0 112.561 178.397 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 29' ' ' ILE . . . . . 0.537 ' HB ' ' CE2' ' A' ' 31' ' ' TYR . 2.7 mm -115.35 150.36 17.32 Favored 'Isoleucine or valine' 0 C--O 1.234 0.257 0 N-CA-C 110.059 -0.349 . . . . 0.0 110.059 -179.86 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 30' ' ' CYS . . . . . 0.529 ' HA ' ' O ' ' A' ' 20' ' ' THR . 32.2 m -79.9 105.18 10.99 Favored 'General case' 0 C--O 1.236 0.372 0 CA-C-O 121.372 0.606 . . . . 0.0 111.408 -179.745 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 31' ' ' TYR . . . . . 0.709 ' HB2' HD12 ' A' ' 22' ' ' ILE . 37.1 m-85 -129.57 167.93 17.18 Favored 'General case' 0 C--O 1.234 0.28 0 CA-C-N 114.922 -1.036 . . . . 0.0 111.085 -179.466 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 2.7 tp -100.25 130.71 49.04 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.617 0 CA-C-N 116.275 -0.421 . . . . 0.0 110.317 179.402 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 33' ' ' ILE . . . . . 0.5 HG23 HD11 ' A' ' 22' ' ' ILE . 1.9 pp . . . . . 0 C--O 1.249 1.031 0 CA-C-O 118.206 -0.902 . . . . 0.0 111.454 179.911 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 4.4 p . . . . . 0 N--CA 1.486 1.36 0 CA-C-O 119.752 -0.166 . . . . 0.0 111.294 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' A' A ' 2' ' ' PRO . . . . . 0.433 ' HD3' ' ND2' ' A' ' 13' ' ' ASN . 98.3 Cg_endo -82.49 -172.16 1.35 Allowed 'Trans proline' 0 C--N 1.366 1.478 0 C-N-CA 122.594 2.196 . . . . 0.0 112.939 179.646 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -145.7 -155.47 6.5 Favored Glycine 0 C--N 1.338 0.676 0 N-CA-C 111.901 -0.48 . . . . 0.0 111.901 179.386 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 18.0 tt0 -73.35 129.52 38.19 Favored 'General case' 0 N--CA 1.474 0.738 0 C-N-CA 122.536 0.334 . . . . 0.0 111.198 179.658 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 85.6 16.28 64.25 Favored Glycine 0 C--N 1.339 0.748 0 CA-C-N 115.741 -0.663 . . . . 0.0 113.196 -179.849 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 43.1 mt-10 -127.61 161.49 28.73 Favored 'General case' 0 C--O 1.237 0.447 0 C-N-CA 122.188 0.195 . . . . 0.0 110.824 -179.862 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 7' ' ' GLN . . . . . 0.723 ' HA ' ' O ' ' A' ' 28' ' ' GLY . 18.7 tt0 -84.94 134.24 34.26 Favored 'General case' 0 C--N 1.345 0.381 0 CA-C-O 121.228 0.537 . . . . 0.0 111.293 179.804 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 8' ' ' CYS . . . . . 0.411 ' SG ' ' SG ' ' A' ' 30' ' ' CYS . 3.7 p -127.99 160.62 31.34 Favored 'General case' 0 C--O 1.237 0.447 0 CA-C-N 114.584 -1.189 . . . . 0.0 111.116 -179.383 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 9' ' ' ASP . . . . . 0.431 ' OD2' ' HB2' ' A' ' 11' ' ' GLU . 15.7 t70 -114.7 151.72 33.17 Favored 'General case' 0 C--O 1.236 0.352 0 CA-C-N 115.496 -0.774 . . . . 0.0 109.497 178.623 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 15.6 m -102.37 16.8 4.69 Favored 'Isoleucine or valine' 0 CA--C 1.544 0.717 0 N-CA-C 111.912 0.338 . . . . 0.0 111.912 -179.339 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 11' ' ' GLU . . . . . 0.431 ' HB2' ' OD2' ' A' ' 9' ' ' ASP . 9.5 mm-40 -110.34 -52.49 2.78 Favored 'General case' 0 N--CA 1.466 0.326 0 N-CA-C 112.082 0.401 . . . . 0.0 112.082 -178.979 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 12' ' ' PHE . . . . . . . . . . . . . 10.9 t80 -137.74 -17.51 1.26 Allowed 'General case' 0 N--CA 1.469 0.52 0 N-CA-C 112.589 0.588 . . . . 0.0 112.589 -178.812 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 13' ' ' ASN . . . . . 0.433 ' ND2' ' HD3' ' A' ' 2' ' ' PRO . 7.9 t30 -120.21 73.43 20.23 Favored Pre-proline 0 CA--C 1.547 0.851 0 N-CA-C 111.373 0.138 . . . . 0.0 111.373 -179.184 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 60.4 Cg_endo -76.79 177.6 8.65 Favored 'Trans proline' 0 C--N 1.371 1.729 0 C-N-CA 122.352 2.035 . . . . 0.0 112.314 179.027 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 1.3 t -79.79 120.2 23.72 Favored 'General case' 0 N--CA 1.471 0.605 0 CA-C-O 120.508 0.194 . . . . 0.0 110.911 179.895 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER -56.94 -53.44 65.11 Favored Pre-proline 0 N--CA 1.477 0.89 0 CA-C-O 119.09 -0.481 . . . . 0.0 111.634 179.425 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 17' ' ' PRO . . . . . 0.519 ' HG2' HD12 ' A' ' 19' ' ' LEU . 44.8 Cg_endo -68.62 169.25 17.79 Favored 'Trans proline' 0 C--N 1.379 2.163 0 C-N-CA 122.152 1.901 . . . . 0.0 111.789 178.057 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 55.6 Cg_endo -72.3 50.46 1.57 Allowed 'Trans proline' 0 C--N 1.371 1.755 0 C-N-CA 122.085 1.857 . . . . 0.0 112.538 178.728 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 19' ' ' LEU . . . . . 0.519 HD12 ' HG2' ' A' ' 17' ' ' PRO . 20.9 mt -111.41 167.92 9.93 Favored 'General case' 0 C--O 1.235 0.317 0 CA-C-N 115.626 -0.716 . . . . 0.0 111.383 -179.386 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 20' ' ' THR . . . . . 0.525 ' O ' ' HA ' ' A' ' 30' ' ' CYS . 33.5 m -105.6 153.47 21.74 Favored 'General case' 0 CA--C 1.533 0.291 0 CA-C-N 115.622 -0.717 . . . . 0.0 110.995 -178.774 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 2.0 t -102.77 103.36 13.57 Favored 'General case' 0 C--O 1.236 0.389 0 CA-C-N 115.709 -0.678 . . . . 0.0 109.676 178.932 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 22' ' ' ILE . . . . . 0.703 HD12 ' HB2' ' A' ' 31' ' ' TYR . 2.8 mt -125.43 129.13 24.53 Favored Pre-proline 0 CA--C 1.542 0.635 0 CA-C-N 115.754 -0.657 . . . . 0.0 110.259 -178.99 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 38.1 Cg_endo -67.69 -48.15 0.26 Allowed 'Cis proline' 0 C--N 1.375 1.933 0 C-N-CA 124.688 -0.963 . . . . 0.0 113.906 0.056 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 81.58 36.45 19.84 Favored Glycine 0 C--N 1.348 1.202 0 C-N-CA 121.153 -0.546 . . . . 0.0 112.899 -179.968 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 8.4 m-20 -139.91 82.73 17.16 Favored Pre-proline 0 CA--C 1.544 0.726 0 C-N-CA 122.587 0.355 . . . . 0.0 110.636 -179.743 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 2.9 Cg_endo -80.37 -32.06 4.23 Favored 'Cis proline' 0 C--N 1.372 1.773 0 C-N-CA 125.134 -0.778 . . . . 0.0 112.933 -0.118 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 27' ' ' TYR . . . . . . . . . . . . . 59.6 m-85 -107.24 175.06 5.62 Favored 'General case' 0 C--O 1.239 0.535 0 CA-C-N 115.785 -0.643 . . . . 0.0 111.643 -179.014 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 28' ' ' GLY . . . . . 0.723 ' O ' ' HA ' ' A' ' 7' ' ' GLN . . . -175.7 -161.18 24.59 Favored Glycine 0 CA--C 1.504 -0.609 0 CA-C-N 115.734 -0.666 . . . . 0.0 112.574 178.468 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 29' ' ' ILE . . . . . 0.541 ' HB ' ' CE2' ' A' ' 31' ' ' TYR . 2.7 mm -115.83 150.04 17.9 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 O-C-N 123.801 0.354 . . . . 0.0 110.067 -179.738 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 30' ' ' CYS . . . . . 0.525 ' HA ' ' O ' ' A' ' 20' ' ' THR . 23.7 m -79.88 104.99 10.83 Favored 'General case' 0 CA--C 1.535 0.402 0 CA-C-O 121.319 0.581 . . . . 0.0 111.303 -179.767 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 31' ' ' TYR . . . . . 0.703 ' HB2' HD12 ' A' ' 22' ' ' ILE . 36.7 m-85 -129.25 168.08 16.72 Favored 'General case' 0 C--O 1.233 0.197 0 CA-C-N 114.889 -1.051 . . . . 0.0 111.019 -179.465 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 2.7 tp -100.29 130.9 48.79 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.627 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.277 179.449 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 33' ' ' ILE . . . . . 0.49 HG23 HD11 ' A' ' 22' ' ' ILE . 1.9 pp . . . . . 0 C--O 1.249 1.061 0 CA-C-O 118.328 -0.844 . . . . 0.0 111.479 179.865 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 N--CA 1.486 1.353 0 CA-C-O 119.629 -0.224 . . . . 0.0 111.081 . . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 2' ' ' PRO . . . . . 0.584 ' HD2' ' O ' ' A' ' 14' ' ' PRO . 73.4 Cg_endo -69.49 -170.78 0.39 Allowed 'Trans proline' 0 C--N 1.374 1.902 0 C-N-CA 123.184 2.589 . . . . 0.0 113.9 -178.918 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -142.76 -159.52 7.98 Favored Glycine 0 C--N 1.342 0.888 0 O-C-N 123.544 0.528 . . . . 0.0 112.487 179.832 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 17.4 tt0 -68.42 122.51 18.57 Favored 'General case' 0 N--CA 1.474 0.73 0 C-N-CA 122.816 0.447 . . . . 0.0 111.515 -179.925 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 92.41 14.54 55.52 Favored Glycine 0 C--N 1.341 0.82 0 CA-C-N 115.578 -0.737 . . . . 0.0 113.243 -179.882 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 43.1 mt-10 -127.42 165.64 19.41 Favored 'General case' 0 C--O 1.239 0.546 0 C-N-CA 122.438 0.295 . . . . 0.0 110.946 179.962 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 7' ' ' GLN . . . . . 0.51 ' HA ' ' O ' ' A' ' 28' ' ' GLY . 0.9 OUTLIER -83.46 145.55 28.89 Favored 'General case' 0 N--CA 1.469 0.478 0 CA-C-N 116.357 -0.383 . . . . 0.0 111.372 179.886 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 8.1 p -139.18 155.38 47.87 Favored 'General case' 0 C--O 1.237 0.44 0 CA-C-N 115.544 -0.753 . . . . 0.0 111.317 -179.786 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 6.9 t70 -118.87 153.13 35.03 Favored 'General case' 0 C--O 1.236 0.364 0 CA-C-N 115.42 -0.809 . . . . 0.0 109.652 179.045 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 14.9 m -101.86 20.89 2.47 Favored 'Isoleucine or valine' 0 CA--C 1.544 0.746 0 CA-C-N 116.296 -0.411 . . . . 0.0 111.99 -179.404 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 44.6 mt-10 -117.8 -53.03 2.42 Favored 'General case' 0 N--CA 1.465 0.32 0 N-CA-C 112.319 0.489 . . . . 0.0 112.319 -179.252 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 12' ' ' PHE . . . . . . . . . . . . . 15.7 t80 -138.96 -7.28 1.4 Allowed 'General case' 0 N--CA 1.47 0.574 0 N-CA-C 112.58 0.585 . . . . 0.0 112.58 -178.771 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 13' ' ' ASN . . . . . . . . . . . . . 8.6 t30 -129.44 63.47 67.83 Favored Pre-proline 0 CA--C 1.551 1.006 0 N-CA-C 111.369 0.137 . . . . 0.0 111.369 -179.093 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 14' ' ' PRO . . . . . 0.584 ' O ' ' HD2' ' A' ' 2' ' ' PRO . 15.8 Cg_exo -69.08 177.7 4.86 Favored 'Trans proline' 0 C--N 1.372 1.812 0 C-N-CA 122.733 2.288 . . . . 0.0 112.253 179.282 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 1.5 m -79.45 119.6 22.68 Favored 'General case' 0 N--CA 1.471 0.577 0 C-N-CA 122.382 0.273 . . . . 0.0 111.352 -179.848 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 16' ' ' CYS . . . . . 0.573 ' HB2' ' O ' ' A' ' 2' ' ' PRO . 0.0 OUTLIER -57.36 -53.2 67.98 Favored Pre-proline 0 N--CA 1.481 1.112 0 CA-C-N 115.971 -0.559 . . . . 0.0 111.518 179.548 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 17' ' ' PRO . . . . . 0.479 ' HG2' HD12 ' A' ' 19' ' ' LEU . 57.7 Cg_endo -72.72 169.34 22.21 Favored 'Trans proline' 0 C--N 1.38 2.205 0 C-N-CA 122.042 1.828 . . . . 0.0 111.8 178.168 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 55.8 Cg_endo -72.21 44.54 0.7 Allowed 'Trans proline' 0 C--N 1.371 1.759 0 C-N-CA 122.034 1.823 . . . . 0.0 112.956 178.86 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 19' ' ' LEU . . . . . 0.479 HD12 ' HG2' ' A' ' 17' ' ' PRO . 12.9 mt -104.43 172.78 6.61 Favored 'General case' 0 CA--C 1.534 0.336 0 CA-C-N 115.875 -0.602 . . . . 0.0 110.917 -179.634 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 25.5 m -103.38 150.2 24.04 Favored 'General case' 0 CA--C 1.534 0.335 0 CA-C-N 115.934 -0.575 . . . . 0.0 111.034 -178.793 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 5.5 t -100.32 103.13 14.53 Favored 'General case' 0 C--O 1.237 0.427 0 CA-C-N 115.874 -0.603 . . . . 0.0 109.381 178.491 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 22' ' ' ILE . . . . . 0.716 HD12 ' HB2' ' A' ' 31' ' ' TYR . 2.5 mt -127.36 129.27 23.91 Favored Pre-proline 0 CA--C 1.543 0.697 0 CA-C-N 115.825 -0.625 . . . . 0.0 110.72 -178.462 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 38.0 Cg_endo -67.94 -48.55 0.25 Allowed 'Cis proline' 0 C--N 1.374 1.902 0 C-N-CA 124.77 -0.929 . . . . 0.0 113.71 -0.441 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 79.67 37.13 24.11 Favored Glycine 0 C--N 1.346 1.137 0 C-N-CA 121.39 -0.434 . . . . 0.0 112.835 179.954 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 8.4 m-20 -140.31 81.25 18.24 Favored Pre-proline 0 CA--C 1.544 0.721 0 C-N-CA 122.477 0.311 . . . . 0.0 110.837 -179.694 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 2.2 Cg_endo -81.62 -32.17 3.85 Favored 'Cis proline' 0 C--N 1.372 1.787 0 C-N-CA 125.027 -0.822 . . . . 0.0 112.928 -0.166 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 27' ' ' TYR . . . . . . . . . . . . . 66.7 m-85 -102.35 173.29 6.43 Favored 'General case' 0 C--O 1.238 0.496 0 CA-C-N 115.77 -0.65 . . . . 0.0 111.561 -179.125 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 28' ' ' GLY . . . . . 0.51 ' O ' ' HA ' ' A' ' 7' ' ' GLN . . . -175.59 -159.31 21.32 Favored Glycine 0 C--N 1.338 0.658 0 CA-C-N 115.75 -0.659 . . . . 0.0 112.451 178.974 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 29' ' ' ILE . . . . . 0.56 ' HB ' ' CE2' ' A' ' 31' ' ' TYR . 1.3 mm -123.17 152.13 27.85 Favored 'Isoleucine or valine' 0 C--O 1.235 0.332 0 N-CA-C 109.882 -0.414 . . . . 0.0 109.882 179.713 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 30' ' ' CYS . . . . . 0.443 ' SG ' ' HB2' ' A' ' 19' ' ' LEU . 0.5 OUTLIER -80.07 106.92 12.44 Favored 'General case' 0 C--O 1.238 0.472 0 CA-C-N 116.029 -0.532 . . . . 0.0 110.923 -179.975 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 31' ' ' TYR . . . . . 0.716 ' HB2' HD12 ' A' ' 22' ' ' ILE . 36.2 m-85 -132.11 167.04 20.43 Favored 'General case' 0 N--CA 1.466 0.334 0 CA-C-N 115.534 -0.757 . . . . 0.0 111.088 -179.251 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 2.8 tp -101.88 131.8 49.09 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.614 0 CA-C-N 116.081 -0.509 . . . . 0.0 110.347 179.458 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 33' ' ' ILE . . . . . 0.465 ' H ' HG13 ' A' ' 33' ' ' ILE . 1.9 pp . . . . . 0 C--O 1.247 0.961 0 CA-C-O 118.357 -0.83 . . . . 0.0 111.399 179.976 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 3.7 p . . . . . 0 N--CA 1.486 1.332 0 CA-C-O 119.71 -0.186 . . . . 0.0 111.323 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' A' A ' 2' ' ' PRO . . . . . 0.494 ' HD3' HD21 ' A' ' 13' ' ' ASN . 95.6 Cg_endo -83.52 -171.8 1.18 Allowed 'Trans proline' 0 C--N 1.368 1.567 0 C-N-CA 122.562 2.175 . . . . 0.0 112.937 179.634 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -145.39 -154.0 6.03 Favored Glycine 0 C--N 1.339 0.711 0 N-CA-C 111.813 -0.515 . . . . 0.0 111.813 179.493 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 18.5 tt0 -73.27 129.68 38.55 Favored 'General case' 0 N--CA 1.472 0.667 0 C-N-CA 122.68 0.392 . . . . 0.0 111.319 179.596 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 85.92 15.45 65.2 Favored Glycine 0 C--N 1.34 0.754 0 CA-C-N 115.793 -0.639 . . . . 0.0 113.554 -179.984 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 12.7 tt0 -126.87 161.9 27.18 Favored 'General case' 0 C--O 1.238 0.462 0 CA-C-N 116.604 0.202 . . . . 0.0 110.656 -179.842 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 7' ' ' GLN . . . . . 0.682 ' HA ' ' O ' ' A' ' 28' ' ' GLY . 18.6 tt0 -86.81 136.35 33.01 Favored 'General case' 0 C--N 1.344 0.331 0 CA-C-O 121.218 0.533 . . . . 0.0 111.407 179.962 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 8' ' ' CYS . . . . . 0.405 ' SG ' ' SG ' ' A' ' 30' ' ' CYS . 2.6 p -130.65 161.34 31.83 Favored 'General case' 0 C--O 1.239 0.517 0 CA-C-N 114.465 -1.243 . . . . 0.0 111.023 -179.58 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 9' ' ' ASP . . . . . 0.59 ' OD1' ' HB3' ' A' ' 13' ' ' ASN . 0.7 OUTLIER -120.52 143.54 48.52 Favored 'General case' 0 N--CA 1.465 0.276 0 CA-C-N 115.687 -0.688 . . . . 0.0 110.09 178.494 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 22.3 m -92.02 14.63 1.69 Allowed 'Isoleucine or valine' 0 CA--C 1.542 0.655 0 CA-C-N 116.083 -0.508 . . . . 0.0 111.509 -179.245 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 9.9 mm-40 -98.68 -51.56 3.88 Favored 'General case' 0 C--O 1.234 0.283 0 CA-C-N 116.159 -0.473 . . . . 0.0 112.085 -178.789 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 12' ' ' PHE . . . . . . . . . . . . . 6.9 t80 -144.09 -22.84 0.56 Allowed 'General case' 0 N--CA 1.472 0.67 0 N-CA-C 112.698 0.629 . . . . 0.0 112.698 -178.877 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 13' ' ' ASN . . . . . 0.59 ' HB3' ' OD1' ' A' ' 9' ' ' ASP . 13.9 t30 -119.32 75.74 16.64 Favored Pre-proline 0 CA--C 1.548 0.901 0 CA-C-N 117.539 0.154 . . . . 0.0 111.355 -178.969 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 61.7 Cg_endo -76.77 -176.09 2.97 Favored 'Trans proline' 0 C--N 1.372 1.763 0 C-N-CA 122.542 2.162 . . . . 0.0 112.22 178.676 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 0.9 OUTLIER -79.94 121.76 25.85 Favored 'General case' 0 N--CA 1.471 0.609 0 CA-C-O 120.454 0.168 . . . . 0.0 111.252 179.95 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER -58.38 -53.76 62.79 Favored Pre-proline 0 N--CA 1.478 0.949 0 CA-C-N 116.124 -0.489 . . . . 0.0 111.552 179.115 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 44.0 Cg_endo -67.8 169.79 15.41 Favored 'Trans proline' 0 C--N 1.379 2.171 0 C-N-CA 122.187 1.925 . . . . 0.0 111.851 178.21 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 55.5 Cg_endo -72.08 47.46 1.03 Allowed 'Trans proline' 0 C--N 1.371 1.724 0 C-N-CA 122.027 1.818 . . . . 0.0 112.792 178.839 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 42.9 mt -108.68 166.3 10.9 Favored 'General case' 0 C--O 1.234 0.266 0 CA-C-N 115.926 -0.579 . . . . 0.0 111.201 -179.588 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 20' ' ' THR . . . . . 0.522 ' O ' ' HA ' ' A' ' 30' ' ' CYS . 33.5 m -103.58 152.74 21.38 Favored 'General case' 0 CA--C 1.532 0.287 0 CA-C-N 115.503 -0.771 . . . . 0.0 110.962 -178.848 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 2.3 t -102.44 99.93 10.02 Favored 'General case' 0 C--O 1.239 0.535 0 CA-C-N 115.725 -0.67 . . . . 0.0 109.601 178.841 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 22' ' ' ILE . . . . . 0.707 HD12 ' HB2' ' A' ' 31' ' ' TYR . 3.0 mt -121.04 128.7 25.62 Favored Pre-proline 0 CA--C 1.541 0.622 0 CA-C-N 115.783 -0.644 . . . . 0.0 110.424 -178.976 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 37.1 Cg_endo -66.89 -47.47 0.26 Allowed 'Cis proline' 0 C--N 1.375 1.958 0 C-N-CA 124.69 -0.962 . . . . 0.0 113.874 -0.187 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 78.92 34.4 34.1 Favored Glycine 0 C--N 1.346 1.131 0 C-N-CA 121.379 -0.438 . . . . 0.0 112.942 179.977 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 4.6 t70 -139.91 83.05 16.69 Favored Pre-proline 0 CA--C 1.546 0.823 0 C-N-CA 122.607 0.363 . . . . 0.0 110.345 -179.68 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 3.2 Cg_exo -80.86 -32.02 4.15 Favored 'Cis proline' 0 C--N 1.371 1.743 0 C-N-CA 125.095 -0.794 . . . . 0.0 112.895 0.036 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 27' ' ' TYR . . . . . 0.558 ' CD2' ' HB3' ' A' ' 9' ' ' ASP . 63.6 m-85 -106.91 172.68 6.69 Favored 'General case' 0 CA--C 1.537 0.448 0 CA-C-N 115.838 -0.619 . . . . 0.0 111.592 -178.892 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 28' ' ' GLY . . . . . 0.682 ' O ' ' HA ' ' A' ' 7' ' ' GLN . . . -176.53 -163.88 29.64 Favored Glycine 0 C--N 1.339 0.716 0 CA-C-N 115.629 -0.714 . . . . 0.0 112.636 178.558 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 29' ' ' ILE . . . . . 0.541 ' HB ' ' CE2' ' A' ' 31' ' ' TYR . 2.5 mm -114.68 151.15 16.47 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 O-C-N 123.748 0.322 . . . . 0.0 110.259 -179.898 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 30' ' ' CYS . . . . . 0.522 ' HA ' ' O ' ' A' ' 20' ' ' THR . 33.9 m -79.88 105.42 11.15 Favored 'General case' 0 CA--C 1.535 0.392 0 CA-C-O 121.328 0.585 . . . . 0.0 111.365 -179.717 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 31' ' ' TYR . . . . . 0.707 ' HB2' HD12 ' A' ' 22' ' ' ILE . 37.1 m-85 -130.28 166.88 19.43 Favored 'General case' 0 C--O 1.233 0.193 0 CA-C-N 114.917 -1.038 . . . . 0.0 111.02 -179.472 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 2.9 tp -99.59 130.24 48.93 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.604 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.372 179.496 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 33' ' ' ILE . . . . . 0.485 HG23 HD11 ' A' ' 22' ' ' ILE . 1.4 pt . . . . . 0 C--O 1.249 1.045 0 CA-C-O 118.136 -0.935 . . . . 0.0 111.463 179.883 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 5.7 p . . . . . 0 N--CA 1.486 1.345 0 CA-C-O 119.716 -0.183 . . . . 0.0 111.253 . . . . . . . . . 0 0 . 1 . 011 nuclear nobuild full ' A' A ' 2' ' ' PRO . . . . . 0.551 ' HD3' ' ND2' ' A' ' 13' ' ' ASN . 95.1 Cg_endo -82.24 -172.34 1.41 Allowed 'Trans proline' 0 C--N 1.367 1.529 0 C-N-CA 122.581 2.187 . . . . 0.0 112.827 179.498 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -147.3 -161.39 9.38 Favored Glycine 0 C--N 1.337 0.632 0 N-CA-C 111.593 -0.603 . . . . 0.0 111.593 179.216 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 19.0 tt0 -68.33 124.06 22.46 Favored 'General case' 0 N--CA 1.473 0.679 0 C-N-CA 122.548 0.339 . . . . 0.0 111.183 179.851 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 91.28 14.69 56.99 Favored Glycine 0 C--N 1.338 0.682 0 CA-C-N 115.646 -0.706 . . . . 0.0 113.228 -179.699 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 6' ' ' GLU . . . . . 0.453 ' HG2' ' NE2' ' A' ' 7' ' ' GLN . 13.9 tt0 -129.0 166.18 19.7 Favored 'General case' 0 C--O 1.238 0.479 0 C-N-CA 122.287 0.235 . . . . 0.0 110.599 -179.933 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 7' ' ' GLN . . . . . 0.453 ' NE2' ' HG2' ' A' ' 6' ' ' GLU . 0.2 OUTLIER -82.07 153.3 26.18 Favored 'General case' 0 C--N 1.346 0.433 0 O-C-N 123.288 0.367 . . . . 0.0 110.929 -179.876 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 3.3 p -142.64 151.8 41.81 Favored 'General case' 0 C--O 1.235 0.306 0 CA-C-N 115.817 -0.629 . . . . 0.0 111.297 -179.4 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -110.23 139.8 45.02 Favored 'General case' 0 C--O 1.234 0.253 0 CA-C-N 115.765 -0.652 . . . . 0.0 109.559 179.348 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 10' ' ' VAL . . . . . 0.489 HG22 ' O ' ' A' ' 26' ' ' PRO . 7.7 m -94.89 26.65 0.48 Allowed 'Isoleucine or valine' 0 CA--C 1.543 0.702 0 O-C-N 123.31 0.381 . . . . 0.0 111.635 -179.842 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 42.6 mt-10 -124.2 -52.26 1.75 Allowed 'General case' 0 N--CA 1.465 0.291 0 N-CA-C 112.251 0.464 . . . . 0.0 112.251 -179.135 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 12' ' ' PHE . . . . . . . . . . . . . 11.5 t80 -138.51 -10.38 1.41 Allowed 'General case' 0 N--CA 1.471 0.617 0 N-CA-C 112.833 0.679 . . . . 0.0 112.833 -178.627 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 13' ' ' ASN . . . . . 0.551 ' ND2' ' HD3' ' A' ' 2' ' ' PRO . 6.9 t30 -129.88 64.86 73.62 Favored Pre-proline 0 CA--C 1.549 0.928 0 CA-C-N 117.458 0.117 . . . . 0.0 111.206 -179.151 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 14' ' ' PRO . . . . . 0.4 ' O ' ' HD2' ' A' ' 2' ' ' PRO . 16.4 Cg_exo -68.86 179.81 2.98 Favored 'Trans proline' 0 C--N 1.373 1.843 0 C-N-CA 122.948 2.432 . . . . 0.0 112.22 179.141 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 15' ' ' CYS . . . . . 0.519 ' SG ' ' HB2' ' A' ' 19' ' ' LEU . 3.8 t -79.71 122.0 26.03 Favored 'General case' 0 N--CA 1.471 0.603 0 O-C-N 123.102 0.251 . . . . 0.0 111.247 -179.786 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER -60.85 -54.16 57.16 Favored Pre-proline 0 N--CA 1.476 0.855 0 CA-C-O 119.023 -0.513 . . . . 0.0 111.443 179.298 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 56.3 Cg_endo -70.95 169.27 20.84 Favored 'Trans proline' 0 C--N 1.379 2.176 0 C-N-CA 122.115 1.877 . . . . 0.0 111.702 178.173 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 49.7 Cg_endo -70.76 58.09 2.0 Allowed 'Trans proline' 0 C--N 1.371 1.748 0 C-N-CA 121.975 1.784 . . . . 0.0 112.909 179.01 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 19' ' ' LEU . . . . . 0.519 ' HB2' ' SG ' ' A' ' 15' ' ' CYS . 93.8 mt -118.19 167.8 11.17 Favored 'General case' 0 C--O 1.235 0.331 0 CA-C-N 115.704 -0.68 . . . . 0.0 111.24 -179.876 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 89.3 m -106.99 150.84 26.07 Favored 'General case' 0 CA--C 1.533 0.303 0 CA-C-N 115.315 -0.857 . . . . 0.0 110.94 -179.277 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 21' ' ' CYS . . . . . 0.505 ' HA ' ' O ' ' A' ' 29' ' ' ILE . 1.9 t -97.3 106.71 19.09 Favored 'General case' 0 C--O 1.238 0.476 0 CA-C-N 115.732 -0.667 . . . . 0.0 110.029 178.949 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 22' ' ' ILE . . . . . 0.723 HD12 ' HB2' ' A' ' 31' ' ' TYR . 5.7 mt -125.32 128.69 24.68 Favored Pre-proline 0 CA--C 1.543 0.697 0 CA-C-N 115.807 -0.633 . . . . 0.0 110.564 -179.16 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 37.3 Cg_endo -67.24 -47.78 0.26 Allowed 'Cis proline' 0 C--N 1.376 2.009 0 C-N-CA 124.681 -0.966 . . . . 0.0 113.81 -0.223 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 81.66 38.11 15.04 Favored Glycine 0 C--N 1.347 1.144 0 C-N-CA 121.332 -0.461 . . . . 0.0 112.88 179.822 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 8.0 m-20 -142.58 80.64 14.19 Favored Pre-proline 0 CA--C 1.546 0.817 0 C-N-CA 122.445 0.298 . . . . 0.0 111.052 -179.565 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 26' ' ' PRO . . . . . 0.489 ' O ' HG22 ' A' ' 10' ' ' VAL . 67.9 Cg_endo -84.08 -29.38 5.12 Favored 'Cis proline' 0 C--N 1.372 1.788 0 C-N-CA 124.698 -0.959 . . . . 0.0 113.439 -0.236 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 27' ' ' TYR . . . . . . . . . . . . . 57.0 m-85 -95.31 161.49 14.07 Favored 'General case' 0 N--CA 1.469 0.492 0 O-C-N 123.513 0.508 . . . . 0.0 111.304 -179.097 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 28' ' ' GLY . . . . . 0.433 ' O ' HD13 ' A' ' 29' ' ' ILE . . . -159.03 -161.91 11.53 Favored Glycine 0 C--N 1.341 0.842 0 C-N-CA 120.917 -0.659 . . . . 0.0 113.089 179.832 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 29' ' ' ILE . . . . . 0.505 ' O ' ' HA ' ' A' ' 21' ' ' CYS . 5.1 mm -129.95 155.17 41.31 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.238 0 N-CA-C 109.674 -0.491 . . . . 0.0 109.674 -179.932 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 30' ' ' CYS . . . . . . . . . . . . . 28.8 m -83.68 92.8 7.77 Favored 'General case' 0 CA--C 1.538 0.482 0 CA-C-O 121.368 0.604 . . . . 0.0 111.362 -179.955 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 31' ' ' TYR . . . . . 0.723 ' HB2' HD12 ' A' ' 22' ' ' ILE . 37.8 m-85 -124.33 166.81 15.28 Favored 'General case' 0 N--CA 1.464 0.26 0 CA-C-N 114.972 -1.013 . . . . 0.0 110.992 179.822 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 2.8 tp -99.76 131.49 47.05 Favored 'Isoleucine or valine' 0 CA--C 1.542 0.644 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.448 179.401 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 33' ' ' ILE . . . . . 0.472 HG23 HD11 ' A' ' 22' ' ' ILE . 1.8 pp . . . . . 0 C--O 1.249 1.056 0 CA-C-O 118.168 -0.92 . . . . 0.0 111.429 179.843 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 N--CA 1.487 1.385 0 CA-C-O 119.771 -0.157 . . . . 0.0 111.093 . . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 2' ' ' PRO . . . . . 0.598 ' HD2' ' O ' ' A' ' 14' ' ' PRO . 73.0 Cg_endo -69.33 -170.71 0.38 Allowed 'Trans proline' 0 C--N 1.376 1.989 0 C-N-CA 123.23 2.62 . . . . 0.0 113.935 -179.044 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -143.5 -159.68 8.08 Favored Glycine 0 C--N 1.341 0.837 0 CA-C-N 116.146 -0.479 . . . . 0.0 112.477 179.83 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 16.7 tt0 -66.43 124.23 22.18 Favored 'General case' 0 N--CA 1.474 0.734 0 C-N-CA 122.841 0.456 . . . . 0.0 111.603 -179.711 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 95.03 -11.01 69.89 Favored Glycine 0 C--N 1.34 0.772 0 CA-C-N 115.641 -0.708 . . . . 0.0 113.282 -179.971 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 42.8 mt-10 -101.16 166.66 10.67 Favored 'General case' 0 C--O 1.24 0.601 0 C-N-CA 122.432 0.293 . . . . 0.0 110.967 -179.8 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 7' ' ' GLN . . . . . . . . . . . . . 0.2 OUTLIER -84.85 154.83 22.05 Favored 'General case' 0 C--N 1.346 0.446 0 CA-C-N 116.167 -0.47 . . . . 0.0 111.039 179.899 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 7.9 p -147.54 155.02 41.45 Favored 'General case' 0 N--CA 1.466 0.371 0 CA-C-N 115.886 -0.597 . . . . 0.0 111.511 -179.131 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 8.0 t70 -120.17 150.52 40.5 Favored 'General case' 0 C--O 1.234 0.275 0 CA-C-N 115.325 -0.852 . . . . 0.0 109.633 178.885 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 15.6 m -98.7 18.8 2.28 Favored 'Isoleucine or valine' 0 CA--C 1.543 0.677 0 CA-C-N 116.287 -0.415 . . . . 0.0 112.072 -179.41 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 46.2 mt-10 -110.13 -55.46 2.45 Favored 'General case' 0 N--CA 1.466 0.358 0 N-CA-C 112.11 0.411 . . . . 0.0 112.11 -179.106 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 12' ' ' PHE . . . . . . . . . . . . . 12.2 t80 -137.99 -15.2 1.34 Allowed 'General case' 0 N--CA 1.47 0.556 0 N-CA-C 112.429 0.529 . . . . 0.0 112.429 -178.939 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 13' ' ' ASN . . . . . 0.454 HD21 ' HD3' ' A' ' 2' ' ' PRO . 11.5 t30 -120.21 73.01 19.61 Favored Pre-proline 0 CA--C 1.55 0.955 0 O-C-N 122.969 0.168 . . . . 0.0 111.161 -179.377 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 14' ' ' PRO . . . . . 0.598 ' O ' ' HD2' ' A' ' 2' ' ' PRO . 60.4 Cg_endo -76.13 178.74 7.09 Favored 'Trans proline' 0 C--N 1.371 1.744 0 C-N-CA 122.314 2.009 . . . . 0.0 112.501 179.587 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 1.4 m -79.38 118.65 21.47 Favored 'General case' 0 N--CA 1.47 0.547 0 O-C-N 123.118 0.261 . . . . 0.0 111.195 179.972 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 16' ' ' CYS . . . . . 0.573 ' HB2' ' O ' ' A' ' 2' ' ' PRO . 0.0 OUTLIER -56.58 -53.27 66.22 Favored Pre-proline 0 N--CA 1.48 1.073 0 CA-C-O 118.961 -0.542 . . . . 0.0 111.679 179.581 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 17' ' ' PRO . . . . . 0.474 ' HG2' HD12 ' A' ' 19' ' ' LEU . 57.7 Cg_endo -72.65 169.23 22.42 Favored 'Trans proline' 0 C--N 1.378 2.13 0 C-N-CA 122.028 1.819 . . . . 0.0 111.738 178.194 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 55.7 Cg_endo -72.51 45.33 0.83 Allowed 'Trans proline' 0 C--N 1.373 1.839 0 C-N-CA 122.012 1.808 . . . . 0.0 112.865 178.826 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 19' ' ' LEU . . . . . 0.474 HD12 ' HG2' ' A' ' 17' ' ' PRO . 11.8 mt -104.92 172.9 6.54 Favored 'General case' 0 C--O 1.237 0.401 0 CA-C-N 115.931 -0.577 . . . . 0.0 111.046 -179.628 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 24.5 m -103.98 149.3 25.27 Favored 'General case' 0 CA--C 1.531 0.228 0 CA-C-N 115.966 -0.561 . . . . 0.0 111.046 -178.945 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 5.9 t -99.35 102.74 14.43 Favored 'General case' 0 C--O 1.237 0.444 0 CA-C-N 115.856 -0.611 . . . . 0.0 109.39 178.467 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 22' ' ' ILE . . . . . 0.723 HD12 ' HB2' ' A' ' 31' ' ' TYR . 2.5 mt -126.78 129.65 24.0 Favored Pre-proline 0 CA--C 1.543 0.679 0 CA-C-N 115.787 -0.642 . . . . 0.0 110.68 -178.571 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 37.5 Cg_endo -67.65 -48.13 0.26 Allowed 'Cis proline' 0 C--N 1.374 1.885 0 C-N-CA 124.699 -0.959 . . . . 0.0 113.814 -0.434 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 78.57 37.61 26.6 Favored Glycine 0 C--N 1.348 1.242 0 C-N-CA 121.308 -0.472 . . . . 0.0 113.013 -179.962 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 4.5 t70 -140.55 80.7 18.28 Favored Pre-proline 0 CA--C 1.548 0.884 0 C-N-CA 122.372 0.269 . . . . 0.0 110.533 -179.614 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 1.9 Cg_endo -82.07 -31.81 3.98 Favored 'Cis proline' 0 C--N 1.372 1.787 0 C-N-CA 125.058 -0.809 . . . . 0.0 112.956 -0.2 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 27' ' ' TYR . . . . . . . . . . . . . 70.0 m-85 -102.0 172.55 6.85 Favored 'General case' 0 C--O 1.237 0.434 0 CA-C-N 115.822 -0.626 . . . . 0.0 111.578 -179.033 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -175.95 -160.57 23.67 Favored Glycine 0 C--N 1.337 0.634 0 CA-C-N 115.657 -0.701 . . . . 0.0 112.207 179.071 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 29' ' ' ILE . . . . . 0.559 ' HB ' ' CE2' ' A' ' 31' ' ' TYR . 1.8 mm -122.6 153.04 27.23 Favored 'Isoleucine or valine' 0 C--O 1.236 0.36 0 N-CA-C 109.87 -0.418 . . . . 0.0 109.87 179.691 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 30' ' ' CYS . . . . . 0.438 ' SG ' ' HB2' ' A' ' 19' ' ' LEU . 0.5 OUTLIER -79.92 106.72 12.15 Favored 'General case' 0 CA--C 1.539 0.521 0 CA-C-N 116.018 -0.537 . . . . 0.0 110.916 -179.919 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 31' ' ' TYR . . . . . 0.723 ' HB2' HD12 ' A' ' 22' ' ' ILE . 39.1 m-85 -131.34 166.68 20.71 Favored 'General case' 0 N--CA 1.463 0.216 0 CA-C-N 115.479 -0.782 . . . . 0.0 111.201 -179.314 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 2.7 tp -101.76 132.04 48.48 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.582 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.437 179.434 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 33' ' ' ILE . . . . . 0.477 ' H ' HG13 ' A' ' 33' ' ' ILE . 1.9 pp . . . . . 0 C--O 1.249 1.078 0 CA-C-O 118.346 -0.835 . . . . 0.0 111.504 179.945 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 4.5 p . . . . . 0 N--CA 1.486 1.346 0 CA-C-O 119.746 -0.169 . . . . 0.0 111.272 . . . . . . . . . 0 0 . 1 . 013 nuclear nobuild full ' A' A ' 2' ' ' PRO . . . . . 0.435 ' HD3' ' ND2' ' A' ' 13' ' ' ASN . 95.3 Cg_endo -82.36 -172.35 1.41 Allowed 'Trans proline' 0 C--N 1.367 1.539 0 C-N-CA 122.598 2.199 . . . . 0.0 112.969 179.474 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -145.39 -155.44 6.47 Favored Glycine 0 C--N 1.339 0.727 0 N-CA-C 111.687 -0.565 . . . . 0.0 111.687 179.45 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 18.0 tt0 -73.24 129.16 37.43 Favored 'General case' 0 N--CA 1.47 0.55 0 C-N-CA 122.575 0.35 . . . . 0.0 111.221 179.74 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 85.68 16.25 64.14 Favored Glycine 0 C--N 1.339 0.738 0 CA-C-N 115.832 -0.622 . . . . 0.0 113.294 -179.844 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 12.9 tt0 -127.86 162.52 26.5 Favored 'General case' 0 C--O 1.236 0.39 0 C-N-CA 122.176 0.19 . . . . 0.0 110.488 -179.865 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 7' ' ' GLN . . . . . 0.719 ' HA ' ' O ' ' A' ' 28' ' ' GLY . 18.6 tt0 -85.35 134.76 34.08 Favored 'General case' 0 C--N 1.345 0.386 0 CA-C-O 121.298 0.571 . . . . 0.0 111.239 -179.994 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 8' ' ' CYS . . . . . 0.412 ' SG ' ' SG ' ' A' ' 30' ' ' CYS . 3.6 p -127.77 160.2 32.46 Favored 'General case' 0 C--O 1.239 0.508 0 CA-C-N 114.545 -1.207 . . . . 0.0 111.098 -179.396 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 9' ' ' ASP . . . . . 0.432 ' OD2' ' HB2' ' A' ' 11' ' ' GLU . 16.8 t70 -114.86 150.52 35.43 Favored 'General case' 0 CA--C 1.532 0.272 0 CA-C-N 115.542 -0.754 . . . . 0.0 109.477 178.766 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 15.5 m -100.91 20.12 2.47 Favored 'Isoleucine or valine' 0 CA--C 1.543 0.689 0 CA-C-N 116.22 -0.446 . . . . 0.0 112.008 -179.465 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 11' ' ' GLU . . . . . 0.432 ' HB2' ' OD2' ' A' ' 9' ' ' ASP . 44.7 mt-10 -117.51 -52.46 2.47 Favored 'General case' 0 N--CA 1.465 0.313 0 N-CA-C 112.224 0.453 . . . . 0.0 112.224 -178.969 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 12' ' ' PHE . . . . . . . . . . . . . 14.6 t80 -138.42 -8.43 1.49 Allowed 'General case' 0 N--CA 1.472 0.652 0 N-CA-C 112.596 0.591 . . . . 0.0 112.596 -178.689 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 13' ' ' ASN . . . . . 0.435 ' ND2' ' HD3' ' A' ' 2' ' ' PRO . 6.3 t30 -129.6 63.79 69.26 Favored Pre-proline 0 CA--C 1.55 0.959 0 N-CA-C 111.552 0.205 . . . . 0.0 111.552 -179.091 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 14.0 Cg_exo -70.09 177.12 6.13 Favored 'Trans proline' 0 C--N 1.371 1.744 0 C-N-CA 122.86 2.373 . . . . 0.0 112.002 178.885 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 1.1 t -79.9 121.02 24.92 Favored 'General case' 0 N--CA 1.471 0.58 0 CA-C-O 120.503 0.192 . . . . 0.0 111.052 -179.983 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER -57.57 -53.09 69.18 Favored Pre-proline 0 N--CA 1.478 0.943 0 CA-C-O 119.069 -0.491 . . . . 0.0 111.541 179.282 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 17' ' ' PRO . . . . . 0.511 ' HG2' HD12 ' A' ' 19' ' ' LEU . 44.4 Cg_endo -68.81 169.44 17.66 Favored 'Trans proline' 0 C--N 1.38 2.199 0 C-N-CA 122.159 1.906 . . . . 0.0 111.782 178.059 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 55.5 Cg_endo -72.22 49.33 1.34 Allowed 'Trans proline' 0 C--N 1.373 1.833 0 C-N-CA 122.044 1.829 . . . . 0.0 112.589 178.799 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 19' ' ' LEU . . . . . 0.511 HD12 ' HG2' ' A' ' 17' ' ' PRO . 20.9 mt -110.1 168.24 9.58 Favored 'General case' 0 C--O 1.236 0.372 0 CA-C-N 115.741 -0.663 . . . . 0.0 111.34 -179.337 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 20' ' ' THR . . . . . 0.537 ' O ' ' HA ' ' A' ' 30' ' ' CYS . 29.3 m -105.31 153.82 21.11 Favored 'General case' 0 CA--C 1.533 0.31 0 CA-C-N 115.624 -0.716 . . . . 0.0 111.056 -178.804 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 2.0 t -103.42 103.89 13.93 Favored 'General case' 0 C--O 1.238 0.493 0 CA-C-N 115.678 -0.692 . . . . 0.0 109.666 178.869 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 22' ' ' ILE . . . . . 0.71 HD12 ' HB2' ' A' ' 31' ' ' TYR . 2.9 mt -125.9 129.11 24.39 Favored Pre-proline 0 CA--C 1.541 0.634 0 CA-C-N 115.768 -0.651 . . . . 0.0 110.223 -179.157 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 38.4 Cg_endo -67.77 -48.26 0.25 Allowed 'Cis proline' 0 C--N 1.375 1.941 0 C-N-CA 124.679 -0.967 . . . . 0.0 113.941 -0.155 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 81.92 36.83 17.63 Favored Glycine 0 C--N 1.348 1.229 0 C-N-CA 121.108 -0.568 . . . . 0.0 112.852 -179.977 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 8.3 m-20 -139.99 82.58 17.18 Favored Pre-proline 0 CA--C 1.543 0.701 0 C-N-CA 122.53 0.332 . . . . 0.0 110.701 -179.91 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 3.0 Cg_endo -80.54 -32.07 4.18 Favored 'Cis proline' 0 C--N 1.372 1.795 0 C-N-CA 125.191 -0.754 . . . . 0.0 112.923 0.077 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 27' ' ' TYR . . . . . . . . . . . . . 59.3 m-85 -106.96 175.07 5.62 Favored 'General case' 0 C--O 1.238 0.466 0 CA-C-N 115.68 -0.691 . . . . 0.0 111.532 -179.001 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 28' ' ' GLY . . . . . 0.719 ' O ' ' HA ' ' A' ' 7' ' ' GLN . . . -175.52 -161.26 24.65 Favored Glycine 0 C--N 1.339 0.701 0 CA-C-N 115.626 -0.715 . . . . 0.0 112.618 178.49 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 29' ' ' ILE . . . . . 0.527 ' HB ' ' CE2' ' A' ' 31' ' ' TYR . 2.8 mm -115.6 149.76 17.74 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 N-CA-C 110.084 -0.339 . . . . 0.0 110.084 -179.814 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 30' ' ' CYS . . . . . 0.537 ' HA ' ' O ' ' A' ' 20' ' ' THR . 26.8 m -79.85 105.1 10.89 Favored 'General case' 0 C--O 1.238 0.464 0 CA-C-N 115.955 -0.566 . . . . 0.0 111.35 -179.802 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 31' ' ' TYR . . . . . 0.71 ' HB2' HD12 ' A' ' 22' ' ' ILE . 36.9 m-85 -128.74 168.46 15.81 Favored 'General case' 0 C--O 1.233 0.205 0 CA-C-N 115.087 -0.961 . . . . 0.0 111.099 -179.552 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 1.8 tt -101.06 130.33 50.64 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.585 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.363 179.651 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 33' ' ' ILE . . . . . 0.458 ' H ' HG13 ' A' ' 33' ' ' ILE . 1.6 pp . . . . . 0 C--O 1.248 0.986 0 CA-C-O 118.386 -0.816 . . . . 0.0 111.525 179.881 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 N--CA 1.488 1.455 0 CA-C-O 119.757 -0.163 . . . . 0.0 111.045 . . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 2' ' ' PRO . . . . . 0.576 ' HD2' ' O ' ' A' ' 14' ' ' PRO . 73.7 Cg_endo -69.22 -170.6 0.36 Allowed 'Trans proline' 0 C--N 1.376 1.991 0 C-N-CA 123.204 2.603 . . . . 0.0 113.949 -178.955 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -143.5 -159.09 7.83 Favored Glycine 0 C--N 1.34 0.778 0 O-C-N 123.511 0.507 . . . . 0.0 112.543 179.877 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 16.6 tt0 -68.39 122.93 19.43 Favored 'General case' 0 N--CA 1.472 0.642 0 C-N-CA 122.849 0.46 . . . . 0.0 111.524 -179.893 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 92.12 14.47 56.05 Favored Glycine 0 C--N 1.339 0.736 0 CA-C-N 115.681 -0.691 . . . . 0.0 113.242 -179.864 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 43.0 mt-10 -127.9 165.83 19.46 Favored 'General case' 0 C--O 1.239 0.535 0 C-N-CA 122.447 0.299 . . . . 0.0 110.813 179.942 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 7' ' ' GLN . . . . . 0.526 ' HA ' ' O ' ' A' ' 28' ' ' GLY . 15.6 mt-30 -85.11 145.15 27.79 Favored 'General case' 0 C--N 1.346 0.415 0 CA-C-N 116.371 -0.377 . . . . 0.0 111.515 179.966 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 7.4 p -138.26 155.59 48.48 Favored 'General case' 0 C--O 1.236 0.385 0 CA-C-N 115.274 -0.876 . . . . 0.0 111.292 -179.51 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 6.1 t70 -118.25 152.46 35.68 Favored 'General case' 0 C--O 1.235 0.335 0 CA-C-N 115.35 -0.841 . . . . 0.0 109.668 179.003 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 14.4 m -101.1 21.63 1.97 Allowed 'Isoleucine or valine' 0 CA--C 1.541 0.624 0 CA-C-N 116.18 -0.464 . . . . 0.0 112.058 -179.466 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 44.5 mt-10 -118.51 -53.0 2.34 Favored 'General case' 0 N--CA 1.465 0.319 0 N-CA-C 112.196 0.443 . . . . 0.0 112.196 -179.18 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 12' ' ' PHE . . . . . . . . . . . . . 15.1 t80 -139.01 -7.49 1.39 Allowed 'General case' 0 N--CA 1.47 0.564 0 N-CA-C 112.534 0.568 . . . . 0.0 112.534 -178.784 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 13' ' ' ASN . . . . . . . . . . . . . 8.6 t30 -129.34 63.22 66.74 Favored Pre-proline 0 CA--C 1.55 0.943 0 N-CA-C 111.415 0.154 . . . . 0.0 111.415 -179.144 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 14' ' ' PRO . . . . . 0.576 ' O ' ' HD2' ' A' ' 2' ' ' PRO . 15.6 Cg_exo -68.93 178.03 4.44 Favored 'Trans proline' 0 C--N 1.373 1.865 0 C-N-CA 122.828 2.352 . . . . 0.0 112.372 179.235 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 1.5 m -79.54 119.45 22.54 Favored 'General case' 0 N--CA 1.471 0.605 0 O-C-N 123.144 0.278 . . . . 0.0 111.315 -179.86 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 16' ' ' CYS . . . . . 0.576 ' HB2' ' O ' ' A' ' 2' ' ' PRO . 0.0 OUTLIER -57.13 -53.18 67.97 Favored Pre-proline 0 N--CA 1.483 1.182 0 CA-C-N 115.923 -0.581 . . . . 0.0 111.554 179.489 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 17' ' ' PRO . . . . . 0.48 ' HG2' HD12 ' A' ' 19' ' ' LEU . 57.9 Cg_endo -72.71 169.28 22.35 Favored 'Trans proline' 0 C--N 1.38 2.191 0 C-N-CA 121.994 1.796 . . . . 0.0 111.815 178.178 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 55.9 Cg_endo -72.27 44.69 0.72 Allowed 'Trans proline' 0 C--N 1.371 1.76 0 C-N-CA 122.012 1.808 . . . . 0.0 113.062 178.778 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 19' ' ' LEU . . . . . 0.48 HD12 ' HG2' ' A' ' 17' ' ' PRO . 12.2 mt -104.39 172.74 6.63 Favored 'General case' 0 C--O 1.236 0.361 0 CA-C-N 115.911 -0.586 . . . . 0.0 110.996 -179.761 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 25.4 m -103.32 150.19 24.01 Favored 'General case' 0 CA--C 1.534 0.335 0 CA-C-N 115.987 -0.551 . . . . 0.0 110.982 -178.903 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 5.1 t -100.38 103.03 14.4 Favored 'General case' 0 C--O 1.238 0.453 0 CA-C-N 115.724 -0.671 . . . . 0.0 109.407 178.412 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 22' ' ' ILE . . . . . 0.715 HD12 ' HB2' ' A' ' 31' ' ' TYR . 2.5 mt -127.16 129.04 24.02 Favored Pre-proline 0 CA--C 1.541 0.629 0 CA-C-N 115.803 -0.635 . . . . 0.0 110.826 -178.457 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 37.6 Cg_endo -67.99 -48.52 0.25 Allowed 'Cis proline' 0 C--N 1.375 1.938 0 C-N-CA 124.674 -0.969 . . . . 0.0 113.726 -0.261 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 79.12 37.79 24.14 Favored Glycine 0 C--N 1.347 1.19 0 C-N-CA 121.456 -0.402 . . . . 0.0 112.883 -179.991 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 4.6 t70 -140.12 80.57 19.92 Favored Pre-proline 0 CA--C 1.549 0.912 0 C-N-CA 122.338 0.255 . . . . 0.0 110.461 -179.686 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 1.9 Cg_endo -82.24 -31.71 4.0 Favored 'Cis proline' 0 C--N 1.372 1.774 0 C-N-CA 125.112 -0.787 . . . . 0.0 112.973 -0.134 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 27' ' ' TYR . . . . . . . . . . . . . 66.8 m-85 -101.7 171.98 7.22 Favored 'General case' 0 C--O 1.237 0.424 0 CA-C-N 115.796 -0.638 . . . . 0.0 111.591 -179.146 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 28' ' ' GLY . . . . . 0.526 ' O ' ' HA ' ' A' ' 7' ' ' GLN . . . -174.93 -160.26 22.6 Favored Glycine 0 C--N 1.337 0.621 0 CA-C-N 115.667 -0.697 . . . . 0.0 112.409 178.905 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 29' ' ' ILE . . . . . 0.56 ' HB ' ' CE2' ' A' ' 31' ' ' TYR . 1.4 mm -122.37 152.14 26.48 Favored 'Isoleucine or valine' 0 C--O 1.233 0.191 0 N-CA-C 109.807 -0.442 . . . . 0.0 109.807 179.609 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 30' ' ' CYS . . . . . 0.443 ' SG ' ' HB2' ' A' ' 19' ' ' LEU . 0.5 OUTLIER -80.02 106.92 12.4 Favored 'General case' 0 CA--C 1.537 0.467 0 CA-C-N 115.961 -0.563 . . . . 0.0 110.919 -179.986 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 31' ' ' TYR . . . . . 0.715 ' HB2' HD12 ' A' ' 22' ' ' ILE . 36.3 m-85 -132.15 167.17 20.24 Favored 'General case' 0 N--CA 1.463 0.222 0 CA-C-N 115.449 -0.796 . . . . 0.0 111.155 -179.332 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 2.7 tp -101.82 131.67 49.28 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.611 0 CA-C-N 116.081 -0.509 . . . . 0.0 110.412 179.493 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 33' ' ' ILE . . . . . 0.466 ' H ' HG13 ' A' ' 33' ' ' ILE . 1.9 pp . . . . . 0 C--O 1.249 1.04 0 CA-C-O 118.133 -0.937 . . . . 0.0 111.568 179.873 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 4.8 p . . . . . 0 N--CA 1.485 1.313 0 CA-C-O 119.719 -0.182 . . . . 0.0 111.263 . . . . . . . . . 0 0 . 1 . 015 nuclear nobuild full ' A' A ' 2' ' ' PRO . . . . . 0.511 ' HD3' ' ND2' ' A' ' 13' ' ' ASN . 81.2 Cg_endo -82.88 -172.65 1.45 Allowed 'Trans proline' 0 C--N 1.367 1.508 0 C-N-CA 122.619 2.213 . . . . 0.0 112.886 179.59 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -145.28 -156.63 6.92 Favored Glycine 0 C--N 1.34 0.767 0 N-CA-C 111.562 -0.615 . . . . 0.0 111.562 179.151 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 18.1 tt0 -73.43 129.49 38.11 Favored 'General case' 0 N--CA 1.471 0.624 0 C-N-CA 122.445 0.298 . . . . 0.0 111.208 179.595 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 88.13 14.14 62.89 Favored Glycine 0 C--N 1.34 0.778 0 CA-C-N 115.765 -0.652 . . . . 0.0 113.274 -179.845 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 43.2 mt-10 -129.81 162.19 29.04 Favored 'General case' 0 C--O 1.237 0.404 0 C-N-CA 122.277 0.231 . . . . 0.0 110.733 -179.897 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 7' ' ' GLN . . . . . 0.496 ' HA ' ' O ' ' A' ' 28' ' ' GLY . 9.4 tt0 -83.82 136.77 34.01 Favored 'General case' 0 C--N 1.345 0.374 0 CA-C-O 121.305 0.574 . . . . 0.0 111.296 179.815 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 4.0 p -125.57 160.25 30.06 Favored 'General case' 0 C--O 1.243 0.712 0 CA-C-N 114.471 -1.241 . . . . 0.0 110.89 -179.554 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 9' ' ' ASP . . . . . 0.444 ' OD1' ' HD2' ' A' ' 27' ' ' TYR . 2.5 m-20 -114.58 150.11 35.51 Favored 'General case' 0 C--O 1.235 0.313 0 CA-C-N 115.58 -0.736 . . . . 0.0 109.684 179.432 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 11.2 m -103.24 16.78 5.1 Favored 'Isoleucine or valine' 0 CA--C 1.542 0.64 0 CA-C-N 116.398 -0.364 . . . . 0.0 111.766 -179.686 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 9.6 mm-40 -110.73 -52.53 2.78 Favored 'General case' 0 C--O 1.235 0.312 0 N-CA-C 112.118 0.414 . . . . 0.0 112.118 -178.937 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 12' ' ' PHE . . . . . . . . . . . . . 17.2 t80 -142.01 -7.84 0.93 Allowed 'General case' 0 N--CA 1.472 0.663 0 N-CA-C 112.569 0.581 . . . . 0.0 112.569 -178.788 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 13' ' ' ASN . . . . . 0.511 ' ND2' ' HD3' ' A' ' 2' ' ' PRO . 6.7 t30 -129.58 64.37 71.38 Favored Pre-proline 0 CA--C 1.55 0.952 0 N-CA-C 111.559 0.207 . . . . 0.0 111.559 -179.075 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 15.0 Cg_exo -69.64 179.95 3.28 Favored 'Trans proline' 0 C--N 1.372 1.792 0 C-N-CA 122.888 2.392 . . . . 0.0 111.993 178.947 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 1.3 t -79.76 121.25 25.12 Favored 'General case' 0 N--CA 1.47 0.573 0 CA-C-O 120.519 0.2 . . . . 0.0 111.142 -179.951 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER -57.88 -53.61 63.96 Favored Pre-proline 0 N--CA 1.478 0.952 0 CA-C-O 118.992 -0.528 . . . . 0.0 111.573 179.325 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 17' ' ' PRO . . . . . 0.552 ' HG2' HD12 ' A' ' 19' ' ' LEU . 45.1 Cg_endo -69.06 169.61 17.63 Favored 'Trans proline' 0 C--N 1.378 2.099 0 C-N-CA 122.12 1.88 . . . . 0.0 111.725 178.181 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -71.8 49.67 1.27 Allowed 'Trans proline' 0 C--N 1.372 1.794 0 C-N-CA 121.957 1.771 . . . . 0.0 112.688 178.794 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 19' ' ' LEU . . . . . 0.552 HD12 ' HG2' ' A' ' 17' ' ' PRO . 22.0 mt -110.08 168.32 9.52 Favored 'General case' 0 C--O 1.236 0.389 0 CA-C-N 115.703 -0.681 . . . . 0.0 111.284 -179.363 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 20' ' ' THR . . . . . 0.519 ' O ' ' HA ' ' A' ' 30' ' ' CYS . 27.9 m -105.19 154.48 20.14 Favored 'General case' 0 CA--C 1.533 0.304 0 CA-C-N 115.641 -0.709 . . . . 0.0 111.191 -178.71 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 1.8 t -103.78 102.37 12.19 Favored 'General case' 0 C--O 1.238 0.453 0 CA-C-N 115.594 -0.73 . . . . 0.0 109.626 178.817 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 22' ' ' ILE . . . . . 0.711 HD12 ' HB2' ' A' ' 31' ' ' TYR . 2.8 mt -125.31 129.86 24.33 Favored Pre-proline 0 CA--C 1.542 0.665 0 CA-C-N 115.655 -0.702 . . . . 0.0 110.308 -179.071 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 35.3 Cg_endo -65.93 -48.9 0.21 Allowed 'Cis proline' 0 C--N 1.375 1.922 0 C-N-CA 124.723 -0.949 . . . . 0.0 113.817 -0.21 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 77.97 33.62 40.67 Favored Glycine 0 C--N 1.347 1.179 0 C-N-CA 121.256 -0.497 . . . . 0.0 112.901 179.872 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 4.6 t70 -139.49 82.84 17.92 Favored Pre-proline 0 CA--C 1.546 0.794 0 C-N-CA 122.556 0.343 . . . . 0.0 110.166 -179.641 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 2.5 Cg_endo -81.52 -32.54 3.61 Favored 'Cis proline' 0 C--N 1.37 1.7 0 C-N-CA 125.146 -0.772 . . . . 0.0 113.048 -0.028 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 27' ' ' TYR . . . . . 0.444 ' HD2' ' OD1' ' A' ' 9' ' ' ASP . 46.4 m-85 -103.46 167.59 9.71 Favored 'General case' 0 C--O 1.239 0.5 0 O-C-N 123.669 0.606 . . . . 0.0 111.476 -178.889 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 28' ' ' GLY . . . . . 0.496 ' O ' ' HA ' ' A' ' 7' ' ' GLN . . . -170.0 -163.14 23.54 Favored Glycine 0 C--N 1.342 0.899 0 C-N-CA 120.853 -0.689 . . . . 0.0 113.327 178.543 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 29' ' ' ILE . . . . . 0.501 ' HB ' ' CE2' ' A' ' 31' ' ' TYR . 2.7 mm -118.21 154.86 20.28 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.284 0 O-C-N 124.108 0.534 . . . . 0.0 110.149 -179.931 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 30' ' ' CYS . . . . . 0.519 ' HA ' ' O ' ' A' ' 20' ' ' THR . 24.5 m -83.29 103.48 12.71 Favored 'General case' 0 C--O 1.237 0.431 0 CA-C-N 115.941 -0.572 . . . . 0.0 111.22 -179.961 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 31' ' ' TYR . . . . . 0.711 ' HB2' HD12 ' A' ' 22' ' ' ILE . 38.6 m-85 -129.55 167.37 18.01 Favored 'General case' 0 CA--C 1.531 0.212 0 CA-C-N 115.01 -0.996 . . . . 0.0 111.074 -179.586 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 2.8 tp -100.43 131.11 48.6 Favored 'Isoleucine or valine' 0 CA--C 1.542 0.639 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.271 179.534 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 33' ' ' ILE . . . . . 0.496 HG23 HD11 ' A' ' 22' ' ' ILE . 1.9 pp . . . . . 0 C--O 1.248 0.988 0 CA-C-O 118.387 -0.816 . . . . 0.0 111.48 179.866 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 6.0 p . . . . . 0 N--CA 1.485 1.295 0 CA-C-O 119.796 -0.145 . . . . 0.0 111.22 . . . . . . . . . 0 0 . 1 . 016 nuclear nobuild full ' A' A ' 2' ' ' PRO . . . . . 0.532 ' HD3' ' ND2' ' A' ' 13' ' ' ASN . 84.7 Cg_endo -83.12 -172.29 1.34 Allowed 'Trans proline' 0 C--N 1.367 1.528 0 C-N-CA 122.545 2.164 . . . . 0.0 112.926 179.629 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -148.23 -158.42 7.96 Favored Glycine 0 C--N 1.338 0.671 0 N-CA-C 111.63 -0.588 . . . . 0.0 111.63 179.276 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 17.9 tt0 -70.32 123.83 22.68 Favored 'General case' 0 N--CA 1.473 0.702 0 C-N-CA 122.489 0.316 . . . . 0.0 111.516 179.891 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 98.42 -11.19 63.34 Favored Glycine 0 C--N 1.34 0.799 0 CA-C-N 115.748 -0.66 . . . . 0.0 113.58 179.809 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 43.0 mt-10 -105.34 166.02 10.71 Favored 'General case' 0 C--O 1.238 0.465 0 CA-C-N 116.705 0.253 . . . . 0.0 111.01 -179.735 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 7' ' ' GLN . . . . . 0.457 ' HA ' ' HA ' ' A' ' 29' ' ' ILE . 6.5 tt0 -86.73 140.39 29.81 Favored 'General case' 0 C--N 1.347 0.466 0 CA-C-O 121.113 0.482 . . . . 0.0 111.132 179.744 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 8' ' ' CYS . . . . . 0.421 ' SG ' ' SG ' ' A' ' 15' ' ' CYS . 5.8 p -127.02 158.49 36.8 Favored 'General case' 0 C--O 1.239 0.53 0 CA-C-N 114.696 -1.138 . . . . 0.0 111.128 -179.599 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -114.92 149.73 36.78 Favored 'General case' 0 C--O 1.234 0.27 0 CA-C-N 115.377 -0.829 . . . . 0.0 109.711 179.348 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 10' ' ' VAL . . . . . 0.525 HG22 ' O ' ' A' ' 26' ' ' PRO . 10.4 m -103.83 17.87 4.78 Favored 'Isoleucine or valine' 0 CA--C 1.542 0.661 0 O-C-N 123.31 0.381 . . . . 0.0 111.621 179.926 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 9.7 mm-40 -109.45 -53.08 2.7 Favored 'General case' 0 C--O 1.234 0.287 0 CA-C-N 116.347 -0.388 . . . . 0.0 111.997 -179.186 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 12' ' ' PHE . . . . . . . . . . . . . 12.2 t80 -139.74 -18.05 0.96 Allowed 'General case' 0 N--CA 1.471 0.62 0 N-CA-C 112.423 0.527 . . . . 0.0 112.423 -179.04 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 13' ' ' ASN . . . . . 0.532 ' ND2' ' HD3' ' A' ' 2' ' ' PRO . 8.3 t30 -118.7 74.67 12.46 Favored Pre-proline 0 CA--C 1.549 0.929 0 O-C-N 122.977 0.173 . . . . 0.0 111.222 -179.25 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 14' ' ' PRO . . . . . 0.405 ' O ' ' HD2' ' A' ' 2' ' ' PRO . 60.0 Cg_endo -75.48 178.11 7.78 Favored 'Trans proline' 0 C--N 1.372 1.768 0 C-N-CA 122.421 2.081 . . . . 0.0 112.649 179.201 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 15' ' ' CYS . . . . . 0.421 ' SG ' ' SG ' ' A' ' 8' ' ' CYS . 1.6 m -79.66 119.83 23.14 Favored 'General case' 0 N--CA 1.471 0.596 0 O-C-N 123.151 0.282 . . . . 0.0 111.623 179.983 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER -58.91 -54.27 58.11 Favored Pre-proline 0 N--CA 1.477 0.908 0 CA-C-N 115.91 -0.586 . . . . 0.0 111.598 179.667 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 48.0 Cg_endo -68.95 169.02 18.82 Favored 'Trans proline' 0 C--N 1.38 2.207 0 C-N-CA 121.965 1.777 . . . . 0.0 111.687 178.382 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 56.1 Cg_endo -72.43 45.89 0.9 Allowed 'Trans proline' 0 C--N 1.37 1.702 0 C-N-CA 121.929 1.752 . . . . 0.0 112.939 179.048 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 19' ' ' LEU . . . . . 0.506 ' HB2' ' SG ' ' A' ' 30' ' ' CYS . 44.4 mt -106.44 169.83 8.28 Favored 'General case' 0 C--O 1.236 0.358 0 CA-C-N 116.118 -0.492 . . . . 0.0 111.038 -179.632 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 32.6 m -104.12 149.89 24.83 Favored 'General case' 0 CA--C 1.533 0.31 0 CA-C-N 115.737 -0.665 . . . . 0.0 111.095 -178.904 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 2.7 t -98.44 102.54 14.32 Favored 'General case' 0 C--O 1.238 0.464 0 CA-C-N 115.88 -0.6 . . . . 0.0 109.555 178.545 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 22' ' ' ILE . . . . . 0.723 HD12 ' HB2' ' A' ' 31' ' ' TYR . 2.4 mt -126.64 130.68 23.8 Favored Pre-proline 0 CA--C 1.542 0.671 0 CA-C-N 115.704 -0.68 . . . . 0.0 110.457 -178.728 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 36.8 Cg_endo -66.88 -48.22 0.24 Allowed 'Cis proline' 0 C--N 1.374 1.917 0 C-N-CA 124.833 -0.903 . . . . 0.0 113.784 -0.088 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 75.31 41.23 31.5 Favored Glycine 0 C--N 1.348 1.246 0 C-N-CA 121.31 -0.471 . . . . 0.0 112.811 -179.948 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 8.1 m-20 -136.24 75.36 53.13 Favored Pre-proline 0 CA--C 1.545 0.761 0 C-N-CA 122.428 0.291 . . . . 0.0 110.863 -179.627 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 26' ' ' PRO . . . . . 0.525 ' O ' HG22 ' A' ' 10' ' ' VAL . 56.8 Cg_endo -88.49 -16.91 22.33 Favored 'Cis proline' 0 C--N 1.37 1.708 0 C-N-CA 124.79 -0.921 . . . . 0.0 113.773 -0.088 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 27' ' ' TYR . . . . . 0.475 ' CE2' ' HG2' ' A' ' 26' ' ' PRO . 21.0 m-85 -106.82 163.97 12.5 Favored 'General case' 0 C--O 1.238 0.497 0 CA-C-N 116.276 -0.42 . . . . 0.0 111.457 -179.026 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 28' ' ' GLY . . . . . 0.403 ' O ' ' HA ' ' A' ' 7' ' ' GLN . . . -173.64 -162.18 25.08 Favored Glycine 0 C--N 1.341 0.846 0 C-N-CA 120.889 -0.672 . . . . 0.0 113.291 178.493 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 29' ' ' ILE . . . . . 0.549 ' HB ' ' CE2' ' A' ' 31' ' ' TYR . 1.9 mm -118.51 154.68 20.68 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.232 0 O-C-N 124.031 0.489 . . . . 0.0 110.049 -179.912 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 30' ' ' CYS . . . . . 0.506 ' SG ' ' HB2' ' A' ' 19' ' ' LEU . 0.5 OUTLIER -81.97 105.49 13.12 Favored 'General case' 0 CA--C 1.537 0.464 0 CA-C-N 115.893 -0.594 . . . . 0.0 110.986 179.974 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 31' ' ' TYR . . . . . 0.723 ' HB2' HD12 ' A' ' 22' ' ' ILE . 38.4 m-85 -131.04 165.44 23.22 Favored 'General case' 0 N--CA 1.464 0.23 0 CA-C-N 115.406 -0.815 . . . . 0.0 111.205 -179.415 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 2.9 tp -100.08 131.3 47.8 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.592 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.461 179.571 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 33' ' ' ILE . . . . . 0.476 ' H ' HG13 ' A' ' 33' ' ' ILE . 1.9 pp . . . . . 0 C--O 1.249 1.033 0 CA-C-O 118.191 -0.909 . . . . 0.0 111.468 179.956 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 0.3 OUTLIER . . . . . 0 N--CA 1.487 1.417 0 CA-C-O 119.794 -0.146 . . . . 0.0 111.07 . . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 2' ' ' PRO . . . . . 0.581 ' O ' ' HB2' ' A' ' 16' ' ' CYS . 87.5 Cg_endo -71.35 -172.28 0.73 Allowed 'Trans proline' 0 C--N 1.375 1.923 0 C-N-CA 123.224 2.616 . . . . 0.0 113.854 -178.885 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -134.49 -154.56 7.23 Favored Glycine 0 C--N 1.342 0.895 0 CA-C-N 116.09 -0.504 . . . . 0.0 112.287 179.979 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 16.1 tt0 -73.72 137.67 44.17 Favored 'General case' 0 N--CA 1.472 0.637 0 C-N-CA 122.845 0.458 . . . . 0.0 111.407 -179.854 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 82.61 12.92 79.37 Favored Glycine 0 C--N 1.341 0.832 0 CA-C-N 115.689 -0.687 . . . . 0.0 113.277 -179.771 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 43.1 mt-10 -125.95 161.53 27.29 Favored 'General case' 0 C--O 1.237 0.421 0 C-N-CA 122.346 0.258 . . . . 0.0 110.935 -179.875 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 7' ' ' GLN . . . . . 0.722 ' HA ' ' O ' ' A' ' 28' ' ' GLY . 21.0 tt0 -88.54 133.96 34.0 Favored 'General case' 0 C--N 1.344 0.363 0 CA-C-O 121.216 0.532 . . . . 0.0 111.275 179.872 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 2.0 p -128.73 161.64 29.24 Favored 'General case' 0 C--O 1.239 0.54 0 CA-C-N 114.557 -1.201 . . . . 0.0 111.149 -179.738 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 12.2 t70 -117.1 147.02 42.76 Favored 'General case' 0 C--O 1.234 0.254 0 CA-C-N 115.677 -0.692 . . . . 0.0 109.562 178.769 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 15.8 m -93.73 24.98 0.52 Allowed 'Isoleucine or valine' 0 CA--C 1.544 0.74 0 CA-C-N 116.268 -0.423 . . . . 0.0 111.805 -179.43 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 43.7 mt-10 -121.51 -52.79 2.02 Favored 'General case' 0 CA--C 1.533 0.293 0 N-CA-C 112.268 0.47 . . . . 0.0 112.268 -178.98 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 12' ' ' PHE . . . . . . . . . . . . . 9.9 t80 -138.27 -10.59 1.46 Allowed 'General case' 0 N--CA 1.47 0.546 0 N-CA-C 112.812 0.671 . . . . 0.0 112.812 -178.622 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 13' ' ' ASN . . . . . . . . . . . . . 7.3 t30 -129.57 62.79 65.19 Favored Pre-proline 0 CA--C 1.55 0.953 0 N-CA-C 111.655 0.243 . . . . 0.0 111.655 -179.277 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 14' ' ' PRO . . . . . 0.558 ' O ' ' HD2' ' A' ' 2' ' ' PRO . 13.5 Cg_exo -70.1 -179.97 3.45 Favored 'Trans proline' 0 C--N 1.374 1.878 0 C-N-CA 122.649 2.233 . . . . 0.0 111.962 178.985 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 1.8 t -79.57 120.83 24.48 Favored 'General case' 0 N--CA 1.47 0.541 0 C-N-CA 121.989 0.116 . . . . 0.0 110.849 -179.947 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 16' ' ' CYS . . . . . 0.581 ' HB2' ' O ' ' A' ' 2' ' ' PRO . 0.0 OUTLIER -55.66 -52.56 71.05 Favored Pre-proline 0 N--CA 1.483 1.214 0 CA-C-O 118.952 -0.547 . . . . 0.0 111.643 179.572 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 17' ' ' PRO . . . . . 0.554 ' HG2' HD12 ' A' ' 19' ' ' LEU . 56.5 Cg_endo -71.98 169.84 20.36 Favored 'Trans proline' 0 C--N 1.378 2.13 0 C-N-CA 122.155 1.903 . . . . 0.0 111.667 178.111 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 55.2 Cg_endo -71.91 48.55 1.13 Allowed 'Trans proline' 0 C--N 1.373 1.861 0 C-N-CA 121.976 1.784 . . . . 0.0 112.928 178.857 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 19' ' ' LEU . . . . . 0.554 HD12 ' HG2' ' A' ' 17' ' ' PRO . 28.2 mt -108.32 171.06 7.63 Favored 'General case' 0 C--O 1.236 0.383 0 CA-C-N 115.679 -0.691 . . . . 0.0 111.271 -179.655 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 20' ' ' THR . . . . . 0.527 ' O ' ' HA ' ' A' ' 30' ' ' CYS . 20.0 m -105.07 153.56 21.32 Favored 'General case' 0 CA--C 1.533 0.294 0 CA-C-N 115.927 -0.579 . . . . 0.0 111.044 -178.879 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 2.7 t -105.58 99.5 9.1 Favored 'General case' 0 C--O 1.236 0.367 0 CA-C-N 115.646 -0.706 . . . . 0.0 109.366 178.776 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 22' ' ' ILE . . . . . 0.727 HD12 ' HB2' ' A' ' 31' ' ' TYR . 3.6 mt -120.71 129.92 25.09 Favored Pre-proline 0 CA--C 1.543 0.682 0 CA-C-N 115.595 -0.729 . . . . 0.0 110.345 -178.782 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 36.8 Cg_endo -66.78 -47.01 0.27 Allowed 'Cis proline' 0 C--N 1.375 1.93 0 C-N-CA 124.647 -0.981 . . . . 0.0 113.965 -0.069 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 79.51 33.43 34.84 Favored Glycine 0 C--N 1.346 1.09 0 C-N-CA 121.223 -0.513 . . . . 0.0 112.957 179.8 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 8.3 m-20 -139.26 83.97 17.06 Favored Pre-proline 0 CA--C 1.544 0.735 0 C-N-CA 122.523 0.329 . . . . 0.0 110.588 -179.762 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 2.9 Cg_endo -80.25 -31.67 4.54 Favored 'Cis proline' 0 C--N 1.37 1.697 0 C-N-CA 125.074 -0.803 . . . . 0.0 112.907 -0.044 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 27' ' ' TYR . . . . . . . . . . . . . 59.8 m-85 -108.22 173.16 6.44 Favored 'General case' 0 C--O 1.239 0.541 0 CA-C-N 115.824 -0.625 . . . . 0.0 111.701 -179.053 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 28' ' ' GLY . . . . . 0.722 ' O ' ' HA ' ' A' ' 7' ' ' GLN . . . -175.54 -164.32 29.82 Favored Glycine 0 C--N 1.338 0.685 0 CA-C-N 115.694 -0.685 . . . . 0.0 112.491 178.495 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 29' ' ' ILE . . . . . 0.549 ' HB ' ' CE2' ' A' ' 31' ' ' TYR . 2.3 mm -113.99 152.82 15.61 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 O-C-N 123.654 0.267 . . . . 0.0 110.282 -179.825 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 30' ' ' CYS . . . . . 0.527 ' HA ' ' O ' ' A' ' 20' ' ' THR . 33.9 m -79.73 106.02 11.44 Favored 'General case' 0 C--O 1.237 0.409 0 CA-C-N 115.918 -0.583 . . . . 0.0 111.432 -179.874 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 31' ' ' TYR . . . . . 0.727 ' HB2' HD12 ' A' ' 22' ' ' ILE . 38.6 m-85 -130.51 167.83 18.03 Favored 'General case' 0 C--O 1.233 0.187 0 CA-C-N 115.081 -0.963 . . . . 0.0 111.113 -179.463 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 2.8 tp -101.21 131.13 49.54 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.551 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.31 179.514 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 33' ' ' ILE . . . . . 0.489 HG23 HD11 ' A' ' 22' ' ' ILE . 1.8 pp . . . . . 0 C--O 1.249 1.074 0 CA-C-O 118.158 -0.925 . . . . 0.0 111.443 179.913 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 0.2 OUTLIER . . . . . 0 N--CA 1.487 1.418 0 CA-C-O 119.803 -0.141 . . . . 0.0 111.094 . . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 2' ' ' PRO . . . . . 0.584 ' HD2' ' O ' ' A' ' 14' ' ' PRO . 91.6 Cg_endo -71.51 -172.46 0.78 Allowed 'Trans proline' 0 C--N 1.375 1.946 0 C-N-CA 123.252 2.635 . . . . 0.0 113.961 -178.761 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -135.86 -157.74 7.96 Favored Glycine 0 C--N 1.341 0.817 0 CA-C-N 115.977 -0.556 . . . . 0.0 112.053 179.778 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 18.0 tt0 -73.07 135.46 44.82 Favored 'General case' 0 N--CA 1.471 0.608 0 C-N-CA 122.721 0.408 . . . . 0.0 111.345 -179.957 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 88.31 9.44 69.86 Favored Glycine 0 C--N 1.34 0.797 0 CA-C-N 115.797 -0.638 . . . . 0.0 113.396 -179.707 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 42.6 mt-10 -128.6 166.62 18.52 Favored 'General case' 0 C--O 1.239 0.505 0 C-N-CA 122.298 0.239 . . . . 0.0 110.883 -179.963 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 7' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER -81.74 152.48 27.0 Favored 'General case' 0 C--N 1.347 0.483 0 CA-C-N 116.581 -0.281 . . . . 0.0 110.867 179.909 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 4.9 p -140.48 150.58 43.95 Favored 'General case' 0 C--O 1.235 0.327 0 CA-C-N 115.852 -0.613 . . . . 0.0 111.116 -179.283 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -111.01 141.87 43.91 Favored 'General case' 0 C--O 1.234 0.277 0 CA-C-N 115.4 -0.818 . . . . 0.0 109.59 179.671 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 10' ' ' VAL . . . . . 0.45 HG22 ' O ' ' A' ' 26' ' ' PRO . 6.8 m -96.09 22.58 0.92 Allowed 'Isoleucine or valine' 0 CA--C 1.541 0.611 0 CA-C-N 116.559 -0.291 . . . . 0.0 111.651 -179.926 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 45.3 mt-10 -115.29 -54.34 2.55 Favored 'General case' 0 C--O 1.235 0.305 0 N-CA-C 112.079 0.4 . . . . 0.0 112.079 -179.067 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 12' ' ' PHE . . . . . . . . . . . . . 11.9 t80 -141.53 -9.17 0.95 Allowed 'General case' 0 N--CA 1.473 0.676 0 N-CA-C 112.548 0.573 . . . . 0.0 112.548 -178.791 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 13' ' ' ASN . . . . . 0.456 HD21 ' HD3' ' A' ' 2' ' ' PRO . 9.9 t30 -129.94 63.53 68.91 Favored Pre-proline 0 CA--C 1.551 0.981 0 N-CA-C 111.369 0.137 . . . . 0.0 111.369 -179.19 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 14' ' ' PRO . . . . . 0.584 ' O ' ' HD2' ' A' ' 2' ' ' PRO . 13.3 Cg_exo -70.37 -174.54 1.05 Allowed 'Trans proline' 0 C--N 1.375 1.922 0 C-N-CA 122.784 2.322 . . . . 0.0 112.039 179.118 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 2.1 t -79.27 120.61 23.98 Favored 'General case' 0 N--CA 1.472 0.627 0 O-C-N 122.909 0.131 . . . . 0.0 110.991 -179.902 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 16' ' ' CYS . . . . . 0.572 ' HB2' ' O ' ' A' ' 2' ' ' PRO . 0.0 OUTLIER -57.03 -52.5 73.67 Favored Pre-proline 0 N--CA 1.483 1.198 0 CA-C-O 119.073 -0.489 . . . . 0.0 111.551 179.458 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 17' ' ' PRO . . . . . 0.591 ' HG2' HD12 ' A' ' 19' ' ' LEU . 56.9 Cg_endo -72.29 169.95 20.36 Favored 'Trans proline' 0 C--N 1.38 2.205 0 C-N-CA 122.1 1.867 . . . . 0.0 111.712 178.013 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 53.1 Cg_endo -71.45 49.86 1.19 Allowed 'Trans proline' 0 C--N 1.373 1.861 0 C-N-CA 121.978 1.785 . . . . 0.0 112.852 178.871 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 19' ' ' LEU . . . . . 0.591 HD12 ' HG2' ' A' ' 17' ' ' PRO . 32.9 mt -108.7 172.5 6.81 Favored 'General case' 0 CA--C 1.533 0.321 0 CA-C-N 115.722 -0.672 . . . . 0.0 111.235 -179.574 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 20' ' ' THR . . . . . 0.424 ' O ' ' HA ' ' A' ' 30' ' ' CYS . 25.0 m -106.63 153.96 21.61 Favored 'General case' 0 CA--C 1.533 0.308 0 CA-C-N 115.811 -0.631 . . . . 0.0 111.462 -178.497 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 3.5 t -103.57 104.18 14.2 Favored 'General case' 0 C--O 1.236 0.392 0 CA-C-N 115.512 -0.767 . . . . 0.0 109.474 178.568 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 22' ' ' ILE . . . . . 0.721 HD12 ' HB2' ' A' ' 31' ' ' TYR . 4.8 mt -125.56 129.66 24.33 Favored Pre-proline 0 CA--C 1.543 0.703 0 CA-C-N 115.757 -0.656 . . . . 0.0 110.665 -178.914 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 35.6 Cg_endo -66.45 -48.11 0.24 Allowed 'Cis proline' 0 C--N 1.376 1.998 0 C-N-CA 124.683 -0.965 . . . . 0.0 113.801 -0.207 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 80.46 34.4 28.86 Favored Glycine 0 C--N 1.347 1.141 0 C-N-CA 121.253 -0.498 . . . . 0.0 112.904 179.877 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 8.0 m-20 -142.81 84.27 10.87 Favored Pre-proline 0 CA--C 1.544 0.719 0 C-N-CA 122.525 0.33 . . . . 0.0 110.542 -179.604 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 26' ' ' PRO . . . . . 0.45 ' O ' HG22 ' A' ' 10' ' ' VAL . 1.1 Cg_endo -81.77 -31.73 4.12 Favored 'Cis proline' 0 C--N 1.373 1.821 0 C-N-CA 125.075 -0.802 . . . . 0.0 113.06 -0.098 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 27' ' ' TYR . . . . . . . . . . . . . 41.2 m-85 -101.26 167.56 10.12 Favored 'General case' 0 C--O 1.239 0.532 0 CA-C-N 115.797 -0.638 . . . . 0.0 111.158 -178.981 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -164.88 -161.21 13.37 Favored Glycine 0 C--N 1.34 0.799 0 C-N-CA 120.839 -0.696 . . . . 0.0 113.264 179.619 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 29' ' ' ILE . . . . . 0.489 ' HB ' ' CE2' ' A' ' 31' ' ' TYR . 3.9 mm -127.93 155.26 39.32 Favored 'Isoleucine or valine' 0 C--O 1.234 0.268 0 CA-C-N 115.175 -0.512 . . . . 0.0 109.877 179.944 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 30' ' ' CYS . . . . . 0.424 ' HA ' ' O ' ' A' ' 20' ' ' THR . 23.7 m -81.96 100.61 9.77 Favored 'General case' 0 CA--C 1.536 0.435 0 CA-C-O 121.278 0.561 . . . . 0.0 111.446 -179.911 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 31' ' ' TYR . . . . . 0.721 ' HB2' HD12 ' A' ' 22' ' ' ILE . 38.4 m-85 -130.04 166.16 20.72 Favored 'General case' 0 N--CA 1.464 0.246 0 CA-C-N 115.12 -0.946 . . . . 0.0 110.937 -179.872 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 2.9 tp -101.0 131.71 48.15 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.546 0 CA-C-N 116.077 -0.511 . . . . 0.0 110.367 179.558 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 33' ' ' ILE . . . . . 0.496 HG23 HD11 ' A' ' 22' ' ' ILE . 1.8 pp . . . . . 0 C--O 1.25 1.097 0 CA-C-O 118.241 -0.885 . . . . 0.0 111.486 179.876 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 0.2 OUTLIER . . . . . 0 N--CA 1.486 1.34 0 CA-C-O 119.777 -0.154 . . . . 0.0 111.068 . . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 2' ' ' PRO . . . . . 0.579 ' O ' ' HB2' ' A' ' 16' ' ' CYS . 92.3 Cg_endo -71.43 -172.32 0.75 Allowed 'Trans proline' 0 C--N 1.375 1.929 0 C-N-CA 123.27 2.647 . . . . 0.0 113.907 -178.842 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -135.79 -156.54 7.59 Favored Glycine 0 C--N 1.342 0.894 0 CA-C-N 116.027 -0.533 . . . . 0.0 112.387 179.829 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 16.0 tt0 -74.31 138.78 43.76 Favored 'General case' 0 N--CA 1.471 0.593 0 C-N-CA 122.693 0.397 . . . . 0.0 111.377 -179.707 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 84.53 10.62 79.27 Favored Glycine 0 C--N 1.34 0.754 0 CA-C-N 115.809 -0.632 . . . . 0.0 113.333 179.99 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 43.1 mt-10 -129.16 160.98 31.17 Favored 'General case' 0 N--CA 1.467 0.4 0 C-N-CA 122.206 0.202 . . . . 0.0 110.846 -179.841 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 7' ' ' GLN . . . . . 0.516 ' HA ' ' O ' ' A' ' 28' ' ' GLY . 7.5 tt0 -84.85 133.65 34.31 Favored 'General case' 0 C--N 1.344 0.366 0 CA-C-O 121.331 0.586 . . . . 0.0 111.215 179.765 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 3.3 p -122.85 161.75 23.48 Favored 'General case' 0 C--O 1.241 0.615 0 CA-C-N 114.44 -1.254 . . . . 0.0 110.824 -179.638 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 9' ' ' ASP . . . . . 0.452 ' OD1' ' HD2' ' A' ' 27' ' ' TYR . 1.8 m-20 -114.91 152.01 33.04 Favored 'General case' 0 C--O 1.235 0.31 0 CA-C-N 115.511 -0.768 . . . . 0.0 109.77 179.41 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 10.1 m -103.79 13.03 7.44 Favored 'Isoleucine or valine' 0 CA--C 1.542 0.651 0 O-C-N 123.254 0.346 . . . . 0.0 111.801 -179.818 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 45.9 mt-10 -100.95 -55.67 2.51 Favored 'General case' 0 C--O 1.235 0.304 0 N-CA-C 111.812 0.301 . . . . 0.0 111.812 -179.073 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 12' ' ' PHE . . . . . . . . . . . . . 12.6 t80 -141.25 -14.23 0.89 Allowed 'General case' 0 N--CA 1.47 0.564 0 N-CA-C 112.218 0.451 . . . . 0.0 112.218 -179.251 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 13' ' ' ASN . . . . . 0.484 HD21 ' HD3' ' A' ' 2' ' ' PRO . 12.6 t30 -120.47 72.91 21.09 Favored Pre-proline 0 CA--C 1.55 0.955 0 O-C-N 122.903 0.127 . . . . 0.0 111.184 -179.406 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 14' ' ' PRO . . . . . 0.575 ' O ' ' HD2' ' A' ' 2' ' ' PRO . 60.8 Cg_endo -76.44 -176.4 3.08 Favored 'Trans proline' 0 C--N 1.371 1.735 0 C-N-CA 122.367 2.044 . . . . 0.0 112.207 179.245 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 2.0 t -79.34 119.64 22.67 Favored 'General case' 0 N--CA 1.473 0.71 0 O-C-N 123.017 0.198 . . . . 0.0 110.642 179.861 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 16' ' ' CYS . . . . . 0.579 ' HB2' ' O ' ' A' ' 2' ' ' PRO . 0.0 OUTLIER -54.94 -52.48 70.49 Favored Pre-proline 0 N--CA 1.483 1.178 0 CA-C-O 119.005 -0.521 . . . . 0.0 111.664 179.715 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 17' ' ' PRO . . . . . 0.561 ' HG2' HD12 ' A' ' 19' ' ' LEU . 57.6 Cg_endo -72.39 169.79 20.83 Favored 'Trans proline' 0 C--N 1.378 2.126 0 C-N-CA 122.06 1.84 . . . . 0.0 111.789 178.021 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 55.1 Cg_endo -71.87 50.28 1.4 Allowed 'Trans proline' 0 C--N 1.374 1.895 0 C-N-CA 122.065 1.844 . . . . 0.0 112.742 178.808 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 19' ' ' LEU . . . . . 0.561 HD12 ' HG2' ' A' ' 17' ' ' PRO . 32.4 mt -110.03 172.13 7.04 Favored 'General case' 0 CA--C 1.533 0.323 0 CA-C-N 115.666 -0.697 . . . . 0.0 111.311 -179.33 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 20' ' ' THR . . . . . 0.497 ' O ' ' HA ' ' A' ' 30' ' ' CYS . 21.2 m -106.04 154.38 20.71 Favored 'General case' 0 CA--C 1.533 0.293 0 CA-C-N 115.606 -0.724 . . . . 0.0 111.002 -178.948 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 2.0 t -105.35 99.7 9.3 Favored 'General case' 0 C--O 1.237 0.398 0 CA-C-N 115.644 -0.707 . . . . 0.0 109.363 178.597 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 22' ' ' ILE . . . . . 0.73 HD12 ' HB2' ' A' ' 31' ' ' TYR . 3.0 mt -122.53 130.53 24.62 Favored Pre-proline 0 CA--C 1.542 0.658 0 CA-C-N 115.559 -0.746 . . . . 0.0 110.382 -178.713 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 32.5 Cg_endo -65.07 -48.47 0.21 Allowed 'Cis proline' 0 C--N 1.375 1.944 0 C-N-CA 124.76 -0.933 . . . . 0.0 113.942 -0.226 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 77.19 31.36 52.51 Favored Glycine 0 C--N 1.348 1.215 0 C-N-CA 121.165 -0.54 . . . . 0.0 113.004 179.725 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 8.3 m-20 -138.86 83.71 18.56 Favored Pre-proline 0 CA--C 1.544 0.717 0 C-N-CA 122.49 0.316 . . . . 0.0 110.432 -179.771 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 3.0 Cg_exo -81.17 -32.34 3.83 Favored 'Cis proline' 0 C--N 1.372 1.772 0 C-N-CA 125.101 -0.791 . . . . 0.0 113.07 -0.08 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 27' ' ' TYR . . . . . 0.452 ' HD2' ' OD1' ' A' ' 9' ' ' ASP . 45.4 m-85 -104.4 166.76 10.19 Favored 'General case' 0 N--CA 1.469 0.485 0 CA-C-N 115.864 -0.607 . . . . 0.0 111.465 -178.884 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 28' ' ' GLY . . . . . 0.516 ' O ' ' HA ' ' A' ' 7' ' ' GLN . . . -169.95 -164.85 26.36 Favored Glycine 0 C--N 1.341 0.842 0 C-N-CA 120.93 -0.652 . . . . 0.0 113.356 178.492 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 29' ' ' ILE . . . . . 0.536 ' HB ' ' CE2' ' A' ' 31' ' ' TYR . 1.9 mm -117.38 153.07 19.22 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.225 0 O-C-N 124.045 0.497 . . . . 0.0 110.22 -179.938 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 30' ' ' CYS . . . . . 0.497 ' HA ' ' O ' ' A' ' 20' ' ' THR . 20.5 m -80.06 104.66 10.78 Favored 'General case' 0 CA--C 1.536 0.42 0 CA-C-N 115.923 -0.581 . . . . 0.0 111.21 -179.866 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 31' ' ' TYR . . . . . 0.73 ' HB2' HD12 ' A' ' 22' ' ' ILE . 39.7 m-85 -130.12 167.51 18.24 Favored 'General case' 0 C--O 1.233 0.223 0 CA-C-N 115.098 -0.956 . . . . 0.0 111.044 -179.54 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 2.6 tp -100.95 131.84 47.82 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.524 0 CA-C-N 116.056 -0.52 . . . . 0.0 110.426 179.486 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 33' ' ' ILE . . . . . 0.451 ' O ' HD12 ' A' ' 33' ' ' ILE . 1.7 pp . . . . . 0 C--O 1.248 0.998 0 CA-C-O 118.383 -0.818 . . . . 0.0 111.522 179.856 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 0.2 OUTLIER . . . . . 0 N--CA 1.487 1.402 0 CA-C-O 119.753 -0.165 . . . . 0.0 111.045 . . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 2' ' ' PRO . . . . . 0.594 ' HD2' ' O ' ' A' ' 14' ' ' PRO . 94.6 Cg_endo -71.52 -172.63 0.81 Allowed 'Trans proline' 0 C--N 1.375 1.931 0 C-N-CA 123.299 2.666 . . . . 0.0 113.801 -178.816 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -136.4 -158.1 7.97 Favored Glycine 0 C--N 1.342 0.89 0 CA-C-N 115.852 -0.613 . . . . 0.0 112.232 179.749 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 18.3 tt0 -73.52 136.51 44.11 Favored 'General case' 0 N--CA 1.472 0.625 0 C-N-CA 122.717 0.407 . . . . 0.0 111.382 -179.978 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 87.85 9.23 71.61 Favored Glycine 0 C--N 1.339 0.703 0 O-C-N 123.775 0.672 . . . . 0.0 113.398 -179.796 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 3.2 tp10 -129.0 166.49 19.09 Favored 'General case' 0 C--O 1.239 0.53 0 C-N-CA 122.218 0.207 . . . . 0.0 110.576 -179.816 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 7' ' ' GLN . . . . . . . . . . . . . 0.2 OUTLIER -80.6 152.81 28.36 Favored 'General case' 0 C--N 1.347 0.483 0 CA-C-N 116.517 -0.31 . . . . 0.0 110.822 179.782 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 6.2 p -140.85 152.24 44.97 Favored 'General case' 0 C--O 1.234 0.245 0 CA-C-N 115.958 -0.565 . . . . 0.0 111.163 -179.12 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -112.41 146.12 38.92 Favored 'General case' 0 C--O 1.235 0.337 0 CA-C-N 115.397 -0.82 . . . . 0.0 109.626 179.498 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 10' ' ' VAL . . . . . 0.452 HG22 ' O ' ' A' ' 26' ' ' PRO . 6.5 m -101.26 17.91 3.63 Favored 'Isoleucine or valine' 0 CA--C 1.543 0.674 0 CA-C-N 116.46 -0.336 . . . . 0.0 111.604 179.988 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 47.0 mt-10 -107.55 -55.01 2.41 Favored 'General case' 0 N--CA 1.467 0.383 0 CA-C-N 116.346 -0.388 . . . . 0.0 111.873 -179.155 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 12' ' ' PHE . . . . . . . . . . . . . 10.8 t80 -140.35 -16.77 0.92 Allowed 'General case' 0 N--CA 1.471 0.596 0 N-CA-C 112.31 0.485 . . . . 0.0 112.31 -179.193 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 13' ' ' ASN . . . . . 0.498 HD21 ' HD3' ' A' ' 2' ' ' PRO . 13.3 t30 -120.56 72.98 21.76 Favored Pre-proline 0 CA--C 1.548 0.899 0 O-C-N 122.937 0.148 . . . . 0.0 111.139 -179.337 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 14' ' ' PRO . . . . . 0.594 ' O ' ' HD2' ' A' ' 2' ' ' PRO . 62.4 Cg_endo -76.71 -175.13 2.44 Favored 'Trans proline' 0 C--N 1.372 1.806 0 C-N-CA 122.484 2.123 . . . . 0.0 112.347 179.318 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 2.2 t -79.48 119.59 22.68 Favored 'General case' 0 N--CA 1.472 0.651 0 CA-C-O 120.452 0.168 . . . . 0.0 110.727 179.932 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 16' ' ' CYS . . . . . 0.579 ' HB2' ' O ' ' A' ' 2' ' ' PRO . 0.0 OUTLIER -56.25 -52.59 71.8 Favored Pre-proline 0 N--CA 1.481 1.101 0 CA-C-O 119.005 -0.521 . . . . 0.0 111.712 179.611 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 17' ' ' PRO . . . . . 0.582 ' HG2' HD12 ' A' ' 19' ' ' LEU . 56.9 Cg_endo -72.36 169.67 21.1 Favored 'Trans proline' 0 C--N 1.38 2.205 0 C-N-CA 122.065 1.844 . . . . 0.0 111.721 177.969 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -71.69 51.87 1.6 Allowed 'Trans proline' 0 C--N 1.373 1.859 0 C-N-CA 121.963 1.776 . . . . 0.0 112.769 178.79 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 19' ' ' LEU . . . . . 0.582 HD12 ' HG2' ' A' ' 17' ' ' PRO . 37.5 mt -110.6 173.12 6.48 Favored 'General case' 0 C--O 1.236 0.37 0 CA-C-N 115.58 -0.736 . . . . 0.0 111.333 -179.565 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 28.8 m -107.92 152.88 23.85 Favored 'General case' 0 CA--C 1.533 0.318 0 CA-C-N 115.874 -0.603 . . . . 0.0 111.346 -178.565 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 3.9 t -101.82 104.25 15.0 Favored 'General case' 0 C--O 1.238 0.471 0 CA-C-N 115.437 -0.801 . . . . 0.0 109.622 178.463 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 22' ' ' ILE . . . . . 0.726 HD12 ' HB2' ' A' ' 31' ' ' TYR . 4.5 mt -125.92 129.75 24.2 Favored Pre-proline 0 CA--C 1.544 0.717 0 CA-C-N 115.918 -0.583 . . . . 0.0 110.544 -178.775 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 23' ' ' PRO . . . . . 0.48 ' HB2' ' OD2' ' A' ' 25' ' ' ASP . 35.2 Cg_endo -66.01 -48.76 0.21 Allowed 'Cis proline' 0 C--N 1.376 1.979 0 C-N-CA 124.71 -0.954 . . . . 0.0 113.807 -0.354 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 80.55 35.61 25.38 Favored Glycine 0 C--N 1.347 1.156 0 C-N-CA 121.299 -0.477 . . . . 0.0 112.91 179.826 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 25' ' ' ASP . . . . . 0.48 ' OD2' ' HB2' ' A' ' 23' ' ' PRO . 2.5 p30 -143.72 84.1 10.11 Favored Pre-proline 0 CA--C 1.548 0.898 0 C-N-CA 122.551 0.34 . . . . 0.0 110.759 -179.789 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 26' ' ' PRO . . . . . 0.452 ' O ' HG22 ' A' ' 10' ' ' VAL . 1.2 Cg_endo -81.41 -32.1 3.95 Favored 'Cis proline' 0 C--N 1.371 1.712 0 C-N-CA 125.15 -0.771 . . . . 0.0 113.087 0.011 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 27' ' ' TYR . . . . . . . . . . . . . 40.1 m-85 -101.79 169.69 8.64 Favored 'General case' 0 C--O 1.239 0.533 0 CA-C-N 115.754 -0.657 . . . . 0.0 111.213 -178.888 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -167.49 -159.42 13.04 Favored Glycine 0 C--N 1.341 0.815 0 C-N-CA 120.888 -0.672 . . . . 0.0 113.243 179.517 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 29' ' ' ILE . . . . . 0.493 ' HB ' ' CE2' ' A' ' 31' ' ' TYR . 4.2 mm -128.17 154.4 38.78 Favored 'Isoleucine or valine' 0 C--O 1.233 0.193 0 CA-C-N 115.276 -0.462 . . . . 0.0 109.853 179.969 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 30' ' ' CYS . . . . . . . . . . . . . 18.2 m -81.55 101.48 9.99 Favored 'General case' 0 CA--C 1.536 0.42 0 CA-C-N 116.02 -0.536 . . . . 0.0 111.395 179.989 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 31' ' ' TYR . . . . . 0.726 ' HB2' HD12 ' A' ' 22' ' ' ILE . 38.4 m-85 -130.0 166.53 19.9 Favored 'General case' 0 N--CA 1.464 0.228 0 CA-C-N 115.145 -0.934 . . . . 0.0 110.995 -179.714 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 2.8 tp -101.5 131.96 48.29 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.624 0 CA-C-N 116.141 -0.482 . . . . 0.0 110.377 179.51 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 33' ' ' ILE . . . . . 0.488 ' H ' HG13 ' A' ' 33' ' ' ILE . 1.8 pp . . . . . 0 C--O 1.249 1.057 0 CA-C-O 118.382 -0.818 . . . . 0.0 111.521 179.945 . . . . . . . . 1 1 . 1 stop_ save_